assay_id,assay_organism,tissue_id,chembl_id,description,assay_test_type,doc_id,assay_tissue,tid,variant_id,assay_category,bao_format,src_assay_id,curated_by,assay_subcellular_fraction,assay_tax_id,assay_type,assay_strain,assay_cell_type
1,,,CHEMBL615117,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,,11087,,12052,,,BAO_0000019,,Autocuration,,,B,,
2,,,CHEMBL615118,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,,684,,22226,,,BAO_0000219,,Autocuration,,,F,,
3,,,CHEMBL615119,,,15453,,22226,,,BAO_0000019,,Autocuration,,,B,,
4,Bos taurus,,CHEMBL615120,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,,17841,,104729,,,BAO_0000249,,Autocuration,,9913.0,B,,
5,Homo sapiens,,CHEMBL615121,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,17430,,80001,,,BAO_0000219,,Intermediate,,9606.0,F,,143B
6,Homo sapiens,,CHEMBL615122,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,17430,,80001,,,BAO_0000219,,Intermediate,,9606.0,F,,143B
7,Mus musculus,,CHEMBL615123,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,,13799,,80001,,,BAO_0000219,,Intermediate,,10090.0,F,,143B
8,Homo sapiens,,CHEMBL615124,In vitro cell cytotoxicity was determined against 143B cell line,,17774,,80001,,,BAO_0000219,,Expert,,9606.0,F,,143B
9,Homo sapiens,,CHEMBL615125,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,,3801,,80001,,,BAO_0000219,,Intermediate,,9606.0,F,,143B
10,Homo sapiens,,CHEMBL615126,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,17430,,80001,,,BAO_0000219,,Intermediate,,9606.0,F,,143B
11,Homo sapiens,,CHEMBL615127,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,17430,,80001,,,BAO_0000219,,Intermediate,,9606.0,F,,143B
12,Homo sapiens,,CHEMBL615128,In vitro cell cytotoxicity was determined against 143B-LTK cell line,,17774,,80001,,,BAO_0000219,,Expert,,9606.0,F,,143B
13,Staphylococcus aureus,,CHEMBL857900,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,11324,,50185,,,BAO_0000218,,Intermediate,,1280.0,F,,
14,Staphylococcus aureus,,CHEMBL615129,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,11324,,50185,,,BAO_0000218,,Intermediate,,1280.0,F,,
15,Staphylococcus aureus,,CHEMBL615130,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,11324,,50185,,,BAO_0000218,,Intermediate,,1280.0,F,,
16,Staphylococcus aureus,,CHEMBL615131,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,11324,,50185,,,BAO_0000218,,Intermediate,,1280.0,F,,
17,Rattus norvegicus,,CHEMBL884521,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,,11347,,100122,,,BAO_0000357,,Expert,,10116.0,A,,
18,,,CHEMBL615132,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),,16474,,12054,,,BAO_0000357,,Autocuration,,,B,,
19,,,CHEMBL615133,Inhibition of partially purified 15-lipoxygenase from human leukocytes,,10091,,12054,,,BAO_0000019,,Autocuration,,,B,,
20,,,CHEMBL615134,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,16474,,12054,,,BAO_0000357,,Autocuration,,,B,,
21,,,CHEMBL615135,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),,16474,,12054,,,BAO_0000357,,Autocuration,,,B,,
22,,,CHEMBL615136,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,16474,,12054,,,BAO_0000357,,Autocuration,,,B,,
23,,,CHEMBL615137,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,16474,,12054,,,BAO_0000357,,Autocuration,,,B,,
24,,,CHEMBL615138,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,16474,,12054,,,BAO_0000357,,Autocuration,,,B,,
25,,,CHEMBL836324,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",,14352,,22226,,,BAO_0000219,,Autocuration,,,B,,
26,Oryctolagus cuniculus,,CHEMBL615139,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,,5646,,12054,,,BAO_0000357,,Autocuration,,9986.0,B,,
27,Oryctolagus cuniculus,,CHEMBL615140,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),,5646,,12054,,,BAO_0000357,,Autocuration,,9986.0,B,,
28,,,CHEMBL615141,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,,10997,,12426,,,BAO_0000219,,Autocuration,,,B,,
29,soya bean,,CHEMBL615142,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,,6309,,12054,,,BAO_0000357,,Autocuration,,3847.0,B,,
30,Glycine max,,CHEMBL615143,Inhibitory activity against soybean 15-lipoxygenase was evaluated,,167,,12054,,,BAO_0000357,,Autocuration,,3847.0,B,,
31,Glycine max,,CHEMBL615144,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,,167,,12054,,,BAO_0000357,,Autocuration,,3847.0,B,,
32,Glycine max,,CHEMBL872867,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,,11087,,12054,,,BAO_0000357,,Autocuration,,3847.0,B,,
33,Glycine max,,CHEMBL615145,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,,11087,,12054,,,BAO_0000357,,Autocuration,,3847.0,B,,
34,Glycine max,,CHEMBL615146,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,,13622,,12054,,,BAO_0000357,,Autocuration,,3847.0,B,,
35,Glycine max,,CHEMBL615147,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,,13622,,12054,,,BAO_0000357,,Autocuration,,3847.0,B,,
36,Rattus norvegicus,,CHEMBL615148,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,,11347,,22226,,,BAO_0000019,,Autocuration,,10116.0,A,,
37,Escherichia coli,,CHEMBL615149,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,,5926,,22226,,,BAO_0000019,,Autocuration,,562.0,B,,
38,,,CHEMBL615150,Dissociation constant with dimeric 16S rRNA RNA construct B,,4567,,22226,,,BAO_0000019,,Autocuration,,,B,,
39,,,CHEMBL615151,Dissociation constant towards 16S rRNA construct A,,3782,,22222,,,BAO_0000225,,Intermediate,,,B,,
40,,,CHEMBL615152,Dissociation constant towards 16S rRNA construct B,,3782,,22222,,,BAO_0000225,,Intermediate,,,B,,
41,Escherichia coli,,CHEMBL615153,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,,4466,,100263,,,BAO_0000225,,Expert,,562.0,B,,
42,Escherichia coli,,CHEMBL615154,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,,6592,,100263,,,BAO_0000225,,Expert,,562.0,B,,
43,,,CHEMBL615155,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,898,,13053,,,BAO_0000019,,Autocuration,,,B,,
44,,,CHEMBL615156,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,898,,13053,,,BAO_0000019,,Autocuration,,,B,,
45,Homo sapiens,,CHEMBL615157,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,13163,,20001,,,BAO_0000019,,Autocuration,,9606.0,B,,
46,Homo sapiens,,CHEMBL615158,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,13163,,20001,,,BAO_0000019,,Autocuration,,9606.0,B,,
47,Rattus norvegicus,,CHEMBL615159,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,10691,,12971,,,BAO_0000019,,Expert,,10116.0,B,,
48,Rattus norvegicus,,CHEMBL615172,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,10691,,12971,,,BAO_0000019,,Expert,,10116.0,B,,
49,Rattus norvegicus,,CHEMBL615173,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,10691,,12971,,,BAO_0000019,,Expert,,10116.0,B,,
50,Rattus norvegicus,,CHEMBL615174,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,10691,,12971,,,BAO_0000019,,Expert,,10116.0,B,,
51,,,CHEMBL884518,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,898,,13053,,,BAO_0000019,,Autocuration,,,B,,
52,,,CHEMBL615175,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),,912,,11512,,,BAO_0000357,,Autocuration,,,B,,
53,,,CHEMBL615176,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,,912,,11512,,,BAO_0000357,,Autocuration,,,B,,
54,,,CHEMBL615177,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,,912,,11512,,,BAO_0000357,,Autocuration,,,B,,
55,Rattus norvegicus,,CHEMBL615178,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,,15103,,104740,,,BAO_0000249,,Autocuration,Membranes,10116.0,B,,
56,Homo sapiens,,CHEMBL615179,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,,5116,,80002,,,BAO_0000219,,Intermediate,,9606.0,F,,1A9
57,Rattus norvegicus,,CHEMBL615180,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,,14578,,104835,,,BAO_0000219,,Autocuration,,10116.0,F,,Oocytes
58,Rattus norvegicus,,CHEMBL615181,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,,14578,,104821,,,BAO_0000219,,Autocuration,,10116.0,F,,Oocytes
59,Rattus norvegicus,,CHEMBL615182,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,,14578,,104848,,,BAO_0000219,,Autocuration,,10116.0,F,,Oocytes
60,Homo sapiens,,CHEMBL615183,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,,4787,,80002,,,BAO_0000219,,Expert,,9606.0,F,,1A9
61,Homo sapiens,,CHEMBL615184,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,,4787,,80002,,,BAO_0000219,,Intermediate,,9606.0,F,,1A9
62,Homo sapiens,,CHEMBL615185,Cytotoxic activity against human ovarian cancer (1A9) cell line,,3547,,80002,,,BAO_0000219,,Intermediate,,9606.0,F,,1A9
63,Homo sapiens,,CHEMBL615186,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,,3547,,80002,,,BAO_0000219,,Intermediate,,9606.0,F,,1A9
64,Homo sapiens,,CHEMBL615187,Effective dose of compound against replication of 1A9 cell line was evaluated,,6726,,80002,,,BAO_0000219,,Intermediate,,9606.0,F,,1A9
65,Homo sapiens,,CHEMBL885343,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,,3455,,80002,,,BAO_0000219,,Expert,,9606.0,F,,1A9
66,Homo sapiens,,CHEMBL615188,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),,5726,,80002,,,BAO_0000219,,Intermediate,,9606.0,F,,1A9
67,Homo sapiens,,CHEMBL615189,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,,5726,,80002,,,BAO_0000219,,Intermediate,,9606.0,F,,1A9
68,Homo sapiens,,CHEMBL615190,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,,5726,,80002,,,BAO_0000219,,Intermediate,,9606.0,F,,1A9
69,Homo sapiens,,CHEMBL615191,Inhibitory activity against Taxol resistant 1A9 cell lines,,3395,,80002,,,BAO_0000219,,Intermediate,,9606.0,F,,1A9
70,Homo sapiens,,CHEMBL615192,Cytotoxicity against human ovarian cancer (1A9) cell lines.,,3415,,80002,,,BAO_0000219,,Expert,,9606.0,F,,1A9
71,Homo sapiens,,CHEMBL827083,Percentage inhibition of human ovarian cancer (1A9) cell lines.,,3415,,80002,,,BAO_0000219,,Expert,,9606.0,F,,1A9
72,Homo sapiens,,CHEMBL615193,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,,17099,,80002,,,BAO_0000219,,Expert,,9606.0,F,,1A9
73,Homo sapiens,,CHEMBL615194,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,,17099,,80002,,,BAO_0000219,,Intermediate,,9606.0,F,,1A9
74,Homo sapiens,,CHEMBL615195,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,,17099,,80002,,,BAO_0000219,,Intermediate,,9606.0,F,,1A9
75,Homo sapiens,,CHEMBL615196,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,,17099,,80002,,,BAO_0000219,,Intermediate,,9606.0,F,,1A9
76,Homo sapiens,,CHEMBL615197,Inhibitory concentration against Jurkat cells,,17721,,81072,,,BAO_0000219,,Intermediate,,9606.0,F,,Jurkat
77,,,CHEMBL615198,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,,1229,,22226,,,BAO_0000019,,Intermediate,,,F,,
78,Rattus norvegicus,,CHEMBL615199,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,,11347,,100121,,,BAO_0000357,,Expert,,10116.0,A,,
79,,,CHEMBL615200,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,17117,,11231,,,BAO_0000357,,Expert,,,B,,
80,,,CHEMBL615201,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,17117,,11231,,,BAO_0000357,,Expert,,,B,,
81,,,CHEMBL615202,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",,17117,,11231,,,BAO_0000357,,Expert,,,B,,
82,Candida albicans,,CHEMBL615203,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",,11375,,11231,,,BAO_0000251,,Autocuration,Microsomes,5476.0,B,,
83,Candida albicans,,CHEMBL615204,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",,11375,,11231,,,BAO_0000251,,Autocuration,Microsomes,5476.0,B,,
84,Saccharomyces cerevisiae,,CHEMBL615205,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",,11375,,11231,,,BAO_0000251,,Autocuration,Microsomes,4932.0,B,,
85,Saccharomyces cerevisiae,,CHEMBL615206,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",,11375,,11231,,,BAO_0000251,,Autocuration,Microsomes,4932.0,B,,
86,Sus scrofa,2107.0,CHEMBL615207,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",,11375,Liver,12083,,,BAO_0000251,,Autocuration,Microsomes,9823.0,B,,
87,Rattus norvegicus,,CHEMBL827084,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",,791,,11231,,,BAO_0000019,,Autocuration,,10116.0,B,,
88,Rattus norvegicus,,CHEMBL615208,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",,791,,11231,,,BAO_0000019,,Autocuration,,10116.0,B,,
89,Rattus norvegicus,,CHEMBL615209,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",,791,,11231,,,BAO_0000019,,Autocuration,,10116.0,B,,
90,Rattus norvegicus,2107.0,CHEMBL615210,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",,11375,Liver,12083,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
91,Rattus norvegicus,2107.0,CHEMBL615211,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",,11375,Liver,12083,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
92,Rattus norvegicus,2107.0,CHEMBL615212,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",,153,Liver,12083,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
93,,,CHEMBL615213,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),,8269,,11377,,,BAO_0000357,,Expert,,,B,,
94,,,CHEMBL615273,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,,8269,,11377,,,BAO_0000357,,Expert,,,B,,
95,Homo sapiens,,CHEMBL615274,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,17653,,81020,,,BAO_0000219,,Expert,,9606.0,F,,HepG2
96,Homo sapiens,,CHEMBL615275,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,,14277,,81020,,,BAO_0000219,,Intermediate,,9606.0,F,,HepG2
97,Homo sapiens,,CHEMBL615276,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,,1717,,81020,,,BAO_0000219,,Intermediate,,9606.0,F,,HepG2
98,Homo sapiens,,CHEMBL615277,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,,14091,,81020,,,BAO_0000219,,Intermediate,,9606.0,F,,HepG2
99,Homo sapiens,,CHEMBL615326,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,,14091,,81020,,,BAO_0000219,,Intermediate,,9606.0,F,,HepG2
100,Hepatitis B virus,,CHEMBL883130,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,17653,,50606,,,BAO_0000218,,Expert,,10407.0,F,,
101,Homo sapiens,,CHEMBL884519,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,,13105,,81020,,,BAO_0000219,,Intermediate,,9606.0,F,,HepG2
102,Homo sapiens,,CHEMBL615327,Concentration required to inhibit 50% of 2.2.15 cell line,,1717,,81020,,,BAO_0000219,,Intermediate,,9606.0,F,,HepG2
103,Homo sapiens,,CHEMBL615328,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,,13105,,81020,,,BAO_0000219,,Intermediate,,9606.0,A,,HepG2
104,Homo sapiens,,CHEMBL615329,Cytotoxic activity of compound against uninfected 2.2.15 cells.,,13600,,50587,,,BAO_0000218,,Intermediate,,9606.0,F,,2.2.15
105,Homo sapiens,,CHEMBL615330,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,,13467,,50587,,,BAO_0000218,,Intermediate,,9606.0,F,,2.2.15
106,Hepatitis B virus,,CHEMBL615331,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",,17477,,50606,,,BAO_0000218,,Expert,,10407.0,F,,2.2.15
107,Homo sapiens,,CHEMBL615332,In vitro anti-HBV activity in 2.2.15 cells,,1593,,50587,,,BAO_0000218,,Intermediate,,9606.0,F,,2.2.15
108,Homo sapiens,,CHEMBL615333,In vitro anti-HBV activity in 2.2.15 cells; Not determined,,1593,,50587,,,BAO_0000218,,Intermediate,,9606.0,F,,2.2.15
109,Homo sapiens,,CHEMBL615334,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,,15089,,50587,,,BAO_0000218,,Intermediate,,9606.0,F,,2.2.15
110,Homo sapiens,,CHEMBL615335,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,,15089,,50587,,,BAO_0000218,,Intermediate,,9606.0,F,,2.2.15
111,Homo sapiens,,CHEMBL615336,Cytotoxicity in 2.2.15 cells,,1593,,50587,,,BAO_0000218,,Intermediate,,9606.0,F,,2.2.15
112,Homo sapiens,,CHEMBL615337,Cytotoxicity in 2.2.15 cells; Not determined,,1593,,50587,,,BAO_0000218,,Intermediate,,9606.0,F,,2.2.15
113,Homo sapiens,,CHEMBL615338,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,,13600,,50587,,,BAO_0000218,,Intermediate,,9606.0,F,,2.2.15
114,Homo sapiens,,CHEMBL615339,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,,13467,,50587,,,BAO_0000218,,Intermediate,,9606.0,F,,2.2.15
115,Homo sapiens,,CHEMBL615340,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,,13467,,50587,,,BAO_0000218,,Intermediate,,9606.0,F,,2.2.15
116,Homo sapiens,,CHEMBL615341,Antiviral activity against HBV was determined in 2.215 cell line,,14764,,81020,,,BAO_0000219,,Intermediate,,9606.0,F,,HepG2
117,Homo sapiens,,CHEMBL615342,Inhibition of 20-HETE synthesis in human renal microsomes,,6531,,22226,,,BAO_0000251,,Autocuration,Microsomes,9606.0,B,,
118,,,CHEMBL615343,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,,17322,,22226,,,BAO_0000019,,Autocuration,,,B,,
119,Homo sapiens,,CHEMBL615344,Inhibitory concentration against 2008 (ovarian) cells,,17072,,80612,,,BAO_0000219,,Intermediate,,9606.0,F,,2008
120,Homo sapiens,,CHEMBL615345,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,,16936,,80612,,,BAO_0000219,,Intermediate,,9606.0,F,,2008
121,Homo sapiens,,CHEMBL615346,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),,16936,,80612,,,BAO_0000219,,Intermediate,,9606.0,F,,2008
122,Homo sapiens,,CHEMBL615347,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,,17146,,80612,,,BAO_0000219,,Intermediate,,9606.0,F,,2008
123,Homo sapiens,,CHEMBL615348,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,,17146,,80612,,,BAO_0000219,,Intermediate,,9606.0,F,,2008
124,Homo sapiens,,CHEMBL827085,In vitro inhibition of 2008/R ovarian cancer cell line,,10797,,80613,,,BAO_0000219,,Intermediate,,9606.0,F,,2008/R
125,Homo sapiens,,CHEMBL615349,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,,10797,,80613,,,BAO_0000219,,Intermediate,,9606.0,F,,2008/R
126,Homo sapiens,,CHEMBL615350,In vitro inhibition of 2008/S ovarian cancer cell line,,10797,,80614,,,BAO_0000219,,Intermediate,,9606.0,F,,2008/S
127,Homo sapiens,,CHEMBL615351,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,,10797,,80614,,,BAO_0000219,,Intermediate,,9606.0,F,,2008/S
128,Homo sapiens,,CHEMBL615352,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,,4823,,100256,,,BAO_0000220,,Expert,,9606.0,B,,
129,Homo sapiens,,CHEMBL615353,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,,12912,,100256,,,BAO_0000220,,Intermediate,,9606.0,B,,
130,,,CHEMBL615354,Inhibition of chymotrypsin-like activity of 20S proteasome,,2957,,100256,,,BAO_0000220,,Expert,,,B,,
131,,,CHEMBL615355,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,,2957,,100256,,,BAO_0000220,,Expert,,,B,,
132,,,CHEMBL615356,Inhibitory activity against 20S proteosome,,3260,,100256,,,BAO_0000220,,Intermediate,,,B,,
133,Homo sapiens,,CHEMBL615357,Compound was tested for inhibitory activity against tryptase,,3451,,22226,,,BAO_0000019,,Autocuration,,9606.0,B,,
134,Homo sapiens,,CHEMBL615358,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,,13885,,81020,,,BAO_0000219,,Intermediate,,9606.0,F,,HepG2
135,Homo sapiens,,CHEMBL827086,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,,13885,,81020,,,BAO_0000219,,Intermediate,,9606.0,F,,HepG2
136,,,CHEMBL615359,Compound was tested for the inhibition of Alpha-glucosidase,,3676,,22226,,,BAO_0000019,,Autocuration,,,B,,
137,,,CHEMBL615360,Inhibitory concentration against human neutrophil elastase (HNE),,6043,,235,,,BAO_0000357,,Autocuration,,,B,,
138,Rattus norvegicus,948.0,CHEMBL615361,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,,11140,Heart,22226,,,BAO_0000218,,Autocuration,,10116.0,F,,
139,,,CHEMBL615362,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,10543,,19640,,,BAO_0000019,,Autocuration,,,F,,
140,,,CHEMBL615363,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,10543,,19640,,,BAO_0000019,,Expert,,,F,,
141,,,CHEMBL615364,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,10543,,19640,,,BAO_0000357,,Autocuration,,,B,,
142,,,CHEMBL615365,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,10543,,19640,,,BAO_0000019,,Expert,,,F,,
143,Mus musculus,,CHEMBL615366,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,,11365,,80360,,,BAO_0000219,,Intermediate,,10090.0,F,,P338
144,Mus musculus,,CHEMBL615367,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,,11365,,80360,,,BAO_0000219,,Intermediate,,10090.0,F,,P338
145,Homo sapiens,,CHEMBL615368,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,,11803,,80384,,,BAO_0000219,,Intermediate,,9606.0,F,,PBL
146,Ovis aries,,CHEMBL615369,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,,11803,,22226,,,BAO_0000019,,Autocuration,,9940.0,F,,
147,Ovis aries,,CHEMBL615370,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,,11803,,22226,,,BAO_0000019,,Autocuration,,9940.0,F,,
148,,,CHEMBL615673,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),,12278,,191,,,BAO_0000357,,Autocuration,,,B,,
149,Homo sapiens,,CHEMBL615674,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,,8249,,22226,,,BAO_0000019,,Autocuration,,9606.0,F,,
150,Homo sapiens,,CHEMBL615675,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,,8249,,22226,,,BAO_0000019,,Autocuration,,9606.0,F,,
151,Homo sapiens,,CHEMBL615676,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,,8249,,22226,,,BAO_0000219,,Autocuration,,9606.0,F,,CCRF-CEM
152,Homo sapiens,,CHEMBL615677,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,,8249,,22226,,,BAO_0000219,,Autocuration,,9606.0,F,,CCRF-CEM
153,Homo sapiens,,CHEMBL615678,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,,8249,,22226,,,BAO_0000219,,Autocuration,,9606.0,F,,CCRF-CEM
154,Homo sapiens,,CHEMBL615679,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,,8249,,22226,,,BAO_0000219,,Autocuration,,9606.0,F,,CCRF-CEM
155,Homo sapiens,,CHEMBL615680,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,,8249,,22226,,,BAO_0000019,,Autocuration,,9606.0,F,,
156,Homo sapiens,,CHEMBL615681,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,,8249,,22226,,,BAO_0000019,,Autocuration,,9606.0,F,,
157,,,CHEMBL857972,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,,16992,,104290,,,BAO_0000249,,Autocuration,,,B,,
158,Streptococcus pyogenes,,CHEMBL857899,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,,10543,,50264,,,BAO_0000218,,Intermediate,,1314.0,F,,
159,Human herpesvirus 3,,CHEMBL615371,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),,17833,,50527,,,BAO_0000218,,Intermediate,,10335.0,F,,
160,vericilla zoster virus,,CHEMBL615372,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,,17290,,50527,,,BAO_0000218,,Expert,,10335.0,F,,HEL
161,vericilla zoster virus,,CHEMBL615373,Antiviral activity against 07/1 strain of VZV; ND: No data,,17290,,50527,,,BAO_0000218,,Intermediate,,10335.0,F,,
162,vericilla zoster virus,,CHEMBL615374,Antiviral activity against 07/1 strain of VZV; ND=No data,,17290,,50527,,,BAO_0000218,,Intermediate,,10335.0,F,,
163,escherichia cloac,,CHEMBL615375,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",,10932,,50145,,,BAO_0000218,,Intermediate,,561.0,F,,
164,,,CHEMBL615376,Ratio of Ki at A2 to Ki at A1 receptors,,9707,,22226,,,BAO_0000019,,Autocuration,,,B,,
165,Candida albicans,,CHEMBL615377,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",,2346,,11143,,,BAO_0000249,,Expert,,5476.0,B,,
166,Candida glabrata CBS 138,,CHEMBL615378,"Inhibition of 1,3-beta-glucan synthase",,2205,,18077,,,BAO_0000357,,Expert,,284593.0,B,,
167,Homo sapiens,,CHEMBL615379,Inhibition of growth of 1-87 human tumor cell line,,11900,,80609,,,BAO_0000219,,Intermediate,,9606.0,F,,1-87 tumor cell line
168,Rattus norvegicus,,CHEMBL615380,Inhibition of 1-lipoxygenase (LOX)in RBL cells,,14864,,12166,,,BAO_0000219,,Expert,,10116.0,B,,
169,Glycine max,,CHEMBL615381,Inhibitory activity against soybean 1-lipoxygenase (SLO),,16474,,100171,,,BAO_0000357,,Autocuration,,3847.0,B,,
170,Glycine max,,CHEMBL615382,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,,16474,,100171,,,BAO_0000357,,Autocuration,,3847.0,B,,
171,Glycine max,,CHEMBL615383,% inhibition against soybean 1-lipoxygenase (SLO),,16474,,100171,,,BAO_0000357,,Autocuration,,3847.0,B,,
172,Glycine max,,CHEMBL615384,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,,16474,,100171,,,BAO_0000357,,Autocuration,,3847.0,B,,
173,Glycine max,,CHEMBL615385,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,,3094,,100171,,,BAO_0000357,,Autocuration,,3847.0,B,,
174,Glycine max,,CHEMBL615386,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,,3094,,100171,,,BAO_0000357,,Autocuration,,3847.0,B,,
175,Glycine max,,CHEMBL615387,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,,3094,,100171,,,BAO_0000357,,Autocuration,,3847.0,B,,
176,Glycine max,,CHEMBL615388,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,,3094,,100171,,,BAO_0000357,,Autocuration,,3847.0,B,,
177,Glycine max,,CHEMBL615214,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,,3094,,100171,,,BAO_0000357,,Autocuration,,3847.0,B,,
178,Glycine max,,CHEMBL827087,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,,3094,,100171,,,BAO_0000357,,Autocuration,,3847.0,B,,
179,Glycine max,,CHEMBL615215,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,,3094,,100171,,,BAO_0000357,,Autocuration,,3847.0,B,,
180,Glycine max,,CHEMBL615216,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,,3094,,100171,,,BAO_0000357,,Autocuration,,3847.0,B,,
181,Glycine max,,CHEMBL615217,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,,3094,,100171,,,BAO_0000357,,Autocuration,,3847.0,B,,
182,Glycine max,,CHEMBL615218,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,,3094,,100171,,,BAO_0000357,,Autocuration,,3847.0,B,,
183,Glycine max,,CHEMBL615219,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,,3094,,100171,,,BAO_0000357,,Autocuration,,3847.0,B,,
184,Mus musculus,,CHEMBL615220,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,,10413,,22226,,,BAO_0000019,,Autocuration,,10090.0,B,,
185,Mus musculus,,CHEMBL615221,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),,16929,,80049,,,BAO_0000219,,Intermediate,,10090.0,F,,C3H 10T1/2
186,,,CHEMBL615222,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,,1229,,22226,,,BAO_0000019,,Intermediate,,,F,,
187,,,CHEMBL615223,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,16587,,11489,,,BAO_0000357,,Autocuration,,,B,,
188,,,CHEMBL615224,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,16587,,11862,,,BAO_0000357,,Autocuration,,,B,,
189,,,CHEMBL615225,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,,16587,,11862,,,BAO_0000357,,Autocuration,,,B,,
190,,,CHEMBL615226,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,,16587,,11489,,,BAO_0000357,,Autocuration,,,B,,
191,,,CHEMBL615227,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,,16587,,11862,,,BAO_0000357,,Autocuration,,,B,,
192,Bos taurus,,CHEMBL615228,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,,8058,,12347,,,BAO_0000019,,Expert,,9913.0,F,,
193,Rattus norvegicus,,CHEMBL615229,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,,9065,,100120,,,BAO_0000357,,Expert,,10116.0,B,,
194,Rattus norvegicus,2369.0,CHEMBL615230,Inhibition of 11 beta-hydroxylase from rat adrenal gland,,8865,Adrenal gland,100120,,,BAO_0000357,,Expert,,10116.0,B,,
195,Rattus norvegicus,,CHEMBL615231,Inhibition of rat adrenal 11-beta-hydroxylase,,9066,,100120,,,BAO_0000357,,Expert,,10116.0,B,,
196,Rattus norvegicus,,CHEMBL884520,Inhibition of rat adrenal 11-beta-hydroxylase,,8394,,100120,,,BAO_0000357,,Expert,,10116.0,B,,
197,Rattus norvegicus,,CHEMBL615232,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,,8394,,100120,,,BAO_0000357,,Expert,,10116.0,B,,
198,,,CHEMBL615233,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,,6431,,10328,,,BAO_0000019,,Autocuration,,,B,,
199,,,CHEMBL827088,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,6431,,11490,,,BAO_0000357,,Autocuration,,,B,,
200,,,CHEMBL615234,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,6431,,11490,,,BAO_0000357,,Autocuration,,,B,,
201,,,CHEMBL615235,Compound was tested for the percent of inhibition against 12-LO at 10 uM,,9295,,11134,,,BAO_0000019,,Autocuration,,,F,,
202,,,CHEMBL615236,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,10193,,12052,,,BAO_0000019,,Autocuration,,,B,,
203,,,CHEMBL615237,Compound was tested in vitro for inhibition of 12-LO human platelet,,13622,,11134,,,BAO_0000019,,Autocuration,,,B,,
204,,,CHEMBL615238,Inhibitory concentration against human platelet 12-lipoxygenase,,12079,,11134,,,BAO_0000019,,Autocuration,,,F,,
205,,,CHEMBL615239,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,,13622,,11134,,,BAO_0000019,,Autocuration,,,B,,
206,Homo sapiens,,CHEMBL615240,Inhibitory concentration against human platelet 12-lipoxygenase,,12079,,11134,,,BAO_0000019,,Autocuration,,9606.0,F,,
207,,,CHEMBL615241,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,,13500,,11835,,,BAO_0000019,,Expert,,,B,,
208,,,CHEMBL615242,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,,13723,,11601,,,BAO_0000357,,Expert,,,B,,
209,,,CHEMBL615243,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),,16474,,11134,,,BAO_0000019,,Autocuration,,,B,,
210,,,CHEMBL615244,Inhibitory activity against human platelet 12-lipoxygenase,,1630,,11134,,,BAO_0000019,,Autocuration,,,B,,
211,,,CHEMBL615245,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,,167,,11134,,,BAO_0000019,,Autocuration,,,B,,
212,,,CHEMBL615246,% inhibition against human platelet 12-lipoxygenase (12-HLO),,16474,,11134,,,BAO_0000019,,Autocuration,,,B,,
213,,,CHEMBL615247,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,,167,,11134,,,BAO_0000019,,Autocuration,,,B,,
214,,,CHEMBL615248,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,,16474,,11134,,,BAO_0000019,,Autocuration,,,B,,
215,,,CHEMBL615249,Inhibitory activity towards porcine 12-lipoxygenase,,10091,,11601,,,BAO_0000357,,Autocuration,,,B,,
216,,,CHEMBL615250,Tested for inhibition against porcine 12-LO,,11966,,11601,,,BAO_0000357,,Autocuration,,,B,,
217,,,CHEMBL615251,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,,951,,12052,,,BAO_0000019,,Autocuration,,,B,,
218,,,CHEMBL615252,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,,10997,,12052,,,BAO_0000019,,Autocuration,,,B,,
219,,,CHEMBL828340,In vitro inhibition of rat platelet 12-lipoxygenase,,10193,,12052,,,BAO_0000019,,Expert,,,B,,
220,,,CHEMBL615253,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,10193,,12052,,,BAO_0000019,,Autocuration,,,B,,
221,,,CHEMBL615254,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,,10193,,12052,,,BAO_0000019,,Autocuration,,,B,,
222,,,CHEMBL615255,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,,10193,,12052,,,BAO_0000019,,Autocuration,,,B,,
223,,,CHEMBL615256,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,10193,,12052,,,BAO_0000019,,Autocuration,,,B,,
224,,,CHEMBL615257,In vitro inhibitory activity against rat platelet 12-lipoxygenase,,10193,,12052,,,BAO_0000019,,Autocuration,,,B,,
225,,,CHEMBL615258,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,,11087,,12052,,,BAO_0000019,,Autocuration,,,B,,
226,Homo sapiens,,CHEMBL615259,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,,15569,,80007,,,BAO_0000219,,Intermediate,,9606.0,F,,41M
227,Homo sapiens,,CHEMBL615260,In vitro antitumor activity against 41M cell line.,,12989,,80007,,,BAO_0000219,,Expert,,9606.0,F,,41M
228,Homo sapiens,,CHEMBL615261,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,,16745,,80007,,,BAO_0000219,,Intermediate,,9606.0,F,,41M
229,Homo sapiens,,CHEMBL615262,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,,15569,,80007,,,BAO_0000219,,Intermediate,,9606.0,F,,41M
230,Homo sapiens,,CHEMBL615263,In vitro antitumor activity against 41McisR cell line.,,12989,,80007,,,BAO_0000219,,Expert,,9606.0,F,,41M
231,Homo sapiens,,CHEMBL838393,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,,12989,,80007,,,BAO_0000219,,Expert,,9606.0,F,,41M
232,Homo sapiens,,CHEMBL615264,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,,16745,,80007,,,BAO_0000219,,Intermediate,,9606.0,F,,41M
233,Homo sapiens,,CHEMBL615265,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),,6210,,84,,,BAO_0000357,,Expert,,9606.0,B,,
234,Homo sapiens,,CHEMBL615266,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,6210,,68,,,BAO_0000357,,Expert,,9606.0,B,,
235,,,CHEMBL615267,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,6226,,68,,,BAO_0000357,,Expert,,,B,,
236,,,CHEMBL615268,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,,17855,,10201,,,BAO_0000357,,Expert,,,B,,
237,,,CHEMBL615269,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,,17855,,10201,,,BAO_0000357,,Expert,,,B,,
238,,,CHEMBL615270,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,,17855,,10201,,,BAO_0000357,,Expert,,,B,,
239,,,CHEMBL615271,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,10413,,12220,,,BAO_0000357,,Autocuration,,,B,,
240,Escherichia coli,,CHEMBL615272,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,10413,,11303,,,BAO_0000357,,Autocuration,,562.0,B,,
241,Escherichia coli,,CHEMBL615103,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,10413,,11303,,,BAO_0000357,,Autocuration,,562.0,B,,
242,Escherichia coli,,CHEMBL615104,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",,10413,,11303,,,BAO_0000357,,Autocuration,,562.0,B,,
243,,,CHEMBL615105,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,10413,,12220,,,BAO_0000357,,Autocuration,,,B,,
244,,,CHEMBL872866,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",,10413,,12220,,,BAO_0000357,,Autocuration,,,B,,
245,Sus scrofa,,CHEMBL615106,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,7587,,11303,,,BAO_0000357,,Autocuration,,9823.0,B,,
246,Sus scrofa,,CHEMBL615107,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",,7587,,11303,,,BAO_0000019,,Autocuration,,9823.0,B,,
247,Sus scrofa,,CHEMBL615108,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",,7587,,11303,,,BAO_0000357,,Autocuration,,9823.0,B,,
248,Sus scrofa,,CHEMBL615109,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",,7587,,11303,,,BAO_0000357,,Autocuration,,9823.0,B,,
249,Sus scrofa,,CHEMBL615110,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,7587,,11303,,,BAO_0000357,,Autocuration,,9823.0,B,,
250,Sus scrofa,,CHEMBL840105,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,7587,,11303,,,BAO_0000019,,Autocuration,,9823.0,B,,
251,Sus scrofa,,CHEMBL615111,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",,7587,,11303,,,BAO_0000019,,Autocuration,,9823.0,B,,
252,Sus scrofa,,CHEMBL615112,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",,7587,,11303,,,BAO_0000019,,Autocuration,,9823.0,B,,
253,Sus scrofa,,CHEMBL615113,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",,7587,,11303,,,BAO_0000019,,Autocuration,,9823.0,B,,
254,Sus scrofa,,CHEMBL615114,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",,7587,,11303,,,BAO_0000019,,Autocuration,,9823.0,B,,
255,Sus scrofa,,CHEMBL615115,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,7587,,11303,,,BAO_0000357,,Autocuration,,9823.0,B,,
256,Sus scrofa,,CHEMBL615116,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,7587,,11303,,,BAO_0000019,,Autocuration,,9823.0,B,,
257,,,CHEMBL615698,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",,7323,,11303,,,BAO_0000357,,Autocuration,,,B,,
258,Sus scrofa,,CHEMBL615699,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",,7587,,22226,,,BAO_0000019,,Autocuration,,9823.0,B,,
259,Sus scrofa,,CHEMBL615700,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",,7587,,22226,,,BAO_0000019,,Autocuration,,9823.0,B,,
260,Saccharomyces cerevisiae,,CHEMBL615701,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,,13750,,100249,,,BAO_0000357,,Expert,,4932.0,B,,
261,Rattus norvegicus,,CHEMBL615702,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,7662,,22226,,,BAO_0000019,,Autocuration,,10116.0,B,,
262,Rattus norvegicus,,CHEMBL615703,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,7662,,22226,,,BAO_0000019,,Autocuration,,10116.0,B,,
263,Rattus norvegicus,,CHEMBL615704,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",,7662,,22226,,,BAO_0000019,,Autocuration,,10116.0,B,,
264,,,CHEMBL615705,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,12211,,104698,,,BAO_0000019,,Autocuration,,,F,,
265,,,CHEMBL615706,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,12211,,104698,,,BAO_0000019,,Autocuration,,,F,,
266,Cavia porcellus,2116.0,CHEMBL615707,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,,12211,Ileum,20033,,,BAO_0000221,,Intermediate,,10141.0,F,,
267,,,CHEMBL615708,Stimulatory activity of intragastric pressure was tested in the rat,,12211,,10623,,,BAO_0000019,,Expert,,,F,,
268,,,CHEMBL615709,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,,15453,,121,,,BAO_0000357,,Autocuration,,,B,,
269,Rattus norvegicus,,CHEMBL615710,Dose to reduce neuronal firing against 5-HT cells in rats (iv),,11884,,22226,,,BAO_0000218,,Autocuration,,10116.0,F,,
270,,,CHEMBL615711,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,7185,,12688,,,BAO_0000019,,Autocuration,,,F,,
271,Homo sapiens,,CHEMBL615712,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,,6876,,121,,,BAO_0000357,,Expert,,9606.0,B,,
272,Homo sapiens,,CHEMBL836325,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,,6876,,121,,,BAO_0000357,,Expert,,9606.0,B,,
273,,,CHEMBL615713,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,,11863,,12198,,,BAO_0000019,,Autocuration,,,F,,
274,,,CHEMBL615714,Inhibition constant of high-affinity 5-HT uptake,,11863,,12198,,,BAO_0000357,,Autocuration,,,B,,
275,,,CHEMBL615715,Michaelis-Menten constant was reported for high affinity transport of 5-HT,,11863,,12198,,,BAO_0000019,,Autocuration,,,F,,
276,,,CHEMBL615716,Maximum rate was determined for high affinity transport of 5-HT,,11863,,12198,,,BAO_0000019,,Autocuration,,,F,,
277,,,CHEMBL615717,Compound was tested for agonistic activity against 5-HT uptake,,4639,,104714,,,BAO_0000019,,Autocuration,,,F,,
278,,,CHEMBL881818,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,,15796,,10577,,,BAO_0000019,,Expert,,,B,,
279,Bos taurus,,CHEMBL884540,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,,15796,,105,,,BAO_0000357,,Expert,,9913.0,B,,
280,Rattus norvegicus,,CHEMBL615718,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,12801,,104744,,,BAO_0000224,,Autocuration,,10116.0,B,,
281,,,CHEMBL615719,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,,12801,,104744,,,BAO_0000224,,Autocuration,,,B,,
282,,,CHEMBL615720,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,,12120,,104744,,,BAO_0000249,,Autocuration,Membranes,,B,,
283,,,CHEMBL615721,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,,12120,,104744,,,BAO_0000249,,Autocuration,Membranes,,B,,
284,,,CHEMBL615722,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,11963,,104744,,,BAO_0000019,,Autocuration,,,B,,
285,,,CHEMBL615723,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,,11701,,51,,,BAO_0000019,,Autocuration,,,F,,
286,,10000000.0,CHEMBL615724,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,9995,Hippocampus,51,,,BAO_0000221,,Autocuration,,,B,,
287,,10000000.0,CHEMBL615725,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,9995,Hippocampus,51,,,BAO_0000221,,Autocuration,,,B,,
288,,10000000.0,CHEMBL615726,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,9995,Hippocampus,51,,,BAO_0000221,,Autocuration,,,B,,
289,,,CHEMBL615727,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),In vivo,16394,,10576,,,BAO_0000218,,Autocuration,,,F,,
290,Cavia porcellus,,CHEMBL615728,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,,11574,,105570,,,BAO_0000019,,Intermediate,,10141.0,F,,
291,,,CHEMBL857971,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,15779,,279,,,BAO_0000219,,Autocuration,,,B,,CHO
292,,,CHEMBL615729,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,,15363,,107,,,BAO_0000357,,Autocuration,,,B,,
293,Rattus norvegicus,,CHEMBL615730,Efficacy against 5-hydroxytryptamine 2A receptor,,15363,,12687,,,BAO_0000019,,Expert,,10116.0,F,,
294,,,CHEMBL615731,Intrinsic activity towards 5-HT2A receptor of rat tail artery,,15329,,12687,,,BAO_0000019,,Expert,,,F,,
295,,,CHEMBL615732,Relative potency towards 5-HT2A receptor of rat tail artery,,15329,,12687,,,BAO_0000019,,Expert,,,F,,
296,,,CHEMBL615733,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,,15329,,12687,,,BAO_0000019,,Expert,,,F,,
297,,,CHEMBL615734,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,,15329,,12687,,,BAO_0000019,,Expert,,,F,,
298,,,CHEMBL615735,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,,15329,,12687,,,BAO_0000019,,Autocuration,,,F,,
299,,,CHEMBL615736,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,,15329,,12687,,,BAO_0000019,,Expert,,,F,,
300,Cavia porcellus,2116.0,CHEMBL615737,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,273,Ileum,20033,,,BAO_0000221,,Intermediate,,10141.0,F,,
301,Cavia porcellus,2116.0,CHEMBL615738,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),,273,Ileum,20033,,,BAO_0000221,,Intermediate,,10141.0,F,,
302,Cavia porcellus,2116.0,CHEMBL615739,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,273,Ileum,20033,,,BAO_0000221,,Intermediate,,10141.0,F,,
303,,,CHEMBL615278,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,,12092,,10623,,,BAO_0000357,,Autocuration,,,B,,
304,Rattus norvegicus,,CHEMBL615279,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,1317,,10623,,,BAO_0000019,,Expert,,10116.0,F,,
305,,,CHEMBL615280,Binding affinity against 5-hydroxytryptamine 4 receptor,,12409,,168,,,BAO_0000357,,Expert,,,B,,
306,Gallus gallus,,CHEMBL615281,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,,11126,,22226,,,BAO_0000019,,Autocuration,,9031.0,B,,
307,Homo sapiens,,CHEMBL615282,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,,11126,,22226,,,BAO_0000019,,Autocuration,,9606.0,F,,
308,Homo sapiens,,CHEMBL615283,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,,11126,,22226,,,BAO_0000019,,Autocuration,,9606.0,F,,
309,Homo sapiens,,CHEMBL615284,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,,11126,,80156,,,BAO_0000219,,Autocuration,,9606.0,B,,HL-60
310,Homo sapiens,,CHEMBL615285,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,,11126,,22226,,,BAO_0000019,,Autocuration,,9606.0,B,,
311,Homo sapiens,,CHEMBL615286,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,,11126,,22226,,,BAO_0000019,,Autocuration,,9606.0,B,,
312,Homo sapiens,,CHEMBL615287,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,,17807,,104703,,,BAO_0000219,,Autocuration,,9606.0,B,,Oocytes
313,,,CHEMBL615288,Chymotryptic inhibitory activity against 26S proteasome,,16575,,100256,,,BAO_0000220,,Intermediate,,,F,,
314,,,CHEMBL615289,Inhibitory activity against 26S proteasome degradation of IkB,,15407,,100256,,,BAO_0000220,,Intermediate,,,B,,
315,Homo sapiens,,CHEMBL615290,In vitro inhibition of 2780/DOX ovarian cancer cell line,,10797,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
316,Homo sapiens,,CHEMBL884522,In vitro inhibition of 2780/S ovarian cancer cell line,,10797,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
317,Homo sapiens,,CHEMBL615291,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,,3469,,22226,,,BAO_0000019,,Autocuration,,9606.0,F,,
318,,,CHEMBL615292,Association constant for binding to AATT 28-mer AATT hairpin,,16037,,22222,,,BAO_0000225,,Intermediate,,,B,,
319,,,CHEMBL615293,Kinetically Defined Association Constant for 28-mer AATT hairpin.,,16037,,22222,,,BAO_0000225,,Intermediate,,,B,,
320,,,CHEMBL615294,Reaction Rate Parameter for 28-mer AATT hairpin,,16037,,22222,,,BAO_0000225,,Intermediate,,,B,,
321,,,CHEMBL615295,Reaction Rate Parameter for 28-mer AATT hairpin,,16037,,22222,,,BAO_0000225,,Intermediate,,,B,,
322,Homo sapiens,,CHEMBL825021,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),,16524,,22226,,,BAO_0000019,,Autocuration,,9606.0,F,,
323,Homo sapiens,,CHEMBL615296,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),,16524,,22226,,,BAO_0000019,,Autocuration,,9606.0,F,,
324,Homo sapiens,,CHEMBL615297,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,,16524,,22226,,,BAO_0000019,,Autocuration,,9606.0,F,,
325,Cricetulus griseus,,CHEMBL615298,Cytotoxicity against cell line 2SC/20 determined by MTT test,,16758,,22226,,,BAO_0000019,,Autocuration,,10029.0,F,,
326,Cricetulus griseus,,CHEMBL615299,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,,16758,,22226,,,BAO_0000019,,Autocuration,,10029.0,F,,
327,Cricetulus griseus,,CHEMBL615300,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,,16758,,22226,,,BAO_0000019,,Autocuration,,10029.0,F,,
328,,,CHEMBL615301,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,,14360,,241,,,BAO_0000357,,Autocuration,,,B,,
329,Homo sapiens,,CHEMBL615302,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,,14360,,241,,,BAO_0000357,,Expert,,9606.0,B,,
330,Rattus norvegicus,,CHEMBL615303,Selectivity ratio of ID50 in liver and heart,,9964,,22226,,,BAO_0000019,,Autocuration,,10116.0,B,,
331,,,CHEMBL615304,"Selectivity, ratio of relative ID50 in liver and heart",,9964,,12132,,,BAO_0000019,,Autocuration,,,B,,
332,,,CHEMBL615305,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,,9964,,12132,,,BAO_0000019,,Autocuration,,,B,,
333,,,CHEMBL615306,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,9964,,12132,,,BAO_0000218,,Autocuration,,,B,,
334,,,CHEMBL615307,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,9964,,12132,,,BAO_0000218,,Autocuration,,,B,,
335,,,CHEMBL615308,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",In vivo,9964,,12132,,,BAO_0000218,,Autocuration,,,B,,
336,,,CHEMBL615309,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",In vivo,9964,,12132,,,BAO_0000218,,Autocuration,,,F,,
337,,,CHEMBL615310,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",,9964,,22226,,,BAO_0000019,,Autocuration,,,B,,
338,,,CHEMBL615311,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,,9964,,12132,,,BAO_0000019,,Autocuration,,,B,,
339,Homo sapiens,,CHEMBL615312,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",,9964,,22226,,,BAO_0000019,,Autocuration,,9606.0,B,,
340,,,CHEMBL615313,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,9964,,12132,,,BAO_0000019,,Autocuration,,,B,,
341,,,CHEMBL615314,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,9964,,12132,,,BAO_0000019,,Autocuration,,,F,,
342,,,CHEMBL615315,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",,9964,,12132,,,BAO_0000019,,Autocuration,,,B,,
343,Rattus norvegicus,,CHEMBL615316,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",,9964,,22226,,,BAO_0000218,,Autocuration,,10116.0,B,,
344,,,CHEMBL615317,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,In vivo,9964,,12132,,,BAO_0000218,,Autocuration,,,B,,
345,,,CHEMBL615318,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,9964,,12132,,,BAO_0000218,,Autocuration,,,B,,
346,Rattus norvegicus,,CHEMBL615319,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",,9964,,22226,,,BAO_0000218,,Autocuration,,10116.0,B,,
347,,,CHEMBL615320,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,9964,,12132,,,BAO_0000019,,Autocuration,,,B,,
348,,,CHEMBL615321,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,9964,,12132,,,BAO_0000019,,Autocuration,,,F,,
349,Rattus norvegicus,,CHEMBL615322,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",,3796,,22226,,,BAO_0000019,,Autocuration,,10116.0,B,,
350,Escherichia coli,,CHEMBL615323,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,4251,,19690,,,BAO_0000357,,Autocuration,,562.0,B,,
351,Escherichia coli,,CHEMBL615407,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,4251,,19690,,,BAO_0000357,,Autocuration,,562.0,B,,
352,Escherichia coli,,CHEMBL857267,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,4251,,19690,,,BAO_0000357,,Autocuration,,562.0,B,,
353,Escherichia coli,,CHEMBL615408,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,4251,,19690,,,BAO_0000357,,Autocuration,,562.0,B,,
354,,,CHEMBL615409,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,,166,,19690,,,BAO_0000357,,Autocuration,,,B,,
355,,,CHEMBL615410,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,,17861,,19690,,,BAO_0000357,,Autocuration,,,B,,
356,,,CHEMBL615411,Inhibition constant against 3-dehydroquinate synthase,,166,,19690,,,BAO_0000357,,Autocuration,,,B,,
357,,,CHEMBL615412,Association rate constant against 3-dehydroquinate synthase,,166,,19690,,,BAO_0000357,,Autocuration,,,B,,
358,,,CHEMBL615413,Rate constant against 3-dehydroquinate synthase,,166,,19690,,,BAO_0000357,,Autocuration,,,B,,
359,,,CHEMBL615414,Inhibitory activity against fuc-TVII,,3548,,22226,,,BAO_0000019,,Autocuration,,,B,,
360,Rattus norvegicus,2107.0,CHEMBL615415,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,9877,Liver,12236,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
361,Rattus norvegicus,2107.0,CHEMBL615416,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,9877,Liver,12236,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
362,Rattus norvegicus,2107.0,CHEMBL615417,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,9877,Liver,12236,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
363,Rattus norvegicus,2107.0,CHEMBL615418,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,9877,Liver,12236,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
364,Rattus norvegicus,2107.0,CHEMBL615419,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,9877,Liver,12236,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
365,Rattus norvegicus,2107.0,CHEMBL615420,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,,9877,Liver,12236,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
366,Rattus norvegicus,2107.0,CHEMBL615421,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,,9877,Liver,12236,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
367,Rattus norvegicus,2107.0,CHEMBL615422,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,,9877,Liver,12236,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
368,Rattus norvegicus,2107.0,CHEMBL615423,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,,9877,Liver,12236,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
369,Rattus norvegicus,2107.0,CHEMBL872868,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,,9877,Liver,12236,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
370,Rattus norvegicus,2107.0,CHEMBL615424,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,,9877,Liver,12236,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
371,,,CHEMBL825022,Inhibitory activity against 3-phosphoglycerate kinase.,,3003,,104832,,,BAO_0000224,,Autocuration,,,B,,
372,,,CHEMBL615425,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,,3003,,104832,,,BAO_0000224,,Autocuration,,,B,,
373,,,CHEMBL615426,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",,3003,,104832,,,BAO_0000224,,Autocuration,,,B,,
374,Homo sapiens,,CHEMBL615427,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,,17185,,10612,,,BAO_0000357,,Expert,,9606.0,B,,
375,Homo sapiens,,CHEMBL615428,Cytotoxicity on 3677 melanoma cells,,6072,,80616,,,BAO_0000219,,Intermediate,,9606.0,F,,3677 melanoma cell line
376,Homo sapiens,,CHEMBL615429,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,,6072,,80616,,,BAO_0000219,,Intermediate,,9606.0,F,,3677 melanoma cell line
377,Mus musculus,,CHEMBL615430,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,,5018,,80617,,,BAO_0000219,,Intermediate,,10090.0,F,,MC-38
378,Homo sapiens,,CHEMBL615431,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,,2852,,22226,,,BAO_0000019,,Intermediate,,9606.0,F,,
379,,,CHEMBL615432,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,,8663,,22226,,,BAO_0000218,,Autocuration,,,F,,B16
380,,,CHEMBL615433,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,,8663,,22226,,,BAO_0000218,,Autocuration,,,F,,B16
381,Human rhinovirus 14,,CHEMBL615434,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,,3245,,12464,,,BAO_0000019,,Expert,,12131.0,F,,
382,Human rhinovirus sp.,,CHEMBL615435,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,,3245,,50085,,,BAO_0000218,,Intermediate,,169066.0,F,,
383,human rhinovirus type 14,,CHEMBL615436,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,,3877,,50679,,,BAO_0000218,,Intermediate,,169066.0,F,,
384,human rhinovirus type 14,,CHEMBL615437,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,,3877,,50679,,,BAO_0000218,,Intermediate,,169066.0,F,,
385,Human rhinovirus 14,,CHEMBL615438,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,5861,,12464,,,BAO_0000019,,Expert,,12131.0,F,,
386,Human rhinovirus 14,,CHEMBL615439,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,5861,,12464,,,BAO_0000019,,Expert,,12131.0,F,,
387,Human rhinovirus 14,,CHEMBL615440,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,5861,,12464,,,BAO_0000019,,Expert,,12131.0,F,,
388,Human rhinovirus 14,,CHEMBL615441,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,,5861,,12464,,,BAO_0000019,,Expert,,12131.0,F,,
389,Enterovirus,,CHEMBL615641,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,,13748,,50665,,,BAO_0000218,,Intermediate,,12059.0,F,,
390,Enterovirus,,CHEMBL872065,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,,13748,,50665,,,BAO_0000218,,Intermediate,,12059.0,F,,
391,Enterovirus,,CHEMBL825023,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,,13748,,50665,,,BAO_0000218,,Intermediate,,12059.0,F,,
392,Enterovirus,,CHEMBL615642,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,,13748,,50665,,,BAO_0000218,,Intermediate,,12059.0,F,,
393,Human rhinovirus B,,CHEMBL615643,Inhibition of human rhinovirus 3C protease,,13748,,12464,,,BAO_0000357,,Expert,,147712.0,B,,
394,Homo sapiens,,CHEMBL615644,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,,17699,,22226,,,BAO_0000019,,Autocuration,,9606.0,B,,
395,Mus musculus,,CHEMBL615645,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),,7145,,80619,,,BAO_0000218,,Intermediate,,10090.0,F,,3EM 37
396,Mus musculus,,CHEMBL615646,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),,7145,,80619,,,BAO_0000218,,Intermediate,,10090.0,F,,3EM 37
397,Mus musculus,,CHEMBL615647,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),,7145,,80619,,,BAO_0000218,,Intermediate,,10090.0,F,,3EM 37
398,Mus musculus,,CHEMBL615648,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),,7145,,80619,,,BAO_0000218,,Intermediate,,10090.0,F,,3EM 37
399,Mus musculus,,CHEMBL615649,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,,7145,,80619,,,BAO_0000218,,Intermediate,,10090.0,F,,3EM 37
400,Mus musculus,,CHEMBL615650,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,,7145,,80619,,,BAO_0000218,,Intermediate,,10090.0,F,,3EM 37
401,Mus musculus,,CHEMBL615651,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,5325,,80620,,,BAO_0000218,,Intermediate,,10090.0,F,,3LL cell line
402,Mus musculus,,CHEMBL615652,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,5325,,80620,,,BAO_0000218,,Intermediate,,10090.0,F,,3LL cell line
403,Mus musculus,,CHEMBL615653,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,,5325,,80620,,,BAO_0000218,,Expert,,10090.0,F,,3LL cell line
404,Mus musculus,,CHEMBL615654,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,,16169,,80620,,,BAO_0000219,,Intermediate,,10090.0,F,,3LL cell line
405,Mus musculus,,CHEMBL615655,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,,16169,,80620,,,BAO_0000219,,Intermediate,,10090.0,F,,3LL cell line
406,Mus musculus,,CHEMBL825024,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,,16169,,80620,,,BAO_0000219,,Intermediate,,10090.0,F,,3LL cell line
407,Mus musculus,,CHEMBL615656,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,,16169,,80620,,,BAO_0000219,,Intermediate,,10090.0,F,,3LL cell line
408,Mus musculus,,CHEMBL615657,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,,16169,,80620,,,BAO_0000219,,Intermediate,,10090.0,F,,3LL cell line
409,Mus musculus,,CHEMBL615658,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,,16169,,80620,,,BAO_0000219,,Intermediate,,10090.0,F,,3LL cell line
410,Mus musculus,,CHEMBL615659,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,,16169,,80620,,,BAO_0000219,,Intermediate,,10090.0,F,,3LL cell line
411,Mus musculus,,CHEMBL615660,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,,16169,,80620,,,BAO_0000219,,Intermediate,,10090.0,F,,3LL cell line
412,Mus musculus,,CHEMBL615661,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,16169,,80620,,,BAO_0000219,,Intermediate,,10090.0,F,,3LL cell line
413,Mus musculus,,CHEMBL615662,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,,16169,,80620,,,BAO_0000219,,Intermediate,,10090.0,F,,3LL cell line
414,Mus musculus,,CHEMBL615663,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,,16169,,80620,,,BAO_0000219,,Intermediate,,10090.0,F,,3LL cell line
415,Mus musculus,,CHEMBL615664,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,,16169,,80620,,,BAO_0000219,,Intermediate,,10090.0,F,,3LL cell line
416,Mus musculus,,CHEMBL615665,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,,16169,,80620,,,BAO_0000219,,Intermediate,,10090.0,F,,3LL cell line
417,Mus musculus,,CHEMBL615666,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,16169,,80620,,,BAO_0000219,,Intermediate,,10090.0,F,,3LL cell line
418,Mus musculus,,CHEMBL615667,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,,16169,,80620,,,BAO_0000219,,Intermediate,,10090.0,F,,3LL cell line
419,Mus musculus,,CHEMBL615668,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,,16169,,80620,,,BAO_0000219,,Intermediate,,10090.0,F,,3LL cell line
420,Mus musculus,,CHEMBL615669,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,,16169,,80620,,,BAO_0000219,,Intermediate,,10090.0,F,,3LL cell line
421,Mus musculus,,CHEMBL615670,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,,16169,,80620,,,BAO_0000219,,Intermediate,,10090.0,F,,3LL cell line
422,Mus musculus,,CHEMBL836739,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,,16169,,80620,,,BAO_0000219,,Intermediate,,10090.0,F,,3LL cell line
423,Mus musculus,,CHEMBL615671,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,,16169,,80620,,,BAO_0000219,,Intermediate,,10090.0,F,,3LL cell line
424,Mus musculus,,CHEMBL615672,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,,16169,,80620,,,BAO_0000219,,Intermediate,,10090.0,F,,3LL cell line
425,Mus musculus,,CHEMBL615791,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,,16169,,80620,,,BAO_0000219,,Intermediate,,10090.0,F,,3LL cell line
426,Mus musculus,,CHEMBL615792,spermine levels in 3LL cells after the treatment of 1 uM of Compound,,16169,,80620,,,BAO_0000219,,Intermediate,,10090.0,F,,3LL cell line
427,Mus musculus,,CHEMBL615793,spermine levels in 3LL cells after the treatment of 10 uM of Compound,,16169,,80620,,,BAO_0000219,,Intermediate,,10090.0,F,,3LL cell line
428,Mus musculus,,CHEMBL615794,spermine levels in 3LL cells after the treatment of 250 uM of Compound,,16169,,80620,,,BAO_0000219,,Intermediate,,10090.0,F,,3LL cell line
429,Mus musculus,,CHEMBL615795,spermine levels in 3LL cells after the treatment of 50 uM of Compound,,16169,,80620,,,BAO_0000219,,Intermediate,,10090.0,F,,3LL cell line
430,Homo sapiens,,CHEMBL615590,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,,15547,,80621,,,BAO_0000219,,Intermediate,,9606.0,F,,3LLD122
431,,,CHEMBL615591,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,,8663,,22226,,,BAO_0000218,,Autocuration,,,F,,
432,,,CHEMBL615592,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,,8663,,22226,,,BAO_0000218,,Autocuration,,,F,,
433,,,CHEMBL615593,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,,8663,,22226,,,BAO_0000218,,Autocuration,,,F,,
434,,,CHEMBL615594,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,,8663,,22226,,,BAO_0000218,,Autocuration,,,F,,
435,Mus musculus,,CHEMBL615595,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,4504,,80951,,,BAO_0000219,,Intermediate,,10090.0,F,,NIH3T3
436,Mus musculus,,CHEMBL615596,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,4504,,80951,,,BAO_0000219,,Intermediate,,10090.0,F,,NIH3T3
437,,,CHEMBL615597,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,,12695,,11169,,,BAO_0000219,,Expert,,,F,,NIH3T3
438,Mus musculus,,CHEMBL615598,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,,12695,,80951,,,BAO_0000219,,Intermediate,,10090.0,F,,NIH3T3
439,Mus musculus,,CHEMBL615599,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,,12695,,80951,,,BAO_0000219,,Intermediate,,10090.0,F,,NIH3T3
440,Mus musculus,,CHEMBL615600,Effective dose against murine 3T3 fibroblasts cells,,17642,,80951,,,BAO_0000219,,Expert,,10090.0,F,,NIH3T3
441,Mus musculus,,CHEMBL615601,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,,17642,,80951,,,BAO_0000219,,Expert,,10090.0,F,,NIH3T3
442,Mus musculus,,CHEMBL615602,Cytotoxic effect on 3T3 cells,,12340,,80951,,,BAO_0000219,,Expert,,10090.0,F,,NIH3T3
443,Mus musculus,,CHEMBL615603,Cytotoxic effect on 3T3 cells,,12340,,80951,,,BAO_0000219,,Expert,,10090.0,F,,NIH3T3
444,Mus musculus,,CHEMBL615604,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,,12716,,80951,,,BAO_0000219,,Intermediate,,10090.0,F,,NIH3T3
445,Mus musculus,,CHEMBL615605,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,6277,,80951,,,BAO_0000219,,Intermediate,,10090.0,F,,NIH3T3
446,Mus musculus,,CHEMBL615606,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,,6277,,80951,,,BAO_0000219,,Intermediate,,10090.0,F,,NIH3T3
447,Mus musculus,,CHEMBL884526,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,,6277,,80951,,,BAO_0000219,,Expert,,10090.0,F,,NIH3T3
448,Mus musculus,,CHEMBL615607,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,,6277,,80951,,,BAO_0000219,,Expert,,10090.0,F,,NIH3T3
449,Mus musculus,,CHEMBL615608,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,,6277,,80951,,,BAO_0000219,,Intermediate,,10090.0,F,,NIH3T3
450,Mus musculus,,CHEMBL615609,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,,6277,,80951,,,BAO_0000219,,Expert,,10090.0,F,,NIH3T3
451,Mus musculus,,CHEMBL615682,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,,6277,,80951,,,BAO_0000219,,Expert,,10090.0,F,,NIH3T3
452,Mus musculus,,CHEMBL615683,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,,6277,,80951,,,BAO_0000219,,Intermediate,,10090.0,F,,NIH3T3
453,Mus musculus,,CHEMBL615684,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,,17780,,80951,,,BAO_0000218,,Expert,,10090.0,F,,NIH3T3
454,Mus musculus,,CHEMBL615685,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,,12751,,104860,,,BAO_0000219,,Autocuration,,10090.0,F,,
455,Mus musculus,,CHEMBL615686,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,,12380,,80951,,,BAO_0000219,,Expert,,10090.0,F,,NIH3T3
456,Mus musculus,,CHEMBL615687,Inhibitory activity against 3T3 cell line,,14892,,80951,,,BAO_0000219,,Intermediate,,10090.0,F,,NIH3T3
457,Mus musculus,,CHEMBL884523,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,,12695,,80951,,,BAO_0000219,,Intermediate,,10090.0,F,,NIH3T3
458,,,CHEMBL615688,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,,12695,,11169,,,BAO_0000019,,Expert,,,F,,
459,Mus musculus,,CHEMBL615689,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,,12695,,80951,,,BAO_0000219,,Intermediate,,10090.0,F,,NIH3T3
460,Mus musculus,,CHEMBL615690,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,,12695,,80951,,,BAO_0000219,,Intermediate,,10090.0,F,,NIH3T3
461,,,CHEMBL615691,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,,12695,,11169,,,BAO_0000019,,Expert,,,F,,
462,,,CHEMBL615692,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,,12695,,11169,,,BAO_0000019,,Expert,,,F,,
463,Mus musculus,,CHEMBL615693,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,6277,,80951,,,BAO_0000219,,Intermediate,,10090.0,F,,NIH3T3
464,Mus musculus,,CHEMBL615324,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,,6277,,80951,,,BAO_0000219,,Expert,,10090.0,F,,NIH3T3
465,Homo sapiens,,CHEMBL615325,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,,4959,,9,,,BAO_0000219,,Expert,,9606.0,F,,NIH3T3
466,Homo sapiens,,CHEMBL615490,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),,4959,,9,,,BAO_0000219,,Expert,,9606.0,F,,NIH3T3
467,Homo sapiens,,CHEMBL615491,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,,4959,,188,,,BAO_0000219,,Expert,,9606.0,F,,NIH3T3
468,Homo sapiens,,CHEMBL615492,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),,4959,,188,,,BAO_0000219,,Expert,,9606.0,F,,NIH3T3
469,Mus musculus,,CHEMBL615493,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,,12082,,80951,,,BAO_0000219,,Intermediate,,10090.0,F,,NIH3T3
470,Mus musculus,,CHEMBL615494,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,,12082,,80951,,,BAO_0000219,,Intermediate,,10090.0,F,,NIH3T3
471,Mus musculus,,CHEMBL615495,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,,12082,,80951,,,BAO_0000219,,Intermediate,,10090.0,F,,NIH3T3
472,Mus musculus,,CHEMBL615496,Inhibitory concentration was calculated on 3T3 cells by using growth assay,,12082,,80951,,,BAO_0000219,,Intermediate,,10090.0,F,,NIH3T3
473,Mus musculus,,CHEMBL615497,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,,2643,,80951,,,BAO_0000219,,Intermediate,,10090.0,F,,NIH3T3
474,Mus musculus,,CHEMBL615498,Inhibition of Swiss 3T3 mouse fibroblast proliferation,,11926,,80951,,,BAO_0000219,,Expert,,10090.0,F,,NIH3T3
475,Mus musculus,,CHEMBL615499,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,,15204,,80951,,,BAO_0000219,,Intermediate,,10090.0,A,,NIH3T3
476,Mus musculus,,CHEMBL835522,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,,15992,,80951,,,BAO_0000219,,Expert,,10090.0,F,,NIH3T3
477,Mus musculus,,CHEMBL615500,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,,16279,,80951,,,BAO_0000219,,Intermediate,,10090.0,F,,NIH3T3
478,Mus musculus,,CHEMBL615501,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,16279,,80951,,,BAO_0000219,,Intermediate,,10090.0,F,,NIH3T3
479,Mus musculus,,CHEMBL615502,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,16279,,80951,,,BAO_0000219,,Intermediate,,10090.0,F,,NIH3T3
480,Mus musculus,,CHEMBL615503,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,16279,,80951,,,BAO_0000219,,Intermediate,,10090.0,F,,NIH3T3
481,Mus musculus,,CHEMBL615504,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,16279,,80951,,,BAO_0000219,,Intermediate,,10090.0,F,,NIH3T3
482,Mus musculus,,CHEMBL615505,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,16279,,80951,,,BAO_0000219,,Intermediate,,10090.0,F,,NIH3T3
483,Mus musculus,,CHEMBL615506,Inhibition of swiss 3T3 mouse fibroblast proliferation,,12831,,80951,,,BAO_0000219,,Expert,,10090.0,F,,NIH3T3
484,Mus musculus,,CHEMBL615507,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,,13497,,80951,,,BAO_0000219,,Intermediate,,10090.0,F,,NIH3T3
485,,,CHEMBL615508,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,13715,,80006,,,BAO_0000218,,Intermediate,,,F,,3T3-L1
486,Mus musculus,,CHEMBL615509,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,,13618,,80006,,,BAO_0000219,,Intermediate,,10090.0,F,,3T3-L1
487,Mus musculus,,CHEMBL615510,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,,11902,,80006,,,BAO_0000219,,Intermediate,,10090.0,F,,3T3-L1
488,Mus musculus,,CHEMBL615511,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,,11902,,80006,,,BAO_0000219,,Intermediate,,10090.0,F,,3T3-L1
489,Mus musculus,,CHEMBL615512,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,,11902,,80006,,,BAO_0000219,,Intermediate,,10090.0,F,,3T3-L1
490,Mus musculus,,CHEMBL615513,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",,14840,,80006,,,BAO_0000218,,Intermediate,,10090.0,F,,3T3-L1
491,Mus musculus,,CHEMBL615514,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",,14840,,80006,,,BAO_0000218,,Intermediate,,10090.0,F,,3T3-L1
492,,,CHEMBL615515,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,,13715,,80006,,,BAO_0000219,,Intermediate,,,F,,3T3-L1
493,,,CHEMBL615516,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,13715,,80006,,,BAO_0000219,,Intermediate,,,F,,3T3-L1
494,,,CHEMBL615517,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,13715,,80006,,,BAO_0000219,,Intermediate,,,F,,3T3-L1
495,,,CHEMBL615518,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,13715,,80006,,,BAO_0000219,,Intermediate,,,F,,3T3-L1
496,,,CHEMBL615519,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,13715,,80006,,,BAO_0000219,,Intermediate,,,F,,3T3-L1
497,,,CHEMBL615520,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,,13715,,80006,,,BAO_0000218,,Intermediate,,,F,,3T3-L1
498,,,CHEMBL615521,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,,13715,,80006,,,BAO_0000218,,Intermediate,,,F,,3T3-L1
499,,,CHEMBL615522,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,13715,,80006,,,BAO_0000218,,Intermediate,,,F,,3T3-L1
500,,,CHEMBL615523,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,13715,,80006,,,BAO_0000218,,Intermediate,,,F,,3T3-L1
501,,,CHEMBL615524,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,13715,,80006,,,BAO_0000218,,Expert,,,F,,3T3-L1
502,,,CHEMBL615525,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,13715,,80006,,,BAO_0000218,,Expert,,,F,,3T3-L1
503,,,CHEMBL615526,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,13715,,80006,,,BAO_0000218,,Intermediate,,,F,,3T3-L1
504,,,CHEMBL615527,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,13715,,80006,,,BAO_0000218,,Intermediate,,,F,,3T3-L1
505,,,CHEMBL615528,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,,13715,,80006,,,BAO_0000218,,Intermediate,,,F,,3T3-L1
506,,,CHEMBL615529,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,13715,,80006,,,BAO_0000218,,Expert,,,F,,3T3-L1
507,,,CHEMBL615530,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,13715,,80006,,,BAO_0000218,,Expert,,,F,,3T3-L1
508,,,CHEMBL615531,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,13715,,80006,,,BAO_0000218,,Expert,,,F,,3T3-L1
509,,,CHEMBL615532,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,13715,,80006,,,BAO_0000219,,Intermediate,,,F,,3T3-L1
510,,,CHEMBL615533,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,13715,,80006,,,BAO_0000219,,Intermediate,,,F,,3T3-L1
511,,,CHEMBL615534,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,13715,,80006,,,BAO_0000219,,Intermediate,,,F,,3T3-L1
512,,,CHEMBL615535,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,13715,,80006,,,BAO_0000218,,Intermediate,,,F,,3T3-L1
513,,,CHEMBL615536,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,13715,,80006,,,BAO_0000218,,Intermediate,,,F,,3T3-L1
514,,,CHEMBL615537,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,13715,,80006,,,BAO_0000218,,Intermediate,,,F,,3T3-L1
515,,,CHEMBL615538,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,13715,,80006,,,BAO_0000218,,Intermediate,,,F,,3T3-L1
516,,,CHEMBL836166,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,13715,,80006,,,BAO_0000218,,Intermediate,,,F,,3T3-L1
517,,,CHEMBL615539,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,,6411,,11214,,,BAO_0000219,,Expert,,,F,,3T3-L1
518,Mus musculus,,CHEMBL615540,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,,6411,,80006,,,BAO_0000219,,Intermediate,,10090.0,F,,3T3-L1
519,,,CHEMBL615541,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,,6411,,11214,,,BAO_0000219,,Expert,,,F,,3T3-L1
520,Mus musculus,,CHEMBL615542,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,,3966,,80006,,,BAO_0000219,,Expert,,10090.0,F,,3T3-L1
521,Mus musculus,,CHEMBL615543,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,,3966,,80006,,,BAO_0000219,,Intermediate,,10090.0,F,,3T3-L1
522,Mus musculus,,CHEMBL615544,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,,15556,,80006,,,BAO_0000219,,Expert,,10090.0,F,,3T3-L1
523,Mus musculus,,CHEMBL615545,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,5845,,80006,,,BAO_0000219,,Expert,,10090.0,F,,3T3-L1
524,Mus musculus,,CHEMBL615546,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,14422,,80006,,,BAO_0000219,,Expert,,10090.0,F,,3T3-L1
525,Mus musculus,,CHEMBL615547,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,,5845,,80006,,,BAO_0000219,,Expert,,10090.0,F,,3T3-L1
526,Mus musculus,,CHEMBL615548,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,,14508,,80006,,,BAO_0000219,,Expert,,10090.0,F,,3T3-L1
527,Mus musculus,,CHEMBL615549,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,,14508,,80006,,,BAO_0000219,,Expert,,10090.0,F,,3T3-L1
528,Mus musculus,,CHEMBL615550,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,,14508,,80006,,,BAO_0000219,,Expert,,10090.0,F,,3T3-L1
529,Rattus norvegicus,,CHEMBL615551,Inhibitory activity against rat fibroblast (3Y1) cell line,,6349,,80622,,,BAO_0000219,,Intermediate,,10116.0,F,,3Y1 cell line
530,Rattus norvegicus,,CHEMBL615552,Mean concentration causing inhibition of cell growth in 3Y1 cells.,,15899,,80622,,,BAO_0000219,,Expert,,10116.0,F,,3Y1 cell line
531,Rattus norvegicus,,CHEMBL615553,Cytotoxicity in 3Y1 cells.,,15899,,80622,,,BAO_0000219,,Expert,,10116.0,F,,3Y1 cell line
532,Rattus norvegicus,,CHEMBL615554,Cytostatic effect in 3Y1 cells.,,15899,,80622,,,BAO_0000219,,Expert,,10116.0,F,,3Y1 cell line
533,Rattus norvegicus,,CHEMBL615555,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",,15899,,80622,,,BAO_0000219,,Intermediate,,10116.0,F,,3Y1 cell line
534,Rattus norvegicus,,CHEMBL615556,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,,17038,,80622,,,BAO_0000219,,Expert,,10116.0,F,,3Y1 cell line
535,,,CHEMBL615557,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,,12421,,22226,,,BAO_0000019,,Autocuration,,,B,,
536,,,CHEMBL615558,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,12947,,22226,,,BAO_0000019,,Autocuration,,,B,,
537,,,CHEMBL872066,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,12947,,22226,,,BAO_0000019,,Autocuration,,,B,,
538,Sus scrofa,,CHEMBL615559,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,,4896,,11607,,,BAO_0000019,,Expert,,9823.0,B,,
539,,,CHEMBL615560,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,,6148,,11607,,,BAO_0000019,,Autocuration,,,B,,
540,,,CHEMBL615561,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,,16432,,11607,,,BAO_0000019,,Autocuration,,,B,,
541,,,CHEMBL857062,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,,4978,,11607,,,BAO_0000019,,Expert,,,B,,
542,,,CHEMBL615562,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),,4978,,11607,,,BAO_0000019,,Expert,,,B,,
543,,,CHEMBL615563,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,,3723,,11607,,,BAO_0000019,,Autocuration,,,B,,
544,,,CHEMBL615564,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),,3518,,11607,,,BAO_0000357,,Autocuration,,,B,,
545,,,CHEMBL615565,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,,4164,,11607,,,BAO_0000019,,Autocuration,,,B,,
546,,,CHEMBL615566,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,,3518,,11607,,,BAO_0000019,,Autocuration,,,B,,
547,Sus scrofa,,CHEMBL615567,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,,4164,,11607,,,BAO_0000019,,Expert,,9823.0,B,,
548,,,CHEMBL615568,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,,3518,,11607,,,BAO_0000019,,Autocuration,,,B,,
549,,,CHEMBL615569,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),,3518,,11607,,,BAO_0000357,,Autocuration,,,B,,
550,,,CHEMBL615570,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,,4978,,11607,,,BAO_0000019,,Autocuration,,,B,,
551,,,CHEMBL615571,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),,4978,,11607,,,BAO_0000019,,Autocuration,,,B,,
552,,,CHEMBL615572,Binding affinity against melatonin (MT1) receptor (pC1),,6455,,104733,,,BAO_0000224,,Autocuration,,,B,,
553,,,CHEMBL615573,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,,2222,,22226,,,BAO_0000019,,Autocuration,,,B,,
554,,,CHEMBL615574,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,,13020,,22226,,,BAO_0000019,,Autocuration,,,B,,
555,,,CHEMBL615575,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,,13021,,22226,,,BAO_0000019,,Autocuration,,,B,,
556,,,CHEMBL615576,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,,14532,,10619,,,BAO_0000357,,Autocuration,,,B,,
557,,,CHEMBL615577,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,14118,,10619,,,BAO_0000357,,Autocuration,,,B,,
558,,10000000.0,CHEMBL615578,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,,11884,Hippocampus,51,,,BAO_0000221,,Autocuration,,,B,,
559,,,CHEMBL615579,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,,13969,,51,,,BAO_0000357,,Expert,,,B,,
560,,,CHEMBL615580,Binding affinity for 5-hydroxytryptamine 1A receptor,,13392,,51,,,BAO_0000357,,Expert,,,B,,
561,,,CHEMBL615581,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,,14430,,51,,,BAO_0000019,,Expert,,,B,,
562,,10000000.0,CHEMBL615582,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,12248,Hippocampus,51,,,BAO_0000221,,Autocuration,,,B,,
563,,10000000.0,CHEMBL615583,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,12249,Hippocampus,51,,,BAO_0000221,,Autocuration,,,B,,
564,,10000000.0,CHEMBL615584,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,9995,Hippocampus,51,,,BAO_0000221,,Autocuration,,,B,,
565,,10000000.0,CHEMBL833691,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,9995,Hippocampus,51,,,BAO_0000221,,Autocuration,,,B,,
566,,10000000.0,CHEMBL615585,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,9995,Hippocampus,51,,,BAO_0000221,,Autocuration,,,B,,
567,,10000000.0,CHEMBL615586,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,9995,Hippocampus,51,,,BAO_0000221,,Autocuration,,,B,,
568,,10000000.0,CHEMBL884524,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,9995,Hippocampus,51,,,BAO_0000221,,Autocuration,,,B,,
569,,10000000.0,CHEMBL615587,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,12249,Hippocampus,51,,,BAO_0000221,,Autocuration,,,B,,
570,,10000000.0,CHEMBL615588,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,11799,Hippocampus,51,,,BAO_0000221,,Autocuration,,,B,,
571,Rattus norvegicus,,CHEMBL615589,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,,14331,,10576,,,BAO_0000249,,Expert,Membranes,10116.0,B,,
572,Bos taurus,10000000.0,CHEMBL615442,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,,11884,Hippocampus,51,,,BAO_0000221,,Expert,,9913.0,B,,
573,,10000000.0,CHEMBL615443,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,,14331,Hippocampus,51,,,BAO_0000221,,Autocuration,,,B,,
574,,10000000.0,CHEMBL615444,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,,11701,Hippocampus,51,,,BAO_0000221,,Autocuration,,,B,,
575,,10000000.0,CHEMBL615445,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,,11701,Hippocampus,51,,,BAO_0000221,,Expert,,,B,,
576,,10000000.0,CHEMBL615446,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,,12248,Hippocampus,51,,,BAO_0000221,,Autocuration,,,B,,
577,,,CHEMBL615447,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,,12248,,51,,,BAO_0000219,,Autocuration,,,B,,CHO
578,,10000000.0,CHEMBL615448,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,12248,Hippocampus,51,,,BAO_0000221,,Expert,,,B,,
579,,10000000.0,CHEMBL615449,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,12249,Hippocampus,51,,,BAO_0000221,,Expert,,,B,,
580,,,CHEMBL615450,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,12248,,51,,,BAO_0000219,,Autocuration,,,B,,CHO
581,,10000000.0,CHEMBL615451,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,11799,Hippocampus,51,,,BAO_0000221,,Expert,,,B,,
582,,,CHEMBL615452,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,634,,51,,,BAO_0000357,,Autocuration,,,B,,
583,,10000000.0,CHEMBL615453,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,9995,Hippocampus,51,,,BAO_0000221,,Autocuration,,,B,,
584,,10000000.0,CHEMBL615454,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,9995,Hippocampus,51,,,BAO_0000221,,Autocuration,,,B,,
585,,10000000.0,CHEMBL615455,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,9995,Hippocampus,51,,,BAO_0000221,,Autocuration,,,B,,
586,,10000000.0,CHEMBL615456,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,9995,Hippocampus,51,,,BAO_0000221,,Autocuration,,,B,,
587,,10000000.0,CHEMBL615457,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,9995,Hippocampus,51,,,BAO_0000221,,Autocuration,,,B,,
588,,10000000.0,CHEMBL615458,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,,12210,Hippocampus,51,,,BAO_0000218,,Expert,,,B,,
589,,10000000.0,CHEMBL615459,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,13311,Hippocampus,51,,,BAO_0000221,,Expert,,,B,,
590,Homo sapiens,,CHEMBL615460,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",,2331,,51,,,BAO_0000219,,Expert,,9606.0,B,,CHO
591,Cavia porcellus,,CHEMBL615461,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,,1375,,51,,,BAO_0000019,,Autocuration,,10141.0,F,,
592,Cavia porcellus,,CHEMBL615462,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,,1375,,51,,,BAO_0000019,,Autocuration,,10141.0,F,,
593,Cavia porcellus,10000000.0,CHEMBL615463,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,,11574,Hippocampus,51,,,BAO_0000221,,Autocuration,,10141.0,F,,
594,Cavia porcellus,2116.0,CHEMBL615464,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,12867,Ileum,51,,,BAO_0000221,,Autocuration,,10141.0,B,,
595,Cavia porcellus,2116.0,CHEMBL615465,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,12867,Ileum,51,,,BAO_0000221,,Autocuration,,10141.0,B,,
596,Cavia porcellus,2116.0,CHEMBL615466,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,12867,Ileum,51,,,BAO_0000221,,Autocuration,,10141.0,B,,
597,Cavia porcellus,2116.0,CHEMBL615467,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,12867,Ileum,51,,,BAO_0000221,,Autocuration,,10141.0,B,,
598,Cavia porcellus,2116.0,CHEMBL615468,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,12867,Ileum,51,,,BAO_0000221,,Autocuration,,10141.0,B,,
599,Cavia porcellus,2116.0,CHEMBL615469,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,,12867,Ileum,51,,,BAO_0000221,,Autocuration,,10141.0,B,,
600,Cavia porcellus,,CHEMBL615470,Binding affinity against 5-hydroxytryptamine 1A receptor,,11574,,51,,,BAO_0000357,,Autocuration,,10141.0,B,,
601,Cavia porcellus,,CHEMBL615471,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,,13114,,51,,,BAO_0000357,,Autocuration,,10141.0,B,,
602,Cavia porcellus,,CHEMBL615472,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,,13181,,51,,,BAO_0000357,,Autocuration,,10141.0,B,,
603,Cavia porcellus,10000000.0,CHEMBL883242,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,10639,Hippocampus,106,,,BAO_0000221,,Autocuration,,10141.0,B,,
604,Cavia porcellus,10000000.0,CHEMBL615473,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,10639,Hippocampus,106,,,BAO_0000221,,Autocuration,,10141.0,F,,
605,Cricetulus griseus,,CHEMBL615474,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,11883,,11863,,,BAO_0000218,,Autocuration,,10029.0,B,,CHO
606,,,CHEMBL615475,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,,17785,,51,,,BAO_0000357,,Autocuration,,,B,,
607,,,CHEMBL615476,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,,1558,,51,,,BAO_0000219,,Autocuration,,,F,,HeLa
608,,,CHEMBL615477,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,,1558,,51,,,BAO_0000219,,Autocuration,,,F,,HeLa
609,,,CHEMBL615478,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,15740,,51,,,BAO_0000019,,Autocuration,,,F,,
610,,,CHEMBL615160,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,17624,,51,,,BAO_0000219,,Autocuration,,,F,,CHO
611,,,CHEMBL615161,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,17624,,51,,,BAO_0000219,,Expert,,,F,,CHO
612,,,CHEMBL615162,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,,17624,,51,,,BAO_0000219,,Autocuration,,,F,,CHO
613,,,CHEMBL615163,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,,17624,,51,,,BAO_0000219,,Autocuration,,,F,,CHO
614,,,CHEMBL615164,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,17624,,51,,,BAO_0000219,,Expert,,,B,,CHO
615,,,CHEMBL615165,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,17624,,51,,,BAO_0000219,,Expert,,,B,,CHO
616,,,CHEMBL615166,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,,17624,,51,,,BAO_0000219,,Autocuration,,,B,,CHO
617,,,CHEMBL615167,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,,14256,,51,,,BAO_0000219,,Autocuration,,,F,,
618,Homo sapiens,,CHEMBL615168,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,3445,,51,,,BAO_0000219,,Expert,,9606.0,B,,HeLa
619,Homo sapiens,,CHEMBL615169,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,,3445,,51,,,BAO_0000219,,Expert,,9606.0,B,,HeLa
620,Homo sapiens,,CHEMBL615170,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,,17200,,51,,,BAO_0000219,,Expert,,9606.0,B,,CHO
621,Homo sapiens,,CHEMBL615171,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,,17200,,51,,,BAO_0000219,,Expert,,9606.0,B,,CHO
622,,,CHEMBL615694,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,15180,,51,,,BAO_0000019,,Autocuration,,,F,,
623,,,CHEMBL615695,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,15180,,51,,,BAO_0000019,,Autocuration,,,F,,
624,,,CHEMBL615696,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,16026,,51,,,BAO_0000019,,Autocuration,,,F,,
625,,,CHEMBL615697,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,2759,,51,,,BAO_0000219,,Autocuration,,,F,,CHO
626,Homo sapiens,,CHEMBL859410,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,2759,,51,,,BAO_0000219,,Expert,,9606.0,F,,CHO
627,,,CHEMBL615841,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,2759,,51,,,BAO_0000219,,Autocuration,,,F,,CHO
628,Homo sapiens,,CHEMBL615842,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,2759,,51,,,BAO_0000219,,Expert,,9606.0,F,,CHO
629,,,CHEMBL835003,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,2759,,51,,,BAO_0000219,,Autocuration,,,F,,CHO
630,,,CHEMBL615843,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),,2759,,51,,,BAO_0000219,,Autocuration,,,F,,CHO
631,Homo sapiens,,CHEMBL615979,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,2759,,51,,,BAO_0000219,,Expert,,9606.0,F,,CHO
632,,,CHEMBL615980,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,2759,,51,,,BAO_0000219,,Autocuration,,,F,,CHO
633,Homo sapiens,,CHEMBL615981,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,2759,,51,,,BAO_0000219,,Expert,,9606.0,F,,CHO
634,Homo sapiens,,CHEMBL615982,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,,3445,,51,,,BAO_0000019,,Expert,,9606.0,F,,
635,Homo sapiens,,CHEMBL615983,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,5272,,51,,,BAO_0000019,,Expert,,9606.0,F,,
636,Homo sapiens,,CHEMBL615984,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",,5272,,51,,,BAO_0000019,,Expert,,9606.0,F,,
637,Homo sapiens,,CHEMBL615985,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",,5272,,51,,,BAO_0000019,,Expert,,9606.0,F,,
638,,,CHEMBL615986,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,17624,,51,,,BAO_0000219,,Autocuration,,,F,,CHO
639,,,CHEMBL615987,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,17624,,51,,,BAO_0000219,,Autocuration,,,F,,CHO
640,,,CHEMBL615988,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,17624,,51,,,BAO_0000219,,Autocuration,,,F,,CHO
641,,,CHEMBL615989,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,17624,,51,,,BAO_0000219,,Expert,,,F,,CHO
642,,,CHEMBL615990,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,17624,,51,,,BAO_0000219,,Autocuration,,,F,,CHO
643,,,CHEMBL615991,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,,17624,,51,,,BAO_0000219,,Autocuration,,,F,,CHO
644,,,CHEMBL615992,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,17624,,51,,,BAO_0000219,,Autocuration,,,F,,CHO
645,,,CHEMBL615993,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,,17624,,51,,,BAO_0000219,,Autocuration,,,F,,CHO
646,,,CHEMBL615994,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,17624,,51,,,BAO_0000219,,Expert,,,F,,CHO
647,,,CHEMBL615995,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,,17624,,51,,,BAO_0000219,,Autocuration,,,F,,CHO
648,,,CHEMBL615996,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,17624,,51,,,BAO_0000219,,Autocuration,,,F,,CHO
649,,,CHEMBL615997,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,,17624,,51,,,BAO_0000219,,Autocuration,,,F,,CHO
650,,,CHEMBL615998,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,6563,,51,,,BAO_0000019,,Autocuration,,,F,,
651,,,CHEMBL615999,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,6563,,51,,,BAO_0000019,,Autocuration,,,F,,
652,,,CHEMBL616000,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,6563,,51,,,BAO_0000019,,Autocuration,,,F,,
653,,,CHEMBL616001,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,17296,,51,,,BAO_0000219,,Autocuration,,,F,,HEK293
654,Homo sapiens,,CHEMBL616002,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",,6876,,51,,,BAO_0000019,,Expert,,9606.0,F,,
655,,,CHEMBL616003,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",,6876,,51,,,BAO_0000019,,Expert,,,F,,
656,Homo sapiens,,CHEMBL616004,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,,5272,,51,,,BAO_0000019,,Expert,,9606.0,F,,
657,Homo sapiens,,CHEMBL616005,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,,5272,,51,,,BAO_0000019,,Expert,,9606.0,F,,
658,,,CHEMBL616006,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,5548,,51,,,BAO_0000019,,Autocuration,,,F,,
659,,,CHEMBL616007,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",,5548,,51,,,BAO_0000019,,Expert,,,F,,
660,,,CHEMBL616008,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,5548,,51,,,BAO_0000019,,Autocuration,,,F,,
661,,,CHEMBL616009,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,5548,,51,,,BAO_0000019,,Autocuration,,,F,,
662,,,CHEMBL616010,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",,5929,,51,,,BAO_0000019,,Expert,,,F,,
663,Homo sapiens,,CHEMBL616011,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",,5929,,51,,,BAO_0000019,,Expert,,9606.0,F,,
664,Homo sapiens,,CHEMBL615740,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",,5929,,51,,,BAO_0000019,,Expert,,9606.0,F,,
665,,,CHEMBL615741,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",,16245,,51,,,BAO_0000019,,Autocuration,,,F,,
666,,,CHEMBL615742,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,5640,,51,,,BAO_0000019,,Expert,,,F,,
667,,,CHEMBL615743,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",,5640,,51,,,BAO_0000019,,Autocuration,,,F,,
668,,,CHEMBL615744,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,,14509,,51,,,BAO_0000219,,Autocuration,,,F,,CHO
669,,,CHEMBL615745,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,,14509,,51,,,BAO_0000219,,Expert,,,F,,CHO
670,,,CHEMBL615746,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,15331,,51,,,BAO_0000357,,Autocuration,,,B,,
671,,,CHEMBL615747,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,15331,,51,,,BAO_0000357,,Autocuration,,,B,,
672,,,CHEMBL615748,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,6563,,51,,,BAO_0000019,,Autocuration,,,F,,
673,,,CHEMBL615749,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",,6563,,51,,,BAO_0000019,,Autocuration,,,F,,
674,,,CHEMBL615750,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,6563,,51,,,BAO_0000019,,Autocuration,,,F,,
675,Homo sapiens,,CHEMBL616259,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,,6563,,51,,,BAO_0000019,,Expert,,9606.0,F,,
676,,,CHEMBL616260,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,6563,,51,,,BAO_0000019,,Autocuration,,,F,,
677,Homo sapiens,,CHEMBL616261,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,,5272,,51,,,BAO_0000019,,Expert,,9606.0,F,,
678,Homo sapiens,,CHEMBL616262,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,5272,,51,,,BAO_0000019,,Expert,,9606.0,F,,
679,Homo sapiens,,CHEMBL616263,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,5272,,51,,,BAO_0000019,,Expert,,9606.0,F,,
680,Homo sapiens,,CHEMBL616264,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,,5272,,51,,,BAO_0000019,,Expert,,9606.0,F,,
681,Homo sapiens,,CHEMBL616265,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,,5272,,51,,,BAO_0000019,,Expert,,9606.0,F,,
682,Homo sapiens,,CHEMBL616266,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,5272,,51,,,BAO_0000019,,Expert,,9606.0,F,,
683,Homo sapiens,,CHEMBL616267,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,5272,,51,,,BAO_0000019,,Expert,,9606.0,F,,
684,Homo sapiens,,CHEMBL616268,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,,5272,,51,,,BAO_0000019,,Expert,,9606.0,F,,
685,Homo sapiens,,CHEMBL616269,Inhibition of human 5-hydroxytryptamine 1A receptor,,16146,,51,,,BAO_0000357,,Expert,,9606.0,B,,
686,,,CHEMBL884528,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,17624,,51,,,BAO_0000219,,Autocuration,,,B,,CHO
687,,,CHEMBL616270,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,,13706,,105,,,BAO_0000219,,Expert,,,B,,HEK293
688,,,CHEMBL616271,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,,15250,,51,,,BAO_0000219,,Autocuration,,,B,,CHO
689,,,CHEMBL616272,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,17624,,51,,,BAO_0000219,,Autocuration,,,F,,CHO
690,,,CHEMBL616273,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,,6861,,51,,,BAO_0000357,,Expert,,,B,,
691,Homo sapiens,,CHEMBL616274,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,17200,,51,,,BAO_0000357,,Expert,,9606.0,B,,
692,,,CHEMBL616275,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,,17624,,51,,,BAO_0000219,,Autocuration,,,B,,CHO
693,,,CHEMBL616276,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,17624,,51,,,BAO_0000219,,Autocuration,,,B,,CHO
694,Rattus norvegicus,,CHEMBL616277,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,In vivo,12058,,22226,,,BAO_0000218,,Autocuration,,10116.0,F,,
695,Rattus norvegicus,,CHEMBL616278,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,In vivo,12058,,22226,,,BAO_0000218,,Autocuration,,10116.0,F,,
696,Rattus norvegicus,,CHEMBL616279,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,In vivo,12058,,22226,,,BAO_0000218,,Autocuration,,10116.0,F,,
697,Rattus norvegicus,,CHEMBL616280,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,In vivo,12058,,22226,,,BAO_0000218,,Autocuration,,10116.0,F,,
698,Rattus norvegicus,,CHEMBL616281,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,In vivo,12058,,22226,,,BAO_0000218,,Autocuration,,10116.0,F,,
699,Rattus norvegicus,,CHEMBL616282,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,In vivo,12058,,22226,,,BAO_0000218,,Autocuration,,10116.0,F,,
700,Rattus norvegicus,,CHEMBL616283,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,In vivo,12058,,22226,,,BAO_0000218,,Autocuration,,10116.0,F,,
701,Rattus norvegicus,,CHEMBL616284,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,In vivo,12058,,22226,,,BAO_0000218,,Autocuration,,10116.0,F,,
702,Rattus norvegicus,,CHEMBL616285,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,In vivo,12058,,22226,,,BAO_0000218,,Autocuration,,10116.0,F,,
703,Rattus norvegicus,,CHEMBL616286,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,In vivo,12058,,22226,,,BAO_0000218,,Autocuration,,10116.0,F,,
704,Rattus norvegicus,,CHEMBL616287,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,In vivo,12058,,22226,,,BAO_0000218,,Autocuration,,10116.0,F,,
705,Rattus norvegicus,,CHEMBL616288,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,In vivo,12058,,22226,,,BAO_0000218,,Autocuration,,10116.0,F,,
706,Rattus norvegicus,,CHEMBL616289,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,In vivo,12058,,22226,,,BAO_0000218,,Autocuration,,10116.0,F,,
707,Rattus norvegicus,,CHEMBL615610,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,In vivo,12058,,22226,,,BAO_0000218,,Autocuration,,10116.0,F,,
708,Rattus norvegicus,,CHEMBL615611,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,In vivo,12058,,22226,,,BAO_0000218,,Autocuration,,10116.0,F,,
709,Rattus norvegicus,,CHEMBL615612,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,In vivo,12058,,22226,,,BAO_0000218,,Autocuration,,10116.0,F,,
710,Rattus norvegicus,,CHEMBL615613,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,In vivo,12058,,22226,,,BAO_0000218,,Autocuration,,10116.0,F,,
711,Rattus norvegicus,,CHEMBL615614,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,In vivo,12058,,22226,,,BAO_0000218,,Autocuration,,10116.0,F,,
712,Rattus norvegicus,,CHEMBL615615,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,In vivo,12058,,22226,,,BAO_0000218,,Autocuration,,10116.0,F,,
713,,,CHEMBL615616,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,,11440,,105093,,,BAO_0000019,,Autocuration,,,B,,
714,,1898.0,CHEMBL615617,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,,6238,Hypothalamus,11923,,,BAO_0000249,,Autocuration,,,B,,
715,,,CHEMBL615618,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,,10046,,10577,,,BAO_0000019,,Autocuration,,,B,,
716,,,CHEMBL615619,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,,10046,,10577,,,BAO_0000019,,Autocuration,,,B,,
717,,,CHEMBL615620,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,10046,,10577,,,BAO_0000019,,Expert,,,B,,
718,,,CHEMBL615621,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",,167,,55,,,BAO_0000357,,Autocuration,,,B,,
719,,,CHEMBL615622,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",,167,,55,,,BAO_0000357,,Autocuration,,,B,,
720,,,CHEMBL615623,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),,11520,,12166,,,BAO_0000019,,Autocuration,,,F,,
721,,,CHEMBL615624,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,11520,,12166,,,BAO_0000019,,Autocuration,,,F,,
722,,,CHEMBL615625,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,11520,,12166,,,BAO_0000019,,Autocuration,,,F,,
723,,,CHEMBL767045,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,11520,,12166,,,BAO_0000019,,Autocuration,,,F,,
724,Cavia porcellus,,CHEMBL615626,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,,135,,55,,,BAO_0000019,,Autocuration,,10141.0,F,,
725,Cavia porcellus,,CHEMBL615627,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,,135,,55,,,BAO_0000019,,Autocuration,,10141.0,F,,
726,Cavia porcellus,,CHEMBL615628,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,,11311,,55,,,BAO_0000019,,Autocuration,,10141.0,B,,
727,Cavia porcellus,,CHEMBL615629,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,10193,,55,,,BAO_0000357,,Autocuration,,10141.0,B,,
728,Homo sapiens,,CHEMBL615630,Inhibitory concentration against 5-lipoxygenase from human whole blood,,12281,,55,,,BAO_0000357,,Expert,,9606.0,B,,
729,,,CHEMBL615631,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],,11311,,55,,,BAO_0000219,,Autocuration,,,B,,
730,,,CHEMBL615632,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,12576,,17087,,,BAO_0000218,,Autocuration,,,F,,
731,,,CHEMBL615633,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,,12281,,17087,,,BAO_0000357,,Autocuration,,,B,,
732,,,CHEMBL615634,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,12576,,17087,,,BAO_0000218,,Autocuration,,,F,,
733,Sus scrofa,,CHEMBL615635,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,,11089,,55,,,BAO_0000019,,Expert,,9823.0,B,,
734,,,CHEMBL615636,In vitro inhibition of rat 5-Lipoxygenase,,11006,,12166,,,BAO_0000357,,Expert,,,B,,
735,Rattus norvegicus,,CHEMBL615637,Inhibitory activity against 5-Lipoxygenase,,11481,,12166,,,BAO_0000357,,Expert,,10116.0,B,,
736,,,CHEMBL615638,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,,10864,,12166,,,BAO_0000219,,Expert,,,B,,RBL-1
737,,,CHEMBL615639,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,3595,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
738,,,CHEMBL615640,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,,11311,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
739,,,CHEMBL615796,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,,11311,,12166,,,BAO_0000019,,Autocuration,,,B,,
740,,,CHEMBL615845,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],,11311,,12166,,,BAO_0000219,,Autocuration,,,B,,
741,,,CHEMBL615846,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,11006,,12166,,,BAO_0000357,,Autocuration,,,B,,
742,,,CHEMBL615847,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,3595,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
743,,,CHEMBL615848,The compound was tested for inhibition of isolated 5-Lipoxygenase,,11311,,12166,,,BAO_0000357,,Autocuration,,,B,,
744,Rattus norvegicus,,CHEMBL615849,Ratio of IC50 against 5-LO and COX,,11481,,22226,,,BAO_0000019,,Autocuration,,10116.0,B,,
745,,,CHEMBL615850,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,11006,,12166,,,BAO_0000357,,Autocuration,,,B,,
746,,,CHEMBL615851,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,,11006,,12166,,,BAO_0000357,,Autocuration,,,B,,
747,,,CHEMBL615852,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,,11311,,12166,,,BAO_0000219,,Autocuration,,,B,,
748,,,CHEMBL615853,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,,11006,,12166,,,BAO_0000019,,Autocuration,,,F,,
749,,2367.0,CHEMBL884527,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,,4288,Prostate gland,120,,,BAO_0000357,,Autocuration,,,B,,
750,Columba livia,,CHEMBL872871,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,,7587,,22226,,,BAO_0000019,,Autocuration,,8932.0,B,,
751,Columba livia,,CHEMBL615854,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,,7587,,22226,,,BAO_0000019,,Autocuration,,8932.0,B,,
752,Columba livia,,CHEMBL767046,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,,7587,,22226,,,BAO_0000019,,Autocuration,,8932.0,B,,
753,,,CHEMBL615855,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,,11249,,10732,,,BAO_0000357,,Autocuration,,,B,,
754,Rattus norvegicus,,CHEMBL615856,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,,8003,,12198,,,BAO_0000019,,Expert,,10116.0,F,,
755,Rattus norvegicus,,CHEMBL615857,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,8003,,12198,,,BAO_0000019,,Expert,,10116.0,F,,
756,Rattus norvegicus,,CHEMBL615858,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,8003,,12198,,,BAO_0000019,,Expert,,10116.0,F,,
757,,10000000.0,CHEMBL615859,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,12416,Hippocampus,10576,,,BAO_0000221,,Expert,,,B,,
758,,,CHEMBL615860,Binding affinity towards human 5-hydroxytryptamine 1 receptor,,16293,,51,,,BAO_0000357,,Autocuration,,,B,,
759,Oryctolagus cuniculus,,CHEMBL615861,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,13047,,22226,,,BAO_0000019,,Autocuration,,9986.0,B,,
760,Oryctolagus cuniculus,,CHEMBL615862,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,13047,,22226,,,BAO_0000019,,Autocuration,,9986.0,B,,
761,Oryctolagus cuniculus,,CHEMBL615863,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,,13047,,22226,,,BAO_0000019,,Autocuration,,9986.0,B,,
762,Oryctolagus cuniculus,,CHEMBL615864,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,13047,,22226,,,BAO_0000019,,Autocuration,,9986.0,B,,
763,,10000000.0,CHEMBL615865,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,10085,Hippocampus,104744,,,BAO_0000221,,Autocuration,,,B,,
764,,10000000.0,CHEMBL615866,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,10085,Hippocampus,104744,,,BAO_0000221,,Autocuration,,,B,,
765,,10000000.0,CHEMBL615867,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,10085,Hippocampus,104744,,,BAO_0000221,,Autocuration,,,B,,
766,,,CHEMBL615868,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,,9841,,104744,,,BAO_0000249,,Autocuration,Membranes,,B,,
767,Rattus norvegicus,,CHEMBL615869,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,,8822,,104744,,,BAO_0000249,,Autocuration,,10116.0,B,,
768,Rattus norvegicus,,CHEMBL615870,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,,9806,,104744,,,BAO_0000019,,Autocuration,,10116.0,B,,
769,Rattus norvegicus,,CHEMBL615871,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,,9806,,104744,,,BAO_0000019,,Autocuration,,10116.0,B,,
770,,,CHEMBL615872,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,,8868,,104744,,,BAO_0000224,,Autocuration,,,B,,
771,,10000000.0,CHEMBL833492,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,,9036,Hippocampus,104744,,,BAO_0000221,,Autocuration,,,B,,
772,,10000000.0,CHEMBL615873,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,,11374,Hippocampus,104744,,,BAO_0000221,,Autocuration,,,B,,
773,,,CHEMBL615479,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,,10881,,104744,,,BAO_0000224,,Autocuration,,,B,,
774,,,CHEMBL615480,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,,8822,,104744,,,BAO_0000019,,Autocuration,,,B,,
775,Rattus norvegicus,,CHEMBL615481,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,,9806,,104744,,,BAO_0000249,,Autocuration,,10116.0,B,,
776,,,CHEMBL872869,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,15463,,104744,,,BAO_0000019,,Autocuration,,,B,,
777,,,CHEMBL615482,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,15463,,104744,,,BAO_0000019,,Autocuration,,,B,,
778,,955.0,CHEMBL615483,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,14542,Brain,104744,,,BAO_0000221,,Autocuration,,,B,,
779,,955.0,CHEMBL615484,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,14542,Brain,104744,,,BAO_0000221,,Autocuration,,,B,,
780,,,CHEMBL615485,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,,8569,,104744,,,BAO_0000019,,Autocuration,,,B,,
781,Rattus norvegicus,,CHEMBL615486,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,,10062,,104744,,,BAO_0000224,,Autocuration,,10116.0,B,,
782,,,CHEMBL615487,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,,4771,,104744,,,BAO_0000224,,Autocuration,,,B,,
783,,,CHEMBL615488,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,10062,,104744,,,BAO_0000224,,Autocuration,,,B,,
784,,,CHEMBL615489,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,10062,,104744,,,BAO_0000224,,Autocuration,,,B,,
785,,,CHEMBL615389,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,10062,,104744,,,BAO_0000224,,Autocuration,,,B,,
786,,,CHEMBL615390,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,15463,,104744,,,BAO_0000019,,Autocuration,,,B,,
787,,,CHEMBL615391,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,15463,,104744,,,BAO_0000019,,Autocuration,,,B,,
788,,,CHEMBL615392,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,,9098,,104744,,,BAO_0000224,,Autocuration,,,B,,
789,Rattus norvegicus,,CHEMBL615393,Affinity for 5-hydroxytryptamine 1 receptor,,3070,,22226,,,BAO_0000019,,Autocuration,,10116.0,B,,
790,,955.0,CHEMBL615394,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,,14542,Brain,104744,,,BAO_0000221,,Autocuration,,,B,,
791,,955.0,CHEMBL615395,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,14542,Brain,104744,,,BAO_0000221,,Autocuration,,,B,,
792,,,CHEMBL615396,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,,6398,,104744,,,BAO_0000224,,Autocuration,,,B,,
793,,955.0,CHEMBL615397,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,,1344,Brain,104744,,,BAO_0000221,,Autocuration,,,B,,
794,,,CHEMBL615398,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,11963,,104744,,,BAO_0000019,,Autocuration,,,B,,
795,Rattus norvegicus,,CHEMBL615399,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,,8908,,22226,,,BAO_0000019,,Autocuration,,10116.0,B,,
796,,,CHEMBL615400,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,,9098,,104744,,,BAO_0000019,,Autocuration,,,B,,
797,Rattus norvegicus,,CHEMBL615401,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,,8841,,104744,,,BAO_0000019,,Autocuration,,10116.0,B,,
798,Rattus norvegicus,,CHEMBL615402,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,,8814,,22226,,,BAO_0000019,,Autocuration,,10116.0,B,,
799,,,CHEMBL615403,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,,11752,,104744,,,BAO_0000019,,Autocuration,,,B,,
800,,955.0,CHEMBL615404,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,,11642,Brain,104744,,,BAO_0000221,,Autocuration,,,B,,
801,,,CHEMBL615781,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,,11642,,104744,,,BAO_0000019,,Autocuration,,,B,,
802,,955.0,CHEMBL615782,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,,9231,Brain,104744,,,BAO_0000220,,Autocuration,,,B,,
803,,955.0,CHEMBL615783,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,,11351,Brain,104744,,,BAO_0000221,,Autocuration,,,B,,
804,,,CHEMBL873481,Compound was tested for binding affinity against 5-HT1 receptor,,4639,,22226,,,BAO_0000019,,Autocuration,,,B,,
805,,,CHEMBL615784,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,,1205,,22226,,,BAO_0000019,,Autocuration,,,B,,
806,,,CHEMBL615785,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,10025,,10576,,,BAO_0000357,,Expert,,,B,,
807,,,CHEMBL615786,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,13241,,10576,,,BAO_0000249,,Autocuration,,,F,,
808,,,CHEMBL615787,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,In vivo,16245,,10576,,,BAO_0000218,,Autocuration,,,F,,
809,,,CHEMBL615788,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,In vivo,16245,,10576,,,BAO_0000218,,Autocuration,,,F,,
810,,,CHEMBL767044,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,,12438,,10576,,,BAO_0000019,,Autocuration,,,F,,
811,,,CHEMBL615789,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,In vivo,16245,,10576,,,BAO_0000218,,Autocuration,,,F,,
812,,,CHEMBL615790,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,In vivo,16245,,10576,,,BAO_0000218,,Autocuration,,,F,,
813,,,CHEMBL615813,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,,15740,,10576,,,BAO_0000019,,Autocuration,,,F,,
814,,,CHEMBL615814,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,,15535,,10576,,,BAO_0000219,,Autocuration,,,F,,
815,,,CHEMBL615815,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,,15535,,51,,,BAO_0000219,,Expert,,,F,,
816,,,CHEMBL615816,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,,15535,,10576,,,BAO_0000219,,Autocuration,,,F,,
817,,,CHEMBL615817,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,,9888,,10576,,,BAO_0000249,,Expert,,,B,,
818,,10000000.0,CHEMBL615818,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,,10085,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
819,,10000000.0,CHEMBL615819,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,,10085,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
820,,,CHEMBL615820,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,,17331,,10576,,,BAO_0000249,,Expert,Membranes,,B,,
821,Rattus norvegicus,10000000.0,CHEMBL615821,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,,10845,Hippocampus,10576,,,BAO_0000221,,Expert,,10116.0,B,,
822,Rattus norvegicus,10000000.0,CHEMBL615822,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,10845,Hippocampus,10576,,,BAO_0000221,,Expert,,10116.0,B,,
823,,10000000.0,CHEMBL615823,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,,10845,Hippocampus,10576,,,BAO_0000221,,Expert,,,B,,
824,Rattus norvegicus,10000000.0,CHEMBL615824,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,,10845,Hippocampus,10576,,,BAO_0000221,,Expert,,10116.0,B,,
825,Rattus norvegicus,10000000.0,CHEMBL615825,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,10845,Hippocampus,10576,,,BAO_0000221,,Expert,,10116.0,B,,
826,,,CHEMBL615826,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,,13730,,10576,,,BAO_0000357,,Expert,,,B,,
827,,,CHEMBL615827,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,,13508,,10576,,,BAO_0000249,,Expert,,,B,,
828,,10000000.0,CHEMBL615828,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,,13508,Hippocampus,10576,,,BAO_0000249,,Expert,,,B,,
829,,10000000.0,CHEMBL615829,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,12073,Hippocampus,10576,,,BAO_0000221,,Expert,,,B,,
830,,10000000.0,CHEMBL615830,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,,4671,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
831,,10000000.0,CHEMBL615831,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,,13631,Hippocampus,10576,,,BAO_0000221,,Expert,,,B,,
832,,,CHEMBL615832,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,,12438,,10576,,,BAO_0000357,,Autocuration,,,B,,
833,,,CHEMBL615833,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,,10483,,10576,,,BAO_0000019,,Autocuration,,,B,,
834,,10000000.0,CHEMBL615834,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,,10483,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
835,,,CHEMBL615835,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,,12352,,10576,,,BAO_0000249,,Intermediate,,,B,,
836,,10000000.0,CHEMBL615836,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,,14732,Hippocampus,10576,,,BAO_0000249,,Autocuration,,,B,,
837,Rattus norvegicus,,CHEMBL615837,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,,11049,,10576,,,BAO_0000019,,Expert,,10116.0,B,,
838,Rattus norvegicus,,CHEMBL615838,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,,11049,,10576,,,BAO_0000019,,Expert,,10116.0,B,,
839,,,CHEMBL615839,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",,13657,,10576,,,BAO_0000249,,Expert,,,B,,
840,,,CHEMBL884525,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,,11473,,10576,,,BAO_0000019,,Autocuration,,,B,,
841,,,CHEMBL615840,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,2014,,10576,,,BAO_0000249,,Autocuration,,,B,,
842,,10000000.0,CHEMBL615405,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,3086,Hippocampus,10576,,,BAO_0000221,,Expert,,,B,,
843,,,CHEMBL615406,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,15854,,10576,,,BAO_0000019,,Expert,,,B,,
844,,10000000.0,CHEMBL615900,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,10922,Hippocampus,10576,,,BAO_0000221,,Expert,,,B,,
845,,10000000.0,CHEMBL615901,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,,13346,Hippocampus,10576,,,BAO_0000221,,Expert,,,B,,
846,,,CHEMBL615902,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,,15311,,10576,,,BAO_0000357,,Expert,,,B,,
847,,10000000.0,CHEMBL615903,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,10922,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
848,,,CHEMBL615904,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,,10025,,10576,,,BAO_0000357,,Autocuration,,,B,,
849,,,CHEMBL615905,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,10025,,10576,,,BAO_0000357,,Expert,,,B,,
850,,,CHEMBL615906,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,9742,,10576,,,BAO_0000019,,Autocuration,,,B,,
851,,,CHEMBL615907,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,9742,,10576,,,BAO_0000019,,Autocuration,,,F,,
852,,,CHEMBL615908,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,12304,,10576,,,BAO_0000019,,Expert,,,B,,
853,,10000000.0,CHEMBL615909,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,,15789,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
854,,,CHEMBL615910,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",,9912,,10576,,,BAO_0000019,,Autocuration,,,B,,
855,,,CHEMBL615911,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",,9912,,10576,,,BAO_0000019,,Autocuration,,,B,,
856,,,CHEMBL615912,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",,9912,,10576,,,BAO_0000019,,Autocuration,,,B,,
857,,,CHEMBL615913,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,16693,,10576,,,BAO_0000019,,Expert,,,B,,
858,,,CHEMBL615914,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,13276,,10576,,,BAO_0000357,,Expert,,,B,,
859,,10000000.0,CHEMBL615915,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,12678,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
860,,,CHEMBL615916,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,,11825,,10576,,,BAO_0000357,,Autocuration,,,B,,
861,,,CHEMBL615917,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,,12443,,10576,,,BAO_0000357,,Expert,,,B,,
862,,,CHEMBL615918,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,13830,,10576,,,BAO_0000357,,Expert,,,B,,
863,,10000000.0,CHEMBL615919,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,,14286,Hippocampus,10576,,,BAO_0000249,,Expert,,,B,,
864,Rattus norvegicus,10000000.0,CHEMBL615920,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,14356,Hippocampus,10576,,,BAO_0000221,,Expert,,10116.0,B,,
865,,,CHEMBL615921,Inhibition concentration against 5-hydroxytryptamine 1A receptor,,15306,,10576,,,BAO_0000357,,Autocuration,,,B,,
866,,,CHEMBL615922,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),,15306,,10576,,,BAO_0000357,,Expert,,,B,,
867,Rattus norvegicus,,CHEMBL881290,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,16616,,10576,,,BAO_0000249,,Expert,,10116.0,F,,
868,,10000000.0,CHEMBL615923,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",,3651,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
869,,10000000.0,CHEMBL615924,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,14331,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,F,,
870,,10000000.0,CHEMBL615925,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,14331,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,F,,
871,Rattus norvegicus,,CHEMBL615926,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,,14178,,10576,,,BAO_0000357,,Expert,,10116.0,B,,
872,Rattus norvegicus,,CHEMBL615927,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,,10639,,10576,,,BAO_0000019,,Expert,,10116.0,B,,
873,,10000000.0,CHEMBL615928,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,12306,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
874,Rattus norvegicus,,CHEMBL615929,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,,1348,,10576,,,BAO_0000357,,Expert,,10116.0,B,,
875,,10000000.0,CHEMBL615930,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,,13605,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
876,,,CHEMBL615931,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,17624,,51,,,BAO_0000219,,Autocuration,,,B,,CHO
877,,,CHEMBL615932,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,17624,,51,,,BAO_0000219,,Autocuration,,,F,,CHO
878,,,CHEMBL615933,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,17624,,51,,,BAO_0000219,,Autocuration,,,F,,CHO
879,,,CHEMBL615934,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,15267,,51,,,BAO_0000357,,Autocuration,,,B,,
880,,,CHEMBL615935,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,,16532,,51,,,BAO_0000357,,Autocuration,,,B,,
881,,,CHEMBL615936,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,6563,,51,,,BAO_0000019,,Autocuration,,,F,,
882,,,CHEMBL615937,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,,4751,,51,,,BAO_0000219,,Autocuration,,,B,,CHO
883,,,CHEMBL615938,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,,15463,,51,,,BAO_0000357,,Autocuration,,,B,,
884,,,CHEMBL615797,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),,3805,,51,,,BAO_0000357,,Autocuration,,,B,,
885,,,CHEMBL615798,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,5640,,51,,,BAO_0000357,,Autocuration,,,B,,
886,,,CHEMBL872870,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,,6563,,51,,,BAO_0000357,,Autocuration,,,B,,
887,,,CHEMBL615799,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,,5548,,51,,,BAO_0000357,,Autocuration,,,B,,
888,,,CHEMBL615800,Percent binding affinity against 5-hydroxytryptamine 1A receptor,,6347,,51,,,BAO_0000357,,Autocuration,,,B,,
889,,,CHEMBL615801,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,17296,,51,,,BAO_0000219,,Autocuration,,,F,,HEK293
890,,,CHEMBL615802,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,,13047,,51,,,BAO_0000019,,Autocuration,,,B,,
891,,,CHEMBL615803,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,,15740,,51,,,BAO_0000357,,Autocuration,,,B,,
892,,,CHEMBL835002,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,5640,,51,,,BAO_0000019,,Expert,,,F,,
893,,,CHEMBL615804,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",,5640,,51,,,BAO_0000019,,Autocuration,,,F,,
894,,,CHEMBL615805,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,,17211,,51,,,BAO_0000219,,Expert,,,B,,HeLa
895,,,CHEMBL615806,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,,4751,,51,,,BAO_0000219,,Autocuration,,,B,,CHO
896,Homo sapiens,,CHEMBL615807,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,,6491,,51,,,BAO_0000357,,Expert,,9606.0,B,,
897,,,CHEMBL615808,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,,4707,,51,,,BAO_0000357,,Autocuration,,,B,,
898,Homo sapiens,,CHEMBL615809,Binding affinity against 5-hydroxytryptamine 1A receptor,,13910,,51,,,BAO_0000357,,Expert,,9606.0,B,,
899,,,CHEMBL615810,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,,16190,,51,,,BAO_0000219,,Autocuration,,,B,,HeLa
900,,,CHEMBL615811,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,16633,,51,,,BAO_0000357,,Autocuration,,,B,,
901,,,CHEMBL615812,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,,11898,,51,,,BAO_0000219,,Autocuration,,,B,,CHO
902,,,CHEMBL615751,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,11898,,51,,,BAO_0000219,,Autocuration,,,B,,CHO
903,,,CHEMBL615752,Binding affinity against human 5-hydroxytryptamine 1A receptor,,14331,,51,,,BAO_0000357,,Autocuration,,,B,,
904,,,CHEMBL615753,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,,17624,,51,,,BAO_0000219,,Expert,,,B,,CHO
905,,,CHEMBL615754,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,,17624,,51,,,BAO_0000219,,Autocuration,,,B,,CHO
906,,,CHEMBL615755,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,,3307,,51,,,BAO_0000357,,Autocuration,,,B,,
907,Homo sapiens,,CHEMBL615756,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,6563,,51,,,BAO_0000219,,Expert,,9606.0,B,,CHO
908,,,CHEMBL615757,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,,14165,,51,,,BAO_0000019,,Autocuration,,,B,,
909,,,CHEMBL615758,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,5732,,51,,,BAO_0000357,,Autocuration,,,B,,
910,,,CHEMBL615759,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,13366,,51,,,BAO_0000357,,Expert,,,B,,
911,,,CHEMBL615760,Binding affinity towards human 5-hydroxytryptamine 1A receptor,,17626,,51,,,BAO_0000357,,Autocuration,,,B,,
912,,,CHEMBL615761,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,,6588,,51,,,BAO_0000219,,Expert,,,B,,HeLa
913,,,CHEMBL872104,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,,16209,,51,,,BAO_0000357,,Autocuration,,,B,,
914,,,CHEMBL615762,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,15463,,51,,,BAO_0000357,,Autocuration,,,B,,
915,,,CHEMBL615763,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,15463,,51,,,BAO_0000357,,Autocuration,,,B,,
916,,,CHEMBL615764,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,,14770,,51,,,BAO_0000357,,Autocuration,,,B,,
917,,,CHEMBL615765,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),,16245,,51,,,BAO_0000219,,Autocuration,,,B,,Cell line
918,,,CHEMBL615766,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),,16245,,51,,,BAO_0000019,,Autocuration,,,B,,
919,,,CHEMBL615767,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,,5548,,51,,,BAO_0000357,,Autocuration,,,B,,
920,,,CHEMBL615768,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,5548,,51,,,BAO_0000357,,Expert,,,B,,
921,,,CHEMBL615769,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,5548,,51,,,BAO_0000357,,Autocuration,,,B,,
922,,,CHEMBL615770,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,,6876,,51,,,BAO_0000357,,Expert,,,B,,
923,,,CHEMBL615771,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,2598,,51,,,BAO_0000357,,Autocuration,,,B,,
924,,,CHEMBL615772,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,,17785,,51,,,BAO_0000357,,Expert,,,B,,
925,,,CHEMBL615773,Binding affinity towards 5-hydroxytryptamine 1A receptor,,6013,,51,,,BAO_0000357,,Autocuration,,,B,,
926,,,CHEMBL615774,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,5929,,51,,,BAO_0000357,,Expert,,,B,,
927,,,CHEMBL615775,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,16633,,51,,,BAO_0000357,,Autocuration,,,B,,
928,,,CHEMBL615776,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,1558,,51,,,BAO_0000357,,Autocuration,,,B,,
929,,,CHEMBL615777,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,16026,,51,,,BAO_0000357,,Expert,,,B,,
930,,,CHEMBL615778,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,,12469,,51,,,BAO_0000219,,Autocuration,,,B,,
931,Homo sapiens,,CHEMBL615779,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,15874,,51,,,BAO_0000357,,Expert,,9606.0,B,,
932,,,CHEMBL615780,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,15874,,51,,,BAO_0000357,,Autocuration,,,B,,
933,,,CHEMBL616298,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,,3935,,51,,,BAO_0000357,,Autocuration,,,B,,
934,,,CHEMBL616299,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,,15818,,51,,,BAO_0000357,,Autocuration,,,B,,
935,,,CHEMBL616300,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,,13706,,51,,,BAO_0000219,,Autocuration,,,B,,CHO-K1
936,,,CHEMBL616301,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,,13729,,51,,,BAO_0000219,,Expert,,,F,,CHO-K1
937,,,CHEMBL616302,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,,15413,,51,,,BAO_0000019,,Autocuration,,,B,,
938,,,CHEMBL616117,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),,15413,,51,,,BAO_0000019,,Autocuration,,,B,,
939,,,CHEMBL616118,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),,15413,,51,,,BAO_0000019,,Autocuration,,,B,,
940,,,CHEMBL616119,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,,15413,,51,,,BAO_0000019,,Autocuration,,,B,,
941,Homo sapiens,,CHEMBL616120,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,3445,,51,,,BAO_0000219,,Expert,,9606.0,B,,HeLa
942,,,CHEMBL616121,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,15740,,51,,,BAO_0000357,,Autocuration,,,B,,
943,,,CHEMBL616122,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,,15740,,51,,,BAO_0000357,,Autocuration,,,B,,
944,,,CHEMBL616123,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,,17626,,51,,,BAO_0000357,,Autocuration,,,B,,
945,Homo sapiens,,CHEMBL616124,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,,4234,,51,,,BAO_0000357,,Expert,,9606.0,B,,
946,,,CHEMBL616125,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,5640,,51,,,BAO_0000357,,Expert,,,B,,
947,Rattus norvegicus,,CHEMBL616126,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,,5272,,51,,,BAO_0000357,,Expert,,10116.0,B,,
948,,,CHEMBL616127,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,,4622,,51,,,BAO_0000219,,Autocuration,,,B,,CHO
949,,,CHEMBL616128,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,,17085,,51,,,BAO_0000019,,Expert,,,B,,
950,,,CHEMBL616129,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,3025,,51,,,BAO_0000357,,Autocuration,,,B,,
951,,,CHEMBL616130,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,15315,,51,,,BAO_0000357,,Expert,,,B,,
952,,,CHEMBL616131,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,,15267,,51,,,BAO_0000357,,Autocuration,,,B,,
953,,,CHEMBL616132,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,,17158,,51,,,BAO_0000219,,Autocuration,,,B,,HeLa
954,Homo sapiens,,CHEMBL616133,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,,14214,,51,,,BAO_0000219,,Expert,,9606.0,B,,HeLa
955,,,CHEMBL616134,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,17133,,51,,,BAO_0000357,,Autocuration,,,B,,
956,,,CHEMBL616135,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,,16532,,51,,,BAO_0000357,,Autocuration,,,B,,
957,Homo sapiens,,CHEMBL616136,Affinity for 5-hydroxytryptamine 1A receptor subtype,,2391,,51,,,BAO_0000357,,Expert,,9606.0,B,,
958,,,CHEMBL616137,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,,14447,,51,,,BAO_0000019,,Autocuration,,,B,,
959,,,CHEMBL872105,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,,14447,,51,,,BAO_0000019,,Autocuration,,,B,,
960,,,CHEMBL616138,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,,15086,,51,,,BAO_0000357,,Autocuration,,,B,,
961,Homo sapiens,,CHEMBL616139,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,13051,,51,,,BAO_0000357,,Expert,,9606.0,B,,
962,,,CHEMBL616140,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",,16026,,51,,,BAO_0000019,,Autocuration,,,F,,
963,,,CHEMBL616141,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,,17085,,51,,,BAO_0000019,,Expert,,,B,,
964,,,CHEMBL616142,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,17133,,51,,,BAO_0000357,,Autocuration,,,B,,
965,,,CHEMBL616143,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,,17133,,51,,,BAO_0000357,,Autocuration,,,B,,
966,,,CHEMBL616144,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,17211,,51,,,BAO_0000219,,Autocuration,,,B,,HeLa
967,,,CHEMBL616145,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,,17211,,51,,,BAO_0000219,,Autocuration,,,B,,HeLa
968,,,CHEMBL616012,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,17211,,51,,,BAO_0000219,,Autocuration,,,B,,HeLa
969,,,CHEMBL616013,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,17211,,51,,,BAO_0000219,,Autocuration,,,B,,HeLa
970,,,CHEMBL616014,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,16394,,51,,,BAO_0000019,,Autocuration,,,F,,
971,,,CHEMBL616015,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,16394,,51,,,BAO_0000019,,Autocuration,,,F,,
972,,,CHEMBL616016,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,16394,,51,,,BAO_0000019,,Autocuration,,,F,,
973,,,CHEMBL616017,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,In vivo,16394,,51,,,BAO_0000218,,Autocuration,,,F,,
974,,,CHEMBL616018,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,,16394,,51,,,BAO_0000019,,Autocuration,,,B,,
975,,,CHEMBL616019,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,,15740,,51,,,BAO_0000019,,Autocuration,,,F,,
976,,,CHEMBL616020,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,,15740,,51,,,BAO_0000019,,Autocuration,,,F,,
977,,,CHEMBL858018,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,15740,,51,,,BAO_0000357,,Autocuration,,,B,,
978,,,CHEMBL616021,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,17296,,51,,,BAO_0000219,,Autocuration,,,F,,HEK293
979,,,CHEMBL616022,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",,5640,,51,,,BAO_0000019,,Expert,,,F,,
980,,,CHEMBL616023,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",,5640,,51,,,BAO_0000019,,Autocuration,,,F,,
981,,,CHEMBL616024,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",,5640,,51,,,BAO_0000019,,Autocuration,,,F,,
982,,,CHEMBL616025,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",,5640,,51,,,BAO_0000019,,Autocuration,,,F,,
983,,,CHEMBL616026,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,2759,,51,,,BAO_0000219,,Autocuration,,,F,,CHO
984,,,CHEMBL616027,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",,16394,,51,,,BAO_0000019,,Autocuration,,,F,,
985,Homo sapiens,,CHEMBL616028,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",,16394,,51,,,BAO_0000019,,Expert,,9606.0,F,,
986,Homo sapiens,,CHEMBL616029,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,,3445,,51,,,BAO_0000019,,Expert,,9606.0,F,,
987,,,CHEMBL616030,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,,4316,,51,,,BAO_0000219,,Expert,,,B,,CHO
988,,,CHEMBL616031,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,,4316,,51,,,BAO_0000019,,Expert,,,B,,
989,Homo sapiens,,CHEMBL616032,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,15180,,51,,,BAO_0000019,,Expert,,9606.0,F,,
990,Homo sapiens,,CHEMBL616033,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,15180,,51,,,BAO_0000019,,Expert,,9606.0,F,,
991,,,CHEMBL616034,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,15042,,51,,,BAO_0000019,,Autocuration,,,F,,
992,,,CHEMBL616035,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,15042,,51,,,BAO_0000019,,Autocuration,,,F,,
993,,,CHEMBL616036,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,15042,,51,,,BAO_0000019,,Autocuration,,,F,,
994,,,CHEMBL616037,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,15042,,51,,,BAO_0000019,,Autocuration,,,F,,
995,,,CHEMBL616038,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,15042,,51,,,BAO_0000019,,Autocuration,,,F,,
996,,,CHEMBL616039,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,15042,,51,,,BAO_0000019,,Autocuration,,,F,,
997,,,CHEMBL616040,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,15042,,51,,,BAO_0000019,,Autocuration,,,F,,
998,Homo sapiens,,CHEMBL616041,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,15180,,51,,,BAO_0000219,,Expert,,9606.0,F,,HeLa
999,Homo sapiens,,CHEMBL616042,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,15180,,51,,,BAO_0000219,,Expert,,9606.0,F,,HeLa
1000,Homo sapiens,,CHEMBL616043,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,15180,,51,,,BAO_0000219,,Expert,,9606.0,F,,HeLa
1001,,,CHEMBL616044,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",,16245,,51,,,BAO_0000019,,Autocuration,,,F,,
1002,,,CHEMBL616045,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,16026,,51,,,BAO_0000019,,Autocuration,,,F,,
1003,,,CHEMBL616046,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,17296,,51,,,BAO_0000219,,Autocuration,,,F,,HEK293
1004,,,CHEMBL616047,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,2759,,51,,,BAO_0000219,,Autocuration,,,F,,CHO
1005,,,CHEMBL616048,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,2759,,51,,,BAO_0000219,,Autocuration,,,F,,CHO
1006,Homo sapiens,,CHEMBL616049,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),,2759,,51,,,BAO_0000219,,Expert,,9606.0,F,,CHO
1007,,,CHEMBL616050,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,2759,,51,,,BAO_0000219,,Autocuration,,,F,,CHO
1008,,,CHEMBL616051,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,,15419,,51,,,BAO_0000219,,Expert,,,F,,
1009,,,CHEMBL616212,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,,15419,,51,,,BAO_0000219,,Autocuration,,,F,,
1010,,,CHEMBL616213,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,16026,,51,,,BAO_0000019,,Autocuration,,,F,,
1011,,,CHEMBL616214,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,In vitro,1414,,51,,,BAO_0000219,,Expert,,,B,,
1012,,,CHEMBL616215,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,In vitro,1414,,51,,,BAO_0000219,,Expert,,,B,,
1013,,,CHEMBL616216,Binding activity radioligand.,,12861,,51,,,BAO_0000357,,Autocuration,,,B,,
1014,,,CHEMBL616217,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,12861,,51,,,BAO_0000019,,Autocuration,,,B,,
1015,,,CHEMBL616218,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,5104,,51,,,BAO_0000357,,Autocuration,,,B,,
1016,,,CHEMBL616219,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,5105,,51,,,BAO_0000357,,Autocuration,,,B,,
1017,,,CHEMBL616220,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,,16312,,51,,,BAO_0000357,,Autocuration,,,B,,
1018,Homo sapiens,,CHEMBL833493,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,,15180,,51,,,BAO_0000357,,Expert,,9606.0,B,,
1019,,,CHEMBL616221,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,,5033,,51,,,BAO_0000357,,Autocuration,,,B,,
1020,Homo sapiens,,CHEMBL616222,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,16909,,51,,,BAO_0000219,,Expert,,9606.0,B,,CHO
1021,,,CHEMBL616223,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,,2590,,51,,,BAO_0000019,,Autocuration,,,F,,
1022,,,CHEMBL616224,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,,2590,,51,,,BAO_0000019,,Autocuration,,,F,,
1023,,,CHEMBL616225,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,,16394,,51,,,BAO_0000019,,Expert,,,B,,
1024,Homo sapiens,,CHEMBL616226,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,,4540,,51,,,BAO_0000219,,Expert,,9606.0,B,,HEK293
1025,,,CHEMBL616227,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,,17296,,51,,,BAO_0000219,,Autocuration,,,B,,HEK293
1026,,,CHEMBL616228,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,,17296,,51,,,BAO_0000219,,Autocuration,,,B,,HEK293
1027,,,CHEMBL616229,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,15779,,51,,,BAO_0000219,,Autocuration,,,B,,HEK293
1028,,,CHEMBL616230,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,,15779,,51,,,BAO_0000219,,Autocuration,,,B,,HEK293
1029,,,CHEMBL616231,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,,15779,,51,,,BAO_0000219,,Autocuration,,,B,,HEK293
1030,,,CHEMBL616232,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,6166,,51,,,BAO_0000357,,Autocuration,,,B,,
1031,,,CHEMBL616233,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,15779,,51,,,BAO_0000219,,Autocuration,,,B,,HEK293
1032,,,CHEMBL857973,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,,4199,,51,,,BAO_0000219,,Autocuration,,,B,,HEK293
1033,,,CHEMBL616234,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,,15316,,51,,,BAO_0000219,,Autocuration,,,B,,
1034,,,CHEMBL616235,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,,14875,,51,,,BAO_0000357,,Autocuration,,,B,,
1035,,,CHEMBL616236,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,14727,,51,,,BAO_0000219,,Expert,,,B,,HeLa
1036,,,CHEMBL616237,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,14727,,51,,,BAO_0000019,,Expert,,,B,,
1037,,,CHEMBL616238,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,,15146,,51,,,BAO_0000219,,Autocuration,,,B,,HEK293
1038,,,CHEMBL616239,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,,5213,,51,,,BAO_0000219,,Autocuration,,,B,,HEK293
1039,,,CHEMBL616240,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,,16429,,51,,,BAO_0000219,,Autocuration,,,B,,
1040,Homo sapiens,,CHEMBL616241,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,,15042,,51,,,BAO_0000219,,Expert,,9606.0,B,,HeLa
1041,,,CHEMBL616242,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,,14818,,51,,,BAO_0000219,,Autocuration,,,B,,HEK293
1042,,,CHEMBL616243,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",,4829,,51,,,BAO_0000219,,Autocuration,,,B,,HEK293
1043,,,CHEMBL616244,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,17200,,51,,,BAO_0000357,,Expert,,,B,,
1044,Homo sapiens,,CHEMBL616245,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,,13051,,51,,,BAO_0000357,,Autocuration,,9606.0,B,,
1045,,,CHEMBL616246,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,5486,,106,,,BAO_0000357,,Autocuration,,,B,,
1046,,,CHEMBL616247,Binding affinity against 5-HT1D receptor,,5254,,105,,,BAO_0000357,,Autocuration,,,B,,
1047,,,CHEMBL616248,Binding affinity against 5-hydroxytryptamine 1A receptor,,5254,,105,,,BAO_0000357,,Autocuration,,,B,,
1048,,,CHEMBL616249,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,15331,,107,,,BAO_0000357,,Autocuration,,,B,,
1049,Homo sapiens,,CHEMBL616250,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,13506,,10576,,,BAO_0000357,,Autocuration,,9606.0,B,,
1050,,,CHEMBL616251,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,15267,,51,,,BAO_0000357,,Autocuration,,,B,,
1051,,,CHEMBL616252,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,In vivo,16616,,11863,,,BAO_0000218,,Autocuration,,,F,,
1052,,,CHEMBL616253,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,In vivo,16616,,11863,,,BAO_0000218,,Autocuration,,,F,,
1053,,,CHEMBL616254,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,In vivo,16616,,11863,,,BAO_0000218,,Autocuration,,,F,,
1054,Mus musculus,,CHEMBL616255,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,,16616,,11863,,,BAO_0000218,,Expert,,10090.0,F,,
1055,Mus musculus,,CHEMBL832872,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,,16616,,11863,,,BAO_0000218,,Expert,,10090.0,F,,
1056,Mus musculus,,CHEMBL616256,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,,16616,,11863,,,BAO_0000218,,Expert,,10090.0,F,,
1057,Mus musculus,,CHEMBL616257,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,,16616,,11863,,,BAO_0000218,,Expert,,10090.0,F,,
1058,Mus musculus,,CHEMBL616258,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,,16616,,11863,,,BAO_0000218,,Expert,,10090.0,F,,
1059,Mus musculus,,CHEMBL616384,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,,16616,,11863,,,BAO_0000218,,Expert,,10090.0,F,,
1060,,10000000.0,CHEMBL616385,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,10297,Hippocampus,11863,,,BAO_0000221,,Autocuration,,,B,,
1061,,,CHEMBL616386,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,,13704,,11863,,,BAO_0000357,,Expert,,,B,,
1062,Mus musculus,10000000.0,CHEMBL616387,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,10297,Hippocampus,11863,,,BAO_0000221,,Expert,,10090.0,B,,
1063,,10000000.0,CHEMBL616388,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,10297,Hippocampus,11863,,,BAO_0000221,,Autocuration,,,B,,
1064,Mus musculus,10000000.0,CHEMBL616389,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,10297,Hippocampus,11863,,,BAO_0000221,,Expert,,10090.0,B,,
1065,,10000000.0,CHEMBL616390,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,10297,Hippocampus,11863,,,BAO_0000221,,Autocuration,,,B,,
1066,,,CHEMBL616391,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,,217,,11863,,,BAO_0000357,,Autocuration,,,B,,
1067,Mus musculus,10000000.0,CHEMBL616392,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,10297,Hippocampus,11863,,,BAO_0000221,,Expert,,10090.0,B,,
1068,Sus scrofa,,CHEMBL616393,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,,4921,,51,,,BAO_0000357,,Autocuration,,9823.0,B,,
1069,Sus scrofa,,CHEMBL616394,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,,4921,,51,,,BAO_0000357,,Autocuration,,9823.0,B,,
1070,Sus scrofa,,CHEMBL616395,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,,4996,,51,,,BAO_0000019,,Autocuration,,9823.0,B,,
1071,Sus scrofa,,CHEMBL616396,Compound was evaluated for the binding affinity at 5- HT1A receptor,,12918,,51,,,BAO_0000357,,Autocuration,,9823.0,B,,
1072,Sus scrofa,,CHEMBL872907,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,5333,,51,,,BAO_0000019,,Autocuration,,9823.0,B,,
1073,Sus scrofa,,CHEMBL616397,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,4437,,51,,,BAO_0000019,,Autocuration,,9823.0,B,,
1074,Sus scrofa,,CHEMBL616398,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,,1742,,51,,,BAO_0000019,,Autocuration,,9823.0,B,,
1075,Sus scrofa,,CHEMBL616399,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,,16688,,51,,,BAO_0000357,,Expert,,9823.0,B,,
1076,Sus scrofa,,CHEMBL857065,Binding activity radioligand.,,12861,,51,,,BAO_0000357,,Autocuration,,9823.0,B,,
1077,Sus scrofa,,CHEMBL616400,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,12861,,51,,,BAO_0000019,,Expert,,9823.0,B,,
1078,Sus scrofa,,CHEMBL616401,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,12861,,51,,,BAO_0000019,,Autocuration,,9823.0,B,,
1079,,,CHEMBL616402,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,,12490,,10624,,,BAO_0000019,,Expert,,,B,,
1080,Sus scrofa,,CHEMBL616403,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,,11828,,51,,,BAO_0000019,,Expert,,9823.0,B,,
1081,Sus scrofa,10000000.0,CHEMBL616404,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,,11866,Hippocampus,51,,,BAO_0000221,,Autocuration,,9823.0,B,,
1082,Sus scrofa,,CHEMBL616405,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,,12827,,51,,,BAO_0000249,,Autocuration,,9823.0,B,,
1083,Sus scrofa,,CHEMBL616406,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,,12918,,51,,,BAO_0000019,,Autocuration,,9823.0,B,,
1084,Sus scrofa,,CHEMBL616407,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,,12919,,51,,,BAO_0000019,,Expert,,9823.0,F,,
1085,Oryctolagus cuniculus,,CHEMBL616408,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,,13047,,51,,,BAO_0000019,,Autocuration,,9986.0,B,,
1086,Rattus norvegicus,,CHEMBL616409,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,,15796,,10576,,,BAO_0000249,,Expert,,10116.0,B,,
1087,Rattus norvegicus,10000000.0,CHEMBL616410,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",,3651,Hippocampus,10576,,,BAO_0000221,,Expert,,10116.0,B,,
1088,,,CHEMBL616411,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,,188,,10576,,,BAO_0000357,,Autocuration,,,B,,
1089,Rattus norvegicus,,CHEMBL616412,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,16616,,10576,,,BAO_0000249,,Expert,Membranes,10116.0,F,,
1090,Rattus norvegicus,10000000.0,CHEMBL616413,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",,16616,Hippocampus,10576,,,BAO_0000249,,Expert,Membranes,10116.0,F,,
1091,,10000000.0,CHEMBL616414,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,12306,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1092,Rattus norvegicus,10000000.0,CHEMBL616415,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,,17167,Hippocampus,10576,,,BAO_0000221,,Expert,,10116.0,B,,
1093,,,CHEMBL616416,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,,14776,,10576,,,BAO_0000019,,Autocuration,,,B,,
1094,,,CHEMBL616417,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,,12158,,10576,,,BAO_0000357,,Expert,,,B,,
1095,,,CHEMBL616418,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,,13481,,10576,,,BAO_0000357,,Autocuration,,,B,,
1096,,,CHEMBL616419,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,In vitro,13427,,10576,,,BAO_0000219,,Autocuration,,,B,,
1097,,,CHEMBL616420,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,,10210,,10576,,,BAO_0000357,,Autocuration,,,B,,
1098,,,CHEMBL616421,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,10205,,10576,,,BAO_0000249,,Autocuration,Membranes,,B,,
1099,,,CHEMBL616422,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,10205,,10576,,,BAO_0000249,,Autocuration,Membranes,,B,,
1100,,,CHEMBL616423,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,,10205,,10576,,,BAO_0000249,,Expert,Membranes,,B,,
1101,Rattus norvegicus,,CHEMBL616424,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,,12280,,10576,,,BAO_0000357,,Expert,,10116.0,B,,
1102,,,CHEMBL616425,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,,17386,,10576,,,BAO_0000357,,Expert,,,B,,
1103,,,CHEMBL616426,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,,13654,,10576,,,BAO_0000357,,Expert,,,B,,
1104,,10000000.0,CHEMBL616427,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,,14423,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1105,,10000000.0,CHEMBL616428,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,,15412,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1106,,10000000.0,CHEMBL616290,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,12073,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1107,Rattus norvegicus,,CHEMBL616052,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,,4101,,10576,,,BAO_0000357,,Expert,,10116.0,B,,
1108,,,CHEMBL616053,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,,10062,,10576,,,BAO_0000357,,Autocuration,,,B,,
1109,,,CHEMBL616054,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,,6238,,10576,,,BAO_0000249,,Autocuration,,,B,,
1110,,,CHEMBL616055,Binding affinity towards 5-hydroxytryptamine 1A receptor,,16273,,10576,,,BAO_0000357,,Autocuration,,,B,,
1111,,,CHEMBL616056,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,,11139,,10576,,,BAO_0000357,,Autocuration,,,B,,
1112,,,CHEMBL616057,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,16796,,10576,,,BAO_0000019,,Expert,,,B,,
1113,Rattus norvegicus,955.0,CHEMBL616058,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,9548,Brain,10576,,,BAO_0000221,,Expert,,10116.0,B,,
1114,,955.0,CHEMBL616059,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,10381,Brain,10576,,,BAO_0000221,,Autocuration,,,B,,
1115,,,CHEMBL616060,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,,13408,,10576,,,BAO_0000249,,Autocuration,,,B,,
1116,Rattus norvegicus,10000000.0,CHEMBL616061,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,,13825,Hippocampus,10576,,,BAO_0000221,,Expert,,10116.0,B,,
1117,,10000000.0,CHEMBL616062,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,,11147,Hippocampus,10576,,,BAO_0000221,,Expert,,,B,,
1118,,,CHEMBL616063,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,,10552,,10576,,,BAO_0000249,,Autocuration,,,B,,
1119,,2435.0,CHEMBL616064,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,10552,Striatum,10576,,,BAO_0000249,,Autocuration,,,B,,
1120,Rattus norvegicus,,CHEMBL616065,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,,17136,,10576,,,BAO_0000249,,Expert,Membranes,10116.0,B,,
1121,Rattus norvegicus,,CHEMBL616066,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,,5778,,10576,,,BAO_0000249,,Expert,Membranes,10116.0,B,,
1122,,10000000.0,CHEMBL616067,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,13481,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1123,,10000000.0,CHEMBL616068,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,,13481,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1124,,10000000.0,CHEMBL616069,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,,13630,Hippocampus,10576,,,BAO_0000221,,Intermediate,,,B,,
1125,,,CHEMBL616070,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,16245,,10576,,,BAO_0000249,,Expert,,,B,,
1126,,10000000.0,CHEMBL616071,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,,14509,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1127,,10000000.0,CHEMBL616072,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,,14509,Hippocampus,10576,,,BAO_0000221,,Expert,,,B,,
1128,,10000000.0,CHEMBL616073,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,,14509,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1129,,10000000.0,CHEMBL616074,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,,14509,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1130,,,CHEMBL616075,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,,14256,,10576,,,BAO_0000019,,Expert,,,B,,
1131,,,CHEMBL616076,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,,11139,,10576,,,BAO_0000357,,Autocuration,,,B,,
1132,Rattus norvegicus,,CHEMBL616077,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,,11047,,10576,,,BAO_0000019,,Expert,,10116.0,B,,
1133,Rattus norvegicus,,CHEMBL616078,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,,11047,,10576,,,BAO_0000019,,Expert,,10116.0,B,,
1134,Rattus norvegicus,,CHEMBL616079,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,,11047,,10576,,,BAO_0000019,,Expert,,10116.0,B,,
1135,Rattus norvegicus,,CHEMBL616080,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,2395,,10576,,,BAO_0000219,,Expert,,10116.0,B,,CHO-K1
1136,,,CHEMBL616081,Binding affinity towards 5-hydroxytryptamine 1A receptor,,9699,,10576,,,BAO_0000357,,Autocuration,,,B,,
1137,Rattus norvegicus,10000000.0,CHEMBL616082,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,,12028,Hippocampus,10576,,,BAO_0000221,,Expert,,10116.0,B,,
1138,,10000000.0,CHEMBL616083,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,,12028,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1139,,,CHEMBL616084,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,5815,,10576,,,BAO_0000019,,Autocuration,,,B,,
1140,,,CHEMBL616085,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,,16616,,10576,,,BAO_0000019,,Expert,,,B,,
1141,,,CHEMBL616086,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,,5815,,10576,,,BAO_0000019,,Autocuration,,,B,,
1142,,10000000.0,CHEMBL616087,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",,2761,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1143,,,CHEMBL616088,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,,13133,,10576,,,BAO_0000357,,Expert,,,B,,
1144,,,CHEMBL616089,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,,10444,,10576,,,BAO_0000019,,Autocuration,,,B,,
1145,Rattus norvegicus,,CHEMBL616090,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,,13278,,10576,,,BAO_0000357,,Expert,,10116.0,B,,
1146,,,CHEMBL616091,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,15874,,10576,,,BAO_0000357,,Autocuration,,,B,,
1147,,2435.0,CHEMBL616092,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,10552,Striatum,10576,,,BAO_0000249,,Autocuration,Membranes,,B,,
1148,,,CHEMBL616093,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),,11130,,10576,,,BAO_0000357,,Autocuration,,,B,,
1149,,,CHEMBL616094,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),In vivo,11130,,10576,,,BAO_0000218,,Autocuration,,,B,,
1150,,955.0,CHEMBL616095,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,,14542,Brain,10576,,,BAO_0000221,,Autocuration,,,B,,
1151,Rattus norvegicus,,CHEMBL616096,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,13670,,10576,,,BAO_0000357,,Expert,,10116.0,B,,
1152,,,CHEMBL616097,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,,9888,,10576,,,BAO_0000249,,Expert,,,B,,
1153,Rattus norvegicus,,CHEMBL616098,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,,3678,,10576,,,BAO_0000249,,Expert,Membranes,10116.0,B,,
1154,,10000000.0,CHEMBL616099,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,11332,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1155,,10000000.0,CHEMBL616100,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,11332,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1156,,,CHEMBL616101,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,1185,,10576,,,BAO_0000357,,Expert,,,B,,
1157,,,CHEMBL616102,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,,2014,,10576,,,BAO_0000249,,Expert,,,B,,
1158,,,CHEMBL616103,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,1185,,10576,,,BAO_0000357,,Autocuration,,,B,,
1159,,,CHEMBL616104,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,,14429,,10576,,,BAO_0000019,,Expert,,,B,,
1160,,,CHEMBL616105,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",,16288,,10576,,,BAO_0000019,,Expert,,,B,,
1161,Rattus norvegicus,,CHEMBL616106,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,,5432,,10576,,,BAO_0000019,,Expert,,10116.0,B,,
1162,,,CHEMBL616107,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,,14429,,10576,,,BAO_0000019,,Autocuration,,,B,,
1163,,,CHEMBL616108,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,,13672,,10576,,,BAO_0000357,,Expert,,,B,,
1164,,10000000.0,CHEMBL616109,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,11296,Hippocampus,10576,,,BAO_0000221,,Expert,,,B,,
1165,,,CHEMBL616110,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,,11296,,10576,,,BAO_0000357,,Autocuration,,,B,,
1166,,,CHEMBL616111,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,,14749,,10576,,,BAO_0000219,,Expert,,,B,,CHO
1167,,,CHEMBL616112,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,,15086,,10576,,,BAO_0000019,,Expert,,,B,,
1168,,10000000.0,CHEMBL616113,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,,13462,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1169,,,CHEMBL616114,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,15363,,10576,,,BAO_0000019,,Autocuration,,,B,,
1170,,,CHEMBL616115,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,15363,,10576,,,BAO_0000019,,Autocuration,,,B,,
1171,,,CHEMBL616116,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,,10796,,10576,,,BAO_0000357,,Autocuration,,,B,,
1172,,955.0,CHEMBL615844,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,,12816,Brain,10576,,,BAO_0000221,,Expert,,,B,,
1173,,10000000.0,CHEMBL615939,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,13542,Hippocampus,10576,,,BAO_0000221,,Expert,,,B,,
1174,,,CHEMBL615940,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,,13308,,10576,,,BAO_0000019,,Expert,,,B,,
1175,,10000000.0,CHEMBL615941,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,,13541,Hippocampus,10576,,,BAO_0000221,,Expert,,,B,,
1176,,10000000.0,CHEMBL615942,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,,10058,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1177,,10000000.0,CHEMBL615943,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,10058,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1178,,10000000.0,CHEMBL615944,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,,10058,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1179,,10000000.0,CHEMBL615945,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,,10058,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1180,,10000000.0,CHEMBL615946,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,,10058,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1181,,10000000.0,CHEMBL615947,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,,10058,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1182,,10000000.0,CHEMBL615948,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,,10058,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1183,,10000000.0,CHEMBL615949,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,,10058,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1184,,10000000.0,CHEMBL615950,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,,10058,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1185,,10000000.0,CHEMBL615951,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,,10058,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1186,,10000000.0,CHEMBL615952,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,,10058,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1187,,10000000.0,CHEMBL615953,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,,10058,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1188,,10000000.0,CHEMBL615954,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,,10058,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1189,Rattus norvegicus,10000000.0,CHEMBL615955,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,10058,Hippocampus,10576,,,BAO_0000221,,Expert,,10116.0,B,,
1190,,10000000.0,CHEMBL615956,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,,10058,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1191,,10000000.0,CHEMBL615957,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,,10058,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1192,,,CHEMBL615958,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,,12879,,10576,,,BAO_0000019,,Expert,,,B,,
1193,,,CHEMBL615959,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,,11964,,10576,,,BAO_0000019,,Expert,,,B,,
1194,,,CHEMBL615960,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),,11964,,10576,,,BAO_0000019,,Autocuration,,,B,,
1195,,,CHEMBL615961,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),,11964,,10576,,,BAO_0000019,,Autocuration,,,B,,
1196,,955.0,CHEMBL615962,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,9548,Brain,10576,,,BAO_0000221,,Expert,,,B,,
1197,,,CHEMBL615963,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,,9098,,10576,,,BAO_0000019,,Expert,,,B,,
1198,,,CHEMBL615964,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,,9098,,10576,,,BAO_0000019,,Autocuration,,,B,,
1199,,,CHEMBL615965,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,,9098,,10576,,,BAO_0000019,,Autocuration,,,B,,
1200,,,CHEMBL615966,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,,13248,,10576,,,BAO_0000219,,Expert,,,B,,CHO
1201,,,CHEMBL615967,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,,3147,,10576,,,BAO_0000249,,Expert,,,B,,
1202,,,CHEMBL615968,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,13949,,10576,,,BAO_0000019,,Expert,,,B,,
1203,,,CHEMBL615969,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,11883,,10576,,,BAO_0000218,,Autocuration,,,B,,CHO
1204,,,CHEMBL615970,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),,11883,,10576,,,BAO_0000218,,Autocuration,,,B,,
1205,Rattus norvegicus,,CHEMBL615971,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,,11883,,10576,,,BAO_0000357,,Expert,,10116.0,B,,
1206,,,CHEMBL615972,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,15535,,10576,,,BAO_0000249,,Expert,Membranes,,B,,
1207,,,CHEMBL615973,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,,15535,,10576,,,BAO_0000249,,Autocuration,,,B,,
1208,,,CHEMBL615974,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,,15535,,10576,,,BAO_0000249,,Autocuration,,,B,,
1209,Homo sapiens,,CHEMBL615975,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,16372,,51,,,BAO_0000219,,Expert,,9606.0,B,,CHO
1210,,,CHEMBL615976,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,,14608,,10576,,,BAO_0000249,,Expert,,,B,,
1211,Rattus norvegicus,10000000.0,CHEMBL872106,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,,4795,Hippocampus,10576,,,BAO_0000221,,Expert,,10116.0,B,,
1212,,,CHEMBL615977,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,13863,,10576,,,BAO_0000357,,Autocuration,,,B,,
1213,,,CHEMBL615978,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,,13863,,10576,,,BAO_0000357,,Autocuration,,,B,,
1214,,,CHEMBL616166,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,,13863,,10576,,,BAO_0000357,,Autocuration,,,B,,
1215,,,CHEMBL616167,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,,13863,,10576,,,BAO_0000357,,Autocuration,,,B,,
1216,,,CHEMBL616168,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,,13863,,10576,,,BAO_0000357,,Autocuration,,,B,,
1217,,,CHEMBL616169,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,,13863,,10576,,,BAO_0000357,,Autocuration,,,B,,
1218,,,CHEMBL616170,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,,13863,,10576,,,BAO_0000357,,Autocuration,,,B,,
1219,,,CHEMBL616171,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,,13863,,10576,,,BAO_0000357,,Autocuration,,,B,,
1220,,,CHEMBL616172,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,,13863,,10576,,,BAO_0000357,,Autocuration,,,B,,
1221,,,CHEMBL616173,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,,13863,,10576,,,BAO_0000357,,Autocuration,,,B,,
1222,,,CHEMBL616174,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,,13863,,10576,,,BAO_0000357,,Autocuration,,,B,,
1223,,,CHEMBL616175,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,,13863,,10576,,,BAO_0000357,,Autocuration,,,B,,
1224,,,CHEMBL616176,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,,13863,,10576,,,BAO_0000357,,Autocuration,,,B,,
1225,,,CHEMBL616177,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,,13863,,10576,,,BAO_0000357,,Autocuration,,,B,,
1226,,,CHEMBL616178,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,,13863,,10576,,,BAO_0000357,,Autocuration,,,B,,
1227,,,CHEMBL616179,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,,9742,,10576,,,BAO_0000019,,Autocuration,,,B,,
1228,,,CHEMBL616180,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,,12073,,10576,,,BAO_0000357,,Autocuration,,,B,,
1229,,,CHEMBL616181,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,,4101,,10576,,,BAO_0000357,,Autocuration,,,B,,
1230,,,CHEMBL616182,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,,15360,,10576,,,BAO_0000019,,Autocuration,,,B,,
1231,,10000000.0,CHEMBL616183,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,11576,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1232,,,CHEMBL615874,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,,5834,,10576,,,BAO_0000019,,Expert,,,B,,
1233,Rattus norvegicus,,CHEMBL615875,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,2395,,10576,,,BAO_0000219,,Expert,,10116.0,B,,CHO-K1
1234,,,CHEMBL615876,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,,1375,,10576,,,BAO_0000019,,Autocuration,,,B,,
1235,,,CHEMBL615877,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,,1375,,10576,,,BAO_0000019,,Autocuration,,,B,,
1236,,,CHEMBL615878,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),,3967,,10576,,,BAO_0000357,,Autocuration,,,B,,
1237,,,CHEMBL615879,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,,12884,,10576,,,BAO_0000357,,Expert,,,B,,
1238,,,CHEMBL615880,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,,2343,,10576,,,BAO_0000357,,Expert,,,B,,
1239,,,CHEMBL615881,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,11511,,10576,,,BAO_0000019,,Autocuration,,,B,,
1240,Rattus norvegicus,,CHEMBL615882,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,11511,,10576,,,BAO_0000019,,Expert,,10116.0,B,,
1241,,,CHEMBL615883,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,In vivo,16394,,10576,,,BAO_0000218,,Autocuration,,,F,,
1242,,,CHEMBL615884,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),In vivo,16394,,10576,,,BAO_0000218,,Autocuration,,,F,,
1243,,,CHEMBL615885,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),In vivo,16394,,10576,,,BAO_0000218,,Autocuration,,,F,,
1244,,,CHEMBL615886,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),In vivo,16394,,10576,,,BAO_0000218,,Autocuration,,,F,,
1245,,,CHEMBL615887,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),In vivo,16394,,10576,,,BAO_0000218,,Autocuration,,,F,,
1246,,,CHEMBL615888,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),In vivo,16394,,10576,,,BAO_0000218,,Autocuration,,,F,,
1247,,,CHEMBL615889,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),In vivo,16394,,10576,,,BAO_0000218,,Autocuration,,,F,,
1248,,,CHEMBL615890,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),In vivo,16394,,10576,,,BAO_0000218,,Autocuration,,,F,,
1249,,,CHEMBL615891,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),In vivo,16394,,10576,,,BAO_0000218,,Autocuration,,,F,,
1250,,,CHEMBL615892,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),In vivo,16394,,10576,,,BAO_0000218,,Autocuration,,,F,,
1251,,,CHEMBL615893,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),In vivo,16394,,10576,,,BAO_0000218,,Autocuration,,,F,,
1252,,,CHEMBL615894,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),In vivo,16394,,10576,,,BAO_0000218,,Autocuration,,,F,,
1253,,,CHEMBL615895,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),In vivo,16394,,10576,,,BAO_0000218,,Autocuration,,,F,,
1254,,,CHEMBL615896,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),In vivo,16394,,10576,,,BAO_0000218,,Autocuration,,,F,,
1255,,,CHEMBL615897,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,In vivo,16394,,10576,,,BAO_0000218,,Autocuration,,,F,,
1256,Rattus norvegicus,,CHEMBL615898,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,16616,,10576,,,BAO_0000249,,Expert,Membranes,10116.0,F,,
1257,,,CHEMBL615899,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,,16796,,10576,,,BAO_0000019,,Autocuration,,,B,,
1258,,,CHEMBL616291,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,16796,,10576,,,BAO_0000019,,Autocuration,,,B,,
1259,,,CHEMBL616292,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,,15629,,10576,,,BAO_0000357,,Autocuration,,,B,,
1260,,,CHEMBL616293,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,13241,,10576,,,BAO_0000249,,Autocuration,,,F,,
1261,,10000000.0,CHEMBL616294,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,12073,Hippocampus,10576,,,BAO_0000221,,Expert,,,B,,
1262,,10000000.0,CHEMBL616295,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,,14286,Hippocampus,10576,,,BAO_0000249,,Autocuration,,,B,,
1263,,955.0,CHEMBL616296,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,,14542,Brain,10576,,,BAO_0000221,,Autocuration,,,B,,
1264,,,CHEMBL616297,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,13630,,10576,,,BAO_0000019,,Autocuration,,,F,,
1265,,,CHEMBL616605,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,,13630,,10576,,,BAO_0000019,,Autocuration,,,F,,
1266,,,CHEMBL616606,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,,13630,,10576,,,BAO_0000019,,Autocuration,,,F,,
1267,,,CHEMBL616607,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,13630,,10576,,,BAO_0000019,,Autocuration,,,F,,
1268,,,CHEMBL616608,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,13630,,10576,,,BAO_0000019,,Expert,,,F,,
1269,,,CHEMBL616609,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,,13630,,10576,,,BAO_0000019,,Autocuration,,,F,,
1270,Rattus norvegicus,,CHEMBL616610,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,,13630,,10576,,,BAO_0000019,,Expert,,10116.0,F,,
1271,,,CHEMBL616611,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,13630,,10576,,,BAO_0000019,,Autocuration,,,F,,
1272,,,CHEMBL616612,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,,13630,,10576,,,BAO_0000019,,Expert,,,F,,
1273,,,CHEMBL616613,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,,13630,,10576,,,BAO_0000019,,Autocuration,,,F,,
1274,,,CHEMBL616614,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,,13630,,10576,,,BAO_0000019,,Expert,,,F,,
1275,,,CHEMBL616615,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,,13630,,10576,,,BAO_0000019,,Autocuration,,,F,,
1276,,,CHEMBL616616,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,13630,,10576,,,BAO_0000019,,Expert,,,F,,
1277,,,CHEMBL616617,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,,13630,,10576,,,BAO_0000019,,Autocuration,,,F,,
1278,,,CHEMBL616618,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,13630,,10576,,,BAO_0000019,,Autocuration,,,F,,
1279,,,CHEMBL616619,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,,13630,,10576,,,BAO_0000019,,Autocuration,,,F,,
1280,,,CHEMBL616620,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,,13630,,10576,,,BAO_0000019,,Expert,,,F,,
1281,,,CHEMBL616621,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,13630,,10576,,,BAO_0000019,,Expert,,,F,,
1282,,,CHEMBL616622,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,,13630,,10576,,,BAO_0000019,,Autocuration,,,F,,
1283,,,CHEMBL616146,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,,13630,,10576,,,BAO_0000019,,Expert,,,F,,
1284,,,CHEMBL832873,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,,13630,,10576,,,BAO_0000019,,Autocuration,,,F,,
1285,,,CHEMBL616147,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,,13630,,10576,,,BAO_0000019,,Autocuration,,,F,,
1286,,,CHEMBL872872,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,13630,,10576,,,BAO_0000019,,Autocuration,,,F,,
1287,,,CHEMBL616148,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,13630,,10576,,,BAO_0000019,,Autocuration,,,F,,
1288,,10000000.0,CHEMBL616149,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,,9783,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1289,,10000000.0,CHEMBL616150,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,,9783,Hippocampus,10576,,,BAO_0000221,,Expert,,,B,,
1290,Rattus norvegicus,,CHEMBL616151,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,,14331,,10576,,,BAO_0000249,,Expert,Membranes,10116.0,B,,
1291,,10000000.0,CHEMBL872873,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,,15260,Hippocampus,10576,,,BAO_0000221,,Expert,,,B,,
1292,,10000000.0,CHEMBL616670,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,,15260,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1293,,10000000.0,CHEMBL616671,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,,15260,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1294,Rattus norvegicus,,CHEMBL884861,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,16616,,10576,,,BAO_0000249,,Expert,,10116.0,F,,
1295,,,CHEMBL616672,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,,15629,,10576,,,BAO_0000357,,Autocuration,,,B,,
1296,,,CHEMBL616673,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,15086,,10576,,,BAO_0000019,,Autocuration,,,B,,
1297,,,CHEMBL616674,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,5717,,10576,,,BAO_0000019,,Expert,,,F,,
1298,,,CHEMBL616675,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,12652,,10576,,,BAO_0000357,,Autocuration,,,B,,
1299,,10000000.0,CHEMBL616676,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,,14608,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1300,,10000000.0,CHEMBL616677,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,12306,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1301,,10000000.0,CHEMBL616678,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,12306,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1302,Rattus norvegicus,,CHEMBL616679,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,15247,,10576,,,BAO_0000357,,Expert,,10116.0,B,,
1303,,10000000.0,CHEMBL616680,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,,17529,Hippocampus,10576,,,BAO_0000221,,Expert,,,B,,
1304,,10000000.0,CHEMBL616681,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,14826,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1305,,10000000.0,CHEMBL616682,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,14826,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1306,,10000000.0,CHEMBL616683,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,13241,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1307,,10000000.0,CHEMBL616684,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,,14093,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1308,,10000000.0,CHEMBL616685,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,,14093,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1309,,955.0,CHEMBL616686,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,,14442,Brain,10576,,,BAO_0000221,,Autocuration,,,B,,
1310,,,CHEMBL616687,Affinity for 5-hydroxytryptamine 1A receptor site,,9919,,10576,,,BAO_0000357,,Autocuration,,,B,,
1311,,,CHEMBL616688,Affinity for 5-hydroxytryptamine 1A receptor site,,9919,,10576,,,BAO_0000357,,Autocuration,,,B,,
1312,,10000000.0,CHEMBL616689,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,,11440,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1313,,,CHEMBL616690,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,,11257,,10576,,,BAO_0000357,,Autocuration,,,B,,
1314,,,CHEMBL616691,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,,10330,,10576,,,BAO_0000357,,Expert,,,B,,
1315,Rattus norvegicus,10000000.0,CHEMBL616692,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,,17331,Hippocampus,10576,,,BAO_0000221,,Expert,,10116.0,B,,
1316,,,CHEMBL616693,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,,16567,,10576,,,BAO_0000249,,Expert,,,B,,
1317,Rattus norvegicus,,CHEMBL616694,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,12058,,10576,,,BAO_0000019,,Expert,,10116.0,B,,
1318,,10000000.0,CHEMBL616695,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,,9699,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1319,,,CHEMBL616696,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,,9547,,10576,,,BAO_0000357,,Autocuration,,,B,,
1320,,,CHEMBL616697,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,,10330,,10576,,,BAO_0000357,,Autocuration,,,B,,
1321,,,CHEMBL616698,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,14331,,10576,,,BAO_0000357,,Autocuration,,,B,,
1322,Rattus norvegicus,,CHEMBL616949,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,,14060,,10576,,,BAO_0000019,,Expert,,10116.0,B,,
1323,,10000000.0,CHEMBL616950,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,,14744,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1324,,,CHEMBL832875,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,13506,,10576,,,BAO_0000357,,Autocuration,,,B,,
1325,,955.0,CHEMBL616951,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,10862,Brain,10576,,,BAO_0000221,,Expert,,,B,,
1326,,955.0,CHEMBL616952,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,10862,Brain,10576,,,BAO_0000221,,Expert,,,B,,
1327,,,CHEMBL616953,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,,10062,,10576,,,BAO_0000357,,Expert,,,B,,
1328,,,CHEMBL616954,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,,12073,,10576,,,BAO_0000357,,Autocuration,,,B,,
1329,,,CHEMBL616955,GTPgammaS radioligand binding assay,,14875,,106,,,BAO_0000357,,Autocuration,,,B,,
1330,,,CHEMBL616956,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,2391,,106,,,BAO_0000357,,Autocuration,,,B,,
1331,,,CHEMBL616957,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,,2391,,106,,,BAO_0000019,,Autocuration,,,F,,
1332,,,CHEMBL616958,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,,2391,,106,,,BAO_0000019,,Autocuration,,,F,,
1333,,,CHEMBL616959,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,2391,,106,,,BAO_0000357,,Autocuration,,,B,,
1334,,,CHEMBL616960,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,2391,,106,,,BAO_0000357,,Autocuration,,,B,,
1335,,,CHEMBL616961,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,,2391,,106,,,BAO_0000019,,Autocuration,,,F,,
1336,,,CHEMBL616962,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,,17211,,106,,,BAO_0000219,,Expert,,,B,,HeLa
1337,,,CHEMBL616963,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,,17211,,106,,,BAO_0000219,,Autocuration,,,B,,HeLa
1338,Homo sapiens,,CHEMBL616524,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,,6491,,106,,,BAO_0000357,,Expert,,9606.0,B,,
1339,,,CHEMBL616525,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,16190,,106,,,BAO_0000219,,Autocuration,,,B,,CHO
1340,,,CHEMBL872908,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,,14165,,106,,,BAO_0000019,,Autocuration,,,B,,
1341,,,CHEMBL616526,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,,14165,,106,,,BAO_0000019,,Autocuration,,,B,,
1342,Homo sapiens,,CHEMBL616527,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,,4234,,106,,,BAO_0000357,,Expert,,9606.0,B,,
1343,,,CHEMBL616528,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,6328,,106,,,BAO_0000219,,Expert,,,B,,
1344,,,CHEMBL616529,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,14770,,106,,,BAO_0000357,,Autocuration,,,B,,
1345,,,CHEMBL616530,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,,2598,,106,,,BAO_0000357,,Autocuration,,,B,,
1346,,,CHEMBL616531,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,6897,,106,,,BAO_0000357,,Expert,,,B,,
1347,,,CHEMBL616532,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,6897,,106,,,BAO_0000357,,Autocuration,,,B,,
1348,,,CHEMBL616533,Binding affinity towards 5-hydroxytryptamine 1B receptor,,6013,,106,,,BAO_0000357,,Autocuration,,,B,,
1349,,,CHEMBL616534,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,5843,,106,,,BAO_0000357,,Expert,,,B,,
1350,,,CHEMBL616535,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,,14454,,106,,,BAO_0000357,,Expert,,,B,,
1351,,,CHEMBL616536,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,,16209,,106,,,BAO_0000357,,Autocuration,,,B,,
1352,,,CHEMBL616537,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,,3935,,106,,,BAO_0000357,,Autocuration,,,B,,
1353,,,CHEMBL616538,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,,13729,,106,,,BAO_0000219,,Expert,,,F,,CHO-K1
1354,,,CHEMBL616539,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,,14251,,106,,,BAO_0000019,,Expert,,,F,,
1355,,,CHEMBL616540,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,,17085,,106,,,BAO_0000019,,Expert,,,B,,
1356,,,CHEMBL616429,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,3025,,106,,,BAO_0000357,,Autocuration,,,B,,
1357,,,CHEMBL616430,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,,15315,,106,,,BAO_0000357,,Expert,,,B,,
1358,Homo sapiens,,CHEMBL616431,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,,14214,,106,,,BAO_0000219,,Expert,,9606.0,B,,
1359,Homo sapiens,,CHEMBL616432,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,3804,,106,,,BAO_0000357,,Expert,,9606.0,B,,
1360,Homo sapiens,,CHEMBL616433,Affinity for 5-hydroxytryptamine 1B receptor subtype,,2391,,106,,,BAO_0000357,,Expert,,9606.0,B,,
1361,Homo sapiens,,CHEMBL616434,Binding affinity for human 5-hydroxytryptamine 1B receptor,,4175,,106,,,BAO_0000357,,Expert,,9606.0,B,,
1362,,,CHEMBL616435,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,,17296,,106,,,BAO_0000219,,Autocuration,,,B,,CHO
1363,,,CHEMBL616436,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,,17085,,106,,,BAO_0000019,,Expert,,,B,,
1364,,,CHEMBL616437,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,17211,,106,,,BAO_0000219,,Autocuration,,,B,,HeLa
1365,,,CHEMBL616438,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,,17211,,106,,,BAO_0000219,,Autocuration,,,B,,HeLa
1366,,,CHEMBL616439,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,17211,,106,,,BAO_0000219,,Autocuration,,,B,,HeLa
1367,Homo sapiens,,CHEMBL616440,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,,15926,,106,,,BAO_0000357,,Expert,,9606.0,B,,
1368,,,CHEMBL616441,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,,16312,,106,,,BAO_0000219,,Autocuration,,,B,,CHO-K1
1369,,,CHEMBL616442,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,,5843,,106,,,BAO_0000357,,Expert,,,B,,
1370,,,CHEMBL616443,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,,5843,,106,,,BAO_0000357,,Autocuration,,,B,,
1371,,,CHEMBL616444,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,,16312,,106,,,BAO_0000219,,Expert,,,B,,CHO-K1
1372,Homo sapiens,,CHEMBL616445,Binding activity against human 5-hydroxytryptamine 1B receptor,,15926,,106,,,BAO_0000357,,Expert,,9606.0,B,,
1373,Homo sapiens,,CHEMBL616446,Binding activity against human 5-hydroxytryptamine 1B receptor,,15926,,106,,,BAO_0000357,,Expert,,9606.0,B,,
1374,Homo sapiens,,CHEMBL616447,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,4540,,106,,,BAO_0000219,,Expert,,9606.0,B,,CHO
1375,,,CHEMBL616448,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,,6166,,106,,,BAO_0000357,,Autocuration,,,B,,
1376,,,CHEMBL616449,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,,17296,,106,,,BAO_0000219,,Autocuration,,,B,,CHO
1377,,,CHEMBL616450,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,,17296,,106,,,BAO_0000219,,Autocuration,,,B,,CHO
1378,,,CHEMBL857974,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,,17296,,106,,,BAO_0000219,,Autocuration,,,B,,CHO
1379,,,CHEMBL616451,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,15779,,106,,,BAO_0000219,,Autocuration,,,B,,CHO
1380,,,CHEMBL616452,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,15779,,106,,,BAO_0000219,,Autocuration,,,B,,CHO
1381,,,CHEMBL616453,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,,15779,,106,,,BAO_0000219,,Autocuration,,,B,,CHO
1382,,,CHEMBL616454,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,,4199,,106,,,BAO_0000219,,Autocuration,,,B,,CHO
1383,Homo sapiens,,CHEMBL616455,Binding affinity for human 5-hydroxytryptamine 1B receptor,,14875,,106,,,BAO_0000357,,Expert,,9606.0,B,,
1384,,,CHEMBL616456,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,15146,,106,,,BAO_0000219,,Autocuration,,,B,,CHO
1385,,,CHEMBL616457,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,,5213,,106,,,BAO_0000357,,Autocuration,,,B,,
1386,,,CHEMBL616458,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,14818,,106,,,BAO_0000219,,Autocuration,,,B,,CHO
1387,,,CHEMBL616459,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",,4829,,106,,,BAO_0000219,,Autocuration,,,B,,CHO
1388,,,CHEMBL616460,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,,14454,,106,,,BAO_0000019,,Expert,,,F,,
1389,,,CHEMBL616461,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,,14454,,106,,,BAO_0000019,,Expert,,,F,,
1390,,,CHEMBL616462,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",,14875,,106,,,BAO_0000219,,Autocuration,,,F,,CHO
1391,,,CHEMBL616463,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",,14875,,106,,,BAO_0000219,,Autocuration,,,F,,CHO
1392,,,CHEMBL616464,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",,15250,,105,,,BAO_0000019,,Autocuration,,,F,,
1393,,,CHEMBL616465,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,,15250,,105,,,BAO_0000219,,Autocuration,,,B,,CHO
1394,,,CHEMBL832874,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,15086,,17105,,,BAO_0000357,,Autocuration,,,B,,
1395,Oryctolagus cuniculus,,CHEMBL616184,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,,3025,,106,,,BAO_0000019,,Autocuration,,9986.0,F,,
1396,Oryctolagus cuniculus,,CHEMBL616185,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,,14998,,106,,,BAO_0000019,,Autocuration,,9986.0,B,,
1397,Oryctolagus cuniculus,,CHEMBL616186,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",,14998,,106,,,BAO_0000019,,Intermediate,,9986.0,B,,
1398,Oryctolagus cuniculus,,CHEMBL616187,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,,14998,,106,,,BAO_0000019,,Autocuration,,9986.0,B,,
1399,,,CHEMBL616188,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,,13969,,10577,,,BAO_0000357,,Expert,,,B,,
1400,,,CHEMBL873475,Binding affinity for 5-hydroxytryptamine 1B receptor,,13392,,10577,,,BAO_0000357,,Intermediate,,,B,,
1401,Rattus norvegicus,2435.0,CHEMBL616189,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,,3651,Striatum,10577,,,BAO_0000019,,Expert,,10116.0,B,,
1402,,,CHEMBL616190,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,10025,,10577,,,BAO_0000357,,Expert,,,B,,
1403,,,CHEMBL616191,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,,13863,,10576,,,BAO_0000357,,Autocuration,,,B,,
1404,,,CHEMBL616192,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,,13863,,10576,,,BAO_0000357,,Autocuration,,,B,,
1405,,,CHEMBL616193,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,,13863,,10576,,,BAO_0000357,,Autocuration,,,B,,
1406,,,CHEMBL616194,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,,13863,,10576,,,BAO_0000357,,Autocuration,,,B,,
1407,,,CHEMBL616195,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,,13863,,10576,,,BAO_0000357,,Autocuration,,,B,,
1408,,,CHEMBL616196,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,,13863,,10576,,,BAO_0000357,,Autocuration,,,B,,
1409,,10000000.0,CHEMBL616197,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,,4622,Hippocampus,10576,,,BAO_0000249,,Autocuration,,,B,,
1410,,,CHEMBL616198,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,14911,,10576,,,BAO_0000019,,Intermediate,,,B,,
1411,,10000000.0,CHEMBL616199,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,12678,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1412,,10000000.0,CHEMBL616200,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,,12678,Hippocampus,10576,,,BAO_0000221,,Expert,,,B,,
1413,,10000000.0,CHEMBL616201,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,14235,Hippocampus,10576,,,BAO_0000221,,Expert,,,B,,
1414,,10000000.0,CHEMBL616202,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,14949,Hippocampus,10576,,,BAO_0000221,,Expert,,,B,,
1415,,10000000.0,CHEMBL616203,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,14949,Hippocampus,10576,,,BAO_0000221,,Expert,,,B,,
1416,,10000000.0,CHEMBL616204,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,,14949,Hippocampus,10576,,,BAO_0000221,,Expert,,,B,,
1417,,10000000.0,CHEMBL616205,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,,14949,Hippocampus,10576,,,BAO_0000221,,Expert,,,B,,
1418,,10000000.0,CHEMBL616206,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,,14949,Hippocampus,10576,,,BAO_0000221,,Expert,,,B,,
1419,,,CHEMBL616207,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,16118,,10576,,,BAO_0000249,,Expert,,,B,,
1420,,,CHEMBL616208,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,,3268,,10576,,,BAO_0000249,,Autocuration,,,B,,
1421,,,CHEMBL616209,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,,3268,,10576,,,BAO_0000249,,Autocuration,,,B,,
1422,,,CHEMBL616210,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,,16117,,10576,,,BAO_0000357,,Expert,,,B,,
1423,,10000000.0,CHEMBL616211,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,,9783,Hippocampus,10576,,,BAO_0000221,,Expert,,,B,,
1424,,10000000.0,CHEMBL616504,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,,9783,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1425,Rattus norvegicus,10000000.0,CHEMBL616505,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,14356,Hippocampus,10576,,,BAO_0000221,,Expert,,10116.0,B,,
1426,,,CHEMBL616506,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,15740,,10576,,,BAO_0000019,,Autocuration,,,F,,
1427,,10000000.0,CHEMBL872107,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,12306,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1428,Rattus norvegicus,10000000.0,CHEMBL616507,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,,13348,Hippocampus,10576,,,BAO_0000221,,Expert,,10116.0,B,,
1429,,,CHEMBL616303,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,,10394,,10576,,,BAO_0000249,,Autocuration,,,B,,
1430,,10000000.0,CHEMBL616304,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,,15260,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1431,,10000000.0,CHEMBL616305,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,10046,Hippocampus,10576,,,BAO_0000221,,Expert,,,B,,
1432,,10000000.0,CHEMBL616306,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,,15260,Hippocampus,10576,,,BAO_0000221,,Intermediate,,,F,,
1433,,,CHEMBL616307,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,,12851,,10576,,,BAO_0000357,,Autocuration,,,B,,
1434,Rattus norvegicus,10000000.0,CHEMBL881829,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,,2148,Hippocampus,10576,,,BAO_0000221,,Expert,,10116.0,B,,
1435,,,CHEMBL616308,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,,13134,,10576,,,BAO_0000357,,Expert,,,B,,
1436,,,CHEMBL616309,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,,12462,,10576,,,BAO_0000019,,Autocuration,,,B,,
1437,,,CHEMBL616310,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,,12462,,10576,,,BAO_0000019,,Expert,,,B,,
1438,,,CHEMBL616311,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,,12462,,10576,,,BAO_0000219,,Autocuration,,,B,,CHO
1439,,,CHEMBL616312,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,,11933,,10576,,,BAO_0000357,,Expert,,,B,,
1440,,,CHEMBL616313,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,,11933,,10576,,,BAO_0000357,,Autocuration,,,B,,
1441,Rattus norvegicus,10000000.0,CHEMBL616314,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,403,Hippocampus,10576,,,BAO_0000221,,Expert,,10116.0,B,,
1442,,10000000.0,CHEMBL616315,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,,15538,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1443,,10000000.0,CHEMBL616567,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,,15538,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1444,,10000000.0,CHEMBL616568,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,,15538,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1445,,,CHEMBL616569,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,,12464,,10576,,,BAO_0000019,,Intermediate,,,B,,
1446,,,CHEMBL616570,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,,1455,,10576,,,BAO_0000357,,Expert,,,B,,
1447,,,CHEMBL616571,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,12652,,10576,,,BAO_0000357,,Autocuration,,,B,,
1448,,10000000.0,CHEMBL616572,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,,12639,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1449,,,CHEMBL616573,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,,13949,,10576,,,BAO_0000249,,Expert,,,B,,
1450,Rattus norvegicus,,CHEMBL616574,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,,12463,,10576,,,BAO_0000357,,Expert,,10116.0,B,,
1451,,10000000.0,CHEMBL616575,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,,14829,Hippocampus,10576,,,BAO_0000221,,Expert,,,B,,
1452,,10000000.0,CHEMBL872108,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,,14829,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1453,,,CHEMBL616576,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,,12092,,10576,,,BAO_0000357,,Autocuration,,,B,,
1454,,,CHEMBL616577,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,,403,,10576,,,BAO_0000249,,Autocuration,,,B,,
1455,,,CHEMBL616578,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,,403,,10576,,,BAO_0000249,,Autocuration,,,B,,
1456,,,CHEMBL616579,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,,3967,,10576,,,BAO_0000357,,Expert,,,B,,
1457,Rattus norvegicus,,CHEMBL616580,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,,12771,,10576,,,BAO_0000019,,Expert,,10116.0,B,,
1458,,,CHEMBL616581,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,15086,,10576,,,BAO_0000019,,Autocuration,,,B,,
1459,,10000000.0,CHEMBL616582,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,14909,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1460,,10000000.0,CHEMBL616583,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,14949,Hippocampus,10576,,,BAO_0000221,,Expert,,,B,,
1461,Rattus norvegicus,10000000.0,CHEMBL616584,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,,2309,Hippocampus,10576,,,BAO_0000221,,Expert,,10116.0,B,,
1462,,,CHEMBL616585,Binding affinity towards 5-hydroxytryptamine 1A receptor,,4170,,10576,,,BAO_0000357,,Expert,,,B,,
1463,Rattus norvegicus,10000000.0,CHEMBL616586,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,,11642,Hippocampus,10576,,,BAO_0000221,,Expert,,10116.0,B,,
1464,,10000000.0,CHEMBL616587,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,,11642,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1465,,10000000.0,CHEMBL616588,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,,12953,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1466,,10000000.0,CHEMBL616589,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,,12953,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1467,,10000000.0,CHEMBL616590,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,,12953,Hippocampus,10576,,,BAO_0000221,,Expert,,,B,,
1468,,,CHEMBL616591,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",,12903,,10576,,,BAO_0000219,,Expert,,,B,,CHO
1469,,,CHEMBL616592,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,12536,,10576,,,BAO_0000357,,Expert,,,B,,
1470,,,CHEMBL616593,The inhibition activity of 5-HT1A at 1 uM,,10058,,10576,,,BAO_0000357,,Autocuration,,,B,,
1471,,,CHEMBL616594,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",,12902,,10576,,,BAO_0000219,,Expert,,,B,,CHO-K1
1472,,,CHEMBL616595,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,,14057,,10576,,,BAO_0000249,,Expert,,,B,,
1473,,,CHEMBL616596,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,,11296,,10576,,,BAO_0000357,,Autocuration,,,B,,
1474,,10000000.0,CHEMBL616597,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,11296,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1475,,10000000.0,CHEMBL616598,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,11296,Hippocampus,10576,,,BAO_0000221,,Expert,,,B,,
1476,Rattus norvegicus,,CHEMBL616599,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,,16616,,10576,,,BAO_0000249,,Expert,Membranes,10116.0,F,,
1477,Rattus norvegicus,10000000.0,CHEMBL616600,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",,16616,Hippocampus,10576,,,BAO_0000249,,Expert,Membranes,10116.0,F,,
1478,,,CHEMBL616601,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,,16567,,10576,,,BAO_0000019,,Autocuration,,,B,,
1479,,,CHEMBL616602,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,,16567,,10576,,,BAO_0000019,,Autocuration,,,B,,
1480,,,CHEMBL616603,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,,16567,,10576,,,BAO_0000019,,Autocuration,,,B,,
1481,,,CHEMBL616604,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,,16567,,10576,,,BAO_0000019,,Autocuration,,,B,,
1482,,,CHEMBL616316,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,,17136,,10576,,,BAO_0000249,,Autocuration,,,B,,
1483,,,CHEMBL616317,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,,17136,,10576,,,BAO_0000249,,Autocuration,,,B,,
1484,Rattus norvegicus,,CHEMBL616318,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,,16616,,10576,,,BAO_0000019,,Expert,,10116.0,B,,
1485,,10000000.0,CHEMBL616319,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,,17331,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1486,,10000000.0,CHEMBL616320,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,,17331,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1487,Rattus norvegicus,10000000.0,CHEMBL616321,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,,17167,Hippocampus,10576,,,BAO_0000221,,Expert,,10116.0,B,,
1488,,,CHEMBL616322,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,15740,,10576,,,BAO_0000019,,Autocuration,,,F,,
1489,,,CHEMBL616323,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,,15740,,10576,,,BAO_0000019,,Autocuration,,,F,,
1490,,,CHEMBL616324,Ratio of binding affinity to 5-HT 1A and D2 receptor,,4671,,10576,,,BAO_0000357,,Autocuration,,,B,,
1491,,10000000.0,CHEMBL616325,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,10058,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1492,,10000000.0,CHEMBL616326,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,10058,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1493,,10000000.0,CHEMBL616327,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,,10058,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1494,,,CHEMBL616328,Percentage inhibition against 5-hydroxytryptamine 1A receptor,,12073,,10576,,,BAO_0000357,,Autocuration,,,B,,
1495,,,CHEMBL858110,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,2759,,10576,,,BAO_0000249,,Autocuration,,,B,,
1496,,,CHEMBL616329,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,2759,,10576,,,BAO_0000249,,Autocuration,,,F,,
1497,,,CHEMBL616330,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,2759,,10576,,,BAO_0000249,,Autocuration,,,B,,
1498,,,CHEMBL616331,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,2759,,10576,,,BAO_0000249,,Autocuration,,,F,,
1499,,,CHEMBL616332,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,2759,,10576,,,BAO_0000249,,Autocuration,,,F,,
1500,,955.0,CHEMBL857063,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,9737,Brain,10576,,,BAO_0000249,,Autocuration,,,B,,
1501,,,CHEMBL616333,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,,9737,,10576,,,BAO_0000019,,Autocuration,,,B,,
1502,,,CHEMBL616334,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,,5717,,10576,,,BAO_0000019,,Expert,,,F,,
1503,,10000000.0,CHEMBL616335,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,12253,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1504,,,CHEMBL616336,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,,14025,,10576,,,BAO_0000019,,Autocuration,,,B,,
1505,,,CHEMBL616337,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,,10425,,10576,,,BAO_0000249,,Expert,,,B,,
1506,,,CHEMBL616338,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,,14998,,10576,,,BAO_0000019,,Autocuration,,,B,,
1507,,10000000.0,CHEMBL616339,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,,13694,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1508,,10000000.0,CHEMBL616340,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,,13694,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1509,,,CHEMBL616341,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,,4342,,10576,,,BAO_0000357,,Autocuration,,,B,,
1510,Rattus norvegicus,,CHEMBL616342,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,12936,,10576,,,BAO_0000357,,Expert,,10116.0,B,,
1511,Rattus norvegicus,,CHEMBL616343,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,,13144,,10576,,,BAO_0000019,,Expert,,10116.0,B,,
1512,,,CHEMBL616344,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,,13343,,10576,,,BAO_0000019,,Expert,,,B,,
1513,,,CHEMBL616345,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,12132,,10576,,,BAO_0000357,,Expert,,,B,,
1514,,,CHEMBL616346,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,,15419,,10576,,,BAO_0000019,,Expert,,,B,,
1515,,10000000.0,CHEMBL616347,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,1479,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1516,,,CHEMBL616348,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,,14287,,10576,,,BAO_0000019,,Expert,,,B,,
1517,,,CHEMBL616349,Binding affinity at 5-hydroxytryptamine 1A receptor,,13116,,10576,,,BAO_0000357,,Expert,,,B,,
1518,Rattus norvegicus,,CHEMBL616152,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,,2759,,10576,,,BAO_0000249,,Expert,Membranes,10116.0,B,,
1519,,,CHEMBL616153,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,2759,,10576,,,BAO_0000249,,Autocuration,,,B,,
1520,,,CHEMBL616154,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",,14748,,10576,,,BAO_0000019,,Expert,,,B,,
1521,,,CHEMBL616155,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,12304,,10576,,,BAO_0000019,,Autocuration,,,B,,
1522,Rattus norvegicus,10000000.0,CHEMBL616156,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,,12409,Hippocampus,10576,,,BAO_0000221,,Expert,,10116.0,B,,
1523,Rattus norvegicus,10000000.0,CHEMBL616157,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,,12409,Hippocampus,10576,,,BAO_0000221,,Expert,,10116.0,B,,
1524,,10000000.0,CHEMBL616158,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,,13267,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
1525,,,CHEMBL616159,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,15194,,10576,,,BAO_0000357,,Autocuration,,,B,,
1526,,,CHEMBL616160,pKi value against rat 5-hydroxytryptamine 1A receptor.,,14256,,10576,,,BAO_0000357,,Expert,,,B,,
1527,,,CHEMBL616161,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,,16567,,10576,,,BAO_0000019,,Autocuration,,,B,,
1528,,,CHEMBL616162,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,15740,,10576,,,BAO_0000019,,Autocuration,,,F,,
1529,Rattus norvegicus,,CHEMBL616163,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,13278,,12687,,,BAO_0000357,,Expert,,10116.0,B,,
1530,,,CHEMBL616164,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,1970,,10626,,,BAO_0000249,,Expert,Membranes,,B,,
1531,,955.0,CHEMBL616165,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,,10034,Brain,10576,,,BAO_0000221,,Autocuration,,,B,,
1532,Rattus norvegicus,,CHEMBL616355,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,,13348,,51,,,BAO_0000019,,Autocuration,,10116.0,B,,
1533,,,CHEMBL616356,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,13630,,10576,,,BAO_0000019,,Autocuration,,,F,,
1534,,955.0,CHEMBL616357,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,10862,Brain,10576,,,BAO_0000221,,Autocuration,,,B,,
1535,,,CHEMBL616358,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,12058,,10576,,,BAO_0000019,,Autocuration,,,B,,
1536,,,CHEMBL616359,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,,4639,,51,,,BAO_0000357,,Autocuration,,,B,,
1537,,,CHEMBL616360,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,,15453,,51,,,BAO_0000357,,Expert,,,B,,
1538,,,CHEMBL616361,Binding affinity towards 5-hydroxytryptamine 1A receptor,,4820,,51,,,BAO_0000357,,Expert,,,B,,
1539,,,CHEMBL616362,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,,1089,,51,,,BAO_0000357,,Autocuration,,,B,,
1540,,,CHEMBL616363,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,,386,,51,,,BAO_0000249,,Autocuration,Brain membranes,,B,,
1541,,,CHEMBL616364,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,,6011,,51,,,BAO_0000357,,Autocuration,,,B,,
1542,,,CHEMBL616365,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,,5014,,51,,,BAO_0000357,,Autocuration,,,B,,
1543,,,CHEMBL616366,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,,4402,,51,,,BAO_0000357,,Expert,,,B,,
1544,,,CHEMBL872906,Binding affinity towards 5-hydroxytryptamine 1A receptor,,17066,,51,,,BAO_0000357,,Expert,,,B,,
1545,,,CHEMBL616367,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,,17515,,51,,,BAO_0000357,,Autocuration,,,B,,
1546,,,CHEMBL616368,Binding affinity against 5-hydroxytryptamine 1A receptor,,2474,,51,,,BAO_0000357,,Autocuration,,,B,,
1547,,,CHEMBL616369,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,,4775,,51,,,BAO_0000357,,Autocuration,,,B,,
1548,Homo sapiens,,CHEMBL616370,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,,14294,,51,,,BAO_0000357,,Expert,,9606.0,B,,
1549,Homo sapiens,,CHEMBL616371,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,,14294,,51,,,BAO_0000357,,Expert,,9606.0,B,,
1550,,,CHEMBL616372,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,12249,,51,,,BAO_0000219,,Autocuration,,,B,,CHO
1551,,,CHEMBL616373,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,,11376,,51,,,BAO_0000219,,Expert,,,B,,
1552,,,CHEMBL616374,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,In vivo,2474,,51,,,BAO_0000218,,Autocuration,,,B,,
1553,,10000000.0,CHEMBL616375,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,13311,Hippocampus,51,,,BAO_0000221,,Autocuration,,,B,,
1554,,,CHEMBL616376,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,,4373,,51,,,BAO_0000357,,Autocuration,,,B,,
1555,,,CHEMBL857064,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,,1633,,51,,,BAO_0000357,,Expert,,,B,,
1556,,,CHEMBL616377,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,11866,,51,,,BAO_0000357,,Autocuration,,,B,,
1557,,,CHEMBL616378,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,4373,,51,,,BAO_0000357,,Autocuration,,,B,,
1558,,,CHEMBL616379,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,,4687,,51,,,BAO_0000357,,Autocuration,,,B,,
1559,,,CHEMBL616380,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,16946,,11863,,,BAO_0000357,,Autocuration,,,B,,
1560,,,CHEMBL616381,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,,13291,,11863,,,BAO_0000357,,Autocuration,,,B,,
1561,,,CHEMBL616382,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,,14159,,11863,,,BAO_0000357,,Autocuration,,,B,,
1562,,,CHEMBL616383,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,,10812,,11863,,,BAO_0000357,,Autocuration,,,B,,
1563,Mus musculus,,CHEMBL616350,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,,3032,,11863,,,BAO_0000219,,Expert,,10090.0,B,,CHO
1564,,,CHEMBL616351,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,16655,,11863,,,BAO_0000357,,Autocuration,,,B,,
1565,,,CHEMBL616352,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,,14532,,11863,,,BAO_0000357,,Autocuration,,,B,,
1566,,,CHEMBL616353,Binding affinity against 5-hydroxytryptamine 1A receptor,,13944,,11863,,,BAO_0000357,,Autocuration,,,B,,
1567,,,CHEMBL616354,Binding affinity against serotonergic 5-HT1a receptor,,13033,,11863,,,BAO_0000357,,Autocuration,,,B,,
1568,,,CHEMBL616508,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,,10321,,11863,,,BAO_0000357,,Autocuration,,,B,,
1569,Mus musculus,,CHEMBL616559,Binding affinity for 5-hydroxytryptamine 1A receptor,,2968,,11863,,,BAO_0000357,,Expert,,10090.0,B,,
1570,,,CHEMBL616560,Binding affinity at 5-hydroxytryptamine 1A receptor,,13964,,11863,,,BAO_0000357,,Autocuration,,,B,,
1571,,,CHEMBL616561,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",,15527,,11863,,,BAO_0000357,,Autocuration,,,B,,
1572,,,CHEMBL616562,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,12248,,11863,,,BAO_0000219,,Autocuration,,,B,,CHO
1573,,,CHEMBL616563,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,12249,,11863,,,BAO_0000219,,Autocuration,,,B,,CHO
1574,,,CHEMBL616564,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,,15120,,11863,,,BAO_0000357,,Autocuration,,,B,,
1575,,,CHEMBL616565,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,,13313,,11863,,,BAO_0000357,,Autocuration,,,B,,
1576,,,CHEMBL616566,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,,2613,,11863,,,BAO_0000218,,Autocuration,,,B,,
1577,,,CHEMBL616989,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,,16700,,11863,,,BAO_0000357,,Autocuration,,,B,,
1578,,,CHEMBL857975,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,,2201,,11863,,,BAO_0000357,,Autocuration,,,B,,
1579,Mus musculus,,CHEMBL616990,Binding affinity against 5-hydroxytryptamine 1A receptor,,1274,,11863,,,BAO_0000357,,Expert,,10090.0,B,,
1580,,,CHEMBL616991,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,,1317,,11863,,,BAO_0000357,,Autocuration,,,B,,
1581,,,CHEMBL616992,Tested against 5-hydroxytryptamine 1A receptor,,12146,,11863,,,BAO_0000357,,Autocuration,,,B,,
1582,,,CHEMBL616993,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,,14059,,11863,,,BAO_0000357,,Autocuration,,,B,,
1583,Oryctolagus cuniculus,,CHEMBL616994,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,,14025,,106,,,BAO_0000019,,Expert,,9986.0,B,,
1584,Oryctolagus cuniculus,,CHEMBL616995,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,,14025,,106,,,BAO_0000019,,Autocuration,,9986.0,B,,
1585,Gorilla gorilla,,CHEMBL616996,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,14447,,105571,,,BAO_0000219,,Intermediate,,9593.0,B,,HEK293
1586,Cavia porcellus,,CHEMBL616997,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,In vivo,3025,,106,,,BAO_0000218,,Autocuration,,10141.0,F,,
1587,Cavia porcellus,,CHEMBL616998,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,In vivo,3025,,106,,,BAO_0000218,,Autocuration,,10141.0,F,,
1588,Cavia porcellus,,CHEMBL616999,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,,15329,,106,,,BAO_0000019,,Autocuration,,10141.0,F,,
1589,Cavia porcellus,,CHEMBL617000,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,,15329,,106,,,BAO_0000019,,Autocuration,,10141.0,F,,
1590,Cavia porcellus,,CHEMBL617001,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,,15847,,106,,,BAO_0000019,,Autocuration,,10141.0,F,,
1591,Cavia porcellus,,CHEMBL858111,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,,15847,,106,,,BAO_0000019,,Autocuration,,10141.0,F,,
1592,,,CHEMBL617002,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,,14165,,106,,,BAO_0000019,,Autocuration,,,F,,
1593,,,CHEMBL617003,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),,14214,,106,,,BAO_0000019,,Autocuration,,,F,,
1594,,,CHEMBL617004,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),,14214,,106,,,BAO_0000019,,Autocuration,,,F,,
1595,Homo sapiens,,CHEMBL617005,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,,14214,,106,,,BAO_0000019,,Expert,,9606.0,F,,
1596,Homo sapiens,,CHEMBL616623,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,,13729,,106,,,BAO_0000219,,Expert,,9606.0,F,,CHO-K1
1597,,,CHEMBL616624,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,,3025,,106,,,BAO_0000219,,Autocuration,,,F,,CHO
1598,,,CHEMBL883243,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,2391,,106,,,BAO_0000357,,Autocuration,,,B,,
1599,,,CHEMBL616625,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,,2391,,106,,,BAO_0000019,,Autocuration,,,F,,
1600,,,CHEMBL616626,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",,14956,,106,,,BAO_0000219,,Expert,,,F,,CHO
1601,,,CHEMBL616627,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,,2598,,106,,,BAO_0000219,,Autocuration,,,F,,CHO
1602,,,CHEMBL616628,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,,2598,,106,,,BAO_0000219,,Autocuration,,,F,,CHO
1603,,,CHEMBL616629,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,,2598,,106,,,BAO_0000219,,Autocuration,,,F,,CHO
1604,,,CHEMBL616630,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,,2598,,106,,,BAO_0000219,,Autocuration,,,F,,CHO
1605,,,CHEMBL616631,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",,14956,,106,,,BAO_0000019,,Expert,,,F,,
1606,,,CHEMBL616632,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",,14956,,106,,,BAO_0000019,,Autocuration,,,F,,
1607,Homo sapiens,,CHEMBL616633,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,,14214,,106,,,BAO_0000357,,Expert,,9606.0,B,,
1608,,,CHEMBL616634,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,,3463,,106,,,BAO_0000219,,Expert,,,B,,CHO
1609,,,CHEMBL616635,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,,15331,,106,,,BAO_0000357,,Autocuration,,,B,,
1610,Homo sapiens,,CHEMBL885358,Binding affinity against 5-hydroxytryptamine 1B receptor,,16146,,106,,,BAO_0000357,,Expert,,9606.0,B,,
1611,Homo sapiens,,CHEMBL616636,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,14159,,106,,,BAO_0000219,,Expert,,9606.0,B,,CHO
1612,,,CHEMBL616637,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,,14158,,106,,,BAO_0000219,,Expert,,,B,,CHO
1613,,,CHEMBL616638,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,,14159,,106,,,BAO_0000357,,Autocuration,,,B,,
1614,,,CHEMBL616639,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,15250,,106,,,BAO_0000219,,Expert,,,B,,CHO
1615,,,CHEMBL616640,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,,15250,,106,,,BAO_0000219,,Expert,,,B,,CHO
1616,,,CHEMBL616641,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,15331,,106,,,BAO_0000219,,Expert,,,B,,CHO
1617,,,CHEMBL616642,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,,15332,,106,,,BAO_0000219,,Expert,,,B,,CHO
1618,,,CHEMBL616643,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,14956,,106,,,BAO_0000219,,Expert,,,B,,CHO
1619,,,CHEMBL616644,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),,3805,,106,,,BAO_0000357,,Autocuration,,,B,,
1620,,,CHEMBL616645,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,,14875,,106,,,BAO_0000357,,Autocuration,,,B,,
1621,Oryctolagus cuniculus,,CHEMBL616646,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,14454,,105,,,BAO_0000019,,Autocuration,,9986.0,F,,
1622,Oryctolagus cuniculus,,CHEMBL616647,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,14454,,105,,,BAO_0000019,,Expert,,9986.0,F,,
1623,,,CHEMBL616509,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),,16288,,105,,,BAO_0000357,,Autocuration,,,B,,
1624,,,CHEMBL616510,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),,16288,,105,,,BAO_0000357,,Autocuration,,,B,,
1625,,,CHEMBL616511,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,,16312,,105,,,BAO_0000357,,Autocuration,,,B,,
1626,Bos taurus,,CHEMBL616512,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,,1348,,105,,,BAO_0000357,,Expert,,9913.0,B,,
1627,Bos taurus,,CHEMBL616513,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,,5834,,105,,,BAO_0000357,,Autocuration,,9913.0,B,,
1628,Bos taurus,2435.0,CHEMBL616514,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,13366,Striatum,105,,,BAO_0000019,,Autocuration,,9913.0,B,,
1629,Bos taurus,,CHEMBL616515,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,,1414,,105,,,BAO_0000357,,Expert,,9913.0,B,,
1630,Bos taurus,,CHEMBL616516,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,,14998,,105,,,BAO_0000019,,Autocuration,,9913.0,B,,
1631,Bos taurus,,CHEMBL616517,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,11473,,105,,,BAO_0000357,,Autocuration,,9913.0,B,,
1632,Bos taurus,,CHEMBL616518,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,11473,,105,,,BAO_0000357,,Autocuration,,9913.0,B,,
1633,Bos taurus,,CHEMBL616519,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,10639,,105,,,BAO_0000357,,Autocuration,,9913.0,B,,
1634,Bos taurus,,CHEMBL616520,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,10639,,105,,,BAO_0000357,,Autocuration,,9913.0,B,,
1635,Bos taurus,,CHEMBL616521,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,,1375,,105,,,BAO_0000357,,Autocuration,,9913.0,B,,
1636,Bos taurus,,CHEMBL616522,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,,1375,,105,,,BAO_0000357,,Autocuration,,9913.0,B,,
1637,Bos taurus,,CHEMBL884531,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,16532,,105,,,BAO_0000357,,Autocuration,,9913.0,B,,
1638,Bos taurus,,CHEMBL616523,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,,11147,,105,,,BAO_0000357,,Autocuration,,9913.0,B,,
1639,Bos taurus,2435.0,CHEMBL616731,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,13366,Striatum,105,,,BAO_0000019,,Autocuration,,9913.0,B,,
1640,Bos taurus,,CHEMBL616732,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,,10444,,105,,,BAO_0000019,,Autocuration,,9913.0,B,,
1641,Bos taurus,,CHEMBL616733,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,,16532,,105,,,BAO_0000357,,Autocuration,,9913.0,B,,
1642,Bos taurus,,CHEMBL616734,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,16532,,105,,,BAO_0000357,,Autocuration,,9913.0,B,,
1643,Bos taurus,,CHEMBL616735,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,,12827,,105,,,BAO_0000249,,Autocuration,,9913.0,B,,
1644,Bos taurus,,CHEMBL616736,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,,12827,,105,,,BAO_0000249,,Autocuration,,9913.0,B,,
1645,Bos taurus,,CHEMBL616737,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,12919,,105,,,BAO_0000019,,Expert,,9913.0,F,,
1646,Bos taurus,,CHEMBL616738,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,,14025,,105,,,BAO_0000019,,Autocuration,,9913.0,B,,
1647,Bos taurus,,CHEMBL616739,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,12919,,105,,,BAO_0000019,,Expert,,9913.0,F,,
1648,Bos taurus,,CHEMBL616740,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,12919,,105,,,BAO_0000019,,Expert,,9913.0,F,,
1649,Bos taurus,,CHEMBL616741,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,12919,,105,,,BAO_0000019,,Expert,,9913.0,F,,
1650,Gorilla gorilla,,CHEMBL616742,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,14447,,105,,,BAO_0000219,,Autocuration,,9593.0,B,,HEK293
1651,Cavia porcellus,,CHEMBL616743,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,,1375,,105570,,,BAO_0000019,,Intermediate,,10141.0,B,,
1652,Cavia porcellus,,CHEMBL616744,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,,1375,,105570,,,BAO_0000019,,Intermediate,,10141.0,B,,
1653,Cavia porcellus,,CHEMBL616745,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,,12409,,105570,,,BAO_0000019,,Intermediate,,10141.0,F,,
1654,Cavia porcellus,,CHEMBL616746,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,12409,,105570,,,BAO_0000019,,Intermediate,,10141.0,F,,
1655,Cavia porcellus,,CHEMBL616747,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,,12409,,105570,,,BAO_0000019,,Intermediate,,10141.0,F,,
1656,Cavia porcellus,,CHEMBL616748,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,,12409,,105570,,,BAO_0000019,,Intermediate,,10141.0,F,,
1657,Cavia porcellus,,CHEMBL616648,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,,12409,,105570,,,BAO_0000019,,Intermediate,,10141.0,F,,
1658,Cavia porcellus,,CHEMBL616649,Binding affinity against 5-hydroxytryptamine 1D receptor,,11574,,105570,,,BAO_0000357,,Intermediate,,10141.0,B,,
1659,Cavia porcellus,,CHEMBL616650,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,,1558,,105570,,,BAO_0000357,,Intermediate,,10141.0,B,,
1660,Cavia porcellus,,CHEMBL616651,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,12409,,105570,,,BAO_0000218,,Intermediate,,10141.0,F,,
1661,Cavia porcellus,,CHEMBL616652,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,12409,,105570,,,BAO_0000218,,Intermediate,,10141.0,F,,
1662,Cavia porcellus,,CHEMBL616653,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,12409,,105570,,,BAO_0000218,,Intermediate,,10141.0,F,,
1663,Cavia porcellus,,CHEMBL616654,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,,12409,,105570,,,BAO_0000218,,Intermediate,,10141.0,F,,
1664,Cavia porcellus,,CHEMBL616655,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,,12253,,105570,,,BAO_0000019,,Intermediate,,10141.0,B,,
1665,Cavia porcellus,,CHEMBL616656,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,,12936,,105570,,,BAO_0000357,,Intermediate,,10141.0,B,,
1666,Cavia porcellus,,CHEMBL616657,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,,13181,,105,,,BAO_0000019,,Autocuration,,10141.0,B,,
1667,Cavia porcellus,2435.0,CHEMBL616658,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,,12409,Striatum,105570,,,BAO_0000357,,Intermediate,,10141.0,B,,
1668,Cavia porcellus,,CHEMBL616659,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,,10639,,105570,,,BAO_0000357,,Intermediate,,10141.0,B,,
1669,,,CHEMBL616660,Binding affinity against 5-hydroxytryptamine 1D receptor,,5254,,51,,,BAO_0000357,,Autocuration,,,B,,
1670,,,CHEMBL616661,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,,13051,,106,,,BAO_0000357,,Autocuration,,,B,,
1671,,,CHEMBL616662,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,,3463,,105,,,BAO_0000019,,Expert,,,F,,
1672,,,CHEMBL616663,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,,15315,,105,,,BAO_0000019,,Autocuration,,,F,,
1673,,,CHEMBL616664,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,,6011,,105,,,BAO_0000019,,Autocuration,,,F,,
1674,Homo sapiens,,CHEMBL881820,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",,14159,,105,,,BAO_0000219,,Expert,,9606.0,F,,CHO
1675,,,CHEMBL616665,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",,14159,,105,,,BAO_0000219,,Autocuration,,,F,,CHO
1676,,,CHEMBL616666,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,15250,,105,,,BAO_0000219,,Expert,,,B,,CHO
1677,,,CHEMBL616667,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,,15250,,105,,,BAO_0000219,,Autocuration,,,B,,CHO
1678,,,CHEMBL616668,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,15331,,105,,,BAO_0000219,,Expert,,,F,,CHO
1679,Homo sapiens,,CHEMBL616669,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,15332,,105,,,BAO_0000219,,Expert,,9606.0,F,,CHO
1680,,,CHEMBL617040,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",,15332,,105,,,BAO_0000219,,Expert,,,F,,CHO
1681,,,CHEMBL617041,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",,3294,,105,,,BAO_0000219,,Autocuration,,,F,,CHO
1682,,,CHEMBL617042,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",,14158,,105,,,BAO_0000219,,Expert,,,F,,CHO
1683,,,CHEMBL617043,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",,14956,,105,,,BAO_0000219,,Expert,,,F,,CHO
1684,,,CHEMBL617044,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,,12469,,105,,,BAO_0000019,,Autocuration,,,F,,
1685,,,CHEMBL617045,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,3463,,105,,,BAO_0000219,,Expert,,,F,,CHO
1686,Homo sapiens,,CHEMBL617046,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,15250,,105,,,BAO_0000219,,Expert,,9606.0,F,,CHO
1687,Homo sapiens,,CHEMBL617047,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,15250,,105,,,BAO_0000219,,Expert,,9606.0,F,,CHO
1688,,,CHEMBL617048,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",,14956,,105,,,BAO_0000019,,Expert,,,F,,
1689,,,CHEMBL616897,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",,14159,,105,,,BAO_0000019,,Autocuration,,,F,,
1690,Homo sapiens,,CHEMBL616898,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",,14159,,105,,,BAO_0000019,,Expert,,9606.0,F,,
1691,Homo sapiens,,CHEMBL858201,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,,14499,,105,,,BAO_0000219,,Expert,,9606.0,F,,CHO
1692,,,CHEMBL616899,Intrinsic activity for 5-hydroxytryptamine 1D receptor,,15315,,105,,,BAO_0000019,,Autocuration,,,F,,
1693,,,CHEMBL616900,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),In vitro,3294,,105,,,BAO_0000219,,Autocuration,,,B,,
1694,,,CHEMBL616901,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,,3463,,105,,,BAO_0000219,,Expert,,,B,,CHO
1695,,,CHEMBL616902,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,,15331,,105,,,BAO_0000357,,Autocuration,,,B,,
1696,Homo sapiens,,CHEMBL616903,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,14159,,105,,,BAO_0000219,,Expert,,9606.0,B,,CHO
1697,,,CHEMBL616904,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,,14158,,105,,,BAO_0000219,,Expert,,,B,,CHO
1698,,,CHEMBL616905,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,,14159,,105,,,BAO_0000357,,Autocuration,,,B,,
1699,,,CHEMBL616906,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,,15250,,105,,,BAO_0000219,,Expert,,,B,,CHO
1700,,,CHEMBL616907,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,15250,,105,,,BAO_0000219,,Expert,,,B,,CHO
1701,,,CHEMBL616908,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,15331,,105,,,BAO_0000219,,Expert,,,B,,CHO
1702,Homo sapiens,,CHEMBL616909,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,15332,,105,,,BAO_0000219,,Expert,,9606.0,B,,CHO
1703,Homo sapiens,,CHEMBL616910,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,14499,,105,,,BAO_0000219,,Expert,,9606.0,B,,CHO
1704,,,CHEMBL616911,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,15332,,105,,,BAO_0000219,,Expert,,,B,,CHO
1705,,,CHEMBL616912,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,14956,,105,,,BAO_0000219,,Expert,,,B,,CHO
1706,,,CHEMBL616913,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),,3805,,105,,,BAO_0000357,,Autocuration,,,B,,
1707,Homo sapiens,,CHEMBL616914,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,,6011,,105,,,BAO_0000219,,Expert,,9606.0,B,,CHO
1708,,,CHEMBL616915,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,16190,,105,,,BAO_0000219,,Autocuration,,,B,,CHO
1709,,,CHEMBL616916,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,,14165,,105,,,BAO_0000019,,Autocuration,,,B,,
1710,Homo sapiens,,CHEMBL616917,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,,4234,,105,,,BAO_0000357,,Expert,,9606.0,B,,
1711,,,CHEMBL616918,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",,15527,,105,,,BAO_0000357,,Autocuration,,,B,,
1712,,,CHEMBL616919,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,6328,,105,,,BAO_0000219,,Expert,,,B,,
1713,,,CHEMBL616920,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,,16209,,105,,,BAO_0000357,,Autocuration,,,B,,
1714,,,CHEMBL872914,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,,14770,,105,,,BAO_0000357,,Autocuration,,,B,,
1715,,,CHEMBL616921,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,,2598,,105,,,BAO_0000357,,Autocuration,,,B,,
1716,,,CHEMBL616922,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,,6897,,105,,,BAO_0000357,,Expert,,,B,,
1717,,,CHEMBL616923,Binding affinity towards 5-hydroxytryptamine 1D receptor,,6013,,105,,,BAO_0000357,,Autocuration,,,B,,
1718,,,CHEMBL616924,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,5843,,105,,,BAO_0000357,,Expert,,,B,,
1719,,,CHEMBL875909,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,,14454,,105,,,BAO_0000357,,Expert,,,B,,
1720,,,CHEMBL616925,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,,14454,,105,,,BAO_0000357,,Autocuration,,,B,,
1721,,,CHEMBL616926,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,,14454,,105,,,BAO_0000357,,Autocuration,,,B,,
1722,,,CHEMBL616927,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,,15818,,105,,,BAO_0000357,,Autocuration,,,B,,
1723,,,CHEMBL616928,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,,13729,,105,,,BAO_0000219,,Expert,,,F,,CHO-K1
1724,Homo sapiens,,CHEMBL616929,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),In vitro,6011,,105,,,BAO_0000219,,Expert,,9606.0,B,,
1725,Homo sapiens,,CHEMBL616930,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,,4234,,105,,,BAO_0000357,,Expert,,9606.0,B,,
1726,,,CHEMBL616931,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,17085,,105,,,BAO_0000019,,Expert,,,B,,
1727,,,CHEMBL616932,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,3025,,105,,,BAO_0000357,,Autocuration,,,B,,
1728,,,CHEMBL616933,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,,15315,,105,,,BAO_0000357,,Expert,,,B,,
1729,Homo sapiens,,CHEMBL616934,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,,14214,,105,,,BAO_0000219,,Expert,,9606.0,B,,
1730,Homo sapiens,,CHEMBL616935,Binding affinity for human 5-hydroxytryptamine 1D receptor,,3804,,105,,,BAO_0000357,,Expert,,9606.0,B,,
1731,,,CHEMBL616936,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,,16700,,105,,,BAO_0000357,,Autocuration,,,B,,
1732,Homo sapiens,,CHEMBL616937,Affinity for 5-hydroxytryptamine 1D receptor subtype,,2391,,105,,,BAO_0000357,,Expert,,9606.0,B,,
1733,Homo sapiens,,CHEMBL616938,Binding affinity for human 5-hydroxytryptamine 1D receptor,,4175,,105,,,BAO_0000357,,Expert,,9606.0,B,,
1734,,,CHEMBL616939,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,17085,,105,,,BAO_0000019,,Autocuration,,,B,,
1735,,,CHEMBL616940,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,,17085,,105,,,BAO_0000019,,Expert,,,B,,
1736,Homo sapiens,,CHEMBL616941,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,,15926,,105,,,BAO_0000357,,Expert,,9606.0,B,,
1737,,,CHEMBL616942,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,,16312,,105,,,BAO_0000219,,Autocuration,,,B,,CHO-K1
1738,,,CHEMBL616943,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,,16312,,105,,,BAO_0000219,,Autocuration,,,B,,CHO-K1
1739,,,CHEMBL616944,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,,14956,,104802,,,BAO_0000219,,Autocuration,,,B,,CHO
1740,,,CHEMBL616945,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",,3294,,105,,,BAO_0000019,,Autocuration,,,F,,
1741,,,CHEMBL616946,Binding activity radioligand.,,12861,,105,,,BAO_0000357,,Autocuration,,,B,,
1742,,,CHEMBL616947,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,12861,,105,,,BAO_0000019,,Autocuration,,,B,,
1743,,,CHEMBL616948,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,,16312,,105,,,BAO_0000219,,Expert,,,B,,CHO-K1
1744,,,CHEMBL616851,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,5104,,105,,,BAO_0000357,,Autocuration,,,B,,
1745,,,CHEMBL616852,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,5105,,105,,,BAO_0000357,,Autocuration,,,B,,
1746,,,CHEMBL616853,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,,14499,,105,,,BAO_0000357,,Autocuration,,,B,,
1747,Homo sapiens,,CHEMBL616854,Binding activity against human 5-hydroxytryptamine 1D receptor,,15926,,105,,,BAO_0000357,,Expert,,9606.0,B,,
1748,Homo sapiens,,CHEMBL616855,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,4540,,105,,,BAO_0000219,,Expert,,9606.0,B,,CHO
1749,,,CHEMBL616856,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,,15779,,105,,,BAO_0000219,,Autocuration,,,B,,CHO
1750,,,CHEMBL616857,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,15779,,105,,,BAO_0000219,,Autocuration,,,B,,CHO
1751,,,CHEMBL616858,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,6166,,105,,,BAO_0000357,,Autocuration,,,B,,
1752,,,CHEMBL616859,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,,15779,,105,,,BAO_0000219,,Autocuration,,,B,,CHO
1753,,,CHEMBL616860,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,,15779,,105,,,BAO_0000219,,Autocuration,,,B,,CHO
1754,,,CHEMBL616861,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,17451,,105,,,BAO_0000219,,Autocuration,,,B,,HEK293
1755,,,CHEMBL616541,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,17451,,105,,,BAO_0000219,,Autocuration,,,B,,HEK293
1756,,,CHEMBL616542,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,,17451,,105,,,BAO_0000219,,Autocuration,,,B,,HEK293
1757,,,CHEMBL616543,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,,4199,,105,,,BAO_0000219,,Autocuration,,,B,,CHO
1758,Homo sapiens,,CHEMBL616544,Binding affinity for human 5-hydroxytryptamine 1D receptor,,14875,,105,,,BAO_0000357,,Expert,,9606.0,B,,
1759,,,CHEMBL616545,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,,15146,,105,,,BAO_0000219,,Autocuration,,,B,,CHO
1760,,,CHEMBL616546,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,,5213,,105,,,BAO_0000357,,Autocuration,,,B,,
1761,,,CHEMBL616547,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,,14818,,105,,,BAO_0000219,,Autocuration,,,B,,CHO
1762,,,CHEMBL616548,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",,4829,,105,,,BAO_0000219,,Autocuration,,,B,,CHO
1763,,,CHEMBL616549,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,,14454,,105,,,BAO_0000019,,Expert,,,F,,
1764,,,CHEMBL616550,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,,14454,,105,,,BAO_0000019,,Expert,,,F,,
1765,,,CHEMBL857066,Binding affinity against 5-HT2C receptor,,5254,,108,,,BAO_0000357,,Autocuration,,,B,,
1766,,,CHEMBL616551,Binding affinity against 5-hydroxytryptamine 1D receptor,,5254,,108,,,BAO_0000357,,Autocuration,,,B,,
1767,,,CHEMBL616552,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,10639,,10577,,,BAO_0000357,,Autocuration,,,B,,
1768,,,CHEMBL832876,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,10639,,10577,,,BAO_0000019,,Autocuration,,,F,,
1769,,,CHEMBL616553,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",,12352,,10577,,,BAO_0000019,,Expert,,,B,,
1770,,,CHEMBL616554,Binding affinity towards 5-HT1B was determined,,9098,,10577,,,BAO_0000357,,Autocuration,,,B,,
1771,,,CHEMBL616555,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,,14430,,10577,,,BAO_0000019,,Expert,,,B,,
1772,,,CHEMBL616556,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",,13657,,10577,,,BAO_0000019,,Expert,,,B,,
1773,,,CHEMBL616557,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",,13657,,10577,,,BAO_0000019,,Autocuration,,,B,,
1774,,,CHEMBL616558,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,15854,,10577,,,BAO_0000019,,Expert,,,B,,
1775,Rattus norvegicus,,CHEMBL616749,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,,10639,,10577,,,BAO_0000019,,Expert,,10116.0,B,,
1776,,,CHEMBL616750,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,10025,,10577,,,BAO_0000357,,Autocuration,,,B,,
1777,,,CHEMBL616751,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",,10025,,10577,,,BAO_0000357,,Autocuration,,,B,,
1778,,,CHEMBL616752,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,14286,,10577,,,BAO_0000249,,Autocuration,,,B,,
1779,,2435.0,CHEMBL616753,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,,3651,Striatum,10577,,,BAO_0000019,,Autocuration,,,B,,
1780,Rattus norvegicus,,CHEMBL616754,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,,14178,,10577,,,BAO_0000357,,Expert,,10116.0,B,,
1781,,,CHEMBL616755,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,,10639,,10577,,,BAO_0000019,,Autocuration,,,B,,
1782,,2435.0,CHEMBL616756,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,,13605,Striatum,10577,,,BAO_0000019,,Autocuration,,,B,,
1783,,2435.0,CHEMBL616757,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,,5834,Striatum,10577,,,BAO_0000019,,Autocuration,,,B,,
1784,,2435.0,CHEMBL616758,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,,10922,Striatum,10577,,,BAO_0000357,,Autocuration,,,B,,
1785,,,CHEMBL616759,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,14286,,10577,,,BAO_0000249,,Autocuration,,,B,,
1786,,,CHEMBL616760,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,,11825,,10577,,,BAO_0000357,,Autocuration,,,B,,
1787,,2435.0,CHEMBL616761,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,,14826,Striatum,10577,,,BAO_0000019,,Autocuration,,,B,,
1788,,2435.0,CHEMBL616762,Binding affinity against 5-HT1B serotonin receptor in rat striatum,,9699,Striatum,10577,,,BAO_0000019,,Autocuration,,,B,,
1789,,,CHEMBL616763,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,,14423,,10577,,,BAO_0000019,,Autocuration,,,B,,
1790,,,CHEMBL872909,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,,10062,,10577,,,BAO_0000357,,Expert,,,B,,
1791,,,CHEMBL616764,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,10062,,10577,,,BAO_0000357,,Autocuration,,,B,,
1792,Rattus norvegicus,,CHEMBL616765,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,,12280,,10577,,,BAO_0000357,,Expert,,10116.0,B,,
1793,,2435.0,CHEMBL616766,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,,15412,Striatum,10577,,,BAO_0000357,,Autocuration,,,B,,
1794,,2435.0,CHEMBL616767,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,,15412,Striatum,10577,,,BAO_0000357,,Autocuration,,,B,,
1795,,,CHEMBL616768,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,10062,,10577,,,BAO_0000357,,Autocuration,,,B,,
1796,,,CHEMBL616769,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,11147,,10577,,,BAO_0000357,,Autocuration,,,B,,
1797,,,CHEMBL616770,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,,9547,,10577,,,BAO_0000019,,Autocuration,,,B,,
1798,,,CHEMBL616771,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,,10444,,10577,,,BAO_0000019,,Autocuration,,,B,,
1799,,2435.0,CHEMBL616772,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,,12469,Striatum,10577,,,BAO_0000019,,Autocuration,,,B,,
1800,,,CHEMBL616773,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,,9098,,10577,,,BAO_0000019,,Expert,,,B,,
1801,,,CHEMBL616774,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,,9098,,10577,,,BAO_0000019,,Autocuration,,,B,,
1802,,,CHEMBL616775,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,,9699,,10577,,,BAO_0000357,,Autocuration,,,B,,
1803,,,CHEMBL616776,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,,10394,,10577,,,BAO_0000249,,Autocuration,,,B,,
1804,,,CHEMBL616777,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,,12092,,10577,,,BAO_0000357,,Autocuration,,,B,,
1805,,,CHEMBL616778,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,,16700,,10577,,,BAO_0000357,,Autocuration,,,B,,
1806,Rattus norvegicus,,CHEMBL616779,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,,403,,10577,,,BAO_0000249,,Expert,,10116.0,B,,
1807,Rattus norvegicus,,CHEMBL616780,Binding affinity towards 5-hydroxytryptamine 1B receptor,,12771,,10577,,,BAO_0000357,,Expert,,10116.0,B,,
1808,,,CHEMBL616781,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,,11642,,10577,,,BAO_0000019,,Autocuration,,,B,,
1809,,,CHEMBL616782,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,,12953,,10577,,,BAO_0000357,,Autocuration,,,B,,
1810,,,CHEMBL616783,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,,12953,,10577,,,BAO_0000357,,Autocuration,,,B,,
1811,,2435.0,CHEMBL616784,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,,12953,Striatum,10577,,,BAO_0000019,,Expert,,,B,,
1812,,,CHEMBL616785,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,,12953,,10577,,,BAO_0000357,,Autocuration,,,B,,
1813,,955.0,CHEMBL857067,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,9737,Brain,10577,,,BAO_0000249,,Autocuration,,,B,,
1814,,,CHEMBL616786,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,,9737,,10577,,,BAO_0000019,,Autocuration,,,B,,
1815,,955.0,CHEMBL616787,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,9737,Brain,10577,,,BAO_0000249,,Autocuration,,,B,,
1816,,,CHEMBL616788,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,,12827,,10577,,,BAO_0000357,,Autocuration,,,B,,
1817,,,CHEMBL616789,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,,5033,,10577,,,BAO_0000357,,Autocuration,,,B,,
1818,Rattus norvegicus,,CHEMBL616790,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,,9786,,10577,,,BAO_0000019,,Expert,,10116.0,B,,
1819,,,CHEMBL616791,Binding affinity at 5-hydroxytryptamine 1B receptor,,13116,,10577,,,BAO_0000357,,Expert,,,B,,
1820,,,CHEMBL616792,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,,16429,,10577,,,BAO_0000019,,Autocuration,,,B,,
1821,Rattus norvegicus,,CHEMBL616793,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,,12409,,10577,,,BAO_0000249,,Expert,,10116.0,B,,
1822,,,CHEMBL616794,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,15194,,10577,,,BAO_0000357,,Autocuration,,,B,,
1823,,,CHEMBL616795,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,15194,,10577,,,BAO_0000357,,Autocuration,,,B,,
1824,,,CHEMBL616796,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,,5486,,104686,,,BAO_0000019,,Autocuration,,,B,,
1825,,,CHEMBL616797,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,4639,,106,,,BAO_0000357,,Autocuration,,,B,,
1826,,,CHEMBL616798,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,,386,,106,,,BAO_0000249,,Autocuration,Brain membranes,,B,,
1827,,,CHEMBL616799,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,,2474,,106,,,BAO_0000357,,Autocuration,,,B,,
1828,,,CHEMBL616800,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,,6011,,106,,,BAO_0000357,,Autocuration,,,B,,
1829,,,CHEMBL616801,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,,5014,,106,,,BAO_0000357,,Autocuration,,,B,,
1830,,,CHEMBL616802,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,,17515,,106,,,BAO_0000357,,Autocuration,,,B,,
1831,,,CHEMBL616803,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,,4373,,106,,,BAO_0000357,,Autocuration,,,B,,
1832,,,CHEMBL857068,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,,1633,,106,,,BAO_0000357,,Expert,,,B,,
1833,,,CHEMBL616804,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,,1633,,106,,,BAO_0000357,,Autocuration,,,B,,
1834,,,CHEMBL616805,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,,4373,,106,,,BAO_0000357,,Autocuration,,,B,,
1835,,,CHEMBL616806,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,,4687,,106,,,BAO_0000357,,Autocuration,,,B,,
1836,,,CHEMBL616807,Binding affinity against 5-hydroxytryptamine 1B receptor,,11574,,106,,,BAO_0000357,,Autocuration,,,B,,
1837,,,CHEMBL616808,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,,10321,,106,,,BAO_0000357,,Autocuration,,,B,,
1838,,,CHEMBL616809,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,15527,,106,,,BAO_0000357,,Autocuration,,,B,,
1839,,,CHEMBL616810,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,,17200,,106,,,BAO_0000357,,Autocuration,,,B,,
1840,,,CHEMBL616811,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,,14423,,104802,,,BAO_0000224,,Autocuration,,,B,,
1841,Bos taurus,,CHEMBL616812,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,,5834,,108,,,BAO_0000357,,Autocuration,,9913.0,B,,
1842,Sus scrofa,,CHEMBL616813,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,11473,,108,,,BAO_0000357,,Autocuration,,9823.0,B,,
1843,Sus scrofa,,CHEMBL616814,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,,11473,,108,,,BAO_0000357,,Autocuration,,9823.0,B,,
1844,Sus scrofa,,CHEMBL616815,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,10639,,108,,,BAO_0000357,,Autocuration,,9823.0,B,,
1845,Sus scrofa,,CHEMBL616816,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,10639,,108,,,BAO_0000357,,Autocuration,,9823.0,B,,
1846,Sus scrofa,,CHEMBL616817,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,,14331,,108,,,BAO_0000357,,Autocuration,,9823.0,B,,
1847,Sus scrofa,,CHEMBL616818,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,,10796,,108,,,BAO_0000357,,Autocuration,,9823.0,B,,
1848,Sus scrofa,,CHEMBL616819,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,,9098,,108,,,BAO_0000357,,Expert,,9823.0,B,,
1849,Sus scrofa,,CHEMBL616820,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,,14331,,108,,,BAO_0000357,,Expert,,9823.0,B,,
1850,Sus scrofa,,CHEMBL616821,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,,11828,,108,,,BAO_0000019,,Expert,,9823.0,B,,
1851,Sus scrofa,,CHEMBL616822,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,,11866,,108,,,BAO_0000357,,Autocuration,,9823.0,B,,
1852,Oryctolagus cuniculus,,CHEMBL616823,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,13047,,108,,,BAO_0000019,,Autocuration,,9986.0,B,,
1853,Rattus norvegicus,,CHEMBL616824,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,,188,,12689,,,BAO_0000357,,Autocuration,,10116.0,B,,
1854,Rattus norvegicus,,CHEMBL616825,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,11825,,12689,,,BAO_0000357,,Autocuration,,10116.0,B,,
1855,Rattus norvegicus,,CHEMBL616826,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,11825,,12689,,,BAO_0000357,,Autocuration,,10116.0,B,,
1856,Rattus norvegicus,,CHEMBL616827,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,,11624,,12689,,,BAO_0000019,,Expert,,10116.0,B,,
1857,Rattus norvegicus,,CHEMBL616828,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,,11139,,12689,,,BAO_0000357,,Autocuration,,10116.0,B,,
1858,Rattus norvegicus,,CHEMBL616829,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,11147,,12689,,,BAO_0000357,,Autocuration,,10116.0,B,,
1859,Rattus norvegicus,,CHEMBL616830,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,,10444,,12689,,,BAO_0000019,,Autocuration,,10116.0,B,,
1860,Rattus norvegicus,,CHEMBL616831,Binding affinity against 5-hydroxytryptamine 1C receptor,,11624,,12689,,,BAO_0000357,,Expert,,10116.0,B,,
1861,Rattus norvegicus,,CHEMBL616832,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,11662,,12689,,,BAO_0000019,,Autocuration,,10116.0,B,,
1862,Rattus norvegicus,,CHEMBL616833,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,11662,,12689,,,BAO_0000019,,Autocuration,,10116.0,B,,
1863,Rattus norvegicus,,CHEMBL616834,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,11662,,12689,,,BAO_0000019,,Expert,,10116.0,B,,
1864,Rattus norvegicus,,CHEMBL829595,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,11662,,12689,,,BAO_0000019,,Autocuration,,10116.0,B,,
1865,Rattus norvegicus,,CHEMBL616835,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,,9098,,12689,,,BAO_0000357,,Autocuration,,10116.0,B,,
1866,Rattus norvegicus,,CHEMBL872910,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,,10394,,12689,,,BAO_0000249,,Autocuration,,10116.0,B,,
1867,,,CHEMBL616836,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,,11933,,12689,,,BAO_0000357,,Expert,,,B,,
1868,Rattus norvegicus,,CHEMBL616837,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,,12092,,12689,,,BAO_0000357,,Autocuration,,10116.0,B,,
1869,Rattus norvegicus,,CHEMBL616466,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,,12253,,12689,,,BAO_0000019,,Autocuration,,10116.0,B,,
1870,Rattus norvegicus,,CHEMBL616467,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,,12253,,12689,,,BAO_0000219,,Autocuration,,10116.0,B,,HEK293
1871,,,CHEMBL616468,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,1558,,108,,,BAO_0000357,,Autocuration,,,B,,
1872,,,CHEMBL616469,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,2474,,108,,,BAO_0000357,,Autocuration,,,B,,
1873,,,CHEMBL616470,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,2474,,108,,,BAO_0000357,,Autocuration,,,B,,
1874,,,CHEMBL616471,Binding affinity against 5-hydroxytryptamine 1C receptor,,11574,,12689,,,BAO_0000357,,Autocuration,,,B,,
1875,,,CHEMBL616472,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,1558,,12689,,,BAO_0000357,,Autocuration,,,B,,
1876,,,CHEMBL616473,Binding affinity against 5-hydroxytryptamine 1C receptor,,13944,,12689,,,BAO_0000357,,Autocuration,,,B,,
1877,,,CHEMBL616474,Binding affinity against serotonergic 5-HT1c receptor,,13033,,12689,,,BAO_0000357,,Autocuration,,,B,,
1878,,,CHEMBL616475,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,,10321,,12689,,,BAO_0000357,,Autocuration,,,B,,
1879,,,CHEMBL616476,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,,11866,,12689,,,BAO_0000357,,Autocuration,,,B,,
1880,Oryctolagus cuniculus,,CHEMBL616477,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,14454,,105,,,BAO_0000019,,Autocuration,,9986.0,B,,
1881,,,CHEMBL616478,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,,11574,,104686,,,BAO_0000224,,Autocuration,,,B,,
1882,,,CHEMBL616479,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,,11574,,104686,,,BAO_0000224,,Autocuration,,,B,,
1883,,,CHEMBL616480,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,,13631,,104686,,,BAO_0000019,,Autocuration,,,B,,
1884,Rattus norvegicus,,CHEMBL616481,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,,9630,,104686,,,BAO_0000019,,Autocuration,,10116.0,B,,
1885,Rattus norvegicus,,CHEMBL616482,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,,8822,,104686,,,BAO_0000249,,Autocuration,,10116.0,B,,
1886,Rattus norvegicus,955.0,CHEMBL884713,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,,9064,Brain,104686,,,BAO_0000221,,Autocuration,,10116.0,B,,
1887,,,CHEMBL616483,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,,8868,,104686,,,BAO_0000224,,Autocuration,,,B,,
1888,,,CHEMBL616484,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,,9064,,104686,,,BAO_0000224,,Autocuration,,,B,,
1889,,,CHEMBL616485,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,,9806,,104686,,,BAO_0000019,,Autocuration,,,B,,
1890,,,CHEMBL616486,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,9098,,104686,,,BAO_0000224,,Autocuration,,,B,,
1891,,,CHEMBL616487,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,,8868,,104686,,,BAO_0000224,,Autocuration,,,B,,
1892,,,CHEMBL616488,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,12765,,104686,,,BAO_0000224,,Autocuration,,,B,,
1893,,,CHEMBL616489,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,11049,,104686,,,BAO_0000019,,Autocuration,,,B,,
1894,,,CHEMBL616490,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,11049,,104686,,,BAO_0000019,,Autocuration,,,B,,
1895,,,CHEMBL616491,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,,11049,,104686,,,BAO_0000019,,Autocuration,,,B,,
1896,,,CHEMBL616492,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,,11049,,104686,,,BAO_0000019,,Autocuration,,,B,,
1897,,,CHEMBL616493,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,11049,,104686,,,BAO_0000019,,Autocuration,,,B,,
1898,,,CHEMBL616494,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,,11473,,104686,,,BAO_0000019,,Autocuration,,,B,,
1899,,,CHEMBL616495,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,,11473,,104686,,,BAO_0000019,,Autocuration,,,B,,
1900,,,CHEMBL616496,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,,3086,,104686,,,BAO_0000019,,Autocuration,,,B,,
1901,,,CHEMBL616497,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,11049,,104686,,,BAO_0000019,,Autocuration,,,B,,
1902,,,CHEMBL616498,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,11049,,104686,,,BAO_0000019,,Autocuration,,,B,,
1903,,,CHEMBL616499,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,,10639,,104686,,,BAO_0000019,,Autocuration,,,B,,
1904,,,CHEMBL616500,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,,10922,,104686,,,BAO_0000019,,Autocuration,,,B,,
1905,Rattus norvegicus,955.0,CHEMBL616501,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,9064,Brain,104686,,,BAO_0000221,,Autocuration,,10116.0,B,,
1906,,955.0,CHEMBL616502,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,,10748,Brain,104686,,,BAO_0000221,,Autocuration,,,B,,
1907,,,CHEMBL884529,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,11614,,104686,,,BAO_0000249,,Autocuration,Membranes,,B,,
1908,,,CHEMBL616503,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,11615,,104686,,,BAO_0000249,,Autocuration,Membranes,,B,,
1909,,,CHEMBL616964,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,,11615,,104686,,,BAO_0000224,,Autocuration,,,B,,
1910,,,CHEMBL616965,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,11614,,104686,,,BAO_0000249,,Autocuration,Membranes,,B,,
1911,,,CHEMBL616966,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,,11702,,104686,,,BAO_0000224,,Autocuration,,,B,,
1912,,,CHEMBL616967,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,,11702,,104686,,,BAO_0000224,,Autocuration,,,B,,
1913,Rattus norvegicus,,CHEMBL616968,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,,11702,,104686,,,BAO_0000224,,Autocuration,,10116.0,B,,
1914,,,CHEMBL616969,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,,11702,,104686,,,BAO_0000224,,Autocuration,,,B,,
1915,,,CHEMBL884530,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,,13346,,104686,,,BAO_0000019,,Autocuration,,,B,,
1916,,,CHEMBL616970,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,,10025,,104686,,,BAO_0000224,,Autocuration,,,B,,
1917,,,CHEMBL616971,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,10025,,104686,,,BAO_0000224,,Autocuration,,,B,,
1918,,,CHEMBL616972,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,10025,,104686,,,BAO_0000224,,Autocuration,,,B,,
1919,,,CHEMBL616973,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,,9036,,104686,,,BAO_0000224,,Autocuration,,,B,,
1920,,,CHEMBL616974,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,,9036,,104686,,,BAO_0000224,,Autocuration,,,B,,
1921,,,CHEMBL616975,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,,9161,,104686,,,BAO_0000019,,Autocuration,,,B,,
1922,,,CHEMBL616976,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,,12304,,104686,,,BAO_0000019,,Autocuration,,,B,,
1923,,,CHEMBL616977,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,,13276,,104686,,,BAO_0000224,,Autocuration,,,B,,
1924,,,CHEMBL616978,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,11825,,104686,,,BAO_0000224,,Autocuration,,,B,,
1925,,,CHEMBL616979,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,,12443,,104686,,,BAO_0000224,,Autocuration,,,B,,
1926,,,CHEMBL616980,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,,13830,,104686,,,BAO_0000224,,Autocuration,,,B,,
1927,,,CHEMBL616981,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,,9592,,104686,,,BAO_0000249,,Autocuration,Membranes,,B,,
1928,,,CHEMBL616982,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,,9592,,104686,,,BAO_0000249,,Autocuration,Membranes,,B,,
1929,,,CHEMBL616983,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,,10881,,104686,,,BAO_0000224,,Autocuration,,,B,,
1930,,,CHEMBL616984,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,,13605,,104686,,,BAO_0000019,,Autocuration,,,B,,
1931,Rattus norvegicus,,CHEMBL616985,Inhibitory activity against 5-hydroxytryptamine 2 receptor,,11624,,104686,,,BAO_0000224,,Autocuration,,10116.0,B,,
1932,,,CHEMBL616986,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,4101,,104686,,,BAO_0000224,,Autocuration,,,B,,
1933,,,CHEMBL616987,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,4101,,104686,,,BAO_0000224,,Autocuration,,,B,,
1934,,,CHEMBL616988,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,,15360,,104686,,,BAO_0000019,,Autocuration,,,B,,
1935,,,CHEMBL617243,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,,11576,,104686,,,BAO_0000019,,Autocuration,,,B,,
1936,,,CHEMBL617244,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,,5834,,104686,,,BAO_0000019,,Autocuration,,,B,,
1937,Rattus norvegicus,,CHEMBL617245,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,2395,,104686,,,BAO_0000219,,Autocuration,,10116.0,B,,CHO-K1
1938,,,CHEMBL617246,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,11965,,104686,,,BAO_0000249,,Autocuration,Membranes,,B,,
1939,,,CHEMBL617546,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),,3967,,104686,,,BAO_0000224,,Autocuration,,,B,,
1940,,,CHEMBL617547,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),,11130,,104686,,,BAO_0000249,,Autocuration,Brain membranes,,B,,
1941,,,CHEMBL617548,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,In vitro,13427,,104686,,,BAO_0000219,,Autocuration,,,B,,
1942,,,CHEMBL617549,Binding affinity towards 5-hydroxytryptamine 2 receptor,,9443,,104686,,,BAO_0000224,,Autocuration,,,B,,
1943,,,CHEMBL617550,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,9443,,104686,,,BAO_0000224,,Autocuration,,,B,,
1944,,,CHEMBL617551,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,11825,,104686,,,BAO_0000224,,Autocuration,,,B,,
1945,,,CHEMBL617552,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,,12120,,104686,,,BAO_0000249,,Autocuration,Membranes,,B,,
1946,,,CHEMBL617553,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,,12120,,104686,,,BAO_0000249,,Autocuration,Membranes,,B,,
1947,,1515.0,CHEMBL617554,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,,11963,Thoracic aorta,104686,,,BAO_0000019,,Autocuration,,,F,,
1948,,,CHEMBL617555,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,,9069,,104686,,,BAO_0000019,,Autocuration,,,B,,
1949,,,CHEMBL617556,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,8868,,104686,,,BAO_0000224,,Autocuration,,,B,,
1950,,,CHEMBL617557,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,17200,,10624,,,BAO_0000357,,Autocuration,,,B,,
1951,,,CHEMBL617558,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,17200,,10624,,,BAO_0000357,,Autocuration,,,B,,
1952,,,CHEMBL617559,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,,13969,,17106,,,BAO_0000357,,Expert,,,B,,
1953,,,CHEMBL617560,Binding affinity for 5-hydroxytryptamine 1D receptor,,13392,,17106,,,BAO_0000357,,Expert,,,B,,
1954,,,CHEMBL617561,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,1742,,17106,,,BAO_0000249,,Autocuration,,,B,,
1955,,,CHEMBL617562,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,1742,,17106,,,BAO_0000249,,Autocuration,,,B,,
1956,,2435.0,CHEMBL617563,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,,14331,Striatum,17106,,,BAO_0000357,,Autocuration,,,B,,
1957,,,CHEMBL617564,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,,12861,,17106,,,BAO_0000019,,Autocuration,,,F,,
1958,,,CHEMBL617565,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,,12861,,17106,,,BAO_0000019,,Expert,,,B,,
1959,,,CHEMBL856076,Binding activity radioligand.,,12861,,17106,,,BAO_0000357,,Autocuration,,,B,,
1960,,,CHEMBL617566,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,12861,,17106,,,BAO_0000019,,Autocuration,,,B,,
1961,,,CHEMBL875911,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,12861,,17106,,,BAO_0000019,,Expert,,,B,,
1962,,,CHEMBL617567,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,12861,,17106,,,BAO_0000019,,Autocuration,,,B,,
1963,,,CHEMBL617568,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,675,,17106,,,BAO_0000249,,Autocuration,,,B,,
1964,,,CHEMBL617569,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,,12490,,17106,,,BAO_0000019,,Expert,,,B,,
1965,,,CHEMBL617570,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,,11828,,17106,,,BAO_0000249,,Expert,,,B,,
1966,,,CHEMBL617571,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,,11866,,17106,,,BAO_0000357,,Autocuration,,,B,,
1967,Sus scrofa,,CHEMBL617572,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,,773,,105,,,BAO_0000357,,Autocuration,,9823.0,B,,
1968,Oryctolagus cuniculus,,CHEMBL617573,The compound was tested for intrinsic activity against 5-HT1D receptor,,13047,,105,,,BAO_0000357,,Expert,,9986.0,B,,
1969,Oryctolagus cuniculus,,CHEMBL617574,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,13047,,105,,,BAO_0000019,,Autocuration,,9986.0,B,,
1970,Oryctolagus cuniculus,,CHEMBL617575,The compound was tested for binding affinity against 5-HT1D receptor,,13047,,105,,,BAO_0000357,,Expert,,9986.0,B,,
1971,,,CHEMBL617576,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,,188,,10578,,,BAO_0000357,,Autocuration,,,B,,
1972,,,CHEMBL617577,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,,10639,,10578,,,BAO_0000019,,Autocuration,,,F,,
1973,,,CHEMBL617578,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,,12438,,10578,,,BAO_0000019,,Autocuration,,,F,,
1974,,,CHEMBL617579,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,,12438,,10578,,,BAO_0000357,,Autocuration,,,B,,
1975,,,CHEMBL617580,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,15854,,10578,,,BAO_0000019,,Expert,,,B,,
1976,,,CHEMBL617581,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,,10394,,10578,,,BAO_0000249,,Autocuration,,,B,,
1977,,,CHEMBL617582,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,,12092,,10578,,,BAO_0000357,,Autocuration,,,B,,
1978,,,CHEMBL617583,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,,3389,,10578,,,BAO_0000019,,Expert,,,B,,
1979,,,CHEMBL617584,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,,6011,,105,,,BAO_0000357,,Autocuration,,,B,,
1980,,,CHEMBL617585,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,,4639,,105,,,BAO_0000357,,Autocuration,,,B,,
1981,,,CHEMBL875912,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,,2474,,105,,,BAO_0000357,,Autocuration,,,B,,
1982,,,CHEMBL617586,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,,5014,,105,,,BAO_0000357,,Autocuration,,,B,,
1983,,,CHEMBL617587,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,,17515,,105,,,BAO_0000357,,Autocuration,,,B,,
1984,,,CHEMBL617588,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,,11866,,105,,,BAO_0000357,,Autocuration,,,B,,
1985,,,CHEMBL857980,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,,4687,,105,,,BAO_0000357,,Autocuration,,,B,,
1986,,,CHEMBL617589,Tested against 5-hydroxytryptamine 1D receptor,,12146,,105,,,BAO_0000357,,Autocuration,,,B,,
1987,,,CHEMBL617590,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,,10321,,105,,,BAO_0000357,,Autocuration,,,B,,
1988,,,CHEMBL617591,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,13267,,105,,,BAO_0000219,,Autocuration,,,B,,HEK293
1989,Homo sapiens,,CHEMBL617592,Binding affinity against 5-Hydroxytryptamine 1D receptor,,1274,,105,,,BAO_0000357,,Expert,,9606.0,B,,
1990,,,CHEMBL617593,,,15250,,105,,,BAO_0000357,,Autocuration,,,B,,
1991,,,CHEMBL617594,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,13706,,106,,,BAO_0000219,,Autocuration,,,B,,CHO-K1
1992,,,CHEMBL617595,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,13706,,105,,,BAO_0000219,,Autocuration,,,B,,CHO-K1
1993,,,CHEMBL617596,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,,13706,,105,,,BAO_0000219,,Autocuration,,,B,,HEK293
1994,,,CHEMBL617597,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,13706,,105,,,BAO_0000219,,Autocuration,,,B,,HEK293
1995,,,CHEMBL617598,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,13047,,105,,,BAO_0000019,,Autocuration,,,B,,
1996,,,CHEMBL872916,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,,13366,,105,,,BAO_0000357,,Autocuration,,,B,,
1997,,,CHEMBL617599,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,,13366,,105,,,BAO_0000357,,Expert,,,B,,
1998,,,CHEMBL617091,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,,1558,,105,,,BAO_0000357,,Autocuration,,,B,,
1999,,,CHEMBL617092,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",,12902,,105,,,BAO_0000219,,Expert,,,B,,CHO-K1
2000,,,CHEMBL617093,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,13706,,105,,,BAO_0000219,,Autocuration,,,B,,CHO-K1
2001,,,CHEMBL617094,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,,13706,,105,,,BAO_0000019,,Autocuration,,,F,,
2002,,,CHEMBL617095,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,13706,,105,,,BAO_0000019,,Autocuration,,,F,,
2003,,,CHEMBL617096,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,14251,,105,,,BAO_0000019,,Autocuration,,,F,,
2004,,,CHEMBL617097,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,14251,,105,,,BAO_0000019,,Autocuration,,,F,,
2005,,,CHEMBL617098,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,14251,,105,,,BAO_0000019,,Autocuration,,,F,,
2006,,,CHEMBL617301,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,,13313,,105,,,BAO_0000357,,Autocuration,,,B,,
2007,,,CHEMBL617302,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,,13313,,105,,,BAO_0000357,,Autocuration,,,B,,
2008,,,CHEMBL617303,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,,13366,,105,,,BAO_0000357,,Autocuration,,,B,,
2009,,,CHEMBL617304,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,,13051,,105,,,BAO_0000357,,Expert,,,B,,
2010,,,CHEMBL617305,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",,12903,,105,,,BAO_0000219,,Expert,,,B,,CHO
2011,Homo sapiens,,CHEMBL617306,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,,12469,,105,,,BAO_0000219,,Autocuration,,9606.0,B,,
2012,,,CHEMBL617307,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,,5619,,17106,,,BAO_0000357,,Autocuration,,,B,,
2013,Oryctolagus cuniculus,,CHEMBL617308,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,13047,,105,,,BAO_0000019,,Autocuration,,9986.0,B,,
2014,,,CHEMBL617309,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,,16633,,105,,,BAO_0000357,,Autocuration,,,B,,
2015,,,CHEMBL617310,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,16633,,105,,,BAO_0000357,,Autocuration,,,B,,
2016,,,CHEMBL617311,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,16633,,105,,,BAO_0000357,,Autocuration,,,B,,
2017,,,CHEMBL617312,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,,16633,,105,,,BAO_0000357,,Autocuration,,,B,,
2018,,,CHEMBL617313,Affinity against 5-hydroxytryptamine 1D receptor alpha,,3269,,105,,,BAO_0000357,,Autocuration,,,B,,
2019,,,CHEMBL617314,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,,12409,,105,,,BAO_0000357,,Expert,,,B,,
2020,,,CHEMBL617315,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,13706,,106,,,BAO_0000019,,Autocuration,,,F,,
2021,,,CHEMBL617316,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,,13706,,106,,,BAO_0000219,,Autocuration,,,B,,HEK293
2022,,,CHEMBL617317,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,13706,,106,,,BAO_0000219,,Autocuration,,,B,,HEK293
2023,,,CHEMBL617318,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,12903,,106,,,BAO_0000219,,Autocuration,,,B,,CHO
2024,,,CHEMBL617319,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,13047,,106,,,BAO_0000019,,Autocuration,,,B,,
2025,,,CHEMBL617320,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,13366,,106,,,BAO_0000357,,Expert,,,B,,
2026,,,CHEMBL617321,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,13366,,106,,,BAO_0000357,,Expert,,,B,,
2027,,,CHEMBL617322,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,13366,,106,,,BAO_0000357,,Expert,,,B,,
2028,,,CHEMBL616862,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,,13366,,106,,,BAO_0000357,,Autocuration,,,B,,
2029,,,CHEMBL616863,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,,13366,,106,,,BAO_0000357,,Autocuration,,,B,,
2030,,,CHEMBL616864,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,,12469,,106,,,BAO_0000219,,Autocuration,,,B,,CHO
2031,,,CHEMBL616865,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,,13706,,106,,,BAO_0000219,,Autocuration,,,B,,CHO-K1
2032,,,CHEMBL616866,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,,13706,,106,,,BAO_0000219,,Autocuration,,,B,,CHO-K1
2033,,,CHEMBL616867,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,13706,,106,,,BAO_0000019,,Autocuration,,,F,,
2034,,,CHEMBL616868,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",,12902,,106,,,BAO_0000219,,Expert,,,B,,CHO-K1
2035,,,CHEMBL616869,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,,13051,,105,,,BAO_0000357,,Expert,,,B,,
2036,,,CHEMBL616870,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,12903,,106,,,BAO_0000219,,Expert,,,B,,CHO
2037,,,CHEMBL616871,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,,1558,,105,,,BAO_0000219,,Autocuration,,,F,,CHO-K1
2038,,,CHEMBL616872,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,,1558,,105,,,BAO_0000219,,Autocuration,,,F,,CHO-K1
2039,,,CHEMBL616873,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,,1558,,105,,,BAO_0000219,,Autocuration,,,F,,CHO-K1
2040,,,CHEMBL616838,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,,1558,,105,,,BAO_0000219,,Autocuration,,,F,,CHO-K1
2041,,,CHEMBL616839,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,,1558,,105,,,BAO_0000357,,Autocuration,,,B,,
2042,Oryctolagus cuniculus,,CHEMBL616840,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,,13047,,106,,,BAO_0000019,,Autocuration,,9986.0,B,,
2043,,,CHEMBL616841,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,,13313,,105,,,BAO_0000357,,Autocuration,,,B,,
2044,,,CHEMBL616842,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,,13313,,105,,,BAO_0000357,,Autocuration,,,B,,
2045,,,CHEMBL857976,Binding affinity against 5-hydroxytryptamine 1D receptor beta,,12409,,105,,,BAO_0000357,,Expert,,,B,,
2046,,,CHEMBL616843,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,,15250,,10618,,,BAO_0000219,,Autocuration,,,B,,CHO
2047,Homo sapiens,,CHEMBL616844,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,,1348,,10618,,,BAO_0000357,,Expert,,9606.0,B,,
2048,,,CHEMBL616845,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,,1348,,10618,,,BAO_0000357,,Autocuration,,,B,,
2049,Homo sapiens,,CHEMBL616846,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,,4234,,10618,,,BAO_0000357,,Expert,,9606.0,B,,
2050,,,CHEMBL616847,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,,16209,,10618,,,BAO_0000357,,Autocuration,,,B,,
2051,,,CHEMBL616848,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,,10444,,10618,,,BAO_0000019,,Autocuration,,,B,,
2052,,,CHEMBL616849,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,,3935,,10618,,,BAO_0000357,,Autocuration,,,B,,
2053,,,CHEMBL872911,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,,15818,,10618,,,BAO_0000357,,Autocuration,,,B,,
2054,,,CHEMBL616850,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,,17085,,10618,,,BAO_0000019,,Autocuration,,,B,,
2055,Homo sapiens,,CHEMBL616699,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,,12936,,10618,,,BAO_0000219,,Expert,,9606.0,B,,CHO
2056,,,CHEMBL616700,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,,6166,,10618,,,BAO_0000357,,Autocuration,,,B,,
2057,,,CHEMBL616701,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,15779,,10618,,,BAO_0000219,,Autocuration,,,B,,CHO
2058,,,CHEMBL616702,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,,15779,,10618,,,BAO_0000219,,Autocuration,,,B,,CHO
2059,,,CHEMBL616703,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,,15779,,10618,,,BAO_0000219,,Autocuration,,,B,,CHO
2060,,,CHEMBL616704,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,,13181,,10618,,,BAO_0000357,,Autocuration,,,B,,
2061,,,CHEMBL616705,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,,4199,,10618,,,BAO_0000219,,Autocuration,,,B,,CHO
2062,,,CHEMBL616706,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,,14875,,10618,,,BAO_0000357,,Autocuration,,,B,,
2063,,,CHEMBL616707,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,,15146,,10618,,,BAO_0000219,,Autocuration,,,B,,CHO
2064,,,CHEMBL616708,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,,5213,,10618,,,BAO_0000357,,Autocuration,,,B,,
2065,,,CHEMBL616709,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,,12146,,10618,,,BAO_0000357,,Autocuration,,,B,,
2066,,,CHEMBL616710,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,,13267,,10618,,,BAO_0000219,,Autocuration,,,B,,CHO
2067,,,CHEMBL616711,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,,14818,,10618,,,BAO_0000219,,Autocuration,,,B,,CHO
2068,,,CHEMBL616712,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",,4829,,10618,,,BAO_0000219,,Autocuration,,,B,,CHO
2069,,,CHEMBL616713,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,,4373,,10618,,,BAO_0000357,,Autocuration,,,B,,
2070,,,CHEMBL616714,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,,4373,,10618,,,BAO_0000357,,Autocuration,,,B,,
2071,,,CHEMBL616715,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,,14159,,10618,,,BAO_0000357,,Autocuration,,,B,,
2072,,,CHEMBL616716,Binding affinity towards 5-hydroxytryptamine 1E receptor,,16633,,10618,,,BAO_0000357,,Autocuration,,,B,,
2073,,,CHEMBL616717,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",,17085,,279,,,BAO_0000019,,Autocuration,,,F,,
2074,,,CHEMBL616718,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",,17085,,279,,,BAO_0000019,,Expert,,,F,,
2075,,,CHEMBL875905,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,,16209,,279,,,BAO_0000019,,Autocuration,,,F,,
2076,,,CHEMBL616719,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,,16209,,279,,,BAO_0000019,,Autocuration,,,F,,
2077,,,CHEMBL616720,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",,17085,,279,,,BAO_0000019,,Expert,,,F,,
2078,,,CHEMBL616721,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,,14159,,279,,,BAO_0000357,,Autocuration,,,B,,
2079,,,CHEMBL616722,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,,15250,,279,,,BAO_0000219,,Autocuration,,,B,,CHO
2080,,,CHEMBL616723,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),,3805,,279,,,BAO_0000357,,Autocuration,,,B,,
2081,,,CHEMBL616724,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,,16190,,279,,,BAO_0000219,,Autocuration,,,B,,CHO
2082,,,CHEMBL616725,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,,16190,,279,,,BAO_0000357,,Autocuration,,,B,,
2083,,,CHEMBL616726,Binding affinity towards human 5-hydroxytryptamine 1F receptor,,16209,,279,,,BAO_0000357,,Autocuration,,,B,,
2084,,,CHEMBL616727,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,,16209,,279,,,BAO_0000357,,Autocuration,,,B,,
2085,,,CHEMBL616728,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,,16209,,279,,,BAO_0000357,,Autocuration,,,B,,
2086,,,CHEMBL616729,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,,6866,,279,,,BAO_0000357,,Autocuration,,,B,,
2087,,,CHEMBL616730,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,,17085,,279,,,BAO_0000019,,Expert,,,B,,
2088,,,CHEMBL617125,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,,16312,,279,,,BAO_0000357,,Autocuration,,,B,,
2089,,,CHEMBL857977,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,,6166,,279,,,BAO_0000357,,Autocuration,,,B,,
2090,,,CHEMBL617126,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,15779,,279,,,BAO_0000219,,Autocuration,,,B,,CHO
2091,,,CHEMBL617127,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,,4199,,279,,,BAO_0000219,,Autocuration,,,B,,CHO
2092,,,CHEMBL617128,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,,14875,,279,,,BAO_0000357,,Autocuration,,,B,,
2093,,,CHEMBL617129,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,,15146,,279,,,BAO_0000219,,Autocuration,,,B,,CHO
2094,,,CHEMBL617130,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,,5213,,279,,,BAO_0000357,,Autocuration,,,B,,
2095,,,CHEMBL617131,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,,14818,,279,,,BAO_0000219,,Autocuration,,,B,,CHO
2096,,,CHEMBL617132,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,4829,,279,,,BAO_0000219,,Autocuration,,,B,,CHO
2097,,,CHEMBL617133,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,4829,,279,,,BAO_0000219,,Autocuration,,,B,,CHO
2098,,,CHEMBL617134,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,,4373,,279,,,BAO_0000357,,Autocuration,,,B,,
2099,,,CHEMBL617135,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,,4373,,279,,,BAO_0000357,,Autocuration,,,B,,
2100,,,CHEMBL617136,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,,5014,,279,,,BAO_0000357,,Autocuration,,,B,,
2101,,,CHEMBL617137,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",,11662,,104686,,,BAO_0000019,,Autocuration,,,B,,
2102,,,CHEMBL617138,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,11662,,104686,,,BAO_0000019,,Autocuration,,,B,,
2103,,,CHEMBL617139,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,11662,,104686,,,BAO_0000019,,Autocuration,,,B,,
2104,,,CHEMBL617140,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,14093,,12687,,,BAO_0000019,,Autocuration,,,B,,
2105,,,CHEMBL617141,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",In vivo,11200,,104686,,,BAO_0000218,,Autocuration,,,F,,
2106,,,CHEMBL858112,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,11200,,104686,,,BAO_0000019,,Autocuration,,,F,,
2107,,,CHEMBL617142,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,,12352,,17005,,,BAO_0000019,,Intermediate,,,B,,
2108,Bos taurus,,CHEMBL617143,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",,13657,,22226,,,BAO_0000019,,Autocuration,,9913.0,B,,
2109,Bos taurus,,CHEMBL617144,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,,14331,,22226,,,BAO_0000019,,Autocuration,,9913.0,B,,
2110,Bos taurus,,CHEMBL617145,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,,14331,,22226,,,BAO_0000019,,Autocuration,,9913.0,B,,
2111,,,CHEMBL617146,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,,14331,,22226,,,BAO_0000019,,Autocuration,,,B,,
2112,Cavia porcellus,,CHEMBL617147,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,,12685,,104784,,,BAO_0000019,,Autocuration,,10141.0,B,,
2113,Cavia porcellus,,CHEMBL617148,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,,14389,,104784,,,BAO_0000019,,Autocuration,,10141.0,B,,
2114,Cavia porcellus,,CHEMBL617149,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,,14386,,104784,,,BAO_0000019,,Autocuration,,10141.0,B,,
2115,,,CHEMBL617150,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,,5732,,104784,,,BAO_0000224,,Autocuration,,,B,,
2116,,,CHEMBL617151,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,16293,,104784,,,BAO_0000224,,Autocuration,,,B,,
2117,,,CHEMBL617201,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,,2078,,104784,,,BAO_0000224,,Autocuration,,,B,,
2118,,,CHEMBL617202,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,5486,,10209,,,BAO_0000357,,Autocuration,,,B,,
2119,,,CHEMBL617203,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,In vivo,11820,,104826,,,BAO_0000218,,Autocuration,,,B,,
2120,,,CHEMBL617204,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,10297,,104826,,,BAO_0000019,,Autocuration,,,B,,
2121,,,CHEMBL617205,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,,13704,,104826,,,BAO_0000224,,Autocuration,,,B,,
2122,Mus musculus,,CHEMBL617206,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,,10297,,104826,,,BAO_0000019,,Autocuration,,10090.0,B,,
2123,,,CHEMBL617207,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,In vivo,11820,,104826,,,BAO_0000218,,Autocuration,,,B,,
2124,Mus musculus,,CHEMBL617208,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,,10297,,104826,,,BAO_0000019,,Autocuration,,10090.0,B,,
2125,,,CHEMBL617209,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,,11555,,104826,,,BAO_0000224,,Autocuration,,,B,,
2126,,,CHEMBL617210,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,,11555,,104826,,,BAO_0000224,,Autocuration,,,B,,
2127,,,CHEMBL617211,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,,11555,,104826,,,BAO_0000224,,Autocuration,,,B,,
2128,Mus musculus,,CHEMBL617212,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,10297,,104826,,,BAO_0000019,,Autocuration,,10090.0,B,,
2129,Sus scrofa,,CHEMBL617213,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,,16688,,104784,,,BAO_0000224,,Autocuration,,9823.0,B,,
2130,Sus scrofa,,CHEMBL617214,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,,16688,,104784,,,BAO_0000224,,Autocuration,,9823.0,B,,
2131,,,CHEMBL617215,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,5333,,22226,,,BAO_0000221,,Autocuration,,,B,,
2132,,,CHEMBL617216,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,4437,,22226,,,BAO_0000221,,Autocuration,,,B,,
2133,Sus scrofa,,CHEMBL617217,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,,5033,,17005,,,BAO_0000357,,Autocuration,,9823.0,B,,
2134,,,CHEMBL617218,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,15267,,104686,,,BAO_0000019,,Autocuration,,,B,,
2135,,,CHEMBL872913,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,15267,,104686,,,BAO_0000019,,Autocuration,,,B,,
2136,,,CHEMBL617219,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,,11820,,104826,,,BAO_0000019,,Autocuration,,,B,,
2137,,,CHEMBL873482,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,9069,,104686,,,BAO_0000224,,Autocuration,,,B,,
2138,Rattus norvegicus,,CHEMBL617220,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,,9162,,104686,,,BAO_0000019,,Autocuration,,10116.0,B,,
2139,,,CHEMBL617221,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,,9162,,104686,,,BAO_0000019,,Autocuration,,,B,,
2140,,,CHEMBL617222,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,,9162,,104686,,,BAO_0000019,,Autocuration,,,B,,
2141,,,CHEMBL875906,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,,10428,,104686,,,BAO_0000019,,Autocuration,,,F,,
2142,,,CHEMBL617223,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,,9628,,104686,,,BAO_0000019,,Autocuration,,,B,,
2143,,,CHEMBL617224,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,,12704,,104686,,,BAO_0000224,,Autocuration,,,B,,
2144,Rattus norvegicus,,CHEMBL617225,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,15453,,104686,,,BAO_0000224,,Autocuration,,10116.0,B,,
2145,,,CHEMBL617226,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,,188,,104686,,,BAO_0000224,,Autocuration,,,B,,
2146,,,CHEMBL617227,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,,10349,,104686,,,BAO_0000224,,Autocuration,,,B,,
2147,,,CHEMBL617228,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,,10349,,104686,,,BAO_0000224,,Autocuration,,,B,,
2148,,,CHEMBL617229,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,8868,,104686,,,BAO_0000224,,Autocuration,,,B,,
2149,,,CHEMBL617230,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,10025,,104686,,,BAO_0000224,,Autocuration,,,B,,
2150,,,CHEMBL617231,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,10025,,104686,,,BAO_0000224,,Autocuration,,,B,,
2151,,,CHEMBL617232,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,,11702,,104686,,,BAO_0000224,,Autocuration,,,B,,
2152,,,CHEMBL617233,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,,11702,,104686,,,BAO_0000224,,Autocuration,,,B,,
2153,,,CHEMBL617234,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,,11702,,104686,,,BAO_0000224,,Autocuration,,,B,,
2154,,,CHEMBL617235,Compound was tested for the inhibition of quipazine induced head twitches in rats,,11702,,104686,,,BAO_0000019,,Autocuration,,,F,,
2155,,,CHEMBL617236,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,,11702,,104686,,,BAO_0000019,,Autocuration,,,F,,
2156,,10000000.0,CHEMBL617237,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,,10085,Hippocampus,104686,,,BAO_0000221,,Autocuration,,,B,,
2157,,10000000.0,CHEMBL617238,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,,10085,Hippocampus,104686,,,BAO_0000221,,Autocuration,,,B,,
2158,Rattus norvegicus,955.0,CHEMBL617239,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,,9630,Brain,104686,,,BAO_0000221,,Autocuration,,10116.0,B,,
2159,,,CHEMBL617240,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,,11070,,104686,,,BAO_0000019,,Autocuration,,,B,,
2160,,,CHEMBL617241,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,9841,,104686,,,BAO_0000249,,Autocuration,Membranes,,B,,
2161,,,CHEMBL875907,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,9841,,104686,,,BAO_0000249,,Autocuration,Membranes,,B,,
2162,,,CHEMBL617242,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,,13291,,104686,,,BAO_0000019,,Autocuration,,,B,,
2163,,,CHEMBL617152,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,,10590,,104686,,,BAO_0000019,,Autocuration,,,F,,
2164,Rattus norvegicus,955.0,CHEMBL617153,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,9064,Brain,104686,,,BAO_0000221,,Autocuration,,10116.0,B,,
2165,Rattus norvegicus,,CHEMBL617154,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,,12268,,104686,,,BAO_0000249,,Autocuration,Membranes,10116.0,B,,
2166,,955.0,CHEMBL617155,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,,13508,Brain,104686,,,BAO_0000221,,Autocuration,,,B,,
2167,,,CHEMBL617156,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,11279,,104686,,,BAO_0000019,,Autocuration,,,F,,
2168,,,CHEMBL617157,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,,11200,,104686,,,BAO_0000019,,Autocuration,,,F,,
2169,,,CHEMBL617158,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,11200,,104686,,,BAO_0000019,,Autocuration,,,F,,
2170,,,CHEMBL617159,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,11200,,104686,,,BAO_0000019,,Autocuration,,,F,,
2171,,,CHEMBL617160,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,11200,,104686,,,BAO_0000019,,Autocuration,,,F,,
2172,,,CHEMBL858113,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,11200,,104686,,,BAO_0000019,,Autocuration,,,F,,
2173,,955.0,CHEMBL617247,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,,9231,Brain,104686,,,BAO_0000220,,Autocuration,,,B,,
2174,,,CHEMBL617248,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,9737,,104686,,,BAO_0000019,,Autocuration,,,B,,
2175,,955.0,CHEMBL617249,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,9737,Brain,104686,,,BAO_0000249,,Autocuration,,,B,,
2176,,,CHEMBL617250,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,,9737,,104686,,,BAO_0000019,,Autocuration,,,B,,
2177,,,CHEMBL617251,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,9737,,104686,,,BAO_0000019,,Autocuration,,,B,,
2178,Rattus norvegicus,,CHEMBL617252,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,,11828,,104686,,,BAO_0000019,,Autocuration,,10116.0,B,,
2179,,,CHEMBL617006,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,,12253,,104686,,,BAO_0000019,,Autocuration,,,B,,
2180,,,CHEMBL617007,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,,12253,,104686,,,BAO_0000019,,Autocuration,,,B,,
2181,,,CHEMBL617008,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",,11279,,104686,,,BAO_0000019,,Autocuration,,,F,,
2182,,,CHEMBL617009,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,,11866,,104686,,,BAO_0000019,,Autocuration,,,B,,
2183,Rattus norvegicus,,CHEMBL617010,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,,14424,,104686,,,BAO_0000224,,Autocuration,,10116.0,B,,
2184,Rattus norvegicus,,CHEMBL857978,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,15180,,104686,,,BAO_0000019,,Autocuration,,10116.0,B,,
2185,Rattus norvegicus,,CHEMBL617011,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,15180,,104686,,,BAO_0000019,,Autocuration,,10116.0,B,,
2186,Rattus norvegicus,,CHEMBL617012,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,,9786,,104686,,,BAO_0000019,,Autocuration,,10116.0,B,,
2187,,,CHEMBL617013,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,,12132,,104686,,,BAO_0000224,,Autocuration,,,B,,
2188,,,CHEMBL617014,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,,5486,,104686,,,BAO_0000249,,Autocuration,,,B,,
2189,,,CHEMBL617015,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,,15316,,104686,,,BAO_0000019,,Autocuration,,,B,,
2190,,,CHEMBL617016,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,,16429,,104686,,,BAO_0000019,,Autocuration,,,B,,
2191,,,CHEMBL617017,pKi value for 5-hydroxytryptamine 2 receptor binding site,,14617,,104686,,,BAO_0000224,,Autocuration,,,B,,
2192,,955.0,CHEMBL617018,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,,11351,Brain,104686,,,BAO_0000221,,Autocuration,,,B,,
2193,,,CHEMBL617019,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,11279,,104686,,,BAO_0000019,,Autocuration,,,F,,
2194,,,CHEMBL617020,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,9523,,105075,,,BAO_0000019,,Autocuration,,,B,,
2195,,,CHEMBL617021,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,9523,,105075,,,BAO_0000019,,Autocuration,,,B,,
2196,,,CHEMBL617022,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,9523,,105075,,,BAO_0000019,,Autocuration,,,B,,
2197,,,CHEMBL617023,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,9523,,105075,,,BAO_0000019,,Autocuration,,,B,,
2198,,,CHEMBL617024,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,9523,,105075,,,BAO_0000019,,Autocuration,,,B,,
2199,,,CHEMBL617025,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,9523,,105075,,,BAO_0000019,,Autocuration,,,B,,
2200,,,CHEMBL617026,Hill coefficient of compound was determined,,9523,,105075,,,BAO_0000224,,Autocuration,,,B,,
2201,,,CHEMBL617027,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,,4771,,22226,,,BAO_0000019,,Autocuration,,,B,,
2202,Rattus norvegicus,,CHEMBL617028,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,,5033,,104686,,,BAO_0000019,,Autocuration,,10116.0,B,,
2203,,,CHEMBL617029,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,,10845,,12687,,,BAO_0000019,,Expert,,,B,,
2204,,,CHEMBL875908,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,,10845,,12687,,,BAO_0000019,,Expert,,,B,,
2205,,,CHEMBL617030,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),,16288,,12687,,,BAO_0000357,,Autocuration,,,B,,
2206,,,CHEMBL617031,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),,16288,,12687,,,BAO_0000019,,Autocuration,,,B,,
2207,,,CHEMBL617032,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,,16190,,12687,,,BAO_0000019,,Autocuration,,,B,,
2208,Rattus norvegicus,,CHEMBL617033,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,,12463,,104686,,,BAO_0000224,,Autocuration,,10116.0,B,,
2209,,,CHEMBL617034,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",,9699,,104686,,,BAO_0000224,,Autocuration,,,B,,
2210,,,CHEMBL617035,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,,9699,,104686,,,BAO_0000224,,Autocuration,,,B,,
2211,,,CHEMBL617036,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,11662,,104686,,,BAO_0000019,,Autocuration,,,B,,
2212,,,CHEMBL617037,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,,1205,,104784,,,BAO_0000224,,Autocuration,,,B,,
2213,,,CHEMBL617038,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,,11376,,22226,,,BAO_0000219,,Autocuration,,,B,,
2214,,,CHEMBL617039,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",,11376,,104784,,,BAO_0000219,,Autocuration,,,B,,
2215,,,CHEMBL617161,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,,4639,,104784,,,BAO_0000224,,Autocuration,,,B,,
2216,,,CHEMBL617162,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,,2222,,104784,,,BAO_0000224,,Autocuration,,,B,,
2217,,,CHEMBL617163,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,,1558,,104784,,,BAO_0000224,,Autocuration,,,B,,
2218,,,CHEMBL617164,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,,1089,,104784,,,BAO_0000224,,Autocuration,,,B,,
2219,,,CHEMBL617165,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,,386,,104784,,,BAO_0000249,,Autocuration,Brain membranes,,B,,
2220,,,CHEMBL617166,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,,2474,,104784,,,BAO_0000224,,Autocuration,,,B,,
2221,,,CHEMBL617167,Binding affinity towards 5-HT2 receptor,,17066,,104784,,,BAO_0000224,,Autocuration,,,B,,
2222,,,CHEMBL872912,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,959,,104784,,,BAO_0000224,,Autocuration,,,B,,
2223,,,CHEMBL617168,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,,6398,,104784,,,BAO_0000224,,Autocuration,,,B,,
2224,,,CHEMBL617169,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,,11889,,104686,,,BAO_0000224,,Autocuration,,,B,,
2225,,,CHEMBL617170,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,4221,,104784,,,BAO_0000224,,Autocuration,,,B,,
2226,,,CHEMBL617171,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,,11026,,104784,,,BAO_0000224,,Autocuration,,,B,,
2227,,,CHEMBL617172,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,,11866,,104784,,,BAO_0000224,,Autocuration,,,B,,
2228,,,CHEMBL617173,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,4221,,104784,,,BAO_0000224,,Autocuration,,,B,,
2229,,,CHEMBL617174,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,,13950,,22226,,,BAO_0000019,,Autocuration,,,B,,
2230,,,CHEMBL617175,5-hydroxytryptamine 2 receptor binding affinity,,1263,,104784,,,BAO_0000224,,Autocuration,,,B,,
2231,,,CHEMBL617176,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,,13291,,17005,,,BAO_0000357,,Autocuration,,,B,,
2232,,,CHEMBL617177,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,,10812,,17005,,,BAO_0000357,,Autocuration,,,B,,
2233,,,CHEMBL617178,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,13020,,104784,,,BAO_0000224,,Autocuration,,,B,,
2234,,,CHEMBL617179,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,,13021,,104784,,,BAO_0000224,,Autocuration,,,B,,
2235,,,CHEMBL617180,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,13020,,104784,,,BAO_0000224,,Autocuration,,,B,,
2236,,,CHEMBL617181,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,,14532,,17005,,,BAO_0000357,,Autocuration,,,B,,
2237,,,CHEMBL617182,Binding affinity against 5-hydroxytryptamine 2 receptor,,13944,,17005,,,BAO_0000357,,Autocuration,,,B,,
2238,,,CHEMBL617183,Binding affinity against 5-hydroxytryptamine 2 receptor,,14331,,17005,,,BAO_0000357,,Autocuration,,,B,,
2239,,,CHEMBL617184,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,14118,,17005,,,BAO_0000357,,Autocuration,,,B,,
2240,,,CHEMBL617185,Binding affinity against serotonergic 5-HT2 receptor,,13033,,17005,,,BAO_0000357,,Autocuration,,,B,,
2241,,,CHEMBL617186,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,,10321,,17005,,,BAO_0000357,,Autocuration,,,B,,
2242,,,CHEMBL617187,Compound was evaluated for the binding affinity at 5- HT2 receptor,,12918,,17005,,,BAO_0000357,,Autocuration,,,B,,
2243,,,CHEMBL617188,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,,15120,,17005,,,BAO_0000357,,Autocuration,,,B,,
2244,,,CHEMBL617189,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,,2613,,17005,,,BAO_0000218,,Autocuration,,,B,,
2245,Homo sapiens,,CHEMBL617190,Inhibitory activity against cloned human 5-HT2 receptor,,13378,,104784,,,BAO_0000224,,Autocuration,,9606.0,B,,
2246,Homo sapiens,,CHEMBL617191,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",,2331,,104784,,,BAO_0000219,,Autocuration,,9606.0,B,,CHO
2247,Homo sapiens,,CHEMBL617192,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",,2331,,104784,,,BAO_0000219,,Autocuration,,9606.0,B,,CHO
2248,Homo sapiens,,CHEMBL617193,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",,2331,,104784,,,BAO_0000219,,Autocuration,,9606.0,B,,CHO
2249,Homo sapiens,,CHEMBL617194,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",,2331,,104784,,,BAO_0000219,,Autocuration,,9606.0,B,,CHO
2250,,,CHEMBL617195,Binding affinity towards 5-hydroxytryptamine 2 receptor,,4170,,104784,,,BAO_0000224,,Autocuration,,,B,,
2251,,,CHEMBL881830,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,15453,,104784,,,BAO_0000224,,Autocuration,,,B,,
2252,,,CHEMBL617196,Binding affinity towards 5-hydroxytryptamine 2 receptor,,1479,,17005,,,BAO_0000357,,Autocuration,,,B,,
2253,,,CHEMBL617197,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,,11139,,104686,,,BAO_0000224,,Autocuration,,,B,,
2254,,,CHEMBL617198,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,,13969,,17005,,,BAO_0000357,,Expert,,,B,,
2255,,,CHEMBL873476,Binding affinity towards 5-hydroxytryptamine 2A receptor,,13392,,17005,,,BAO_0000357,,Expert,,,B,,
2256,,,CHEMBL617199,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,,14430,,17005,,,BAO_0000019,,Expert,,,B,,
2257,Cavia porcellus,,CHEMBL617200,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,13181,,107,,,BAO_0000357,,Autocuration,,10141.0,B,,
2258,,,CHEMBL617484,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,17200,,51,,,BAO_0000357,,Autocuration,,,B,,
2259,,,CHEMBL617485,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,17200,,107,,,BAO_0000357,,Autocuration,,,B,,
2260,,,CHEMBL617486,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,17200,,51,,,BAO_0000357,,Autocuration,,,B,,
2261,,,CHEMBL858022,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,,13463,,107,,,BAO_0000357,,Autocuration,,,B,,
2262,,,CHEMBL617049,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,6347,,107,,,BAO_0000219,,Autocuration,,,B,,CHO
2263,Homo sapiens,,CHEMBL617050,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,,6857,,107,,,BAO_0000219,,Expert,,9606.0,F,,CHO
2264,,,CHEMBL617051,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,4176,,107,,,BAO_0000219,,Autocuration,,,F,,
2265,,,CHEMBL617052,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,,4176,,107,,,BAO_0000219,,Autocuration,,,F,,
2266,,,CHEMBL617053,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,4176,,107,,,BAO_0000219,,Autocuration,,,F,,
2267,,,CHEMBL617054,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",,6347,,107,,,BAO_0000219,,Autocuration,,,B,,CHO
2268,,,CHEMBL617055,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",,6347,,107,,,BAO_0000219,,Autocuration,,,B,,CHO
2269,,,CHEMBL882924,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,,15331,,107,,,BAO_0000357,,Autocuration,,,B,,
2270,Homo sapiens,,CHEMBL617056,Inhibition of human 5-hydroxytryptamine 2A receptor,,16146,,107,,,BAO_0000357,,Expert,,9606.0,B,,
2271,,,CHEMBL617057,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,15250,,107,,,BAO_0000219,,Autocuration,,,B,,CHO
2272,,,CHEMBL617058,Inhibitory concentration against human 5-HT2A receptor in BEK cells,,13631,,107,,,BAO_0000219,,Expert,,,B,,
2273,,,CHEMBL617059,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),,3805,,107,,,BAO_0000357,,Autocuration,,,B,,
2274,,,CHEMBL617060,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,,4011,,107,,,BAO_0000219,,Autocuration,,,B,,CHO
2275,,,CHEMBL617061,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,,4012,,107,,,BAO_0000219,,Expert,,,B,,CHO
2276,,,CHEMBL617062,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,,6366,,107,,,BAO_0000219,,Expert,,,B,,L929
2277,,,CHEMBL617063,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,15949,,107,,,BAO_0000219,,Expert,,,B,,CHO
2278,,,CHEMBL617064,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,,14093,,107,,,BAO_0000019,,Autocuration,,,F,,
2279,,,CHEMBL617065,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,13481,,107,,,BAO_0000019,,Autocuration,,,F,,
2280,,,CHEMBL617066,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,6347,,107,,,BAO_0000219,,Autocuration,,,B,,CHO
2281,,,CHEMBL617067,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,,6347,,107,,,BAO_0000219,,Autocuration,,,B,,CHO
2282,,,CHEMBL617068,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,,14093,,107,,,BAO_0000019,,Autocuration,,,F,,
2283,,,CHEMBL617069,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,,14093,,107,,,BAO_0000019,,Autocuration,,,F,,
2284,,,CHEMBL617070,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,13481,,107,,,BAO_0000019,,Autocuration,,,F,,
2285,,,CHEMBL617071,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,,14442,,107,,,BAO_0000357,,Autocuration,,,B,,
2286,,,CHEMBL872915,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,14442,,107,,,BAO_0000357,,Autocuration,,,B,,
2287,,,CHEMBL617072,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,,14755,,107,,,BAO_0000357,,Autocuration,,,B,,
2288,,,CHEMBL617073,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,,16441,,107,,,BAO_0000357,,Autocuration,,,B,,
2289,,,CHEMBL617074,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,,14744,,107,,,BAO_0000357,,Autocuration,,,B,,
2290,,,CHEMBL617075,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,16659,,107,,,BAO_0000219,,Expert,,,B,,CHO
2291,,,CHEMBL617076,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,,3307,,107,,,BAO_0000357,,Autocuration,,,B,,
2292,Homo sapiens,,CHEMBL617077,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,,6857,,107,,,BAO_0000019,,Expert,,9606.0,B,,
2293,,,CHEMBL617078,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,,5635,,107,,,BAO_0000357,,Expert,,,B,,
2294,Homo sapiens,,CHEMBL617079,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,,4234,,107,,,BAO_0000357,,Expert,,9606.0,B,,
2295,,,CHEMBL617080,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,15527,,107,,,BAO_0000357,,Autocuration,,,B,,
2296,,,CHEMBL617081,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,,6588,,107,,,BAO_0000219,,Expert,,,B,,CHO
2297,,,CHEMBL617082,Binding affinity towards human 5-HT2A receptor in BEK cells,,13631,,107,,,BAO_0000219,,Expert,,,B,,
2298,,,CHEMBL617083,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,,17723,,107,,,BAO_0000357,,Autocuration,,,B,,
2299,,,CHEMBL617084,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,14770,,107,,,BAO_0000357,,Autocuration,,,B,,
2300,Homo sapiens,,CHEMBL617085,Binding affinity for human 5-hydroxytryptamine 2A receptor,,16293,,107,,,BAO_0000357,,Expert,,9606.0,B,,
2301,,,CHEMBL617086,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,16209,,107,,,BAO_0000357,,Autocuration,,,B,,
2302,,,CHEMBL617087,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,,12469,,107,,,BAO_0000219,,Autocuration,,,B,,
2303,,,CHEMBL617088,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,,15363,,107,,,BAO_0000357,,Autocuration,,,B,,
2304,,,CHEMBL617089,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,,15363,,107,,,BAO_0000357,,Autocuration,,,B,,
2305,,,CHEMBL617090,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",,16441,,107,,,BAO_0000019,,Expert,,,B,,
2306,,,CHEMBL617513,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,,8,,107,,,BAO_0000357,,Autocuration,,,B,,
2307,,,CHEMBL617514,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,,4176,,107,,,BAO_0000219,,Autocuration,,,B,,HEK293
2308,,,CHEMBL617515,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,,17085,,107,,,BAO_0000019,,Autocuration,,,B,,
2309,,,CHEMBL617516,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,17200,,107,,,BAO_0000357,,Autocuration,,,B,,
2310,Homo sapiens,,CHEMBL617517,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,17200,,107,,,BAO_0000357,,Expert,,9606.0,B,,
2311,Homo sapiens,,CHEMBL617518,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,,4013,,107,,,BAO_0000219,,Expert,,9606.0,B,,CHO
2312,,,CHEMBL617519,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,,5088,,107,,,BAO_0000357,,Autocuration,,,B,,
2313,Homo sapiens,,CHEMBL617520,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,,5088,,107,,,BAO_0000357,,Expert,,9606.0,B,,
2314,,,CHEMBL617521,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,,5088,,107,,,BAO_0000357,,Autocuration,,,B,,
2315,Homo sapiens,,CHEMBL617522,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,,5088,,107,,,BAO_0000357,,Expert,,9606.0,B,,
2316,,,CHEMBL617523,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,,5088,,107,,,BAO_0000357,,Autocuration,,,B,,
2317,,,CHEMBL617524,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,5088,,107,,,BAO_0000357,,Autocuration,,,B,,
2318,,,CHEMBL617525,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,,9786,,104686,,,BAO_0000019,,Autocuration,,,B,,
2319,Rattus norvegicus,,CHEMBL617526,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,,9205,,104686,,,BAO_0000019,,Autocuration,,10116.0,B,,
2320,,,CHEMBL617527,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,,11257,,104686,,,BAO_0000224,,Autocuration,,,B,,
2321,,,CHEMBL617528,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,9362,,104686,,,BAO_0000019,,Autocuration,,,B,,
2322,,,CHEMBL617529,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,9362,,104686,,,BAO_0000019,,Autocuration,,,B,,
2323,,,CHEMBL617530,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,,10590,,104686,,,BAO_0000224,,Autocuration,,,B,,
2324,,,CHEMBL617531,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,10468,,104686,,,BAO_0000019,,Autocuration,,,B,,
2325,,,CHEMBL617532,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,,13050,,104686,,,BAO_0000019,,Autocuration,,,B,,
2326,,,CHEMBL617533,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,,11624,,104686,,,BAO_0000019,,Autocuration,,,B,,
2327,,,CHEMBL617534,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,10468,,104686,,,BAO_0000019,,Autocuration,,,B,,
2328,,,CHEMBL617535,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,10330,,104686,,,BAO_0000224,,Autocuration,,,B,,
2329,,,CHEMBL617536,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,10062,,104686,,,BAO_0000224,,Autocuration,,,B,,
2330,,,CHEMBL617537,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,11642,,104686,,,BAO_0000224,,Autocuration,,,B,,
2331,,,CHEMBL617538,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,10062,,104686,,,BAO_0000224,,Autocuration,,,B,,
2332,,,CHEMBL617539,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,In vitro,13427,,104686,,,BAO_0000219,,Autocuration,,,B,,
2333,Rattus norvegicus,,CHEMBL617540,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,12280,,104686,,,BAO_0000224,,Autocuration,,10116.0,B,,
2334,Rattus norvegicus,,CHEMBL617541,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,,4101,,104686,,,BAO_0000224,,Autocuration,,10116.0,B,,
2335,,,CHEMBL617542,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,,10062,,104686,,,BAO_0000224,,Autocuration,,,B,,
2336,,,CHEMBL617543,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,,11147,,104686,,,BAO_0000224,,Autocuration,,,B,,
2337,Rattus norvegicus,,CHEMBL617544,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,2395,,104686,,,BAO_0000219,,Autocuration,,10116.0,B,,CHO-K1
2338,Rattus norvegicus,,CHEMBL617545,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,2395,,104686,,,BAO_0000219,,Autocuration,,10116.0,B,,CHO-K1
2339,Rattus norvegicus,,CHEMBL617413,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,,9098,,104686,,,BAO_0000019,,Autocuration,,10116.0,B,,
2340,,,CHEMBL617414,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,,9098,,104686,,,BAO_0000019,,Autocuration,,,B,,
2341,Rattus norvegicus,,CHEMBL617415,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,,9098,,104686,,,BAO_0000019,,Autocuration,,10116.0,B,,
2342,,,CHEMBL617416,Binding affinity towards 5-hydroxytryptamine 2 receptor,,9443,,104686,,,BAO_0000224,,Autocuration,,,B,,
2343,,,CHEMBL617417,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,9443,,104686,,,BAO_0000224,,Autocuration,,,B,,
2344,,,CHEMBL617418,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",,9699,,104686,,,BAO_0000019,,Autocuration,,,B,,
2345,,,CHEMBL617419,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,,9699,,104686,,,BAO_0000019,,Autocuration,,,B,,
2346,,,CHEMBL617420,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,9098,,104686,,,BAO_0000224,,Autocuration,,,B,,
2347,Rattus norvegicus,,CHEMBL617421,Affinity for 5-hydroxytryptamine 2 receptor,,3070,,104686,,,BAO_0000224,,Autocuration,,10116.0,B,,
2348,,,CHEMBL617422,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,,9547,,104686,,,BAO_0000224,,Autocuration,,,B,,
2349,,,CHEMBL617423,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,,10444,,104686,,,BAO_0000019,,Autocuration,,,B,,
2350,,,CHEMBL617424,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,,14617,,104686,,,BAO_0000019,,Autocuration,,,B,,
2351,,,CHEMBL617425,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,,14617,,104686,,,BAO_0000019,,Autocuration,,,B,,
2352,,,CHEMBL617426,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),,11130,,104686,,,BAO_0000224,,Autocuration,,,B,,
2353,,,CHEMBL617427,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),In vivo,11130,,104686,,,BAO_0000218,,Autocuration,,,B,,
2354,,955.0,CHEMBL617428,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,,14542,Brain,104686,,,BAO_0000221,,Autocuration,,,B,,
2355,,,CHEMBL617429,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,,2797,,104686,,,BAO_0000224,,Autocuration,,,B,,
2356,,,CHEMBL617430,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,11332,,104686,,,BAO_0000019,,Autocuration,,,B,,
2357,,,CHEMBL617431,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,11332,,104686,,,BAO_0000019,,Autocuration,,,B,,
2358,,1870.0,CHEMBL617432,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,,10752,Frontal cortex,104686,,,BAO_0000019,,Autocuration,,,B,,
2359,,,CHEMBL617433,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,1185,,104686,,,BAO_0000224,,Autocuration,,,B,,
2360,,,CHEMBL617434,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,1185,,104686,,,BAO_0000224,,Autocuration,,,B,,
2361,Rattus norvegicus,,CHEMBL617435,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,,11624,,104686,,,BAO_0000224,,Autocuration,,10116.0,B,,
2362,,,CHEMBL617436,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,,1344,,104686,,,BAO_0000019,,Autocuration,,,B,,
2363,Rattus norvegicus,2435.0,CHEMBL617437,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,,15453,Striatum,104686,,,BAO_0000019,,Autocuration,,10116.0,B,,
2364,,,CHEMBL617438,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,11662,,104686,,,BAO_0000019,,Autocuration,,,B,,
2365,,,CHEMBL617439,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,11662,,104686,,,BAO_0000019,,Autocuration,,,B,,
2366,,,CHEMBL617440,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,,10796,,104686,,,BAO_0000224,,Autocuration,,,B,,
2367,,,CHEMBL617441,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,9069,,104686,,,BAO_0000224,,Autocuration,,,B,,
2368,Rattus norvegicus,,CHEMBL872918,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,,8814,,104686,,,BAO_0000019,,Autocuration,,10116.0,B,,
2369,Rattus norvegicus,,CHEMBL617442,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,,8908,,104686,,,BAO_0000019,,Autocuration,,10116.0,B,,
2370,,,CHEMBL617443,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,9098,,104686,,,BAO_0000019,,Autocuration,,,B,,
2371,,,CHEMBL617444,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,,9098,,104686,,,BAO_0000019,,Autocuration,,,B,,
2372,,,CHEMBL617445,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,9098,,104686,,,BAO_0000019,,Autocuration,,,B,,
2373,,,CHEMBL617446,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,,9098,,104686,,,BAO_0000019,,Autocuration,,,B,,
2374,,,CHEMBL617447,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,,9098,,104686,,,BAO_0000249,,Autocuration,,,B,,
2375,,,CHEMBL617448,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,,9098,,104686,,,BAO_0000019,,Autocuration,,,B,,
2376,,,CHEMBL617449,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,,9098,,104686,,,BAO_0000019,,Autocuration,,,B,,
2377,,,CHEMBL617450,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,,9161,,104686,,,BAO_0000019,,Autocuration,,,B,,
2378,,,CHEMBL617451,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,,9161,,104686,,,BAO_0000019,,Autocuration,,,B,,
2379,,,CHEMBL617452,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,,9161,,104686,,,BAO_0000019,,Autocuration,,,B,,
2380,,,CHEMBL617453,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,,9161,,104686,,,BAO_0000019,,Autocuration,,,B,,
2381,,,CHEMBL617660,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,,9161,,104686,,,BAO_0000019,,Autocuration,,,B,,
2382,,,CHEMBL617661,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,,9161,,104686,,,BAO_0000019,,Autocuration,,,B,,
2383,,,CHEMBL617662,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,,9161,,104686,,,BAO_0000019,,Autocuration,,,B,,
2384,,,CHEMBL872919,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,,9161,,104686,,,BAO_0000019,,Autocuration,,,B,,
2385,,,CHEMBL617663,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,,9161,,104686,,,BAO_0000019,,Autocuration,,,B,,
2386,,,CHEMBL617664,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,,9161,,104686,,,BAO_0000019,,Autocuration,,,B,,
2387,,,CHEMBL617665,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,,9161,,104686,,,BAO_0000019,,Autocuration,,,B,,
2388,,,CHEMBL617666,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,,9161,,104686,,,BAO_0000019,,Autocuration,,,B,,
2389,,,CHEMBL617667,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,,12094,,104686,,,BAO_0000019,,Autocuration,,,B,,
2390,,,CHEMBL617668,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,,12018,,104686,,,BAO_0000249,,Autocuration,,,B,,
2391,,,CHEMBL617669,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,,10394,,104686,,,BAO_0000249,,Autocuration,,,B,,
2392,,,CHEMBL617670,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,,15260,,104686,,,BAO_0000224,,Autocuration,,,B,,
2393,Rattus norvegicus,,CHEMBL617671,Inhibitory constant against 5-hydroxytryptamine 2 receptor,,11624,,104686,,,BAO_0000224,,Autocuration,,10116.0,B,,
2394,,,CHEMBL617672,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,,13654,,104686,,,BAO_0000224,,Autocuration,,,B,,
2395,,,CHEMBL617673,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,,9541,,104686,,,BAO_0000019,,Autocuration,,,B,,
2396,,,CHEMBL617674,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,,11933,,104686,,,BAO_0000224,,Autocuration,,,B,,
2397,,,CHEMBL617675,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,,15538,,104686,,,BAO_0000019,,Autocuration,,,B,,
2398,,,CHEMBL617676,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,,15538,,104686,,,BAO_0000019,,Autocuration,,,B,,
2399,,,CHEMBL617677,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,,15538,,104686,,,BAO_0000019,,Autocuration,,,B,,
2400,,,CHEMBL617678,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,,8841,,104686,,,BAO_0000019,,Autocuration,,,B,,
2401,,,CHEMBL617679,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,,1455,,104686,,,BAO_0000224,,Autocuration,,,B,,
2402,,,CHEMBL617680,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,,1455,,104686,,,BAO_0000224,,Autocuration,,,B,,
2403,,,CHEMBL617681,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,,11752,,104686,,,BAO_0000019,,Autocuration,,,B,,
2404,,955.0,CHEMBL617682,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,,11642,Brain,104686,,,BAO_0000221,,Autocuration,,,B,,
2405,,,CHEMBL617683,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,,12092,,104686,,,BAO_0000224,,Autocuration,,,B,,
2406,,,CHEMBL617684,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,,3967,,104686,,,BAO_0000224,,Autocuration,,,B,,
2407,Rattus norvegicus,,CHEMBL617685,Binding affinity towards 5-hydroxytryptamine 2 receptor,,12771,,104686,,,BAO_0000224,,Autocuration,,10116.0,B,,
2408,,,CHEMBL617686,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,,11642,,104686,,,BAO_0000019,,Autocuration,,,B,,
2409,,,CHEMBL617687,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,,11628,,104686,,,BAO_0000224,,Autocuration,,,B,,
2410,,,CHEMBL617688,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,13654,,104686,,,BAO_0000224,,Autocuration,,,B,,
2411,,,CHEMBL617689,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,11200,,104686,,,BAO_0000019,,Autocuration,,,F,,
2412,,,CHEMBL617690,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,11200,,104686,,,BAO_0000019,,Autocuration,,,F,,
2413,,,CHEMBL617691,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",In vivo,11200,,104686,,,BAO_0000218,,Autocuration,,,F,,
2414,,,CHEMBL617692,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",In vivo,11200,,104686,,,BAO_0000218,,Autocuration,,,F,,
2415,,,CHEMBL617693,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",In vivo,11200,,104686,,,BAO_0000218,,Autocuration,,,F,,
2416,,,CHEMBL617694,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",In vivo,11200,,104686,,,BAO_0000218,,Autocuration,,,F,,
2417,,955.0,CHEMBL857985,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,,15436,Brain,12687,,,BAO_0000221,,Expert,,,B,,
2418,Rattus norvegicus,,CHEMBL617695,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,15436,,12687,,,BAO_0000019,,Expert,,10116.0,B,,
2419,,,CHEMBL617696,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,,14025,,12687,,,BAO_0000019,,Autocuration,,,B,,
2420,,,CHEMBL617697,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,,4342,,12687,,,BAO_0000357,,Autocuration,,,B,,
2421,Rattus norvegicus,,CHEMBL617257,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,,13735,,12687,,,BAO_0000019,,Expert,,10116.0,B,,
2422,Rattus norvegicus,,CHEMBL617258,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,5816,,12687,,,BAO_0000357,,Expert,,10116.0,B,,
2423,,,CHEMBL617259,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,,14287,,12687,,,BAO_0000019,,Expert,,,B,,
2424,,,CHEMBL617260,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,,15738,,12687,,,BAO_0000357,,Autocuration,,,B,,
2425,Rattus norvegicus,,CHEMBL617261,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,,15738,,12687,,,BAO_0000357,,Expert,,10116.0,B,,
2426,,,CHEMBL617262,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,,15026,,12687,,,BAO_0000019,,Autocuration,,,B,,
2427,,,CHEMBL617263,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,16647,,12687,,,BAO_0000019,,Expert,,,B,,
2428,,,CHEMBL617264,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,,16647,,12687,,,BAO_0000019,,Autocuration,,,B,,
2429,Rattus norvegicus,,CHEMBL617265,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,,13345,,12687,,,BAO_0000019,,Expert,,10116.0,B,,
2430,,,CHEMBL617266,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,,1543,,12687,,,BAO_0000249,,Autocuration,Membranes,,B,,
2431,,,CHEMBL617267,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,,12444,,12687,,,BAO_0000019,,Autocuration,,,B,,
2432,,,CHEMBL617268,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,,16404,,12687,,,BAO_0000019,,Expert,,,B,,
2433,,,CHEMBL617269,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,16404,,12687,,,BAO_0000219,,Autocuration,,,B,,CHO
2434,,,CHEMBL617323,Kinetic inhibition constant evaluated by measuring serotonergic activity,,15577,,12687,,,BAO_0000357,,Expert,,,B,,
2435,,,CHEMBL617324,Serotonergic activity of the compound.,,15577,,12687,,,BAO_0000357,,Autocuration,,,B,,
2436,,,CHEMBL617325,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,,2495,,12687,,,BAO_0000249,,Autocuration,,,B,,
2437,Rattus norvegicus,,CHEMBL617326,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,,15042,,12687,,,BAO_0000019,,Expert,,10116.0,B,,
2438,,,CHEMBL617327,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,,15026,,12687,,,BAO_0000249,,Expert,,,B,,
2439,Rattus norvegicus,,CHEMBL617328,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,12919,,12687,,,BAO_0000019,,Expert,,10116.0,F,,
2440,Rattus norvegicus,,CHEMBL617329,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,12919,,12687,,,BAO_0000019,,Expert,,10116.0,F,,
2441,Rattus norvegicus,,CHEMBL617330,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,12919,,12687,,,BAO_0000019,,Expert,,10116.0,F,,
2442,,,CHEMBL617331,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,15194,,12687,,,BAO_0000357,,Autocuration,,,B,,
2443,,,CHEMBL617332,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,,15194,,12687,,,BAO_0000357,,Autocuration,,,B,,
2444,,,CHEMBL617333,Binding affinity towards 5-hydroxytryptamine 2A receptor,,4820,,107,,,BAO_0000357,,Expert,,,B,,
2445,,,CHEMBL617334,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,,6736,,107,,,BAO_0000357,,Autocuration,,,B,,
2446,,,CHEMBL617335,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,,5163,,107,,,BAO_0000357,,Autocuration,,,B,,
2447,,,CHEMBL617336,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,,5163,,107,,,BAO_0000357,,Autocuration,,,B,,
2448,,,CHEMBL617337,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,,6011,,107,,,BAO_0000357,,Autocuration,,,B,,
2449,Homo sapiens,,CHEMBL617338,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,,14294,,107,,,BAO_0000357,,Expert,,9606.0,B,,
2450,,,CHEMBL617339,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,,5014,,107,,,BAO_0000357,,Autocuration,,,B,,
2451,,,CHEMBL617340,Binding affinity towards 5-hydroxytryptamine 2A receptor,,17066,,107,,,BAO_0000357,,Expert,,,B,,
2452,,,CHEMBL617341,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,,17515,,107,,,BAO_0000357,,Autocuration,,,B,,
2453,,,CHEMBL617342,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,,6736,,107,,,BAO_0000357,,Expert,,,B,,
2454,,,CHEMBL617343,Affinity for 5-hydroxytryptamine 2A receptor,,5163,,107,,,BAO_0000357,,Expert,,,B,,
2455,,,CHEMBL617344,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,,16911,,107,,,BAO_0000219,,Expert,,,B,,NIH3T3
2456,,,CHEMBL617345,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,6841,,107,,,BAO_0000357,,Expert,,,B,,
2457,,,CHEMBL617346,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,,6119,,107,,,BAO_0000357,,Expert,,,B,,
2458,,,CHEMBL617347,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,,3962,,107,,,BAO_0000357,,Autocuration,,,B,,
2459,,,CHEMBL617348,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,,4373,,107,,,BAO_0000357,,Autocuration,,,B,,
2460,,,CHEMBL617349,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,,4373,,107,,,BAO_0000357,,Autocuration,,,B,,
2461,,,CHEMBL617350,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,,3962,,107,,,BAO_0000019,,Autocuration,,,F,,
2462,,,CHEMBL872339,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,,1633,,107,,,BAO_0000357,,Expert,,,B,,
2463,,,CHEMBL617351,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,,4373,,107,,,BAO_0000357,,Autocuration,,,B,,
2464,,,CHEMBL617352,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,,6576,,107,,,BAO_0000357,,Expert,,,B,,
2465,,,CHEMBL617353,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,,4687,,107,,,BAO_0000357,,Autocuration,,,B,,
2466,,,CHEMBL617354,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,,16946,,107,,,BAO_0000357,,Autocuration,,,B,,
2467,,,CHEMBL617355,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,,14159,,107,,,BAO_0000357,,Autocuration,,,B,,
2468,Mus musculus,,CHEMBL617356,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,,3032,,107,,,BAO_0000219,,Expert,,10090.0,B,,CHO
2469,,,CHEMBL617357,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,,16655,,107,,,BAO_0000357,,Autocuration,,,B,,
2470,,,CHEMBL617358,Binding affinity at 5-hydroxytryptamine 2A receptor,,13964,,107,,,BAO_0000357,,Autocuration,,,B,,
2471,,,CHEMBL617359,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,,16989,,107,,,BAO_0000357,,Expert,,,B,,
2472,,,CHEMBL617360,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,,16117,,107,,,BAO_0000357,,Autocuration,,,B,,
2473,,,CHEMBL875913,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,,16700,,107,,,BAO_0000357,,Autocuration,,,B,,
2474,,,CHEMBL617361,Affinity against 5-hydroxytryptamine 2A receptor,,3269,,107,,,BAO_0000357,,Autocuration,,,B,,
2475,Homo sapiens,,CHEMBL617362,Binding affinity against 5-Hydroxytryptamine 2A receptor,,1274,,107,,,BAO_0000357,,Expert,,9606.0,B,,
2476,,,CHEMBL617363,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,,1317,,107,,,BAO_0000357,,Autocuration,,,B,,
2477,,,CHEMBL617364,Tested against 5-hydroxytryptamine 2A receptor,,12146,,107,,,BAO_0000357,,Autocuration,,,B,,
2478,,,CHEMBL617365,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,12652,,105075,,,BAO_0000224,,Autocuration,,,B,,
2479,,,CHEMBL617366,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,,12652,,105075,,,BAO_0000224,,Autocuration,,,B,,
2480,,,CHEMBL617367,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,,12652,,105075,,,BAO_0000224,,Autocuration,,,B,,
2481,,,CHEMBL617368,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,12652,,105075,,,BAO_0000224,,Autocuration,,,B,,
2482,,,CHEMBL617369,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),,16647,,107,,,BAO_0000357,,Autocuration,,,B,,
2483,Homo sapiens,,CHEMBL617370,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,,15851,,227,,,BAO_0000219,,Expert,,9606.0,B,,HEK293
2484,Homo sapiens,,CHEMBL617371,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,,6857,,227,,,BAO_0000219,,Expert,,9606.0,F,,CHO
2485,,,CHEMBL617372,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),,3805,,227,,,BAO_0000357,,Autocuration,,,B,,
2486,Homo sapiens,,CHEMBL617373,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,,6491,,227,,,BAO_0000357,,Expert,,9606.0,B,,
2487,,,CHEMBL617374,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,,14093,,227,,,BAO_0000019,,Autocuration,,,F,,
2488,,,CHEMBL617375,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,,13481,,227,,,BAO_0000019,,Autocuration,,,F,,
2489,,,CHEMBL617376,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,,14093,,227,,,BAO_0000019,,Autocuration,,,F,,
2490,,,CHEMBL617377,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,,14093,,227,,,BAO_0000019,,Autocuration,,,F,,
2491,,,CHEMBL617378,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,,14093,,227,,,BAO_0000019,,Autocuration,,,F,,
2492,,,CHEMBL617379,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,13481,,227,,,BAO_0000019,,Autocuration,,,F,,
2493,,,CHEMBL617380,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,,14442,,227,,,BAO_0000357,,Autocuration,,,B,,
2494,,,CHEMBL617381,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,,14442,,227,,,BAO_0000357,,Autocuration,,,B,,
2495,,,CHEMBL617382,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,14442,,227,,,BAO_0000357,,Autocuration,,,B,,
2496,,,CHEMBL617383,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,,12369,,107,,,BAO_0000357,,Autocuration,,,B,,
2497,,,CHEMBL617384,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,,12369,,107,,,BAO_0000357,,Expert,,,B,,
2498,,,CHEMBL617385,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,,12369,,107,,,BAO_0000357,,Expert,,,B,,
2499,,,CHEMBL617386,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,,14447,,107,,,BAO_0000019,,Autocuration,,,B,,
2500,,,CHEMBL617387,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,,14447,,107,,,BAO_0000019,,Autocuration,,,B,,
2501,,,CHEMBL617388,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,17451,,107,,,BAO_0000219,,Autocuration,,,B,,NIH3T3
2502,,,CHEMBL617389,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,6857,,107,,,BAO_0000219,,Autocuration,,,F,,CHO
2503,Homo sapiens,,CHEMBL617390,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,6857,,107,,,BAO_0000219,,Expert,,9606.0,F,,CHO
2504,,,CHEMBL617391,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,,5635,,104817,,,BAO_0000224,,Autocuration,,,B,,
2505,,,CHEMBL617392,Binding activity radioligand.,,12861,,107,,,BAO_0000357,,Autocuration,,,B,,
2506,,,CHEMBL617393,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,12861,,107,,,BAO_0000019,,Autocuration,,,B,,
2507,,,CHEMBL617394,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,5105,,107,,,BAO_0000219,,Autocuration,,,B,,L929
2508,,,CHEMBL617395,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,5104,,107,,,BAO_0000219,,Expert,,,B,,L929
2509,,,CHEMBL617396,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,5105,,107,,,BAO_0000219,,Expert,,,B,,L929
2510,,,CHEMBL617397,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,,5105,,107,,,BAO_0000219,,Autocuration,,,B,,L929
2511,,,CHEMBL617398,Binding affinity against 5-HT2A receptor,,5254,,107,,,BAO_0000357,,Autocuration,,,B,,
2512,,,CHEMBL617399,Binding affinity against 5-hydroxytryptamine 2A receptor,,5254,,107,,,BAO_0000357,,Autocuration,,,B,,
2513,,,CHEMBL617400,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,13267,,107,,,BAO_0000219,,Autocuration,,,B,,HEK293
2514,,,CHEMBL617401,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,13267,,107,,,BAO_0000219,,Autocuration,,,B,,HEK293
2515,Homo sapiens,,CHEMBL617402,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,,14157,,107,,,BAO_0000219,,Expert,,9606.0,B,,HEK293
2516,Homo sapiens,,CHEMBL617403,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,12936,,107,,,BAO_0000219,,Expert,,9606.0,B,,HEK293
2517,,,CHEMBL617404,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,,14068,,107,,,BAO_0000357,,Expert,,,B,,
2518,Homo sapiens,,CHEMBL857981,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,12936,,107,,,BAO_0000219,,Expert,,9606.0,B,,HEK293
2519,Homo sapiens,,CHEMBL617405,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,12936,,107,,,BAO_0000219,,Expert,,9606.0,B,,HEK293
2520,Homo sapiens,,CHEMBL617253,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,,4540,,107,,,BAO_0000219,,Expert,,9606.0,B,,HEK293
2521,,,CHEMBL617254,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,,6166,,107,,,BAO_0000357,,Expert,,,B,,
2522,,,CHEMBL617255,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,17296,,107,,,BAO_0000219,,Autocuration,,,B,,HEK293
2523,,,CHEMBL617256,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,17296,,107,,,BAO_0000219,,Autocuration,,,B,,HEK293
2524,,,CHEMBL616874,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,,17296,,107,,,BAO_0000219,,Autocuration,,,B,,HEK293
2525,Homo sapiens,,CHEMBL616875,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,,15779,,107,,,BAO_0000219,,Expert,,9606.0,B,,HEK293
2526,,,CHEMBL616876,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,,14391,,107,,,BAO_0000219,,Expert,,,B,,HEK293
2527,,,CHEMBL616877,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",,15851,,107,,,BAO_0000219,,Expert,,,B,,HEK293
2528,Homo sapiens,,CHEMBL616878,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,,15851,,107,,,BAO_0000219,,Expert,,9606.0,B,,HEK293
2529,,,CHEMBL616879,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,,3832,,107,,,BAO_0000219,,Expert,,,B,,HEK293
2530,,,CHEMBL616880,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,,3833,,107,,,BAO_0000219,,Expert,,,B,,HEK293
2531,Homo sapiens,,CHEMBL616881,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,12936,,107,,,BAO_0000219,,Expert,,9606.0,B,,HEK293
2532,,,CHEMBL616882,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,17451,,107,,,BAO_0000219,,Autocuration,,,B,,NIH3T3
2533,,,CHEMBL616883,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,17451,,107,,,BAO_0000219,,Autocuration,,,B,,NIH3T3
2534,,,CHEMBL616884,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,17451,,107,,,BAO_0000219,,Autocuration,,,B,,NIH3T3
2535,,,CHEMBL616885,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,,4199,,107,,,BAO_0000219,,Autocuration,,,B,,HEK293
2536,,,CHEMBL616886,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,,1883,,107,,,BAO_0000219,,Autocuration,,,B,,CHO-K1
2537,,,CHEMBL616887,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,,1883,,107,,,BAO_0000219,,Expert,,,B,,CHO-K1
2538,Homo sapiens,,CHEMBL616888,Binding affinity for human 5-hydroxytryptamine 2A receptor,,14875,,107,,,BAO_0000357,,Expert,,9606.0,B,,
2539,,,CHEMBL616889,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,,15146,,107,,,BAO_0000219,,Autocuration,,,B,,HEK293
2540,,,CHEMBL616890,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,,5213,,107,,,BAO_0000219,,Autocuration,,,B,,HEK293
2541,Homo sapiens,,CHEMBL616891,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,16404,,107,,,BAO_0000219,,Expert,,9606.0,B,,CHO
2542,,,CHEMBL616892,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,,14818,,107,,,BAO_0000219,,Autocuration,,,B,,HEK293
2543,,,CHEMBL616893,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",,4829,,107,,,BAO_0000219,,Autocuration,,,B,,HEK293
2544,,,CHEMBL616894,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,,12652,,10620,,,BAO_0000219,,Autocuration,,,F,,NIH3T3
2545,,,CHEMBL616895,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,,4682,,107,,,BAO_0000219,,Expert,,,B,,NIH3T3
2546,,,CHEMBL616896,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,,12652,,10620,,,BAO_0000019,,Autocuration,,,F,,
2547,,,CHEMBL617099,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,,4921,,10621,,,BAO_0000357,,Autocuration,,,B,,
2548,,,CHEMBL617100,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,,4921,,10621,,,BAO_0000357,,Autocuration,,,B,,
2549,Oryctolagus cuniculus,,CHEMBL884532,Binding affinity against rabbit aorta 5-HT2A receptor,,16312,,107,,,BAO_0000357,,Autocuration,,9986.0,B,,
2550,Oryctolagus cuniculus,,CHEMBL617101,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,,14998,,107,,,BAO_0000357,,Expert,,9986.0,B,,
2551,Oryctolagus cuniculus,,CHEMBL617102,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,,14025,,107,,,BAO_0000357,,Expert,,9986.0,B,,
2552,Oryctolagus cuniculus,,CHEMBL617103,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,13047,,107,,,BAO_0000019,,Autocuration,,9986.0,B,,
2553,Oryctolagus cuniculus,,CHEMBL617104,The compound was tested for binding affinity against 5-HT2A receptor,,13047,,107,,,BAO_0000357,,Expert,,9986.0,B,,
2554,,,CHEMBL857979,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,,1883,,10576,,,BAO_0000219,,Autocuration,,,B,,CHO-K1
2555,,,CHEMBL857502,Binding affinity analysed towards 5-HT 2A in rat jugular vein,,13463,,12687,,,BAO_0000019,,Autocuration,,,B,,
2556,,,CHEMBL617105,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,13463,,12687,,,BAO_0000019,,Autocuration,,,B,,
2557,,945.0,CHEMBL858021,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,,13463,Stomach,12687,,,BAO_0000019,,Autocuration,,,B,,
2558,Rattus norvegicus,945.0,CHEMBL875910,Binding affinity for 5-HT 2A in rat stomach fundus,,13463,Stomach,12687,,,BAO_0000019,,Expert,,10116.0,B,,
2559,,,CHEMBL617106,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,13463,,12687,,,BAO_0000019,,Autocuration,,,B,,
2560,,,CHEMBL617107,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,,16326,,12687,,,BAO_0000219,,Expert,,,B,,NIH3T3
2561,,,CHEMBL617108,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,,14093,,12687,,,BAO_0000019,,Autocuration,,,F,,
2562,,,CHEMBL617109,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,,14093,,12687,,,BAO_0000019,,Autocuration,,,F,,
2563,,,CHEMBL617110,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,15740,,12687,,,BAO_0000357,,Autocuration,,,B,,
2564,,,CHEMBL617111,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,,16633,,12687,,,BAO_0000357,,Autocuration,,,B,,
2565,Rattus norvegicus,,CHEMBL617112,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,,17200,,12687,,,BAO_0000019,,Expert,,10116.0,F,,
2566,,,CHEMBL617113,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,17133,,12687,,,BAO_0000357,,Autocuration,,,B,,
2567,,,CHEMBL617114,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,17133,,12687,,,BAO_0000357,,Autocuration,,,B,,
2568,,,CHEMBL617115,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,17133,,12687,,,BAO_0000357,,Autocuration,,,B,,
2569,,,CHEMBL617116,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,17200,,12687,,,BAO_0000219,,Autocuration,,,F,,
2570,,,CHEMBL617117,Efficacy at 5-hydroxytryptamine 2A receptor,,15363,,12687,,,BAO_0000019,,Autocuration,,,F,,
2571,,,CHEMBL617118,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,17200,,12687,,,BAO_0000357,,Autocuration,,,B,,
2572,Rattus norvegicus,,CHEMBL617119,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,17200,,12687,,,BAO_0000357,,Expert,,10116.0,B,,
2573,Rattus norvegicus,,CHEMBL617120,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),,17200,,12687,,,BAO_0000357,,Expert,,10116.0,B,,
2574,Rattus norvegicus,,CHEMBL617121,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,17200,,12687,,,BAO_0000219,,Expert,,10116.0,F,,
2575,,,CHEMBL617122,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,17200,,12687,,,BAO_0000219,,Autocuration,,,F,,
2576,,,CHEMBL617123,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,,17211,,12687,,,BAO_0000019,,Autocuration,,,B,,
2577,,,CHEMBL617124,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,,17331,,12687,,,BAO_0000019,,Expert,,,B,,
2578,,,CHEMBL617600,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,,13565,,12687,,,BAO_0000249,,Expert,,,B,,
2579,,,CHEMBL617601,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,,13730,,12687,,,BAO_0000357,,Expert,,,B,,
2580,,,CHEMBL882923,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,,12416,,12687,,,BAO_0000019,,Expert,,,B,,
2581,,,CHEMBL617602,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,,15295,,12687,,,BAO_0000357,,Autocuration,,,B,,
2582,,,CHEMBL617603,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,,1742,,12687,,,BAO_0000019,,Autocuration,,,B,,
2583,,,CHEMBL617604,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,,15295,,12687,,,BAO_0000357,,Autocuration,,,B,,
2584,,,CHEMBL617605,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,,14970,,12687,,,BAO_0000019,,Expert,,,B,,
2585,,,CHEMBL617606,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,,16693,,12687,,,BAO_0000019,,Expert,,,B,,
2586,Rattus norvegicus,,CHEMBL617607,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,,14776,,12687,,,BAO_0000019,,Expert,,10116.0,B,,
2587,,,CHEMBL617455,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,,14286,,12687,,,BAO_0000249,,Autocuration,,,B,,
2588,Rattus norvegicus,,CHEMBL617456,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,17200,,12687,,,BAO_0000019,,Expert,,10116.0,B,,
2589,,,CHEMBL617457,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),,15306,,12687,,,BAO_0000357,,Expert,,,B,,
2590,Rattus norvegicus,,CHEMBL617458,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,,14178,,12687,,,BAO_0000357,,Expert,,10116.0,B,,
2591,Rattus norvegicus,,CHEMBL617459,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,,14229,,12687,,,BAO_0000019,,Expert,,10116.0,B,,
2592,,,CHEMBL617460,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,,12884,,12687,,,BAO_0000357,,Expert,,,B,,
2593,,,CHEMBL617461,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",,13149,,12687,,,BAO_0000357,,Expert,,,B,,
2594,Rattus norvegicus,,CHEMBL617462,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,,15295,,12687,,,BAO_0000019,,Expert,,10116.0,B,,
2595,,,CHEMBL617463,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,,15740,,12687,,,BAO_0000357,,Autocuration,,,B,,
2596,,,CHEMBL617464,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",,15185,,12687,,,BAO_0000019,,Autocuration,,,B,,
2597,,,CHEMBL617465,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",,15185,,12687,,,BAO_0000019,,Autocuration,,,B,,
2598,,,CHEMBL617466,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,,17529,,12687,,,BAO_0000019,,Expert,,,B,,
2599,,,CHEMBL617467,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,14826,,12687,,,BAO_0000019,,Autocuration,,,B,,
2600,,,CHEMBL617468,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,,17211,,12687,,,BAO_0000019,,Expert,,,B,,
2601,,,CHEMBL617469,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,14826,,12687,,,BAO_0000019,,Autocuration,,,B,,
2602,,,CHEMBL617470,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,14093,,12687,,,BAO_0000019,,Autocuration,,,B,,
2603,,,CHEMBL617471,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,,14093,,12687,,,BAO_0000019,,Autocuration,,,B,,
2604,,,CHEMBL617472,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,,13246,,12687,,,BAO_0000219,,Expert,,,B,,NIH3T3
2605,,,CHEMBL617473,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,,13246,,12687,,,BAO_0000357,,Expert,,,B,,
2606,Rattus norvegicus,,CHEMBL617474,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,15436,,12687,,,BAO_0000019,,Expert,,10116.0,B,,
2607,Rattus norvegicus,,CHEMBL617475,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,15436,,12687,,,BAO_0000019,,Expert,,10116.0,B,,
2608,,955.0,CHEMBL617476,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,,14442,Brain,12687,,,BAO_0000221,,Autocuration,,,B,,
2609,,,CHEMBL617477,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,,12457,,12687,,,BAO_0000357,,Expert,,,B,,
2610,,,CHEMBL617478,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,,12457,,12687,,,BAO_0000219,,Expert,,,B,,NIH3T3
2611,,,CHEMBL617479,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",,14755,,12687,,,BAO_0000221,,Autocuration,,,F,,
2612,,,CHEMBL617480,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,,4707,,12687,,,BAO_0000357,,Autocuration,,,B,,
2613,,,CHEMBL617481,Binding affinity against 5-hydroxytryptamine 2A receptor,,13297,,12687,,,BAO_0000357,,Expert,,,B,,
2614,,,CHEMBL617482,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,,17331,,12687,,,BAO_0000019,,Expert,,,B,,
2615,,,CHEMBL617483,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,,4664,,12687,,,BAO_0000019,,Autocuration,,,B,,
2616,,,CHEMBL621528,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,16633,,12687,,,BAO_0000357,,Autocuration,,,B,,
2617,Rattus norvegicus,,CHEMBL621529,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,,4664,,12687,,,BAO_0000219,,Expert,,10116.0,B,,NIH3T3
2618,,,CHEMBL621530,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,16133,,12687,,,BAO_0000357,,Expert,,,B,,
2619,,,CHEMBL621531,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,16133,,12687,,,BAO_0000357,,Expert,,,B,,
2620,Rattus norvegicus,,CHEMBL621532,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,,14060,,12687,,,BAO_0000019,,Expert,,10116.0,B,,
2621,,,CHEMBL621533,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,16326,,12687,,,BAO_0000357,,Expert,,,B,,
2622,,,CHEMBL621534,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,16659,,12687,,,BAO_0000219,,Expert,,,B,,CHO
2623,,,CHEMBL621535,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,,14776,,12687,,,BAO_0000019,,Autocuration,,,B,,
2624,,,CHEMBL621536,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,,13481,,12687,,,BAO_0000357,,Autocuration,,,B,,
2625,,,CHEMBL621537,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,,17386,,12687,,,BAO_0000357,,Autocuration,,,B,,
2626,Rattus norvegicus,,CHEMBL621538,Binding affinity for 5-hydroxytryptamine 2A receptor,,6611,,12687,,,BAO_0000357,,Expert,,10116.0,B,,
2627,,,CHEMBL621539,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,,14423,,12687,,,BAO_0000019,,Autocuration,,,B,,
2628,,,CHEMBL621540,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,,15412,,12687,,,BAO_0000019,,Autocuration,,,B,,
2629,,,CHEMBL621541,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,,15412,,12687,,,BAO_0000019,,Autocuration,,,B,,
2630,,,CHEMBL621542,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,,6238,,12687,,,BAO_0000019,,Autocuration,,,B,,
2631,,,CHEMBL621543,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,,6648,,12687,,,BAO_0000357,,Expert,,,B,,
2632,,,CHEMBL621544,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,,5667,,12687,,,BAO_0000357,,Expert,,,B,,
2633,Rattus norvegicus,,CHEMBL621545,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,,6611,,12687,,,BAO_0000357,,Expert,,10116.0,B,,
2634,,,CHEMBL621546,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,13481,,12687,,,BAO_0000357,,Autocuration,,,B,,
2635,,,CHEMBL621547,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,,13481,,12687,,,BAO_0000357,,Autocuration,,,B,,
2636,,,CHEMBL618692,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,,15558,,12687,,,BAO_0000219,,Expert,,,B,,NIH3T3
2637,,,CHEMBL618693,Binding affinity towards 5-hydroxytryptamine 2A receptor,,6013,,12687,,,BAO_0000357,,Autocuration,,,B,,
2638,,,CHEMBL872922,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,16633,,12687,,,BAO_0000357,,Autocuration,,,B,,
2639,,,CHEMBL618694,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,,6013,,12687,,,BAO_0000357,,Autocuration,,,B,,
2640,Rattus norvegicus,,CHEMBL618695,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,,6013,,12687,,,BAO_0000357,,Expert,,10116.0,B,,
2641,,,CHEMBL618696,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,,6013,,12687,,,BAO_0000357,,Autocuration,,,B,,
2642,,,CHEMBL618697,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,,6013,,12687,,,BAO_0000357,,Expert,,,B,,
2643,,,CHEMBL618892,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,,6013,,12687,,,BAO_0000357,,Autocuration,,,B,,
2644,,,CHEMBL618893,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,,6013,,12687,,,BAO_0000357,,Autocuration,,,B,,
2645,,,CHEMBL618894,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,,16293,,12687,,,BAO_0000357,,Autocuration,,,B,,
2646,,,CHEMBL618895,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,,17175,,12687,,,BAO_0000219,,Expert,,,B,,NIH3T3
2647,Rattus norvegicus,,CHEMBL618896,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,13278,,12687,,,BAO_0000357,,Expert,,10116.0,B,,
2648,,5383.0,CHEMBL618897,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,,3682,Caudate-putamen,12687,,,BAO_0000019,,Autocuration,,,B,,
2649,,,CHEMBL618898,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,,2014,,12687,,,BAO_0000357,,Autocuration,,,B,,
2650,,,CHEMBL618899,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,,2014,,12687,,,BAO_0000357,,Autocuration,,,B,,
2651,,,CHEMBL618900,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,,4932,,12687,,,BAO_0000357,,Autocuration,,,B,,
2652,,,CHEMBL618901,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,,4932,,12687,,,BAO_0000019,,Autocuration,,,B,,
2653,,,CHEMBL618902,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,,3935,,12687,,,BAO_0000357,,Autocuration,,,B,,
2654,Rattus norvegicus,10000000.0,CHEMBL618903,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,,5432,Hippocampus,12687,,,BAO_0000221,,Expert,,10116.0,B,,
2655,,,CHEMBL618904,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,,15818,,12687,,,BAO_0000357,,Autocuration,,,B,,
2656,,,CHEMBL618905,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,,13672,,12687,,,BAO_0000357,,Autocuration,,,B,,
2657,,,CHEMBL618906,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,,13672,,12687,,,BAO_0000357,,Autocuration,,,B,,
2658,,,CHEMBL618907,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,,14749,,12687,,,BAO_0000219,,Expert,,,B,,NIH3T3
2659,,,CHEMBL618908,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,,13462,,12687,,,BAO_0000019,,Autocuration,,,B,,
2660,,,CHEMBL617909,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,15740,,12687,,,BAO_0000357,,Autocuration,,,B,,
2661,,,CHEMBL617910,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,16647,,12687,,,BAO_0000019,,Expert,,,B,,
2662,,955.0,CHEMBL617911,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,,13345,Brain,12687,,,BAO_0000221,,Autocuration,,,B,,
2663,,,CHEMBL872923,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,16740,,12687,,,BAO_0000249,,Autocuration,,,B,,
2664,,,CHEMBL617912,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,16740,,12687,,,BAO_0000249,,Autocuration,,,B,,
2665,Rattus norvegicus,,CHEMBL617913,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,,15535,,12687,,,BAO_0000019,,Expert,,10116.0,B,,
2666,,,CHEMBL617914,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,16740,,12687,,,BAO_0000249,,Expert,,,B,,
2667,,,CHEMBL617915,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,16740,,12687,,,BAO_0000249,,Autocuration,,,B,,
2668,,,CHEMBL617916,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,,16740,,12687,,,BAO_0000249,,Autocuration,,,B,,
2669,Rattus norvegicus,,CHEMBL617917,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,,4795,,12687,,,BAO_0000019,,Expert,,10116.0,B,,
2670,,,CHEMBL617918,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,,8,,12687,,,BAO_0000019,,Expert,,,B,,
2671,,,CHEMBL617919,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,,8,,12687,,,BAO_0000019,,Autocuration,,,B,,
2672,Rattus norvegicus,,CHEMBL617920,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,17200,,12687,,,BAO_0000019,,Expert,,10116.0,B,,
2673,Rattus norvegicus,,CHEMBL617921,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,,2148,,12687,,,BAO_0000019,,Expert,,10116.0,B,,
2674,Rattus norvegicus,,CHEMBL617922,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",,13345,,105102,,,BAO_0000224,,Expert,,10116.0,B,,
2675,,,CHEMBL617923,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,5088,,12687,,,BAO_0000357,,Autocuration,,,B,,
2676,,,CHEMBL617924,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,5088,,12687,,,BAO_0000357,,Autocuration,,,B,,
2677,,,CHEMBL617925,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,,17133,,12687,,,BAO_0000357,,Autocuration,,,B,,
2678,Rattus norvegicus,,CHEMBL617926,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,,17133,,12687,,,BAO_0000357,,Expert,,10116.0,B,,
2679,,,CHEMBL617927,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,,16532,,12687,,,BAO_0000357,,Autocuration,,,B,,
2680,,,CHEMBL617928,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,,15086,,12687,,,BAO_0000357,,Autocuration,,,B,,
2681,Rattus norvegicus,,CHEMBL617929,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,2309,,12687,,,BAO_0000019,,Expert,,10116.0,B,,
2682,,,CHEMBL617930,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,,12953,,12687,,,BAO_0000019,,Expert,,,B,,
2683,,,CHEMBL617931,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,,12953,,12687,,,BAO_0000019,,Autocuration,,,B,,
2684,,,CHEMBL617932,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,,12953,,12687,,,BAO_0000019,,Autocuration,,,B,,
2685,,,CHEMBL617933,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,,16659,,12687,,,BAO_0000219,,Autocuration,,,B,,CHO
2686,,,CHEMBL617934,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,16740,,12687,,,BAO_0000019,,Autocuration,,,B,,
2687,,,CHEMBL617935,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,16740,,12687,,,BAO_0000019,,Autocuration,,,B,,
2688,,,CHEMBL617936,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,,17133,,12687,,,BAO_0000357,,Autocuration,,,B,,
2689,,,CHEMBL617937,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,,17211,,12687,,,BAO_0000019,,Autocuration,,,B,,
2690,,,CHEMBL617938,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,,17331,,12687,,,BAO_0000019,,Autocuration,,,B,,
2691,,,CHEMBL617939,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,,16633,,12687,,,BAO_0000218,,Autocuration,,,B,,
2692,,,CHEMBL617940,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,,16633,,12687,,,BAO_0000218,,Autocuration,,,B,,
2693,,,CHEMBL617941,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,,16633,,12687,,,BAO_0000218,,Autocuration,,,B,,
2694,,,CHEMBL617942,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,,15026,,12687,,,BAO_0000357,,Expert,,,B,,
2695,,,CHEMBL617943,Ratio of pKi of 5-HT2A to that of D2 receptor,,15026,,12687,,,BAO_0000357,,Expert,,,B,,
2696,,,CHEMBL617944,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,16404,,105093,,,BAO_0000224,,Expert,,,B,,
2697,,,CHEMBL617945,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,16404,,105093,,,BAO_0000224,,Expert,,,B,,
2698,,,CHEMBL617946,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,,16404,,105075,,,BAO_0000224,,Expert,,,B,,
2699,,,CHEMBL617947,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,,16404,,12687,,,BAO_0000357,,Autocuration,,,B,,
2700,,,CHEMBL617948,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,,16326,,12687,,,BAO_0000357,,Expert,,,B,,
2701,,,CHEMBL858116,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,,15847,,12687,,,BAO_0000019,,Autocuration,,,F,,
2702,,,CHEMBL617949,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,,15847,,12687,,,BAO_0000019,,Autocuration,,,F,,
2703,,,CHEMBL617950,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,,15329,,12687,,,BAO_0000019,,Autocuration,,,F,,
2704,,1515.0,CHEMBL617951,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,,16404,Thoracic aorta,12687,,,BAO_0000019,,Expert,,,F,,
2705,,1515.0,CHEMBL617952,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,,16404,Thoracic aorta,12687,,,BAO_0000019,,Expert,,,F,,
2706,,1515.0,CHEMBL617953,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,,16404,Thoracic aorta,12687,,,BAO_0000019,,Autocuration,,,F,,
2707,,,CHEMBL617954,Binding activity radioligand.,,12861,,12687,,,BAO_0000357,,Autocuration,,,B,,
2708,,,CHEMBL617955,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,12861,,12687,,,BAO_0000019,,Expert,,,B,,
2709,,,CHEMBL857071,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,12861,,12687,,,BAO_0000019,,Autocuration,,,B,,
2710,,,CHEMBL617270,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,,12490,,12687,,,BAO_0000019,,Expert,,,B,,
2711,,,CHEMBL617271,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,,12827,,12687,,,BAO_0000219,,Autocuration,,,B,,N1E-115
2712,,,CHEMBL617272,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,,12827,,12687,,,BAO_0000219,,Autocuration,,,B,,N1E-115
2713,,,CHEMBL617273,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,,12918,,12687,,,BAO_0000019,,Autocuration,,,B,,
2714,Rattus norvegicus,,CHEMBL617274,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,,12919,,12687,,,BAO_0000019,,Expert,,10116.0,F,,
2715,,,CHEMBL617275,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,,17723,,108,,,BAO_0000357,,Autocuration,,,B,,
2716,,,CHEMBL617276,Binding affinity towards 5-hydroxytryptamine 2C receptor,,6013,,108,,,BAO_0000357,,Autocuration,,,B,,
2717,,,CHEMBL617277,Binding affinity towards human 5-hydroxytryptamine 2C receptor,,16293,,108,,,BAO_0000357,,Autocuration,,,B,,
2718,,,CHEMBL617278,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,3857,,108,,,BAO_0000019,,Expert,,,B,,
2719,,,CHEMBL617279,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,,3857,,108,,,BAO_0000019,,Expert,,,B,,
2720,,,CHEMBL617280,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,3857,,108,,,BAO_0000019,,Expert,,,B,,
2721,,,CHEMBL617281,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,15363,,108,,,BAO_0000357,,Autocuration,,,B,,
2722,,,CHEMBL617282,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,15363,,108,,,BAO_0000357,,Autocuration,,,B,,
2723,,,CHEMBL617283,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,,16441,,108,,,BAO_0000019,,Expert,,,B,,
2724,,,CHEMBL617284,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,,16441,,108,,,BAO_0000019,,Expert,,,B,,
2725,,,CHEMBL617285,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,,4176,,108,,,BAO_0000219,,Autocuration,,,B,,HEK293
2726,,,CHEMBL617286,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,,17085,,108,,,BAO_0000019,,Autocuration,,,B,,
2727,Homo sapiens,,CHEMBL617287,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,,17200,,108,,,BAO_0000357,,Expert,,9606.0,B,,
2728,,,CHEMBL617288,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,,5088,,108,,,BAO_0000357,,Expert,,,B,,
2729,,,CHEMBL617289,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,,5088,,108,,,BAO_0000357,,Autocuration,,,B,,
2730,,,CHEMBL872917,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,5088,,108,,,BAO_0000357,,Autocuration,,,B,,
2731,,,CHEMBL617290,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,5088,,108,,,BAO_0000357,,Autocuration,,,B,,
2732,,,CHEMBL617291,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,16659,,108,,,BAO_0000219,,Autocuration,,,B,,CHO
2733,,,CHEMBL617292,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,,16659,,108,,,BAO_0000219,,Autocuration,,,B,,CHO
2734,,,CHEMBL617293,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,17451,,108,,,BAO_0000219,,Autocuration,,,B,,NIH3T3
2735,Homo sapiens,,CHEMBL617294,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,6857,,108,,,BAO_0000219,,Expert,,9606.0,F,,CHO
2736,,,CHEMBL617295,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,3857,,108,,,BAO_0000019,,Expert,,,B,,
2737,,,CHEMBL617296,Binding activity radioligand.,,12861,,108,,,BAO_0000357,,Autocuration,,,B,,
2738,,,CHEMBL617297,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,12861,,108,,,BAO_0000019,,Autocuration,,,B,,
2739,,,CHEMBL617298,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,,5104,,108,,,BAO_0000219,,Expert,,,B,,CHO
2740,,,CHEMBL617299,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,,5105,,108,,,BAO_0000219,,Expert,,,B,,CHO
2741,,,CHEMBL617300,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,,5105,,108,,,BAO_0000219,,Autocuration,,,B,,CHO
2742,,,CHEMBL617454,Binding affinity against 5-HT2C receptor,,5254,,108,,,BAO_0000357,,Autocuration,,,B,,
2743,,,CHEMBL617505,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,13267,,108,,,BAO_0000219,,Autocuration,,,B,,HEK293
2744,Homo sapiens,,CHEMBL617506,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,,14157,,108,,,BAO_0000219,,Expert,,9606.0,B,,HEK293
2745,Homo sapiens,,CHEMBL617507,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,12936,,108,,,BAO_0000219,,Expert,,9606.0,B,,HEK293
2746,,,CHEMBL617508,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,,14068,,108,,,BAO_0000357,,Expert,,,B,,
2747,Homo sapiens,,CHEMBL857982,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,12936,,108,,,BAO_0000219,,Expert,,9606.0,B,,HEK293
2748,Homo sapiens,,CHEMBL617509,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,,4540,,108,,,BAO_0000219,,Expert,,9606.0,B,,HEK293
2749,Homo sapiens,,CHEMBL617510,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,,4540,,108,,,BAO_0000219,,Expert,,9606.0,B,,HEK293
2750,,,CHEMBL617511,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,,6166,,108,,,BAO_0000357,,Autocuration,,,B,,
2751,,,CHEMBL617512,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,,17296,,108,,,BAO_0000219,,Autocuration,,,B,,HEK293
2752,,,CHEMBL617749,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,,17296,,108,,,BAO_0000219,,Autocuration,,,B,,HEK293
2753,,,CHEMBL617750,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,15779,,108,,,BAO_0000219,,Autocuration,,,B,,HEK293
2754,,,CHEMBL617751,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,15779,,108,,,BAO_0000219,,Autocuration,,,B,,HEK293
2755,,,CHEMBL617752,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,,14391,,108,,,BAO_0000219,,Expert,,,B,,HEK293
2756,,,CHEMBL617753,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",,15779,,108,,,BAO_0000219,,Autocuration,,,B,,HEK293
2757,,,CHEMBL617754,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",,15851,,108,,,BAO_0000219,,Expert,,,B,,HEK293
2758,Homo sapiens,,CHEMBL617755,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,,15851,,108,,,BAO_0000219,,Expert,,9606.0,B,,HEK293
2759,,,CHEMBL617756,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",,15779,,108,,,BAO_0000219,,Autocuration,,,B,,HEK293
2760,,,CHEMBL617757,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,,3832,,108,,,BAO_0000219,,Expert,,,B,,HEK293
2761,,,CHEMBL617758,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,,3833,,108,,,BAO_0000219,,Expert,,,B,,HEK293
2762,,,CHEMBL617759,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,17451,,108,,,BAO_0000219,,Autocuration,,,B,,NIH3T3
2763,,,CHEMBL617760,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,,4199,,108,,,BAO_0000219,,Autocuration,,,B,,HEK293
2764,,,CHEMBL617761,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,,1883,,108,,,BAO_0000219,,Expert,,,B,,CHO-K1
2765,Homo sapiens,,CHEMBL617762,Binding affinity against 5-hydroxytryptamine 2C receptor,,4321,,108,,,BAO_0000357,,Expert,,9606.0,B,,
2766,,,CHEMBL617763,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,,14875,,108,,,BAO_0000357,,Autocuration,,,B,,
2767,,,CHEMBL857983,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,,15146,,108,,,BAO_0000219,,Autocuration,,,B,,HEK293
2768,,,CHEMBL617764,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,,5213,,108,,,BAO_0000219,,Autocuration,,,B,,HEK293
2769,,,CHEMBL617765,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,,16404,,108,,,BAO_0000219,,Autocuration,,,B,,HeLa
2770,,,CHEMBL617766,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,,13267,,108,,,BAO_0000019,,Autocuration,,,F,,
2771,,10000000.0,CHEMBL617767,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,,13267,Hippocampus,108,,,BAO_0000221,,Autocuration,,,F,,
2772,,,CHEMBL617768,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,,14818,,108,,,BAO_0000219,,Autocuration,,,B,,HEK293
2773,,,CHEMBL617769,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",,4829,,108,,,BAO_0000219,,Autocuration,,,B,,HEK293
2774,,,CHEMBL858023,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,,13463,,11864,,,BAO_0000357,,Autocuration,,,B,,
2775,,945.0,CHEMBL617770,Binding affinity analysed on 5-HT 2C in rat stomach fundus,,13463,Stomach,11864,,,BAO_0000019,,Autocuration,,,B,,
2776,,945.0,CHEMBL617771,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,,13463,Stomach,11864,,,BAO_0000019,,Autocuration,,,B,,
2777,,,CHEMBL617772,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,,12652,,11864,,,BAO_0000219,,Autocuration,,,F,,A9
2778,,,CHEMBL617773,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,4682,,11864,,,BAO_0000219,,Autocuration,,,B,,NIH3T3
2779,,,CHEMBL617850,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,,4682,,11864,,,BAO_0000219,,Autocuration,,,B,,NIH3T3
2780,,,CHEMBL617851,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,4682,,11864,,,BAO_0000219,,Autocuration,,,B,,NIH3T3
2781,,,CHEMBL617852,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,,12652,,11864,,,BAO_0000019,,Autocuration,,,F,,
2782,Mus musculus,945.0,CHEMBL858024,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,,13463,Stomach,12689,,,BAO_0000019,,Autocuration,,10090.0,B,,
2783,Rattus norvegicus,945.0,CHEMBL617853,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,,13463,Stomach,12689,,,BAO_0000019,,Expert,,10116.0,B,,
2784,,,CHEMBL617854,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,,13969,,108,,,BAO_0000357,,Expert,,,B,,
2785,Sus scrofa,,CHEMBL873477,Binding affinity for 5-hydroxytryptamine 2C receptor,,13392,,108,,,BAO_0000357,,Expert,,9823.0,B,,
2786,,,CHEMBL617855,Binding affinity towards 5-hydroxytryptamine 2C receptor,,13392,,108,,,BAO_0000357,,Expert,,,B,,
2787,,,CHEMBL617856,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,,14430,,108,,,BAO_0000019,,Expert,,,B,,
2788,,,CHEMBL617857,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,,1742,,108,,,BAO_0000019,,Autocuration,,,B,,
2789,,,CHEMBL617858,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,,14286,,108,,,BAO_0000249,,Autocuration,,,B,,
2790,,,CHEMBL617859,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,,5619,,108,,,BAO_0000357,,Autocuration,,,B,,
2791,,,CHEMBL617860,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,15086,,108,,,BAO_0000357,,Autocuration,,,B,,
2792,,,CHEMBL617861,Binding activity radioligand.,,12861,,108,,,BAO_0000357,,Autocuration,,,B,,
2793,,,CHEMBL617862,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,12861,,108,,,BAO_0000019,,Expert,,,B,,
2794,,,CHEMBL617863,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,12861,,108,,,BAO_0000019,,Autocuration,,,B,,
2795,,,CHEMBL617864,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,,12827,,108,,,BAO_0000249,,Autocuration,,,B,,
2796,,,CHEMBL617649,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,,12827,,108,,,BAO_0000249,,Autocuration,,,B,,
2797,Sus scrofa,,CHEMBL617650,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,12919,,108,,,BAO_0000019,,Expert,,9823.0,F,,
2798,Sus scrofa,,CHEMBL617651,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,12919,,108,,,BAO_0000019,,Expert,,9823.0,F,,
2799,Sus scrofa,,CHEMBL617652,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,,16429,,108,,,BAO_0000357,,Autocuration,,9823.0,B,,
2800,Sus scrofa,,CHEMBL857072,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,,773,,108,,,BAO_0000019,,Autocuration,,9823.0,B,,
2801,Sus scrofa,,CHEMBL617653,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,,5033,,108,,,BAO_0000357,,Autocuration,,9823.0,B,,
2802,,,CHEMBL617654,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,12861,,12687,,,BAO_0000019,,Autocuration,,,B,,
2803,,,CHEMBL617655,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,,14093,,12689,,,BAO_0000019,,Autocuration,,,F,,
2804,,,CHEMBL617656,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,,14970,,12689,,,BAO_0000357,,Expert,,,B,,
2805,,,CHEMBL617657,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,,14970,,12689,,,BAO_0000357,,Autocuration,,,B,,
2806,,,CHEMBL617658,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,,14970,,12689,,,BAO_0000357,,Autocuration,,,B,,
2807,Rattus norvegicus,,CHEMBL617659,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,,14178,,12689,,,BAO_0000357,,Expert,,10116.0,B,,
2808,Rattus norvegicus,,CHEMBL617838,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,,14178,,12689,,,BAO_0000357,,Expert,,10116.0,B,,
2809,Rattus norvegicus,,CHEMBL617839,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,,14229,,12689,,,BAO_0000249,,Expert,Brain membranes,10116.0,B,,
2810,,,CHEMBL617840,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,,16532,,12689,,,BAO_0000357,,Autocuration,,,B,,
2811,,,CHEMBL617841,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,,14826,,12689,,,BAO_0000019,,Autocuration,,,B,,
2812,,,CHEMBL875915,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,,17211,,12689,,,BAO_0000019,,Autocuration,,,B,,
2813,,,CHEMBL617842,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,In vitro,17211,,12689,,,BAO_0000219,,Expert,,,B,,
2814,,,CHEMBL617843,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,,13246,,12689,,,BAO_0000219,,Expert,,,B,,NIH3T3
2815,,,CHEMBL617844,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,,13246,,12689,,,BAO_0000357,,Expert,,,B,,
2816,,,CHEMBL617845,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,,12457,,12689,,,BAO_0000357,,Expert,,,B,,
2817,,,CHEMBL617846,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,,12457,,12689,,,BAO_0000219,,Expert,,,B,,NIH3T3
2818,,,CHEMBL617847,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,,4707,,12689,,,BAO_0000357,,Autocuration,,,B,,
2819,,,CHEMBL617848,Binding affinity against 5-hydroxytryptamine 2C receptor,,13297,,12689,,,BAO_0000357,,Expert,,,B,,
2820,,,CHEMBL617849,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,16633,,12689,,,BAO_0000357,,Autocuration,,,B,,
2821,,,CHEMBL621507,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,16133,,12689,,,BAO_0000357,,Expert,,,B,,
2822,,,CHEMBL621508,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,,16326,,12689,,,BAO_0000357,,Expert,,,B,,
2823,,,CHEMBL621509,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,,14423,,12689,,,BAO_0000019,,Autocuration,,,B,,
2824,,,CHEMBL621510,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,,15412,,12689,,,BAO_0000019,,Autocuration,,,B,,
2825,,,CHEMBL621511,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,,15412,,12689,,,BAO_0000019,,Autocuration,,,B,,
2826,,,CHEMBL621512,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,,15558,,12689,,,BAO_0000219,,Expert,,,B,,A9
2827,,,CHEMBL621513,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,16633,,12689,,,BAO_0000357,,Autocuration,,,B,,
2828,,,CHEMBL621514,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,,6013,,12689,,,BAO_0000357,,Expert,,,B,,
2829,,,CHEMBL621515,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,In vitro,17175,,12689,,,BAO_0000219,,Expert,,,B,,
2830,,,CHEMBL621516,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,,12469,,12689,,,BAO_0000219,,Autocuration,,,B,,
2831,,5383.0,CHEMBL621517,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,,3682,Caudate-putamen,12689,,,BAO_0000019,,Autocuration,,,B,,
2832,,,CHEMBL621518,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,,4932,,12689,,,BAO_0000357,,Autocuration,,,B,,
2833,,,CHEMBL621519,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,,4932,,12689,,,BAO_0000019,,Autocuration,,,B,,
2834,,,CHEMBL621520,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,,3935,,12689,,,BAO_0000357,,Autocuration,,,B,,
2835,,,CHEMBL621521,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,,15818,,12689,,,BAO_0000357,,Autocuration,,,B,,
2836,,,CHEMBL621522,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,,15818,,12689,,,BAO_0000357,,Autocuration,,,B,,
2837,,,CHEMBL621523,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,,14749,,12689,,,BAO_0000219,,Expert,,,B,,
2838,,,CHEMBL621524,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,,15740,,12689,,,BAO_0000357,,Autocuration,,,B,,
2839,Rattus norvegicus,,CHEMBL621525,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,,17133,,12689,,,BAO_0000357,,Expert,,10116.0,B,,
2840,,,CHEMBL872921,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,,16532,,12689,,,BAO_0000357,,Autocuration,,,B,,
2841,,,CHEMBL621526,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,,12369,,12689,,,BAO_0000357,,Autocuration,,,B,,
2842,,,CHEMBL621527,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,,12369,,12689,,,BAO_0000219,,Expert,,,B,,
2843,Rattus norvegicus,,CHEMBL617865,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,,2309,,12689,,,BAO_0000019,,Expert,,10116.0,B,,
2844,,,CHEMBL617866,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,,12953,,12689,,,BAO_0000357,,Autocuration,,,B,,
2845,,,CHEMBL617867,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,,12953,,12689,,,BAO_0000019,,Autocuration,,,B,,
2846,,,CHEMBL617487,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,,12953,,12689,,,BAO_0000357,,Autocuration,,,B,,
2847,,,CHEMBL617488,Binding affinity for 5-hydroxytryptamine 2C receptor,,12953,,12689,,,BAO_0000357,,Expert,,,B,,
2848,,,CHEMBL617489,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,,17133,,12689,,,BAO_0000357,,Autocuration,,,B,,
2849,,,CHEMBL617490,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,,17211,,12689,,,BAO_0000019,,Autocuration,,,B,,
2850,,,CHEMBL617491,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,,17211,,12689,,,BAO_0000019,,Autocuration,,,B,,
2851,,,CHEMBL617492,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,,14025,,12689,,,BAO_0000019,,Autocuration,,,B,,
2852,,,CHEMBL617493,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,,14998,,12689,,,BAO_0000019,,Autocuration,,,B,,
2853,,,CHEMBL617494,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,,4342,,12689,,,BAO_0000357,,Autocuration,,,B,,
2854,Rattus norvegicus,,CHEMBL617495,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,,13735,,12689,,,BAO_0000019,,Expert,,10116.0,B,,
2855,,,CHEMBL617496,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,13181,,12689,,,BAO_0000357,,Autocuration,,,B,,
2856,,,CHEMBL617497,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,,1883,,12689,,,BAO_0000219,,Autocuration,,,B,,CHO-K1
2857,,,CHEMBL617498,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,15194,,12689,,,BAO_0000357,,Autocuration,,,B,,
2858,,,CHEMBL617499,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,,15194,,12689,,,BAO_0000357,,Autocuration,,,B,,
2859,,,CHEMBL617500,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,,14579,,12689,,,BAO_0000019,,Autocuration,,,F,,
2860,,,CHEMBL617501,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,4639,,108,,,BAO_0000357,,Autocuration,,,B,,
2861,,,CHEMBL617502,Binding affinity towards 5-hydroxytryptamine 2C receptor,,4820,,108,,,BAO_0000357,,Expert,,,B,,
2862,,,CHEMBL617503,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,,14442,,227,,,BAO_0000357,,Autocuration,,,B,,
2863,,,CHEMBL617504,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,,14755,,227,,,BAO_0000357,,Autocuration,,,B,,
2864,,,CHEMBL617406,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,,14744,,227,,,BAO_0000357,,Autocuration,,,B,,
2865,Homo sapiens,,CHEMBL617407,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,,6857,,227,,,BAO_0000019,,Expert,,9606.0,B,,
2866,,,CHEMBL617408,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,,16209,,227,,,BAO_0000357,,Autocuration,,,B,,
2867,,,CHEMBL617409,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,15363,,227,,,BAO_0000357,,Autocuration,,,B,,
2868,,,CHEMBL617410,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,15363,,227,,,BAO_0000357,,Autocuration,,,B,,
2869,,,CHEMBL617411,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,,15363,,227,,,BAO_0000357,,Autocuration,,,B,,
2870,,,CHEMBL617412,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,,17085,,227,,,BAO_0000019,,Autocuration,,,B,,
2871,Homo sapiens,,CHEMBL617774,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,,17200,,227,,,BAO_0000357,,Expert,,9606.0,B,,
2872,Homo sapiens,,CHEMBL617775,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,15851,,227,,,BAO_0000219,,Expert,,9606.0,B,,HEK293
2873,Homo sapiens,,CHEMBL617776,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,15851,,227,,,BAO_0000219,,Expert,,9606.0,B,,HEK293
2874,Homo sapiens,,CHEMBL617777,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,6857,,227,,,BAO_0000219,,Expert,,9606.0,F,,CHO
2875,Homo sapiens,,CHEMBL617778,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,6857,,227,,,BAO_0000219,,Expert,,9606.0,F,,CHO
2876,,,CHEMBL617779,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,15779,,227,,,BAO_0000219,,Autocuration,,,B,,HEK293
2877,,,CHEMBL617780,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,,15851,,227,,,BAO_0000219,,Expert,,,B,,HEK293
2878,,,CHEMBL617781,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",,15779,,227,,,BAO_0000219,,Autocuration,,,B,,HEK293
2879,Homo sapiens,,CHEMBL617782,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,,14157,,227,,,BAO_0000219,,Expert,,9606.0,B,,HEK293
2880,Homo sapiens,,CHEMBL617783,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,,4540,,227,,,BAO_0000219,,Expert,,9606.0,B,,HEK293
2881,,,CHEMBL617784,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,,6166,,227,,,BAO_0000357,,Autocuration,,,B,,
2882,,,CHEMBL617785,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,,15779,,227,,,BAO_0000219,,Autocuration,,,B,,HEK293
2883,,,CHEMBL857984,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,,14391,,227,,,BAO_0000219,,Expert,,,B,,HEK293
2884,,,CHEMBL617786,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,,3832,,227,,,BAO_0000219,,Expert,,,B,,HEK293
2885,,,CHEMBL617787,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,,3833,,227,,,BAO_0000219,,Expert,,,B,,HEK293
2886,Homo sapiens,,CHEMBL617788,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,,15851,,227,,,BAO_0000219,,Expert,,9606.0,B,,HEK293
2887,Homo sapiens,,CHEMBL617789,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,,15851,,227,,,BAO_0000219,,Expert,,9606.0,B,,HEK293
2888,,,CHEMBL617790,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,,4199,,227,,,BAO_0000219,,Autocuration,,,B,,HEK293
2889,,,CHEMBL617791,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,,1883,,227,,,BAO_0000219,,Expert,,,B,,CHO-K1
2890,,,CHEMBL617608,Binding affinity against 5-hydroxytryptamine 2B receptor,,4321,,227,,,BAO_0000357,,Expert,,,B,,
2891,,,CHEMBL617609,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,,15146,,227,,,BAO_0000219,,Autocuration,,,B,,HEK293
2892,,,CHEMBL617610,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,,5213,,227,,,BAO_0000219,,Autocuration,,,B,,HEK293
2893,,,CHEMBL617611,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,,14818,,227,,,BAO_0000219,,Autocuration,,,B,,HEK293
2894,,,CHEMBL617612,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,4829,,227,,,BAO_0000219,,Autocuration,,,B,,HEK293
2895,,,CHEMBL617613,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,4829,,227,,,BAO_0000219,,Autocuration,,,B,,HEK293
2896,Oryctolagus cuniculus,,CHEMBL617614,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,,14025,,227,,,BAO_0000019,,Autocuration,,9986.0,B,,
2897,,945.0,CHEMBL617615,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,,13463,Stomach,12688,,,BAO_0000019,,Expert,,,B,,
2898,,945.0,CHEMBL858114,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,,7259,Stomach,12688,,,BAO_0000357,,Expert,,,B,,
2899,,945.0,CHEMBL617616,Affinity against serotonergic receptor in the isolated rat stomach fundus,,7259,Stomach,12688,,,BAO_0000357,,Autocuration,,,B,,
2900,Rattus norvegicus,945.0,CHEMBL617617,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,,7185,Stomach,12688,,,BAO_0000019,,Expert,,10116.0,F,,
2901,Rattus norvegicus,,CHEMBL875914,Antagonistic against 5-hydroxytryptamine 2B receptor,,7185,,12688,,,BAO_0000019,,Expert,,10116.0,F,,
2902,,945.0,CHEMBL617618,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,,13267,Stomach,12688,,,BAO_0000019,,Autocuration,,,F,,
2903,Rattus norvegicus,945.0,CHEMBL617619,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,,13735,Stomach,12688,,,BAO_0000357,,Expert,,10116.0,B,,
2904,,,CHEMBL617620,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,,15738,,12688,,,BAO_0000019,,Autocuration,,,F,,
2905,,,CHEMBL617621,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,,15738,,12688,,,BAO_0000019,,Autocuration,,,F,,
2906,,,CHEMBL617622,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,,15738,,12688,,,BAO_0000019,,Autocuration,,,F,,
2907,Rattus norvegicus,945.0,CHEMBL617623,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,12936,Stomach,12688,,,BAO_0000357,,Expert,,10116.0,B,,
2908,Rattus norvegicus,945.0,CHEMBL617624,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,12936,Stomach,12688,,,BAO_0000357,,Expert,,10116.0,B,,
2909,Rattus norvegicus,945.0,CHEMBL617625,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,12936,Stomach,12688,,,BAO_0000357,,Expert,,10116.0,B,,
2910,Rattus norvegicus,945.0,CHEMBL617626,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,12936,Stomach,12688,,,BAO_0000357,,Expert,,10116.0,B,,
2911,,945.0,CHEMBL617627,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,16404,Stomach,12688,,,BAO_0000019,,Autocuration,,,F,,
2912,,945.0,CHEMBL617628,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,16404,Stomach,12688,,,BAO_0000019,,Expert,,,F,,
2913,,945.0,CHEMBL617629,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,,16404,Stomach,12688,,,BAO_0000019,,Autocuration,,,F,,
2914,,945.0,CHEMBL858115,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,,16404,Stomach,12688,,,BAO_0000019,,Autocuration,,,F,,
2915,Rattus norvegicus,945.0,CHEMBL617630,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,,16404,Stomach,12688,,,BAO_0000019,,Expert,,10116.0,F,,
2916,,1515.0,CHEMBL617631,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,,16404,Thoracic aorta,12688,,,BAO_0000019,,Autocuration,,,F,,
2917,,,CHEMBL617632,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,7483,,12688,,,BAO_0000357,,Autocuration,,,B,,
2918,,,CHEMBL617633,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,,7483,,12688,,,BAO_0000357,,Expert,,,B,,
2919,,,CHEMBL617634,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,7483,,12688,,,BAO_0000357,,Autocuration,,,B,,
2920,,,CHEMBL617635,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,,7483,,12688,,,BAO_0000357,,Autocuration,,,B,,
2922,Rattus norvegicus,945.0,CHEMBL617637,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,16404,Stomach,12688,,,BAO_0000019,,Autocuration,,10116.0,F,,
2923,,,CHEMBL617638,Binding affinity against 5-hydroxytryptamine 1A receptor,,6347,,227,,,BAO_0000357,,Autocuration,,,B,,
2924,,,CHEMBL617639,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,,4373,,227,,,BAO_0000357,,Autocuration,,,B,,
2925,,,CHEMBL617640,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,,4373,,227,,,BAO_0000357,,Autocuration,,,B,,
2926,,,CHEMBL617641,Evaluated for the binding affinity to 5-HT 2B receptor,,4687,,227,,,BAO_0000357,,Autocuration,,,B,,
2927,,,CHEMBL617642,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,,16946,,227,,,BAO_0000357,,Autocuration,,,B,,
2928,,,CHEMBL617643,Binding affinities against 5-hydroxytryptamine 2B receptor,,16633,,227,,,BAO_0000357,,Autocuration,,,B,,
2929,,,CHEMBL617644,Binding affinities towards 5-hydroxytryptamine 2B receptor,,16633,,227,,,BAO_0000357,,Autocuration,,,B,,
2930,,,CHEMBL617645,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,,16633,,227,,,BAO_0000357,,Autocuration,,,B,,
2931,,,CHEMBL617646,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,15026,,108,,,BAO_0000357,,Expert,,,B,,
2932,Bos taurus,,CHEMBL617647,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,15738,,108,,,BAO_0000357,,Autocuration,,9913.0,B,,
2933,Bos taurus,,CHEMBL617648,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,,15738,,108,,,BAO_0000357,,Autocuration,,9913.0,B,,
2934,Bos taurus,,CHEMBL617875,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,,15738,,108,,,BAO_0000357,,Autocuration,,9913.0,B,,
2935,Bos taurus,,CHEMBL617876,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,,15738,,108,,,BAO_0000357,,Autocuration,,9913.0,B,,
2936,Bos taurus,,CHEMBL617877,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,,16404,,108,,,BAO_0000357,,Expert,,9913.0,B,,
2937,Bos taurus,,CHEMBL617878,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,15026,,108,,,BAO_0000357,,Expert,,9913.0,B,,
2938,Bos taurus,,CHEMBL617879,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,15738,,108,,,BAO_0000357,,Autocuration,,9913.0,B,,
2939,Cavia porcellus,,CHEMBL617880,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,,16312,,108,,,BAO_0000019,,Autocuration,,10141.0,B,,
2940,Cavia porcellus,2435.0,CHEMBL617881,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,,5486,Striatum,20033,,,BAO_0000357,,Intermediate,,10141.0,B,,
2941,,,CHEMBL857073,Binding affinity against 5-HT1A receptor,,5254,,51,,,BAO_0000357,,Autocuration,,,B,,
2942,,,CHEMBL617882,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,,3857,,108,,,BAO_0000219,,Expert,,,F,,CHO
2943,Homo sapiens,,CHEMBL617883,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,,6857,,108,,,BAO_0000219,,Expert,,9606.0,F,,CHO
2944,,,CHEMBL617884,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,,4176,,108,,,BAO_0000219,,Autocuration,,,F,,
2945,,,CHEMBL617885,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,,6347,,108,,,BAO_0000219,,Autocuration,,,B,,CHO
2946,,,CHEMBL617886,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",,6347,,108,,,BAO_0000219,,Autocuration,,,B,,CHO
2947,Homo sapiens,,CHEMBL617887,Inhibition of human 5-hydroxytryptamine 2C receptor,,16146,,108,,,BAO_0000357,,Expert,,9606.0,B,,
2948,,,CHEMBL617888,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),,3805,,108,,,BAO_0000357,,Autocuration,,,B,,
2949,,,CHEMBL617889,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,3857,,108,,,BAO_0000019,,Autocuration,,,B,,
2950,,,CHEMBL617890,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,,5635,,108,,,BAO_0000357,,Autocuration,,,B,,
2951,,,CHEMBL617891,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,5635,,108,,,BAO_0000357,,Autocuration,,,B,,
2952,,,CHEMBL617892,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,5635,,108,,,BAO_0000357,,Autocuration,,,B,,
2953,,,CHEMBL617893,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,,4012,,108,,,BAO_0000219,,Expert,,,B,,CHO
2954,,,CHEMBL617894,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,,6366,,108,,,BAO_0000219,,Expert,,,B,,CHO
2955,,,CHEMBL617895,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,15949,,108,,,BAO_0000219,,Expert,,,B,,CHO
2956,,,CHEMBL617896,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,,17211,,108,,,BAO_0000219,,Autocuration,,,B,,CHO
2957,Homo sapiens,,CHEMBL617897,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,,6491,,108,,,BAO_0000357,,Expert,,9606.0,B,,
2958,,,CHEMBL617898,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,,14093,,108,,,BAO_0000019,,Autocuration,,,F,,
2959,,,CHEMBL617899,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,13481,,108,,,BAO_0000019,,Autocuration,,,F,,
2960,Rattus norvegicus,,CHEMBL617900,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,,6347,,108,,,BAO_0000219,,Expert,,10116.0,B,,CHO
2961,,,CHEMBL617901,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,,14093,,108,,,BAO_0000019,,Autocuration,,,F,,
2962,,,CHEMBL617902,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,,14093,,108,,,BAO_0000019,,Autocuration,,,F,,
2963,,,CHEMBL617903,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,13481,,108,,,BAO_0000019,,Autocuration,,,F,,
2964,,,CHEMBL617904,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,,14442,,108,,,BAO_0000357,,Autocuration,,,B,,
2965,,,CHEMBL617905,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,,14442,,108,,,BAO_0000357,,Autocuration,,,B,,
2966,,,CHEMBL617906,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,,14442,,108,,,BAO_0000357,,Autocuration,,,B,,
2967,,,CHEMBL617907,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,,14755,,108,,,BAO_0000357,,Autocuration,,,B,,
2968,,,CHEMBL617908,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,,14744,,108,,,BAO_0000357,,Autocuration,,,B,,
2969,,,CHEMBL620617,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,16659,,108,,,BAO_0000219,,Expert,,,B,,CHO
2970,Homo sapiens,,CHEMBL620618,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,,6857,,108,,,BAO_0000019,,Expert,,9606.0,B,,
2971,,,CHEMBL620619,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,,5635,,108,,,BAO_0000357,,Expert,,,B,,
2972,Homo sapiens,,CHEMBL620620,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,,4234,,108,,,BAO_0000357,,Expert,,9606.0,B,,
2973,,,CHEMBL620621,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,,16209,,108,,,BAO_0000357,,Autocuration,,,B,,
2974,Rattus norvegicus,,CHEMBL872920,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,,5778,,104698,,,BAO_0000249,,Autocuration,Membranes,10116.0,B,,
2975,,,CHEMBL620622,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,,5094,,104698,,,BAO_0000223,,Autocuration,,,B,,
2976,Rattus norvegicus,,CHEMBL620623,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,,809,,104698,,,BAO_0000019,,Autocuration,,10116.0,B,,
2977,,,CHEMBL620624,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,,1578,,104698,,,BAO_0000019,,Autocuration,,,B,,
2978,,,CHEMBL620625,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,,809,,104698,,,BAO_0000019,,Autocuration,,,B,,
2979,,,CHEMBL620626,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,,12469,,104698,,,BAO_0000219,,Autocuration,,,B,,
2980,,,CHEMBL621307,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,,14290,,104698,,,BAO_0000019,,Autocuration,,,B,,
2981,,,CHEMBL621308,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,,14290,,104698,,,BAO_0000019,,Autocuration,,,B,,
2982,,,CHEMBL621309,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,,10609,,104698,,,BAO_0000223,,Autocuration,,,B,,
2983,,,CHEMBL621310,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,,10609,,104698,,,BAO_0000223,,Autocuration,,,B,,
2984,,,CHEMBL621311,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,,10609,,104698,,,BAO_0000223,,Autocuration,,,B,,
2985,,,CHEMBL621502,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,15253,,104698,,,BAO_0000249,,Autocuration,,,B,,
2986,,,CHEMBL621503,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,15253,,104698,,,BAO_0000249,,Autocuration,,,B,,
2987,,,CHEMBL621504,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,,11683,,104698,,,BAO_0000249,,Autocuration,Membranes,,B,,
2988,,,CHEMBL621505,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,,12092,,104698,,,BAO_0000223,,Autocuration,,,B,,
2989,,,CHEMBL621506,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,1946,,104698,,,BAO_0000019,,Autocuration,,,B,,
2990,,,CHEMBL619781,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,,11623,,104698,,,BAO_0000223,,Autocuration,,,B,,
2991,,,CHEMBL619782,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,,11623,,104698,,,BAO_0000223,,Autocuration,,,B,,
2992,,,CHEMBL619783,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,,14788,,104698,,,BAO_0000019,,Autocuration,,,B,,
2993,Rattus norvegicus,,CHEMBL619784,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,,5432,,104698,,,BAO_0000019,,Autocuration,,10116.0,B,,
2994,,,CHEMBL619785,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,14826,,104698,,,BAO_0000249,,Autocuration,,,B,,
2995,,,CHEMBL619786,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,2222,,104698,,,BAO_0000223,,Autocuration,,,B,,
2996,,,CHEMBL619787,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,,11963,,104698,,,BAO_0000019,,Autocuration,,,B,,
2997,,,CHEMBL872925,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,,14145,,104698,,,BAO_0000019,,Autocuration,,,B,,
2998,,,CHEMBL619788,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,,17819,,104698,,,BAO_0000019,,Autocuration,,,B,,
2999,,,CHEMBL619789,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,10394,,104698,,,BAO_0000249,,Autocuration,,,B,,
3000,,,CHEMBL619790,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,10394,,104698,,,BAO_0000249,,Autocuration,,,B,,
3001,,,CHEMBL619791,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,15034,,104698,,,BAO_0000019,,Autocuration,,,B,,
3002,,,CHEMBL619792,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,691,,104698,,,BAO_0000019,,Autocuration,,,B,,
3003,,,CHEMBL619793,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,,12092,,104698,,,BAO_0000249,,Autocuration,Membranes,,B,,
3004,Rattus norvegicus,,CHEMBL619794,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,,11752,,104698,,,BAO_0000223,,Autocuration,,10116.0,B,,
3005,,955.0,CHEMBL619795,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,,11752,Brain,104698,,,BAO_0000221,,Autocuration,,,B,,
3006,,,CHEMBL619796,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,,301,,104698,,,BAO_0000019,,Autocuration,,,B,,
3007,,,CHEMBL620448,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,,16532,,104698,,,BAO_0000223,,Autocuration,,,B,,
3008,,,CHEMBL620449,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,16532,,104698,,,BAO_0000223,,Autocuration,,,B,,
3009,,,CHEMBL620450,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,,12092,,104698,,,BAO_0000223,,Autocuration,,,B,,
3010,,,CHEMBL620451,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,,11684,,104698,,,BAO_0000223,,Autocuration,,,B,,
3011,,,CHEMBL620631,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,,11684,,104698,,,BAO_0000223,,Autocuration,,,B,,
3012,,,CHEMBL620632,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,,12953,,104698,,,BAO_0000019,,Autocuration,,,B,,
3013,,,CHEMBL620633,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,,12953,,104698,,,BAO_0000019,,Autocuration,,,B,,
3014,,,CHEMBL620634,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,,12953,,104698,,,BAO_0000223,,Autocuration,,,B,,
3015,,,CHEMBL620635,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,12861,,104698,,,BAO_0000019,,Autocuration,,,B,,
3016,,,CHEMBL620636,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,In vivo,11454,,104698,,,BAO_0000218,,Autocuration,,,F,,
3017,,,CHEMBL620637,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,In vivo,11454,,104698,,,BAO_0000218,,Autocuration,,,F,,
3018,,,CHEMBL620638,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,In vivo,11454,,104698,,,BAO_0000218,,Autocuration,,,F,,
3019,,,CHEMBL620639,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,In vivo,11454,,104698,,,BAO_0000218,,Autocuration,,,F,,
3020,,,CHEMBL620640,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,In vivo,11454,,104698,,,BAO_0000218,,Autocuration,,,F,,
3021,,,CHEMBL620641,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,In vivo,11454,,104698,,,BAO_0000218,,Autocuration,,,F,,
3022,,,CHEMBL620642,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,In vivo,11454,,104698,,,BAO_0000218,,Autocuration,,,F,,
3023,,,CHEMBL620643,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,In vivo,11454,,104698,,,BAO_0000218,,Autocuration,,,F,,
3024,,,CHEMBL620644,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,In vivo,11454,,104698,,,BAO_0000218,,Autocuration,,,F,,
3025,,,CHEMBL620645,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,In vivo,11454,,104698,,,BAO_0000218,,Autocuration,,,F,,
3026,,,CHEMBL620646,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,In vivo,11454,,104698,,,BAO_0000218,,Autocuration,,,F,,
3027,,,CHEMBL620647,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,In vivo,11454,,104698,,,BAO_0000218,,Autocuration,,,F,,
3028,,,CHEMBL620648,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,In vivo,11454,,104698,,,BAO_0000218,,Autocuration,,,F,,
3029,,,CHEMBL620649,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,In vivo,11454,,104698,,,BAO_0000218,,Autocuration,,,F,,
3030,,,CHEMBL620650,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,In vivo,11454,,104698,,,BAO_0000218,,Autocuration,,,F,,
3031,,,CHEMBL620651,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,In vivo,11454,,104698,,,BAO_0000218,,Autocuration,,,F,,
3032,,,CHEMBL872875,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,In vivo,11454,,104698,,,BAO_0000218,,Autocuration,,,F,,
3033,,,CHEMBL620652,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,In vivo,11454,,104698,,,BAO_0000218,,Autocuration,,,F,,
3034,,,CHEMBL620653,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,,10609,,104698,,,BAO_0000019,,Autocuration,,,F,,
3035,,,CHEMBL857076,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,,12861,,104698,,,BAO_0000019,,Autocuration,,,B,,
3036,Rattus norvegicus,,CHEMBL620654,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,,12861,,104698,,,BAO_0000019,,Autocuration,,10116.0,B,,
3037,,,CHEMBL620655,Binding activity radioligand.,,12861,,104698,,,BAO_0000223,,Autocuration,,,B,,
3038,,,CHEMBL620656,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,,10728,,104698,,,BAO_0000249,,Autocuration,Brain membranes,,B,,
3039,,,CHEMBL620657,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,,10728,,104698,,,BAO_0000249,,Autocuration,Brain membranes,,B,,
3040,,,CHEMBL620658,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,,5163,,108,,,BAO_0000357,,Autocuration,,,B,,
3041,,,CHEMBL620659,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,,5163,,108,,,BAO_0000357,,Autocuration,,,B,,
3042,,,CHEMBL620660,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,,6011,,108,,,BAO_0000357,,Autocuration,,,B,,
3043,,,CHEMBL620661,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,,5014,,108,,,BAO_0000357,,Autocuration,,,B,,
3044,,,CHEMBL620662,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,,5635,,108,,,BAO_0000357,,Autocuration,,,B,,
3045,,,CHEMBL620663,Affinity for 5-hydroxytryptamine 2C receptor,,5163,,108,,,BAO_0000357,,Expert,,,B,,
3046,,,CHEMBL620664,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,6841,,108,,,BAO_0000357,,Autocuration,,,B,,
3047,,,CHEMBL620665,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,,6119,,108,,,BAO_0000357,,Expert,,,B,,
3048,,,CHEMBL620666,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,,4373,,108,,,BAO_0000357,,Autocuration,,,B,,
3049,,,CHEMBL620667,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,,1633,,108,,,BAO_0000357,,Autocuration,,,B,,
3050,,,CHEMBL620668,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,,1633,,108,,,BAO_0000357,,Expert,,,B,,
3051,,,CHEMBL620669,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,,4373,,108,,,BAO_0000357,,Autocuration,,,B,,
3052,,,CHEMBL620670,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,,6576,,108,,,BAO_0000357,,Expert,,,B,,
3053,,,CHEMBL620671,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,,4687,,108,,,BAO_0000357,,Autocuration,,,B,,
3054,,,CHEMBL620672,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,,12146,,108,,,BAO_0000357,,Autocuration,,,B,,
3055,,,CHEMBL620673,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,,12146,,108,,,BAO_0000357,,Autocuration,,,B,,
3056,,,CHEMBL620674,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,,16946,,108,,,BAO_0000357,,Autocuration,,,B,,
3057,,,CHEMBL620675,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,,14159,,108,,,BAO_0000357,,Autocuration,,,B,,
3058,,,CHEMBL620676,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,,16700,,108,,,BAO_0000357,,Autocuration,,,B,,
3059,,,CHEMBL621382,Affinity against 5-hydroxytryptamine 2C receptor,,3269,,108,,,BAO_0000357,,Autocuration,,,B,,
3060,Homo sapiens,,CHEMBL621383,Binding affinity against 5-hydroxytryptamine 2C receptor,,1274,,108,,,BAO_0000357,,Expert,,9606.0,B,,
3061,,,CHEMBL621384,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,,1317,,108,,,BAO_0000357,,Autocuration,,,B,,
3062,Bos taurus,,CHEMBL621385,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,,5834,,144,,,BAO_0000357,,Autocuration,,9913.0,B,,
3063,Bos taurus,,CHEMBL617989,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,,11147,,144,,,BAO_0000357,,Autocuration,,9913.0,B,,
3064,Cavia porcellus,,CHEMBL617990,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,,14145,,104714,,,BAO_0000019,,Expert,,10141.0,F,,
3065,Cavia porcellus,2116.0,CHEMBL875085,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,10561,Ileum,104714,,,BAO_0000221,,Autocuration,,10141.0,B,,
3066,Cavia porcellus,,CHEMBL617991,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,,15847,,104714,,,BAO_0000019,,Autocuration,,10141.0,F,,
3067,Cavia porcellus,,CHEMBL617992,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,,15847,,104714,,,BAO_0000019,,Autocuration,,10141.0,F,,
3068,Cavia porcellus,2116.0,CHEMBL617993,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,10561,Ileum,104714,,,BAO_0000221,,Autocuration,,10141.0,B,,
3069,Cavia porcellus,2116.0,CHEMBL617994,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,,11454,Ileum,104714,,,BAO_0000221,,Autocuration,,10141.0,B,,
3070,Cavia porcellus,,CHEMBL617995,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,,4639,,104714,,,BAO_0000019,,Autocuration,,10141.0,F,,
3071,Cavia porcellus,,CHEMBL617996,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,,4639,,104714,,,BAO_0000019,,Autocuration,,10141.0,F,,
3072,Cavia porcellus,,CHEMBL617997,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,,4639,,104714,,,BAO_0000019,,Autocuration,,10141.0,F,,
3073,Cavia porcellus,,CHEMBL617998,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,,4639,,104714,,,BAO_0000019,,Autocuration,,10141.0,F,,
3074,Cavia porcellus,,CHEMBL617999,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,,4639,,104714,,,BAO_0000019,,Autocuration,,10141.0,F,,
3075,Cavia porcellus,,CHEMBL618000,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,,4639,,104714,,,BAO_0000019,,Autocuration,,10141.0,F,,
3076,Cavia porcellus,2116.0,CHEMBL617815,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",,15253,Ileum,104714,,,BAO_0000221,,Autocuration,,10141.0,F,,
3077,Cavia porcellus,2116.0,CHEMBL617816,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",,15253,Ileum,104714,,,BAO_0000221,,Autocuration,,10141.0,F,,
3078,Cavia porcellus,2116.0,CHEMBL617817,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,,11963,Ileum,104714,,,BAO_0000221,,Autocuration,,10141.0,F,,
3079,Cavia porcellus,2116.0,CHEMBL617818,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,,1946,Ileum,104714,,,BAO_0000221,,Autocuration,,10141.0,B,,
3080,Cavia porcellus,2116.0,CHEMBL617819,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,,1946,Ileum,104714,,,BAO_0000221,,Autocuration,,10141.0,B,,
3081,Cavia porcellus,,CHEMBL617820,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,,12045,,104714,,,BAO_0000223,,Autocuration,,10141.0,B,,
3082,Cavia porcellus,2116.0,CHEMBL617821,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,1559,Ileum,104714,,,BAO_0000221,,Autocuration,,10141.0,B,,
3083,Cavia porcellus,2116.0,CHEMBL617822,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,273,Ileum,104714,,,BAO_0000221,,Autocuration,,10141.0,F,,
3084,Cavia porcellus,2116.0,CHEMBL617823,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),,273,Ileum,104714,,,BAO_0000221,,Autocuration,,10141.0,F,,
3085,Cavia porcellus,2116.0,CHEMBL617824,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,,188,Ileum,104714,,,BAO_0000221,,Autocuration,,10141.0,F,,
3086,Cavia porcellus,2116.0,CHEMBL617825,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,,12919,Ileum,104714,,,BAO_0000221,,Autocuration,,10141.0,F,,
3087,Cavia porcellus,2116.0,CHEMBL617826,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,,12918,Ileum,104714,,,BAO_0000221,,Autocuration,,10141.0,F,,
3088,Cavia porcellus,2116.0,CHEMBL617827,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,1559,Ileum,104714,,,BAO_0000221,,Autocuration,,10141.0,B,,
3089,Cavia porcellus,2116.0,CHEMBL617828,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,273,Ileum,104714,,,BAO_0000221,,Autocuration,,10141.0,F,,
3090,Cavia porcellus,2116.0,CHEMBL617829,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,1559,Ileum,104714,,,BAO_0000221,,Autocuration,,10141.0,B,,
3091,Cavia porcellus,2116.0,CHEMBL617830,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,,1559,Ileum,104714,,,BAO_0000221,,Autocuration,,10141.0,B,,
3092,Cavia porcellus,2116.0,CHEMBL617831,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,,1559,Ileum,104714,,,BAO_0000221,,Autocuration,,10141.0,B,,
3093,Cavia porcellus,2116.0,CHEMBL617832,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,,14424,Ileum,104714,,,BAO_0000221,,Autocuration,,10141.0,B,,
3094,Cavia porcellus,,CHEMBL617833,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,13181,,22226,,,BAO_0000019,,Autocuration,,10141.0,B,,
3095,,,CHEMBL617834,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,,5486,,51,,,BAO_0000357,,Autocuration,,,B,,
3096,Homo sapiens,,CHEMBL617835,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,,6491,,104714,,,BAO_0000223,,Expert,,9606.0,B,,
3097,,,CHEMBL617836,Binding affinity towards 5-HT3 receptor,,6013,,104714,,,BAO_0000223,,Autocuration,,,B,,
3098,,,CHEMBL617837,Binding activity radioligand.,,12861,,104714,,,BAO_0000223,,Autocuration,,,B,,
3099,,,CHEMBL620392,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,,12861,,104714,,,BAO_0000019,,Autocuration,,,B,,
3100,,,CHEMBL620393,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,5104,,104714,,,BAO_0000223,,Autocuration,,,B,,
3101,,,CHEMBL620394,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,5105,,104714,,,BAO_0000223,,Autocuration,,,B,,
3102,,,CHEMBL620395,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,,5104,,104714,,,BAO_0000223,,Autocuration,,,B,,
3103,,,CHEMBL620396,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,,3935,,22226,,,BAO_0000019,,Autocuration,,,B,,
3104,,,CHEMBL620582,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,,13657,,105030,,,BAO_0000219,,Expert,,,B,,NG108-15
3105,,,CHEMBL620583,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",In vivo,10369,,105030,,,BAO_0000218,,Autocuration,,,B,,
3106,,,CHEMBL620584,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,10369,,105030,,,BAO_0000019,,Autocuration,,,B,,
3107,,,CHEMBL620585,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,,12918,,105030,,,BAO_0000224,,Autocuration,,,B,,
3108,,,CHEMBL620586,Compound was evaluated for the binding affinity at 5- HT3 receptor,,12918,,105030,,,BAO_0000224,,Autocuration,,,B,,
3109,,,CHEMBL620587,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,10369,,105030,,,BAO_0000019,,Autocuration,,,B,,
3110,,,CHEMBL620588,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,773,,105030,,,BAO_0000019,,Autocuration,,,B,,
3111,,,CHEMBL620589,5-hydroxytryptamine 3 receptor agonism in mouse,,12918,,105030,,,BAO_0000218,,Autocuration,,,F,,
3112,,,CHEMBL620590,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,,10561,,105030,,,BAO_0000219,,Autocuration,,,B,,
3113,,,CHEMBL617956,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,12827,,105030,,,BAO_0000019,,Autocuration,,,B,,
3114,,,CHEMBL617957,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,12827,,105030,,,BAO_0000019,,Autocuration,,,B,,
3115,,,CHEMBL617958,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,,12918,,105030,,,BAO_0000224,,Autocuration,,,B,,
3116,,,CHEMBL617959,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,273,,105030,,,BAO_0000219,,Autocuration,,,B,,
3117,,,CHEMBL617960,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,273,,105030,,,BAO_0000219,,Autocuration,,,B,,
3118,,,CHEMBL617961,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,10561,,105030,,,BAO_0000224,,Autocuration,,,B,,
3119,,,CHEMBL617962,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,In vitro,5033,,105030,,,BAO_0000219,,Autocuration,,,B,,
3120,,,CHEMBL617963,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,,16429,,105030,,,BAO_0000219,,Autocuration,,,B,,N1E-115
3121,,,CHEMBL617964,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,10322,,11765,,,BAO_0000019,,Autocuration,,,B,,
3122,,,CHEMBL617965,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,,14331,,11765,,,BAO_0000219,,Autocuration,,,B,,
3123,Mus musculus,,CHEMBL617966,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,,13462,,10630,,,BAO_0000357,,Autocuration,,10090.0,B,,
3124,,,CHEMBL857074,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,12861,,17106,,,BAO_0000019,,Autocuration,,,B,,
3125,Sus scrofa,,CHEMBL617967,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,,15086,,144,,,BAO_0000357,,Autocuration,,9823.0,B,,
3126,Sus scrofa,,CHEMBL617968,Binding activity radioligand.,,12861,,144,,,BAO_0000357,,Autocuration,,9823.0,B,,
3127,Oryctolagus cuniculus,,CHEMBL617969,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,,10561,,104714,,,BAO_0000223,,Autocuration,,9986.0,B,,
3128,Oryctolagus cuniculus,,CHEMBL617970,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,10561,,104714,,,BAO_0000223,,Autocuration,,9986.0,B,,
3129,Oryctolagus cuniculus,,CHEMBL617971,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,,10561,,104714,,,BAO_0000223,,Autocuration,,9986.0,B,,
3130,Oryctolagus cuniculus,,CHEMBL617972,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,10561,,104714,,,BAO_0000019,,Autocuration,,9986.0,B,,
3131,Oryctolagus cuniculus,,CHEMBL617973,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,273,,104714,,,BAO_0000019,,Autocuration,,9986.0,F,,
3132,Oryctolagus cuniculus,,CHEMBL617974,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,273,,104714,,,BAO_0000019,,Autocuration,,9986.0,F,,
3133,Oryctolagus cuniculus,2116.0,CHEMBL617975,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,273,Ileum,104714,,,BAO_0000221,,Autocuration,,9986.0,F,,
3134,Oryctolagus cuniculus,,CHEMBL617976,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,273,,104714,,,BAO_0000019,,Autocuration,,9986.0,F,,
3135,Oryctolagus cuniculus,,CHEMBL617977,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,273,,104714,,,BAO_0000019,,Autocuration,,9986.0,F,,
3136,Oryctolagus cuniculus,,CHEMBL617978,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,273,,104714,,,BAO_0000019,,Autocuration,,9986.0,F,,
3137,Oryctolagus cuniculus,,CHEMBL617979,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,273,,104714,,,BAO_0000019,,Autocuration,,9986.0,F,,
3138,Oryctolagus cuniculus,,CHEMBL617980,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,,13047,,104714,,,BAO_0000219,,Autocuration,,9986.0,B,,CHO
3139,Rattus norvegicus,,CHEMBL617981,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,,1650,,104698,,,BAO_0000019,,Autocuration,,10116.0,B,,
3140,,,CHEMBL617982,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),,16288,,12020,,,BAO_0000019,,Autocuration,,,B,,
3141,,,CHEMBL617983,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),,16288,,12020,,,BAO_0000357,,Autocuration,,,B,,
3142,Rattus norvegicus,,CHEMBL617984,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,,10254,,104698,,,BAO_0000019,,Autocuration,,10116.0,B,,
3143,,,CHEMBL617985,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",,14532,,104698,,,BAO_0000019,,Autocuration,,,B,,
3144,,948.0,CHEMBL617986,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",In vivo,13392,Heart,104698,,,BAO_0000218,,Autocuration,,,F,,
3145,,948.0,CHEMBL617987,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,13392,Heart,104698,,,BAO_0000019,,Autocuration,,,F,,
3146,,948.0,CHEMBL617988,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,13392,Heart,104698,,,BAO_0000019,,Autocuration,,,F,,
3147,,948.0,CHEMBL617792,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",,13392,Heart,104698,,,BAO_0000019,,Autocuration,,,F,,
3148,,948.0,CHEMBL617793,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,13392,Heart,104698,,,BAO_0000019,,Autocuration,,,F,,
3149,,,CHEMBL617794,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",,13392,,104698,,,BAO_0000019,,Autocuration,,,F,,
3150,,,CHEMBL617795,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,13392,,104698,,,BAO_0000019,,Autocuration,,,F,,
3151,,,CHEMBL617796,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,13392,,104698,,,BAO_0000019,,Autocuration,,,F,,
3152,,,CHEMBL617797,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",,13392,,104698,,,BAO_0000019,,Autocuration,,,F,,
3153,Rattus norvegicus,,CHEMBL617798,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),In vivo,1089,,104698,,,BAO_0000218,,Autocuration,,10116.0,F,,
3154,,,CHEMBL617799,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),In vivo,1089,,104698,,,BAO_0000218,,Autocuration,,,F,,
3155,Rattus norvegicus,,CHEMBL617800,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,In vivo,11454,,104698,,,BAO_0000218,,Autocuration,,10116.0,F,,
3156,Rattus norvegicus,,CHEMBL617801,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,,11454,,104698,,,BAO_0000019,,Autocuration,,10116.0,F,,
3157,Rattus norvegicus,,CHEMBL617802,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,In vivo,12205,,104698,,,BAO_0000218,,Autocuration,,10116.0,F,,
3158,Rattus norvegicus,,CHEMBL617803,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),,1089,,104698,,,BAO_0000019,,Autocuration,,10116.0,F,,
3159,,,CHEMBL617804,Binding affinity towards 5-HT3 receptor in rat was evaluated,,5094,,104698,,,BAO_0000019,,Autocuration,,,B,,
3160,Rattus norvegicus,,CHEMBL617805,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,,2622,,104698,,,BAO_0000019,,Autocuration,,10116.0,B,,
3161,,,CHEMBL617806,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,,245,,104698,,,BAO_0000223,,Autocuration,,,B,,
3162,,,CHEMBL617807,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,,14788,,104698,,,BAO_0000019,,Autocuration,,,B,,
3163,,,CHEMBL617808,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,,14788,,104698,,,BAO_0000019,,Autocuration,,,B,,
3164,,,CHEMBL617809,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,,3020,,104698,,,BAO_0000249,,Autocuration,,,B,,
3165,,,CHEMBL617810,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,,1742,,104698,,,BAO_0000019,,Autocuration,,,B,,
3166,,955.0,CHEMBL617811,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,,17394,Brain,104698,,,BAO_0000249,,Autocuration,,,B,,
3167,,955.0,CHEMBL617812,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,,17394,Brain,104698,,,BAO_0000221,,Autocuration,,,B,,
3168,,,CHEMBL617813,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,,17394,,104698,,,BAO_0000249,,Autocuration,,,B,,
3169,,,CHEMBL617814,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,14286,,104698,,,BAO_0000249,,Autocuration,,,B,,
3170,,,CHEMBL617698,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,,14178,,104698,,,BAO_0000019,,Autocuration,,,B,,
3171,Rattus norvegicus,,CHEMBL617699,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,,14178,,104698,,,BAO_0000019,,Autocuration,,10116.0,B,,
3172,Rattus norvegicus,,CHEMBL617700,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,,14178,,104698,,,BAO_0000019,,Autocuration,,10116.0,B,,
3173,Rattus norvegicus,,CHEMBL617701,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,,14178,,104698,,,BAO_0000223,,Autocuration,,10116.0,B,,
3174,,,CHEMBL617702,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,15034,,104698,,,BAO_0000019,,Autocuration,,,B,,
3175,,,CHEMBL617703,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",,1089,,104698,,,BAO_0000249,,Autocuration,Membranes,,B,,
3176,Rattus norvegicus,,CHEMBL617704,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,,1089,,104698,,,BAO_0000019,,Autocuration,,10116.0,B,,
3177,,,CHEMBL617705,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,16532,,104698,,,BAO_0000223,,Autocuration,,,B,,
3178,Rattus norvegicus,,CHEMBL617706,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,,12801,,104698,,,BAO_0000223,,Autocuration,,10116.0,B,,
3179,,,CHEMBL617707,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),,15194,,104698,,,BAO_0000219,,Autocuration,,,B,,NG108-15
3180,,,CHEMBL617708,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,,15194,,104698,,,BAO_0000219,,Autocuration,,,B,,NG108-15
3181,,,CHEMBL617709,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,,15194,,104698,,,BAO_0000019,,Autocuration,,,B,,
3182,,,CHEMBL617710,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,,15194,,104698,,,BAO_0000019,,Autocuration,,,B,,
3183,,,CHEMBL882925,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,,15194,,104698,,,BAO_0000019,,Autocuration,,,B,,
3184,,,CHEMBL617711,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,,15194,,104698,,,BAO_0000019,,Autocuration,,,B,,
3185,,,CHEMBL617712,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,,10610,,104698,,,BAO_0000019,,Autocuration,,,F,,
3186,Rattus norvegicus,,CHEMBL617713,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,,10355,,104698,,,BAO_0000019,,Autocuration,,10116.0,F,,
3187,,,CHEMBL617714,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",,691,,104698,,,BAO_0000019,,Autocuration,,,F,,
3188,,,CHEMBL617715,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,,10611,,104698,,,BAO_0000218,,Autocuration,,,F,,
3189,,,CHEMBL617716,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,In vivo,12801,,104698,,,BAO_0000218,,Autocuration,,,F,,
3190,,,CHEMBL617717,Inhibition of 5-HT evoked reflex bradycardia in rat.,,10609,,104698,,,BAO_0000218,,Autocuration,,,F,,
3191,,,CHEMBL617718,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,In vivo,11454,,104698,,,BAO_0000218,,Autocuration,,,F,,
3192,,,CHEMBL617719,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,In vivo,11454,,104698,,,BAO_0000218,,Autocuration,,,F,,
3193,,,CHEMBL617720,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),In vivo,11454,,104698,,,BAO_0000218,,Autocuration,,,F,,
3194,Rattus norvegicus,,CHEMBL617721,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,In vivo,11454,,104698,,,BAO_0000218,,Autocuration,,10116.0,F,,
3195,,,CHEMBL617722,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,In vivo,11454,,104698,,,BAO_0000218,,Autocuration,,,F,,
3196,,,CHEMBL617723,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,In vivo,11454,,104698,,,BAO_0000218,,Autocuration,,,F,,
3197,,,CHEMBL617724,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,In vivo,11454,,104698,,,BAO_0000218,,Autocuration,,,F,,
3198,,,CHEMBL617725,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,In vivo,11454,,104698,,,BAO_0000218,,Autocuration,,,F,,
3199,,,CHEMBL617726,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,In vivo,11454,,104698,,,BAO_0000218,,Autocuration,,,F,,
3200,,,CHEMBL617727,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,In vivo,11454,,104698,,,BAO_0000218,,Autocuration,,,F,,
3201,,,CHEMBL617728,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,In vivo,11454,,104698,,,BAO_0000218,,Autocuration,,,F,,
3202,,,CHEMBL617729,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,In vivo,11454,,104698,,,BAO_0000218,,Autocuration,,,F,,
3203,,,CHEMBL617730,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,In vivo,11454,,104698,,,BAO_0000218,,Autocuration,,,F,,
3204,,,CHEMBL617731,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,In vivo,11454,,104698,,,BAO_0000218,,Autocuration,,,F,,
3205,,,CHEMBL617732,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,In vivo,11454,,104698,,,BAO_0000218,,Autocuration,,,F,,
3206,,,CHEMBL617733,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,In vivo,11454,,104698,,,BAO_0000218,,Autocuration,,,F,,
3207,,,CHEMBL617734,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,In vivo,11454,,104698,,,BAO_0000218,,Autocuration,,,F,,
3208,,,CHEMBL872874,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,In vivo,11454,,104698,,,BAO_0000218,,Autocuration,,,F,,
3209,,,CHEMBL617735,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,In vivo,11454,,104698,,,BAO_0000218,,Autocuration,,,F,,
3210,,,CHEMBL617736,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,In vivo,11454,,104698,,,BAO_0000218,,Autocuration,,,F,,
3211,,,CHEMBL617737,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,In vivo,11454,,104698,,,BAO_0000218,,Autocuration,,,F,,
3212,,,CHEMBL617738,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,In vivo,11454,,104698,,,BAO_0000218,,Autocuration,,,F,,
3213,,,CHEMBL617739,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,In vivo,11454,,104698,,,BAO_0000218,,Autocuration,,,F,,
3214,,,CHEMBL617740,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,In vivo,11454,,104698,,,BAO_0000218,,Autocuration,,,F,,
3215,,,CHEMBL617741,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,In vivo,11454,,104698,,,BAO_0000218,,Autocuration,,,F,,
3216,,,CHEMBL617742,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,In vivo,11454,,104698,,,BAO_0000218,,Autocuration,,,F,,
3217,,,CHEMBL617743,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,In vivo,11454,,104698,,,BAO_0000218,,Autocuration,,,F,,
3218,,,CHEMBL617744,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,In vivo,11454,,104698,,,BAO_0000218,,Autocuration,,,F,,
3219,,,CHEMBL617745,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,In vivo,11454,,104698,,,BAO_0000218,,Autocuration,,,F,,
3220,,,CHEMBL617746,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",,670,,104698,,,BAO_0000218,,Autocuration,,,F,,
3221,,,CHEMBL617747,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",,670,,104698,,,BAO_0000218,,Autocuration,,,F,,
3222,,,CHEMBL617748,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,In vivo,10321,,104698,,,BAO_0000218,,Autocuration,,,F,,
3223,,,CHEMBL618909,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,In vivo,10321,,104698,,,BAO_0000218,,Autocuration,,,F,,
3224,,,CHEMBL618910,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,In vivo,10321,,104698,,,BAO_0000218,,Autocuration,,,F,,
3225,,,CHEMBL618911,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,In vivo,10321,,104698,,,BAO_0000218,,Autocuration,,,F,,
3226,,,CHEMBL618912,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,In vivo,10321,,104698,,,BAO_0000218,,Autocuration,,,F,,
3227,,,CHEMBL618913,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),In vivo,10322,,104698,,,BAO_0000218,,Autocuration,,,F,,
3228,,,CHEMBL618914,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,15412,,104698,,,BAO_0000019,,Autocuration,,,F,,
3229,,,CHEMBL618915,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,15412,,104698,,,BAO_0000019,,Autocuration,,,F,,
3230,Rattus norvegicus,,CHEMBL618916,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,,15412,,104698,,,BAO_0000223,,Autocuration,,10116.0,B,,
3231,,,CHEMBL618917,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,,15412,,104698,,,BAO_0000019,,Autocuration,,,F,,
3232,,10000000.0,CHEMBL618918,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,,15412,Hippocampus,104698,,,BAO_0000221,,Intermediate,,,B,,
3233,Rattus norvegicus,,CHEMBL618919,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,,15412,,104698,,,BAO_0000019,,Autocuration,,10116.0,B,,
3234,Rattus norvegicus,,CHEMBL618920,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,,17394,,104698,,,BAO_0000019,,Autocuration,,10116.0,B,,
3235,,,CHEMBL618921,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,,12457,,104698,,,BAO_0000223,,Autocuration,,,B,,
3236,,,CHEMBL618922,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,,12457,,104698,,,BAO_0000019,,Autocuration,,,B,,
3237,,,CHEMBL618923,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,,12205,,104698,,,BAO_0000019,,Autocuration,,,B,,
3238,,,CHEMBL618924,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,,14532,,104698,,,BAO_0000019,,Autocuration,,,B,,
3239,,,CHEMBL618925,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,,1122,,104698,,,BAO_0000019,,Autocuration,,,B,,
3240,,,CHEMBL618926,Binding affinity towards 5-HT3 receptor in rat was evaluated,,5094,,104698,,,BAO_0000019,,Autocuration,,,B,,
3241,Cavia porcellus,2116.0,CHEMBL618927,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,,809,Ileum,20033,,,BAO_0000221,,Intermediate,,10141.0,F,,
3242,Cavia porcellus,2116.0,CHEMBL618928,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,,809,Ileum,20033,,,BAO_0000221,,Intermediate,,10141.0,F,,
3243,Cavia porcellus,2116.0,CHEMBL618929,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",,14290,Ileum,20033,,,BAO_0000221,,Intermediate,,10141.0,F,,
3244,Cavia porcellus,2116.0,CHEMBL618930,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",,14290,Ileum,20033,,,BAO_0000221,,Intermediate,,10141.0,F,,
3245,Cavia porcellus,2116.0,CHEMBL618931,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,14290,Ileum,20033,,,BAO_0000221,,Intermediate,,10141.0,F,,
3246,Cavia porcellus,2116.0,CHEMBL619594,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,14290,Ileum,20033,,,BAO_0000221,,Intermediate,,10141.0,F,,
3247,Cavia porcellus,2116.0,CHEMBL619595,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",,14290,Ileum,20033,,,BAO_0000221,,Intermediate,,10141.0,F,,
3248,Cavia porcellus,2116.0,CHEMBL619596,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,,13961,Ileum,20033,,,BAO_0000221,,Intermediate,,10141.0,F,,
3249,Cavia porcellus,2116.0,CHEMBL619755,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,,13961,Ileum,20033,,,BAO_0000221,,Intermediate,,10141.0,F,,
3250,Cavia porcellus,2116.0,CHEMBL619756,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,,809,Ileum,20033,,,BAO_0000221,,Intermediate,,10141.0,F,,
3251,Cavia porcellus,2116.0,CHEMBL619757,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,,809,Ileum,20033,,,BAO_0000221,,Intermediate,,10141.0,F,,
3252,Cavia porcellus,2116.0,CHEMBL619758,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,,809,Ileum,20033,,,BAO_0000221,,Intermediate,,10141.0,F,,
3253,Cavia porcellus,2116.0,CHEMBL619759,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",,14290,Ileum,20033,,,BAO_0000221,,Intermediate,,10141.0,F,,
3254,Cavia porcellus,2116.0,CHEMBL619760,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",,14290,Ileum,20033,,,BAO_0000221,,Intermediate,,10141.0,F,,
3255,Cavia porcellus,2116.0,CHEMBL619761,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",,14290,Ileum,20033,,,BAO_0000221,,Intermediate,,10141.0,F,,
3256,Cavia porcellus,2116.0,CHEMBL619762,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,,14290,Ileum,20033,,,BAO_0000221,,Intermediate,,10141.0,F,,
3257,Cavia porcellus,2116.0,CHEMBL619763,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,14290,Ileum,20033,,,BAO_0000221,,Intermediate,,10141.0,F,,
3258,Cavia porcellus,2116.0,CHEMBL617868,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,14290,Ileum,20033,,,BAO_0000221,,Intermediate,,10141.0,F,,
3259,Cavia porcellus,,CHEMBL617869,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,,15034,,20033,,,BAO_0000357,,Intermediate,,10141.0,B,,
3260,Cavia porcellus,2435.0,CHEMBL882926,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,5094,Striatum,20033,,,BAO_0000249,,Intermediate,,10141.0,B,,
3261,Cavia porcellus,2435.0,CHEMBL617870,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,5094,Striatum,20033,,,BAO_0000249,,Intermediate,,10141.0,B,,
3262,Cavia porcellus,2435.0,CHEMBL617871,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,,5399,Striatum,20033,,,BAO_0000357,,Intermediate,,10141.0,B,,
3263,Cavia porcellus,2435.0,CHEMBL617872,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,,17394,Striatum,20033,,,BAO_0000357,,Intermediate,,10141.0,B,,
3264,Cavia porcellus,2435.0,CHEMBL617873,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,17394,Striatum,20033,,,BAO_0000357,,Intermediate,,10141.0,B,,
3265,Cavia porcellus,2435.0,CHEMBL617874,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,17394,Striatum,20033,,,BAO_0000357,,Intermediate,,10141.0,B,,
3266,Cavia porcellus,2116.0,CHEMBL619067,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,,13961,Ileum,20033,,,BAO_0000221,,Intermediate,,10141.0,F,,
3267,Cavia porcellus,2116.0,CHEMBL619068,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,,13961,Ileum,20033,,,BAO_0000221,,Intermediate,,10141.0,F,,
3268,Cavia porcellus,2116.0,CHEMBL619069,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,13961,Ileum,20033,,,BAO_0000221,,Intermediate,,10141.0,F,,
3269,Cavia porcellus,,CHEMBL619070,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,,16946,,20033,,,BAO_0000357,,Intermediate,,10141.0,B,,
3270,Cavia porcellus,,CHEMBL619071,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,,16946,,20033,,,BAO_0000357,,Intermediate,,10141.0,B,,
3271,Cavia porcellus,,CHEMBL619072,Agonistic activity against 5-hydroxytryptamine 4 receptor,,15034,,20033,,,BAO_0000019,,Intermediate,,10141.0,F,,
3272,Cavia porcellus,,CHEMBL619073,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,,15034,,20033,,,BAO_0000019,,Intermediate,,10141.0,F,,
3273,Cavia porcellus,,CHEMBL619074,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,,12918,,20033,,,BAO_0000019,,Intermediate,,10141.0,F,,
3274,Cavia porcellus,,CHEMBL619075,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,,16946,,20033,,,BAO_0000357,,Intermediate,,10141.0,B,,
3275,Cavia porcellus,2435.0,CHEMBL619076,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,,17394,Striatum,20033,,,BAO_0000357,,Intermediate,,10141.0,B,,
3276,Cavia porcellus,2435.0,CHEMBL619077,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,,15034,Striatum,20033,,,BAO_0000357,,Intermediate,,10141.0,B,,
3277,Cavia porcellus,2435.0,CHEMBL619078,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,5094,Striatum,20033,,,BAO_0000249,,Intermediate,,10141.0,B,,
3278,Cavia porcellus,2435.0,CHEMBL619079,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,5094,Striatum,20033,,,BAO_0000249,,Intermediate,,10141.0,B,,
3279,Cavia porcellus,2116.0,CHEMBL619080,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,,17358,Ileum,20033,,,BAO_0000221,,Intermediate,,10141.0,B,,
3280,Cavia porcellus,,CHEMBL619081,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,,12953,,20033,,,BAO_0000357,,Expert,,10141.0,B,,
3281,Cavia porcellus,,CHEMBL619082,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,12953,,20033,,,BAO_0000357,,Intermediate,,10141.0,B,,
3282,Cavia porcellus,,CHEMBL619083,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,,12953,,20033,,,BAO_0000357,,Intermediate,,10141.0,B,,
3283,Cavia porcellus,,CHEMBL619084,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,12953,,20033,,,BAO_0000357,,Intermediate,,10141.0,B,,
3284,Cavia porcellus,2116.0,CHEMBL859397,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,273,Ileum,20033,,,BAO_0000221,,Intermediate,,10141.0,F,,
3285,Cavia porcellus,2116.0,CHEMBL619085,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,,12918,Ileum,20033,,,BAO_0000221,,Intermediate,,10141.0,F,,
3286,Cavia porcellus,2116.0,CHEMBL619086,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,,12919,Ileum,20033,,,BAO_0000221,,Intermediate,,10141.0,F,,
3287,Cavia porcellus,2116.0,CHEMBL619087,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,,273,Ileum,20033,,,BAO_0000221,,Intermediate,,10141.0,F,,
3288,Cavia porcellus,2116.0,CHEMBL619088,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,273,Ileum,20033,,,BAO_0000221,,Intermediate,,10141.0,F,,
3289,Cavia porcellus,,CHEMBL619089,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,,13181,,20033,,,BAO_0000357,,Intermediate,,10141.0,B,,
3290,Cavia porcellus,,CHEMBL619090,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,,13181,,168,,,BAO_0000357,,Autocuration,,10141.0,B,,
3291,Cavia porcellus,,CHEMBL619091,Antagonistic activity against 5-hydroxytryptamine 4 receptor,,15034,,20033,,,BAO_0000019,,Intermediate,,10141.0,F,,
3292,Cavia porcellus,,CHEMBL619092,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,,5033,,20033,,,BAO_0000357,,Intermediate,,10141.0,B,,
3293,Cavia porcellus,,CHEMBL619093,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,,1980,,20033,,,BAO_0000019,,Intermediate,,10141.0,B,,
3294,Cavia porcellus,,CHEMBL619094,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,,13181,,168,,,BAO_0000219,,Autocuration,,10141.0,B,,HEK293
3295,Cavia porcellus,,CHEMBL619095,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,,14287,,20033,,,BAO_0000019,,Intermediate,,10141.0,B,,
3296,Cavia porcellus,,CHEMBL857988,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,,1317,,20033,,,BAO_0000357,,Intermediate,,10141.0,B,,
3297,Cavia porcellus,,CHEMBL619096,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,,15316,,20033,,,BAO_0000357,,Intermediate,,10141.0,B,,
3298,Cavia porcellus,2435.0,CHEMBL619097,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,,16429,Striatum,20033,,,BAO_0000357,,Intermediate,,10141.0,B,,
3299,Cavia porcellus,10000000.0,CHEMBL619098,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,,14818,Hippocampus,20033,,,BAO_0000221,,Intermediate,,10141.0,B,,
3300,Cavia porcellus,,CHEMBL619751,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,,15194,,20033,,,BAO_0000357,,Intermediate,,10141.0,B,,
3301,Cavia porcellus,,CHEMBL619752,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,,15194,,20033,,,BAO_0000357,,Intermediate,,10141.0,B,,
3302,Cavia porcellus,2116.0,CHEMBL875096,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,13961,Ileum,20033,,,BAO_0000221,,Intermediate,,10141.0,F,,
3303,,,CHEMBL619004,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,,5486,,108,,,BAO_0000357,,Autocuration,,,B,,
3304,,,CHEMBL619005,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,,16209,,168,,,BAO_0000357,,Autocuration,,,B,,
3305,,,CHEMBL619006,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,,17085,,168,,,BAO_0000019,,Autocuration,,,B,,
3306,,,CHEMBL619007,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,,4199,,168,,,BAO_0000219,,Autocuration,,,B,,HeLa
3307,,,CHEMBL619008,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,,15146,,168,,,BAO_0000357,,Autocuration,,,B,,
3308,,,CHEMBL619009,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,,5213,,168,,,BAO_0000357,,Autocuration,,,B,,
3309,,,CHEMBL619010,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",,4829,,168,,,BAO_0000219,,Autocuration,,,B,,HeLa
3310,,,CHEMBL619011,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,,17358,,10622,,,BAO_0000357,,Autocuration,,,B,,
3311,,,CHEMBL619012,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,,17358,,10622,,,BAO_0000357,,Autocuration,,,B,,
3312,,,CHEMBL619013,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,,16946,,10622,,,BAO_0000219,,Autocuration,,,B,,
3313,,,CHEMBL619014,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,,17358,,10622,,,BAO_0000357,,Autocuration,,,B,,
3314,,2081.0,CHEMBL857503,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,,268,Cardiac atrium,11249,,,BAO_0000019,,Autocuration,,,F,,
3315,,2081.0,CHEMBL619015,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,,268,Cardiac atrium,11249,,,BAO_0000019,,Autocuration,,,F,,
3316,,,CHEMBL619016,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,,15086,,11249,,,BAO_0000357,,Autocuration,,,B,,
3317,,10000000.0,CHEMBL619017,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,,14875,Hippocampus,11249,,,BAO_0000221,,Autocuration,,,B,,
3318,Sus scrofa,10000000.0,CHEMBL619018,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,,13267,Hippocampus,168,,,BAO_0000221,,Autocuration,,9823.0,B,,
3319,Oryctolagus cuniculus,,CHEMBL619019,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,,13047,,168,,,BAO_0000019,,Autocuration,,9986.0,B,,
3320,Rattus norvegicus,,CHEMBL619020,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,,1650,,10623,,,BAO_0000357,,Expert,,10116.0,B,,
3321,,,CHEMBL619021,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,567,,10623,,,BAO_0000019,,Autocuration,,,F,,
3322,,,CHEMBL619022,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,,17358,,10623,,,BAO_0000357,,Autocuration,,,B,,
3323,,,CHEMBL619023,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,,188,,10623,,,BAO_0000357,,Autocuration,,,B,,
3324,,,CHEMBL619024,lntrinsic activity relative to 5-HT receptor,,670,,10623,,,BAO_0000019,,Autocuration,,,F,,
3325,,,CHEMBL619025,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,,204,,10623,,,BAO_0000019,,Autocuration,,,F,,
3326,,,CHEMBL619026,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,,1946,,10623,,,BAO_0000019,,Expert,,,F,,
3327,,,CHEMBL619027,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,,6398,,10623,,,BAO_0000019,,Autocuration,,,F,,
3328,,,CHEMBL619028,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,,6398,,10623,,,BAO_0000019,,Autocuration,,,F,,
3329,,,CHEMBL619029,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,,17358,,10623,,,BAO_0000019,,Autocuration,,,F,,
3330,,,CHEMBL619030,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,,6398,,10623,,,BAO_0000019,,Autocuration,,,F,,
3331,,,CHEMBL619031,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,,11752,,10623,,,BAO_0000357,,Expert,,,B,,
3332,,,CHEMBL619032,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,,809,,10623,,,BAO_0000019,,Autocuration,,,F,,
3333,Rattus norvegicus,,CHEMBL619033,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,,14178,,10623,,,BAO_0000357,,Expert,,10116.0,B,,
3334,,,CHEMBL619034,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,567,,10623,,,BAO_0000357,,Autocuration,,,B,,
3335,,,CHEMBL619035,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,,1946,,10623,,,BAO_0000357,,Autocuration,,,B,,
3336,,,CHEMBL619036,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,,1946,,10623,,,BAO_0000357,,Autocuration,,,B,,
3337,Rattus norvegicus,,CHEMBL619037,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,,13961,,10623,,,BAO_0000019,,Expert,,10116.0,B,,
3338,,2435.0,CHEMBL619038,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,,6238,Striatum,10623,,,BAO_0000249,,Autocuration,,,B,,
3339,,,CHEMBL619039,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,,14290,,10623,,,BAO_0000249,,Autocuration,,,B,,
3340,,,CHEMBL619040,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,,14290,,10623,,,BAO_0000249,,Expert,,,B,,
3341,Rattus norvegicus,2435.0,CHEMBL619041,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,809,Striatum,10623,,,BAO_0000019,,Expert,,10116.0,B,,
3342,,2435.0,CHEMBL619042,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,1578,Striatum,10623,,,BAO_0000019,,Autocuration,,,B,,
3343,,2435.0,CHEMBL619043,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,,16709,Striatum,10623,,,BAO_0000249,,Expert,,,B,,
3344,,2435.0,CHEMBL619044,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,,1946,Striatum,10623,,,BAO_0000019,,Expert,,,B,,
3345,,2435.0,CHEMBL619045,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,,15253,Striatum,10623,,,BAO_0000249,,Expert,,,B,,
3346,,2435.0,CHEMBL619046,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,,4535,Striatum,10623,,,BAO_0000249,,Expert,,,B,,
3347,,,CHEMBL619047,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,,13961,,10623,,,BAO_0000249,,Expert,,,B,,
3348,,955.0,CHEMBL619048,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,,17358,Brain,10623,,,BAO_0000221,,Autocuration,,,F,,
3349,,,CHEMBL859398,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,,15847,,10623,,,BAO_0000019,,Autocuration,,,F,,
3350,,,CHEMBL619049,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,,15847,,10623,,,BAO_0000019,,Autocuration,,,F,,
3351,,,CHEMBL857886,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,,670,,10623,,,BAO_0000019,,Autocuration,,,F,,
3352,,,CHEMBL619050,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,,670,,10623,,,BAO_0000019,,Autocuration,,,F,,
3353,,,CHEMBL620591,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,1317,,10623,,,BAO_0000019,,Autocuration,,,F,,
3354,Rattus norvegicus,,CHEMBL620592,Binding affinity against rat 5-hydroxytryptamine 4 receptor,,12936,,10623,,,BAO_0000357,,Expert,,10116.0,B,,
3355,,2435.0,CHEMBL620593,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,,4535,Striatum,10623,,,BAO_0000249,,Expert,,,B,,
3356,Rattus norvegicus,,CHEMBL620594,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,,14424,,10623,,,BAO_0000019,,Expert,,10116.0,F,,
3357,,,CHEMBL875079,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,,14424,,10623,,,BAO_0000019,,Expert,,,F,,
3358,,,CHEMBL620595,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,14424,,10623,,,BAO_0000019,,Expert,,,F,,
3359,Rattus norvegicus,,CHEMBL620596,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,,14424,,10623,,,BAO_0000019,,Expert,,10116.0,F,,
3360,,,CHEMBL620597,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,,14424,,10623,,,BAO_0000019,,Autocuration,,,F,,
3361,,,CHEMBL620598,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,,14424,,10623,,,BAO_0000019,,Expert,,,F,,
3362,,,CHEMBL620599,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),,14424,,10623,,,BAO_0000218,,Expert,,,F,,
3363,,,CHEMBL620600,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,14424,,10623,,,BAO_0000019,,Autocuration,,,F,,
3364,Rattus norvegicus,,CHEMBL620601,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,,1980,,168,,,BAO_0000019,,Autocuration,,10116.0,F,,
3365,,,CHEMBL620602,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,,4639,,168,,,BAO_0000019,,Autocuration,,,F,,
3366,,,CHEMBL620603,Tested for affinity towards 5-hydroxytryptamine 4 receptor,,17358,,168,,,BAO_0000357,,Autocuration,,,B,,
3367,,,CHEMBL620604,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,,17358,,168,,,BAO_0000357,,Autocuration,,,B,,
3368,,,CHEMBL620605,Compound was tested for 5-hydroxytryptamine 4 binding affinity,,17358,,168,,,BAO_0000357,,Autocuration,,,B,,
3369,,,CHEMBL620606,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,,1558,,168,,,BAO_0000357,,Autocuration,,,B,,
3370,,,CHEMBL620607,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,17358,,168,,,BAO_0000019,,Autocuration,,,F,,
3371,,,CHEMBL620608,In vitro binding affinity towards 5-HT4 receptor was determined,,16117,,168,,,BAO_0000357,,Autocuration,,,B,,
3372,,,CHEMBL620609,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,17358,,168,,,BAO_0000019,,Autocuration,,,F,,
3373,,,CHEMBL620610,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,,17358,,168,,,BAO_0000019,,Autocuration,,,F,,
3374,,,CHEMBL620611,Tested for selectivity for 5-hydroxytryptamine 4 receptor,,17358,,168,,,BAO_0000357,,Autocuration,,,B,,
3375,,,CHEMBL620612,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,,17358,,168,,,BAO_0000357,,Autocuration,,,B,,
3376,,,CHEMBL620613,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,,17358,,168,,,BAO_0000357,,Autocuration,,,B,,
3377,,,CHEMBL620614,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,,17358,,168,,,BAO_0000357,,Autocuration,,,B,,
3378,,,CHEMBL620615,Binding affinity against 5-Hydroxytryptamine 4 receptor,,1274,,168,,,BAO_0000357,,Expert,,,B,,
3379,,,CHEMBL857075,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,,10728,,104698,,,BAO_0000249,,Autocuration,Brain membranes,,B,,
3380,,,CHEMBL620616,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,,11695,,104698,,,BAO_0000249,,Autocuration,Brain membranes,,B,,
3381,,,CHEMBL619411,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,,11695,,104698,,,BAO_0000249,,Autocuration,Brain membranes,,B,,
3382,,,CHEMBL619412,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,,12490,,104698,,,BAO_0000019,,Autocuration,,,B,,
3383,Rattus norvegicus,,CHEMBL619413,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,,11828,,104698,,,BAO_0000019,,Autocuration,,10116.0,B,,
3384,,10000000.0,CHEMBL619414,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,,12253,Hippocampus,104698,,,BAO_0000221,,Autocuration,,,B,,
3385,,,CHEMBL619415,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,10561,,104698,,,BAO_0000019,,Autocuration,,,B,,
3386,,,CHEMBL619416,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,,10561,,104698,,,BAO_0000019,,Autocuration,,,B,,
3387,,,CHEMBL619417,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,,14432,,104698,,,BAO_0000019,,Autocuration,,,F,,
3388,Rattus norvegicus,,CHEMBL619418,Binding affinity against rat 5-hydroxytryptamine 3 receptor,,12936,,104698,,,BAO_0000223,,Autocuration,,10116.0,B,,
3389,Rattus norvegicus,,CHEMBL619419,Binding affinity against 5-Hydroxytryptamine 3 receptor,,1274,,104698,,,BAO_0000223,,Autocuration,,10116.0,B,,
3390,,,CHEMBL619420,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,,1980,,104698,,,BAO_0000019,,Autocuration,,,B,,
3391,,,CHEMBL619421,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,,670,,104698,,,BAO_0000249,,Autocuration,,,B,,
3392,Rattus norvegicus,,CHEMBL619422,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,,968,,104698,,,BAO_0000019,,Autocuration,,10116.0,B,,
3393,,,CHEMBL619423,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,,14287,,104698,,,BAO_0000019,,Autocuration,,,B,,
3394,,,CHEMBL875080,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,,567,,104698,,,BAO_0000019,,Autocuration,,,B,,
3395,,,CHEMBL619424,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,,13267,,104698,,,BAO_0000019,,Autocuration,,,B,,
3396,,,CHEMBL619425,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,,14826,,104698,,,BAO_0000249,,Autocuration,,,B,,
3397,,,CHEMBL619426,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,,15194,,104698,,,BAO_0000223,,Autocuration,,,B,,
3398,,,CHEMBL619427,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,,15194,,104698,,,BAO_0000223,,Autocuration,,,B,,
3399,Rattus norvegicus,,CHEMBL619645,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,,10394,,104698,,,BAO_0000223,,Autocuration,,10116.0,B,,
3400,,,CHEMBL619646,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",,13657,,10576,,,BAO_0000249,,Expert,,,B,,
3401,,955.0,CHEMBL619647,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,,1879,Brain,12020,,,BAO_0000221,,Autocuration,,,F,,
3402,,,CHEMBL619648,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,,1879,,12020,,,BAO_0000019,,Autocuration,,,F,,
3403,,,CHEMBL619165,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,,1879,,12020,,,BAO_0000019,,Autocuration,,,F,,
3404,,,CHEMBL620719,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,In vivo,204,,12020,,,BAO_0000218,,Autocuration,,,F,,
3405,,,CHEMBL872924,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,1879,,12020,,,BAO_0000019,,Autocuration,,,B,,
3406,,,CHEMBL620720,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,,1879,,12020,,,BAO_0000357,,Autocuration,,,B,,
3407,,,CHEMBL620721,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,1879,,12020,,,BAO_0000019,,Autocuration,,,B,,
3408,,,CHEMBL620722,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,,1879,,12020,,,BAO_0000019,,Autocuration,,,B,,
3409,,,CHEMBL620723,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",,10641,,104698,,,BAO_0000019,,Autocuration,,,B,,
3410,,,CHEMBL620724,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,773,,12020,,,BAO_0000019,,Autocuration,,,B,,
3411,,,CHEMBL620725,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,,11952,,104698,,,BAO_0000249,,Autocuration,,,B,,
3412,Rattus norvegicus,,CHEMBL620726,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,,14145,,12020,,,BAO_0000019,,Autocuration,,10116.0,F,,
3413,,,CHEMBL620727,Binding affinity towards 5-hydroxytryptamine 3 receptor,,17066,,144,,,BAO_0000357,,Expert,,,B,,
3414,,,CHEMBL620728,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,,6398,,104714,,,BAO_0000223,,Autocuration,,,B,,
3415,,,CHEMBL620729,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,10321,,22226,,,BAO_0000019,,Autocuration,,,B,,
3416,,,CHEMBL858288,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,,511,,104714,,,BAO_0000019,,Autocuration,,,F,,
3417,,,CHEMBL620730,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,,4639,,104714,,,BAO_0000223,,Autocuration,,,B,,
3418,,,CHEMBL620731,Binding affinity towards 5-hydroxytryptamine 3 receptor,,4639,,104714,,,BAO_0000223,,Autocuration,,,B,,
3419,Cavia porcellus,,CHEMBL620732,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,,4639,,104714,,,BAO_0000019,,Autocuration,,10141.0,F,,
3420,Cavia porcellus,,CHEMBL618042,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,4639,,104714,,,BAO_0000019,,Autocuration,,10141.0,F,,
3421,Cavia porcellus,,CHEMBL618043,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,,4639,,104714,,,BAO_0000019,,Autocuration,,10141.0,F,,
3422,,,CHEMBL618044,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,1558,,104714,,,BAO_0000223,,Autocuration,,,B,,
3423,,,CHEMBL618045,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,,268,,104714,,,BAO_0000019,,Autocuration,,,F,,
3424,,,CHEMBL618046,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,,2474,,104714,,,BAO_0000223,,Autocuration,,,B,,
3425,,,CHEMBL618047,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,,5067,,104714,,,BAO_0000019,,Autocuration,,,F,,
3426,,,CHEMBL875084,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,,5067,,104714,,,BAO_0000019,,Autocuration,,,F,,
3427,,,CHEMBL618048,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,,5067,,104714,,,BAO_0000019,,Autocuration,,,F,,
3428,,,CHEMBL618049,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,,5067,,104714,,,BAO_0000223,,Autocuration,,,B,,
3429,,,CHEMBL619764,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,,5067,,104714,,,BAO_0000019,,Autocuration,,,F,,
3430,,,CHEMBL619765,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,,5067,,104714,,,BAO_0000019,,Autocuration,,,F,,
3431,,,CHEMBL619766,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,,5067,,104714,,,BAO_0000019,,Autocuration,,,F,,
3432,,,CHEMBL619767,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,,5067,,104714,,,BAO_0000223,,Autocuration,,,B,,
3433,,,CHEMBL619768,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,,5067,,104714,,,BAO_0000223,,Autocuration,,,B,,
3434,,,CHEMBL619769,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,,5067,,104714,,,BAO_0000019,,Autocuration,,,F,,
3435,,,CHEMBL619770,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,,5067,,104714,,,BAO_0000223,,Autocuration,,,B,,
3436,,,CHEMBL619771,Binding affinity towards 5-hydroxytryptamine 3 receptor,,5067,,104714,,,BAO_0000223,,Autocuration,,,B,,
3437,,,CHEMBL619772,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,,14331,,104714,,,BAO_0000219,,Autocuration,,,B,,
3438,,,CHEMBL619773,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,,5067,,104714,,,BAO_0000223,,Autocuration,,,B,,
3439,,,CHEMBL619774,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,,6179,,104714,,,BAO_0000219,,Autocuration,,,B,,NG108-15
3440,,,CHEMBL875083,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,,4265,,104714,,,BAO_0000019,,Autocuration,,,B,,
3441,,,CHEMBL620718,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,,4265,,104714,,,BAO_0000219,,Autocuration,,,B,,NG108-15
3442,,,CHEMBL618127,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,17358,,104714,,,BAO_0000223,,Autocuration,,,B,,
3443,,,CHEMBL618128,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,,17358,,104714,,,BAO_0000223,,Autocuration,,,B,,
3444,,,CHEMBL618129,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,In vitro,13628,,104714,,,BAO_0000219,,Autocuration,,,B,,
3445,,,CHEMBL618130,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,4612,,104714,,,BAO_0000223,,Autocuration,,,B,,
3446,,,CHEMBL618131,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,,17358,,104714,,,BAO_0000019,,Autocuration,,,F,,
3447,Cavia porcellus,,CHEMBL618132,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,,4639,,104714,,,BAO_0000019,,Autocuration,,10141.0,F,,
3448,Cavia porcellus,,CHEMBL618133,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,,4639,,104714,,,BAO_0000019,,Autocuration,,10141.0,F,,
3449,Cavia porcellus,,CHEMBL618134,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,,4639,,104714,,,BAO_0000019,,Autocuration,,10141.0,F,,
3450,Cavia porcellus,,CHEMBL618135,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,4639,,104714,,,BAO_0000019,,Autocuration,,10141.0,F,,
3451,,,CHEMBL618136,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,,511,,104714,,,BAO_0000223,,Autocuration,,,B,,
3452,,,CHEMBL618137,Binding affinity towards 5-hydroxytryptamine 3 receptor,,1479,,104714,,,BAO_0000223,,Autocuration,,,B,,
3453,,,CHEMBL618138,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,,1317,,104714,,,BAO_0000223,,Autocuration,,,B,,
3454,,,CHEMBL618139,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,,12146,,104714,,,BAO_0000223,,Autocuration,,,B,,
3455,,,CHEMBL618140,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,,12146,,104714,,,BAO_0000223,,Autocuration,,,B,,
3456,,,CHEMBL618141,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,,13969,,104714,,,BAO_0000223,,Autocuration,,,B,,
3457,,,CHEMBL873478,Binding affinity for 5-hydroxytryptamine 2C receptor,,13392,,108,,,BAO_0000357,,Expert,,,B,,
3458,,,CHEMBL618142,Binding affinity towards 5-hydroxytryptamine 3 receptor,,13392,,104698,,,BAO_0000223,,Autocuration,,,B,,
3459,,,CHEMBL618143,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,,14159,,144,,,BAO_0000357,,Autocuration,,,B,,
3460,,,CHEMBL618144,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,1558,,144,,,BAO_0000357,,Autocuration,,,B,,
3461,,,CHEMBL618145,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,,16655,,144,,,BAO_0000357,,Autocuration,,,B,,
3462,,,CHEMBL618146,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,13020,,104714,,,BAO_0000223,,Autocuration,,,B,,
3463,,,CHEMBL618147,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,,13021,,104714,,,BAO_0000223,,Autocuration,,,B,,
3464,,,CHEMBL618148,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,13020,,104714,,,BAO_0000223,,Autocuration,,,B,,
3465,,,CHEMBL618149,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,10321,,144,,,BAO_0000019,,Autocuration,,,B,,
3466,,,CHEMBL872927,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,15818,,144,,,BAO_0000357,,Autocuration,,,B,,
3467,,,CHEMBL618150,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,15818,,144,,,BAO_0000357,,Autocuration,,,B,,
3468,,,CHEMBL618151,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,17358,,144,,,BAO_0000357,,Autocuration,,,B,,
3469,,,CHEMBL875094,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,2222,,144,,,BAO_0000357,,Autocuration,,,B,,
3470,,,CHEMBL618152,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,10322,,144,,,BAO_0000019,,Autocuration,,,B,,
3471,,,CHEMBL618153,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,16117,,144,,,BAO_0000357,,Autocuration,,,B,,
3472,,,CHEMBL618888,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,,17200,,144,,,BAO_0000357,,Autocuration,,,B,,
3473,,,CHEMBL618889,Tested for 5-hydroxytryptamine 3 receptor agonist activity,,17358,,144,,,BAO_0000019,,Autocuration,,,F,,
3474,,,CHEMBL618890,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,,16700,,144,,,BAO_0000357,,Autocuration,,,B,,
3475,,,CHEMBL618891,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,,1980,,144,,,BAO_0000019,,Autocuration,,,B,,
3476,,,CHEMBL619054,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,,1980,,144,,,BAO_0000019,,Autocuration,,,B,,
3477,,,CHEMBL619055,Binding affinity against the 5-hydroxytryptamine 3 receptor,,12409,,104714,,,BAO_0000223,,Autocuration,,,B,,
3478,,,CHEMBL619056,Binding affinity against human 5-hydroxytryptamine 3A receptor,,4365,,144,,,BAO_0000357,,Autocuration,,,B,,
3479,,,CHEMBL619057,Percent efficacy against 5-hydroxytryptamine 3A receptor,,4365,,144,,,BAO_0000019,,Autocuration,,,F,,
3480,,,CHEMBL619058,Binding affinity against human 5-hydroxytryptamine 3A receptor,,4365,,144,,,BAO_0000357,,Autocuration,,,B,,
3481,Rattus norvegicus,,CHEMBL619059,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,,6769,,12020,,,BAO_0000219,,Expert,,10116.0,F,,Oocytes
3482,Rattus norvegicus,,CHEMBL619060,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,,6769,,12020,,,BAO_0000219,,Expert,,10116.0,F,,Oocytes
3483,Rattus norvegicus,,CHEMBL875095,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,,6769,,12020,,,BAO_0000219,,Expert,,10116.0,F,,Oocytes
3484,Cavia porcellus,2116.0,CHEMBL619061,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,,809,Ileum,20033,,,BAO_0000221,,Intermediate,,10141.0,F,,
3485,Cavia porcellus,2116.0,CHEMBL619062,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,,809,Ileum,20033,,,BAO_0000221,,Intermediate,,10141.0,F,,
3486,Cavia porcellus,,CHEMBL619063,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,,14290,,20033,,,BAO_0000019,,Intermediate,,10141.0,F,,
3487,Cavia porcellus,2116.0,CHEMBL619064,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,,17358,Ileum,20033,,,BAO_0000221,,Intermediate,,10141.0,B,,
3488,Cavia porcellus,,CHEMBL619065,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,,17358,,20033,,,BAO_0000357,,Intermediate,,10141.0,B,,
3489,Cavia porcellus,2116.0,CHEMBL619066,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,,17358,Ileum,20033,,,BAO_0000221,,Intermediate,,10141.0,B,,
3490,,2116.0,CHEMBL619775,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,17386,Ileum,10209,,,BAO_0000221,,Autocuration,,,B,,
3491,,,CHEMBL619776,Affinity against 5-hydroxytryptamine 7 receptor,,3269,,10209,,,BAO_0000357,,Autocuration,,,B,,
3492,Cavia porcellus,,CHEMBL619777,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,7721,,104841,,,BAO_0000224,,Autocuration,,10141.0,B,,
3493,Cavia porcellus,,CHEMBL619778,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,7721,,104841,,,BAO_0000224,,Autocuration,,10141.0,B,,
3494,Cavia porcellus,2116.0,CHEMBL619779,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,,9117,Ileum,104841,,,BAO_0000221,,Autocuration,,10141.0,B,,
3495,Cavia porcellus,,CHEMBL619780,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",,7721,,104841,,,BAO_0000224,,Autocuration,,10141.0,B,,
3496,Cavia porcellus,,CHEMBL619166,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",,7721,,104841,,,BAO_0000224,,Autocuration,,10141.0,B,,
3497,Cavia porcellus,,CHEMBL619167,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,15796,,104841,,,BAO_0000019,,Autocuration,,10141.0,F,,
3498,Cavia porcellus,,CHEMBL619168,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,15796,,104841,,,BAO_0000019,,Autocuration,,10141.0,F,,
3499,Homo sapiens,2081.0,CHEMBL619169,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,,15650,Cardiac atrium,168,,,BAO_0000219,,Expert,,9606.0,B,,
3500,Homo sapiens,2081.0,CHEMBL619170,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,,15650,Cardiac atrium,168,,,BAO_0000219,,Expert,,9606.0,B,,
3501,Homo sapiens,,CHEMBL619171,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",,6866,,104841,,,BAO_0000019,,Autocuration,,9606.0,F,,
3502,Homo sapiens,2081.0,CHEMBL619172,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",,15650,Cardiac atrium,168,,,BAO_0000219,,Expert,,9606.0,F,,
3503,Mus musculus,,CHEMBL619173,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,,10063,,22226,,,BAO_0000019,,Autocuration,,10090.0,B,,
3504,Mus musculus,,CHEMBL619174,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,,12665,,22226,,,BAO_0000019,,Autocuration,,10090.0,B,,
3505,,,CHEMBL619175,5-hydroxytryptamine receptor binding affinity was determined in rats,,7504,,104705,,,BAO_0000019,,Autocuration,,,B,,
3506,,,CHEMBL619176,Binding affinity at rat 5-hydroxytryptamine receptor.,,7504,,104705,,,BAO_0000224,,Autocuration,,,B,,
3507,,,CHEMBL619177,Affinity against 5-hydroxytryptamine receptors in rat fundus model,,7038,,104705,,,BAO_0000019,,Autocuration,,,B,,
3508,,,CHEMBL619178,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,,7626,,104705,,,BAO_0000224,,Autocuration,,,B,,
3509,,,CHEMBL619179,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,,7626,,104705,,,BAO_0000224,,Autocuration,,,B,,
3510,,945.0,CHEMBL619180,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,,7185,Stomach,104705,,,BAO_0000019,,Autocuration,,,F,,
3511,,945.0,CHEMBL619181,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,,7185,Stomach,104705,,,BAO_0000019,,Autocuration,,,F,,
3512,,,CHEMBL619182,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,7185,,104705,,,BAO_0000019,,Autocuration,,,F,,
3513,,,CHEMBL619183,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,,6960,,104705,,,BAO_0000224,,Autocuration,,,B,,
3514,,,CHEMBL619184,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",,6960,,104705,,,BAO_0000224,,Autocuration,,,B,,
3515,,10000000.0,CHEMBL619185,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,12416,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
3516,,,CHEMBL619186,Binding affinity for rat 5-hydroxytryptamine transporter.,,15753,,12198,,,BAO_0000357,,Expert,,,B,,
3517,,,CHEMBL619187,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,,8062,,104705,,,BAO_0000019,,Autocuration,,,B,,
3518,Rattus norvegicus,,CHEMBL619188,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,,9036,,104705,,,BAO_0000019,,Autocuration,,10116.0,B,,
3519,Rattus norvegicus,,CHEMBL619189,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,,15067,,104705,,,BAO_0000224,,Autocuration,,10116.0,B,,
3520,Rattus norvegicus,955.0,CHEMBL619190,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,,15753,Brain,12198,,,BAO_0000019,,Expert,,10116.0,F,,
3521,Rattus norvegicus,2037.0,CHEMBL619191,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,,15753,Cerebellum,12198,,,BAO_0000221,,Expert,,10116.0,F,,
3522,Rattus norvegicus,,CHEMBL619192,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,,15295,,104705,,,BAO_0000019,,Autocuration,,10116.0,B,,
3523,Rattus norvegicus,,CHEMBL619193,Percent binding affinity against 5-hydroxytryptamine receptor,,6347,,104705,,,BAO_0000224,,Autocuration,,10116.0,B,,
3524,,,CHEMBL619194,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,,6763,,22226,,,BAO_0000019,,Autocuration,,,B,,
3525,Rattus norvegicus,,CHEMBL619195,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,,12092,,104705,,,BAO_0000224,,Autocuration,,10116.0,B,,
3526,Rattus norvegicus,,CHEMBL619196,Affinity against 5-hydroxytryptamine receptor was determined,,1579,,104705,,,BAO_0000224,,Autocuration,,10116.0,B,,
3527,Rattus norvegicus,945.0,CHEMBL619197,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,,1579,Stomach,104705,,,BAO_0000019,,Autocuration,,10116.0,B,,
3528,Homo sapiens,,CHEMBL619198,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,In vitro,5963,,121,,,BAO_0000219,,Expert,,9606.0,B,,
3529,Homo sapiens,,CHEMBL875081,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,In vitro,5963,,121,,,BAO_0000219,,Expert,,9606.0,B,,
3530,,,CHEMBL884712,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,,5030,,18065,,,BAO_0000357,,Autocuration,,,B,,
3531,,,CHEMBL884710,Inhibition of 5-hydroxytryptamine reuptake,,15796,,121,,,BAO_0000357,,Expert,,,B,,
3532,,,CHEMBL619199,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",,15413,,18065,,,BAO_0000019,,Autocuration,,,F,,
3533,,,CHEMBL619200,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",,15413,,18065,,,BAO_0000019,,Autocuration,,,F,,
3534,,,CHEMBL619201,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",,15413,,18065,,,BAO_0000019,,Autocuration,,,F,,
3535,,,CHEMBL619202,Tested for 5-hydroxytryptamine receptor uptake,,12409,,18065,,,BAO_0000019,,Autocuration,,,F,,
3536,Homo sapiens,,CHEMBL619203,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,16909,,51,,,BAO_0000219,,Expert,,9606.0,B,,CHO
3537,Homo sapiens,,CHEMBL619204,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,,16909,,51,,,BAO_0000019,,Expert,,9606.0,F,,
3538,Homo sapiens,,CHEMBL619205,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,,15629,,10576,,,BAO_0000249,,Autocuration,,9606.0,B,,
3539,,,CHEMBL619206,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,,15629,,10576,,,BAO_0000357,,Autocuration,,,B,,
3540,,,CHEMBL619207,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,,15629,,10576,,,BAO_0000249,,Expert,,,B,,
3541,,2435.0,CHEMBL619208,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,,10034,Striatum,10825,,,BAO_0000019,,Autocuration,,,F,,
3542,,2435.0,CHEMBL619209,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,,10034,Striatum,10825,,,BAO_0000019,,Autocuration,,,F,,
3543,,2435.0,CHEMBL619210,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,,10034,Striatum,10825,,,BAO_0000019,,Autocuration,,,F,,
3544,,2435.0,CHEMBL619211,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,,10034,Striatum,10825,,,BAO_0000019,,Autocuration,,,F,,
3545,,2435.0,CHEMBL619212,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,,10034,Striatum,10825,,,BAO_0000019,,Autocuration,,,F,,
3546,,2435.0,CHEMBL620681,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,,10034,Striatum,10825,,,BAO_0000019,,Autocuration,,,F,,
3547,,2435.0,CHEMBL620682,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,,10034,Striatum,10825,,,BAO_0000019,,Autocuration,,,F,,
3548,,2435.0,CHEMBL620683,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,,10034,Striatum,10825,,,BAO_0000019,,Autocuration,,,F,,
3549,,2435.0,CHEMBL620684,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,,10034,Striatum,10825,,,BAO_0000019,,Autocuration,,,F,,
3550,,2435.0,CHEMBL620685,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,,10034,Striatum,10825,,,BAO_0000019,,Autocuration,,,F,,
3551,,2435.0,CHEMBL620686,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,,10034,Striatum,10825,,,BAO_0000019,,Autocuration,,,F,,
3552,,349.0,CHEMBL620687,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,,10034,Limbic system,10825,,,BAO_0000019,,Autocuration,,,F,,
3553,,349.0,CHEMBL620688,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,10034,Limbic system,10825,,,BAO_0000019,,Autocuration,,,F,,
3554,,349.0,CHEMBL620689,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,,10034,Limbic system,10825,,,BAO_0000019,,Autocuration,,,F,,
3555,,349.0,CHEMBL620690,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,,10034,Limbic system,10825,,,BAO_0000019,,Autocuration,,,F,,
3556,,349.0,CHEMBL620691,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,,10034,Limbic system,10825,,,BAO_0000019,,Autocuration,,,F,,
3557,,349.0,CHEMBL620692,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,,10034,Limbic system,10825,,,BAO_0000019,,Autocuration,,,F,,
3558,,349.0,CHEMBL620693,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,,10034,Limbic system,10825,,,BAO_0000019,,Autocuration,,,F,,
3559,,,CHEMBL620694,Binding affinity against 5-hydroxytryptamine 4 receptor,,1274,,168,,,BAO_0000357,,Expert,,,B,,
3560,,,CHEMBL857986,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,17358,,168,,,BAO_0000019,,Autocuration,,,F,,
3561,,,CHEMBL620695,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,,14532,,168,,,BAO_0000357,,Autocuration,,,B,,
3562,,,CHEMBL620696,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,,16989,,168,,,BAO_0000357,,Expert,,,B,,
3563,,,CHEMBL620697,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,,17200,,168,,,BAO_0000357,,Autocuration,,,B,,
3564,,,CHEMBL620698,Binding affinity towards 5-hydroxytryptamine 4 receptor,,15779,,168,,,BAO_0000357,,Autocuration,,,B,,
3565,,,CHEMBL620699,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,15779,,168,,,BAO_0000357,,Autocuration,,,B,,
3566,,,CHEMBL620700,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,15779,,168,,,BAO_0000357,,Autocuration,,,B,,
3567,,,CHEMBL620701,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,,15650,,168,,,BAO_0000219,,Autocuration,,,B,,COS-7
3568,,,CHEMBL875082,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,,15650,,168,,,BAO_0000219,,Autocuration,,,B,,COS-7
3569,,,CHEMBL620702,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,,15650,,168,,,BAO_0000219,,Autocuration,,,B,,COS-7
3570,,,CHEMBL620703,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,,15650,,168,,,BAO_0000219,,Autocuration,,,B,,COS-7
3571,,,CHEMBL620704,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,17046,,168,,,BAO_0000219,,Autocuration,,,B,,C6
3572,,,CHEMBL620705,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,17046,,168,,,BAO_0000219,,Expert,,,B,,C6
3573,,,CHEMBL620706,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,,15650,,168,,,BAO_0000219,,Expert,,,B,,C6
3574,,,CHEMBL620707,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,,17046,,168,,,BAO_0000219,,Expert,,,B,,C6
3575,,,CHEMBL620708,Binding affinity towards 5-hydroxytryptamine 5 receptor,,17066,,10624,,,BAO_0000357,,Expert,,,B,,
3576,,,CHEMBL620709,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,,17200,,105,,,BAO_0000357,,Autocuration,,,B,,
3577,Homo sapiens,,CHEMBL620710,Binding affinity against 5-hydroxytryptamine 5A receptor,,16146,,10624,,,BAO_0000357,,Expert,,9606.0,B,,
3578,,,CHEMBL620711,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,,15250,,10624,,,BAO_0000219,,Autocuration,,,B,,CHO
3579,Homo sapiens,,CHEMBL620712,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,,6491,,10624,,,BAO_0000357,,Expert,,9606.0,B,,
3580,Homo sapiens,,CHEMBL620713,Binding affinity towards human 5-hydroxytryptamine 5A receptor,,17066,,10624,,,BAO_0000357,,Expert,,9606.0,B,,
3581,Homo sapiens,,CHEMBL620714,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,,17066,,10624,,,BAO_0000357,,Expert,,9606.0,B,,
3582,Homo sapiens,,CHEMBL620715,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,,4234,,10624,,,BAO_0000357,,Expert,,9606.0,B,,
3583,,,CHEMBL620716,Binding affinity towards 5-HT5A receptor,,6013,,10624,,,BAO_0000357,,Autocuration,,,B,,
3584,,,CHEMBL620717,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,,17175,,10624,,,BAO_0000357,,Expert,,,B,,
3585,,,CHEMBL618072,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,,15818,,10624,,,BAO_0000357,,Autocuration,,,B,,
3586,,,CHEMBL857987,Binding affinity towards cloned human 5-HT5A receptor was determined,,6166,,10624,,,BAO_0000357,,Autocuration,,,B,,
3587,,,CHEMBL618073,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,15779,,10624,,,BAO_0000219,,Autocuration,,,B,,HEK293
3588,,,CHEMBL618074,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,15779,,10624,,,BAO_0000219,,Autocuration,,,B,,HEK293
3589,,,CHEMBL618075,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),,5213,,10624,,,BAO_0000219,,Autocuration,,,B,,HEK293
3590,Mus musculus,,CHEMBL618076,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,,17066,,10625,,,BAO_0000357,,Expert,,10090.0,B,,
3591,Mus musculus,,CHEMBL618077,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,,17066,,10625,,,BAO_0000357,,Expert,,10090.0,B,,
3592,Mus musculus,,CHEMBL618078,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,,17066,,10625,,,BAO_0000357,,Expert,,10090.0,B,,
3593,Mus musculus,,CHEMBL881821,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,,17066,,10625,,,BAO_0000357,,Expert,,10090.0,B,,
3594,Mus musculus,,CHEMBL618079,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,,17066,,10625,,,BAO_0000357,,Expert,,10090.0,B,,
3595,,,CHEMBL618080,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,,17175,,10625,,,BAO_0000357,,Expert,,,B,,
3596,,,CHEMBL618081,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,16190,,10576,,,BAO_0000219,,Autocuration,,,B,,HEK293
3597,,,CHEMBL618082,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,16190,,10626,,,BAO_0000219,,Autocuration,,,B,,HEK293
3598,,,CHEMBL618083,Binding affinity towards 5-HT5a receptor,,4820,,10624,,,BAO_0000357,,Expert,,,B,,
3599,Homo sapiens,,CHEMBL618084,Binding affinity towards 5-hydroxytryptamine 5A receptor,,17066,,10624,,,BAO_0000357,,Expert,,9606.0,B,,
3600,,,CHEMBL618085,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,,17066,,10624,,,BAO_0000357,,Expert,,,B,,
3601,,,CHEMBL618086,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,,17175,,10624,,,BAO_0000357,,Expert,,,B,,
3602,,,CHEMBL875092,Binding affinities against 5-hydroxytryptamine 5A receptor,,16633,,10624,,,BAO_0000357,,Autocuration,,,B,,
3603,,,CHEMBL618087,Binding affinities towards 5-hydroxytryptamine 5A receptor,,16633,,10624,,,BAO_0000357,,Autocuration,,,B,,
3604,,,CHEMBL872926,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,,16700,,10624,,,BAO_0000357,,Autocuration,,,B,,
3605,Cavia porcellus,,CHEMBL618088,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,,4639,,104714,,,BAO_0000019,,Autocuration,,10141.0,F,,
3606,,,CHEMBL618089,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,,5486,,104714,,,BAO_0000223,,Autocuration,,,B,,
3607,Homo sapiens,,CHEMBL618090,Inhibition of human 5-hydroxytryptamine 6 receptor,,16146,,10627,,,BAO_0000357,,Expert,,9606.0,B,,
3608,Homo sapiens,,CHEMBL618091,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,,17273,,10627,,,BAO_0000357,,Expert,,9606.0,B,,
3609,,,CHEMBL618092,Inhibition against human 5-hydroxytryptamine 6 receptor,,17687,,10627,,,BAO_0000357,,Autocuration,,,B,,
3610,Homo sapiens,,CHEMBL618093,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,,6491,,10627,,,BAO_0000357,,Expert,,9606.0,B,,
3611,,,CHEMBL618094,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,,16190,,10627,,,BAO_0000219,,Expert,,,B,,HeLa
3612,Homo sapiens,,CHEMBL618095,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,,17066,,10627,,,BAO_0000357,,Expert,,9606.0,B,,
3613,Homo sapiens,,CHEMBL875093,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,17066,,10627,,,BAO_0000357,,Expert,,9606.0,B,,
3614,Homo sapiens,,CHEMBL618096,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,,17066,,10627,,,BAO_0000357,,Expert,,9606.0,B,,
3615,Homo sapiens,,CHEMBL618118,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,,17066,,10627,,,BAO_0000357,,Expert,,9606.0,B,,
3616,Homo sapiens,,CHEMBL618119,Binding affinity against 5-hydroxytryptamine 6 receptor,,3555,,10627,,,BAO_0000357,,Expert,,9606.0,B,,
3617,,,CHEMBL618120,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,5808,,10627,,,BAO_0000357,,Expert,,,B,,
3618,,,CHEMBL618121,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,6013,,10627,,,BAO_0000357,,Autocuration,,,B,,
3619,,,CHEMBL618122,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",,15818,,10627,,,BAO_0000219,,Expert,,,B,,HEK293
3620,,,CHEMBL618123,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,,16209,,10627,,,BAO_0000357,,Autocuration,,,B,,
3621,,,CHEMBL618124,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,,3935,,10627,,,BAO_0000219,,Expert,,,B,,HEK293
3622,,,CHEMBL618125,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,,15818,,10627,,,BAO_0000357,,Autocuration,,,B,,
3623,Homo sapiens,,CHEMBL618126,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,3805,,10627,,,BAO_0000219,,Expert,,9606.0,B,,HEK293
3624,,,CHEMBL618236,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,,16441,,10627,,,BAO_0000019,,Expert,,,B,,
3625,,,CHEMBL618237,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,16441,,10627,,,BAO_0000019,,Expert,,,B,,
3626,,,CHEMBL618238,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,,6786,,10627,,,BAO_0000219,,Expert,,,B,,COS-7
3627,Homo sapiens,,CHEMBL618239,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,,4234,,10627,,,BAO_0000357,,Expert,,9606.0,B,,
3628,,,CHEMBL618240,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,,17085,,10627,,,BAO_0000019,,Autocuration,,,B,,
3629,,,CHEMBL618241,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,,17200,,10627,,,BAO_0000357,,Autocuration,,,B,,
3630,,,CHEMBL859399,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,17451,,10627,,,BAO_0000219,,Autocuration,,,B,,HEK293
3631,,,CHEMBL618242,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,,3935,,10627,,,BAO_0000019,,Autocuration,,,F,,
3632,,,CHEMBL857991,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,,5033,,10627,,,BAO_0000357,,Autocuration,,,B,,
3633,,,CHEMBL619951,Binding affinity against human 5-hydroxytryptamine 6 receptor,,4540,,10627,,,BAO_0000357,,Expert,,,B,,
3634,Homo sapiens,,CHEMBL619952,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,,4540,,10627,,,BAO_0000219,,Expert,,9606.0,B,,HeLa
3635,Homo sapiens,,CHEMBL619953,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,,4540,,10627,,,BAO_0000219,,Expert,,9606.0,B,,HeLa
3636,,,CHEMBL619954,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,,17296,,10627,,,BAO_0000219,,Autocuration,,,B,,HeLa
3637,,,CHEMBL619955,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,17296,,10627,,,BAO_0000219,,Autocuration,,,B,,HeLa
3638,,,CHEMBL619956,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,17296,,10627,,,BAO_0000219,,Autocuration,,,B,,HeLa
3639,,,CHEMBL619957,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,15779,,10627,,,BAO_0000219,,Autocuration,,,B,,CHO
3640,,,CHEMBL619958,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,15779,,10627,,,BAO_0000219,,Autocuration,,,B,,HEK293
3641,,,CHEMBL620627,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,,15779,,10627,,,BAO_0000219,,Autocuration,,,B,,HEK293
3642,,,CHEMBL620628,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,15779,,10627,,,BAO_0000219,,Autocuration,,,B,,HEK293
3643,,,CHEMBL620629,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,,15779,,10627,,,BAO_0000219,,Autocuration,,,B,,HeLa
3644,,,CHEMBL620630,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,6166,,10627,,,BAO_0000357,,Autocuration,,,B,,
3645,,,CHEMBL620782,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,,17451,,10627,,,BAO_0000219,,Autocuration,,,B,,HeLa
3646,,,CHEMBL620783,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,,15316,,10627,,,BAO_0000357,,Autocuration,,,B,,
3647,,,CHEMBL620784,Binding affinity against human 5-hydroxytryptamine 6 receptor,,4199,,10627,,,BAO_0000357,,Expert,,,B,,
3648,,,CHEMBL620785,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,,15146,,10627,,,BAO_0000219,,Expert,,,B,,HeLa
3649,,,CHEMBL857992,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),,5213,,10627,,,BAO_0000357,,Autocuration,,,B,,
3650,,,CHEMBL620786,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,,16429,,10627,,,BAO_0000219,,Autocuration,,,B,,
3651,,,CHEMBL620787,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,,14818,,10627,,,BAO_0000219,,Autocuration,,,B,,HeLa
3652,,,CHEMBL620788,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",,4829,,10627,,,BAO_0000219,,Autocuration,,,B,,HeLa
3653,,,CHEMBL620789,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",,4829,,10627,,,BAO_0000219,,Autocuration,,,B,,HeLa
3654,,,CHEMBL620790,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",,4829,,10627,,,BAO_0000219,,Autocuration,,,B,,HeLa
3655,,,CHEMBL620791,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,,15250,,10628,,,BAO_0000219,,Autocuration,,,B,,CHO
3656,,,CHEMBL620792,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,,14423,,10628,,,BAO_0000019,,Autocuration,,,B,,
3657,,,CHEMBL620793,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,,15086,,10628,,,BAO_0000357,,Autocuration,,,B,,
3658,,,CHEMBL620794,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,,4342,,10628,,,BAO_0000357,,Autocuration,,,B,,
3659,Homo sapiens,,CHEMBL620795,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,,16190,,10627,,,BAO_0000219,,Autocuration,,9606.0,B,,HeLa
3660,,,CHEMBL620796,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,4820,,10627,,,BAO_0000357,,Expert,,,B,,
3661,,,CHEMBL620797,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,,4639,,10627,,,BAO_0000357,,Autocuration,,,B,,
3662,Homo sapiens,,CHEMBL620798,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,17066,,10627,,,BAO_0000019,,Expert,,9606.0,F,,
3663,,,CHEMBL620799,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,,6011,,10627,,,BAO_0000357,,Autocuration,,,B,,
3664,,,CHEMBL620800,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,17066,,10627,,,BAO_0000357,,Expert,,,B,,
3665,,,CHEMBL620801,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,,17515,,10627,,,BAO_0000357,,Autocuration,,,B,,
3666,,,CHEMBL875100,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,,5014,,10627,,,BAO_0000357,,Autocuration,,,B,,
3667,,,CHEMBL620802,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,,4373,,10627,,,BAO_0000357,,Autocuration,,,B,,
3668,,,CHEMBL620803,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,,17066,,10627,,,BAO_0000019,,Expert,,,F,,
3669,,,CHEMBL620804,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,17066,,10627,,,BAO_0000019,,Expert,,,F,,
3670,,,CHEMBL620805,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,,4373,,10627,,,BAO_0000357,,Autocuration,,,B,,
3671,,,CHEMBL620806,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,,4687,,10627,,,BAO_0000357,,Autocuration,,,B,,
3672,,,CHEMBL620807,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,,16946,,10627,,,BAO_0000357,,Autocuration,,,B,,
3673,,,CHEMBL620808,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,,16946,,10627,,,BAO_0000357,,Autocuration,,,B,,
3674,,,CHEMBL620809,Binding affinities against 5-hydroxytryptamine 6 receptor,,16633,,10627,,,BAO_0000357,,Autocuration,,,B,,
3675,,,CHEMBL620810,Binding affinities towards 5-hydroxytryptamine 6 receptor,,16633,,10627,,,BAO_0000357,,Autocuration,,,B,,
3676,Homo sapiens,,CHEMBL620811,Binding affinity towards 5-hydroxytryptamine 6 receptor,,17066,,10627,,,BAO_0000357,,Expert,,9606.0,B,,
3677,,,CHEMBL620812,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,,16700,,10627,,,BAO_0000357,,Autocuration,,,B,,
3678,,,CHEMBL620813,Affinity against 5-hydroxytryptamine 6 receptor,,3269,,10627,,,BAO_0000357,,Autocuration,,,B,,
3679,,,CHEMBL620814,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],,5486,,10627,,,BAO_0000357,,Autocuration,,,B,,
3680,Homo sapiens,,CHEMBL620815,Inhibition of human 5-hydroxytryptamine 7 receptor,,16146,,10209,,,BAO_0000357,,Expert,,9606.0,B,,
3681,,,CHEMBL620816,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,,5014,,10209,,,BAO_0000219,,Autocuration,,,B,,HEK293
3682,,,CHEMBL620817,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,,15463,,10209,,,BAO_0000357,,Autocuration,,,B,,
3683,,,CHEMBL620818,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),,3805,,10209,,,BAO_0000357,,Autocuration,,,B,,
3684,,,CHEMBL620819,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,,5014,,10209,,,BAO_0000219,,Expert,,,B,,HEK293
3685,Homo sapiens,,CHEMBL620820,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,,6491,,10209,,,BAO_0000357,,Expert,,9606.0,B,,
3686,,,CHEMBL620821,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,,16190,,10209,,,BAO_0000219,,Autocuration,,,B,,CHO
3687,Homo sapiens,,CHEMBL620822,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,17066,,10209,,,BAO_0000357,,Expert,,9606.0,B,,
3688,Homo sapiens,,CHEMBL620823,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,,17066,,10209,,,BAO_0000357,,Expert,,9606.0,B,,
3689,Homo sapiens,,CHEMBL620824,Binding affinity against 5-hydroxytryptamine 7 receptor,,3555,,10209,,,BAO_0000357,,Expert,,9606.0,B,,
3690,,,CHEMBL620825,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,,6588,,10209,,,BAO_0000219,,Expert,,,B,,CHO
3691,,,CHEMBL872930,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,,15463,,10209,,,BAO_0000357,,Autocuration,,,B,,
3692,,,CHEMBL620826,Binding affinity towards 5-hydroxytryptamine 7 receptor,,6013,,10209,,,BAO_0000357,,Autocuration,,,B,,
3693,,,CHEMBL620827,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,16209,,10209,,,BAO_0000357,,Autocuration,,,B,,
3694,,,CHEMBL620828,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,,3935,,10209,,,BAO_0000357,,Autocuration,,,B,,
3695,,,CHEMBL620829,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,,15818,,10209,,,BAO_0000357,,Autocuration,,,B,,
3696,,,CHEMBL620830,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,,5014,,10209,,,BAO_0000219,,Expert,,,B,,HEK293
3697,,,CHEMBL620831,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,,16441,,10209,,,BAO_0000019,,Expert,,,B,,
3698,,,CHEMBL620832,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,16441,,10209,,,BAO_0000019,,Expert,,,B,,
3699,Homo sapiens,,CHEMBL621548,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,,4234,,10209,,,BAO_0000357,,Expert,,9606.0,B,,
3700,,,CHEMBL621549,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,,17085,,10209,,,BAO_0000019,,Autocuration,,,B,,
3701,,,CHEMBL621550,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,,17200,,10209,,,BAO_0000357,,Autocuration,,,B,,
3702,,,CHEMBL621551,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,,17451,,10209,,,BAO_0000219,,Autocuration,,,B,,CHO
3703,,,CHEMBL621552,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,,17085,,10209,,,BAO_0000019,,Autocuration,,,B,,
3704,,,CHEMBL857077,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,,5104,,10209,,,BAO_0000357,,Autocuration,,,B,,
3705,,,CHEMBL618158,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,,5104,,10209,,,BAO_0000357,,Autocuration,,,B,,
3706,Homo sapiens,,CHEMBL618159,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,5033,,10209,,,BAO_0000219,,Expert,,9606.0,B,,COS-7
3707,,,CHEMBL875101,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,5486,,10209,,,BAO_0000219,,Autocuration,,,B,,COS-7
3708,Homo sapiens,,CHEMBL618160,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,,4540,,10209,,,BAO_0000219,,Expert,,9606.0,B,,HEK293
3709,,,CHEMBL618161,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,,6166,,10209,,,BAO_0000357,,Expert,,,B,,
3710,,,CHEMBL618162,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,,17342,,10209,,,BAO_0000219,,Expert,,,B,,HEK293
3711,,,CHEMBL618163,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,,17342,,10209,,,BAO_0000357,,Expert,,,B,,
3712,,,CHEMBL618164,Binding affinity against 5-hydroxytryptamine 7 human receptors,,17296,,10209,,,BAO_0000357,,Autocuration,,,B,,
3713,,,CHEMBL618165,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,,16429,,10209,,,BAO_0000219,,Expert,,,B,,
3714,,,CHEMBL618166,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,,15779,,10209,,,BAO_0000219,,Autocuration,,,B,,HEK293
3715,,,CHEMBL857989,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,15779,,10209,,,BAO_0000219,,Autocuration,,,B,,HEK293
3716,,,CHEMBL619888,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,15779,,10209,,,BAO_0000219,,Autocuration,,,B,,HEK293
3717,,,CHEMBL619889,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,15779,,10209,,,BAO_0000219,,Autocuration,,,B,,HEK293
3718,,,CHEMBL619890,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,,15779,,10209,,,BAO_0000219,,Autocuration,,,B,,HEK293
3719,,,CHEMBL619891,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,,17451,,10209,,,BAO_0000219,,Autocuration,,,B,,CHO
3720,,,CHEMBL619892,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),,4199,,10209,,,BAO_0000219,,Autocuration,,,B,,HEK293
3721,,,CHEMBL619893,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,,4199,,10209,,,BAO_0000219,,Expert,,,B,,HEK293
3722,,,CHEMBL619894,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),,4199,,10209,,,BAO_0000219,,Autocuration,,,B,,HEK293
3723,,,CHEMBL619895,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,,3680,,10209,,,BAO_0000219,,Intermediate,,,B,,HEK293
3724,,,CHEMBL619896,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,,3680,,10209,,,BAO_0000357,,Intermediate,,,B,,
3725,,,CHEMBL619897,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,,15316,,10209,,,BAO_0000219,,Autocuration,,,B,,COS-7
3726,,,CHEMBL619898,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,,15146,,10209,,,BAO_0000219,,Autocuration,,,B,,HEK293
3727,,,CHEMBL619899,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,,5213,,10209,,,BAO_0000219,,Expert,,,B,,HEK293
3728,,,CHEMBL619900,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),,5213,,10209,,,BAO_0000219,,Autocuration,,,B,,HEK293
3729,Homo sapiens,,CHEMBL619901,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,,14818,,10209,,,BAO_0000219,,Expert,,9606.0,B,,HEK293
3730,,,CHEMBL620580,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,,14818,,10209,,,BAO_0000219,,Autocuration,,,B,,HEK293
3731,,,CHEMBL620581,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,,14818,,10209,,,BAO_0000219,,Autocuration,,,B,,HEK293
3732,,,CHEMBL620733,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",,4829,,10209,,,BAO_0000219,,Autocuration,,,B,,HEK293
3733,Homo sapiens,,CHEMBL620734,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,,17200,,10209,,,BAO_0000357,,Autocuration,,9606.0,B,,
3734,Mus musculus,,CHEMBL620735,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,17066,,10022,,,BAO_0000357,,Expert,,10090.0,B,,
3735,Oryctolagus cuniculus,,CHEMBL620736,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,,14025,,10209,,,BAO_0000019,,Autocuration,,9986.0,B,,
3736,,,CHEMBL620737,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,,15250,,11923,,,BAO_0000219,,Autocuration,,,B,,CHO
3737,,,CHEMBL620738,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,,16372,,11923,,,BAO_0000219,,Autocuration,,,B,,CHO
3738,,,CHEMBL620739,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,,16372,,11923,,,BAO_0000219,,Autocuration,,,B,,CHO
3739,,,CHEMBL620740,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,,16372,,11923,,,BAO_0000219,,Autocuration,,,B,,CHO
3740,,,CHEMBL620741,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,,16372,,11923,,,BAO_0000219,,Autocuration,,,B,,CHO
3741,,,CHEMBL620742,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,,16372,,11923,,,BAO_0000219,,Autocuration,,,B,,CHO
3742,,,CHEMBL620743,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,,16372,,11923,,,BAO_0000219,,Autocuration,,,B,,CHO
3743,,,CHEMBL620744,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,,16372,,11923,,,BAO_0000219,,Autocuration,,,B,,CHO
3744,,,CHEMBL620745,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,,16372,,11923,,,BAO_0000219,,Autocuration,,,B,,CHO
3745,,,CHEMBL620746,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,,16372,,11923,,,BAO_0000219,,Autocuration,,,B,,CHO
3746,,,CHEMBL620747,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,,16372,,11923,,,BAO_0000219,,Autocuration,,,B,,CHO
3747,,,CHEMBL620748,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,,16372,,11923,,,BAO_0000219,,Autocuration,,,B,,CHO
3748,,,CHEMBL620749,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,,16372,,11923,,,BAO_0000219,,Autocuration,,,B,,CHO
3749,,,CHEMBL620750,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,,17066,,11923,,,BAO_0000357,,Expert,,,B,,
3750,Rattus norvegicus,,CHEMBL620751,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,17066,,11923,,,BAO_0000357,,Expert,,10116.0,B,,
3751,,,CHEMBL620752,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,,17386,,11923,,,BAO_0000357,,Expert,,,B,,
3752,,,CHEMBL872929,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,,14423,,11923,,,BAO_0000019,,Autocuration,,,B,,
3753,Rattus norvegicus,,CHEMBL620753,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,,15874,,11923,,,BAO_0000357,,Expert,,10116.0,B,,
3754,Rattus norvegicus,,CHEMBL620754,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,,15874,,11923,,,BAO_0000357,,Expert,,10116.0,B,,
3755,Rattus norvegicus,,CHEMBL620755,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,,16372,,11923,,,BAO_0000219,,Expert,,10116.0,B,,CHO
3756,,,CHEMBL620756,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,4622,,11923,,,BAO_0000357,,Autocuration,,,B,,
3757,,,CHEMBL620757,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,,15086,,11923,,,BAO_0000357,,Autocuration,,,B,,
3758,,,CHEMBL620758,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",,16372,,11923,,,BAO_0000219,,Autocuration,,,B,,CHO
3759,,,CHEMBL620759,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",,16372,,11923,,,BAO_0000219,,Autocuration,,,B,,CHO
3760,,,CHEMBL620760,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,,16372,,11923,,,BAO_0000219,,Autocuration,,,B,,CHO
3761,,,CHEMBL620761,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,,16372,,11923,,,BAO_0000219,,Autocuration,,,B,,CHO
3762,,2116.0,CHEMBL620762,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,17386,Ileum,11923,,,BAO_0000221,,Autocuration,,,F,,
3763,,2116.0,CHEMBL620763,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,17386,Ileum,11923,,,BAO_0000221,,Autocuration,,,F,,
3764,,2116.0,CHEMBL620764,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,,17386,Ileum,11923,,,BAO_0000221,,Autocuration,,,F,,
3765,Rattus norvegicus,,CHEMBL857990,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,,5831,,11923,,,BAO_0000249,,Expert,Membranes,10116.0,B,,
3766,,,CHEMBL620765,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,,4342,,11923,,,BAO_0000357,,Autocuration,,,B,,
3767,,,CHEMBL620766,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,,17319,,11923,,,BAO_0000357,,Expert,,,B,,
3768,,1898.0,CHEMBL620767,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,,17342,Hypothalamus,11923,,,BAO_0000019,,Expert,,,B,,
3769,,,CHEMBL620768,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,,17342,,11923,,,BAO_0000357,,Autocuration,,,B,,
3770,,1898.0,CHEMBL619051,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,,3680,Hypothalamus,11923,,,BAO_0000249,,Expert,,,B,,
3771,,,CHEMBL619052,Binding affinity towards 5-hydroxytryptamine 7 receptor,,3680,,11923,,,BAO_0000357,,Expert,,,B,,
3772,Rattus norvegicus,,CHEMBL619053,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,,17319,,11923,,,BAO_0000219,,Expert,,10116.0,F,,HEK293
3773,Rattus norvegicus,,CHEMBL619703,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,,17319,,11923,,,BAO_0000219,,Expert,,10116.0,F,,HEK293
3774,Rattus norvegicus,,CHEMBL619704,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,,17319,,11923,,,BAO_0000219,,Autocuration,,10116.0,F,,HEK293
3775,,,CHEMBL619851,Binding affinity towards 5-hydroxytryptamine 7 receptor,,4820,,10209,,,BAO_0000357,,Expert,,,B,,
3776,,,CHEMBL619852,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,,4639,,10209,,,BAO_0000357,,Autocuration,,,B,,
3777,,,CHEMBL619853,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,,6011,,10209,,,BAO_0000357,,Autocuration,,,B,,
3778,Homo sapiens,,CHEMBL619854,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,17066,,10209,,,BAO_0000357,,Expert,,9606.0,B,,
3779,,,CHEMBL619855,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,,17066,,10209,,,BAO_0000357,,Expert,,,B,,
3780,,,CHEMBL619856,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,,17515,,10209,,,BAO_0000357,,Autocuration,,,B,,
3781,,,CHEMBL619857,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,4373,,10209,,,BAO_0000357,,Autocuration,,,B,,
3782,,,CHEMBL619858,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,,17066,,10209,,,BAO_0000019,,Expert,,,F,,
3783,,,CHEMBL619859,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,,4373,,10209,,,BAO_0000357,,Autocuration,,,B,,
3784,,,CHEMBL619860,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,4373,,10209,,,BAO_0000357,,Autocuration,,,B,,
3785,,,CHEMBL619861,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,,4687,,10209,,,BAO_0000357,,Autocuration,,,B,,
3786,,,CHEMBL619862,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,,17342,,10209,,,BAO_0000357,,Expert,,,B,,
3787,,,CHEMBL619863,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,,16946,,10209,,,BAO_0000357,,Autocuration,,,B,,
3788,,,CHEMBL619864,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,,16946,,10209,,,BAO_0000357,,Autocuration,,,B,,
3789,,,CHEMBL872928,Binding affinities against 5-hydroxytryptamine 7 receptor,,16633,,10209,,,BAO_0000357,,Autocuration,,,B,,
3790,,,CHEMBL619865,Binding affinities towards 5-hydroxytryptamine 7 receptor,,16633,,10209,,,BAO_0000357,,Autocuration,,,B,,
3791,,,CHEMBL619866,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,,17066,,10209,,,BAO_0000357,,Expert,,,B,,
3792,,,CHEMBL619867,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,,16700,,10209,,,BAO_0000357,,Autocuration,,,B,,
3793,,2116.0,CHEMBL619868,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,17386,Ileum,10209,,,BAO_0000221,,Autocuration,,,B,,
3794,,,CHEMBL619869,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,,14080,,55,,,BAO_0000019,,Autocuration,,,F,,
3795,Homo sapiens,,CHEMBL619870,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,,14080,,55,,,BAO_0000019,,Expert,,9606.0,F,,
3796,,,CHEMBL619871,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,,409,,55,,,BAO_0000357,,Autocuration,,,B,,
3797,,,CHEMBL619872,In vitro inhibition of human recombinant lipoxygenase enzyme,,409,,55,,,BAO_0000357,,Autocuration,,,B,,
3798,,,CHEMBL619873,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,,409,,55,,,BAO_0000357,,Autocuration,,,B,,
3799,,178.0,CHEMBL619874,Inhibition of 5-lipoxygenase in human whole blood.,,11090,Blood,55,,,BAO_0000357,,Expert,,,B,,
3800,,178.0,CHEMBL619875,Inhibition of 5-lipoxygenase in human whole blood.,,11090,Blood,55,,,BAO_0000357,,Expert,,,B,,
3801,,,CHEMBL619876,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,,948,,55,,,BAO_0000357,,Autocuration,,,B,,
3802,,,CHEMBL619877,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),,948,,55,,,BAO_0000357,,Autocuration,,,B,,
3803,,,CHEMBL619878,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,,13622,,55,,,BAO_0000219,,Expert,,,F,,
3804,,178.0,CHEMBL619879,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,,13622,Blood,55,,,BAO_0000019,,Autocuration,,,F,,
3805,,,CHEMBL619880,In vitro inhibition of 5-lipoxygenase from human polymorphs,,9637,,55,,,BAO_0000357,,Autocuration,,,B,,
3806,,,CHEMBL619881,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),,11320,,55,,,BAO_0000357,,Autocuration,,,B,,
3807,,,CHEMBL619882,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,,11320,,55,,,BAO_0000357,,Expert,,,B,,
3808,,,CHEMBL619883,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,,6838,,55,,,BAO_0000357,,Autocuration,,,B,,
3809,Homo sapiens,178.0,CHEMBL619884,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),,17667,Blood,55,,,BAO_0000357,,Expert,,9606.0,B,,
3810,,,CHEMBL619885,In vitro potency against human 5-Lipoxygenase,,12703,,55,,,BAO_0000357,,Autocuration,,,B,,
3811,Homo sapiens,,CHEMBL619886,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,,14312,,55,,,BAO_0000019,,Expert,,9606.0,F,,
3812,,178.0,CHEMBL619887,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,,14312,Blood,55,,,BAO_0000019,,Autocuration,,,F,,
3813,,,CHEMBL875097,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,5364,,55,,,BAO_0000019,,Autocuration,,,F,,
3814,,,CHEMBL618001,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,,951,,55,,,BAO_0000219,,Autocuration,,,B,,
3815,,,CHEMBL618002,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,,951,,55,,,BAO_0000219,,Autocuration,,,B,,
3816,,,CHEMBL618003,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,,951,,55,,,BAO_0000219,,Autocuration,,,B,,
3817,,,CHEMBL618004,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,,951,,55,,,BAO_0000219,,Autocuration,,,B,,
3818,,,CHEMBL618005,Inhibition of human 5-lipoxygenase in human cells,,12365,,55,,,BAO_0000219,,Autocuration,,,B,,
3819,,,CHEMBL618006,Inhibition of human neutrophil 5-lipoxygenase,,10603,,55,,,BAO_0000357,,Expert,,,B,,
3820,,,CHEMBL875086,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,,10501,,55,,,BAO_0000019,,Autocuration,,,B,,
3821,,178.0,CHEMBL618007,Inhibition of 5-lipoxygenase from human whole blood,,12281,Blood,55,,,BAO_0000357,,Expert,,,B,,
3822,,,CHEMBL618008,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,2567,,55,,,BAO_0000357,,Autocuration,,,B,,
3823,,,CHEMBL618009,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,,2567,,55,,,BAO_0000219,,Autocuration,,,B,,
3824,,,CHEMBL618010,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,,10193,,55,,,BAO_0000357,,Expert,,,B,,
3825,,,CHEMBL618011,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,10193,,55,,,BAO_0000357,,Autocuration,,,B,,
3826,,,CHEMBL618012,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,,13623,,55,,,BAO_0000357,,Expert,,,B,,
3827,,,CHEMBL882927,Tested against 5-lipoxygenase,,12780,,55,,,BAO_0000357,,Autocuration,,,B,,
3828,,,CHEMBL618013,Tested for activity against 5-Lipoxygenase (5-LO),,12780,,55,,,BAO_0000357,,Autocuration,,,B,,
3829,,,CHEMBL618014,Tested for activity against 5-lipoxygenase,,12780,,55,,,BAO_0000357,,Autocuration,,,B,,
3830,,,CHEMBL618015,Tested for inhibition of 5-HPETE production by human 5-LO,,11966,,55,,,BAO_0000357,,Autocuration,,,B,,
3831,,,CHEMBL618016,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,5364,,55,,,BAO_0000019,,Autocuration,,,F,,
3832,,,CHEMBL618017,Inhibition of Human 5-lipoxygenase,,13165,,55,,,BAO_0000357,,Expert,,,B,,
3833,,,CHEMBL618018,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,,5364,,55,,,BAO_0000019,,Autocuration,,,B,,
3834,,,CHEMBL875087,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],,11311,,55,,,BAO_0000219,,Autocuration,,,B,,
3835,,,CHEMBL618019,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],,11311,,55,,,BAO_0000219,,Autocuration,,,B,,
3836,,,CHEMBL618020,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,,14863,,55,,,BAO_0000019,,Autocuration,,,B,,
3837,,,CHEMBL618021,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,,14863,,55,,,BAO_0000019,,Autocuration,,,B,,
3838,,178.0,CHEMBL618022,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),,11087,Blood,55,,,BAO_0000357,,Autocuration,,,B,,
3839,,,CHEMBL618023,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,,455,,55,,,BAO_0000357,,Autocuration,,,B,,
3840,,,CHEMBL618024,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,13183,,55,,,BAO_0000357,,Autocuration,,,B,,
3841,,,CHEMBL873950,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,,10319,,55,,,BAO_0000019,,Expert,,,B,,
3842,,,CHEMBL618025,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,10193,,55,,,BAO_0000357,,Autocuration,,,B,,
3843,,,CHEMBL618026,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,,951,,55,,,BAO_0000219,,Autocuration,,,B,,
3844,,,CHEMBL618027,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,,951,,55,,,BAO_0000219,,Autocuration,,,B,,
3845,,,CHEMBL618028,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,,951,,55,,,BAO_0000219,,Autocuration,,,B,,
3846,,,CHEMBL618029,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,,951,,55,,,BAO_0000219,,Autocuration,,,B,,
3847,,,CHEMBL618030,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,,9859,,55,,,BAO_0000357,,Expert,,,B,,
3848,,,CHEMBL618031,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,,9859,,55,,,BAO_0000357,,Expert,,,B,,
3849,,,CHEMBL618032,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,,9859,,55,,,BAO_0000357,,Autocuration,,,B,,
3850,,,CHEMBL618033,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,2567,,55,,,BAO_0000357,,Autocuration,,,B,,
3851,,,CHEMBL618034,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,,10193,,55,,,BAO_0000357,,Autocuration,,,B,,
3852,,,CHEMBL875088,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,10193,,55,,,BAO_0000357,,Autocuration,,,B,,
3853,,,CHEMBL618035,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,,949,,55,,,BAO_0000019,,Autocuration,,,B,,
3854,,,CHEMBL618036,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,,949,,55,,,BAO_0000019,,Autocuration,,,B,,
3855,,,CHEMBL618037,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,,10603,,55,,,BAO_0000357,,Expert,,,B,,
3856,,,CHEMBL618038,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,10603,,55,,,BAO_0000357,,Expert,,,B,,
3857,,,CHEMBL618761,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,10603,,55,,,BAO_0000019,,Autocuration,,,F,,
3858,,,CHEMBL618762,Inhibition of lipoxygenase at the concentration of 0.1 uM,,10603,,55,,,BAO_0000357,,Expert,,,B,,
3859,,,CHEMBL618763,Inhibition of lipoxygenase at the concentration of 1 uM,,10603,,55,,,BAO_0000357,,Expert,,,B,,
3860,,,CHEMBL618764,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,,10193,,55,,,BAO_0000357,,Autocuration,,,B,,
3861,Homo sapiens,,CHEMBL618765,Inhibition of 5-Lipoxygenase (5-LOX),,14580,,55,,,BAO_0000357,,Expert,,9606.0,B,,
3862,,,CHEMBL618766,Inhibition of 5-lipoxygenase in mouse macrophages.,,11090,,17087,,,BAO_0000357,,Expert,,,B,,
3863,,,CHEMBL618767,Inhibition of 5-lipoxygenase in mouse macrophages.,,11090,,17087,,,BAO_0000357,,Expert,,,B,,
3864,,,CHEMBL619380,Inhibitory activity against lipoxygenase-2 in mice,,6339,,17087,,,BAO_0000357,,Autocuration,,,B,,
3865,,,CHEMBL619381,Inhibitory activity against murine lipoxygenase-2.,,6339,,17087,,,BAO_0000357,,Expert,,,B,,
3866,Mus musculus,,CHEMBL619382,Inhibition of 5-lipoxygenase from mouse macrophage,,12281,,17087,,,BAO_0000357,,Expert,,10090.0,B,,
3867,,,CHEMBL619383,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,,11311,,17087,,,BAO_0000357,,Autocuration,,,B,,
3868,Sus scrofa,,CHEMBL619384,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,,11089,,55,,,BAO_0000019,,Autocuration,,9823.0,B,,
3869,Sus scrofa,,CHEMBL619385,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,,10091,,55,,,BAO_0000019,,Autocuration,,9823.0,B,,
3870,Oryctolagus cuniculus,,CHEMBL882928,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,,14352,,55,,,BAO_0000019,,Autocuration,,9986.0,B,,
3871,Rattus norvegicus,,CHEMBL619386,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,,13329,,12166,,,BAO_0000019,,Expert,,10116.0,B,,
3872,,,CHEMBL619387,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",,13329,,12166,,,BAO_0000019,,Autocuration,,,B,,
3873,,,CHEMBL619388,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,13329,,12166,,,BAO_0000019,,Autocuration,,,B,,
3874,,,CHEMBL619389,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",,13329,,12166,,,BAO_0000019,,Autocuration,,,B,,
3875,,,CHEMBL619390,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),,13329,,12166,,,BAO_0000019,,Expert,,,B,,
3876,,,CHEMBL619391,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",,13329,,12166,,,BAO_0000019,,Expert,,,B,,
3877,,,CHEMBL619392,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,,13329,,12166,,,BAO_0000019,,Autocuration,,,B,,
3878,,,CHEMBL619393,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),,11311,,12166,,,BAO_0000019,,Autocuration,,,B,,
3879,,,CHEMBL619394,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,,11311,,12166,,,BAO_0000019,,Autocuration,,,B,,
3880,,,CHEMBL619395,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,105,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
3881,,,CHEMBL619396,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,105,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
3882,,,CHEMBL619397,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),,9138,,12166,,,BAO_0000357,,Autocuration,,,B,,
3883,,,CHEMBL619398,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",,9138,,12166,,,BAO_0000357,,Autocuration,,,B,,
3884,,,CHEMBL619399,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",,9138,,12166,,,BAO_0000357,,Autocuration,,,B,,
3885,,,CHEMBL619400,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,14427,,12166,,,BAO_0000357,,Autocuration,,,B,,
3886,,,CHEMBL619401,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,13329,,12166,,,BAO_0000019,,Autocuration,,,B,,
3887,,,CHEMBL619402,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",,13329,,12166,,,BAO_0000019,,Autocuration,,,B,,
3888,Rattus norvegicus,,CHEMBL619403,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,,14427,,12166,,,BAO_0000219,,Expert,,10116.0,B,,RBL-2H3
3889,,,CHEMBL619404,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,14427,,12166,,,BAO_0000357,,Autocuration,,,B,,
3890,,,CHEMBL619405,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,,14427,,12166,,,BAO_0000357,,Autocuration,,,B,,
3891,,,CHEMBL619406,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,,10293,,12166,,,BAO_0000219,,Expert,,,B,,RBL-1
3892,Rattus norvegicus,,CHEMBL619407,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,,338,,12166,,,BAO_0000219,,Expert,,10116.0,B,,RBL-1
3893,,,CHEMBL619408,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),,303,,12166,,,BAO_0000357,,Autocuration,,,B,,
3894,,,CHEMBL619409,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,,303,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
3895,,,CHEMBL619410,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,,9247,,12166,,,BAO_0000219,,Expert,,,B,,RBL-1
3896,,,CHEMBL619753,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,9247,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
3897,,,CHEMBL619754,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,,137,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
3898,,,CHEMBL619903,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,,11481,,12166,,,BAO_0000357,,Expert,,,B,,
3899,,,CHEMBL619904,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",,11481,,12166,,,BAO_0000357,,Expert,,,B,,
3900,,,CHEMBL619905,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,,9029,,12166,,,BAO_0000357,,Expert,,,B,,
3901,,,CHEMBL619906,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,,1701,,12166,,,BAO_0000019,,Autocuration,,,B,,
3902,,,CHEMBL619907,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,,1701,,12166,,,BAO_0000019,,Autocuration,,,B,,
3903,,,CHEMBL619908,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,,1701,,12166,,,BAO_0000019,,Autocuration,,,B,,
3904,,,CHEMBL619909,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,,1701,,12166,,,BAO_0000019,,Autocuration,,,B,,
3905,,,CHEMBL619910,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,,13358,,12166,,,BAO_0000219,,Expert,,,F,,RBL-1
3906,,,CHEMBL882929,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,,1175,,12166,,,BAO_0000219,,Expert,,,B,,RBL-1
3907,,,CHEMBL619911,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,,8797,,12166,,,BAO_0000219,,Expert,,,B,,RBL-1
3908,,,CHEMBL619912,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,,8797,,12166,,,BAO_0000019,,Autocuration,,,B,,
3909,Rattus norvegicus,,CHEMBL619913,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,,577,,12166,,,BAO_0000357,,Expert,,10116.0,B,,
3910,,,CHEMBL619914,In vitro inhibitory activity against RBL-1 5-LO,,9295,,12166,,,BAO_0000219,,Expert,,,B,,RBL-1
3911,,,CHEMBL619915,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),,9295,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
3912,,,CHEMBL619916,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),,9295,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
3913,,,CHEMBL619917,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,,9295,,12166,,,BAO_0000218,,Autocuration,,,B,,
3914,,,CHEMBL619918,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,,9295,,12166,,,BAO_0000357,,Autocuration,,,B,,
3915,,,CHEMBL619919,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,,216,,12166,,,BAO_0000218,,Autocuration,,,B,,
3916,,,CHEMBL883710,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,,11090,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
3917,,178.0,CHEMBL619920,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,,11090,Blood,12166,,,BAO_0000019,,Autocuration,,,B,,
3918,,,CHEMBL619921,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,,10091,,12166,,,BAO_0000357,,Expert,,,B,,
3919,,,CHEMBL619922,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,,10274,,12166,,,BAO_0000019,,Autocuration,,,F,,
3920,,,CHEMBL619923,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,,13622,,12166,,,BAO_0000219,,Autocuration,,,F,,
3921,,,CHEMBL619924,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,,12118,,12166,,,BAO_0000219,,Expert,,,B,,RBL-1
3922,,,CHEMBL619925,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,,12576,,12166,,,BAO_0000357,,Expert,,,B,,
3923,,,CHEMBL619926,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,,9546,,12166,,,BAO_0000219,,Expert,,,B,,RBL-1
3924,,,CHEMBL619927,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,,9521,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
3925,,,CHEMBL619928,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,,10626,,12166,,,BAO_0000219,,Expert,,,B,,RBL-1
3926,,,CHEMBL619929,In vitro inhibition of RBL-1 5-lipoxygenase,,9225,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
3927,,,CHEMBL875089,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,,9225,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
3928,,,CHEMBL619930,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,,9225,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
3929,,,CHEMBL619931,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,,9225,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
3930,,,CHEMBL619932,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,,9225,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
3931,,,CHEMBL619933,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,,9225,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
3932,,,CHEMBL619934,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,,9225,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
3933,,,CHEMBL619935,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,,9225,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
3934,,,CHEMBL619936,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,,9225,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
3935,,,CHEMBL619937,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,,9225,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
3936,,,CHEMBL619938,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,,9225,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
3937,,,CHEMBL619939,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,,9225,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
3938,,,CHEMBL619940,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,,9225,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
3939,,,CHEMBL875090,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,,9225,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
3940,,,CHEMBL619941,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,,9225,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
3941,,,CHEMBL619942,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,,9225,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
3942,,,CHEMBL883711,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,,9225,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
3943,,,CHEMBL619943,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,,9225,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
3944,,,CHEMBL619944,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,,9225,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
3945,,,CHEMBL619945,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,,9225,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
3946,,,CHEMBL619946,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,,9225,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
3947,,,CHEMBL619947,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,,9225,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
3948,,,CHEMBL619948,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,,9225,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
3949,,,CHEMBL619949,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,,9225,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
3950,,,CHEMBL619950,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,,9401,,12166,,,BAO_0000019,,Expert,,,B,,
3951,,,CHEMBL618050,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,,10325,,12166,,,BAO_0000019,,Autocuration,,,B,,
3952,,,CHEMBL875091,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,,1556,,12166,,,BAO_0000219,,Expert,,,F,,RBL-2H3
3953,,,CHEMBL618051,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,,1556,,12166,,,BAO_0000219,,Expert,,,F,,RBL-2H3
3954,Rattus norvegicus,,CHEMBL618052,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,,961,,12166,,,BAO_0000219,,Expert,,10116.0,B,,RBL-1
3955,,,CHEMBL618053,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,,6838,,12166,,,BAO_0000019,,Autocuration,,,B,,
3956,,,CHEMBL618054,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),,10325,,12166,,,BAO_0000019,,Expert,,,B,,
3957,Rattus norvegicus,,CHEMBL618055,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,9209,,12166,,,BAO_0000219,,Expert,,10116.0,B,,RBL-1
3958,,,CHEMBL618056,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,,11520,,12166,,,BAO_0000219,,Expert,,,B,,RBL-1
3959,,,CHEMBL618057,In vitro inhibitory activity against 5-lipoxygenase was determined,,137,,12166,,,BAO_0000357,,Autocuration,,,B,,
3960,,,CHEMBL618058,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,,4717,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
3961,,,CHEMBL618059,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,,10636,,12166,,,BAO_0000219,,Expert,,,B,,RBL-1
3962,Rattus norvegicus,,CHEMBL618060,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,,14312,,12166,,,BAO_0000019,,Expert,,10116.0,F,,
3963,,,CHEMBL618061,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,,1203,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
3964,,,CHEMBL618062,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,,1203,,12166,,,BAO_0000019,,Autocuration,,,B,,
3965,,,CHEMBL618063,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,,13622,,12166,,,BAO_0000219,,Expert,,,B,,RBL-1
3966,,,CHEMBL618064,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,,9793,,12166,,,BAO_0000357,,Autocuration,,,B,,
3967,Rattus norvegicus,,CHEMBL618065,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,,1143,,12166,,,BAO_0000219,,Expert,,10116.0,B,,RBL-1
3968,Rattus norvegicus,,CHEMBL618066,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,,11854,,12166,,,BAO_0000219,,Expert,,10116.0,B,,RBL-1
3969,,,CHEMBL618067,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,3595,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
3970,,,CHEMBL618068,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,3595,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
3971,Rattus norvegicus,,CHEMBL618069,Inhibition of 5-lipoxygenase in rat RBL-1 cells,,10501,,12166,,,BAO_0000219,,Expert,,10116.0,B,,RBL-1
3972,,,CHEMBL618070,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,12526,,12166,,,BAO_0000219,,Expert,,,B,,RBL-1
3973,,349.0,CHEMBL618071,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,,10034,Limbic system,10825,,,BAO_0000019,,Autocuration,,,F,,
3974,,349.0,CHEMBL619247,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,10034,Limbic system,10825,,,BAO_0000019,,Autocuration,,,F,,
3975,,,CHEMBL619248,Approximate dose levels for a half maximal reduction of 5-HTP levels,,10034,,10825,,,BAO_0000019,,Autocuration,,,F,,
3976,,10000000.0,CHEMBL619249,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,10046,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
3977,,10000000.0,CHEMBL619250,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,10046,Hippocampus,10576,,,BAO_0000221,,Autocuration,,,B,,
3978,,,CHEMBL619251,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,10046,,10577,,,BAO_0000019,,Autocuration,,,B,,
3979,Canis lupus familiaris,178.0,CHEMBL619252,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,,12079,Blood,55,,,BAO_0000019,,Autocuration,,9615.0,F,,
3980,,178.0,CHEMBL619253,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,,12079,Blood,55,,,BAO_0000019,,Autocuration,,,F,,
3981,,,CHEMBL619254,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,11311,,12166,,,BAO_0000219,,Autocuration,,,B,,
3982,,,CHEMBL619255,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,,12338,,17140,,,BAO_0000219,,Expert,,,B,,
3983,,,CHEMBL619256,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,,12143,,17140,,,BAO_0000219,,Expert,,,B,,
3984,,,CHEMBL875418,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),,12143,,17140,,,BAO_0000219,,Autocuration,,,B,,
3985,,,CHEMBL619257,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,12143,,17140,,,BAO_0000219,,Expert,,,B,,
3986,,,CHEMBL619258,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,12143,,17140,,,BAO_0000219,,Autocuration,,,B,,
3987,,,CHEMBL619259,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,,12365,,17140,,,BAO_0000357,,Expert,,,B,,
3988,,,CHEMBL619260,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,,13500,,17140,,,BAO_0000357,,Expert,,,B,,
3989,Canis lupus familiaris,178.0,CHEMBL619261,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,12832,Blood,55,,,BAO_0000218,,Autocuration,,9615.0,F,,
3990,Canis lupus familiaris,178.0,CHEMBL619263,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,12832,Blood,55,,,BAO_0000218,,Autocuration,,9615.0,F,,
3991,Canis lupus familiaris,178.0,CHEMBL619264,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,12832,Blood,55,,,BAO_0000218,,Autocuration,,9615.0,F,,
3992,Canis lupus familiaris,178.0,CHEMBL619265,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,12832,Blood,55,,,BAO_0000218,,Autocuration,,9615.0,F,,
3993,Canis lupus familiaris,178.0,CHEMBL619266,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,12832,Blood,55,,,BAO_0000218,,Autocuration,,9615.0,F,,
3994,Canis lupus familiaris,178.0,CHEMBL619902,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,12832,Blood,55,,,BAO_0000218,,Autocuration,,9615.0,F,,
3995,Canis lupus familiaris,178.0,CHEMBL620058,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,12832,Blood,55,,,BAO_0000218,,Autocuration,,9615.0,F,,
3996,Canis lupus familiaris,178.0,CHEMBL620059,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,12832,Blood,55,,,BAO_0000218,,Autocuration,,9615.0,F,,
3997,Canis lupus familiaris,178.0,CHEMBL620060,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,12832,Blood,55,,,BAO_0000218,,Autocuration,,9615.0,F,,
3998,Canis lupus familiaris,178.0,CHEMBL620061,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,12832,Blood,55,,,BAO_0000218,,Autocuration,,9615.0,F,,
3999,Canis lupus familiaris,178.0,CHEMBL620062,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",In vivo,12832,Blood,55,,,BAO_0000218,,Autocuration,,9615.0,F,,
4000,Canis lupus familiaris,178.0,CHEMBL620063,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",In vivo,12832,Blood,55,,,BAO_0000218,,Autocuration,,9615.0,F,,
4001,Canis lupus familiaris,178.0,CHEMBL620064,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",In vivo,12832,Blood,55,,,BAO_0000218,,Autocuration,,9615.0,F,,
4002,Canis lupus familiaris,178.0,CHEMBL620065,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,12832,Blood,55,,,BAO_0000218,,Autocuration,,9615.0,F,,
4003,Canis lupus familiaris,178.0,CHEMBL620066,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",In vivo,12832,Blood,55,,,BAO_0000218,,Autocuration,,9615.0,F,,
4004,Canis lupus familiaris,178.0,CHEMBL620067,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",In vivo,12832,Blood,55,,,BAO_0000218,,Autocuration,,9615.0,F,,
4005,Canis lupus familiaris,178.0,CHEMBL620068,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",In vivo,12832,Blood,55,,,BAO_0000218,,Autocuration,,9615.0,F,,
4006,Canis lupus familiaris,178.0,CHEMBL620069,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,12832,Blood,55,,,BAO_0000218,,Autocuration,,9615.0,F,,
4007,Canis lupus familiaris,178.0,CHEMBL620070,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",In vivo,12832,Blood,55,,,BAO_0000218,,Autocuration,,9615.0,F,,
4008,Canis lupus familiaris,178.0,CHEMBL620071,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",In vivo,12832,Blood,55,,,BAO_0000218,,Autocuration,,9615.0,F,,
4009,Canis lupus familiaris,178.0,CHEMBL620072,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",In vivo,12832,Blood,55,,,BAO_0000218,,Autocuration,,9615.0,F,,
4010,Canis lupus familiaris,178.0,CHEMBL620036,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,12832,Blood,55,,,BAO_0000218,,Autocuration,,9615.0,F,,
4011,Canis lupus familiaris,178.0,CHEMBL857702,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",In vivo,12832,Blood,55,,,BAO_0000218,,Autocuration,,9615.0,F,,
4012,Canis lupus familiaris,178.0,CHEMBL620037,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",In vivo,12832,Blood,55,,,BAO_0000218,,Autocuration,,9615.0,F,,
4013,Canis lupus familiaris,178.0,CHEMBL620038,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",In vivo,12832,Blood,55,,,BAO_0000218,,Autocuration,,9615.0,F,,
4014,Canis lupus familiaris,178.0,CHEMBL620039,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,12832,Blood,55,,,BAO_0000218,,Autocuration,,9615.0,F,,
4015,Canis lupus familiaris,178.0,CHEMBL620040,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",In vivo,12832,Blood,55,,,BAO_0000218,,Autocuration,,9615.0,F,,
4016,Canis lupus familiaris,178.0,CHEMBL620041,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",In vivo,12832,Blood,55,,,BAO_0000218,,Autocuration,,9615.0,F,,
4017,Canis lupus familiaris,178.0,CHEMBL620042,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",In vivo,12832,Blood,55,,,BAO_0000218,,Autocuration,,9615.0,F,,
4018,Canis lupus familiaris,178.0,CHEMBL620043,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,12832,Blood,55,,,BAO_0000218,,Autocuration,,9615.0,F,,
4019,Canis lupus familiaris,178.0,CHEMBL620044,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",In vivo,12832,Blood,55,,,BAO_0000218,,Autocuration,,9615.0,F,,
4020,Canis lupus familiaris,178.0,CHEMBL620045,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",In vivo,12832,Blood,55,,,BAO_0000218,,Autocuration,,9615.0,F,,
4021,Canis lupus familiaris,178.0,CHEMBL620046,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",In vivo,12832,Blood,55,,,BAO_0000218,,Autocuration,,9615.0,F,,
4022,Canis lupus familiaris,178.0,CHEMBL620047,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,12832,Blood,55,,,BAO_0000218,,Autocuration,,9615.0,F,,
4023,Canis lupus familiaris,178.0,CHEMBL620048,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",In vivo,12832,Blood,55,,,BAO_0000218,,Autocuration,,9615.0,F,,
4024,Canis lupus familiaris,178.0,CHEMBL857703,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",In vivo,12832,Blood,55,,,BAO_0000218,,Autocuration,,9615.0,F,,
4025,Canis lupus familiaris,178.0,CHEMBL620049,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",In vivo,12832,Blood,55,,,BAO_0000218,,Autocuration,,9615.0,F,,
4026,Canis lupus familiaris,178.0,CHEMBL620050,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,12832,Blood,55,,,BAO_0000218,,Autocuration,,9615.0,F,,
4027,Canis lupus familiaris,178.0,CHEMBL620051,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,12832,Blood,55,,,BAO_0000218,,Autocuration,,9615.0,F,,
4028,Canis lupus familiaris,178.0,CHEMBL619213,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,12832,Blood,55,,,BAO_0000218,,Autocuration,,9615.0,F,,
4029,Canis lupus familiaris,178.0,CHEMBL619214,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,12832,Blood,55,,,BAO_0000218,,Autocuration,,9615.0,F,,
4030,Canis lupus familiaris,178.0,CHEMBL619804,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,12832,Blood,55,,,BAO_0000218,,Autocuration,,9615.0,F,,
4031,Canis lupus familiaris,178.0,CHEMBL619805,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",In vivo,12832,Blood,55,,,BAO_0000218,,Autocuration,,9615.0,F,,
4032,Canis lupus familiaris,178.0,CHEMBL619806,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,12832,Blood,55,,,BAO_0000218,,Autocuration,,9615.0,F,,
4033,Canis lupus familiaris,178.0,CHEMBL619807,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,12832,Blood,55,,,BAO_0000218,,Autocuration,,9615.0,F,,
4034,Canis lupus familiaris,178.0,CHEMBL619808,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,12832,Blood,55,,,BAO_0000218,,Autocuration,,9615.0,F,,
4035,Canis lupus familiaris,,CHEMBL619809,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,,3595,,55,,,BAO_0000218,,Autocuration,,9615.0,B,,
4036,Canis lupus familiaris,,CHEMBL619810,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,,3595,,55,,,BAO_0000218,,Autocuration,,9615.0,B,,
4037,Canis lupus familiaris,,CHEMBL619811,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,,3595,,55,,,BAO_0000218,,Autocuration,,9615.0,B,,
4038,Canis lupus familiaris,,CHEMBL620769,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,,3595,,55,,,BAO_0000218,,Autocuration,,9615.0,B,,
4039,Canis lupus familiaris,,CHEMBL620770,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,,3595,,55,,,BAO_0000218,,Autocuration,,9615.0,B,,
4040,Canis lupus familiaris,,CHEMBL620771,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,,3595,,55,,,BAO_0000218,,Autocuration,,9615.0,B,,
4041,Canis lupus familiaris,,CHEMBL620772,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,,3595,,55,,,BAO_0000218,,Autocuration,,9615.0,B,,
4042,Canis lupus familiaris,,CHEMBL620773,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,,3595,,55,,,BAO_0000218,,Autocuration,,9615.0,B,,
4043,Cavia porcellus,,CHEMBL620774,Ability to inhibit 5-lipoxygenase in guinea pig,,9203,,55,,,BAO_0000357,,Autocuration,,10141.0,B,,
4044,Cavia porcellus,,CHEMBL620775,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),,82,,55,,,BAO_0000357,,Expert,,10141.0,B,,
4045,Cavia porcellus,,CHEMBL620776,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,,11090,,55,,,BAO_0000357,,Autocuration,,10141.0,B,,
4046,Cavia porcellus,178.0,CHEMBL620777,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",,12832,Blood,55,,,BAO_0000218,,Autocuration,,10141.0,B,,
4047,Cavia porcellus,,CHEMBL620778,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,,1065,,55,,,BAO_0000357,,Autocuration,,10141.0,B,,
4048,Cavia porcellus,,CHEMBL620779,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,,1065,,55,,,BAO_0000357,,Autocuration,,10141.0,B,,
4049,Cavia porcellus,,CHEMBL621500,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,,12832,,55,,,BAO_0000019,,Expert,,10141.0,B,,
4050,Cavia porcellus,,CHEMBL621501,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,12832,,55,,,BAO_0000019,,Expert,,10141.0,B,,
4051,Cavia porcellus,,CHEMBL618098,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,12832,,55,,,BAO_0000019,,Autocuration,,10141.0,B,,
4052,Cavia porcellus,,CHEMBL618099,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,10504,,55,,,BAO_0000019,,Autocuration,,10141.0,B,,
4053,Cavia porcellus,,CHEMBL618100,Inhibitory activity against 5-lipoxygenase,,7788,,55,,,BAO_0000357,,Autocuration,,10141.0,B,,
4054,Cavia porcellus,,CHEMBL618101,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,,10001,,55,,,BAO_0000357,,Autocuration,,10141.0,B,,
4055,Cavia porcellus,,CHEMBL618102,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,,10193,,55,,,BAO_0000357,,Autocuration,,10141.0,B,,
4056,Cavia porcellus,,CHEMBL618103,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,,13243,,55,,,BAO_0000357,,Autocuration,,10141.0,B,,
4057,Cavia porcellus,,CHEMBL618104,Inhibitory activity uM,,13243,,55,,,BAO_0000357,,Autocuration,,10141.0,B,,
4058,Cavia porcellus,,CHEMBL883712,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,,969,,55,,,BAO_0000219,,Autocuration,,10141.0,B,,
4059,Cavia porcellus,,CHEMBL618105,Inhibitory activity against 5-lipoxygenase at 10 uM,,10001,,55,,,BAO_0000357,,Autocuration,,10141.0,B,,
4060,Cavia porcellus,,CHEMBL618106,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,7788,,55,,,BAO_0000357,,Autocuration,,10141.0,B,,
4061,Cavia porcellus,,CHEMBL618107,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,,10001,,55,,,BAO_0000357,,Autocuration,,10141.0,B,,
4062,Cavia porcellus,,CHEMBL618108,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,10193,,55,,,BAO_0000357,,Autocuration,,10141.0,B,,
4063,Cavia porcellus,,CHEMBL618109,Inhibitory activity uM,,13243,,55,,,BAO_0000357,,Autocuration,,10141.0,B,,
4064,Cavia porcellus,,CHEMBL618110,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,,13243,,55,,,BAO_0000357,,Autocuration,,10141.0,B,,
4065,Cavia porcellus,,CHEMBL618111,Inhibitory activity uM,,13243,,55,,,BAO_0000357,,Expert,,10141.0,B,,
4066,Cavia porcellus,,CHEMBL618112,Inhibitory activity uM,,13243,,55,,,BAO_0000019,,Autocuration,,10141.0,F,,
4067,Cavia porcellus,,CHEMBL618113,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,10504,,55,,,BAO_0000019,,Autocuration,,10141.0,B,,
4068,Cavia porcellus,,CHEMBL618114,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,7788,,55,,,BAO_0000357,,Autocuration,,10141.0,B,,
4069,Cavia porcellus,2116.0,CHEMBL620871,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,,10546,Ileum,55,,,BAO_0000221,,Expert,,10141.0,F,,
4070,,,CHEMBL620872,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,13183,,55,,,BAO_0000357,,Autocuration,,,B,,
4071,,,CHEMBL620873,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,13183,,55,,,BAO_0000357,,Autocuration,,,B,,
4072,,,CHEMBL620874,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),,2578,,55,,,BAO_0000357,,Autocuration,,,B,,
4073,,,CHEMBL620875,In vitro inhibition of human 5-Lipoxygenase.,,12780,,55,,,BAO_0000357,,Expert,,,B,,
4074,Rattus norvegicus,2107.0,CHEMBL620876,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4075,Rattus norvegicus,2107.0,CHEMBL620877,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4076,Rattus norvegicus,2107.0,CHEMBL857854,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4077,Rattus norvegicus,2107.0,CHEMBL620878,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4078,Rattus norvegicus,2107.0,CHEMBL620879,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4079,Rattus norvegicus,2107.0,CHEMBL620880,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4080,Rattus norvegicus,2107.0,CHEMBL620881,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4081,Rattus norvegicus,2107.0,CHEMBL620882,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4082,Rattus norvegicus,2107.0,CHEMBL620883,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4083,Rattus norvegicus,2107.0,CHEMBL620884,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4084,Rattus norvegicus,2107.0,CHEMBL620885,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4085,Rattus norvegicus,2107.0,CHEMBL620886,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4086,Rattus norvegicus,2107.0,CHEMBL620887,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4087,Rattus norvegicus,2107.0,CHEMBL618039,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4088,Rattus norvegicus,2107.0,CHEMBL618040,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4089,Rattus norvegicus,2107.0,CHEMBL618041,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4090,Rattus norvegicus,2107.0,CHEMBL618216,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4091,Rattus norvegicus,2107.0,CHEMBL618217,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4092,Rattus norvegicus,2107.0,CHEMBL618218,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4093,Rattus norvegicus,2107.0,CHEMBL618219,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4094,Rattus norvegicus,2107.0,CHEMBL618220,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4095,Rattus norvegicus,2107.0,CHEMBL618221,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4096,Rattus norvegicus,2107.0,CHEMBL618222,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4097,Rattus norvegicus,2107.0,CHEMBL618223,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4098,Rattus norvegicus,2107.0,CHEMBL618224,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4099,Rattus norvegicus,2107.0,CHEMBL618225,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4100,Rattus norvegicus,2107.0,CHEMBL618226,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4101,Rattus norvegicus,2107.0,CHEMBL618227,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4102,Rattus norvegicus,2107.0,CHEMBL618228,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4103,Rattus norvegicus,2107.0,CHEMBL618229,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4104,Rattus norvegicus,2107.0,CHEMBL618230,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4105,Rattus norvegicus,2107.0,CHEMBL618231,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4106,Rattus norvegicus,2107.0,CHEMBL618232,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4107,Rattus norvegicus,2107.0,CHEMBL618233,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4108,Rattus norvegicus,2107.0,CHEMBL618234,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4109,Rattus norvegicus,2107.0,CHEMBL618235,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4110,Rattus norvegicus,2107.0,CHEMBL618115,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4111,Rattus norvegicus,2107.0,CHEMBL618116,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4112,Rattus norvegicus,2107.0,CHEMBL618117,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4113,Rattus norvegicus,2107.0,CHEMBL619968,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4114,Rattus norvegicus,2107.0,CHEMBL619969,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4115,Rattus norvegicus,2107.0,CHEMBL619970,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4116,Rattus norvegicus,2107.0,CHEMBL619971,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4117,Rattus norvegicus,2107.0,CHEMBL619972,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4118,Rattus norvegicus,2107.0,CHEMBL619973,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4119,Rattus norvegicus,2107.0,CHEMBL619974,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4120,Rattus norvegicus,2107.0,CHEMBL619975,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4121,Rattus norvegicus,,CHEMBL619976,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,,7411,,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4122,Rattus norvegicus,2107.0,CHEMBL619977,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4123,Rattus norvegicus,2107.0,CHEMBL619978,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4124,Rattus norvegicus,2107.0,CHEMBL619979,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4125,Rattus norvegicus,2107.0,CHEMBL619980,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4126,Rattus norvegicus,2107.0,CHEMBL619981,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4127,Homo sapiens,,CHEMBL619982,In vitro inhibition of 7226/S myeloma cancer cell line,,10797,,80433,,,BAO_0000219,,Intermediate,,9606.0,F,,RPMI-8226
4128,Homo sapiens,,CHEMBL619983,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),,6881,,80698,,,BAO_0000219,,Intermediate,,9606.0,F,,BEL-7404 tumor cell line
4129,Homo sapiens,,CHEMBL620031,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,3838,,80640,,,BAO_0000219,,Intermediate,,9606.0,F,,786-0
4130,Homo sapiens,,CHEMBL620032,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,3838,,80640,,,BAO_0000219,,Intermediate,,9606.0,F,,786-0
4131,Cricetulus griseus,,CHEMBL620033,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,,12981,,81264,,,BAO_0000219,,Expert,,10029.0,F,,V79
4132,Cricetulus griseus,,CHEMBL620034,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,,12981,,81264,,,BAO_0000219,,Expert,,10029.0,F,,V79
4133,Rattus norvegicus,,CHEMBL620035,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,,7653,,80635,,,BAO_0000219,,Intermediate,,10116.0,F,,7800C1 cell line
4134,Rattus norvegicus,,CHEMBL618318,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,,7653,,80635,,,BAO_0000219,,Intermediate,,10116.0,F,,7800C1 cell line
4135,Rattus norvegicus,,CHEMBL618319,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,,7653,,80635,,,BAO_0000219,,Intermediate,,10116.0,F,,7800C1 cell line
4136,Rattus norvegicus,,CHEMBL618320,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,,7653,,80635,,,BAO_0000219,,Intermediate,,10116.0,F,,7800C1 cell line
4137,Rattus norvegicus,,CHEMBL618321,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,,7653,,80635,,,BAO_0000219,,Intermediate,,10116.0,F,,7800C1 cell line
4138,Rattus norvegicus,,CHEMBL883118,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,,7653,,80635,,,BAO_0000219,,Intermediate,,10116.0,F,,7800C1 cell line
4139,Homo sapiens,,CHEMBL883795,In vitro antitumor activity against renal 786-0 tumor cell lines,,17229,,80640,,,BAO_0000219,,Intermediate,,9606.0,F,,786-0
4140,Homo sapiens,,CHEMBL618322,Cytotoxic activity against 786-0 Renal cancer cell line,,12858,,80640,,,BAO_0000219,,Intermediate,,9606.0,F,,786-0
4141,Homo sapiens,,CHEMBL618323,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,,16325,,80640,,,BAO_0000219,,Intermediate,,9606.0,F,,786-0
4142,Homo sapiens,,CHEMBL618324,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,,16325,,80640,,,BAO_0000219,,Intermediate,,9606.0,F,,786-0
4143,Homo sapiens,,CHEMBL618325,In vitro antitumor activity against human renal 786-0 cell line,,5858,,80640,,,BAO_0000219,,Intermediate,,9606.0,F,,786-0
4144,Homo sapiens,,CHEMBL875416,Inhibition of Renal cancer in 786-0 cancer cell lines,,16325,,80640,,,BAO_0000219,,Intermediate,,9606.0,F,,786-0
4145,Homo sapiens,,CHEMBL618326,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,,14696,,80640,,,BAO_0000219,,Intermediate,,9606.0,F,,786-0
4146,Homo sapiens,,CHEMBL618327,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,,3786,,80640,,,BAO_0000219,,Intermediate,,9606.0,F,,786-0
4147,Homo sapiens,,CHEMBL619215,inhibition of the growth of renal cancer(786-0) cell line,,14696,,80640,,,BAO_0000219,,Intermediate,,9606.0,F,,786-0
4148,Homo sapiens,,CHEMBL619216,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,14769,,80640,,,BAO_0000219,,Intermediate,,9606.0,F,,786-0
4149,Homo sapiens,,CHEMBL619217,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,,15354,,80640,,,BAO_0000219,,Intermediate,,9606.0,F,,786-0
4150,Homo sapiens,,CHEMBL619218,The IC50 value was measured on 786-0 cell line in ovarian tumor,,14255,,80640,,,BAO_0000219,,Intermediate,,9606.0,F,,786-0
4151,Homo sapiens,,CHEMBL619219,The IC50 value was measured on 786-0 cell line in ovarian tumor t,,14255,,80640,,,BAO_0000219,,Intermediate,,9606.0,F,,786-0
4152,Homo sapiens,,CHEMBL619220,The IC50 value was measured on 786-0 cell line in renal tumor type.,,14255,,80640,,,BAO_0000219,,Intermediate,,9606.0,F,,786-0
4153,Homo sapiens,,CHEMBL619221,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,,14696,,80640,,,BAO_0000219,,Intermediate,,9606.0,F,,786-0
4154,Homo sapiens,,CHEMBL619222,Tested for cytotoxic activity against renal cancer 786-0 cell line,,12016,,80640,,,BAO_0000219,,Intermediate,,9606.0,F,,786-0
4155,Homo sapiens,,CHEMBL857454,Compound was tested for growth inhibitory activity against 786-0 cell line,,2597,,80640,,,BAO_0000219,,Intermediate,,9606.0,F,,786-0
4156,,,CHEMBL619223,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,,12526,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4157,,,CHEMBL619224,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,,12526,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4158,,,CHEMBL619225,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,14799,,12166,,,BAO_0000019,,Autocuration,,,B,,
4159,,,CHEMBL619226,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,3595,,12166,,,BAO_0000219,,Expert,,,B,,RBL-1
4160,,,CHEMBL619227,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,3595,,12166,,,BAO_0000219,,Expert,,,B,,RBL-1
4161,,,CHEMBL619228,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,,12767,,12166,,,BAO_0000357,,Autocuration,,,B,,
4162,,,CHEMBL619229,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,,10997,,12166,,,BAO_0000219,,Autocuration,,,B,,
4163,,,CHEMBL619230,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,,11388,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4164,,,CHEMBL619231,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,,167,,12166,,,BAO_0000357,,Autocuration,,,B,,
4165,,,CHEMBL619232,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",,167,,12166,,,BAO_0000357,,Autocuration,,,B,,
4166,,,CHEMBL619233,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,,13744,,12166,,,BAO_0000357,,Expert,,,B,,
4167,,,CHEMBL619234,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,,1630,,12166,,,BAO_0000357,,Autocuration,,,B,,
4168,,,CHEMBL619235,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),,1630,,12166,,,BAO_0000357,,Autocuration,,,B,,
4169,Rattus norvegicus,,CHEMBL619236,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",,969,,12166,,,BAO_0000019,,Expert,,10116.0,B,,
4170,,,CHEMBL619237,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,,13621,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4171,,,CHEMBL619238,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,,10089,,12166,,,BAO_0000357,,Autocuration,,,B,,
4172,,,CHEMBL619239,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,,10193,,12166,,,BAO_0000357,,Expert,,,B,,
4173,,,CHEMBL619240,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,,11966,,12166,,,BAO_0000357,,Autocuration,,,B,,
4174,,,CHEMBL875417,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,12251,,12166,,,BAO_0000019,,Autocuration,,,B,,
4175,,,CHEMBL619241,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),,211,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4176,,,CHEMBL619242,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,12251,,12166,,,BAO_0000019,,Expert,,,F,,
4177,,,CHEMBL883796,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,,12495,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4178,,,CHEMBL619243,Tested for its inhibitory activity against 5-lipoxygenase,,414,,12166,,,BAO_0000357,,Autocuration,,,B,,
4179,,,CHEMBL619244,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,,414,,12166,,,BAO_0000357,,Autocuration,,,B,,
4180,,,CHEMBL619245,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",,10325,,12166,,,BAO_0000019,,Expert,,,B,,
4181,,,CHEMBL619246,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,11966,,12166,,,BAO_0000019,,Expert,,,B,,
4182,,,CHEMBL619984,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,,165,,12166,,,BAO_0000219,,Expert,,,B,,RBL-1
4183,,,CHEMBL619985,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,,165,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4184,,,CHEMBL619986,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,165,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4185,,,CHEMBL619987,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,165,,12166,,,BAO_0000219,,Expert,,,B,,RBL-1
4186,,,CHEMBL619988,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,,11311,,12166,,,BAO_0000218,,Autocuration,,,B,,
4187,,,CHEMBL619989,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,,11311,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4188,,,CHEMBL619990,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,11311,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4189,,,CHEMBL619991,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,11311,,12166,,,BAO_0000219,,Autocuration,,,B,,
4190,,,CHEMBL619992,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),,11311,,12166,,,BAO_0000219,,Autocuration,,,B,,
4191,,,CHEMBL619993,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),In vivo,11311,,12166,,,BAO_0000218,,Autocuration,,,B,,
4192,,,CHEMBL619994,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,,11311,,12166,,,BAO_0000219,,Autocuration,,,F,,RBL-2H3
4193,,,CHEMBL619995,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,,11311,,12166,,,BAO_0000219,,Autocuration,,,F,,RBL-2H3
4194,,,CHEMBL619996,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],,11311,,12166,,,BAO_0000019,,Autocuration,,,B,,
4195,,,CHEMBL619997,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,,11732,,12166,,,BAO_0000019,,Autocuration,,,B,,
4196,,,CHEMBL619998,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,,11732,,12166,,,BAO_0000019,,Expert,,,B,,
4197,,,CHEMBL619999,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,,11087,,12166,,,BAO_0000019,,Expert,,,B,,
4198,,,CHEMBL620000,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,,11087,,12166,,,BAO_0000019,,Autocuration,,,B,,
4199,,,CHEMBL620001,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,,11087,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4200,Rattus norvegicus,,CHEMBL620002,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,,11087,,12166,,,BAO_0000357,,Expert,,10116.0,B,,
4201,,,CHEMBL620003,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,,496,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4202,,,CHEMBL620004,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,,13986,,12166,,,BAO_0000219,,Expert,,,F,,RBL-1
4203,,,CHEMBL874063,Compound was evaluated for the inhibition of 5-lipoxygenase,,11520,,12166,,,BAO_0000357,,Autocuration,,,B,,
4204,,,CHEMBL620005,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,,10293,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4205,,,CHEMBL620006,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,,303,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4206,,,CHEMBL620007,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,,303,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4207,,,CHEMBL620008,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,,9247,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4208,Rattus norvegicus,,CHEMBL620009,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,,9247,,12166,,,BAO_0000219,,Expert,,10116.0,B,,RBL-1
4209,,,CHEMBL620010,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,9247,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4210,,,CHEMBL620011,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,,9247,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4211,,,CHEMBL620677,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,,9247,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4212,,,CHEMBL620678,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,,9247,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4213,,,CHEMBL620679,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,,9247,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4214,,,CHEMBL620680,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,,9247,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4215,Rattus norvegicus,,CHEMBL620838,Inhibitory activity against 5-lipoxygenase at 10 uM,,11481,,12166,,,BAO_0000357,,Expert,,10116.0,B,,
4216,,,CHEMBL620839,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,,105,,12166,,,BAO_0000357,,Autocuration,,,B,,
4217,,,CHEMBL620840,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,,9029,,12166,,,BAO_0000357,,Expert,,,B,,
4218,,,CHEMBL620841,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,,1175,,12166,,,BAO_0000219,,Expert,,,B,,RBL-1
4219,,,CHEMBL620842,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,,12118,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4220,,,CHEMBL620843,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,,12118,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4221,,,CHEMBL620844,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,,12118,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4222,,,CHEMBL620845,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,,9225,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4223,,,CHEMBL620846,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,,9401,,12166,,,BAO_0000019,,Autocuration,,,B,,
4224,,,CHEMBL873951,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,137,,12166,,,BAO_0000357,,Autocuration,,,B,,
4225,,,CHEMBL620847,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,137,,12166,,,BAO_0000357,,Autocuration,,,B,,
4226,,,CHEMBL620848,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,4717,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4227,,,CHEMBL620849,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,3595,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4228,,,CHEMBL620850,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,,10501,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4229,,,CHEMBL620851,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,,10501,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4230,,,CHEMBL620852,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,,10501,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4231,,,CHEMBL875098,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,12526,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4232,Rattus norvegicus,,CHEMBL620853,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,,14799,,12166,,,BAO_0000219,,Expert,,10116.0,B,,RBL-1
4233,,,CHEMBL620854,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,,14799,,12166,,,BAO_0000019,,Autocuration,,,B,,
4234,,,CHEMBL620855,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,3595,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4235,,,CHEMBL839884,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,3595,,12166,,,BAO_0000219,,Expert,,,B,,RBL-1
4236,,,CHEMBL620856,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,12526,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4237,,,CHEMBL620857,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,12526,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4238,,,CHEMBL620858,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,10193,,12166,,,BAO_0000019,,Autocuration,,,B,,
4239,,,CHEMBL620859,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,10193,,12166,,,BAO_0000019,,Autocuration,,,B,,
4240,,,CHEMBL620860,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,10193,,12166,,,BAO_0000019,,Autocuration,,,B,,
4241,,,CHEMBL620861,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,,10193,,12166,,,BAO_0000019,,Autocuration,,,B,,
4242,,,CHEMBL620862,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),,9138,,12166,,,BAO_0000357,,Expert,,,B,,
4243,,,CHEMBL620863,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,,9138,,12166,,,BAO_0000357,,Autocuration,,,B,,
4244,,,CHEMBL620864,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,11966,,12166,,,BAO_0000019,,Autocuration,,,B,,
4245,,,CHEMBL620865,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,,165,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4246,,,CHEMBL620866,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,,165,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4247,,,CHEMBL620867,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,,11311,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-2H3
4248,,,CHEMBL620868,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,11311,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-2H3
4249,,,CHEMBL620869,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,11311,,12166,,,BAO_0000219,,Autocuration,,,F,,RBL-2H3
4250,,,CHEMBL873952,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,,11311,,12166,,,BAO_0000019,,Autocuration,,,F,,
4251,,,CHEMBL875099,The compound was tested for inhibition of isolated 5-lipoxygenase,,11311,,12166,,,BAO_0000357,,Autocuration,,,B,,
4252,,,CHEMBL620870,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,,11311,,12166,,,BAO_0000219,,Autocuration,,,F,,RBL-2H3
4253,,,CHEMBL618261,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,,11087,,12166,,,BAO_0000019,,Autocuration,,,B,,
4254,,,CHEMBL618262,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,,11087,,12166,,,BAO_0000019,,Autocuration,,,B,,
4255,,,CHEMBL619428,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,,11087,,12166,,,BAO_0000019,,Autocuration,,,B,,
4256,,,CHEMBL619429,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,11087,,12166,,,BAO_0000019,,Autocuration,,,B,,
4257,,,CHEMBL619430,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,11087,,12166,,,BAO_0000019,,Autocuration,,,B,,
4258,,,CHEMBL620017,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,,496,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4259,,,CHEMBL620018,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,,496,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4260,,,CHEMBL620019,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,,13986,,12166,,,BAO_0000219,,Autocuration,,,F,,RBL-1
4261,,,CHEMBL620020,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,,13986,,12166,,,BAO_0000219,,Autocuration,,,F,,RBL-1
4262,,,CHEMBL620021,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,,13986,,12166,,,BAO_0000219,,Autocuration,,,F,,RBL-1
4263,,,CHEMBL620022,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,,13986,,12166,,,BAO_0000219,,Autocuration,,,F,,RBL-1
4264,,,CHEMBL620023,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,,13986,,12166,,,BAO_0000219,,Autocuration,,,F,,RBL-1
4265,,,CHEMBL620024,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,,13986,,12166,,,BAO_0000219,,Autocuration,,,F,,RBL-1
4266,,,CHEMBL620025,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,,13986,,12166,,,BAO_0000219,,Autocuration,,,F,,RBL-1
4267,,,CHEMBL620026,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,,13986,,12166,,,BAO_0000219,,Autocuration,,,F,,RBL-1
4268,,,CHEMBL620027,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,,13986,,12166,,,BAO_0000219,,Autocuration,,,F,,RBL-1
4269,Rattus norvegicus,,CHEMBL620028,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,,13986,,12166,,,BAO_0000019,,Expert,,10116.0,F,,
4270,,,CHEMBL620029,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,,10193,,12166,,,BAO_0000357,,Autocuration,,,B,,
4271,,,CHEMBL620030,Compound was tested for the percent of inhibition against 5-LO at 10 uM,,9295,,12166,,,BAO_0000357,,Autocuration,,,B,,
4272,,,CHEMBL875415,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,,4717,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4273,,,CHEMBL618256,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,4717,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4274,,,CHEMBL618257,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,,11854,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4275,,,CHEMBL618258,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,,11854,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4276,,,CHEMBL618259,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,,11854,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4277,,,CHEMBL618260,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,10193,,12166,,,BAO_0000019,,Autocuration,,,B,,
4278,,,CHEMBL618215,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,,9295,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4279,,,CHEMBL618390,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,,9295,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4280,,,CHEMBL618391,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,,9295,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4281,,,CHEMBL618392,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,,9295,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4282,,,CHEMBL618393,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,,165,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4283,,,CHEMBL618394,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,,11311,,12166,,,BAO_0000219,,Autocuration,,,B,,
4284,Homo sapiens,,CHEMBL618395,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,10489,,12166,,,BAO_0000219,,Expert,,9606.0,B,,RBL-1
4285,Rattus norvegicus,,CHEMBL618396,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,10489,,12166,,,BAO_0000219,,Expert,,10116.0,B,,RBL-1
4286,Rattus norvegicus,,CHEMBL858253,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),,10489,,12166,,,BAO_0000219,,Expert,,10116.0,B,,RBL-1
4287,Rattus norvegicus,,CHEMBL618397,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,14799,,12166,,,BAO_0000019,,Autocuration,,10116.0,B,,
4288,Glycine max,,CHEMBL618398,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),,9295,,12054,,,BAO_0000357,,Autocuration,,3847.0,B,,
4289,,,CHEMBL618399,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",,16811,,22226,,,BAO_0000019,,Autocuration,,,B,,
4290,,,CHEMBL618400,In vitro inhibition of 5-Lipoxygenase; Inactive.,,168,,55,,,BAO_0000357,,Expert,,,B,,
4291,,,CHEMBL618401,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,,6309,,55,,,BAO_0000357,,Autocuration,,,B,,
4292,,,CHEMBL618402,Inhibitory concentration against 5-lipoxygenase; No inhibition,,6309,,55,,,BAO_0000357,,Autocuration,,,B,,
4293,,,CHEMBL876400,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,,3092,,55,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4294,,,CHEMBL618403,Inhibitory activity against 5-lipoxygenase.,,168,,55,,,BAO_0000357,,Expert,,,B,,
4295,,,CHEMBL618404,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,,168,,55,,,BAO_0000357,,Autocuration,,,B,,
4296,,,CHEMBL618405,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,,168,,55,,,BAO_0000357,,Autocuration,,,B,,
4297,,,CHEMBL618406,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,,168,,55,,,BAO_0000357,,Autocuration,,,B,,
4298,,,CHEMBL618407,Inhibitory concentration against arachidonic acid 5-lipoxygenation,,12338,,55,,,BAO_0000019,,Expert,,,F,,
4299,,,CHEMBL618408,Tested for the inhibitory activity against 5-lipoxygenase,,4501,,55,,,BAO_0000357,,Autocuration,,,B,,
4300,,,CHEMBL618409,Compound was tested for its inhibitory activity against 5-lipoxygenase,,1132,,55,,,BAO_0000357,,Autocuration,,,B,,
4301,,,CHEMBL618410,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,,2117,,55,,,BAO_0000357,,Autocuration,,,B,,
4302,,,CHEMBL618411,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,,168,,55,,,BAO_0000357,,Autocuration,,,B,,
4303,,,CHEMBL618412,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,,168,,55,,,BAO_0000357,,Autocuration,,,B,,
4304,,,CHEMBL618413,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,,13575,,12166,,,BAO_0000219,,Autocuration,,,B,,RBL-1
4305,,,CHEMBL618414,,,11089,,12166,,,BAO_0000357,,Autocuration,,,B,,
4306,,,CHEMBL618415,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),,216,,10102,,,BAO_0000357,,Autocuration,,,B,,
4307,,,CHEMBL618416,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,,13165,,10102,,,BAO_0000019,,Autocuration,,,B,,
4308,,,CHEMBL876401,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,,3278,,10102,,,BAO_0000357,,Autocuration,,,B,,
4309,,,CHEMBL618417,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,,3278,,10102,,,BAO_0000357,,Expert,,,B,,
4310,,,CHEMBL618418,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,,11966,,10102,,,BAO_0000357,,Autocuration,,,B,,
4311,,,CHEMBL618419,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",,175,,10102,,,BAO_0000357,,Autocuration,,,B,,
4312,,,CHEMBL618420,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",,175,,10102,,,BAO_0000357,,Autocuration,,,B,,
4313,,,CHEMBL618421,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,,13449,,10102,,,BAO_0000357,,Autocuration,,,B,,
4314,,,CHEMBL618422,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,,12014,,11238,,,BAO_0000019,,Autocuration,,,B,,
4315,,,CHEMBL618423,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),,12014,,11238,,,BAO_0000019,,Autocuration,,,B,,
4316,,,CHEMBL618424,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),,12014,,11238,,,BAO_0000019,,Autocuration,,,B,,
4317,,,CHEMBL618425,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,,99,,100284,,,BAO_0000220,,Intermediate,,,B,,
4318,Homo sapiens,,CHEMBL618426,The dark toxicity against 543 human galactophore carcinoma cells,,4349,,22226,,,BAO_0000019,,Autocuration,,9606.0,F,,
4319,Homo sapiens,,CHEMBL618427,Tested in vitro for cytotoxicity against 56 human tumor cell lines,,4071,,80623,,,BAO_0000219,,Expert,,9606.0,F,,Panel (56 tumour cell lines)
4320,Homo sapiens,,CHEMBL618428,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,,17589,,80008,,,BAO_0000219,,Expert,,9606.0,F,,5637
4321,Homo sapiens,,CHEMBL618429,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,,15002,,80008,,,BAO_0000219,,Intermediate,,9606.0,F,,5637
4322,Homo sapiens,,CHEMBL618430,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",,13958,,80008,,,BAO_0000219,,Intermediate,,9606.0,F,,5637
4323,Homo sapiens,,CHEMBL618431,Growth inhibition against human 5637 cell lines,,17589,,80008,,,BAO_0000219,,Expert,,9606.0,F,,5637
4324,Homo sapiens,,CHEMBL883799,Antitumor activity against human bladder carcinoma 5637 cells.,,16748,,80008,,,BAO_0000219,,Expert,,9606.0,F,,5637
4325,Homo sapiens,,CHEMBL618432,Antitumor activity against human bladder carcinoma 5637 cells,,16747,,80008,,,BAO_0000219,,Intermediate,,9606.0,F,,5637
4326,Homo sapiens,,CHEMBL618433,Antitumor activity against human bladder carcinoma 5637 cells,,16747,,80008,,,BAO_0000219,,Intermediate,,9606.0,F,,5637
4327,Bos taurus,,CHEMBL618434,In vitro inhibition of bovine trypsin(Trp).,,15285,,10443,,,BAO_0000357,,Expert,,9913.0,B,,
4328,Cercopithecidae,,CHEMBL618435,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,,3726,,240,,,BAO_0000219,,Expert,,9527.0,B,,CV-1
4329,,,CHEMBL876402,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,,5033,,10577,,,BAO_0000357,,Autocuration,,,B,,
4330,,,CHEMBL618436,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,,11756,,104698,,,BAO_0000019,,Autocuration,,,F,,
4331,,,CHEMBL618437,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,In vivo,11953,,22226,,,BAO_0000218,,Autocuration,,,F,,
4332,Cavia porcellus,,CHEMBL618438,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,,5033,,20033,,,BAO_0000357,,Intermediate,,10141.0,B,,
4333,Rattus norvegicus,,CHEMBL883800,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,11347,,17045,,,BAO_0000251,,Expert,Microsomes,10116.0,A,,
4334,Rattus norvegicus,,CHEMBL618439,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,11347,,17045,,,BAO_0000251,,Expert,Microsomes,10116.0,A,,
4335,,,CHEMBL618440,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,1229,,22226,,,BAO_0000019,,Intermediate,,,F,,
4336,,,CHEMBL618441,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,1229,,22226,,,BAO_0000019,,Intermediate,,,F,,
4337,Trypanosoma brucei,,CHEMBL618442,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,,17588,,11938,,,BAO_0000019,,Expert,,5691.0,B,,
4338,Trypanosoma brucei,,CHEMBL618443,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,,17588,,11938,,,BAO_0000019,,Autocuration,,5691.0,B,,
4339,Ovis aries,,CHEMBL619158,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,,17588,,11938,,,BAO_0000019,,Expert,,9940.0,B,,
4340,Ovis aries,,CHEMBL620974,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,,17588,,11938,,,BAO_0000019,,Autocuration,,9940.0,B,,
4341,,,CHEMBL620975,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,,16485,,11938,,,BAO_0000357,,Autocuration,,,B,,
4342,Homo sapiens,,CHEMBL620976,Average inhibitory concentration against 60 human cell lines was reported,,4337,,22226,,,BAO_0000019,,Intermediate,,9606.0,F,,
4343,Homo sapiens,,CHEMBL620977,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,,4112,,22226,,,BAO_0000019,,Expert,,9606.0,F,,
4344,Homo sapiens,,CHEMBL620978,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,,16160,,80315,,,BAO_0000219,,Intermediate,,9606.0,F,,Panel NCI-60 (60 carcinoma cell lines)
4345,Homo sapiens,,CHEMBL620979,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,,16160,,80315,,,BAO_0000219,,Intermediate,,9606.0,F,,Panel NCI-60 (60 carcinoma cell lines)
4346,,,CHEMBL620980,In vitro mean growth inhibitory activity against 60-cell panel,,17376,,80315,,,BAO_0000219,,Expert,,,F,,Panel NCI-60 (60 carcinoma cell lines)
4347,,,CHEMBL620981,In vitro mean growth lethal concentration against 60-cell panel,,17376,,80315,,,BAO_0000219,,Expert,,,F,,Panel NCI-60 (60 carcinoma cell lines)
4348,,,CHEMBL620982,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,,17376,,80315,,,BAO_0000219,,Expert,,,F,,Panel NCI-60 (60 carcinoma cell lines)
4349,,,CHEMBL620983,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,,17376,,80315,,,BAO_0000219,,Expert,,,F,,Panel NCI-60 (60 carcinoma cell lines)
4350,,,CHEMBL620984,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,3241,,104775,,,BAO_0000019,,Autocuration,,,F,,
4351,,,CHEMBL620985,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,3241,,104775,,,BAO_0000019,,Autocuration,,,F,,
4352,,,CHEMBL620986,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,,3725,,275,,,BAO_0000357,,Expert,,,B,,
4353,Plasmodium falciparum,,CHEMBL620987,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,,10805,,50425,,,BAO_0000218,,Expert,,5833.0,F,,
4354,Plasmodium falciparum,,CHEMBL620988,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,,10805,,50425,,,BAO_0000218,,Expert,,5833.0,F,,
4355,Plasmodium falciparum,,CHEMBL620989,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,,10805,,50425,,,BAO_0000218,,Expert,,5833.0,F,,
4356,Plasmodium falciparum,,CHEMBL620990,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,,10805,,50425,,,BAO_0000218,,Expert,,5833.0,F,,
4357,Plasmodium falciparum,,CHEMBL620991,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,,10805,,50425,,,BAO_0000218,,Intermediate,,5833.0,F,,
4358,Mus musculus,,CHEMBL620992,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,10144,,80628,,,BAO_0000218,,Intermediate,,10090.0,F,,6C3HED
4359,Mus musculus,,CHEMBL620993,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,10144,,80628,,,BAO_0000218,,Intermediate,,10090.0,F,,6C3HED
4360,Mus musculus,,CHEMBL620994,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,,10144,,80628,,,BAO_0000218,,Intermediate,,10090.0,F,,6C3HED
4361,Mus musculus,,CHEMBL620995,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,10144,,80628,,,BAO_0000218,,Intermediate,,10090.0,F,,6C3HED
4362,Mus musculus,,CHEMBL620996,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,10144,,80628,,,BAO_0000218,,Intermediate,,10090.0,F,,6C3HED
4363,Mus musculus,,CHEMBL875581,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,,10144,,80628,,,BAO_0000218,,Intermediate,,10090.0,F,,6C3HED
4364,Mus musculus,,CHEMBL620997,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,In vivo,10685,,22224,,,BAO_0000218,,Autocuration,,10090.0,F,,
4365,Mus musculus,,CHEMBL620998,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,In vivo,10685,,22224,,,BAO_0000218,,Autocuration,,10090.0,F,,
4366,Mus musculus,,CHEMBL620999,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),In vivo,10685,,22224,,,BAO_0000218,,Autocuration,,10090.0,F,,
4367,Mus musculus,,CHEMBL621000,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,In vivo,10685,,22224,,,BAO_0000218,,Autocuration,,10090.0,F,,
4368,Mus musculus,,CHEMBL621001,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,In vivo,10685,,22224,,,BAO_0000218,,Autocuration,,10090.0,F,,
4369,Mus musculus,,CHEMBL621002,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,In vivo,10685,,22224,,,BAO_0000218,,Autocuration,,10090.0,F,,
4370,Mus musculus,,CHEMBL621003,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,In vivo,10685,,22224,,,BAO_0000218,,Autocuration,,10090.0,F,,
4371,Mus musculus,,CHEMBL621004,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",In vivo,10685,,22224,,,BAO_0000218,,Autocuration,,10090.0,F,,
4372,Mus musculus,,CHEMBL621005,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),In vivo,10685,,22224,,,BAO_0000218,,Autocuration,,10090.0,F,,
4373,Mus musculus,,CHEMBL621006,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),In vivo,10685,,22224,,,BAO_0000218,,Autocuration,,10090.0,F,,
4374,Mus musculus,,CHEMBL621007,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,In vivo,10685,,22224,,,BAO_0000218,,Autocuration,,10090.0,F,,
4375,Mus musculus,,CHEMBL621008,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,10144,,22224,,,BAO_0000218,,Autocuration,,10090.0,F,,
4376,Mus musculus,,CHEMBL621009,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,10144,,22224,,,BAO_0000218,,Autocuration,,10090.0,F,,
4377,Mus musculus,,CHEMBL857705,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,10144,,22224,,,BAO_0000218,,Autocuration,,10090.0,F,,
4378,Mus musculus,,CHEMBL619828,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,10144,,22224,,,BAO_0000218,,Autocuration,,10090.0,F,,
4379,Mus musculus,,CHEMBL619829,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,,10685,,22224,,,BAO_0000218,,Autocuration,,10090.0,F,,
4380,Mus musculus,,CHEMBL619830,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,,10685,,22224,,,BAO_0000218,,Autocuration,,10090.0,F,,
4381,Mus musculus,,CHEMBL619831,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,,10685,,22224,,,BAO_0000218,,Autocuration,,10090.0,F,,
4382,Mus musculus,,CHEMBL619832,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,,10685,,22224,,,BAO_0000218,,Autocuration,,10090.0,F,,
4383,Mus musculus,,CHEMBL619833,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,,10685,,22224,,,BAO_0000218,,Autocuration,,10090.0,A,,
4384,Mus musculus,,CHEMBL619834,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,,10685,,22224,,,BAO_0000218,,Autocuration,,10090.0,A,,
4385,Mus musculus,,CHEMBL619835,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,,10685,,22224,,,BAO_0000218,,Autocuration,,10090.0,A,,
4386,Mus musculus,,CHEMBL619836,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,,10685,,22224,,,BAO_0000218,,Autocuration,,10090.0,A,,
4387,Mus musculus,,CHEMBL619837,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",,8831,,80628,,,BAO_0000218,,Intermediate,,10090.0,F,,6C3HED
4388,,,CHEMBL619838,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,In vivo,11704,,22224,,,BAO_0000218,,Autocuration,,,F,,
4389,Mus musculus,,CHEMBL619839,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,,11704,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4390,Mus musculus,,CHEMBL619840,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,In vivo,10685,,80628,,,BAO_0000218,,Intermediate,,10090.0,F,,6C3HED
4391,Mus musculus,,CHEMBL619841,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,In vivo,10685,,80628,,,BAO_0000218,,Intermediate,,10090.0,F,,6C3HED
4392,Mus musculus,,CHEMBL857704,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),,11368,,80628,,,BAO_0000218,,Expert,,10090.0,F,,6C3HED
4393,Mus musculus,,CHEMBL619842,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),,11368,,80628,,,BAO_0000218,,Intermediate,,10090.0,F,,6C3HED
4394,Mus musculus,,CHEMBL619843,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),,11368,,80628,,,BAO_0000218,,Expert,,10090.0,F,,6C3HED
4395,Staphylococcus aureus,,CHEMBL619844,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",,17763,,22226,,,BAO_0000019,,Autocuration,,1280.0,B,,
4396,Rattus norvegicus,2107.0,CHEMBL857855,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4397,Rattus norvegicus,2107.0,CHEMBL619845,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4398,Rattus norvegicus,2107.0,CHEMBL619846,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4399,Rattus norvegicus,2107.0,CHEMBL619847,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4400,Rattus norvegicus,2107.0,CHEMBL619848,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4401,Rattus norvegicus,2107.0,CHEMBL620893,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4402,Rattus norvegicus,2107.0,CHEMBL620894,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4403,Rattus norvegicus,2107.0,CHEMBL620895,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4404,Rattus norvegicus,2107.0,CHEMBL620896,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4405,Rattus norvegicus,2107.0,CHEMBL620897,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4406,Rattus norvegicus,2107.0,CHEMBL620898,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4407,Rattus norvegicus,2107.0,CHEMBL620899,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,,7411,Liver,22226,,,BAO_0000251,,Autocuration,Microsomes,10116.0,B,,
4408,Cercopithecidae,1969.0,CHEMBL620900,The apparent total plasma clearance in monkey,In vivo,347,Plasma,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4409,Cercopithecidae,,CHEMBL620901,Compound was evaluated for Hepatic clearance in monkey,In vivo,3341,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4410,Cercopithecidae,,CHEMBL620902,Lower clearance in monkey (i.v.) at 0.5 mpk,In vivo,17853,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4411,Cercopithecidae,,CHEMBL620903,Plasma clearance in rhesus monkey,In vivo,4514,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4412,Cercopithecidae,,CHEMBL620904,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,In vivo,6062,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4413,Cercopithecidae,,CHEMBL620905,Plasma clearance of compound was determined in monkey,In vivo,6821,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4414,Cercopithecidae,,CHEMBL620906,Plasma clearance was calculated in rhesus monkey,In vivo,6057,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4415,Cercopithecidae,,CHEMBL875420,Plasma clearance in rhesus monkey,In vivo,5145,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4416,Cercopithecidae,,CHEMBL620907,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,6641,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4417,Cercopithecidae,,CHEMBL620908,Plasma clearance was evaluated in rhesus,In vivo,5472,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4418,Cercopithecidae,,CHEMBL620909,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,In vivo,4257,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4419,Cercopithecidae,,CHEMBL620910,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,In vivo,5546,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4420,Cercopithecidae,,CHEMBL620911,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),In vivo,5334,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4421,Cercopithecidae,,CHEMBL620912,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),In vivo,5334,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4422,Cercopithecidae,,CHEMBL620913,Cmax 24 hr after 2 mg/kg oral administration in monkeys,In vivo,17509,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4423,Cercopithecidae,,CHEMBL620914,Cmax in monkey after administration of 1 mg/kg iv,In vivo,6535,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4424,Cercopithecidae,,CHEMBL620915,Cmax was determine after peroral administration at 10 mpk in Rhesus,In vivo,5668,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4425,Cercopithecidae,,CHEMBL620916,Cmax in cynomolgus monkey by iv administration,In vivo,5922,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4426,Cercopithecidae,,CHEMBL620917,Cmax in cynomolgus monkey by po administration,In vivo,5922,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4427,Cercopithecidae,,CHEMBL620918,Cmax value evaluated in monkey,In vivo,6078,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4428,Cercopithecidae,,CHEMBL620919,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,In vivo,2661,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4429,Cercopithecidae,1969.0,CHEMBL620920,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,In vivo,3249,Plasma,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4430,Cercopithecidae,1969.0,CHEMBL620921,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,In vivo,3249,Plasma,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4431,Cercopithecidae,1969.0,CHEMBL620922,Maximal plasma concentration in squirrel monkeys,In vivo,5553,Plasma,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4432,Cercopithecidae,,CHEMBL620923,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,In vivo,1916,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4433,Cercopithecidae,1969.0,CHEMBL620924,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,In vivo,6227,Plasma,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4434,Cercopithecidae,,CHEMBL620925,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),In vivo,4809,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4435,Cercopithecidae,,CHEMBL620926,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,In vivo,5355,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4436,Cercopithecidae,,CHEMBL620927,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,In vivo,5355,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4437,Cercopithecidae,,CHEMBL620928,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,In vivo,5355,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4438,Cercopithecidae,,CHEMBL620929,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,In vivo,5355,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4439,Cercopithecidae,1969.0,CHEMBL620930,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,In vivo,6221,Plasma,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4440,Cercopithecidae,,CHEMBL620931,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,,167,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4441,Cercopithecidae,,CHEMBL620932,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,,167,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4442,monkey,,CHEMBL620933,Absolute bioavailability was evaluated in monkey,In vivo,4257,,22224,,,BAO_0000218,,Autocuration,,9443.0,A,,
4443,monkey,,CHEMBL620934,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,In vivo,6221,,22224,,,BAO_0000218,,Autocuration,,9443.0,A,,
4444,monkey,,CHEMBL620935,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,In vivo,17667,,22224,,,BAO_0000218,,Autocuration,,9443.0,A,,
4445,Macaca mulatta,,CHEMBL620936,Bioavailability of compound was determined in rhesus monkey,In vivo,17267,,22224,,,BAO_0000218,,Autocuration,,9544.0,A,,
4446,marmosets,,CHEMBL620937,Bioavailability determined after oral administration in marmoset,In vivo,4256,,22224,,,BAO_0000218,,Autocuration,,38020.0,A,,
4447,Macaca fascicularis,,CHEMBL620938,Oral bioavailability in cynomolgus monkey,In vivo,4256,,22224,,,BAO_0000218,,Autocuration,,9541.0,A,,
4448,monkey,,CHEMBL620939,Bioavailability in monkey (p.o.) at 2.0 mpk,In vivo,17853,,22224,,,BAO_0000218,,Autocuration,,9443.0,A,,
4449,monkey,,CHEMBL620940,Bioavailability was evaluated after oral administration in monkey,In vivo,16365,,22224,,,BAO_0000218,,Autocuration,,9443.0,A,,
4450,Macaca fascicularis,,CHEMBL620941,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,In vivo,1916,,22224,,,BAO_0000218,,Autocuration,,9541.0,A,,
4451,Macaca mulatta,,CHEMBL620942,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),In vivo,5334,,22224,,,BAO_0000218,,Autocuration,,9544.0,A,,
4452,Macaca mulatta,,CHEMBL620943,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),In vivo,5334,,22224,,,BAO_0000218,,Autocuration,,9544.0,A,,
4453,monkey,,CHEMBL620944,Bioavailability of the compound was determined in monkey,In vivo,17592,,22224,,,BAO_0000218,,Autocuration,,9443.0,A,,
4454,Saimiri sciureus,,CHEMBL620945,Bioavailability in squirrel monkey (dose 5 mg/kg),In vivo,1399,,22224,,,BAO_0000218,,Autocuration,,9521.0,A,,
4455,monkey,,CHEMBL620946,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),In vivo,4809,,22224,,,BAO_0000218,,Autocuration,,9443.0,A,,
4456,monkey,,CHEMBL620947,Oral bioavailability in monkey,In vivo,3341,,22224,,,BAO_0000218,,Autocuration,,9443.0,A,,
4457,Saimiri sciureus,,CHEMBL620948,Compound was tested for bioavailability in squirrel monkey,In vivo,64,,22224,,,BAO_0000218,,Autocuration,,9521.0,A,,
4458,Macaca mulatta,,CHEMBL620949,Oral bioavailability in Rhesus monkey,In vivo,5005,,22224,,,BAO_0000218,,Autocuration,,9544.0,A,,
4459,Macaca mulatta,,CHEMBL620950,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),In vivo,5005,,22224,,,BAO_0000218,,Autocuration,,9544.0,A,,
4460,Macaca fascicularis,,CHEMBL620951,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,In vivo,5237,,22224,,,BAO_0000218,,Autocuration,,9541.0,A,,
4461,Macaca fascicularis,,CHEMBL620952,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,In vivo,5237,,22224,,,BAO_0000218,,Autocuration,,9541.0,A,,
4462,monkey,,CHEMBL875421,Oral bioavailability in monkey (dose 5 mg/kg),In vivo,5302,,22224,,,BAO_0000218,,Autocuration,,9443.0,A,,
4463,monkey,,CHEMBL620953,Oral bioavailability of compound at 5 mg/kg in monkey,In vivo,17667,,22224,,,BAO_0000218,,Autocuration,,9443.0,A,,
4464,Canis lupus familiaris,,CHEMBL873491,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,In vivo,6161,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
4465,Canis lupus familiaris,,CHEMBL620954,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,In vivo,6161,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
4466,Canis lupus familiaris,1969.0,CHEMBL620955,Plasma half life determined,,3854,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
4467,Canis lupus familiaris,1969.0,CHEMBL618097,Plasma half life in dog,,993,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
4468,Canis lupus familiaris,1969.0,CHEMBL618268,Plasma half-life in Beagle dogs,,4514,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
4469,Canis lupus familiaris,1969.0,CHEMBL618269,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),In vivo,5334,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
4470,Canis lupus familiaris,1969.0,CHEMBL618270,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),In vivo,5334,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
4471,Canis lupus familiaris,,CHEMBL618271,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,In vivo,1466,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
4472,Canis lupus familiaris,,CHEMBL873493,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,In vivo,1466,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
4473,Canis lupus familiaris,,CHEMBL621031,Tested for the half life period in dog,,5313,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
4474,Canis lupus familiaris,,CHEMBL621032,Tested for the half life period in dog at dosage of 10 mpk,In vivo,5313,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
4475,Canis lupus familiaris,,CHEMBL621033,The compound was tested for half life in dog,,3880,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
4476,Canis lupus familiaris,1969.0,CHEMBL621034,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",,3639,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
4477,Canis lupus familiaris,,CHEMBL621035,The half life was determined,,3880,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
4478,Canis lupus familiaris,1969.0,CHEMBL621036,The plasma half-life in dogs,,3918,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
4479,Canis lupus familiaris,1969.0,CHEMBL621037,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,,16452,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
4480,Canis lupus familiaris,,CHEMBL619812,Half life in dog,,17796,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
4481,Canis lupus familiaris,,CHEMBL619813,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,In vivo,5983,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
4482,Canis lupus familiaris,,CHEMBL873335,tmax upon peroral administration of 10.0 mg/Kg dose in dog,In vivo,1466,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
4483,Canis lupus familiaris,,CHEMBL619814,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,In vivo,16456,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
4484,Mustela putorius furo,,CHEMBL619815,Cmax in ferrets after 30 mg/kg oral dose,In vivo,6113,,50506,,,BAO_0000218,,Expert,,9669.0,A,,
4485,Mustela putorius furo,,CHEMBL619816,Emesis in ferrets at 30 mg/kg oral dose,In vivo,6113,,50506,,,BAO_0000218,,Expert,,9669.0,F,,
4486,Macaca fascicularis,,CHEMBL619817,Bioavailability in cynomolgus monkey,In vivo,17796,,22224,,,BAO_0000218,,Autocuration,,9541.0,A,,
4487,Macaca fascicularis,,CHEMBL619818,Volume of distribution in cynomolgus,In vivo,17796,,100710,,,BAO_0000218,,Intermediate,,9541.0,A,,
4488,Cavia porcellus,1969.0,CHEMBL619819,AUC tested in guinea pig when 3 mg/kg dose was given perorally,,5308,Plasma,22224,,,BAO_0000218,,Autocuration,,10141.0,A,,
4489,Cavia porcellus,,CHEMBL619820,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,,4877,,22224,,,BAO_0000218,,Autocuration,,10141.0,A,,
4490,Cavia porcellus,,CHEMBL875419,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",,4876,,22224,,,BAO_0000218,,Autocuration,,10141.0,A,,
4491,Cavia porcellus,1969.0,CHEMBL619821,AUC in guinea pig after 3mg/kg oral dose,In vivo,4878,Plasma,22224,,,BAO_0000218,,Autocuration,,10141.0,A,,
4492,Cavia porcellus,,CHEMBL619822,Bioavailability in guinea pig was tested,In vivo,5308,,22224,,,BAO_0000218,,Autocuration,,10141.0,A,,
4493,Cavia porcellus,,CHEMBL619823,Tested for oral bioavailability in guinea pig at 5 mg/kg,In vivo,4877,,22224,,,BAO_0000218,,Autocuration,,10141.0,A,,
4494,Cavia porcellus,,CHEMBL619824,Tested for the oral bioavailability of the compound,In vivo,4876,,22224,,,BAO_0000218,,Autocuration,,10141.0,A,,
4495,Cavia porcellus,,CHEMBL619825,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,In vivo,4876,,22224,,,BAO_0000218,,Autocuration,,10141.0,A,,
4496,Cavia porcellus,,CHEMBL619826,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,In vivo,5308,,22224,,,BAO_0000218,,Autocuration,,10141.0,A,,
4497,Cavia porcellus,2048.0,CHEMBL619827,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,In vivo,4877,Lung,22224,,,BAO_0000218,,Autocuration,,10141.0,A,,
4498,Cavia porcellus,,CHEMBL618167,Cmax in guinea pig after 3mg/kg oral dose,In vivo,4878,,22224,,,BAO_0000218,,Autocuration,,10141.0,A,,
4499,Cavia porcellus,178.0,CHEMBL618168,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,,5689,Blood,22224,,,BAO_0000019,,Autocuration,,10141.0,A,,
4500,Cavia porcellus,955.0,CHEMBL618169,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,,5689,Brain,22224,,,BAO_0000019,,Autocuration,,10141.0,A,,
4501,Cavia porcellus,,CHEMBL618170,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,,5689,,22224,,,BAO_0000019,,Autocuration,,10141.0,A,,
4502,Cavia porcellus,160.0,CHEMBL618171,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,,5689,Intestine,22224,,,BAO_0000019,,Autocuration,,10141.0,A,,
4503,Cavia porcellus,2113.0,CHEMBL618172,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,,5689,Kidney,22224,,,BAO_0000019,,Autocuration,,10141.0,A,,
4504,Cavia porcellus,2107.0,CHEMBL618173,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,,5689,Liver,22224,,,BAO_0000019,,Autocuration,,10141.0,A,,
4505,Cavia porcellus,,CHEMBL618174,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,,5689,,22224,,,BAO_0000019,,Autocuration,,10141.0,A,,
4506,Cavia porcellus,2106.0,CHEMBL875408,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,,5689,Spleen,22224,,,BAO_0000019,,Autocuration,,10141.0,A,,
4507,Cavia porcellus,,CHEMBL839827,Elimination T1/2 in Guinea pig (PO dose),In vivo,14465,,22224,,,BAO_0000218,,Autocuration,,10141.0,A,,
4508,Cavia porcellus,,CHEMBL618175,Partition coefficient was measured as -log (counts per min ),,5689,,22224,,,BAO_0000019,,Autocuration,,10141.0,A,,
4509,Cavia porcellus,,CHEMBL618176,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,In vivo,611,,22224,,,BAO_0000218,,Autocuration,,10141.0,A,,
4510,Cavia porcellus,,CHEMBL618177,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,In vivo,611,,22224,,,BAO_0000218,,Autocuration,,10141.0,A,,
4511,Cavia porcellus,,CHEMBL618178,Elimination T1/2 in Guinea pig (PO dose),In vivo,14465,,22224,,,BAO_0000218,,Autocuration,,10141.0,A,,
4512,Cavia porcellus,,CHEMBL618179,"Tested for the half life period of the compound, intravenously",In vivo,4876,,22224,,,BAO_0000218,,Autocuration,,10141.0,A,,
4513,Cavia porcellus,,CHEMBL873489,Half-life was measured,,5689,,22224,,,BAO_0000019,,Autocuration,,10141.0,A,,
4514,Cavia porcellus,,CHEMBL618180,The time required for onset of inotropy after addition of a single dose of delta F75,,7515,,22224,,,BAO_0000019,,Autocuration,,10141.0,A,,
4515,Cavia porcellus,,CHEMBL618181,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,In vivo,17667,,22224,,,BAO_0000218,,Autocuration,,10141.0,A,,
4516,Cavia porcellus,,CHEMBL618182,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,In vivo,17667,,22224,,,BAO_0000218,,Autocuration,,10141.0,A,,
4517,Cricetulus griseus,,CHEMBL618183,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,In vivo,4727,,22224,,,BAO_0000218,,Autocuration,,10029.0,A,,
4518,Mus musculus,,CHEMBL618184,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,10107,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4519,Mus musculus,,CHEMBL618185,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,10107,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4520,Mus musculus,,CHEMBL618186,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,10107,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4521,Mus musculus,,CHEMBL618187,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,10107,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4522,Mus musculus,,CHEMBL618188,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,In vivo,10107,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4523,Mus musculus,,CHEMBL875409,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,10107,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4524,Mus musculus,,CHEMBL618189,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,10107,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4525,Mus musculus,178.0,CHEMBL618190,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,In vivo,3655,Blood,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4526,Mus musculus,178.0,CHEMBL618191,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,In vivo,3655,Blood,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4527,Mus musculus,178.0,CHEMBL618192,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,In vivo,3655,Blood,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4528,Mus musculus,10000001.0,CHEMBL618193,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,In vivo,3655,Bone,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4529,Mus musculus,10000001.0,CHEMBL618194,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,In vivo,3655,Bone,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4530,Mus musculus,10000001.0,CHEMBL618195,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,In vivo,3655,Bone,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4531,Mus musculus,955.0,CHEMBL618196,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,In vivo,3655,Brain,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4532,Mus musculus,955.0,CHEMBL618197,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,In vivo,3655,Brain,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4533,Mus musculus,955.0,CHEMBL618198,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,In vivo,3655,Brain,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4534,Mus musculus,948.0,CHEMBL618199,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,In vivo,3655,Heart,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4535,Mus musculus,948.0,CHEMBL618200,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,In vivo,3655,Heart,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4536,Mus musculus,948.0,CHEMBL618201,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,In vivo,3655,Heart,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4537,Mus musculus,160.0,CHEMBL618202,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,In vivo,3655,Intestine,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4538,Mus musculus,160.0,CHEMBL618203,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,In vivo,3655,Intestine,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4539,Mus musculus,160.0,CHEMBL618204,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,In vivo,3655,Intestine,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4540,Mus musculus,2113.0,CHEMBL618205,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,In vivo,3655,Kidney,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4541,Mus musculus,2113.0,CHEMBL618206,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,In vivo,3655,Kidney,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4542,Mus musculus,2113.0,CHEMBL618207,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,In vivo,3655,Kidney,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4543,Mus musculus,2107.0,CHEMBL618208,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,In vivo,3655,Liver,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4544,Mus musculus,2107.0,CHEMBL618932,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,In vivo,3655,Liver,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4545,Mus musculus,2107.0,CHEMBL618933,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,In vivo,3655,Liver,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4546,Mus musculus,2048.0,CHEMBL618934,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,In vivo,3655,Lung,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4547,Mus musculus,2048.0,CHEMBL618935,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,In vivo,3655,Lung,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4548,Mus musculus,2048.0,CHEMBL618936,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,In vivo,3655,Lung,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4549,Mus musculus,2385.0,CHEMBL618937,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,In vivo,3655,Muscle tissue,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4550,Mus musculus,2385.0,CHEMBL618938,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,In vivo,3655,Muscle tissue,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4551,Mus musculus,2385.0,CHEMBL619104,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,In vivo,3655,Muscle tissue,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4552,Mus musculus,2106.0,CHEMBL619105,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,In vivo,3655,Spleen,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4553,Mus musculus,2106.0,CHEMBL619106,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,In vivo,3655,Spleen,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4554,Mus musculus,2106.0,CHEMBL619107,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,In vivo,3655,Spleen,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4555,Mus musculus,945.0,CHEMBL875410,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,In vivo,3655,Stomach,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4556,Mus musculus,945.0,CHEMBL619108,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,In vivo,3655,Stomach,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4557,Mus musculus,945.0,CHEMBL619109,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,In vivo,3655,Stomach,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4558,Mus musculus,,CHEMBL619110,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,In vivo,16597,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4559,Mus musculus,,CHEMBL619111,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,In vivo,16597,,50594,,,BAO_0000218,,Intermediate,,10090.0,F,,
4560,Mus musculus,,CHEMBL619112,MRT value at a dose of 10 mg/kg intravenous administration in mice.,In vivo,16597,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4561,Mus musculus,,CHEMBL619113,MRT value at a dose of 10 mg/kg peroral administration in mice.,In vivo,16597,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4562,Mus musculus,,CHEMBL619114,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,In vivo,17764,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4563,Mus musculus,,CHEMBL619115,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,In vivo,17764,,50594,,,BAO_0000218,,Intermediate,,10090.0,F,,
4564,Homo sapiens,,CHEMBL619116,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,,3830,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4565,Homo sapiens,,CHEMBL619117,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,,3829,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4566,Homo sapiens,,CHEMBL619118,Compound was evaluated for cytotoxicity against A2780 cell lines.,,2040,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4567,Homo sapiens,,CHEMBL619119,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,,15684,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4568,Homo sapiens,,CHEMBL619120,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,15684,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4569,Homo sapiens,,CHEMBL619121,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,15684,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4570,Homo sapiens,,CHEMBL619122,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,15684,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4571,Homo sapiens,,CHEMBL619123,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,15684,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4572,Homo sapiens,,CHEMBL619124,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,15684,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4573,Homo sapiens,,CHEMBL619125,Compound was evaluated for cytotoxicity against A2780 cell line,,2859,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4574,Homo sapiens,,CHEMBL875411,In vitro inhibitory activity against human tumor cell line A2780,,5618,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4575,Homo sapiens,,CHEMBL619126,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,,15684,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4576,Homo sapiens,,CHEMBL619127,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,15684,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4577,Homo sapiens,,CHEMBL619128,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,15684,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4578,Homo sapiens,,CHEMBL619129,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,15684,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4579,Homo sapiens,,CHEMBL619130,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,,2113,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4580,Homo sapiens,,CHEMBL619131,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,,2113,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4581,Homo sapiens,,CHEMBL619132,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,,16745,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4582,Homo sapiens,,CHEMBL619133,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,16597,,81034,,,BAO_0000218,,Expert,,9606.0,F,,A2780
4583,Homo sapiens,,CHEMBL619134,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,15684,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4584,Homo sapiens,,CHEMBL619135,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,15684,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4585,Homo sapiens,,CHEMBL619136,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,,2040,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4586,Homo sapiens,,CHEMBL619137,Relative resistance factor in A2780 cisplatin-resistant line,,2040,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4587,Homo sapiens,,CHEMBL883713,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,,16165,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4588,Homo sapiens,,CHEMBL875412,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,,16165,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4589,Homo sapiens,,CHEMBL619138,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,16597,,81034,,,BAO_0000218,,Expert,,9606.0,F,,A2780
4590,Homo sapiens,,CHEMBL619262,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,16597,,81034,,,BAO_0000218,,Expert,,9606.0,F,,A2780
4591,Homo sapiens,,CHEMBL619139,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,,3992,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4592,Homo sapiens,,CHEMBL619140,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,,10553,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4593,Homo sapiens,,CHEMBL619141,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,,15608,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4594,Homo sapiens,,CHEMBL619142,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,,15608,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4595,Homo sapiens,,CHEMBL619143,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,,15608,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4596,Homo sapiens,,CHEMBL619144,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,,15608,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4597,Homo sapiens,,CHEMBL619145,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,,15608,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4598,Homo sapiens,,CHEMBL619146,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,,15608,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4599,Homo sapiens,,CHEMBL619147,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,,15569,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4600,Homo sapiens,,CHEMBL619148,Antiproliferative effect of compound on A2780/DX cell line,,17420,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4601,Homo sapiens,,CHEMBL619149,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,,17420,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4602,Homo sapiens,,CHEMBL619150,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),,15099,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4603,Homo sapiens,,CHEMBL619151,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),,15099,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4604,Homo sapiens,,CHEMBL883794,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,,17672,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4605,Homo sapiens,,CHEMBL619152,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,,17672,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4606,Homo sapiens,,CHEMBL619153,In vitro cytotoxicity against A2780ADR cell line,,17270,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4607,Homo sapiens,,CHEMBL619154,In vitro cytotoxicity against A2780CIS cell line,,17270,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4608,Homo sapiens,,CHEMBL619155,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,,5574,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4609,Homo sapiens,,CHEMBL619156,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,,2113,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4610,Homo sapiens,,CHEMBL619157,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",,16913,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4611,Homo sapiens,,CHEMBL619797,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",,16913,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4612,Macaca mulatta,,CHEMBL619798,Oral bioavailability of compound in rhesus macaques,In vivo,17839,,22224,,,BAO_0000218,,Autocuration,,9544.0,A,,
4613,monkey,,CHEMBL619799,Oral bioavailability in monkey,In vivo,6821,,22224,,,BAO_0000218,,Autocuration,,9443.0,A,,
4614,monkey,,CHEMBL619800,Oral bioavailability evaluated in monkey,In vivo,6078,,22224,,,BAO_0000218,,Autocuration,,9443.0,A,,
4615,monkey,,CHEMBL619801,Oral bioavailability in monkey (dose 1 mg/kg p.o.),In vivo,6535,,22224,,,BAO_0000218,,Autocuration,,9443.0,A,,
4616,Macaca mulatta,,CHEMBL619802,Oral bioavailability in Rhesus monkey,In vivo,4449,,22224,,,BAO_0000218,,Autocuration,,9544.0,A,,
4617,Macaca mulatta,,CHEMBL619803,Oral bioavailability was calculated in rhesus monkey,In vivo,6057,,22224,,,BAO_0000218,,Autocuration,,9544.0,A,,
4618,Macaca fascicularis,,CHEMBL619965,Oral bioavailability in cynomolgus monkey,In vivo,5922,,22224,,,BAO_0000218,,Autocuration,,9541.0,A,,
4619,monkey,,CHEMBL619966,Oral bioavailability in monkey,In vivo,5940,,22224,,,BAO_0000218,,Autocuration,,9443.0,A,,
4620,monkey,,CHEMBL619967,Oral bioavailability in monkey,In vivo,6265,,22224,,,BAO_0000218,,Autocuration,,9443.0,A,,
4621,monkey,,CHEMBL620073,Oral bioavailability in monkey (dose 1 mg/kg),In vivo,6265,,22224,,,BAO_0000218,,Autocuration,,9443.0,A,,
4622,monkey,,CHEMBL620074,Oral bioavailability in monkey (dose 5 mg/kg),In vivo,6265,,22224,,,BAO_0000218,,Autocuration,,9443.0,A,,
4623,monkey,,CHEMBL620075,Oral bioavailability in monkey,In vivo,5940,,22224,,,BAO_0000218,,Autocuration,,9443.0,A,,
4624,monkey,,CHEMBL620076,Oral bioavailability in monkey,In vivo,5940,,22224,,,BAO_0000218,,Autocuration,,9443.0,A,,
4625,Macaca mulatta,,CHEMBL620077,Oral bioavailability in rhesus monkey,In vivo,4514,,22224,,,BAO_0000218,,Autocuration,,9544.0,A,,
4626,Macaca mulatta,,CHEMBL620078,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,In vivo,5546,,22224,,,BAO_0000218,,Autocuration,,9544.0,A,,
4627,Saimiri sciureus,,CHEMBL620079,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,In vivo,5553,,22224,,,BAO_0000218,,Autocuration,,9521.0,A,,
4628,monkey,,CHEMBL620080,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,6641,,22224,,,BAO_0000218,,Autocuration,,9443.0,A,,
4629,Macaca mulatta,,CHEMBL620081,Oral bioavailability in Rhesus monkey,In vivo,5472,,22224,,,BAO_0000218,,Autocuration,,9544.0,A,,
4630,Macaca mulatta,,CHEMBL620082,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),In vivo,5668,,22224,,,BAO_0000218,,Autocuration,,9544.0,A,,
4631,monkey,,CHEMBL620083,Oral bioavailability in monkey at 10 mg/kg of the compound,In vivo,5711,,22224,,,BAO_0000218,,Autocuration,,9443.0,A,,
4632,Macaca mulatta,,CHEMBL620084,Bioavailability in Rhesus monkey,In vivo,5145,,22224,,,BAO_0000218,,Autocuration,,9544.0,A,,
4633,Cercopithecidae,,CHEMBL620085,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,3443,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4634,Cercopithecidae,,CHEMBL874595,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,3443,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4635,Cercopithecidae,,CHEMBL873352,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,In vivo,3249,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4636,Cercopithecidae,,CHEMBL620086,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,In vivo,3249,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4637,Cercopithecidae,,CHEMBL620087,Mean residence time was determined after intravenous administration in cynomolgus monkeys,In vivo,5355,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4638,Cercopithecidae,,CHEMBL620088,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,In vivo,5355,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4639,Cercopithecidae,,CHEMBL620089,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,In vivo,5355,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4640,Cercopithecidae,,CHEMBL620090,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),In vivo,4809,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4641,Cercopithecidae,,CHEMBL620091,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),In vivo,4809,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4642,Cercopithecidae,,CHEMBL620092,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),,14294,,22224,,,BAO_0000251,,Autocuration,Microsomes,9527.0,A,,
4643,Cercopithecidae,,CHEMBL620093,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),,14294,,22224,,,BAO_0000251,,Autocuration,Microsomes,9527.0,A,,
4644,Cercopithecidae,,CHEMBL620094,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),,14294,,22224,,,BAO_0000251,,Autocuration,Microsomes,9527.0,A,,
4645,Cercopithecidae,,CHEMBL620095,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),,14294,,22224,,,BAO_0000251,,Autocuration,Microsomes,9527.0,A,,
4646,Cercopithecidae,,CHEMBL620096,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,In vivo,3443,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4647,Cercopithecidae,,CHEMBL620097,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,In vivo,3443,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4648,Cercopithecidae,,CHEMBL620098,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,,11271,,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
4649,Cercopithecidae,,CHEMBL620099,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,3443,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4650,Cercopithecidae,,CHEMBL620100,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,3443,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4651,Cercopithecidae,,CHEMBL620101,Elimination Half-life of compound was determined in monkey,,6821,,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
4652,Cercopithecidae,,CHEMBL620102,Half life of compound was determined in rhesus monkey,,17267,,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
4653,Cercopithecidae,1969.0,CHEMBL620103,Half life in monkey plasma,,5819,Plasma,22224,,,BAO_0000366,,Autocuration,,9527.0,A,,
4654,Cercopithecidae,1969.0,CHEMBL620104,Half life in monkey plasma; Not detected,,5819,Plasma,22224,,,BAO_0000366,,Autocuration,,9527.0,A,,
4655,Cercopithecidae,,CHEMBL874596,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,In vivo,1916,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4656,Cercopithecidae,,CHEMBL873490,Half-life 24 hr after 2 mg/kg iv administration in monkeys,In vivo,17509,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4657,Cercopithecidae,,CHEMBL620105,Terminal half life of the compound.,,1399,,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
4658,Cercopithecidae,,CHEMBL620780,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,In vivo,1916,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4659,Cercopithecidae,,CHEMBL620781,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),In vivo,4809,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4660,Cercopithecidae,,CHEMBL620956,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,5546,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4661,Cercopithecidae,1088.0,CHEMBL620957,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,3443,Urine,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4662,Cercopithecidae,1088.0,CHEMBL620958,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,3443,Urine,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4663,Cercopithecidae,,CHEMBL620959,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,In vivo,4257,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4664,Cercopithecidae,,CHEMBL620960,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,In vivo,6221,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4665,Cercopithecidae,,CHEMBL620961,Volume of distribution was evaluated in rhesus,In vivo,5472,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4666,Cricetulus griseus,,CHEMBL620962,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,In vivo,4727,,22224,,,BAO_0000218,,Autocuration,,10029.0,A,,
4667,Cricetulus griseus,,CHEMBL620963,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,In vivo,4727,,22224,,,BAO_0000218,,Autocuration,,10029.0,A,,
4668,Cricetulus griseus,,CHEMBL620964,Bioavailability in hamster was determined,In vivo,4727,,22224,,,BAO_0000218,,Autocuration,,10029.0,A,,
4669,Cricetulus griseus,,CHEMBL620965,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,In vivo,4727,,22224,,,BAO_0000218,,Autocuration,,10029.0,A,,
4670,Cricetulus griseus,,CHEMBL620966,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,In vivo,4727,,22224,,,BAO_0000218,,Autocuration,,10029.0,A,,
4671,Cricetulus griseus,178.0,CHEMBL620967,Half life of compound was determined in hamster blood,,4727,Blood,22224,,,BAO_0000221,,Autocuration,,10029.0,A,,
4672,Sus scrofa,,CHEMBL620968,Michaelis-Menten constant of the compound.,,1452,,22224,,,BAO_0000019,,Autocuration,,9823.0,A,,
4673,Sus scrofa,,CHEMBL874597,Vmax value was measured at 0 uM concentration of silyl ether.,,1452,,22224,,,BAO_0000019,,Autocuration,,9823.0,A,,
4674,Sus scrofa,,CHEMBL620969,Vmax value was measured at 10 uM concentration of silyl ether.,,1452,,22224,,,BAO_0000019,,Autocuration,,9823.0,A,,
4675,Sus scrofa,,CHEMBL620970,Vmax value was measured at 5 uM concentration of silyl ether.,,1452,,22224,,,BAO_0000019,,Autocuration,,9823.0,A,,
4676,Homo sapiens,,CHEMBL620971,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,,11706,,235,,,BAO_0000357,,Expert,,9606.0,B,,
4677,Homo sapiens,,CHEMBL620972,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,,1916,,22224,,,BAO_0000218,,Autocuration,,9606.0,A,,
4678,Homo sapiens,,CHEMBL620973,Compound was evaluated for area under the curve expressed as (h*ug/ml),,17791,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4679,Homo sapiens,,CHEMBL618243,Active metabolite of ifosfamide determined in humans; A-Active,,7766,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4680,Homo sapiens,,CHEMBL618244,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,,6567,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4681,Homo sapiens,,CHEMBL618245,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,,6567,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4682,Homo sapiens,,CHEMBL618246,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,,6567,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4683,Homo sapiens,,CHEMBL618247,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,,6567,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4684,Homo sapiens,,CHEMBL618248,Compound was evaluated for oral bioavailability in human,,17791,,22224,,,BAO_0000218,,Autocuration,,9606.0,A,,
4685,Homo sapiens,1088.0,CHEMBL618249,Metabolite of ifosfamide determined in urine; NF-Not found,,7766,Urine,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4686,Homo sapiens,,CHEMBL618250,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),,6852,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4687,Homo sapiens,,CHEMBL874598,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,,6852,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4688,Homo sapiens,,CHEMBL618251,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,,6852,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4689,Homo sapiens,,CHEMBL618252,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,,6852,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4690,Homo sapiens,,CHEMBL618253,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,,6852,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4691,Homo sapiens,,CHEMBL618254,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),,6852,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4692,Homo sapiens,,CHEMBL618255,Percent of compound in healthy individuals (Group D),,6852,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4693,Homo sapiens,2107.0,CHEMBL618983,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,,4397,Liver,22224,,,BAO_0000251,,Autocuration,Microsomes,9606.0,A,,
4694,Homo sapiens,,CHEMBL618984,Binding towards human plasma protein at 10 uM,,17409,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4695,Homo sapiens,,CHEMBL618985,Binding towards human plasma protein at 100 uM,,17409,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4696,Homo sapiens,,CHEMBL618986,Human plasma protein binding activity was determined,,17176,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4697,Homo sapiens,,CHEMBL618987,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),,15444,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4698,Homo sapiens,,CHEMBL618988,Percent binding of compound towards human plasma protein was determined,,17267,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4699,Homo sapiens,2107.0,CHEMBL618989,Plasma clearance in human liver microsomes,In vitro,5944,Liver,22224,,,BAO_0000251,,Autocuration,Microsomes,9606.0,A,,
4700,Homo sapiens,2107.0,CHEMBL618990,In vitro intrinsic clearance in human liver microsome,In vitro,5668,Liver,22224,,,BAO_0000251,,Autocuration,Microsomes,9606.0,A,,
4701,Homo sapiens,2107.0,CHEMBL618991,In vitro intrinsic clearance in human liver microsome,In vitro,5669,Liver,22224,,,BAO_0000251,,Autocuration,Microsomes,9606.0,A,,
4702,Homo sapiens,,CHEMBL876725,In vitro microsome metabolism clearance in human was determined,In vitro,5041,,22224,,,BAO_0000251,,Autocuration,Microsomes,9606.0,A,,
4703,Homo sapiens,,CHEMBL618992,In vitro microsome metabolism clearance in human was determined; High,In vitro,5041,,22224,,,BAO_0000251,,Autocuration,Microsomes,9606.0,A,,
4704,Homo sapiens,,CHEMBL618993,In vitro microsome metabolism clearance in human was determined; ND denotes no data,In vitro,5041,,22224,,,BAO_0000251,,Autocuration,Microsomes,9606.0,A,,
4705,Homo sapiens,2107.0,CHEMBL618994,Pharmacokinetic property (clearance) in human liver microsome,In vitro,5676,Liver,22224,,,BAO_0000251,,Autocuration,Microsomes,9606.0,A,,
4706,Homo sapiens,2107.0,CHEMBL618995,Plasma clearance in human liver microsomes,In vitro,5944,Liver,22224,,,BAO_0000251,,Autocuration,Microsomes,9606.0,A,,
4707,Homo sapiens,2107.0,CHEMBL618996,In vitro clearance in human liver microsomes,In vitro,17538,Liver,22224,,,BAO_0000251,,Autocuration,Microsomes,9606.0,A,,
4708,Homo sapiens,2107.0,CHEMBL618997,Intrinsic clearance in human liver microsomes was determined,In vitro,6331,Liver,22224,,,BAO_0000251,,Autocuration,Microsomes,9606.0,A,,
4709,Homo sapiens,2107.0,CHEMBL618998,Intrinsic clearance in human liver microsomes was determined,In vitro,5948,Liver,22224,,,BAO_0000251,,Autocuration,Microsomes,9606.0,A,,
4710,Homo sapiens,,CHEMBL618999,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,In vivo,5965,,22224,,,BAO_0000218,,Autocuration,,9606.0,A,,
4711,Homo sapiens,,CHEMBL620223,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,In vivo,1916,,22224,,,BAO_0000218,,Autocuration,,9606.0,A,,
4712,Homo sapiens,,CHEMBL620224,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,,5965,,22224,,,BAO_0000218,,Autocuration,,9606.0,A,,
4713,Homo sapiens,,CHEMBL620225,Stability in human plasma 2 hr after incubation expressed as percent concentration,,1299,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4714,Homo sapiens,,CHEMBL620226,Stability in human plasma 4 hr after incubation expressed as percent concentration,,1299,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4715,Homo sapiens,1088.0,CHEMBL620227,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,7766,Urine,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4716,Homo sapiens,1088.0,CHEMBL876726,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,7766,Urine,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4717,Homo sapiens,1088.0,CHEMBL620228,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,7766,Urine,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4718,Homo sapiens,1088.0,CHEMBL620229,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,7766,Urine,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4719,Mus musculus,,CHEMBL620230,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,In vivo,17764,,50594,,,BAO_0000218,,Intermediate,,10090.0,F,,
4720,Mus musculus,,CHEMBL620231,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,In vivo,17764,,50594,,,BAO_0000218,,Intermediate,,10090.0,F,,
4721,Mus musculus,,CHEMBL620232,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,In vivo,17764,,50594,,,BAO_0000218,,Intermediate,,10090.0,F,,
4722,Mus musculus,,CHEMBL620233,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,In vivo,17764,,50594,,,BAO_0000218,,Intermediate,,10090.0,F,,
4723,Mus musculus,,CHEMBL620234,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),,14294,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4724,Mus musculus,,CHEMBL620235,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),,14294,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4725,Mus musculus,,CHEMBL620236,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),,14294,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4726,Mus musculus,2107.0,CHEMBL620237,In vitro metabolic potential in mouse liver microsomes,,6251,Liver,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4727,Mus musculus,,CHEMBL620238,Ability of compound to bind to plasma protein was evaluated in HSA cells,,17582,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4728,Mus musculus,2369.0,CHEMBL620239,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),,17811,Adrenal gland,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4729,Mus musculus,955.0,CHEMBL620240,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,,17811,Brain,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4730,Mus musculus,955.0,CHEMBL620241,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,,17811,Brain,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4731,Mus musculus,,CHEMBL876727,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),,17811,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4732,Mus musculus,2113.0,CHEMBL620242,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),,17811,Kidney,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4733,Mus musculus,,CHEMBL620243,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),,17811,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4734,Mus musculus,,CHEMBL620244,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,,5288,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4735,Mus musculus,1977.0,CHEMBL620245,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,,2717,Serum,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4736,Mus musculus,1977.0,CHEMBL620246,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,,2717,Serum,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4737,Mus musculus,1977.0,CHEMBL620247,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,,2717,Serum,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4738,Mus musculus,1969.0,CHEMBL620248,Half life of compound was determined in plasma of mice at 24 mg/Kg,In vivo,17753,Plasma,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4739,Mus musculus,1969.0,CHEMBL873497,Half life of compound was determined in plasma of mice at 40 mg/Kg,In vivo,17753,Plasma,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4740,Mus musculus,1969.0,CHEMBL620249,Half life of compound was determined in plasma of mice at 5 mg/Kg,In vivo,17753,Plasma,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4741,Mus musculus,,CHEMBL620250,Half life after intraperitoneal administration in mice at 18 uM/kg,In vivo,17764,,50594,,,BAO_0000218,,Intermediate,,10090.0,F,,
4742,Mus musculus,,CHEMBL620251,Half life after intraperitoneal administration in mice at 23 uM/kg,In vivo,17764,,50594,,,BAO_0000218,,Intermediate,,10090.0,F,,
4743,Mus musculus,,CHEMBL620252,Half life after intraperitoneal administration in mice at 25 uM/kg,In vivo,17764,,50594,,,BAO_0000218,,Intermediate,,10090.0,F,,
4744,Mus musculus,,CHEMBL620253,Half life after intraperitoneal administration in mice at 26 uM/kg,In vivo,17764,,50594,,,BAO_0000218,,Intermediate,,10090.0,F,,
4745,Mus musculus,,CHEMBL620254,Half life after intravenous administration in mice at 23 uM/kg,In vivo,17764,,50594,,,BAO_0000218,,Intermediate,,10090.0,F,,
4746,Mus musculus,,CHEMBL620255,Half life after intravenous administration in mice at 24 uM/kg,In vivo,17764,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4747,Mus musculus,,CHEMBL620256,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,In vivo,16597,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4748,Mus musculus,,CHEMBL876728,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,In vivo,2675,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4749,Mus musculus,,CHEMBL620257,Maximum time required to reach Cp max was evaluated in mice after oral administration,In vivo,2675,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4750,Mus musculus,,CHEMBL620258,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),In vivo,16597,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4751,Mus musculus,,CHEMBL620259,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",In vivo,4890,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4752,Mus musculus,,CHEMBL620260,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,In vivo,429,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4753,Mus musculus,178.0,CHEMBL620261,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,In vivo,17837,Blood,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4754,Mus musculus,,CHEMBL620262,Half life at a dose of 10 mg/kg intravenous administration in mice.,In vivo,16597,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4755,Mus musculus,,CHEMBL620263,Half life at a dose of 10 mg/kg peroral administration in mice.,In vivo,16597,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4756,Mus musculus,,CHEMBL620264,Half life in ob/ob mice,,6619,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4757,Mus musculus,,CHEMBL620265,Half-life at a single subcutaneous administration of 40 mg/kg in mice,In vivo,4066,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4758,Mus musculus,,CHEMBL620266,Half-life was measured in mouse,,4239,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4759,Mus musculus,,CHEMBL620267,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,In vivo,5969,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4760,Mus musculus,,CHEMBL619364,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,,8999,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4761,Mus musculus,,CHEMBL619365,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,,8999,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4762,Mus musculus,955.0,CHEMBL619366,T2 in brain of mice at the oral dose of 50 mg/kg,,17641,Brain,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4763,Mus musculus,2113.0,CHEMBL619367,T2 in kidney of mice at the oral dose of 50 mg/kg,,17641,Kidney,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4764,Mus musculus,2107.0,CHEMBL619368,T2 in liver of mice at the oral dose of 50 mg/kg,,17641,Liver,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4765,Mus musculus,2048.0,CHEMBL619369,T2 in lungs of mice at the oral dose of 50 mg/kg,,17641,Lung,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4766,Mus musculus,2106.0,CHEMBL876729,T2 in spleen of mice at the oral dose of 50 mg/kg,,17641,Spleen,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4767,Mus musculus,,CHEMBL619370,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,In vivo,16597,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4768,Mus musculus,,CHEMBL619371,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",In vivo,4890,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4769,Mus musculus,,CHEMBL619372,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,In vivo,429,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4770,Mus musculus,,CHEMBL620012,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,In vivo,429,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4771,Mus musculus,,CHEMBL620013,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,In vivo,5969,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4772,Homo sapiens,,CHEMBL620014,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,16913,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4773,Homo sapiens,,CHEMBL620015,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,16913,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4774,Homo sapiens,,CHEMBL621010,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",,16913,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4775,Homo sapiens,,CHEMBL621011,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",,16913,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4776,Homo sapiens,,CHEMBL621012,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,16913,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4777,Homo sapiens,,CHEMBL621013,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,16913,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4778,Homo sapiens,,CHEMBL621014,In vitro cytotoxicity against A2780TAX cell line,,17270,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4779,Homo sapiens,,CHEMBL618154,In vitro inhibitory activity against human tumor cell line A2780cis,,5618,,80017,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780cisR
4780,Homo sapiens,,CHEMBL618155,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,,17777,,81034,,,BAO_0000219,,Expert,,9606.0,F,,A2780
4781,Homo sapiens,,CHEMBL618156,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,,16112,,80017,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780cisR
4782,Homo sapiens,,CHEMBL618157,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,15748,,80017,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780cisR
4783,Homo sapiens,,CHEMBL618328,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,,6633,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4784,Homo sapiens,,CHEMBL618329,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,,16930,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4785,Homo sapiens,,CHEMBL618330,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,,17496,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4786,Homo sapiens,,CHEMBL618331,In vitro antitumor activity against A2780cisR cell line.,,12989,,81034,,,BAO_0000219,,Expert,,9606.0,F,,A2780
4787,Homo sapiens,,CHEMBL618332,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),,4840,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
4788,Homo sapiens,,CHEMBL618333,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,,12989,,81034,,,BAO_0000219,,Expert,,9606.0,F,,A2780
4789,Homo sapiens,,CHEMBL618334,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,,16745,,80017,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780cisR
4790,Homo sapiens,,CHEMBL618335,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,,16597,,81034,,,BAO_0000219,,Expert,,9606.0,F,,A2780
4791,Rattus norvegicus,,CHEMBL618336,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,,16547,,11736,,,BAO_0000019,,Expert,,10116.0,B,,
4792,,,CHEMBL618337,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,16547,,11736,,,BAO_0000019,,Expert,,,F,,
4793,Rattus norvegicus,,CHEMBL618338,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,16547,,11736,,,BAO_0000019,,Expert,,10116.0,F,,
4794,Homo sapiens,,CHEMBL618339,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,,15856,,278,,,BAO_0000219,,Expert,,9606.0,F,,HEK293
4795,Homo sapiens,,CHEMBL618340,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,,15856,,278,,,BAO_0000219,,Expert,,9606.0,F,,HEK293
4796,Mus musculus,,CHEMBL618341,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,,16547,,11831,,,BAO_0000019,,Expert,,10090.0,B,,
4797,,,CHEMBL618342,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,16547,,11831,,,BAO_0000019,,Expert,,,F,,
4798,Mus musculus,,CHEMBL618343,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,16547,,11831,,,BAO_0000019,,Expert,,10090.0,F,,
4799,,,CHEMBL621038,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,,17402,,280,,,BAO_0000357,,Expert,,,B,,
4800,Homo sapiens,,CHEMBL621039,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),,11746,,22226,,,BAO_0000219,,Autocuration,,9606.0,F,,T-cells
4801,Homo sapiens,,CHEMBL621040,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,,11746,,22226,,,BAO_0000219,,Autocuration,,9606.0,F,,T-cells
4802,Homo sapiens,,CHEMBL621041,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,,5455,,80018,,,BAO_0000219,,Intermediate,,9606.0,F,,A-375
4803,Homo sapiens,,CHEMBL621042,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,,2068,,80018,,,BAO_0000219,,Intermediate,,9606.0,F,,A-375
4804,Homo sapiens,,CHEMBL621043,In vitro antitumor activity against A375cell line extracted form melanoma,,2683,,80018,,,BAO_0000219,,Intermediate,,9606.0,F,,A-375
4805,Homo sapiens,,CHEMBL621044,Inhibition of cell growth in (A375) melan cell line,,15313,,80018,,,BAO_0000219,,Expert,,9606.0,F,,A-375
4806,Homo sapiens,,CHEMBL621045,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,,13739,,80018,,,BAO_0000219,,Intermediate,,9606.0,F,,A-375
4807,Homo sapiens,,CHEMBL621046,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,,13739,,80018,,,BAO_0000219,,Intermediate,,9606.0,F,,A-375
4808,Homo sapiens,,CHEMBL621047,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,,14750,,80018,,,BAO_0000219,,Intermediate,,9606.0,F,,A-375
4809,Homo sapiens,,CHEMBL621048,Antiproliferative activity measured against A427 human lung carcinoma,,14777,,80019,,,BAO_0000219,,Intermediate,,9606.0,F,,A-427
4810,Homo sapiens,,CHEMBL883798,Antiproliferative activity measured against A427 human lung carcinoma,,14777,,80019,,,BAO_0000219,,Intermediate,,9606.0,F,,A-427
4811,Homo sapiens,,CHEMBL621049,Cytotoxicity against lung carcinoma A427 tumor cell lines,,17672,,80019,,,BAO_0000219,,Intermediate,,9606.0,F,,A-427
4812,Homo sapiens,,CHEMBL621050,Inhibition of large cell lung carcinoma (A427),,14368,,80019,,,BAO_0000219,,Intermediate,,9606.0,F,,A-427
4813,Homo sapiens,,CHEMBL621051,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,,14368,,80019,,,BAO_0000219,,Intermediate,,9606.0,F,,A-427
4814,Homo sapiens,,CHEMBL621052,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,13866,,80019,,,BAO_0000219,,Intermediate,,9606.0,F,,A-427
4815,Homo sapiens,,CHEMBL621053,Inhibitory concentration in human lung carcinoma A427 cell line,,2545,,80019,,,BAO_0000219,,Intermediate,,9606.0,F,,A-427
4816,Homo sapiens,,CHEMBL621054,Inhibitory concentration in human lung carcinoma A427/VCR cell line,,2545,,80019,,,BAO_0000219,,Intermediate,,9606.0,F,,A-427
4817,Cercopithecidae,,CHEMBL621055,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,In vivo,6062,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4818,Cercopithecidae,,CHEMBL876398,Tested for volume of distribution upon iv administration to african green monkey,In vivo,4578,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4819,Cercopithecidae,,CHEMBL621056,Volume of distribution in monkey,In vivo,17592,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4820,Macaca mulatta,,CHEMBL621057,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,In vivo,5005,,22224,,,BAO_0000218,,Autocuration,,9544.0,A,,
4821,Macaca mulatta,,CHEMBL621058,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,In vivo,5005,,22224,,,BAO_0000218,,Autocuration,,9544.0,A,,
4822,Cercopithecidae,,CHEMBL621059,Pharmacokinetic property(Vdss) in cynomolgus monkey,In vivo,5922,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4823,Cercopithecidae,,CHEMBL621060,The distribution volume after intravenous administration in cynomolgus monkeys,In vivo,5355,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4824,Cercopithecidae,,CHEMBL621061,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,In vivo,5355,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4825,Cercopithecidae,,CHEMBL621062,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,In vivo,5355,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4826,Cercopithecidae,,CHEMBL621063,Volume displacement was calculated in rhesus monkey,In vivo,6057,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4827,Cercopithecidae,,CHEMBL621064,Volume of distribution in steady state was determined in rhesus monkey,In vivo,5145,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4828,Cercopithecidae,,CHEMBL621065,Volume of distribution of compound was determined in monkey,In vivo,6821,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4829,Cercopithecidae,,CHEMBL621066,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),In vivo,5334,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4830,Cercopithecidae,,CHEMBL621067,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),In vivo,5334,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4831,Cercopithecidae,,CHEMBL621068,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,6641,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4832,Cercopithecidae,,CHEMBL876399,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,In vivo,2661,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4833,Cercopithecidae,,CHEMBL621069,Volume distribution in monkey after administration of 1 mg/kg iv,In vivo,6535,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4834,Cercopithecidae,,CHEMBL621070,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),In vivo,4809,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4835,Cercopithecidae,,CHEMBL621071,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,In vivo,6062,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4836,Cercopithecidae,,CHEMBL621072,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,In vivo,3443,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4837,Cercopithecidae,,CHEMBL618209,Oral systemic bioavailability upon iv administration to african green monkey,In vivo,4578,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4838,Cercopithecidae,,CHEMBL618210,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),In vivo,4809,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4839,Cercopithecidae,,CHEMBL618211,Baboon plasma free fraction. ,,11271,,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
4840,Cercopithecidae,,CHEMBL618212,Area under the curve was calculated in rhesus monkey after iv administration,,6057,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4841,Cercopithecidae,,CHEMBL618213,Area under the curve was calculated in rhesus monkey after peroral administration,,6057,,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
4842,Cercopithecidae,,CHEMBL618214,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,,17853,,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
4843,Cercopithecidae,,CHEMBL873492,Half life period in monkey after 5 mg/kg dose,In vivo,5302,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4844,Cercopithecidae,,CHEMBL618272,Half-life was determined in monkey after 3 mg/kg of i.v. dose,In vivo,4257,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4845,Cercopithecidae,,CHEMBL618273,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,In vivo,4257,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4846,Cercopithecidae,1969.0,CHEMBL618274,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,In vivo,13501,Plasma,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4847,Cercopithecidae,,CHEMBL618275,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,In vivo,5394,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4848,Cercopithecidae,,CHEMBL618276,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,In vivo,2661,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4849,Cercopithecidae,,CHEMBL618277,Compound was evaluated for terminal half life in monkey,,3341,,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
4850,Cercopithecidae,,CHEMBL618278,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,In vivo,3045,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4851,Macaca mulatta,1969.0,CHEMBL618279,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,In vivo,5005,Plasma,22224,,,BAO_0000218,,Autocuration,,9544.0,A,,
4852,Cercopithecidae,,CHEMBL618280,Half life of compound was determined in squirrel monkey,,4847,,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
4853,Macaca fascicularis,,CHEMBL618281,Half life after iv administration in cynomolgus monkey,In vivo,4256,,22224,,,BAO_0000218,,Autocuration,,9541.0,A,,
4854,Cercopithecidae,1969.0,CHEMBL618282,Half life in monkey plasma after administration of 1 mg/kg iv,In vivo,6535,Plasma,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4855,Cercopithecidae,,CHEMBL618283,Half life was calculated in rhesus monkey,,6057,,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
4856,Cercopithecidae,,CHEMBL618284,Half life in monkey,,17592,,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
4857,Cercopithecidae,,CHEMBL618285,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,6641,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4858,Cercopithecidae,,CHEMBL618286,Half life was evaluated in rhesus,,5472,,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
4859,Cercopithecidae,,CHEMBL618287,Half life period after oral administration (2.5 mg/kg) in monkey was determined,In vivo,6221,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4860,Cercopithecidae,,CHEMBL618288,Half life period was determine after peroral administration at 10 mpk in Rhesus,In vivo,5668,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4861,Cercopithecidae,,CHEMBL876393,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),In vivo,4809,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4862,Cercopithecidae,,CHEMBL618289,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,In vivo,5546,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4863,Cercopithecidae,,CHEMBL618290,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,In vivo,5553,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4864,Cercopithecidae,,CHEMBL618291,Half-life was calculated in monkey,,6078,,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
4865,Cercopithecidae,,CHEMBL618292,Half-life in Squirrel monkey,,5147,,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
4866,Cercopithecidae,,CHEMBL618293,Half-life in rhesus monkey,,5145,,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
4867,Cercopithecidae,,CHEMBL618294,Half-life was measured in monkey after an iv dose of 1 mg/kg,In vivo,6062,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4868,Cercopithecidae,,CHEMBL618295,Half-life period after intravenous administration in cynomolgus monkeys,In vivo,5355,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4869,Cercopithecidae,,CHEMBL618296,Half-life period after oral administration in cynomolgus monkeys,In vivo,5355,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4870,Cercopithecidae,,CHEMBL618297,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,In vivo,5355,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
4871,Homo sapiens,1088.0,CHEMBL618298,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,7766,Urine,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4872,Homo sapiens,1088.0,CHEMBL618299,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,7766,Urine,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4873,Homo sapiens,1088.0,CHEMBL618300,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,7766,Urine,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4874,Homo sapiens,1088.0,CHEMBL618301,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,7766,Urine,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4875,Homo sapiens,1088.0,CHEMBL618302,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,,7766,Urine,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4876,Homo sapiens,1088.0,CHEMBL876394,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,,7766,Urine,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4877,Homo sapiens,1088.0,CHEMBL618303,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,,7766,Urine,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4878,Homo sapiens,1088.0,CHEMBL618304,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,,7766,Urine,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4879,Homo sapiens,,CHEMBL618305,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,In vivo,1916,,22224,,,BAO_0000218,,Autocuration,,9606.0,A,,
4880,Homo sapiens,,CHEMBL618306,Oral bioavailability in human,In vivo,16643,,22224,,,BAO_0000218,,Autocuration,,9606.0,A,,
4881,Homo sapiens,,CHEMBL618307,Compound was tested for human plasma protein binding,,17248,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4882,Homo sapiens,,CHEMBL618308,Compound was tested for human plasma protein binding; Not determined,,17248,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4883,Homo sapiens,,CHEMBL618309,Protein binding activity of compound in human plasma; % Free,,6241,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4884,Homo sapiens,,CHEMBL618310,Unbound fraction (plasma),,17716,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4885,Homo sapiens,1969.0,CHEMBL873353,Half life for the hydrolysis of compound in human blood serum,,17605,Plasma,22224,,,BAO_0000366,,Autocuration,,9606.0,A,,
4886,Homo sapiens,1969.0,CHEMBL618311,Half life period in human plasma using phosphate buffer (0.08 M),,17625,Plasma,22224,,,BAO_0000366,,Autocuration,,9606.0,A,,
4887,Homo sapiens,1969.0,CHEMBL618312,Half life period in human plasma using phosphate buffer (0.1 M),,17625,Plasma,22224,,,BAO_0000366,,Autocuration,,9606.0,A,,
4888,Homo sapiens,1969.0,CHEMBL618313,Half-life in human plasma was determined,,17747,Plasma,22224,,,BAO_0000366,,Autocuration,,9606.0,A,,
4889,Homo sapiens,,CHEMBL618314,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,,15613,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4890,Homo sapiens,,CHEMBL618315,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),,354,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4891,Homo sapiens,,CHEMBL618316,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,3741,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4892,Homo sapiens,,CHEMBL618317,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,3741,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4893,Homo sapiens,,CHEMBL620138,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,3741,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4894,Homo sapiens,,CHEMBL858280,Partition coefficient (logP),,17599,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4895,Homo sapiens,,CHEMBL620139,In vitro metabolic stability in human was measured as pmol/min/mg/protein,,5486,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4896,Homo sapiens,,CHEMBL620140,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,,5600,,22224,,,BAO_0000251,,Autocuration,Microsomes,9606.0,A,,
4897,Homo sapiens,,CHEMBL620141,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),,14294,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4898,Homo sapiens,,CHEMBL620142,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),,14294,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4899,Homo sapiens,,CHEMBL620143,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),,14294,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4900,Homo sapiens,,CHEMBL620144,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),,14294,,22224,,,BAO_0000251,,Autocuration,Microsomes,9606.0,A,,
4901,Homo sapiens,,CHEMBL620145,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),,14294,,22224,,,BAO_0000251,,Autocuration,Microsomes,9606.0,A,,
4902,Homo sapiens,,CHEMBL620146,Metabolism of compound in human microsomes; Trace,,14294,,22224,,,BAO_0000251,,Autocuration,Microsomes,9606.0,A,,
4903,Homo sapiens,2107.0,CHEMBL620147,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,,6260,Liver,22224,,,BAO_0000251,,Autocuration,Microsomes,9606.0,A,,
4904,Homo sapiens,,CHEMBL620148,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,,6187,,22224,,,BAO_0000251,,Autocuration,Microsomes,9606.0,A,,
4905,Homo sapiens,2107.0,CHEMBL620149,In vitro metabolic potential in human liver microsomes,,6251,Liver,22224,,,BAO_0000251,,Autocuration,Microsomes,9606.0,A,,
4906,Homo sapiens,,CHEMBL876412,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,,3246,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4907,Homo sapiens,,CHEMBL619352,Tested for human plasma protein binding of the compound; Not tested,,17313,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4908,Homo sapiens,,CHEMBL619353,Compound was tested for percent protein binding (PB) in human,,6227,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4909,Homo sapiens,1969.0,CHEMBL619354,Protein binding in human plasma,,5530,Plasma,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4910,Homo sapiens,,CHEMBL619355,Permeability coefficient (B to A) in Caco-2 cell,,6108,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4911,Homo sapiens,,CHEMBL619356,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,,6108,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4912,Homo sapiens,,CHEMBL619357,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),,2774,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4913,Homo sapiens,,CHEMBL619358,In vitro rate of absorption observed as Caco-2 permeability in humans,,16643,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4914,Homo sapiens,,CHEMBL619359,Cellular permeability of compound was determined in Caco-2 cells; High,,17582,,22224,,,BAO_0000219,,Autocuration,,9606.0,A,,Caco-2
4915,Homo sapiens,,CHEMBL619360,Permeability in Caco-2 cells of compound,,6838,,22224,,,BAO_0000219,,Autocuration,,9606.0,A,,Caco-2
4916,Homo sapiens,,CHEMBL619361,Permeability coefficient (A to B) in Caco-2 cell,,6108,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4917,Homo sapiens,,CHEMBL619362,Permeability coefficient (B to A) in Caco-2 cell,,6108,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4918,Homo sapiens,,CHEMBL619363,Permeability coefficient (Papp) (Caco-2 cell monolayer),,6108,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4919,Homo sapiens,,CHEMBL618942,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,,2146,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4920,Homo sapiens,,CHEMBL618943,Compound was tested for protein binding in human plasma,,4514,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4921,Homo sapiens,,CHEMBL618944,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,,6108,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4922,Homo sapiens,1088.0,CHEMBL618945,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,,7766,Urine,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
4923,Mus musculus,,CHEMBL618946,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,In vivo,5969,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4924,Mus musculus,,CHEMBL876413,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),In vivo,3277,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4925,Mus musculus,,CHEMBL618947,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,In vivo,3802,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4926,Mus musculus,1969.0,CHEMBL618948,Time taken to reach maximum concentration in plasma upon oral administration in mouse,In vivo,2862,Plasma,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4927,Mus musculus,1969.0,CHEMBL618949,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,In vivo,6348,Plasma,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4928,Mus musculus,,CHEMBL618950,Tmax after intraperitoneal administration in mice at 23 uM/kg,In vivo,17764,,50594,,,BAO_0000218,,Intermediate,,10090.0,F,,
4929,Mus musculus,,CHEMBL618951,Tmax after oral administration at 30 mg/kg in ICR mouse,In vivo,5781,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4930,Mus musculus,,CHEMBL618952,Tmax after peroral administration in mice at 2.4 uM/kg,In vivo,17764,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4931,Mus musculus,,CHEMBL618953,Tmax at a single subcutaneous administration of 40 mg/kg in mice,In vivo,4066,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4932,Mus musculus,955.0,CHEMBL618954,Tmax in brain of mice at the oral dose of 50 mg/kg,In vivo,17641,Brain,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4933,Mus musculus,2113.0,CHEMBL618955,Tmax in kidney of mice at the oral dose of 50 mg/kg,In vivo,17641,Kidney,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4934,Mus musculus,2107.0,CHEMBL618956,Tmax in liver of mice at the oral dose of 50 mg/kg,In vivo,17641,Liver,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4935,Mus musculus,2048.0,CHEMBL618957,Tmax in lungs of mice at the oral dose of 50 mg/kg,In vivo,17641,Lung,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4936,Mus musculus,,CHEMBL618958,Tmax in mice at 18 uM/kg i.p. administration,In vivo,17764,,50594,,,BAO_0000218,,Intermediate,,10090.0,F,,
4937,Mus musculus,,CHEMBL618959,Tmax in mice at 23 uM/kg i.v. administration,In vivo,17764,,50594,,,BAO_0000218,,Intermediate,,10090.0,F,,
4938,Mus musculus,,CHEMBL618960,Tmax in mice at 25 uM/kg i.p. administration,In vivo,17764,,50594,,,BAO_0000218,,Intermediate,,10090.0,F,,
4939,Mus musculus,,CHEMBL876723,Tmax in mice at 26 uM/kg i.p. administration,In vivo,17764,,50594,,,BAO_0000218,,Intermediate,,10090.0,F,,
4940,Mus musculus,2106.0,CHEMBL618961,Tmax in spleen of mice at the oral dose of 50 mg/kg,In vivo,17641,Spleen,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4941,Mus musculus,,CHEMBL618962,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,In vivo,16597,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4942,Mus musculus,,CHEMBL618963,Tmax value at a dose of 10 mg/kg peroral administration in mice.,In vivo,16597,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4943,Mus musculus,,CHEMBL618964,Tmax value in IRC mice,,5951,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4944,Mus musculus,,CHEMBL618965,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,In vivo,5506,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4945,Mus musculus,,CHEMBL618966,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,In vivo,5506,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4946,Mus musculus,1088.0,CHEMBL618967,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),,429,Urine,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4947,Mus musculus,1088.0,CHEMBL618968,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),,429,Urine,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4948,Mus musculus,1088.0,CHEMBL618969,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),,4066,Urine,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4949,Mus musculus,,CHEMBL618970,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,17734,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4950,Mus musculus,,CHEMBL618971,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,17734,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4951,Mus musculus,,CHEMBL618972,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,In vivo,6062,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4952,Mus musculus,,CHEMBL618973,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,In vivo,5969,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4953,Mus musculus,,CHEMBL618974,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,In vivo,5969,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4954,Mus musculus,,CHEMBL618975,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,In vivo,5969,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4955,Mus musculus,,CHEMBL618976,Vd in mice,In vivo,5980,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4956,Mus musculus,,CHEMBL618977,Volume of distribution in mouse,In vivo,17592,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4957,Mus musculus,,CHEMBL876724,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,In vivo,6348,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4958,Mus musculus,,CHEMBL618978,Volume of distribution of compound in plasma was determined at 24 mg/Kg,In vivo,17753,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4959,Mus musculus,,CHEMBL618979,Volume of distribution of compound in plasma was determined at 40 mg/Kg,In vivo,17753,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4960,Mus musculus,,CHEMBL618980,Volume of distribution of compound in plasma was determined at 5 mg/Kg,In vivo,17753,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4961,Mus musculus,,CHEMBL618981,Pharmacokinetic property (vdss) was measured in mouse,In vivo,4239,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4962,Mus musculus,,CHEMBL618982,Value distribution upon iv administration in mouse,In vivo,2862,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4963,Mus musculus,,CHEMBL620150,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,In vivo,17734,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4964,Mus musculus,,CHEMBL620151,Volume of distribution was evaluated in mice after intravenous administration,In vivo,2675,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4965,Mus musculus,,CHEMBL620152,Volume of distribution was evaluated in mice after oral administration,In vivo,2675,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4966,Mus musculus,,CHEMBL620153,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,In vivo,17837,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4967,Mus musculus,,CHEMBL876395,Steady state volume of distribution was determined in mice,In vivo,5727,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4968,Mus musculus,,CHEMBL620154,Volume distribution (steady state) of compound was determined in mouse,In vivo,17852,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4969,Mus musculus,,CHEMBL620155,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,In vivo,17764,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4970,Mus musculus,,CHEMBL620156,Vss value at a dose of 10 mg/kg intravenous administration in mice.,In vivo,16597,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4971,Mus musculus,,CHEMBL620157,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,In vivo,6062,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4972,Mus musculus,2113.0,CHEMBL620158,Biodistribution of compound (oxidized form) in in kidney tissue,In vivo,16438,Kidney,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4973,Mus musculus,178.0,CHEMBL620159,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,In vivo,16438,Blood,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4974,Mus musculus,178.0,CHEMBL620160,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",In vivo,16438,Blood,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4975,Mus musculus,178.0,CHEMBL620161,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,16438,Blood,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
4976,Homo sapiens,,CHEMBL620162,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,,10708,,80019,,,BAO_0000219,,Intermediate,,9606.0,F,,A-427
4977,Homo sapiens,,CHEMBL620163,Inhibition of A431 human squamous cell carcinoma cell proliferation,,16597,,80852,,,BAO_0000219,,Expert,,9606.0,F,,A-431
4978,Homo sapiens,,CHEMBL620833,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,,16062,,80852,,,BAO_0000219,,Expert,,9606.0,F,,A-431
4979,Homo sapiens,,CHEMBL876396,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,,16062,,80852,,,BAO_0000219,,Expert,,9606.0,F,,A-431
4980,Homo sapiens,,CHEMBL620834,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,,16958,,80852,,,BAO_0000219,,Expert,,9606.0,F,,A-431
4981,Homo sapiens,,CHEMBL620835,Inhibition of A431 human carcinoma cell proliferation,,6700,,80852,,,BAO_0000219,,Expert,,9606.0,F,,A-431
4982,Homo sapiens,,CHEMBL620836,In vitro inhibition of A431 (human carcinoma) cell basal growth.,,17226,,80852,,,BAO_0000219,,Expert,,9606.0,F,,A-431
4983,Homo sapiens,,CHEMBL620837,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,,6828,,80852,,,BAO_0000219,,Intermediate,,9606.0,F,,A-431
4984,Homo sapiens,,CHEMBL621017,In vitro cytotoxicity against epidermoid carcinoma cell line,,12314,,80852,,,BAO_0000219,,Intermediate,,9606.0,F,,A-431
4985,Homo sapiens,,CHEMBL621018,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",,13412,,9,,,BAO_0000218,,Expert,,9606.0,F,,A-431
4986,Homo sapiens,,CHEMBL621019,Antiproliferative activity of compound was measured on human tumor cell line A431.,,13299,,80852,,,BAO_0000219,,Intermediate,,9606.0,F,,A-431
4987,Homo sapiens,,CHEMBL621020,Antiproliferative effect of compound on A431 cell line expressing mutant p53,,17420,,80852,,,BAO_0000219,,Intermediate,,9606.0,F,,A-431
4988,Homo sapiens,,CHEMBL621021,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,,13678,,80852,,,BAO_0000219,,Intermediate,,9606.0,F,,A-431
4989,,,CHEMBL621022,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,,14171,,9,,,BAO_0000219,,Expert,,,F,,A-431
4990,Homo sapiens,,CHEMBL621023,Tested for antiproliferative activity against human A431 cells,,6333,,80852,,,BAO_0000219,,Expert,,9606.0,F,,A-431
4991,Homo sapiens,,CHEMBL621024,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,,2356,,9,,,BAO_0000219,,Expert,,9606.0,F,,A-431
4992,Homo sapiens,,CHEMBL621025,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,,15578,,80852,,,BAO_0000219,,Expert,,9606.0,F,,A-431
4993,Homo sapiens,,CHEMBL621026,Inhibition of A431 cell proliferation,,5126,,80852,,,BAO_0000219,,Expert,,9606.0,F,,A-431
4994,Homo sapiens,,CHEMBL621027,Cytotoxic effect on A431 human epidermoid carcinoma cells,,6844,,80852,,,BAO_0000219,,Expert,,9606.0,F,,A-431
4995,Homo sapiens,,CHEMBL876397,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),,6844,,80852,,,BAO_0000219,,Expert,,9606.0,F,,A-431
4996,Homo sapiens,,CHEMBL883797,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,,4925,,80852,,,BAO_0000219,,Intermediate,,9606.0,F,,A-431
4997,Homo sapiens,,CHEMBL621028,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,,4925,,80852,,,BAO_0000219,,Intermediate,,9606.0,F,,A-431
4998,Homo sapiens,,CHEMBL621029,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,,13978,,80852,,,BAO_0000219,,Intermediate,,9606.0,F,,A-431
4999,Homo sapiens,,CHEMBL621030,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,,16786,,80852,,,BAO_0000219,,Intermediate,,9606.0,F,,A-431
5000,,,CHEMBL621147,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,,13412,,9,,,BAO_0000219,,Expert,,,F,,A-431
5001,Homo sapiens,,CHEMBL621148,In vivo antiproliferative activity against A431 cell line,,17824,,80852,,,BAO_0000218,,Intermediate,,9606.0,F,,A-431
5002,Homo sapiens,,CHEMBL621149,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,,12751,,9,,,BAO_0000219,,Expert,,9606.0,F,,A-431
5003,Homo sapiens,,CHEMBL621150,Inhibition of A431 human epidermoid carcinoma cell proliferation,,12380,,80852,,,BAO_0000219,,Expert,,9606.0,F,,A-431
5004,Homo sapiens,,CHEMBL621151,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,,4959,,9,,,BAO_0000219,,Expert,,9606.0,F,,A-431
5005,Homo sapiens,,CHEMBL621152,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),,6333,,80852,,,BAO_0000219,,Intermediate,,9606.0,F,,A-431
5006,Homo sapiens,,CHEMBL621153,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),,6333,,80852,,,BAO_0000219,,Intermediate,,9606.0,F,,A-431
5007,Homo sapiens,,CHEMBL884000,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),,6333,,80852,,,BAO_0000219,,Intermediate,,9606.0,F,,A-431
5008,Homo sapiens,,CHEMBL621154,Inhibition of EGFR overexpressing A431 cell proliferation,,5296,,9,,,BAO_0000019,,Expert,,9606.0,F,,
5009,Homo sapiens,,CHEMBL621155,Inhibition of A431 cell proliferation,,12624,,80852,,,BAO_0000219,,Expert,,9606.0,F,,A-431
5010,Homo sapiens,,CHEMBL621156,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,,14926,,9,,,BAO_0000219,,Expert,,9606.0,F,,A-431
5011,Homo sapiens,,CHEMBL621157,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",,14926,,9,,,BAO_0000219,,Expert,,9606.0,F,,A-431
5012,,,CHEMBL621158,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),,14926,,9,,,BAO_0000219,,Expert,,,F,,A-431
5013,Homo sapiens,,CHEMBL621159,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,15144,,80852,,,BAO_0000219,,Intermediate,,9606.0,F,,A-431
5014,Homo sapiens,,CHEMBL621160,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,15144,,80852,,,BAO_0000219,,Intermediate,,9606.0,F,,A-431
5015,Homo sapiens,,CHEMBL621161,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,,5245,,80852,,,BAO_0000219,,Intermediate,,9606.0,F,,A-431
5016,Homo sapiens,,CHEMBL621162,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,,5245,,80852,,,BAO_0000219,,Intermediate,,9606.0,F,,A-431
5017,Homo sapiens,,CHEMBL621163,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,5245,,80852,,,BAO_0000219,,Intermediate,,9606.0,F,,A-431
5018,Homo sapiens,,CHEMBL621164,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,,5245,,80852,,,BAO_0000219,,Intermediate,,9606.0,F,,A-431
5019,Homo sapiens,,CHEMBL621165,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,,5245,,80852,,,BAO_0000219,,Intermediate,,9606.0,F,,A-431
5020,Cercopithecidae,,CHEMBL619159,Half-life period in cynomolgus monkey,,5922,,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
5021,Cercopithecidae,1969.0,CHEMBL619160,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",In vitro,1116,Plasma,22224,,,BAO_0000366,,Autocuration,,9527.0,A,,
5022,Cercopithecidae,,CHEMBL619161,Longer half-life in monkey (i.v.) at 0.5 mpk,In vivo,17853,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
5023,Cercopithecidae,1969.0,CHEMBL619162,Plasma half life in monkey,,993,Plasma,22224,,,BAO_0000366,,Autocuration,,9527.0,A,,
5024,Cercopithecidae,1969.0,CHEMBL619163,Plasma half-life in rhesus monkey,,4514,Plasma,22224,,,BAO_0000366,,Autocuration,,9527.0,A,,
5025,Cercopithecidae,1969.0,CHEMBL619164,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),In vivo,5334,Plasma,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
5026,Cercopithecidae,1969.0,CHEMBL619320,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),In vivo,5334,Plasma,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
5027,Cercopithecidae,,CHEMBL619321,Tested for half life upon iv administration to african green monkey,In vivo,4578,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
5028,Cercopithecidae,,CHEMBL873336,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,In vivo,2661,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
5029,Cercopithecidae,,CHEMBL619322,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,In vivo,5355,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
5030,Cercopithecidae,,CHEMBL619323,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,In vivo,5355,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
5031,Cercopithecidae,,CHEMBL619324,The time for peak concentration value after oral administration in cynomolgus monkeys,In vivo,5355,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
5032,Cercopithecidae,,CHEMBL619325,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,,11271,,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
5033,Cercopithecidae,,CHEMBL876411,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,,11271,,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
5034,Cercopithecidae,,CHEMBL619326,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,,11271,,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
5035,Cercopithecidae,,CHEMBL619327,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,,11271,,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
5036,Cercopithecidae,,CHEMBL619328,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,,11271,,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
5037,Cercopithecidae,,CHEMBL619329,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,,11271,,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
5038,Cercopithecidae,,CHEMBL619330,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,,11271,,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
5039,Cercopithecidae,,CHEMBL619331,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,,11271,,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
5040,Cercopithecidae,,CHEMBL619332,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,,11271,,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
5041,Cercopithecidae,,CHEMBL619333,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,,11271,,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
5042,Cercopithecidae,,CHEMBL619334,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,,11271,,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
5043,Cercopithecidae,,CHEMBL619335,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,,11271,,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
5044,Cercopithecidae,,CHEMBL619336,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,,11271,,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
5045,Cercopithecidae,,CHEMBL619337,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,,11271,,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
5046,Cercopithecidae,,CHEMBL619338,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,,11271,,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
5047,Cercopithecidae,,CHEMBL619339,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,,11271,,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
5048,Rattus norvegicus,,CHEMBL619340,Bioavailability in rat (cannulated) (dose 2 mg/kg),In vivo,5809,,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
5049,Rattus norvegicus,1969.0,CHEMBL873496,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,In vivo,17720,Plasma,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
5050,Rattus norvegicus,1969.0,CHEMBL619341,AUC value in rat after IV administration at a dose of 10 mg/kg,,3546,Plasma,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
5051,Rattus norvegicus,1969.0,CHEMBL619342,AUC value in rat after oral administration at a dose of 10 mg/kg,,3546,Plasma,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
5052,Rattus norvegicus,,CHEMBL619343,Cmax value in rat after oral administration at a dose of 10 mg/kg,In vivo,3546,,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
5053,Rattus norvegicus,,CHEMBL619344,Bioavailability in rat after oral administration at a dose of 10 mg/kg,In vivo,3546,,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
5054,Rattus norvegicus,,CHEMBL619345,Tmax value in rat after oral administration at a dose of 10 mg/kg,In vivo,3546,,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
5055,Rattus norvegicus,,CHEMBL619346,Vc value in rat after IV administration at a dose of 10 mg/kg,,3546,,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
5056,Rattus norvegicus,,CHEMBL619347,Half life period in rat after IV administration at a dose of 10 mg/kg,In vivo,3546,,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
5057,Papio hamadryas,,CHEMBL619348,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,10625,,22224,,,BAO_0000019,,Autocuration,,9557.0,A,,
5058,Papio hamadryas,,CHEMBL619349,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),,10625,,22224,,,BAO_0000019,,Autocuration,,9557.0,A,,
5059,Papio hamadryas,,CHEMBL619350,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),,10625,,22224,,,BAO_0000019,,Autocuration,,9557.0,A,,
5060,Papio hamadryas,,CHEMBL619351,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,,10625,,22224,,,BAO_0000019,,Autocuration,,9557.0,A,,
5061,Papio hamadryas,,CHEMBL875953,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,,10625,,22224,,,BAO_0000019,,Autocuration,,9557.0,A,,
5062,Papio hamadryas,,CHEMBL621716,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,,10625,,22224,,,BAO_0000019,,Autocuration,,9557.0,A,,
5063,Papio hamadryas,,CHEMBL621717,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,,10625,,22224,,,BAO_0000019,,Autocuration,,9557.0,A,,
5064,Papio hamadryas,,CHEMBL621718,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,10625,,22224,,,BAO_0000019,,Autocuration,,9557.0,A,,
5065,beagle,,CHEMBL621719,Area under curve after 1 mpk peroral administration to beagles,,3510,,22224,,,BAO_0000019,,Autocuration,,9615.0,A,,
5066,beagle,,CHEMBL621720,Area under curve after 2 mpk peroral administration to beagles,,3510,,22224,,,BAO_0000019,,Autocuration,,9615.0,A,,
5067,beagle,,CHEMBL621721,Cmax value after 1 mpk peroral administration to beagles,In vivo,3510,,22224,,,BAO_0000218,,Autocuration,,9615.0,A,,
5068,Homo sapiens,1088.0,CHEMBL621722,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,,7766,Urine,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
5069,Homo sapiens,1088.0,CHEMBL621723,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,,7766,Urine,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
5070,Homo sapiens,1088.0,CHEMBL621724,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,,7766,Urine,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
5071,Homo sapiens,1088.0,CHEMBL623443,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,,7766,Urine,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
5072,Homo sapiens,1088.0,CHEMBL623444,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,,7766,Urine,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
5073,Homo sapiens,1088.0,CHEMBL623445,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,,7766,Urine,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
5074,Homo sapiens,1088.0,CHEMBL623446,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,,7766,Urine,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
5075,Homo sapiens,2107.0,CHEMBL623447,Metabolic stability observed at 30 min after administration in human liver microsomes,,16643,Liver,22224,,,BAO_0000251,,Autocuration,Microsomes,9606.0,A,,
5076,Homo sapiens,,CHEMBL623448,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,,6852,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
5077,Homo sapiens,,CHEMBL623449,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,,6852,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
5078,Homo sapiens,,CHEMBL623450,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,,6852,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
5079,Homo sapiens,2107.0,CHEMBL623451,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",,6567,Liver,22224,,,BAO_0000251,,Autocuration,Microsomes,9606.0,A,,
5080,Homo sapiens,,CHEMBL623452,Metabolic stability (% remaining at 30 mins) in human S9.,,6570,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
5081,Homo sapiens,,CHEMBL623453,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,,6570,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
5082,Homo sapiens,2107.0,CHEMBL623454,Percent parent compound remaining after 20 min incubation with human liver microsomes,,5237,Liver,22224,,,BAO_0000251,,Autocuration,Microsomes,9606.0,A,,
5083,Homo sapiens,2107.0,CHEMBL623455,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,,5237,Liver,22224,,,BAO_0000251,,Autocuration,Microsomes,9606.0,A,,
5084,Homo sapiens,2107.0,CHEMBL624371,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,,5237,Liver,22224,,,BAO_0000251,,Autocuration,Microsomes,9606.0,A,,
5085,Homo sapiens,,CHEMBL624372,First pass metabolism and metabolic bioavailability using human hepatic microsomes,,5202,,22224,,,BAO_0000218,,Autocuration,,9606.0,A,,
5086,Homo sapiens,,CHEMBL624373,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,,5481,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
5087,Homo sapiens,,CHEMBL624374,Percent remaining in human plasma after incubation for 60 min at 37 C.,,5481,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
5088,Homo sapiens,,CHEMBL624556,The percent remaining in human plasma after 30 min was determined,,3956,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
5089,Homo sapiens,1969.0,CHEMBL624557,Conversion rate of the prodrug in human plasma,,5074,Plasma,22224,,,BAO_0000366,,Autocuration,,9606.0,A,,
5090,Homo sapiens,1969.0,CHEMBL624558,Conversion rate of the prodrug in human plasma; ND means no data,,5074,Plasma,22224,,,BAO_0000366,,Autocuration,,9606.0,A,,
5091,Homo sapiens,178.0,CHEMBL624559,Half life of compound was determined in human blood,,4727,Blood,22224,,,BAO_0000221,,Autocuration,,9606.0,A,,
5092,Homo sapiens,,CHEMBL624560,Half life of compound was determined in man with once daily dosing,,5965,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
5093,Homo sapiens,,CHEMBL624561,Half life in human microsomes,In vitro,5732,,22224,,,BAO_0000251,,Autocuration,Microsomes,9606.0,A,,
5094,Homo sapiens,1969.0,CHEMBL624562,Half life in human plasma,,5819,Plasma,22224,,,BAO_0000366,,Autocuration,,9606.0,A,,
5095,Homo sapiens,1969.0,CHEMBL624563,Half life in human plasma; Not detected,,5819,Plasma,22224,,,BAO_0000366,,Autocuration,,9606.0,A,,
5096,Homo sapiens,,CHEMBL624564,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,In vivo,1916,,22224,,,BAO_0000218,,Autocuration,,9606.0,A,,
5097,Homo sapiens,2107.0,CHEMBL624565,Half-life for oxidative metabolic stability was determined using rat liver microsomes,In vitro,6597,Liver,22224,,,BAO_0000251,,Autocuration,Microsomes,9606.0,A,,
5098,Homo sapiens,1969.0,CHEMBL875152,Half-life in human plasma,,5229,Plasma,22224,,,BAO_0000366,,Autocuration,,9606.0,A,,
5099,Homo sapiens,1969.0,CHEMBL624566,Half-life of the parent prodrug in plasma,,5229,Plasma,22224,,,BAO_0000366,,Autocuration,,9606.0,A,,
5100,Homo sapiens,1969.0,CHEMBL873805,In vitro half life in human plasma was determined,In vitro,2192,Plasma,22224,,,BAO_0000366,,Autocuration,,9606.0,A,,
5101,Homo sapiens,2107.0,CHEMBL624567,The compound was tested In Vitro for half life in human liver microsomes.,In vitro,3032,Liver,22224,,,BAO_0000251,,Autocuration,Microsomes,9606.0,A,,
5102,Homo sapiens,,CHEMBL624568,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,In vivo,1916,,22224,,,BAO_0000218,,Autocuration,,9606.0,A,,
5103,Homo sapiens,,CHEMBL624569,Observed volume of distribution,In vivo,17716,,22224,,,BAO_0000218,,Autocuration,,9606.0,A,,
5104,Homo sapiens,,CHEMBL624570,Oral bioavailability in human,In vivo,15778,,22224,,,BAO_0000218,,Autocuration,,9606.0,A,,
5105,Homo sapiens,,CHEMBL624571,Tested for human plasma protein binding of the compound,,17313,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
5106,Homo sapiens,,CHEMBL624572,"First order rate constant, k was determined in human plasma",,4231,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
5107,Homo sapiens,,CHEMBL624573,Observed rate constant in 80% human plasma at 37 degree Centigrade,,4755,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
5108,Homo sapiens,,CHEMBL875153,Observed rate constant in 80% human plasma at 37 degree Centigrade,,4755,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
5109,Homo sapiens,2107.0,CHEMBL624574,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,,16907,Liver,22224,,,BAO_0000251,,Autocuration,Microsomes,9606.0,A,,
5110,Homo sapiens,,CHEMBL624575,The compound was tested for the plasma binding in human,,10839,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
5111,Homo sapiens,,CHEMBL624576,Plasma protein binding (human),,10839,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
5112,Homo sapiens,2107.0,CHEMBL624577,Compound was evaluated for half-life in human liver microsomes,In vitro,3199,Liver,22224,,,BAO_0000251,,Autocuration,Microsomes,9606.0,A,,
5113,Homo sapiens,178.0,CHEMBL624578,Half life measured in vitro for its stability in human blood,In vitro,1345,Blood,22224,,,BAO_0000221,,Autocuration,,9606.0,A,,
5114,Homo sapiens,1977.0,CHEMBL622796,Half life in human serum,,4297,Serum,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
5115,Homo sapiens,1977.0,CHEMBL622797,Half life in human serum; ND=not determined,,4297,Serum,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
5116,Homo sapiens,,CHEMBL622798,Half life were determined in CEM-SS cell extract in decomposition step 1,,4297,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
5117,Homo sapiens,,CHEMBL622799,Half life were determined in CEM-SS cell extract in decomposition step 2,,4297,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
5118,Homo sapiens,1969.0,CHEMBL622800,Half life of the in human plasma,,4231,Plasma,22224,,,BAO_0000366,,Autocuration,,9606.0,A,,
5119,Homo sapiens,,CHEMBL622801,Half life period in human hepatic S9 fraction was determined,In vitro,5633,,22224,,,BAO_0000220,,Autocuration,S9,9606.0,A,,
5120,Homo sapiens,2107.0,CHEMBL622802,Half life period in human liver microsome was determined,In vitro,5633,Liver,22224,,,BAO_0000251,,Autocuration,Microsomes,9606.0,A,,
5121,Homo sapiens,,CHEMBL622803,Half life period was determined; 6-7,,17791,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
5122,Homo sapiens,,CHEMBL875154,Half life period was evaluated in human,,17791,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
5123,Homo sapiens,1969.0,CHEMBL622804,Half life time in human plasma,,3160,Plasma,22224,,,BAO_0000366,,Autocuration,,9606.0,A,,
5124,Mus musculus,955.0,CHEMBL622805,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,16438,Brain,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5125,Mus musculus,948.0,CHEMBL622611,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,16438,Heart,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5126,Mus musculus,948.0,CHEMBL622612,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,16438,Heart,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5127,Mus musculus,2113.0,CHEMBL875160,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,16438,Kidney,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5128,Mus musculus,2113.0,CHEMBL622613,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",In vivo,16438,Kidney,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5129,Mus musculus,2113.0,CHEMBL622614,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,16438,Kidney,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5130,Mus musculus,2107.0,CHEMBL622615,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,16438,Liver,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5131,Mus musculus,2107.0,CHEMBL622616,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,In vivo,16438,Liver,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5132,Mus musculus,2107.0,CHEMBL622617,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,16438,Liver,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5133,Mus musculus,2106.0,CHEMBL622618,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,In vivo,16438,Spleen,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5134,Mus musculus,2106.0,CHEMBL622619,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",In vivo,16438,Spleen,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5135,Mus musculus,2106.0,CHEMBL622620,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,16438,Spleen,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5136,Mus musculus,955.0,CHEMBL622621,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",In vivo,16438,Brain,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5137,Mus musculus,178.0,CHEMBL622622,Biodistribution of compound (oxidized form) in blood tissue,In vivo,16438,Blood,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5138,Mus musculus,178.0,CHEMBL622623,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,16438,Blood,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5139,Mus musculus,178.0,CHEMBL622624,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",In vivo,16438,Blood,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5140,Mus musculus,178.0,CHEMBL622625,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",In vivo,16438,Blood,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5141,Mus musculus,178.0,CHEMBL622626,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,16438,Blood,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5142,Mus musculus,178.0,CHEMBL622627,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",In vivo,16438,Blood,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5143,Mus musculus,955.0,CHEMBL622628,Biodistribution of compound (oxidized form) in brain tissue of mice,In vivo,16438,Brain,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5144,Mus musculus,955.0,CHEMBL622629,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,16438,Brain,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5145,Mus musculus,955.0,CHEMBL622630,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",In vivo,16438,Brain,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5146,Mus musculus,955.0,CHEMBL622631,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,16438,Brain,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5147,Mus musculus,955.0,CHEMBL622632,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",In vivo,16438,Brain,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5148,Mus musculus,955.0,CHEMBL622633,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",In vivo,16438,Brain,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5149,Mus musculus,948.0,CHEMBL622634,Biodistribution of compound (oxidized form) in heart tissue of mice,In vivo,16438,Heart,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5150,Mus musculus,948.0,CHEMBL622635,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,16438,Heart,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5151,Mus musculus,948.0,CHEMBL875161,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,16438,Heart,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5152,Mus musculus,948.0,CHEMBL622636,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",In vivo,16438,Heart,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5153,Mus musculus,948.0,CHEMBL623335,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,16438,Heart,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5154,Mus musculus,948.0,CHEMBL623336,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",In vivo,16438,Heart,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5155,Mus musculus,2113.0,CHEMBL623337,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,16438,Kidney,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5156,Mus musculus,2113.0,CHEMBL623338,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",In vivo,16438,Kidney,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5157,Mus musculus,2113.0,CHEMBL623339,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",In vivo,16438,Kidney,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5158,Mus musculus,2113.0,CHEMBL623524,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,16438,Kidney,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5159,Mus musculus,2113.0,CHEMBL623525,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",In vivo,16438,Kidney,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5160,Mus musculus,2107.0,CHEMBL623526,Biodistribution of compound (oxidized form) in liver tissue,In vivo,16438,Liver,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5161,Mus musculus,2107.0,CHEMBL623527,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,16438,Liver,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5162,Mus musculus,2107.0,CHEMBL623528,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",In vivo,16438,Liver,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5163,Homo sapiens,,CHEMBL624615,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,,5245,,80852,,,BAO_0000219,,Intermediate,,9606.0,F,,A-431
5164,Homo sapiens,,CHEMBL621672,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,5245,,80852,,,BAO_0000219,,Intermediate,,9606.0,F,,A-431
5165,,,CHEMBL621673,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",,16289,,80852,,,BAO_0000218,,Expert,,,F,,A-431
5166,,,CHEMBL621674,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",,16289,,80852,,,BAO_0000218,,Expert,,,F,,A-431
5167,Homo sapiens,,CHEMBL884002,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,16093,,9,,,BAO_0000219,,Expert,,9606.0,F,,A-431
5168,Homo sapiens,,CHEMBL621850,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",,16825,,80852,,,BAO_0000219,,Intermediate,,9606.0,F,,A-431
5169,Homo sapiens,,CHEMBL621851,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,,4848,,80852,,,BAO_0000219,,Intermediate,,9606.0,F,,A-431
5170,Homo sapiens,,CHEMBL621852,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,,14827,,9,,,BAO_0000219,,Expert,,9606.0,F,,A-431
5171,Homo sapiens,,CHEMBL621853,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,,14827,,9,,,BAO_0000219,,Expert,,9606.0,F,,A-431
5172,,,CHEMBL621854,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",,16289,,80852,,,BAO_0000218,,Expert,,,F,,A-431
5173,,,CHEMBL621855,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,16289,,80852,,,BAO_0000218,,Expert,,,F,,A-431
5174,,,CHEMBL623724,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,16289,,80852,,,BAO_0000218,,Expert,,,F,,A-431
5175,,,CHEMBL623725,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",,16289,,80852,,,BAO_0000218,,Expert,,,F,,A-431
5176,,,CHEMBL623726,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",,16289,,80852,,,BAO_0000218,,Expert,,,F,,A-431
5177,Homo sapiens,,CHEMBL623727,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",,16289,,9,,,BAO_0000219,,Expert,,9606.0,F,,A-431
5178,,,CHEMBL623728,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,,16289,,9,,,BAO_0000219,,Expert,,,F,,A-431
5179,,,CHEMBL623729,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",,16289,,80852,,,BAO_0000218,,Expert,,,F,,A-431
5180,,,CHEMBL623730,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,16289,,80852,,,BAO_0000218,,Expert,,,F,,A-431
5181,,,CHEMBL623731,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,16289,,80852,,,BAO_0000218,,Expert,,,F,,A-431
5182,Mus musculus,,CHEMBL623732,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",,14555,,80852,,,BAO_0000218,,Expert,,10090.0,F,,A-431
5183,Mus musculus,,CHEMBL623733,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",,14555,,80852,,,BAO_0000218,,Expert,,10090.0,F,,A-431
5184,Mus musculus,,CHEMBL623734,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,14555,,80852,,,BAO_0000218,,Expert,,10090.0,F,,A-431
5185,Mus musculus,,CHEMBL623735,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,14555,,80852,,,BAO_0000218,,Expert,,10090.0,F,,A-431
5186,Homo sapiens,,CHEMBL623736,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,,1937,,80852,,,BAO_0000219,,Expert,,9606.0,F,,A-431
5187,Homo sapiens,,CHEMBL623737,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,,13739,,80852,,,BAO_0000219,,Intermediate,,9606.0,F,,A-431
5188,Homo sapiens,,CHEMBL623738,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,,3558,,80852,,,BAO_0000219,,Intermediate,,9606.0,F,,A-431
5189,Homo sapiens,,CHEMBL875168,Dose giving a 50% decrease in the living cell number (A437 cells),,3558,,80852,,,BAO_0000219,,Intermediate,,9606.0,F,,A-431
5190,Homo sapiens,,CHEMBL623739,In vitro inhibitory concentration against proliferation of A459 cell line.,,17686,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
5191,Homo sapiens,,CHEMBL623740,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,,5305,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5192,Homo sapiens,,CHEMBL624424,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,,3614,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5193,Homo sapiens,,CHEMBL624425,In vitro antitumor activity against renal A498 tumor cell lines,,17229,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5194,Homo sapiens,,CHEMBL624426,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",,15935,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5195,Homo sapiens,,CHEMBL624427,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",,15935,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5196,Homo sapiens,,CHEMBL624428,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,,15560,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5197,Homo sapiens,,CHEMBL624429,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,,13891,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5198,Homo sapiens,,CHEMBL624620,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,,13891,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5199,Homo sapiens,,CHEMBL624621,Cytotoxicity on kidney carcinoma (A-498) cell line,,13788,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5200,Homo sapiens,,CHEMBL624622,Compound was evaluated against Human cell line renal A498,,15403,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5201,Homo sapiens,,CHEMBL624623,Compound was tested for inhibition of A498 human renal cancer cell line,,1009,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5202,Homo sapiens,,CHEMBL874365,Growth inhibitory activity against A498 human cancer cell line,,1043,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5203,Homo sapiens,,CHEMBL624624,In vitro antitumor activity against human renal A498 cell line,,5858,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5204,Homo sapiens,,CHEMBL624625,In vitro cytotoxic activity against renal (A498) cell line,,5958,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5205,Homo sapiens,,CHEMBL624626,In vitro cytotoxic activity against human renal cancer (A498) cell line,,5506,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5206,Homo sapiens,,CHEMBL624627,Tested for cytostatic activity against renal A498 cell line,,12781,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5207,Homo sapiens,,CHEMBL883157,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,,14399,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5208,Homo sapiens,,CHEMBL624628,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,,5958,,80021,,,BAO_0000219,,Expert,,9606.0,F,,A498
5209,beagle,,CHEMBL624629,Cmax value after 2 mpk peroral administration to beagles,In vivo,3510,,22224,,,BAO_0000218,,Autocuration,,9615.0,A,,
5210,Canis lupus familiaris,,CHEMBL623551,Bioavailability,In vivo,3510,,22224,,,BAO_0000218,,Autocuration,,9615.0,A,beagle,
5211,Canis lupus familiaris,,CHEMBL623552,Bioavailability after 1 mpk peroral administration to beagles,In vivo,3510,,22224,,,BAO_0000218,,Autocuration,,9615.0,A,beagle,
5212,Canis lupus familiaris,,CHEMBL623553,Bioavailability after 2 mpk peroral administration to beagles,In vivo,3510,,22224,,,BAO_0000218,,Autocuration,,9615.0,A,beagle,
5213,Bos taurus,,CHEMBL623554,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,,3085,,22224,,,BAO_0000019,,Autocuration,,9913.0,A,,
5214,Bos taurus,,CHEMBL623555,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,,3085,,22224,,,BAO_0000019,,Autocuration,,9913.0,A,,
5215,Bos taurus,,CHEMBL623556,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,,3085,,22224,,,BAO_0000019,,Autocuration,,9913.0,A,,
5216,Bos taurus,,CHEMBL623557,Solubility against bovine alpha-chymotrypsin,,9372,,22224,,,BAO_0000019,,Autocuration,,9913.0,A,,
5217,Bos taurus,,CHEMBL623558,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,3085,,22224,,,BAO_0000019,,Autocuration,,9913.0,A,,
5218,Bos taurus,,CHEMBL623559,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,3085,,22224,,,BAO_0000019,,Autocuration,,9913.0,A,,
5219,Bos taurus,2106.0,CHEMBL623560,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,,1469,Spleen,22224,,,BAO_0000221,,Autocuration,,9913.0,A,,
5220,Bos taurus,,CHEMBL623561,Half life in culture medium containing 10% of heat inactivated foetal calf serum,,4297,,22224,,,BAO_0000019,,Autocuration,,9913.0,A,,
5221,Bos taurus,,CHEMBL623562,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,,4297,,22224,,,BAO_0000019,,Autocuration,,9913.0,A,,
5222,Bos taurus,,CHEMBL623563,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,,17585,,22224,,,BAO_0000019,,Autocuration,,9913.0,A,,
5223,Bos taurus,2106.0,CHEMBL623564,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,,1336,Spleen,22224,,,BAO_0000221,,Autocuration,,9913.0,A,,
5224,Bos taurus,,CHEMBL873806,Half life in presence of 2 mg/mL BSA at pH 8.8,,3085,,22224,,,BAO_0000019,,Autocuration,,9913.0,A,,
5225,Bos taurus,,CHEMBL623565,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,,2857,,22224,,,BAO_0000019,,Autocuration,,9913.0,A,,
5226,Bos taurus,,CHEMBL623566,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,,2857,,22224,,,BAO_0000019,,Autocuration,,9913.0,A,,
5227,Bos taurus,,CHEMBL623567,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,,2857,,22224,,,BAO_0000019,,Autocuration,,9913.0,A,,
5228,Bos taurus,,CHEMBL623568,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),,1540,,22224,,,BAO_0000019,,Autocuration,,9913.0,A,,
5229,Canis lupus familiaris,1969.0,CHEMBL623569,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,,6316,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5230,Canis lupus familiaris,1969.0,CHEMBL623570,AUC after administration at 100 mg/kg/day in dogs,,17594,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5231,Canis lupus familiaris,1969.0,CHEMBL624254,AUC in dog at 0-24 hr by peroral administration at 3 mpk,,4953,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5232,Canis lupus familiaris,1969.0,CHEMBL624255,AUC value after 15 mg/kg iv dose in Dogs,,16907,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5233,Canis lupus familiaris,1969.0,CHEMBL624256,AUC value after 30 mg/kg po dose in Dogs,,16907,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5234,Canis lupus familiaris,1969.0,CHEMBL624257,AUC value after administration of 4 mg/Kg oral dose in dog,,2959,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5235,Canis lupus familiaris,1969.0,CHEMBL624258,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,,17594,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5236,Canis lupus familiaris,,CHEMBL875277,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,,5356,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5237,Canis lupus familiaris,,CHEMBL622667,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,,16807,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5238,Canis lupus familiaris,,CHEMBL622668,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,,4527,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5239,Canis lupus familiaris,,CHEMBL622669,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,,4527,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5240,Canis lupus familiaris,,CHEMBL622670,Area under curve determined in dogs after intravenous administration of 3 mg/kg,,15660,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5241,Canis lupus familiaris,,CHEMBL622671,Area under curve determined in dogs after oral administration of 10 mg/kg,,15660,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5242,Canis lupus familiaris,,CHEMBL622672,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,5802,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5243,Canis lupus familiaris,,CHEMBL622673,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,,3598,,50588,,,BAO_0000218,,Expert,,9615.0,A,,
5244,Canis lupus familiaris,,CHEMBL622674,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,,3598,,50588,,,BAO_0000218,,Expert,,9615.0,A,,
5245,Canis lupus familiaris,,CHEMBL622675,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,5944,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5246,Canis lupus familiaris,,CHEMBL622676,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,,5944,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5247,Canis lupus familiaris,,CHEMBL622677,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,5944,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5248,Canis lupus familiaris,,CHEMBL622678,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,,5944,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5249,Canis lupus familiaris,,CHEMBL622679,Area under curve in dog after administration of 20 mg/kg dose through peroral route,,4186,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5250,Canis lupus familiaris,,CHEMBL622680,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,5007,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5251,Canis lupus familiaris,,CHEMBL622681,Area under curve was determine after peroral administration at 10 mpk in dog,,5668,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5252,Canis lupus familiaris,,CHEMBL875278,Area under curve was determine after peroral administration at 5 mpk in dog,,5668,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5253,Canis lupus familiaris,,CHEMBL622682,Area under curve was determined,,5006,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5254,Canis lupus familiaris,,CHEMBL622683,Area under curve in dogs,,5006,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5255,Canis lupus familiaris,,CHEMBL622684,Area under curve in dogs at 10 mg/kg dose fo oral administration,,3771,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5256,Canis lupus familiaris,,CHEMBL622685,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),,3771,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5257,Canis lupus familiaris,,CHEMBL622686,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,,3771,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5258,Canis lupus familiaris,,CHEMBL618344,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,1916,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5259,Canis lupus familiaris,,CHEMBL875582,Area under curve value in dog at a dose of 5 mg/kg,,5302,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5260,Canis lupus familiaris,,CHEMBL618345,Area under curve was determined after 0.1 mg/kg iv administration in dog,,5600,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5261,Canis lupus familiaris,,CHEMBL618346,Area under curve was determined after 0.3 mg/kg po administration in dog,,5600,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5262,Canis lupus familiaris,,CHEMBL618347,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,,17764,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5263,Canis lupus familiaris,,CHEMBL618348,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,,4368,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5264,Homo sapiens,,CHEMBL618349,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,,5318,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
5265,Homo sapiens,,CHEMBL618350,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,5318,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
5266,Homo sapiens,,CHEMBL618351,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,,5318,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
5267,Homo sapiens,,CHEMBL618352,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,,5318,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
5268,Homo sapiens,178.0,CHEMBL873494,Time taken to reduce 50% of the concentration of compound in blood plasma,,14518,Blood,22224,,,BAO_0000221,,Autocuration,,9606.0,A,,
5269,Homo sapiens,1969.0,CHEMBL618353,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",,2209,Plasma,22224,,,BAO_0000366,,Autocuration,,9606.0,A,,
5270,Homo sapiens,1969.0,CHEMBL618354,Half life in human plasma,,6787,Plasma,22224,,,BAO_0000366,,Autocuration,,9606.0,A,,
5271,Homo sapiens,1969.0,CHEMBL875583,Half life in human plasma was reported,,4898,Plasma,22224,,,BAO_0000366,,Autocuration,,9606.0,A,,
5272,Homo sapiens,1977.0,CHEMBL618355,Half life in human serum,,6072,Serum,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
5273,Homo sapiens,1969.0,CHEMBL618356,Half life upon exposure to human plasma,,16907,Plasma,22224,,,BAO_0000366,,Autocuration,,9606.0,A,,
5274,Homo sapiens,,CHEMBL618357,t1/2 in human microsomes,In vitro,5656,,22224,,,BAO_0000251,,Autocuration,Microsomes,9606.0,A,,
5275,Homo sapiens,1969.0,CHEMBL618358,Half life period in 80% human plasma at 37 degree Centigrade,,4755,Plasma,22224,,,BAO_0000366,,Autocuration,,9606.0,A,,
5276,Homo sapiens,14.0,CHEMBL618359,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),,17503,Zone of skin,22224,,,BAO_0000221,,Autocuration,,9606.0,A,,
5277,Homo sapiens,1969.0,CHEMBL618360,Half-life measured in in vitro Cathepsin B assay in human plasma,In vitro,12357,Plasma,22224,,,BAO_0000366,,Autocuration,,9606.0,A,,
5278,Homo sapiens,,CHEMBL618361,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,,3076,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
5279,Homo sapiens,2107.0,CHEMBL618362,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,In vitro,6410,Liver,22224,,,BAO_0000251,,Autocuration,Microsomes,9606.0,A,,
5280,Homo sapiens,1969.0,CHEMBL618363,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,3741,Plasma,22224,,,BAO_0000366,,Autocuration,,9606.0,A,,
5281,Homo sapiens,1969.0,CHEMBL618364,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,3741,Plasma,22224,,,BAO_0000366,,Autocuration,,9606.0,A,,
5282,Homo sapiens,1969.0,CHEMBL875584,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,3741,Plasma,22224,,,BAO_0000366,,Autocuration,,9606.0,A,,
5283,Homo sapiens,,CHEMBL618365,Half-life in the CEM cell extracts,,1540,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
5284,Homo sapiens,1969.0,CHEMBL873495,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,,2905,Plasma,22224,,,BAO_0000366,,Autocuration,,9606.0,A,,
5285,Homo sapiens,1969.0,CHEMBL618366,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,,2905,Plasma,22224,,,BAO_0000366,,Autocuration,,9606.0,A,,
5286,Homo sapiens,,CHEMBL618367,Half-life was determined,,5523,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
5287,Homo sapiens,178.0,CHEMBL618368,Half-life (human blood stability),,1499,Blood,22224,,,BAO_0000221,,Autocuration,,9606.0,A,,
5288,Homo sapiens,178.0,CHEMBL618369,Half-life (human blood stability); no data,,1499,Blood,22224,,,BAO_0000221,,Autocuration,,9606.0,A,,
5289,Homo sapiens,1969.0,CHEMBL618370,Half-life in human plasma,,17065,Plasma,22224,,,BAO_0000366,,Autocuration,,9606.0,A,,
5290,Homo sapiens,,CHEMBL618371,CYP3A4 metabolism half-life (t1/2),,6861,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
5291,Homo sapiens,178.0,CHEMBL618372,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),,1499,Blood,22224,,,BAO_0000221,,Autocuration,,9606.0,A,,
5292,Homo sapiens,1969.0,CHEMBL618373,In vitro half life in human plasma,In vitro,530,Plasma,22224,,,BAO_0000366,,Autocuration,,9606.0,A,,
5293,Homo sapiens,1969.0,CHEMBL618374,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",In vitro,1116,Plasma,22224,,,BAO_0000366,,Autocuration,,9606.0,A,,
5294,Homo sapiens,1969.0,CHEMBL618375,In vitro hydrolysis in human plasma,In vitro,6695,Plasma,22224,,,BAO_0000366,,Autocuration,,9606.0,A,,
5295,Homo sapiens,1969.0,CHEMBL618376,In vitro hydrolysis in human plasma; no data,In vitro,6695,Plasma,22224,,,BAO_0000366,,Autocuration,,9606.0,A,,
5296,Homo sapiens,2107.0,CHEMBL618377,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,In vitro,10,Liver,22224,,,BAO_0000251,,Autocuration,Microsomes,9606.0,A,,
5297,Homo sapiens,1969.0,CHEMBL618378,Plasma half life in human,,993,Plasma,22224,,,BAO_0000366,,Autocuration,,9606.0,A,,
5298,Homo sapiens,1969.0,CHEMBL618379,Stability after incubation with human plasma (at 37 degree C),,15429,Plasma,22224,,,BAO_0000366,,Autocuration,,9606.0,A,,
5299,Homo sapiens,1969.0,CHEMBL618380,T1/2 was evaluated in human plasma,,1675,Plasma,22224,,,BAO_0000366,,Autocuration,,9606.0,A,,
5300,Homo sapiens,1969.0,CHEMBL618381,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",,2209,Plasma,22224,,,BAO_0000366,,Autocuration,,9606.0,A,,
5301,Homo sapiens,1969.0,CHEMBL618382,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",,2209,Plasma,22224,,,BAO_0000366,,Autocuration,,9606.0,A,,
5302,Homo sapiens,,CHEMBL618383,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,5318,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
5303,Homo sapiens,,CHEMBL618384,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,In vitro,2412,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
5304,Homo sapiens,,CHEMBL618385,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,In vitro,2412,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
5305,Homo sapiens,1969.0,CHEMBL619099,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,,2906,Plasma,22224,,,BAO_0000366,,Autocuration,,9606.0,A,,
5306,Homo sapiens,1969.0,CHEMBL619100,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,,2906,Plasma,22224,,,BAO_0000366,,Autocuration,,9606.0,A,,
5307,Homo sapiens,,CHEMBL619101,Time taken for 50% to be consumed by serum PON1 was determined,,5495,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
5308,Homo sapiens,,CHEMBL619102,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,,5495,,22224,,,BAO_0000019,,Autocuration,,9606.0,A,,
5309,Homo sapiens,2107.0,CHEMBL619103,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,,4397,Liver,22224,,,BAO_0000251,,Autocuration,Microsomes,9606.0,A,,
5310,Mus sp.,,CHEMBL619268,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,,2413,,22224,,,BAO_0000218,,Autocuration,,10095.0,A,,
5311,Mus sp.,,CHEMBL619269,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,,2413,,22224,,,BAO_0000218,,Autocuration,,10095.0,A,,
5312,Mus sp.,,CHEMBL619270,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,,2413,,22224,,,BAO_0000218,,Autocuration,,10095.0,A,,
5313,Mus sp.,,CHEMBL619271,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,,2413,,22224,,,BAO_0000218,,Autocuration,,10095.0,A,,
5314,Mus sp.,,CHEMBL875585,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,,2413,,22224,,,BAO_0000218,,Autocuration,,10095.0,A,,
5315,Mus sp.,,CHEMBL619272,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,,2413,,22224,,,BAO_0000218,,Autocuration,,10095.0,A,,
5316,Homo sapiens,,CHEMBL619273,Compound tested for growth inhibition of renal cancer cell line 786-0,,6058,,80640,,,BAO_0000219,,Intermediate,,9606.0,F,,786-0
5317,Homo sapiens,,CHEMBL619274,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,,17708,,80640,,,BAO_0000219,,Intermediate,,9606.0,F,,786-0
5318,Homo sapiens,,CHEMBL619275,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,,14017,,80640,,,BAO_0000219,,Expert,,9606.0,F,,786-0
5319,Homo sapiens,,CHEMBL619276,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",,16818,,80640,,,BAO_0000219,,Intermediate,,9606.0,F,,786-0
5320,Homo sapiens,,CHEMBL619277,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",,16818,,80640,,,BAO_0000219,,Intermediate,,9606.0,F,,786-0
5321,Homo sapiens,,CHEMBL619278,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",,16818,,80640,,,BAO_0000219,,Intermediate,,9606.0,F,,786-0
5322,Homo sapiens,,CHEMBL619279,Tested for cytotoxicity against 786-0 cell lines in renal cancer,,11970,,80640,,,BAO_0000219,,Intermediate,,9606.0,F,,786-0
5323,Homo sapiens,,CHEMBL858458,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,,12400,,80640,,,BAO_0000219,,Intermediate,,9606.0,F,,786-0
5324,Homo sapiens,,CHEMBL619280,Cytotoxic effect on renal cancer line 786-0,,12888,,80640,,,BAO_0000219,,Expert,,9606.0,F,,786-0
5325,Homo sapiens,,CHEMBL619281,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,,15300,,80640,,,BAO_0000219,,Intermediate,,9606.0,F,,786-0
5326,Homo sapiens,,CHEMBL619282,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,14769,,80640,,,BAO_0000219,,Intermediate,,9606.0,F,,786-0
5327,Homo sapiens,,CHEMBL619283,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",,15895,,80640,,,BAO_0000219,,Intermediate,,9606.0,F,,786-0
5328,Homo sapiens,,CHEMBL619284,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,,17376,,80640,,,BAO_0000219,,Intermediate,,9606.0,F,,786-0
5329,Homo sapiens,,CHEMBL619285,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,14882,,80640,,,BAO_0000219,,Intermediate,,9606.0,F,,786-0
5330,Homo sapiens,,CHEMBL619286,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),,14882,,80640,,,BAO_0000219,,Intermediate,,9606.0,F,,786-0
5331,Homo sapiens,,CHEMBL619287,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,,15176,,80640,,,BAO_0000219,,Intermediate,,9606.0,F,,786-0
5332,Homo sapiens,,CHEMBL857455,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,12696,,80640,,,BAO_0000219,,Intermediate,,9606.0,F,,786-0
5333,Homo sapiens,,CHEMBL883801,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),,2496,,80640,,,BAO_0000219,,Intermediate,,9606.0,F,,786-0
5334,Homo sapiens,,CHEMBL619288,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,,11831,,80641,,,BAO_0000219,,Intermediate,,9606.0,F,,791T cell line
5335,Homo sapiens,,CHEMBL619289,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),,11831,,80641,,,BAO_0000219,,Intermediate,,9606.0,F,,791T cell line
5336,Homo sapiens,,CHEMBL619290,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,,11831,,80641,,,BAO_0000219,,Intermediate,,9606.0,F,,791T cell line
5337,Homo sapiens,,CHEMBL619291,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),,11831,,80641,,,BAO_0000219,,Intermediate,,9606.0,F,,791T cell line
5338,Homo sapiens,,CHEMBL619292,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),,11831,,80641,,,BAO_0000219,,Intermediate,,9606.0,F,,791T cell line
5339,Homo sapiens,,CHEMBL619293,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,,11831,,80641,,,BAO_0000219,,Intermediate,,9606.0,F,,791T cell line
5340,Homo sapiens,,CHEMBL619294,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),,11831,,80641,,,BAO_0000219,,Intermediate,,9606.0,F,,791T cell line
5341,Homo sapiens,,CHEMBL619295,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),,11831,,80641,,,BAO_0000219,,Intermediate,,9606.0,F,,791T cell line
5342,Homo sapiens,,CHEMBL619296,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),,11831,,80641,,,BAO_0000219,,Intermediate,,9606.0,F,,791T cell line
5343,Homo sapiens,,CHEMBL619297,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,,11831,,80641,,,BAO_0000219,,Intermediate,,9606.0,F,,791T cell line
5344,Homo sapiens,,CHEMBL619298,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,,12782,,80640,,,BAO_0000219,,Intermediate,,9606.0,F,,786-0
5345,,,CHEMBL619299,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,,1229,,22226,,,BAO_0000019,,Intermediate,,,F,,
5346,Homo sapiens,,CHEMBL619300,Inhibition of cell growth in drug resistant 8226 myeloma cell line,,15313,,80433,,,BAO_0000219,,Expert,,9606.0,F,,RPMI-8226
5347,Homo sapiens,,CHEMBL619301,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,,15313,,80433,,,BAO_0000219,,Expert,,9606.0,F,,RPMI-8226
5348,Homo sapiens,,CHEMBL619302,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,,11544,,80433,,,BAO_0000219,,Intermediate,,9606.0,F,,RPMI-8226
5349,Homo sapiens,,CHEMBL619303,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,9424,,80433,,,BAO_0000219,,Intermediate,,9606.0,F,,RPMI-8226
5350,Homo sapiens,,CHEMBL619304,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,9424,,80433,,,BAO_0000219,,Intermediate,,9606.0,F,,RPMI-8226
5351,Homo sapiens,,CHEMBL857706,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,9424,,80433,,,BAO_0000219,,Intermediate,,9606.0,F,,RPMI-8226
5352,Homo sapiens,,CHEMBL619305,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,9424,,80433,,,BAO_0000219,,Intermediate,,9606.0,F,,RPMI-8226
5353,Homo sapiens,,CHEMBL619306,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,9424,,80433,,,BAO_0000219,,Intermediate,,9606.0,F,,RPMI-8226
5354,Homo sapiens,,CHEMBL619307,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,9424,,80433,,,BAO_0000219,,Intermediate,,9606.0,F,,RPMI-8226
5355,Homo sapiens,,CHEMBL619308,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,9424,,80433,,,BAO_0000219,,Intermediate,,9606.0,F,,RPMI-8226
5356,Homo sapiens,,CHEMBL619309,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,9424,,80433,,,BAO_0000219,,Intermediate,,9606.0,F,,RPMI-8226
5357,Homo sapiens,,CHEMBL619310,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,9424,,80433,,,BAO_0000219,,Intermediate,,9606.0,F,,RPMI-8226
5358,Homo sapiens,,CHEMBL619311,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,14769,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5359,Homo sapiens,,CHEMBL619312,Compound was tested for the growth inhibition of A498 renal tumor cell line,,15354,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5360,Homo sapiens,,CHEMBL619313,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),,17445,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5361,Homo sapiens,,CHEMBL619314,In vitro inhibitory concentration against renal cancer cell line A498,,4337,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5362,Homo sapiens,,CHEMBL619959,Cytotoxicity against A 498 tumor cell line,,15277,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5363,Homo sapiens,,CHEMBL619960,In vitro antitumor activity against A498 human cancer cell line,,4812,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5364,Homo sapiens,,CHEMBL619961,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),,4812,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5365,Homo sapiens,,CHEMBL619962,Inhibitory dose required against A498 human tumor cell lines,,4995,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5366,Homo sapiens,,CHEMBL875586,Anticancer activity against one renal cancer (A498 cell line),,5847,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5367,Homo sapiens,,CHEMBL619963,In vitro cytotoxicity against melanoma A498 cell line,,6557,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5368,Homo sapiens,,CHEMBL619964,Compound was tested for growth inhibitory activity against A498 cell line,,2597,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5369,Homo sapiens,,CHEMBL620108,Compound tested for growth inhibition of renal cancer cell line A498,,6058,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5370,Homo sapiens,,CHEMBL620109,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,,17708,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5371,Homo sapiens,,CHEMBL620110,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,,15176,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5372,Homo sapiens,,CHEMBL620111,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,,15300,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5373,Homo sapiens,,CHEMBL620112,Tested for cytotoxicity against A498 cell lines in renal cancer,,11970,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5374,Homo sapiens,,CHEMBL620113,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,,12400,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5375,Homo sapiens,,CHEMBL620114,Cytotoxic effect on renal cancer lines A498,,12888,,80021,,,BAO_0000219,,Expert,,9606.0,F,,A498
5376,Homo sapiens,,CHEMBL620115,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,,3030,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5377,Homo sapiens,,CHEMBL620116,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,14769,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5378,Homo sapiens,,CHEMBL620117,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,,17376,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5379,Homo sapiens,,CHEMBL620118,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,,16558,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5380,Homo sapiens,,CHEMBL620119,Cytotoxicity against human kidney carcinoma cell lines A4982LM,,5194,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5381,Homo sapiens,,CHEMBL620120,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,,10708,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5382,Homo sapiens,,CHEMBL620121,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,,16880,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
5383,Homo sapiens,,CHEMBL620122,Antitumor activity against A549 human lung carcinoma cell line,,10196,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5384,Homo sapiens,,CHEMBL620123,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,,10196,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5385,Homo sapiens,,CHEMBL620124,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,,10196,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5386,Homo sapiens,,CHEMBL620125,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",,12083,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5387,Homo sapiens,,CHEMBL620126,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,,16464,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
5388,Homo sapiens,,CHEMBL883027,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,16464,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5389,Homo sapiens,,CHEMBL620127,In vitro cytotoxic activity against human lung A549 cell line,,16470,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
5390,Homo sapiens,,CHEMBL620128,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),,16470,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5391,Homo sapiens,,CHEMBL620129,In vitro cytotoxic activity against human lung A549 cell line),,16470,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5392,Homo sapiens,,CHEMBL620130,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,,16470,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5393,Homo sapiens,,CHEMBL620131,In vitro cytotoxicity against human non small-cell-lung cell line A549.,,16582,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
5394,Homo sapiens,,CHEMBL620132,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",,15935,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5395,Homo sapiens,,CHEMBL620133,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",,15935,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5396,Homo sapiens,,CHEMBL620134,Inhibition of A549 human lung carcinoma cell proliferation,,16597,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
5397,Homo sapiens,,CHEMBL620135,Inhibitory activity against A549 lung adenocarcinoma cell line,,17376,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5398,Homo sapiens,,CHEMBL620136,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,,16496,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5399,Homo sapiens,,CHEMBL620137,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,,16152,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5400,Homo sapiens,,CHEMBL620268,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,,16152,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5401,Homo sapiens,,CHEMBL620269,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,16464,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5402,Homo sapiens,,CHEMBL620270,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,,2288,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5403,Homo sapiens,,CHEMBL620271,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,17350,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5404,Homo sapiens,,CHEMBL620272,Inhibition of A549 cancer cell proliferation,,4090,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
5405,Homo sapiens,,CHEMBL620273,Inhibition of A549 cancer cell proliferation (Not tested),,4090,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
5406,Homo sapiens,,CHEMBL620274,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,17350,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5407,Homo sapiens,,CHEMBL620275,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,,4197,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5408,Homo sapiens,,CHEMBL620276,Antiproliferative potency determined as inhibitory concentration against A549 cells,,17072,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5409,Homo sapiens,,CHEMBL620277,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,,17072,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5410,Homo sapiens,,CHEMBL620278,Cytotoxicity against Renal cell lines A549 was determined,,5194,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5411,Canis lupus familiaris,,CHEMBL620279,Area under curve was determined in dog after a 3 mg/kg of oral dose,,4257,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5412,Canis lupus familiaris,,CHEMBL620280,Area under curve was determined in dog after oral administration at 1 mg/kg,,6123,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5413,Canis lupus familiaris,,CHEMBL620281,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,1337,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5414,Canis lupus familiaris,,CHEMBL620282,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,1337,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5415,Canis lupus familiaris,,CHEMBL621134,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),,8833,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5416,Canis lupus familiaris,,CHEMBL621135,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),,8833,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5417,Canis lupus familiaris,,CHEMBL621136,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),,8833,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5418,Canis lupus familiaris,,CHEMBL621137,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),,8833,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5419,Canis lupus familiaris,1969.0,CHEMBL621138,Area under plasma concentration time curve in dog upon oral administration,,17657,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5420,Canis lupus familiaris,1969.0,CHEMBL875587,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,,17650,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5421,Canis lupus familiaris,,CHEMBL621139,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,,1977,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5422,Canis lupus familiaris,,CHEMBL621140,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,,1977,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5423,Canis lupus familiaris,,CHEMBL621141,Area under the curve for the compound was obtained when tested in dog,,3132,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5424,Canis lupus familiaris,,CHEMBL621142,Area under the curve at a dose of 1 mg/kg,,5473,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5425,Canis lupus familiaris,,CHEMBL621143,Area under the curve at a dose of 1 mg/kg (oral),,5474,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5426,Canis lupus familiaris,,CHEMBL621144,Area under the curve at i.v. dose of 0.2 mg/kg,,5474,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5427,Canis lupus familiaris,,CHEMBL621145,Area under the curve was measured in dog after an iv dose of 1 mg/kg,,6062,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5428,Canis lupus familiaris,,CHEMBL621146,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,,4709,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5429,Canis lupus familiaris,,CHEMBL622567,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,,2652,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5430,Canis lupus familiaris,,CHEMBL622568,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,,2652,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5431,Canis lupus familiaris,,CHEMBL622569,Compound was evaluated for area under the curve in dog blood.,,2877,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5432,Canis lupus familiaris,,CHEMBL622570,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,,5444,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5433,Canis lupus familiaris,1969.0,CHEMBL622571,AUC in dog after oral dose (1 mg/kg),,5130,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5434,Canis lupus familiaris,,CHEMBL622572,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,,6265,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5435,Canis lupus familiaris,,CHEMBL622573,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",,4657,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5436,Canis lupus familiaris,,CHEMBL622574,Pharmacokinetic parameter AUC after intravenous administration to dogs,,16367,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5437,Canis lupus familiaris,,CHEMBL622575,Pharmacokinetic parameter AUC after oral administration to dogs,,16367,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5438,Canis lupus familiaris,,CHEMBL622576,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,,9579,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5439,Canis lupus familiaris,,CHEMBL622577,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,,9579,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5440,Canis lupus familiaris,,CHEMBL622578,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,,5983,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5441,Canis lupus familiaris,,CHEMBL622579,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,,6241,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5442,Canis lupus familiaris,,CHEMBL622580,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",,5313,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5443,Canis lupus familiaris,,CHEMBL622581,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",,5313,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5444,Canis lupus familiaris,,CHEMBL622582,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,6642,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5445,Canis lupus familiaris,,CHEMBL622583,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,6642,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5446,Canis lupus familiaris,,CHEMBL622584,Oral AUCN in dog (dosed at 0.5 mpk iv ),,6641,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5447,Canis lupus familiaris,,CHEMBL622585,Oral AUCN in dog (dosed at 0.5 mpk iv ),,6642,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5448,Canis lupus familiaris,,CHEMBL622586,Compound was evaluated for oral bioavailability in dog; 90-100,,17791,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5449,Canis lupus familiaris,,CHEMBL623281,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,,17655,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5450,Canis lupus familiaris,,CHEMBL623282,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,,17655,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5451,Canis lupus familiaris,,CHEMBL623283,PAPP (membrane permeability) in dog kidney cell monolayer assay,,6596,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5452,Canis lupus familiaris,,CHEMBL623284,Oral bioavailability in dog,,3880,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5453,Canis lupus familiaris,,CHEMBL623285,Bioavailability administered orally at a dose of 10 mg/kg to dogs,,16367,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5454,Canis lupus familiaris,1969.0,CHEMBL623463,Plasma protein binding towards dog plasma at 10 uM,,17409,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5455,Canis lupus familiaris,1969.0,CHEMBL875952,Plasma protein binding towards dog plasma at 100 uM,,17409,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5456,Canis lupus familiaris,,CHEMBL621705,Bioavailability in dog (dose 4 mg/kg p.o.),In vivo,2959,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5457,Canis lupus familiaris,,CHEMBL621706,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,In vivo,13501,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5458,Canis lupus familiaris,,CHEMBL621707,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,In vivo,4527,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5459,Canis lupus familiaris,,CHEMBL621708,Bioavailability in dogs,In vivo,15145,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5460,Canis lupus familiaris,,CHEMBL621709,Bioavailability,In vivo,4219,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5461,Canis lupus familiaris,,CHEMBL621710,Oral bioavailability in dog (dose 10 mg/kg),In vivo,17538,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5462,Canis lupus familiaris,,CHEMBL621711,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,In vivo,17538,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5463,Canis lupus familiaris,,CHEMBL621712,Bioavailability in dog (dose 10.0 mg/kg p.o.),In vivo,1466,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5464,Canis lupus familiaris,,CHEMBL621713,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,In vivo,17650,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5465,Canis lupus familiaris,,CHEMBL621714,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,In vivo,3132,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5466,Mus sp.,,CHEMBL621715,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,,2413,,22224,,,BAO_0000218,,Autocuration,,10095.0,A,,
5467,Mus sp.,2107.0,CHEMBL623717,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,,2413,Liver,22224,,,BAO_0000218,,Autocuration,,10095.0,A,,
5468,Mus sp.,2107.0,CHEMBL623718,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,,2413,Liver,22224,,,BAO_0000218,,Autocuration,,10095.0,A,,
5469,Mus sp.,2107.0,CHEMBL623719,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,,2413,Liver,22224,,,BAO_0000218,,Autocuration,,10095.0,A,,
5470,Mus sp.,,CHEMBL623720,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,,2413,,22224,,,BAO_0000218,,Autocuration,,10095.0,A,,
5471,Mus sp.,,CHEMBL623721,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,,2413,,22224,,,BAO_0000218,,Autocuration,,10095.0,A,,
5472,Mus sp.,2385.0,CHEMBL623722,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,,2413,Muscle tissue,22224,,,BAO_0000218,,Autocuration,,10095.0,A,,
5473,Mus sp.,2385.0,CHEMBL623723,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,,2413,Muscle tissue,22224,,,BAO_0000218,,Autocuration,,10095.0,A,,
5474,Mus sp.,2385.0,CHEMBL618543,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,,2413,Muscle tissue,22224,,,BAO_0000218,,Autocuration,,10095.0,A,,
5475,Mus sp.,2106.0,CHEMBL618544,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,,2413,Spleen,22224,,,BAO_0000218,,Autocuration,,10095.0,A,,
5476,Mus sp.,2106.0,CHEMBL875155,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,,2413,Spleen,22224,,,BAO_0000218,,Autocuration,,10095.0,A,,
5477,Mus sp.,,CHEMBL618545,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,,2413,,22224,,,BAO_0000218,,Autocuration,,10095.0,A,,
5478,Mus sp.,,CHEMBL618546,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,,2413,,22224,,,BAO_0000218,,Autocuration,,10095.0,A,,
5479,Mus sp.,,CHEMBL623529,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,,2413,,22224,,,BAO_0000218,,Autocuration,,10095.0,A,,
5480,Mus sp.,,CHEMBL623530,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,,2413,,22224,,,BAO_0000218,,Autocuration,,10095.0,A,,
5481,Mus sp.,,CHEMBL621764,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,,2413,,22224,,,BAO_0000218,,Autocuration,,10095.0,A,,
5482,Cercopithecidae,,CHEMBL621765,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,17827,,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
5483,Cercopithecidae,2037.0,CHEMBL621766,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),,17827,Cerebellum,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
5484,Cercopithecidae,1870.0,CHEMBL621767,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),,17827,Frontal cortex,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
5485,Cercopithecidae,,CHEMBL621768,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),,17827,,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
5486,Cercopithecidae,2435.0,CHEMBL621769,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),,17827,Striatum,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
5487,Cercopithecidae,,CHEMBL621770,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,17827,,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
5488,Cercopithecidae,2037.0,CHEMBL621771,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),,17827,Cerebellum,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
5489,Cercopithecidae,1870.0,CHEMBL621772,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),,17827,Frontal cortex,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
5490,Cercopithecidae,,CHEMBL621773,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),,17827,,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
5491,Cercopithecidae,2435.0,CHEMBL621774,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),,17827,Striatum,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
5492,Cercopithecidae,,CHEMBL621775,Compound was evaluated for oral bioavailability in rats,,17791,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
5493,Cercopithecidae,1969.0,CHEMBL621776,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,In vivo,17667,Plasma,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
5494,Cercopithecidae,,CHEMBL621777,Half life period was evaluated in monkey,,17791,,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
5495,Cercopithecidae,,CHEMBL875162,Half-life in rhesus monkeys by intravenous administration of dose,In vivo,110,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
5496,Mus musculus,1969.0,CHEMBL621778,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,,5781,Plasma,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5497,Mus musculus,1969.0,CHEMBL621779,AUC after intraperitoneal administration of 100 mg/kg in mice,,17734,Plasma,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5498,Mus musculus,1969.0,CHEMBL622479,AUC value was determined after oral administration,,17718,Plasma,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5499,Mus musculus,,CHEMBL622480,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,,4573,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5500,Mus musculus,,CHEMBL622481,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,3277,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5501,Mus musculus,,CHEMBL622482,Area under curve by ioral administration in mouse,,2862,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5502,Mus musculus,,CHEMBL622483,Area under curve by iv administration in mouse,,2862,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5503,Mus musculus,,CHEMBL622484,Area under curve at 0-8 hr in IRC mice after peroral administration,,5951,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5504,Mus musculus,,CHEMBL622641,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,,17729,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5505,Mus musculus,,CHEMBL622642,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,,17728,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5506,Mus musculus,,CHEMBL622643,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,,17728,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5507,Mus musculus,,CHEMBL622644,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,,17729,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5508,Homo sapiens,,CHEMBL622645,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,9424,,80433,,,BAO_0000219,,Intermediate,,9606.0,F,,RPMI-8226
5509,Homo sapiens,,CHEMBL622646,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,9424,,80433,,,BAO_0000219,,Intermediate,,9606.0,F,,RPMI-8226
5510,Homo sapiens,,CHEMBL621238,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,9424,,80433,,,BAO_0000219,,Intermediate,,9606.0,F,,RPMI-8226
5511,Homo sapiens,,CHEMBL621239,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,9424,,80433,,,BAO_0000219,,Intermediate,,9606.0,F,,RPMI-8226
5512,Homo sapiens,,CHEMBL621240,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,9424,,80433,,,BAO_0000219,,Intermediate,,9606.0,F,,RPMI-8226
5513,Homo sapiens,,CHEMBL621241,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,9424,,80433,,,BAO_0000219,,Intermediate,,9606.0,F,,RPMI-8226
5514,Homo sapiens,,CHEMBL621242,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,9424,,80433,,,BAO_0000219,,Intermediate,,9606.0,F,,RPMI-8226
5515,Homo sapiens,,CHEMBL620350,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,9424,,80433,,,BAO_0000219,,Intermediate,,9606.0,F,,RPMI-8226
5516,Homo sapiens,,CHEMBL620351,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,9424,,80433,,,BAO_0000219,,Intermediate,,9606.0,F,,RPMI-8226
5517,Homo sapiens,,CHEMBL620352,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,9424,,80433,,,BAO_0000219,,Intermediate,,9606.0,F,,RPMI-8226
5518,Homo sapiens,,CHEMBL620353,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,9424,,80433,,,BAO_0000219,,Intermediate,,9606.0,F,,RPMI-8226
5519,Homo sapiens,,CHEMBL620354,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,9424,,80433,,,BAO_0000219,,Intermediate,,9606.0,F,,RPMI-8226
5520,Homo sapiens,,CHEMBL620355,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,9424,,80433,,,BAO_0000219,,Intermediate,,9606.0,F,,RPMI-8226
5521,Homo sapiens,,CHEMBL620356,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,9424,,80433,,,BAO_0000219,,Intermediate,,9606.0,F,,RPMI-8226
5522,Homo sapiens,,CHEMBL620357,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,9424,,80433,,,BAO_0000219,,Intermediate,,9606.0,F,,RPMI-8226
5523,Homo sapiens,,CHEMBL620358,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,9424,,80433,,,BAO_0000219,,Intermediate,,9606.0,F,,RPMI-8226
5524,Homo sapiens,,CHEMBL620359,In vitro inhibition of human 8226 myeloma tumor cell line growth.,,9424,,80433,,,BAO_0000219,,Expert,,9606.0,F,,RPMI-8226
5525,Homo sapiens,,CHEMBL620360,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,,11544,,80433,,,BAO_0000219,,Intermediate,,9606.0,F,,RPMI-8226
5526,Homo sapiens,,CHEMBL620361,Cytotoxicity of compound against 8226/DOX1V cells,,17378,,80433,,,BAO_0000219,,Intermediate,,9606.0,F,,RPMI-8226
5527,Homo sapiens,,CHEMBL620362,Cytotoxicity of compound against 8226/S cells,,17378,,80433,,,BAO_0000219,,Intermediate,,9606.0,F,,RPMI-8226
5528,Homo sapiens,,CHEMBL620363,Inhibitory concentration against 8226 myeloma cancer cell line,,17079,,80433,,,BAO_0000219,,Intermediate,,9606.0,F,,RPMI-8226
5529,Homo sapiens,,CHEMBL620364,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,,17079,,80433,,,BAO_0000219,,Intermediate,,9606.0,F,,RPMI-8226
5530,Homo sapiens,,CHEMBL620365,Inhibition of cell growth was studied in human teratocarcinoma (833K).,,13466,,80647,,,BAO_0000219,,Intermediate,,9606.0,F,,833K
5531,Homo sapiens,,CHEMBL620366,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',,13466,,80647,,,BAO_0000219,,Intermediate,,9606.0,F,,833K
5532,Homo sapiens,,CHEMBL620367,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,,2392,,80647,,,BAO_0000219,,Expert,,9606.0,F,,833K
5533,Homo sapiens,,CHEMBL620368,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,,2392,,80647,,,BAO_0000219,,Intermediate,,9606.0,F,,833K
5534,,,CHEMBL620369,Inhibitory activity against caspase-1,,6608,,22226,,,BAO_0000019,,Autocuration,,,B,,
5535,Enterococcus faecalis,,CHEMBL620370,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,,10199,,45,,,BAO_0000357,,Autocuration,,1351.0,B,,
5536,Homo sapiens,,CHEMBL620371,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,,17749,,80648,,,BAO_0000219,,Intermediate,,9606.0,F,,8701-BC
5537,Homo sapiens,,CHEMBL620372,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,,17749,,80648,,,BAO_0000219,,Intermediate,,9606.0,F,,8701-BC
5538,,,CHEMBL876492,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,,1229,,22226,,,BAO_0000019,,Intermediate,,,F,,
5539,,,CHEMBL620373,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,,1229,,22226,,,BAO_0000019,,Intermediate,,,F,,
5540,,,CHEMBL620374,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,,1229,,22226,,,BAO_0000019,,Intermediate,,,F,,
5541,,,CHEMBL620375,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,,6390,,22226,,,BAO_0000019,,Autocuration,,,B,,
5542,Streptococcus pyogenes,,CHEMBL857902,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,16219,,22226,,,BAO_0000019,,Autocuration,,1314.0,F,,
5543,Streptococcus pyogenes,,CHEMBL620376,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,16219,,22226,,,BAO_0000019,,Autocuration,,1314.0,F,,
5544,,,CHEMBL620377,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,,17043,,11922,,,BAO_0000357,,Autocuration,,,B,,
5545,Homo sapiens,,CHEMBL620378,Tested for in vitro cytotoxic potency of compound in 9KB assay,,6929,,81115,,,BAO_0000219,,Intermediate,,9606.0,F,,KB 
5546,Homo sapiens,,CHEMBL620379,Tested for in vitro cytotoxic potency of compound in 9KB assay,,6929,,81115,,,BAO_0000219,,Intermediate,,9606.0,A,,KB 
5547,Homo sapiens,,CHEMBL620380,In vitro cytotoxicity of compound was tested against 9KB cells.,,7083,,22226,,,BAO_0000219,,Autocuration,,9606.0,F,,
5548,Rattus norvegicus,,CHEMBL884006,Cytotoxic concentration against 9L cells was determined on day 3,,12446,,80653,,,BAO_0000219,,Intermediate,,10116.0,F,,9L
5549,Rattus norvegicus,,CHEMBL620381,Tested in vitro for anticancer activity against 9L cells,,15345,,80653,,,BAO_0000219,,Expert,,10116.0,F,,9L
5550,Rattus norvegicus,,CHEMBL620382,Tested in vitro for anticancer activity against 9L cells; Not determined,,15345,,80653,,,BAO_0000219,,Expert,,10116.0,F,,9L
5551,Homo sapiens,,CHEMBL620383,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,,6301,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5552,Homo sapiens,,CHEMBL876493,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,,4833,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5553,Homo sapiens,,CHEMBL620384,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,,4833,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5554,Homo sapiens,,CHEMBL620385,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,,4833,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5555,Homo sapiens,,CHEMBL620386,Cytotoxicity against human lung carcinoma A549 cell line,,13330,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
5556,Homo sapiens,,CHEMBL620387,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,,17517,,25,,,BAO_0000219,,Expert,,9606.0,F,,A549
5557,Homo sapiens,,CHEMBL621404,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",,17517,,25,,,BAO_0000219,,Expert,,9606.0,F,,A549
5558,Homo sapiens,,CHEMBL621405,"In vitro growth inhibition of A549, lung carcinoma",,14425,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5559,Homo sapiens,,CHEMBL621406,"In vitro growth inhibition of A549, lung carcinoma.",,14425,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5560,Homo sapiens,,CHEMBL621407,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,5228,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
5561,Homo sapiens,,CHEMBL621408,Cytotoxic activity against human lung cancer A549 cell line was determined,,5351,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5562,Homo sapiens,,CHEMBL885345,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,,12198,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
5563,Homo sapiens,,CHEMBL621409,Cytotoxicity concentration against human lung carcinoma A-549 cell line,,13891,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5564,Homo sapiens,,CHEMBL876034,Cytotoxicity in A549 (human carcinoma) cell line.,,5677,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
5565,Homo sapiens,,CHEMBL621410,Cytotoxicity on lung carcinoma (A-549) cell line,,13788,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5566,Homo sapiens,,CHEMBL621411,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,,13384,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
5567,Homo sapiens,,CHEMBL621412,Effective dose of compound against replication of A549 cell line was evaluated,,6726,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5568,Homo sapiens,,CHEMBL621413,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,,3455,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
5569,Homo sapiens,,CHEMBL621414,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),,5726,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5570,Homo sapiens,,CHEMBL621415,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,,5726,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5571,Homo sapiens,,CHEMBL621416,The compound was evaluated for antiproliferative activity against A549 cell line,,3936,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5572,Homo sapiens,,CHEMBL621417,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,,14991,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5573,Homo sapiens,,CHEMBL621418,Concentration required for growth inhibition of human lung carcinoma cell line A549,,5243,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5574,Homo sapiens,,CHEMBL621419,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,,12858,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5575,Homo sapiens,,CHEMBL621420,Growth inhibition against A549 cell line was evaluated,,6776,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5576,Homo sapiens,,CHEMBL875823,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,,16558,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5577,Homo sapiens,,CHEMBL621421,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,,4583,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
5578,Homo sapiens,,CHEMBL621422,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,,13514,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5579,Homo sapiens,,CHEMBL884014,Chemosensitivity against DT-diaphorase rich A549 cell lines,,15166,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
5580,Homo sapiens,,CHEMBL621423,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,,13873,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5581,Homo sapiens,,CHEMBL621424,In vitro cytotoxicity against human A549 (lung cancer) cell line.,,6447,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
5582,Homo sapiens,,CHEMBL621425,In vitro antitumor activity against A549 (lung) human tumor cell lines.,,2068,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5583,Homo sapiens,,CHEMBL621426,In vitro cytotoxic activity against human lung carcinoma A549 cell line,,1863,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
5584,Homo sapiens,,CHEMBL621427,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,,13873,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5585,Homo sapiens,,CHEMBL621428,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,13873,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5586,Homo sapiens,,CHEMBL621429,Tested against A549 lung carcinoma in the sulforhodamine B assay.,,13873,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
5587,Homo sapiens,,CHEMBL621430,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),,579,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5588,Homo sapiens,,CHEMBL621431,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,,579,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5589,Homo sapiens,,CHEMBL621432,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,,4584,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5590,Homo sapiens,,CHEMBL621433,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,,5421,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
5591,Homo sapiens,,CHEMBL875824,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,5421,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5592,Homo sapiens,,CHEMBL621434,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,5421,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5593,Homo sapiens,,CHEMBL621435,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,,5421,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5594,Homo sapiens,,CHEMBL621436,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,,14188,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5595,Homo sapiens,,CHEMBL621437,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,,14188,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5596,Homo sapiens,,CHEMBL621438,Compound was tested for the growth inhibition of A549 lung tumor cell line,,15354,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5597,Homo sapiens,,CHEMBL621439,Growth inhibition of human non-small-lung carcinoma (A549) cell line,,14253,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
5598,Homo sapiens,,CHEMBL621440,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,13873,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5599,Canis lupus familiaris,,CHEMBL621441,Oral bioavailability in dog (conscious),In vivo,3043,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5600,Canis lupus familiaris,,CHEMBL621442,Compound was evaluated for the oral bioavailability after oral administration in dog.,In vivo,3045,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5601,Canis lupus familiaris,,CHEMBL621443,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,In vivo,3022,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5602,Canis lupus familiaris,,CHEMBL621444,Oral bioavailability in dog,In vivo,4453,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5603,Canis lupus familiaris,,CHEMBL625133,Oral bioavailability in dog,In vivo,1696,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5604,Canis lupus familiaris,,CHEMBL625134,Oral bioavailability in dog,In vivo,5045,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5605,Canis lupus familiaris,,CHEMBL625135,Oral bioavailability in dog (fasted),In vivo,5356,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5606,Canis lupus familiaris,,CHEMBL625136,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,In vivo,17764,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5607,Canis lupus familiaris,,CHEMBL625137,Oral bioavailability in dog,In vivo,6448,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5608,Canis lupus familiaris,,CHEMBL625138,Oral bioavailability in dog,In vivo,1475,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5609,Canis lupus familiaris,,CHEMBL625139,Percent bioavailability in dog,In vivo,3788,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5610,Canis lupus familiaris,,CHEMBL872264,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,In vivo,3639,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5611,Canis lupus familiaris,,CHEMBL625140,Oral bioavailability in dog,In vivo,13397,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5612,Canis lupus familiaris,,CHEMBL624436,The compound was evaluated for bioavailability in dogs; 34-44,In vivo,2137,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5613,Canis lupus familiaris,,CHEMBL624437,Bioavailability in dog (dose 4 mg/kg p.o.),In vivo,2959,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5614,Canis lupus familiaris,,CHEMBL872261,Oral bioavailability in dog,In vivo,6448,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5615,Canis lupus familiaris,,CHEMBL624438,8 hour trough Blood level in dog was measured after administration of compound,,6084,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5616,Canis lupus familiaris,1969.0,CHEMBL624439,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,In vivo,3639,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5617,Canis lupus familiaris,,CHEMBL624440,C24 after oral administration at 5 mg/kg,,6316,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5618,Canis lupus familiaris,,CHEMBL624441,Clearance after oral and iv dosing in dogs,,5238,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5619,Canis lupus familiaris,1969.0,CHEMBL624442,Clearance of the drug was measured in the plasma of dog,,17796,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5620,Canis lupus familiaris,,CHEMBL624443,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,,2652,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5621,Canis lupus familiaris,,CHEMBL624444,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,In vivo,5654,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5622,Canis lupus familiaris,,CHEMBL624445,Clearance of compound was determined in dogs,In vivo,6621,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5623,Canis lupus familiaris,,CHEMBL624446,Clearance on i.v. administration of 2 mg/kg was measured in dog,In vivo,6505,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5624,Canis lupus familiaris,,CHEMBL624447,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,In vivo,5802,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5625,Canis lupus familiaris,,CHEMBL624448,Plasma clearance in dog was determined,In vivo,17267,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5626,Canis lupus familiaris,,CHEMBL624449,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,In vivo,4521,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5627,Canis lupus familiaris,,CHEMBL624450,Plasma clearance in dog after administration of 0.25 mg/kg iv,In vivo,6535,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5628,Canis lupus familiaris,,CHEMBL875942,Plasma clearance in dog after administration of 1 mg/kg iv,In vivo,6535,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5629,Canis lupus familiaris,,CHEMBL624451,Plasma clearance in dogs,In vivo,6535,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5630,Canis lupus familiaris,,CHEMBL624452,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,In vivo,5542,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5631,Canis lupus familiaris,,CHEMBL624453,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,In vivo,5199,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5632,Canis lupus familiaris,,CHEMBL624454,Plasma clearance after 15 mg/kg iv dose in Dogs,In vivo,16907,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5633,Canis lupus familiaris,,CHEMBL624455,Plasma clearance after 30 mg/kg po dose in Dogs,In vivo,16907,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5634,Canis lupus familiaris,,CHEMBL624456,Plasma administration to dogs,In vivo,16367,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5635,Canis lupus familiaris,,CHEMBL624457,Plasma clearance was determined,In vivo,5505,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5636,Canis lupus familiaris,,CHEMBL624458,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,In vivo,6215,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5637,Canis lupus familiaris,,CHEMBL624459,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,In vivo,1466,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5638,Homo sapiens,2107.0,CHEMBL624460,Intrinsic clearance in human liver microsomes,In vitro,5007,Liver,102164,,,BAO_0000251,,Intermediate,Microsomes,9606.0,A,,
5639,Homo sapiens,2107.0,CHEMBL624461,Intrinsic clearance in human liver microsomes,In vitro,5007,Liver,102164,,,BAO_0000251,,Intermediate,Microsomes,9606.0,A,,
5640,Canis lupus familiaris,,CHEMBL875943,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,In vivo,16452,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5641,Canis lupus familiaris,,CHEMBL624462,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,In vivo,16452,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5642,Canis lupus familiaris,,CHEMBL624463,Clearance in dog (dose 1 mg/kg i.v.),In vivo,16452,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5643,Canis lupus familiaris,,CHEMBL624464,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,In vivo,6221,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5644,Canis lupus familiaris,,CHEMBL624465,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),In vivo,5007,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5645,Canis lupus familiaris,,CHEMBL624466,Plasma clearance after peroral administration at 10 mpk in dog,In vivo,5668,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5646,Canis lupus familiaris,,CHEMBL624467,Plasma clearance after peroral administration at 5 mpk in dog,In vivo,5668,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5647,Canis lupus familiaris,,CHEMBL624468,Plasma clearance after peroral administration at 5 mg/kg in dog,In vivo,5668,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5648,Canis lupus familiaris,,CHEMBL624469,Plasma clearance was measured in dog,In vivo,15660,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5649,Canis lupus familiaris,,CHEMBL624470,Plasma clearance was measured in dog,In vivo,15660,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5650,Canis lupus familiaris,,CHEMBL624471,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,In vivo,5983,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5651,Canis lupus familiaris,,CHEMBL624472,Total clearance was determined after 0.1 mg/kg iv administration in dog,In vivo,5600,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5652,Canis lupus familiaris,,CHEMBL622775,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,In vivo,17764,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5653,Canis lupus familiaris,,CHEMBL622776,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,In vivo,6039,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5654,Canis lupus familiaris,,CHEMBL622777,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,In vivo,6039,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5655,Canis lupus familiaris,,CHEMBL622778,Clearance after peroral administration of 0.2 mg/kg in dog was determined,In vivo,6039,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5656,Canis lupus familiaris,,CHEMBL622779,Clearance by intravenous administration of 1.2 mg/kg in dog,In vivo,4368,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5657,Canis lupus familiaris,,CHEMBL622780,Clearance by iv administration in dogs at a dose of 1 mg/kg,In vivo,4305,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5658,Canis lupus familiaris,1969.0,CHEMBL622781,Clearance value was evaluated in dog plasma,In vivo,1918,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5659,Canis lupus familiaris,,CHEMBL622782,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,In vivo,6005,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5660,Canis lupus familiaris,1969.0,CHEMBL622783,Compound was tested for plasma clearance in dog,In vivo,4839,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5661,Canis lupus familiaris,,CHEMBL622784,Pharmacokinetic property (Plasma clearance) was measured in dog,In vivo,4239,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5662,Mus musculus,,CHEMBL622785,Area under curve when injected perorally in mice at a dose of 50 mg/kg,,17729,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5663,Mus musculus,,CHEMBL622786,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,,17728,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5664,Mus musculus,,CHEMBL622787,Area under curve value in mouse at a dose of 10 mg/kg,,5302,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5665,Mus musculus,,CHEMBL875949,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,,5506,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5666,Mus musculus,,CHEMBL622788,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,,5506,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5667,Mus musculus,,CHEMBL622789,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,17764,,50594,,,BAO_0000218,,Intermediate,,10090.0,F,,
5668,Mus musculus,,CHEMBL622790,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,17764,,50594,,,BAO_0000218,,Intermediate,,10090.0,F,,
5669,Mus musculus,,CHEMBL622791,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,17764,,50594,,,BAO_0000218,,Intermediate,,10090.0,F,,
5670,Mus musculus,,CHEMBL622792,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,17764,,50594,,,BAO_0000218,,Intermediate,,10090.0,F,,
5671,Mus musculus,,CHEMBL622793,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,,17764,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5672,Mus musculus,,CHEMBL622794,Area under curve was determined for the compound at 24 mg/Kg,,17753,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5673,Mus musculus,,CHEMBL622795,Area under curve was determined for the compound at 40 mg/Kg,,17753,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5674,Mus musculus,,CHEMBL621803,Area under curve was determined for the compound at 5 mg/Kg,,17753,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5675,Mus musculus,,CHEMBL621804,Area under the curve for the compound is obtained at dose 25 mg/kg,,3132,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5676,Mus musculus,,CHEMBL621805,Area under the curve for the compound was obtained when tested in mouse,,3132,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5677,Mus musculus,,CHEMBL621806,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,,17837,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5678,Mus musculus,,CHEMBL621807,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,,17837,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5679,Mus musculus,,CHEMBL621808,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,,6062,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5680,Mus musculus,,CHEMBL621809,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,,4066,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5681,Mus musculus,,CHEMBL621810,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,16597,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5682,Mus musculus,,CHEMBL875164,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,,14239,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5683,Mus musculus,,CHEMBL621811,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,,14239,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5684,Mus musculus,,CHEMBL621812,"Compound was evaluated for the pharmacokinetic parameter, area under curve",,4890,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5685,Mus musculus,,CHEMBL621813,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),,429,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5686,Mus musculus,,CHEMBL621814,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),,429,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5687,Mus musculus,,CHEMBL621815,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,,5969,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5688,Mus musculus,,CHEMBL621816,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,,5969,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5689,Mus musculus,,CHEMBL621817,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,5969,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5690,Mus musculus,,CHEMBL621818,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,,6091,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5691,Mus musculus,,CHEMBL621819,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,,6091,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5692,Mus musculus,,CHEMBL621820,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,,6091,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5693,Mus musculus,,CHEMBL621821,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,,6091,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5694,Mus musculus,,CHEMBL621822,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,,6178,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5695,Mus musculus,,CHEMBL619474,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,,6178,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5696,Mus musculus,,CHEMBL619475,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,6619,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5697,Mus musculus,,CHEMBL619476,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,6619,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5698,Mus musculus,,CHEMBL619477,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",,3760,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5699,Mus musculus,,CHEMBL619478,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",,3760,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5700,Mus musculus,,CHEMBL619479,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",,3760,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5701,Mus musculus,,CHEMBL619480,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",,3760,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5702,Mus musculus,,CHEMBL619481,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,,3192,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5703,Mus musculus,,CHEMBL619482,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,,3192,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5704,Mus musculus,,CHEMBL619483,Area under the curve was evaluated in mice after intravenous administration,,2675,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5705,Mus musculus,,CHEMBL619484,Area under the curve was evaluated in mice after oral administration,,2675,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5706,Mus musculus,1969.0,CHEMBL619485,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,,16597,Plasma,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5707,Mus musculus,1969.0,CHEMBL619486,AUC total value at a dose of 10 mg/kg peroral administration in mice.,,16597,Plasma,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5708,Mus musculus,,CHEMBL619487,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,16597,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5709,Mus musculus,,CHEMBL619488,AUMC after intraperitoneal administration of 100 mg/kg in mice,,17734,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5710,Mus musculus,178.0,CHEMBL620106,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,In vivo,7767,Blood,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5711,,,CHEMBL620107,The compound was tested in vitro for anticancer activity against 9L cells,,15345,,80653,,,BAO_0000219,,Intermediate,,,F,,9L
5712,Rattus norvegicus,,CHEMBL620283,Anti proliferation activity determined; Weak effect,,2181,,22226,,,BAO_0000019,,Autocuration,,10116.0,F,,
5713,Rattus norvegicus,,CHEMBL875176,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,,2181,,22226,,,BAO_0000219,,Autocuration,,10116.0,F,,
5714,Rattus norvegicus,,CHEMBL620284,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,,2181,,22226,,,BAO_0000219,,Autocuration,,10116.0,F,,
5715,Rattus norvegicus,,CHEMBL623515,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,,2181,,22226,,,BAO_0000219,,Autocuration,,10116.0,F,,
5716,Mus musculus,,CHEMBL623516,The cytotoxic activity was in vitro tested by 9PS assay method,,10486,,22226,,,BAO_0000019,,Autocuration,,10090.0,F,,
5717,Mus musculus,,CHEMBL623517,The cytotoxic activity was in vitro tested by 9PS assay method.,,10486,,22226,,,BAO_0000019,,Autocuration,,10090.0,F,,
5718,,,CHEMBL857878,Partition coefficient (logD6.5),,15508,,22224,,,BAO_0000019,,Autocuration,,,A,,
5719,Homo sapiens,,CHEMBL623518,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,,5242,,81034,,,BAO_0000219,,Expert,,9606.0,F,,A2780
5720,Homo sapiens,,CHEMBL624195,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),,16167,,80018,,,BAO_0000219,,Intermediate,,9606.0,F,,A-375
5721,Homo sapiens,,CHEMBL624196,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,,4782,,80852,,,BAO_0000219,,Expert,,9606.0,F,,A-431
5722,Homo sapiens,,CHEMBL624197,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,16093,,9,,,BAO_0000219,,Expert,,9606.0,F,,A-431
5723,Homo sapiens,,CHEMBL624198,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,,2596,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5724,Homo sapiens,,CHEMBL621287,in vitro cytotoxicity against A 498 cancer cell line,,2596,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5725,Homo sapiens,,CHEMBL621288,In vitro cytotoxic activity against renal (A 498) cancer cell line.,,3239,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5726,Homo sapiens,,CHEMBL876496,Cytotoxic activity against A 498 renal cancer cell lines.,,1847,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5727,Homo sapiens,,CHEMBL621289,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,,10553,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5728,Staphylococcus aureus,,CHEMBL621290,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,16219,,22226,,,BAO_0000019,,Autocuration,,1280.0,F,,
5729,Staphylococcus aureus,,CHEMBL621291,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,16219,,22226,,,BAO_0000019,,Autocuration,,1280.0,F,,
5730,Staphylococcus aureus,,CHEMBL621292,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,16219,,22226,,,BAO_0000019,,Autocuration,,1280.0,F,,
5731,Staphylococcus aureus,,CHEMBL621293,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,16219,,22226,,,BAO_0000019,,Autocuration,,1280.0,F,,
5732,Homo sapiens,,CHEMBL621294,Inhibitory concentration required against A 549 lung cancer cell line,,4782,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5733,Homo sapiens,,CHEMBL621295,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,,11805,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5734,Homo sapiens,,CHEMBL884007,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,,11805,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5735,Homo sapiens,,CHEMBL621296,In vitro cytotoxicity against lung cancer A 549 cell lines,,2007,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5736,Homo sapiens,,CHEMBL621297,Compound was tested for its cytotoxicity against A 549 cell line,,4594,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5737,Homo sapiens,,CHEMBL839828,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",,6018,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
5738,Homo sapiens,,CHEMBL620397,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",,6018,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5739,Homo sapiens,,CHEMBL620398,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,,3599,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
5740,Homo sapiens,,CHEMBL620399,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,2551,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5741,Homo sapiens,,CHEMBL620400,In vitro inhibition of A549 (human lung cancer) cell growth.,,16132,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
5742,Homo sapiens,,CHEMBL620401,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,,16132,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5743,Homo sapiens,,CHEMBL620402,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,2551,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
5744,Homo sapiens,,CHEMBL620403,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),,2551,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
5745,,,CHEMBL620404,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,,11913,,22226,,,BAO_0000218,,Autocuration,,,F,,
5746,,,CHEMBL620405,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,In vivo,12621,,104694,,,BAO_0000218,,Autocuration,,,F,,
5747,,,CHEMBL620406,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,In vivo,12621,,104694,,,BAO_0000218,,Autocuration,,,F,,
5748,,,CHEMBL620407,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,In vivo,12621,,104694,,,BAO_0000218,,Autocuration,,,F,,
5749,,,CHEMBL620408,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,In vivo,12621,,104694,,,BAO_0000218,,Autocuration,,,F,,
5750,,,CHEMBL620409,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,In vivo,12621,,104694,,,BAO_0000218,,Autocuration,,,F,,
5751,Homo sapiens,,CHEMBL620410,Inhibition of A-498 human Renal cell proliferation,,3600,,80021,,,BAO_0000219,,Expert,,9606.0,F,,A498
5752,Rattus norvegicus,,CHEMBL620411,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",,1796,,22226,,,BAO_0000019,,Autocuration,,10116.0,F,,
5753,Rattus norvegicus,,CHEMBL620412,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",,1796,,22226,,,BAO_0000019,,Autocuration,,10116.0,F,,
5754,Rattus norvegicus,,CHEMBL876596,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",,1796,,22226,,,BAO_0000019,,Autocuration,,10116.0,F,,
5755,Homo sapiens,,CHEMBL620413,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,,16464,,80012,,,BAO_0000219,,Expert,,9606.0,F,,A 172
5756,Homo sapiens,,CHEMBL620414,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,16464,,80012,,,BAO_0000219,,Intermediate,,9606.0,F,,A 172
5757,Homo sapiens,,CHEMBL620415,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,16464,,80012,,,BAO_0000219,,Intermediate,,9606.0,F,,A 172
5758,Homo sapiens,,CHEMBL620416,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,,13617,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
5759,Homo sapiens,,CHEMBL620417,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,,4584,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5760,Homo sapiens,,CHEMBL620418,Cytotoxic activity evaluated against A549 tumor cells,,13799,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
5761,Homo sapiens,,CHEMBL620419,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,,16726,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5762,Homo sapiens,,CHEMBL620420,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,,16109,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5763,Homo sapiens,,CHEMBL620421,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,,16109,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5764,Homo sapiens,,CHEMBL620422,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,,15474,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5765,Homo sapiens,,CHEMBL620423,Cytotoxicity of compound against A549 cell line,,6851,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5766,Homo sapiens,,CHEMBL620424,Cytotoxicity against human lung cell carcinoma A549 cell line,,17534,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
5767,Homo sapiens,,CHEMBL620425,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,,2621,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5768,Homo sapiens,,CHEMBL620426,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,,830,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5769,Homo sapiens,,CHEMBL620427,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,,14255,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5770,Homo sapiens,,CHEMBL620428,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,,14255,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5771,Homo sapiens,,CHEMBL620429,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,,1590,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5772,Homo sapiens,,CHEMBL620430,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,,6146,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
5773,Homo sapiens,,CHEMBL839887,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,17427,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
5774,Homo sapiens,,CHEMBL620431,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,,5280,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5775,Homo sapiens,,CHEMBL884010,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,,16786,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5776,Homo sapiens,,CHEMBL620538,In vitro cytotoxicity against A549 (human lung cancer),,5895,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5777,Homo sapiens,,CHEMBL620539,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,14297,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
5778,Homo sapiens,,CHEMBL623373,In vivo antiproliferative activity against A549 cell line,,17824,,80682,,,BAO_0000218,,Intermediate,,9606.0,F,,A549
5779,Homo sapiens,,CHEMBL623374,Inhibition of non-small-cell lung adenocarcinoma (A549),,14368,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5780,Homo sapiens,,CHEMBL623375,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,,14368,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5781,Homo sapiens,,CHEMBL623376,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,,14254,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5782,Homo sapiens,,CHEMBL623377,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),,15897,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5783,Homo sapiens,,CHEMBL623378,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,13866,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5784,Homo sapiens,,CHEMBL623379,Inhibitory activity of compound against human A549 lung carcinoma cell line.,,13370,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5785,Homo sapiens,,CHEMBL623380,Inhibitory activity against A549 lung cancer cell line,,4862,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5786,Homo sapiens,,CHEMBL623381,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,,4862,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5787,Homo sapiens,,CHEMBL623382,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,,4862,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5788,Homo sapiens,,CHEMBL623383,Inhibitory concentration against A549 (lung cancer) cell line,,15970,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5789,Homo sapiens,,CHEMBL623384,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,17713,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
5790,Homo sapiens,,CHEMBL623385,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,,4833,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5791,Homo sapiens,,CHEMBL623386,Activity against A549 cancer cell line.,,13736,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
5792,Homo sapiens,,CHEMBL884105,The compound was evaluated for cytotoxicity against A549 cell line,,4312,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5793,Homo sapiens,,CHEMBL623387,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,,5421,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5794,Homo sapiens,,CHEMBL621568,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,5421,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5795,Homo sapiens,,CHEMBL621569,Growth inhibitory activity was measured for human A549 tumor cell line.,,14717,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5796,Homo sapiens,,CHEMBL621570,Inhibitory activity against A549 lung cancer cell line,,4634,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5797,Homo sapiens,,CHEMBL621571,Inhibitory activity against A549 cell line; inactive,,1149,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5798,Homo sapiens,,CHEMBL621572,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,5421,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
5799,Homo sapiens,,CHEMBL621573,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,5421,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
5800,Homo sapiens,,CHEMBL621574,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,5421,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5801,Homo sapiens,,CHEMBL621575,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),,3320,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5802,Homo sapiens,,CHEMBL621576,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),,3320,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5803,Homo sapiens,,CHEMBL621577,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),,3320,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5804,Homo sapiens,,CHEMBL621578,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),,3320,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5805,Homo sapiens,,CHEMBL621579,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),,3320,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5806,Homo sapiens,,CHEMBL621580,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,,5726,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5807,Canis lupus familiaris,,CHEMBL621581,Plasma clearance (in vivo) in mongrel dogs was determined,In vivo,17800,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5808,Canis lupus familiaris,,CHEMBL621582,Plasma clearance was measured in dog,In vivo,5985,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5809,Canis lupus familiaris,,CHEMBL621583,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,In vivo,5530,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5810,Canis lupus familiaris,,CHEMBL621584,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,In vivo,5530,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5811,Canis lupus familiaris,1969.0,CHEMBL621585,Tested for plasma clearance in dog,In vivo,4839,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5812,Canis lupus familiaris,,CHEMBL621586,The compound was tested for clearance in dog plasma.,In vivo,3639,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5813,Canis lupus familiaris,,CHEMBL875835,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",In vivo,4838,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5814,Canis lupus familiaris,,CHEMBL621587,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,In vivo,4137,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5815,Canis lupus familiaris,1969.0,CHEMBL621588,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),In vivo,5017,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5816,Canis lupus familiaris,2107.0,CHEMBL621589,In vitro clearance in dog liver microsomes,In vitro,17538,Liver,50588,,,BAO_0000218,,Intermediate,Microsomes,9615.0,A,,
5817,Canis lupus familiaris,,CHEMBL621590,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,In vivo,6161,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5818,Canis lupus familiaris,,CHEMBL621591,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,In vivo,6161,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5819,Canis lupus familiaris,,CHEMBL621592,Plasma clearance in dog,In vivo,1696,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5820,Canis lupus familiaris,,CHEMBL621593,Clearance rate in dog,In vivo,6762,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5821,Canis lupus familiaris,1969.0,CHEMBL621594,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,In vivo,5932,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5822,Canis lupus familiaris,,CHEMBL621595,Clearance in dogs,In vivo,6305,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5823,Canis lupus familiaris,,CHEMBL621596,Plasma clearance in dogs,In vivo,4942,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5824,Canis lupus familiaris,,CHEMBL621597,Plasma clearance was determined,In vivo,4219,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5825,Canis lupus familiaris,,CHEMBL621598,Lower clearance in dog (i.v.) at 0.5 mpk,In vivo,17853,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5826,Canis lupus familiaris,,CHEMBL621599,Plasma clearance in Beagle dogs,In vivo,4514,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5827,Canis lupus familiaris,,CHEMBL875836,Plasma clearance (Clp) in dog,In vivo,6448,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5828,Canis lupus familiaris,,CHEMBL621600,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,In vivo,6227,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5829,Canis lupus familiaris,,CHEMBL621601,Plasma clearance (pharmacokinetic parameter) in dog was determined,In vivo,6227,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5830,Canis lupus familiaris,,CHEMBL618474,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,In vivo,6062,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5831,Canis lupus familiaris,,CHEMBL618475,Plasma clearance of compound was determined in dog,In vivo,6821,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5832,Canis lupus familiaris,,CHEMBL624524,Plasma clearance after intravenous administration of 1 mg/kg in dog,In vivo,4709,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5833,Canis lupus familiaris,,CHEMBL624525,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,In vivo,4521,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5834,Canis lupus familiaris,,CHEMBL624526,Plasma clearance in dog was determined,In vivo,5374,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5835,Canis lupus familiaris,,CHEMBL624527,Plasma clearance was calculated in dog,In vivo,6057,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5836,Canis lupus familiaris,,CHEMBL624528,Plasma clearance at the dose of 2 mg/kg in dog,In vivo,4727,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5837,Canis lupus familiaris,,CHEMBL624529,Plasma clearance in dog,In vivo,5145,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5838,Canis lupus familiaris,,CHEMBL624530,Plasma clearance in dog,In vivo,17657,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5839,Canis lupus familiaris,,CHEMBL624531,Plasma clearance in dog; Unable to calculate,In vivo,17657,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5840,Canis lupus familiaris,,CHEMBL624532,Plasma clearance in rhesus monkey,In vivo,5145,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5841,Canis lupus familiaris,,CHEMBL624533,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),In vivo,6642,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5842,Canis lupus familiaris,,CHEMBL624534,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,6641,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5843,Canis lupus familiaris,,CHEMBL624535,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,6642,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5844,Canis lupus familiaris,,CHEMBL624536,Plasma clearance was evaluated in dog,In vivo,5472,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5845,Canis lupus familiaris,,CHEMBL624537,Plasma clearance was evaluated in dog; Not tested,In vivo,5472,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5846,Canis lupus familiaris,,CHEMBL624538,Plasma clearance was evaluated in rhesus,In vivo,5472,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5847,Canis lupus familiaris,,CHEMBL624539,Plasma clearance was evaluated in rhesus; Not tested,In vivo,5472,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5848,Canis lupus familiaris,,CHEMBL624540,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,In vivo,4257,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5849,Canis lupus familiaris,,CHEMBL624541,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,In vivo,6679,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5850,Canis lupus familiaris,,CHEMBL624542,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,In vivo,5546,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5851,Canis lupus familiaris,,CHEMBL624543,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,In vivo,6348,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5852,Canis lupus familiaris,,CHEMBL624544,Clearance value at a dose of 0.2 mg/kg i.v.,In vivo,5474,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5853,Canis lupus familiaris,1969.0,CHEMBL624545,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,In vivo,6316,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5854,Canis lupus familiaris,,CHEMBL624546,Cmax after oral dose of compound at 3 mg/kg in dogs,In vivo,17594,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5855,Canis lupus familiaris,,CHEMBL875957,Cmax after single intravenous bolus of 1 mg/kg in dogs,In vivo,17594,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5856,Canis lupus familiaris,,CHEMBL624547,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,In vivo,5802,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5857,Canis lupus familiaris,,CHEMBL624548,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,In vivo,6535,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5858,Canis lupus familiaris,,CHEMBL624549,Cmax in dog after administration of 1 mg/kg iv,In vivo,6535,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5859,Canis lupus familiaris,1969.0,CHEMBL624550,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,In vivo,1466,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5860,Canis lupus familiaris,,CHEMBL621613,Cmax on p.o. administration of 10 mg/kg was measured in dog,In vivo,6505,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5861,Canis lupus familiaris,,CHEMBL621614,Cmax was determine after peroral administration at 10 mpk in dog,In vivo,5668,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5862,Canis lupus familiaris,,CHEMBL623431,Cmax was determine after peroral administration at 5 mpk in dog,In vivo,5668,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5863,Canis lupus familiaris,,CHEMBL623432,Cmax was determine after peroral administration at 5 mg/kg in dog,In vivo,5668,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5864,Canis lupus familiaris,,CHEMBL623433,Cmax after 0.3 mg/kg po administration in dog,In vivo,5600,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5865,Canis lupus familiaris,,CHEMBL623434,Cmax after peroral administration in dogs at 2.4 uM/kg,In vivo,17764,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5866,Canis lupus familiaris,,CHEMBL623435,Cmax in dog after oral administration at 1 mg/kg,In vivo,6123,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5867,Canis lupus familiaris,,CHEMBL623436,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,In vivo,6123,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5868,Canis lupus familiaris,,CHEMBL875958,Cmax upon oral administration in male Beagle dog at 10 mg/kg,In vivo,6757,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5869,Canis lupus familiaris,,CHEMBL623437,Cmax value after 15 mg/kg iv dose in Dogs,In vivo,16907,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5870,Mus musculus,178.0,CHEMBL623438,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,7767,Blood,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5871,Mus musculus,178.0,CHEMBL623439,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,7767,Blood,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5872,Mus musculus,10000001.0,CHEMBL623440,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,7767,Bone,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5873,Mus musculus,10000001.0,CHEMBL623441,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,7767,Bone,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5874,Mus musculus,10000001.0,CHEMBL623442,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,7767,Bone,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5875,Mus musculus,,CHEMBL623469,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,7767,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5876,Mus musculus,,CHEMBL623470,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,7767,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5877,Mus musculus,,CHEMBL623471,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,7767,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5878,Mus musculus,948.0,CHEMBL623472,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,7767,Heart,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5879,Mus musculus,948.0,CHEMBL623473,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,7767,Heart,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5880,Mus musculus,948.0,CHEMBL623474,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,7767,Heart,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5881,Mus musculus,2113.0,CHEMBL623475,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,7767,Kidney,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5882,Mus musculus,2113.0,CHEMBL623476,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,7767,Kidney,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5883,Mus musculus,2113.0,CHEMBL623477,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,7767,Kidney,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5884,Mus musculus,160.0,CHEMBL621896,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,7767,Intestine,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5885,Mus musculus,160.0,CHEMBL621897,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,7767,Intestine,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5886,Mus musculus,160.0,CHEMBL621898,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,7767,Intestine,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5887,Mus musculus,2107.0,CHEMBL621899,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,7767,Liver,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5888,Mus musculus,2107.0,CHEMBL621900,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,7767,Liver,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5889,Mus musculus,2107.0,CHEMBL621901,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,7767,Liver,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5890,Mus musculus,2048.0,CHEMBL621902,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,7767,Lung,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5891,Mus musculus,2048.0,CHEMBL621903,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,7767,Lung,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5892,Mus musculus,2048.0,CHEMBL622587,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,7767,Lung,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5893,Mus musculus,2385.0,CHEMBL620285,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,7767,Muscle tissue,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5894,Mus musculus,2385.0,CHEMBL875285,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,7767,Muscle tissue,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5895,Mus musculus,2385.0,CHEMBL620286,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,7767,Muscle tissue,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5896,Mus musculus,,CHEMBL620287,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,7767,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5897,Mus musculus,,CHEMBL620288,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,7767,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5898,Mus musculus,,CHEMBL620289,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,7767,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5899,Mus musculus,160.0,CHEMBL620290,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,7767,Intestine,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5900,Mus musculus,160.0,CHEMBL620291,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,7767,Intestine,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5901,Mus musculus,160.0,CHEMBL620292,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,7767,Intestine,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5902,Mus musculus,2106.0,CHEMBL620293,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,7767,Spleen,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5903,Mus musculus,2106.0,CHEMBL620294,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,7767,Spleen,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5904,Mus musculus,2106.0,CHEMBL618614,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,7767,Spleen,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5905,Mus musculus,945.0,CHEMBL618615,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,7767,Stomach,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5906,Mus musculus,945.0,CHEMBL618616,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,7767,Stomach,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
5907,Homo sapiens,,CHEMBL618617,Cytotoxicity against A-172 human tumor cell lines,,2036,,80012,,,BAO_0000219,,Expert,,9606.0,F,,A 172
5908,Homo sapiens,,CHEMBL618618,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,,2357,,80012,,,BAO_0000219,,Intermediate,,9606.0,F,,A 172
5909,Homo sapiens,,CHEMBL618619,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,,1457,,80014,,,BAO_0000219,,Intermediate,,9606.0,F,,A204
5910,Homo sapiens,,CHEMBL618620,Tested for antiproliferative activity against A-2780 tumoral cell line,,4379,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
5911,Homo sapiens,,CHEMBL618621,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,,1093,,80018,,,BAO_0000219,,Intermediate,,9606.0,F,,A-375
5912,Homo sapiens,,CHEMBL618622,Tested in vitro against A-375 cell line human melanoma,,12152,,80018,,,BAO_0000219,,Intermediate,,9606.0,F,,A-375
5913,Homo sapiens,,CHEMBL618623,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,,16464,,80019,,,BAO_0000219,,Expert,,9606.0,F,,A-427
5914,Homo sapiens,,CHEMBL618624,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,16464,,80019,,,BAO_0000219,,Intermediate,,9606.0,F,,A-427
5915,Homo sapiens,,CHEMBL618625,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,,16582,,80019,,,BAO_0000219,,Expert,,9606.0,F,,A-427
5916,Homo sapiens,,CHEMBL618626,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,16464,,80019,,,BAO_0000219,,Intermediate,,9606.0,F,,A-427
5917,Homo sapiens,,CHEMBL618627,Antitumor activity on A-427 lung carcinoma cell lines,,10413,,80019,,,BAO_0000219,,Intermediate,,9606.0,F,,A-427
5918,Homo sapiens,,CHEMBL618628,Cytotoxic activity against human A-427 lung tumor cell line,,6418,,80019,,,BAO_0000219,,Intermediate,,9606.0,F,,A-427
5919,Homo sapiens,,CHEMBL618629,In vitro antitumor effects against human A-427 cell lines.,,17134,,80019,,,BAO_0000219,,Expert,,9606.0,F,,A-427
5920,Homo sapiens,,CHEMBL618630,In vitro inhibition of A-427 (human lung cancer) cell growth.,,16132,,80019,,,BAO_0000219,,Expert,,9606.0,F,,A-427
5921,Homo sapiens,,CHEMBL618631,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,,16132,,80019,,,BAO_0000219,,Intermediate,,9606.0,F,,A-427
5922,Homo sapiens,,CHEMBL618632,Cytotoxic activity of compound against A-427 lung human tumor cell line,,16780,,80019,,,BAO_0000219,,Intermediate,,9606.0,F,,A-427
5923,Homo sapiens,,CHEMBL618633,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,,4085,,80852,,,BAO_0000219,,Expert,,9606.0,F,,A-431
5924,Homo sapiens,,CHEMBL619315,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,,1276,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5925,Homo sapiens,,CHEMBL619316,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,,3498,,80021,,,BAO_0000219,,Expert,,9606.0,F,,A498
5926,Homo sapiens,,CHEMBL619317,Cytotoxicity against human kidney carcinoma A-498cell lines,,1169,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5927,Homo sapiens,,CHEMBL619318,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,,4450,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5928,Homo sapiens,,CHEMBL619319,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,,3311,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5929,Homo sapiens,,CHEMBL619739,Antitumor cytotoxic activity against A-498 cell line was determined,,4461,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5930,Homo sapiens,,CHEMBL619740,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,,3311,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5931,Homo sapiens,,CHEMBL883158,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,,3311,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5932,Homo sapiens,,CHEMBL884012,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,,1457,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5933,Homo sapiens,,CHEMBL619741,In vitro inhibitory activity against A-498 ovarian cancer cell lines,,3664,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5934,Homo sapiens,,CHEMBL619742,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",,15895,,80021,,,BAO_0000219,,Intermediate,,9606.0,F,,A498
5935,Homo sapiens,,CHEMBL876610,Inhibition of growth lung non-small cell carcinoma A-549 cell line,,11843,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5936,Homo sapiens,,CHEMBL619743,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,,11843,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5937,Homo sapiens,,CHEMBL619744,In vitro antiproliferative activity against human A-549 NSCL cell line,,17705,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5938,Homo sapiens,,CHEMBL619745,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,,17705,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5939,Homo sapiens,,CHEMBL619746,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,,4369,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5940,Homo sapiens,,CHEMBL619747,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,,4369,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5941,Homo sapiens,,CHEMBL619748,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,,4369,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5942,Homo sapiens,,CHEMBL619749,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,,4369,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5943,Homo sapiens,,CHEMBL619750,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,,4369,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5944,Homo sapiens,,CHEMBL624014,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,,4369,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5945,Homo sapiens,,CHEMBL624015,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,,4369,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5946,Homo sapiens,,CHEMBL885344,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,,4787,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
5947,Homo sapiens,,CHEMBL623224,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,,4787,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5948,Homo sapiens,,CHEMBL623225,Cytotoxic activity against A-549 cell line,,6513,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5949,Homo sapiens,,CHEMBL622698,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,,6690,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5950,Homo sapiens,,CHEMBL622699,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,,6690,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5951,Homo sapiens,,CHEMBL622700,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",,12263,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
5952,Homo sapiens,,CHEMBL622701,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),,1054,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5953,Homo sapiens,,CHEMBL622702,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),,1359,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5954,Homo sapiens,,CHEMBL622703,Cytotoxic activity against human lung carcinoma (A-549) cell line,,3547,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5955,Homo sapiens,,CHEMBL622704,Cytotoxic activity towards A-549 cells,,5771,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
5956,Homo sapiens,,CHEMBL622705,"In vitro percent inhibition of A549, lung carcinoma.",,14425,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5957,Homo sapiens,,CHEMBL622706,"In vitro percent inhibition of A549, lung carcinoma",,14425,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5958,Homo sapiens,,CHEMBL622707,"In vitro percent inhibition of A549, lung carcinoma.",,14425,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5959,Homo sapiens,,CHEMBL622708,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",,14425,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5960,Homo sapiens,,CHEMBL622709,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,,5280,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5961,Homo sapiens,,CHEMBL622710,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,,15176,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5962,Homo sapiens,,CHEMBL622711,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,,15300,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5963,Homo sapiens,,CHEMBL622712,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,17824,,80682,,,BAO_0000218,,Intermediate,,9606.0,F,,A549
5964,Homo sapiens,,CHEMBL622713,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,17824,,80682,,,BAO_0000218,,Intermediate,,9606.0,F,,A549
5965,Homo sapiens,,CHEMBL622714,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,17824,,80682,,,BAO_0000218,,Intermediate,,9606.0,F,,A549
5966,Homo sapiens,,CHEMBL622715,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,17824,,80682,,,BAO_0000218,,Intermediate,,9606.0,F,,A549
5967,Homo sapiens,,CHEMBL622716,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,17824,,80682,,,BAO_0000218,,Intermediate,,9606.0,F,,A549
5968,Homo sapiens,,CHEMBL622717,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",,17824,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5969,Homo sapiens,,CHEMBL622718,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),,17528,,80682,,,BAO_0000218,,Intermediate,,9606.0,F,,A549
5970,Homo sapiens,,CHEMBL622719,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,,6870,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
5971,Homo sapiens,,CHEMBL622720,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,6870,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5972,Homo sapiens,,CHEMBL622721,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,,6870,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5973,Homo sapiens,,CHEMBL622722,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,6870,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5974,Homo sapiens,,CHEMBL876030,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,16726,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5975,Homo sapiens,,CHEMBL620206,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",,6170,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5976,Homo sapiens,,CHEMBL620207,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,,6583,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
5977,Homo sapiens,,CHEMBL620208,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,,6583,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
5978,Homo sapiens,,CHEMBL620209,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,,6583,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
5979,Homo sapiens,,CHEMBL620210,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,,6583,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
5980,Homo sapiens,,CHEMBL621639,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,,6583,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
5981,Homo sapiens,,CHEMBL621640,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,,17321,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5982,Homo sapiens,,CHEMBL621641,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,17528,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
5983,Homo sapiens,,CHEMBL621642,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,,12888,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
5984,Homo sapiens,,CHEMBL621643,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,,4312,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5985,Homo sapiens,,CHEMBL621644,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,,4312,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5986,Homo sapiens,,CHEMBL621645,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,,4312,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
5987,Mus musculus,,CHEMBL621646,In vitro antiproliferative activity against A549 cell line,,17737,,80682,,,BAO_0000219,,Intermediate,,10090.0,F,,A549
5988,,,CHEMBL621647,Synergism with indomethacin in A549 cells,,6630,,80682,,,BAO_0000219,,Intermediate,,,F,,A549
5989,,,CHEMBL621648,Synergism with tolmetin in A549 cells,,6630,,80682,,,BAO_0000219,,Intermediate,,,F,,A549
5990,,,CHEMBL621649,Synergism with sulindac in A549 cells,,6630,,80682,,,BAO_0000219,,Intermediate,,,F,,A549
5991,,,CHEMBL621650,Antagonism of indomethacin in A549 cells,,6630,,80682,,,BAO_0000219,,Intermediate,,,F,,A549
5992,,,CHEMBL621651,Antagonism of sulindac in A549 cells,,6630,,80682,,,BAO_0000219,,Intermediate,,,F,,A549
5993,,,CHEMBL621652,Antagonism of tolmetin in A549 cells,,6630,,80682,,,BAO_0000219,,Intermediate,,,F,,A549
5994,,,CHEMBL621653,Synergism with indomethacin in A549 cells,,6630,,80682,,,BAO_0000219,,Intermediate,,,F,,A549
5995,,,CHEMBL621654,Synergism with sulindac in A549 cells,,6630,,80682,,,BAO_0000219,,Intermediate,,,F,,A549
5996,,,CHEMBL621655,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,,6630,,80682,,,BAO_0000219,,Intermediate,,,F,,A549
5997,Canis lupus familiaris,,CHEMBL621656,Cmax value after 30 mg/kg po dose in Dogs,In vivo,16907,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5998,Canis lupus familiaris,,CHEMBL621657,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),In vivo,5944,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
5999,Canis lupus familiaris,,CHEMBL621658,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,In vivo,5944,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6000,Canis lupus familiaris,,CHEMBL621659,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),In vivo,5944,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6001,Canis lupus familiaris,,CHEMBL621660,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,In vivo,5944,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6002,Canis lupus familiaris,,CHEMBL621661,Cmax value after administration of 4 mg/Kg oral dose in dog,In vivo,2959,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6003,Canis lupus familiaris,,CHEMBL621662,Cmax value in dog,In vivo,6241,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6004,Canis lupus familiaris,,CHEMBL621663,Cmax value in dogs after oral administration at 1 mg/kg,In vivo,6241,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6005,Canis lupus familiaris,,CHEMBL621664,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,In vivo,2652,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6006,Canis lupus familiaris,1969.0,CHEMBL621665,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,In vivo,1806,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6007,Canis lupus familiaris,1969.0,CHEMBL621666,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,In vivo,1806,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6008,Canis lupus familiaris,,CHEMBL621667,Concentration maxima after oral dosing in dogs,In vivo,1021,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6009,Canis lupus familiaris,,CHEMBL876738,Concentration maxima after oral dosing in dogs; not available,In vivo,1021,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6010,Canis lupus familiaris,,CHEMBL621668,Concentration maxima after oral dosing in dogs; not available,In vivo,1021,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6011,Canis lupus familiaris,,CHEMBL621669,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,In vivo,5444,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6012,Canis lupus familiaris,,CHEMBL621670,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,In vivo,5444,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6013,Canis lupus familiaris,,CHEMBL621671,In vivo maximal concentration was calculated at 1 mg/kg in dog,In vivo,5444,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6014,Canis lupus familiaris,,CHEMBL622360,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,In vivo,5444,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6015,Canis lupus familiaris,,CHEMBL622361,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,In vivo,5444,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6016,Canis lupus familiaris,1969.0,CHEMBL622362,Cmax in dog plasma after oral dose (1 mg/kg),In vivo,5130,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6017,Canis lupus familiaris,1969.0,CHEMBL622363,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,In vivo,3249,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6018,Canis lupus familiaris,1969.0,CHEMBL622364,Maximal plasma concentration at a dose of 1 mg/kg,In vivo,5473,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6019,Canis lupus familiaris,1969.0,CHEMBL622365,Maximal plasma concentration at a dose of 1 mg/kg (oral),In vivo,5474,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6020,Canis lupus familiaris,1969.0,CHEMBL622533,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,In vivo,4657,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6021,Canis lupus familiaris,,CHEMBL622534,Maximum concentration of compound in dog was evaluated.,In vivo,3031,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6022,Canis lupus familiaris,,CHEMBL622535,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,In vivo,4527,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6023,Canis lupus familiaris,,CHEMBL876739,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,In vivo,4186,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6024,Canis lupus familiaris,,CHEMBL622536,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),In vivo,5007,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6025,Canis lupus familiaris,1969.0,CHEMBL622537,Maximum concentration obtained in dog plasma was determined,In vivo,3132,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6026,Canis lupus familiaris,,CHEMBL622538,Maximum concentration was determined,In vivo,5006,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6027,Canis lupus familiaris,,CHEMBL627867,Maximum concentration at the dose of 2 mg/kg in dog,In vivo,4727,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6028,Canis lupus familiaris,,CHEMBL627868,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,In vivo,1916,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6029,Canis lupus familiaris,1969.0,CHEMBL627869,Maximum concentration was evaluated in dog plasma,In vivo,1918,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6030,Canis lupus familiaris,,CHEMBL627870,Maximum concentration was evaluated after 75 min after administration in dog,In vivo,3045,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6031,Canis lupus familiaris,1969.0,CHEMBL627871,Maximum plasma concentration determined in dog after oral administration of 17b,In vivo,9579,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6032,Canis lupus familiaris,1969.0,CHEMBL627872,Maximum plasma concentration determined in dog after oral administration of 2b,In vivo,9579,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6033,Canis lupus familiaris,1969.0,CHEMBL627873,Maximum plasma concentration in dog,In vivo,933,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6034,Canis lupus familiaris,1969.0,CHEMBL627874,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,In vivo,17839,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6035,Canis lupus familiaris,1969.0,CHEMBL627875,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,In vivo,17839,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6036,Canis lupus familiaris,1969.0,CHEMBL627876,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,In vivo,17839,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6037,Canis lupus familiaris,1969.0,CHEMBL627877,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,In vivo,17839,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6038,Canis lupus familiaris,1969.0,CHEMBL627878,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,In vivo,6348,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6039,Canis lupus familiaris,1969.0,CHEMBL627879,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,In vivo,16367,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6040,Canis lupus familiaris,1969.0,CHEMBL875355,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,In vivo,1337,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6041,Canis lupus familiaris,1969.0,CHEMBL627880,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,In vivo,1337,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6042,Canis lupus familiaris,1969.0,CHEMBL627881,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,In vivo,5199,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6043,Canis lupus familiaris,1969.0,CHEMBL627882,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,In vivo,17650,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6044,Canis lupus familiaris,1969.0,CHEMBL627883,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,In vivo,6679,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6045,Canis lupus familiaris,1969.0,CHEMBL628526,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,In vivo,5356,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6046,Canis lupus familiaris,1969.0,CHEMBL628527,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,In vivo,5356,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6047,Canis lupus familiaris,1969.0,CHEMBL628528,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,In vivo,6227,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6048,Canis lupus familiaris,1969.0,CHEMBL628529,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,In vivo,6227,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6049,Canis lupus familiaris,1969.0,CHEMBL628530,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,In vivo,6227,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6050,Canis lupus familiaris,1969.0,CHEMBL625243,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,In vivo,6227,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6051,Canis lupus familiaris,1969.0,CHEMBL625244,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,In vivo,3598,Plasma,50588,,,BAO_0000218,,Expert,,9615.0,A,,
6052,Canis lupus familiaris,,CHEMBL625245,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,In vivo,4368,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6053,Canis lupus familiaris,,CHEMBL625246,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,In vivo,6265,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6054,Mus musculus,945.0,CHEMBL625247,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,7767,Stomach,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6055,Mus musculus,1088.0,CHEMBL625248,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,7767,Urine,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6056,Mus musculus,1088.0,CHEMBL625249,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,In vivo,7767,Urine,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6057,Mus musculus,1088.0,CHEMBL625250,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,In vivo,7767,Urine,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6058,Mus musculus,,CHEMBL625251,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,,17811,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6059,Mus musculus,,CHEMBL875356,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,,17811,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6060,Mus musculus,,CHEMBL625252,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),,17827,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6061,Mus musculus,178.0,CHEMBL625253,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),,17827,Blood,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6062,Mus musculus,,CHEMBL625254,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),,17827,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6063,Mus musculus,,CHEMBL625255,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),,17827,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6064,Mus musculus,,CHEMBL625256,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),,17827,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6065,Mus musculus,178.0,CHEMBL625257,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),,17827,Blood,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6066,Mus musculus,178.0,CHEMBL625258,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),,17827,Blood,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6067,Mus musculus,,CHEMBL625259,Compound was evaluated for washout rate in mice (Radiolabeled compound),,17827,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6068,Mus musculus,,CHEMBL625260,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,,17827,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6069,Mus musculus,,CHEMBL625261,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,17827,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6070,Mus musculus,,CHEMBL625262,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,17827,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6071,Mus musculus,,CHEMBL622639,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,17827,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6072,Mus musculus,,CHEMBL622640,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,,17257,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6073,Mus musculus,,CHEMBL622812,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,,17257,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6074,Mus musculus,,CHEMBL622813,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,,17257,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6075,Mus musculus,,CHEMBL622814,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,,17257,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6076,Mus musculus,,CHEMBL622815,Time at maximum activity in mice (Radiolabeled compound),,17827,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6077,Mus musculus,,CHEMBL625342,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,,3760,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6078,Mus musculus,,CHEMBL625343,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,,3760,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6079,Mus musculus,,CHEMBL877591,Binding towards mouse plasma protein at 10 uM,,17409,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6080,Mus musculus,,CHEMBL625344,Binding towards mouse plasma protein at 100 uM,,17409,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6081,Mus musculus,,CHEMBL625345,Bioavailability was evaluated in mice after intravenous administration,In vivo,2675,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6082,Mus musculus,,CHEMBL625346,Bioavailability was evaluated in mice after oral administration,In vivo,2675,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6083,Mus musculus,,CHEMBL625347,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,In vivo,3132,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6084,Mus musculus,,CHEMBL625348,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,In vivo,3132,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6085,Mus musculus,,CHEMBL625349,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,In vivo,16597,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6086,Mus musculus,,CHEMBL625350,Oral bioavailability in mouse,In vivo,2862,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6087,Mus musculus,,CHEMBL882952,Oral bioavailability after intravenous administration in mice at 24 uM/kg,In vivo,17764,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6088,Mus musculus,955.0,CHEMBL625351,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,In vivo,846,Brain,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6089,Mus musculus,955.0,CHEMBL625352,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,In vivo,846,Brain,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6090,Mus musculus,955.0,CHEMBL877592,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,846,Brain,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6091,Mus musculus,955.0,CHEMBL625353,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,In vivo,846,Brain,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6092,Mus musculus,955.0,CHEMBL625354,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,846,Brain,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6093,Mus musculus,955.0,CHEMBL626019,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,In vivo,846,Brain,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6094,Mus musculus,948.0,CHEMBL626020,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,In vivo,846,Heart,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6095,Mus musculus,948.0,CHEMBL626021,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,846,Heart,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6096,Mus musculus,948.0,CHEMBL626022,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,In vivo,846,Heart,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6097,Mus musculus,948.0,CHEMBL626192,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,In vivo,846,Heart,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6098,Homo sapiens,,CHEMBL626193,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),,1276,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6099,Homo sapiens,,CHEMBL626194,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,,3498,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
6100,Homo sapiens,,CHEMBL626195,Cytotoxicity against human lung carcinoma A-549 cell lines,,1169,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6101,Homo sapiens,,CHEMBL626196,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,,4450,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6102,Homo sapiens,,CHEMBL626197,In vitro cytotoxicity against human lung carcinoma cell line A-549,,358,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6103,Homo sapiens,,CHEMBL626198,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,,358,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6104,Homo sapiens,,CHEMBL626199,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,,358,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6105,Homo sapiens,,CHEMBL626200,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,,358,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6106,Homo sapiens,,CHEMBL626201,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,,358,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6107,Homo sapiens,,CHEMBL626202,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,,358,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6108,Homo sapiens,,CHEMBL626203,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,,358,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6109,Homo sapiens,,CHEMBL626204,In vitro cytotoxicity against A-549 human lung cancer cells,,15167,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6110,Homo sapiens,,CHEMBL624701,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,,4139,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6111,Homo sapiens,,CHEMBL624702,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,,833,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6112,Homo sapiens,,CHEMBL624703,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,15718,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
6113,Homo sapiens,,CHEMBL624704,Tested in vitro for cytotoxicity against A-549 lung cancer cells,,12373,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6114,Homo sapiens,,CHEMBL624705,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,,637,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6115,Homo sapiens,,CHEMBL624706,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,,14867,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
6116,Homo sapiens,,CHEMBL624707,Antitumor cytotoxic activity against A-549 cell line was determined,,4461,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6117,Homo sapiens,,CHEMBL624708,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",,5406,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6118,Homo sapiens,,CHEMBL624709,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,4457,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6119,Homo sapiens,,CHEMBL884107,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,1386,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
6120,Homo sapiens,,CHEMBL624710,Antitumoral activity was assayed against A-549 cell line,,3265,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6121,Homo sapiens,,CHEMBL624711,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,,2359,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6122,Homo sapiens,,CHEMBL624712,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,4457,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6123,Homo sapiens,,CHEMBL624713,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,12454,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
6124,Homo sapiens,,CHEMBL624714,Compound was tested for inhibition of cell growth of A-549 cells,,1481,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6125,Homo sapiens,,CHEMBL624715,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,,1750,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6126,Homo sapiens,,CHEMBL624716,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,,5065,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6127,Homo sapiens,,CHEMBL619505,In vitro cytotoxicity against A549-human lung carcinoma cells.,,808,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
6128,Homo sapiens,,CHEMBL619506,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,,16364,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
6129,Homo sapiens,,CHEMBL619507,Cytotoxic activity against A-549 cell lines.,,1847,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6130,Homo sapiens,,CHEMBL619508,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,,1747,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
6131,Homo sapiens,,CHEMBL619509,Cytotoxicity against human A549 non small cell lung cell lines,,1003,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6132,Homo sapiens,,CHEMBL619510,Inhibition of cell growth in (A-549) lung cell line,,15313,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
6133,Homo sapiens,,CHEMBL619511,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,,3122,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6134,Homo sapiens,,CHEMBL619512,In vitro antitumor activity against A-549 tumor cells.,,16049,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6135,Homo sapiens,,CHEMBL619513,In vitro antitumor effects against human A-549 cell lines.,,17134,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
6136,Homo sapiens,,CHEMBL619514,In vitro cytotoxic activity of compound against A-549 cell line,,6406,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6137,Homo sapiens,,CHEMBL619515,In vitro cytotoxicity against human lung carcinoma A-549 cell line,,627,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6138,Homo sapiens,,CHEMBL619516,In vitro cytotoxicity against human non-small cell lung carcinoma A549,,12307,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6139,Homo sapiens,,CHEMBL884005,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,,17861,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6140,Homo sapiens,,CHEMBL619517,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,,6682,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
6141,Homo sapiens,,CHEMBL619518,Inhibitory concentration of compound against A-549 cell line,,6663,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6142,Homo sapiens,,CHEMBL619519,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,,2454,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6143,Homo sapiens,,CHEMBL876489,cytotoxic activity against leukemia (A-549) cancer cell line,,14709,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6144,Homo sapiens,,CHEMBL619520,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,15718,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
6145,Homo sapiens,,CHEMBL619521,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,,15718,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6146,Homo sapiens,,CHEMBL619522,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),,17130,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6147,Homo sapiens,,CHEMBL619523,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),,17130,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6148,Homo sapiens,,CHEMBL619524,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),,17130,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6149,Homo sapiens,,CHEMBL619525,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),,17130,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6150,,,CHEMBL619526,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,,6630,,80682,,,BAO_0000219,,Intermediate,,,F,,A549
6151,Homo sapiens,,CHEMBL619527,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,,16726,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6152,Homo sapiens,,CHEMBL619528,Cytotoxicity against A549 cells; No cytotoxicity,,17846,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6153,Homo sapiens,,CHEMBL619529,Cytotoxicity against human lung carcinoma (A549) cell lines,,3415,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
6154,Homo sapiens,,CHEMBL619530,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,,3415,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
6155,Homo sapiens,,CHEMBL876490,In vitro anticancer activity against human lung (A549) cell line,,5609,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6156,Homo sapiens,,CHEMBL619531,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,,17206,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6157,Homo sapiens,,CHEMBL619532,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,,17206,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6158,Homo sapiens,,CHEMBL619533,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,,17206,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6159,Homo sapiens,,CHEMBL619534,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,,17206,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6160,Homo sapiens,,CHEMBL620164,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,,17206,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6161,Homo sapiens,,CHEMBL620165,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,17206,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6162,Homo sapiens,,CHEMBL620166,Inhibition of A549 human lung tumor cell proliferation,,16295,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
6163,Homo sapiens,,CHEMBL620167,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",,16825,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6164,Homo sapiens,,CHEMBL620168,In vitro cytotoxicity against human tumor cell line A549,,3439,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
6165,Homo sapiens,,CHEMBL620338,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,,10870,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6166,Homo sapiens,,CHEMBL620339,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,,4845,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6167,Homo sapiens,,CHEMBL620340,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,,5822,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6168,Homo sapiens,,CHEMBL620341,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,,5822,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6169,Homo sapiens,,CHEMBL876491,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,,5822,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6170,Homo sapiens,,CHEMBL620342,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,16381,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6171,Homo sapiens,,CHEMBL620343,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,16381,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6172,Homo sapiens,,CHEMBL620344,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,16381,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6173,Homo sapiens,,CHEMBL620345,In vitro anticancer activity against human lung (A549) cell line,,5609,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6174,Homo sapiens,,CHEMBL620346,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,,4644,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6175,Homo sapiens,,CHEMBL620347,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,,4644,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6176,Homo sapiens,,CHEMBL620348,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,,4644,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6177,Homo sapiens,,CHEMBL620349,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,,4644,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6178,Homo sapiens,,CHEMBL618667,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,,5822,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6179,Homo sapiens,,CHEMBL618668,Percentage inhibition of human lung carcinoma (A549) cell lines,,3415,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
6180,Homo sapiens,,CHEMBL876031,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,,16726,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6181,Homo sapiens,,CHEMBL618759,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",,17206,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6182,Homo sapiens,,CHEMBL618760,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,17206,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6183,Homo sapiens,,CHEMBL619000,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,17206,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6184,Homo sapiens,,CHEMBL619001,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",,17206,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6185,Homo sapiens,,CHEMBL619002,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",,17206,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6186,Homo sapiens,,CHEMBL619003,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",,17206,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6187,Homo sapiens,,CHEMBL619597,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",,17206,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6188,Homo sapiens,,CHEMBL619598,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",,17206,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6189,Homo sapiens,,CHEMBL619599,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,,17206,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6190,Homo sapiens,,CHEMBL619600,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,,17206,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6191,Homo sapiens,,CHEMBL619601,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,16726,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6192,Homo sapiens,,CHEMBL619602,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,,17206,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6193,Homo sapiens,,CHEMBL619603,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,,17206,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6194,Homo sapiens,,CHEMBL619604,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,,17206,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6195,Homo sapiens,,CHEMBL619605,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,,17206,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6196,Canis lupus familiaris,,CHEMBL619606,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,In vivo,6084,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6197,Canis lupus familiaris,,CHEMBL876032,Pharmacokinetic activity (Cmax) in dog,In vivo,6084,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6198,Canis lupus familiaris,,CHEMBL619607,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),In vivo,4809,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6199,Canis lupus familiaris,,CHEMBL619608,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,In vivo,5983,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6200,Canis lupus familiaris,,CHEMBL619609,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,In vivo,6251,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6201,Canis lupus familiaris,1969.0,CHEMBL619610,Cmax in dog plasma after 30mg/kg oral dose,In vivo,5932,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6202,Canis lupus familiaris,178.0,CHEMBL619611,Tested for the peak blood level in dog,In vivo,4273,Blood,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6203,Canis lupus familiaris,,CHEMBL619612,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",In vivo,5313,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6204,Canis lupus familiaris,,CHEMBL619613,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",In vivo,5313,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6205,Canis lupus familiaris,178.0,CHEMBL619614,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,In vivo,6221,Blood,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6206,Canis lupus familiaris,,CHEMBL619615,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,,4709,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6207,Canis lupus familiaris,,CHEMBL619616,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,,167,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6208,Canis lupus familiaris,1969.0,CHEMBL619617,Final plasma concentration in dogs after oral administration at 1 mg/kg,,6241,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6209,Canis lupus familiaris,,CHEMBL619618,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,,344,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6210,Canis lupus familiaris,,CHEMBL876033,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,,344,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6211,Canis lupus familiaris,,CHEMBL619619,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,,344,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6212,Canis lupus familiaris,,CHEMBL619620,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,,2189,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6213,Canis lupus familiaris,1088.0,CHEMBL619621,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,,2189,Urine,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6214,Canis lupus familiaris,1088.0,CHEMBL619622,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,,2189,Urine,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6215,Canis lupus familiaris,1088.0,CHEMBL618874,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,,2189,Urine,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6216,Canis lupus familiaris,,CHEMBL618875,Absolute bioavailability was evaluated in dog,In vivo,4257,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6217,Canis lupus familiaris,,CHEMBL618876,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,In vivo,6221,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6218,Canis lupus familiaris,,CHEMBL618877,Bioavailability after peroral administration (1 mg/kg) was determined in dog,In vivo,6215,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6219,Canis lupus familiaris,,CHEMBL618878,Bioavailability in dog,In vivo,17267,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6220,Canis lupus familiaris,,CHEMBL618879,Bioavailability in dog,In vivo,6621,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6221,Canis lupus familiaris,,CHEMBL618880,Bioavailability after intravenous administration in dogs,In vivo,3854,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6222,Canis lupus familiaris,,CHEMBL618881,Bioavailability after peroral administration in dogs,In vivo,3854,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6223,Canis lupus familiaris,,CHEMBL618882,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),In vivo,5007,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6224,Canis lupus familiaris,,CHEMBL624226,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,In vivo,4333,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6225,Canis lupus familiaris,1969.0,CHEMBL624227,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,In vivo,4333,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6226,Canis lupus familiaris,,CHEMBL624228,Bioavailability,In vivo,5006,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6227,Canis lupus familiaris,,CHEMBL624229,Bioavailability,In vivo,5199,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6228,Canis lupus familiaris,,CHEMBL624230,Bioavailability by intravenous administration of 1.2 mg/kg in dog,In vivo,4368,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6229,Canis lupus familiaris,,CHEMBL624231,Bioavailability in dog,In vivo,3771,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6230,Canis lupus familiaris,,CHEMBL624232,Bioavailability in dog,In vivo,4953,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6231,Canis lupus familiaris,,CHEMBL625127,Bioavailability in dog,In vivo,5064,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6232,Canis lupus familiaris,,CHEMBL625128,Bioavailability in dog,In vivo,17657,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6233,Canis lupus familiaris,,CHEMBL621675,Bioavailability in dog,In vivo,17796,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6234,Canis lupus familiaris,,CHEMBL621676,Bioavailability in dog (p.o.) at 2.0 mpk,In vivo,17853,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6235,Canis lupus familiaris,,CHEMBL621677,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),In vivo,4521,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6236,Canis lupus familiaris,,CHEMBL621678,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,In vivo,4521,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6237,Canis lupus familiaris,,CHEMBL621679,Bioavailability in dog,In vivo,5006,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6238,Canis lupus familiaris,,CHEMBL621680,Bioavailability was evaluated after oral administration in dog,In vivo,16365,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6239,Canis lupus familiaris,,CHEMBL621681,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,In vivo,1916,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6240,Canis lupus familiaris,,CHEMBL876740,Bioavailability was evaluated in dog,In vivo,1918,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6241,Canis lupus familiaris,,CHEMBL621682,Bioavailability in dog,In vivo,4239,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6242,Canis lupus familiaris,,CHEMBL621683,Bioavailability in dog,In vivo,6505,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6243,Canis lupus familiaris,,CHEMBL621684,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),In vivo,5334,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6244,Canis lupus familiaris,,CHEMBL621685,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),In vivo,5334,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6245,Canis lupus familiaris,,CHEMBL621686,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),In vivo,4809,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6246,Canis lupus familiaris,,CHEMBL621687,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,In vivo,6348,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6247,Canis lupus familiaris,,CHEMBL621688,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,In vivo,6005,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6248,Canis lupus familiaris,,CHEMBL621689,Bioavailability of compound in dog was determined after peroral administration,In vivo,17804,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6249,Canis lupus familiaris,,CHEMBL621690,Oral bioavailability in dog,In vivo,3184,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6250,Canis lupus familiaris,,CHEMBL621691,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,In vivo,1806,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6251,Canis lupus familiaris,,CHEMBL875941,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,In vivo,1806,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6252,Canis lupus familiaris,,CHEMBL621692,Compound was evaluated for oral bioavailability in dogs; 37-38 %,In vivo,1806,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6253,Canis lupus familiaris,,CHEMBL621693,Bioavailability in dog,In vivo,4839,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6254,Canis lupus familiaris,,CHEMBL621694,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),In vivo,5017,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6255,Mus musculus,948.0,CHEMBL621695,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,846,Heart,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6256,Mus musculus,948.0,CHEMBL621696,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,In vivo,846,Heart,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6257,Mus musculus,2113.0,CHEMBL621697,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,In vivo,846,Kidney,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6258,Mus musculus,2113.0,CHEMBL621698,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,In vivo,846,Kidney,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6259,Mus musculus,2113.0,CHEMBL623420,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,846,Kidney,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6260,Mus musculus,2113.0,CHEMBL623421,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,In vivo,846,Kidney,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6261,Mus musculus,2113.0,CHEMBL623422,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,846,Kidney,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6262,Mus musculus,2113.0,CHEMBL623423,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,In vivo,846,Kidney,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6263,Mus musculus,2107.0,CHEMBL623424,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,In vivo,846,Liver,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6264,Mus musculus,2107.0,CHEMBL623425,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,In vivo,846,Liver,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6265,Mus musculus,2107.0,CHEMBL623426,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,846,Liver,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6266,Mus musculus,2107.0,CHEMBL623427,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,In vivo,846,Liver,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6267,Mus musculus,2107.0,CHEMBL623428,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,846,Liver,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6268,Mus musculus,2107.0,CHEMBL875947,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,In vivo,846,Liver,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6269,Mus musculus,2048.0,CHEMBL623429,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,In vivo,846,Lung,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6270,Mus musculus,2048.0,CHEMBL623430,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,In vivo,846,Lung,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6271,Mus musculus,2048.0,CHEMBL622588,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,846,Lung,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6272,Mus musculus,2048.0,CHEMBL622589,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,In vivo,846,Lung,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6273,Mus musculus,2048.0,CHEMBL622751,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,846,Lung,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6274,Mus musculus,2048.0,CHEMBL622752,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,In vivo,846,Lung,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6275,Mus musculus,,CHEMBL622753,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,,6599,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6276,Mus musculus,,CHEMBL622647,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,,6599,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6277,Mus musculus,,CHEMBL875163,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,,6599,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6278,Mus musculus,,CHEMBL622648,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,,6599,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6279,Mus musculus,,CHEMBL622649,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,,6599,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6280,Mus musculus,955.0,CHEMBL622650,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,,6599,Brain,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6281,Mus musculus,955.0,CHEMBL622651,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,,6599,Brain,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6282,Mus musculus,955.0,CHEMBL622652,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,,6599,Brain,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6283,Mus musculus,955.0,CHEMBL622653,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,,6599,Brain,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6284,Mus musculus,955.0,CHEMBL622654,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,,6599,Brain,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6285,Mus musculus,948.0,CHEMBL622655,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,,6599,Heart,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6286,Mus musculus,948.0,CHEMBL622656,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,,6599,Heart,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6287,Mus musculus,948.0,CHEMBL622657,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,,6599,Heart,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6288,Mus musculus,948.0,CHEMBL622658,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,,6599,Heart,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6289,Mus musculus,948.0,CHEMBL622659,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,,6599,Heart,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6290,Mus musculus,2113.0,CHEMBL624630,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,,6599,Kidney,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6291,Mus musculus,2113.0,CHEMBL624631,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,,6599,Kidney,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6292,Mus musculus,2113.0,CHEMBL624632,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,,6599,Kidney,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6293,Homo sapiens,,CHEMBL624633,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,,17130,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6294,Homo sapiens,,CHEMBL624634,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,,17130,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6295,Homo sapiens,,CHEMBL624635,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),,17130,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6296,Homo sapiens,,CHEMBL624636,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),,17130,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6297,Homo sapiens,,CHEMBL857055,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,3263,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
6298,Homo sapiens,,CHEMBL624637,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,,6663,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
6299,Homo sapiens,,CHEMBL624638,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,,6663,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
6300,Homo sapiens,,CHEMBL874366,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,,6663,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
6301,Homo sapiens,,CHEMBL624639,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,,6663,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
6302,Homo sapiens,,CHEMBL624640,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,,6663,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
6303,Homo sapiens,,CHEMBL624641,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,,6663,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6304,Homo sapiens,,CHEMBL624642,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,,6663,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6305,Homo sapiens,,CHEMBL624643,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,,6663,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6306,Homo sapiens,,CHEMBL624644,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,,6663,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6307,Homo sapiens,,CHEMBL624645,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,,6663,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6308,Homo sapiens,,CHEMBL619445,The compound was evaluated for its cytotoxic potency against A-549 cell line,,3983,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6309,Homo sapiens,,CHEMBL839886,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,,11141,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
6310,Homo sapiens,,CHEMBL619446,Cytotoxic activity of compound against A-549 tumor cell line.,,5076,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6311,Homo sapiens,,CHEMBL619447,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,,3311,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6312,Homo sapiens,,CHEMBL619448,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,,3311,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6313,Homo sapiens,,CHEMBL619449,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,,3311,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6314,Homo sapiens,,CHEMBL619450,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,,5076,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6315,Homo sapiens,,CHEMBL619451,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),,4150,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6316,Homo sapiens,,CHEMBL619452,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,,2150,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
6317,Homo sapiens,,CHEMBL619453,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,,4644,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6318,Homo sapiens,,CHEMBL874367,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,,263,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6319,Homo sapiens,,CHEMBL619454,Cytotoxic concentration against A-549 tumor cells.,,11333,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6320,Homo sapiens,,CHEMBL619455,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,,11333,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6321,Homo sapiens,,CHEMBL619456,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",,15895,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6322,Acinetobacter baumannii,,CHEMBL619457,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,,16677,,50191,,,BAO_0000218,,Expert,,470.0,F,,
6323,Acinetobacter calcoaceticus,,CHEMBL619458,Activity against Acinetobacter calcoaceticus (AC54),,10624,,50192,,,BAO_0000218,,Intermediate,,471.0,F,,
6324,Aspergillus flavus,,CHEMBL619459,In vitro antifungal activity against Aspergillus flavus CM74,,16717,,50274,,,BAO_0000218,,Expert,,5059.0,F,,
6325,Aspergillus flavus,,CHEMBL619460,In vitro antifungal activity against Aspergillus flavus CM74,,16717,,50274,,,BAO_0000218,,Expert,,5059.0,F,,
6326,Aspergillus fumigatus,,CHEMBL619461,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,,5513,,50416,,,BAO_0000218,,Intermediate,,746128.0,F,,
6327,Aspergillus fumigatus,,CHEMBL619462,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),,15962,,50416,,,BAO_0000218,,Intermediate,,746128.0,F,,
6328,Aspergillus fumigatus,,CHEMBL620388,Antimicrobial activity against Aspergillus fumigatus (MIC),,15962,,50416,,,BAO_0000218,,Intermediate,,746128.0,F,,
6329,Aspergillus fumigatus,,CHEMBL620389,Antimicrobial activity against Aspergillus fumigatus (MIC),,15962,,50416,,,BAO_0000218,,Intermediate,,746128.0,F,,
6330,Aspergillus fumigatus,,CHEMBL620390,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),,15962,,50416,,,BAO_0000218,,Intermediate,,746128.0,F,,
6331,Aspergillus fumigatus,,CHEMBL620391,In vitro antifungal activity against Aspergillus fumigatus 48238E,,16717,,50416,,,BAO_0000218,,Expert,,746128.0,F,,
6332,Aspergillus fumigatus,,CHEMBL621073,In vitro antifungal activity against Aspergillus fumigatus 48238E,,16717,,50416,,,BAO_0000218,,Expert,,746128.0,F,,
6333,Actinomyces naeslundii,,CHEMBL621074,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,,8117,,50296,,,BAO_0000218,,Intermediate,,1655.0,F,,
6334,Actinomyces viscosus,,CHEMBL621075,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,,8117,,50366,,,BAO_0000218,,Intermediate,,1656.0,F,,
6335,Acanthocheilonema viteae,,CHEMBL619554,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,15472,,50535,,,BAO_0000218,,Intermediate,,6277.0,F,,
6336,Acanthocheilonema viteae,,CHEMBL619555,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,15472,,50535,,,BAO_0000218,,Intermediate,,6277.0,F,,
6337,Aggregatibacter actinomycetemcomitans,,CHEMBL619556,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,,16443,,50169,,,BAO_0000218,,Intermediate,,714.0,F,,
6338,Aggregatibacter actinomycetemcomitans,,CHEMBL619557,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,,16443,,50169,,,BAO_0000218,,Intermediate,,714.0,F,,
6339,Aggregatibacter actinomycetemcomitans,,CHEMBL619558,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,,16443,,50169,,,BAO_0000218,,Intermediate,,714.0,F,,
6340,Homo sapiens,,CHEMBL619559,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,17206,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6341,Homo sapiens,,CHEMBL619560,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,,17206,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6342,Homo sapiens,,CHEMBL619561,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,16381,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6343,Homo sapiens,,CHEMBL619562,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,16381,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6344,Homo sapiens,,CHEMBL619563,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,16381,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6345,Homo sapiens,,CHEMBL857457,GI values against A549 cells (lung cancer),,16381,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6346,Homo sapiens,,CHEMBL619564,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,,17206,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6347,Homo sapiens,,CHEMBL619565,Inhibitory activity against A549 human adenocarcinoma,,16325,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6348,Homo sapiens,,CHEMBL619566,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,,10708,,80682,,,BAO_0000218,,Intermediate,,9606.0,F,,A549
6349,Homo sapiens,,CHEMBL619567,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,,10708,,80682,,,BAO_0000218,,Intermediate,,9606.0,F,,A549
6350,Homo sapiens,,CHEMBL619568,Inhibitory activity against A549 lung adenocarcinoma cell line,,17376,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6351,Homo sapiens,,CHEMBL619569,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,,17376,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6352,Homo sapiens,,CHEMBL619570,Cytotoxicity against human A549 lung cells,,17488,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6353,Homo sapiens,,CHEMBL619571,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,,17404,,80682,,,BAO_0000218,,Intermediate,,9606.0,F,,A549
6354,Homo sapiens,,CHEMBL619572,Growth inhibition of A549 (human lung carcinoma) cell line.,,10958,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
6355,Homo sapiens,,CHEMBL619573,Effective dose required for inhibitory activity against A549 human tumor cell line.,,17099,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
6356,Homo sapiens,,CHEMBL619574,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,,17099,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6357,Homo sapiens,,CHEMBL619575,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,,4096,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6358,Homo sapiens,,CHEMBL619576,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,,4096,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
6359,Homo sapiens,,CHEMBL619577,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,,4096,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6360,Homo sapiens,,CHEMBL619578,In vitro inhibitory activity against A549 tumor cell culture,,2525,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6361,Homo sapiens,,CHEMBL884009,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,,2525,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6362,Homo sapiens,,CHEMBL619579,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),,5302,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6363,Homo sapiens,,CHEMBL619580,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,,16325,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6364,Homo sapiens,,CHEMBL619581,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,,16939,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6365,Homo sapiens,,CHEMBL619582,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,,17229,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6366,Homo sapiens,,CHEMBL619583,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,,17380,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6367,Homo sapiens,,CHEMBL876502,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,,17380,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6368,Homo sapiens,,CHEMBL619584,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,,1903,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6369,Homo sapiens,,CHEMBL619585,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,3838,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6370,Homo sapiens,,CHEMBL619586,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,14696,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6371,Homo sapiens,,CHEMBL619587,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,3838,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6372,Homo sapiens,,CHEMBL619588,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,,1522,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6373,Homo sapiens,,CHEMBL619589,Tested in vitro for cytotoxicity in A549/ATCC cell lines,,12400,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6374,Homo sapiens,,CHEMBL619590,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,14696,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6375,Homo sapiens,,CHEMBL619591,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),,14769,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6376,Homo sapiens,,CHEMBL619592,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,,14696,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6377,Homo sapiens,,CHEMBL619593,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,,1888,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6378,Homo sapiens,,CHEMBL620217,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,,12016,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6379,Homo sapiens,,CHEMBL620218,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,,6058,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6380,Homo sapiens,,CHEMBL620219,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,,17708,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6381,Homo sapiens,,CHEMBL620220,Antitumor activity against A549/ATCC cell line,,12301,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6382,Homo sapiens,,CHEMBL625141,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,,11970,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6383,Homo sapiens,,CHEMBL625142,In vitro cytotoxicity against A549/ATCC cell line.,,11818,,80682,,,BAO_0000219,,Expert,,9606.0,F,,A549
6384,Homo sapiens,,CHEMBL625143,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,,12400,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6385,Homo sapiens,,CHEMBL625144,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,,3381,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6386,Homo sapiens,,CHEMBL622474,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,,17376,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6387,Homo sapiens,,CHEMBL884104,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,,10708,,80682,,,BAO_0000219,,Intermediate,,9606.0,F,,A549
6388,Homo sapiens,,CHEMBL622475,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,,2964,,22226,,,BAO_0000219,,Autocuration,,9606.0,F,,
6389,Canis lupus familiaris,,CHEMBL622476,Compound was tested for oral bioavailability in dogs,In vivo,5005,,22224,,,BAO_0000218,,Intermediate,,9615.0,A,,
6390,Canis lupus familiaris,,CHEMBL875831,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,In vivo,6229,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6391,Canis lupus familiaris,,CHEMBL622477,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,In vivo,6229,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6392,Canis lupus familiaris,,CHEMBL622478,Oral bioavailability in dog,In vivo,5374,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6393,Canis lupus familiaris,,CHEMBL623172,Compound was tested for the oral bioavailability in dog; No availability,In vivo,5374,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6394,Canis lupus familiaris,,CHEMBL623173,Oral bioavailability in dog (dose 5 mg/kg),In vivo,6265,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6395,Canis lupus familiaris,,CHEMBL623174,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,In vivo,5654,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6396,Canis lupus familiaris,,CHEMBL623175,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,In vivo,5654,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6397,Canis lupus familiaris,,CHEMBL623340,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),In vivo,16456,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6398,Canis lupus familiaris,,CHEMBL623341,Oral bioavailability in dog (dose 5 mg/kg),In vivo,5302,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6399,Canis lupus familiaris,,CHEMBL623342,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),In vivo,3624,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6400,Canis lupus familiaris,,CHEMBL623343,Oral bioavailability of active FTIs in dogs,In vivo,16452,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6401,Canis lupus familiaris,,CHEMBL623344,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),In vivo,5802,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6402,Canis lupus familiaris,,CHEMBL623345,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,In vivo,3598,,50588,,,BAO_0000218,,Expert,,9615.0,A,,
6403,Canis lupus familiaris,,CHEMBL875832,Oral bioavailability in dog,In vivo,17839,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6404,Canis lupus familiaris,,CHEMBL623346,Oral bioavailability in dog,In vivo,6762,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6405,Canis lupus familiaris,,CHEMBL623347,Oral bioavailability in dog,In vivo,6821,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6406,Canis lupus familiaris,,CHEMBL623348,Oral bioavailability of compound was determined in dog; Not tested,In vivo,6821,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6407,Canis lupus familiaris,,CHEMBL623349,Oral bioavailability in dog,In vivo,5210,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6408,Canis lupus familiaris,,CHEMBL623350,Oral bioavailability (10 mg/kg) was determined in dog,In vivo,6227,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6409,Canis lupus familiaris,,CHEMBL623351,Oral bioavailability,In vivo,761,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6410,Canis lupus familiaris,,CHEMBL623352,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),In vivo,761,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6411,Canis lupus familiaris,,CHEMBL623353,Oral bioavailability administered in solution in rats,In vivo,761,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6412,Canis lupus familiaris,,CHEMBL875833,Oral bioavailability after 30 mg/kg po dose in Dogs,In vivo,16907,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6413,Canis lupus familiaris,,CHEMBL623354,Oral bioavailability at a dose of 1 mg/kg in dogs,In vivo,5474,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6414,Canis lupus familiaris,,CHEMBL623355,Oral bioavailability in dog (dose 1 mg/kg p.o.),In vivo,6535,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6415,Canis lupus familiaris,,CHEMBL623356,Oral bioavailability in Dog; ND = not determined,In vivo,6535,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6416,Canis lupus familiaris,,CHEMBL623357,Oral bioavailability in dog,In vivo,3352,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6417,Canis lupus familiaris,,CHEMBL623358,Oral bioavailability in dog,In vivo,6168,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6418,Canis lupus familiaris,,CHEMBL623359,Oral bioavailability in dog,In vivo,5988,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6419,Canis lupus familiaris,,CHEMBL623360,Oral bioavailability in dog,In vivo,4942,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6420,Canis lupus familiaris,,CHEMBL623361,Oral bioavailability in dogs; No data,In vivo,4942,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6421,Canis lupus familiaris,,CHEMBL623362,Oral bioavailability measured in dogs,In vivo,14541,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6422,Canis lupus familiaris,,CHEMBL623363,Oral bioavailability in dog,In vivo,4449,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6423,Canis lupus familiaris,,CHEMBL623364,Oral bioavailability was calculated in dog,In vivo,6057,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6424,Canis lupus familiaris,,CHEMBL875834,Oral bioavailability after 0.3 mg/kg po administration in dog,In vivo,5600,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6425,Canis lupus familiaris,,CHEMBL623365,Oral bioavailability in dog (i.v. dosing),In vivo,5542,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6426,Canis lupus familiaris,,CHEMBL623366,Oral bioavailability in dog,In vivo,5542,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6427,Canis lupus familiaris,,CHEMBL623367,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,In vivo,5546,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6428,Canis lupus familiaris,,CHEMBL623368,Oral bioavailability in Beagle dogs,In vivo,4514,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6429,Canis lupus familiaris,,CHEMBL623369,Oral bioavailability in dog,In vivo,3624,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6430,Canis lupus familiaris,,CHEMBL623370,Oral bioavailability in dog,In vivo,3854,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6431,Canis lupus familiaris,,CHEMBL623371,Oral bioavailability in dog,In vivo,5836,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6432,Canis lupus familiaris,,CHEMBL623372,Oral bioavailability in dog,In vivo,5940,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6433,Canis lupus familiaris,,CHEMBL621351,Oral bioavailability in dog,In vivo,6168,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6434,Canis lupus familiaris,,CHEMBL621352,Oral bioavailability in dog,In vivo,6227,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6435,Canis lupus familiaris,,CHEMBL621353,Oral bioavailability in dog,In vivo,6251,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6436,Canis lupus familiaris,,CHEMBL621354,Oral bioavailability in dog,In vivo,6448,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6437,Canis lupus familiaris,,CHEMBL621355,Oral bioavailability in dog,In vivo,6647,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6438,Canis lupus familiaris,,CHEMBL621356,Oral bioavailability in dog,In vivo,5940,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6439,Canis lupus familiaris,,CHEMBL621357,Oral bioavailability in dog,In vivo,933,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6440,Canis lupus familiaris,,CHEMBL621358,Oral bioavailability in dog,In vivo,5210,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6441,Canis lupus familiaris,,CHEMBL621359,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),In vivo,6642,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6442,Canis lupus familiaris,,CHEMBL621360,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),In vivo,6641,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6443,Canis lupus familiaris,,CHEMBL621361,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),In vivo,6642,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6444,Canis lupus familiaris,,CHEMBL621362,Oral bioavailability in dog,In vivo,5472,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6445,Canis lupus familiaris,,CHEMBL621363,Oral bioavailability in dog,In vivo,5985,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6446,Canis lupus familiaris,,CHEMBL621364,Oral bioavailability in dog,In vivo,15660,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6447,Canis lupus familiaris,,CHEMBL621166,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),In vivo,5530,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6448,Canis lupus familiaris,,CHEMBL621167,Oral bioavailability in dog (dose 1 mg/kg i.v.),In vivo,5530,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6449,Canis lupus familiaris,,CHEMBL621168,Oral bioavailability (F) in dogs,In vivo,6305,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6450,Canis lupus familiaris,,CHEMBL621169,Oral bioavailability in dog,In vivo,5210,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6451,Canis lupus familiaris,,CHEMBL875950,Bioavailability in dog,In vivo,5238,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6452,Canis lupus familiaris,,CHEMBL621170,Oral bioavailability in dog (dose 10 mg/kg),In vivo,5668,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6453,Canis lupus familiaris,,CHEMBL621171,Oral bioavailability after peroral administration at 5 mpk in Dog,In vivo,5668,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6454,Canis lupus familiaris,,CHEMBL621172,Oral bioavailability in dog (dose 5 mg/kg),In vivo,5668,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6455,Canis lupus familiaris,,CHEMBL621173,Oral bioavailability in dog (dose 10 mg/kg),In vivo,6084,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6456,Mus musculus,2113.0,CHEMBL621174,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,,6599,Kidney,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6457,Mus musculus,2113.0,CHEMBL621175,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,,6599,Kidney,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6458,Mus musculus,2107.0,CHEMBL621176,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,,6599,Liver,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6459,Mus musculus,2107.0,CHEMBL621177,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,,6599,Liver,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6460,Mus musculus,2107.0,CHEMBL621178,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,,6599,Liver,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6461,Mus musculus,2107.0,CHEMBL621179,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,,6599,Liver,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6462,Mus musculus,2107.0,CHEMBL621180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,,6599,Liver,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6463,Mus musculus,2048.0,CHEMBL875951,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,,6599,Lung,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6464,Mus musculus,2048.0,CHEMBL621181,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,,6599,Lung,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6465,Mus musculus,2048.0,CHEMBL621182,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,,6599,Lung,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6466,Mus musculus,2048.0,CHEMBL621183,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,,6599,Lung,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6467,Mus musculus,2048.0,CHEMBL621184,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,,6599,Lung,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6468,Mus musculus,,CHEMBL621185,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,,6599,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6469,Mus musculus,,CHEMBL621186,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,,6599,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6470,Mus musculus,,CHEMBL621187,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,,6599,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6471,Mus musculus,,CHEMBL621188,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,,6599,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6472,Mus musculus,,CHEMBL621189,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,,6599,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6473,Mus musculus,2106.0,CHEMBL621190,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,,6599,Spleen,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6474,Mus musculus,2106.0,CHEMBL618520,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,,6599,Spleen,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6475,Mus musculus,2106.0,CHEMBL621739,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,,6599,Spleen,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6476,Mus musculus,2106.0,CHEMBL621740,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,,6599,Spleen,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6477,Mus musculus,2106.0,CHEMBL621741,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,,6599,Spleen,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6478,Mus musculus,,CHEMBL621742,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,,6599,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6479,Mus musculus,,CHEMBL621743,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,,6599,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6480,Mus musculus,,CHEMBL621744,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,,6599,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6481,Mus musculus,,CHEMBL621745,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,,6599,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6482,Mus musculus,,CHEMBL621746,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,,6599,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6483,Mus musculus,,CHEMBL621747,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,,6599,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6484,Mus musculus,,CHEMBL621748,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,,6599,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6485,Mus musculus,,CHEMBL621749,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,,6599,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6486,Mus musculus,,CHEMBL621750,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,,6599,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6487,Mus musculus,,CHEMBL621751,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,,6599,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6488,Mus musculus,948.0,CHEMBL621752,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,,6599,Heart,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6489,Mus musculus,948.0,CHEMBL621753,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,,6599,Heart,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6490,Mus musculus,948.0,CHEMBL875955,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,,6599,Heart,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6491,Mus musculus,948.0,CHEMBL621754,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,,6599,Heart,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6492,Mus musculus,948.0,CHEMBL621755,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,,6599,Heart,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6493,Mus musculus,2107.0,CHEMBL621756,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,,6599,Liver,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6494,Mus musculus,2107.0,CHEMBL624199,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,,6599,Liver,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6495,Mus musculus,2107.0,CHEMBL624200,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,,6599,Liver,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6496,Mus musculus,2107.0,CHEMBL624375,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,,6599,Liver,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6497,Mus musculus,2107.0,CHEMBL624376,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,,6599,Liver,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6498,Mus musculus,2048.0,CHEMBL624377,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,,6599,Lung,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6499,Mus musculus,2048.0,CHEMBL624378,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,,6599,Lung,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6500,aeinetobacter anitrotap,,CHEMBL857901,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,12269,,50067,,,BAO_0000218,,Intermediate,,107673.0,F,,
6501,Acinetobacter calcoaceticus subsp. anitratus,,CHEMBL875274,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,12269,,50067,,,BAO_0000218,,Intermediate,,107673.0,F,,
6502,Acinetobacter calcoaceticus subsp. anitratus,,CHEMBL624379,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,12269,,50067,,,BAO_0000218,,Intermediate,,107673.0,F,,
6503,aeinetobacter anitrotap,,CHEMBL624380,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,12269,,50067,,,BAO_0000218,,Intermediate,,107673.0,F,,
6504,Acinetobacter calcoaceticus,,CHEMBL624381,Activity against Acinetobacter calcoaceticus (AC54),,10624,,50192,,,BAO_0000218,,Intermediate,,471.0,F,,
6505,Anolis carolinensis,,CHEMBL624382,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,,17216,,50714,,,BAO_0000218,,Intermediate,,28377.0,F,,
6506,Anolis carolinensis,,CHEMBL624383,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,,17216,,50714,,,BAO_0000218,,Intermediate,,28377.0,F,,
6507,Actinomyces naeslundii,,CHEMBL624384,Chlorohexidine coefficient for Actinomyces naeslundii 631,,9560,,50296,,,BAO_0000218,,Intermediate,,1655.0,F,,
6508,Actinomyces naeslundii,,CHEMBL624385,Chlorohexidine coefficient for Actinomyces naeslundii B74,,9560,,50296,,,BAO_0000218,,Intermediate,,1655.0,F,,
6509,Actinomyces naeslundii,,CHEMBL624386,Chlorohexidine coefficient for Actinomyces naeslundii N/3,,9560,,50296,,,BAO_0000218,,Intermediate,,1655.0,F,,
6510,Actinomyces naeslundii,,CHEMBL624387,Chlorohexidine coefficient for Actinomyces naeslundii N/9,,9560,,50296,,,BAO_0000218,,Intermediate,,1655.0,F,,
6511,Actinomyces naeslundii,,CHEMBL624388,Plaque bactericidal index against Actinomyces naeslundii 631,,9560,,50296,,,BAO_0000218,,Intermediate,,1655.0,F,,
6512,Actinomyces naeslundii,,CHEMBL624389,Plaque bactericidal index against Actinomyces naeslundii N/9,,9560,,50296,,,BAO_0000218,,Intermediate,,1655.0,F,,
6513,Actinomyces naeslundii,,CHEMBL624390,Plaque bactericidal index against Actinomyces naeslundii B74,,9560,,50296,,,BAO_0000218,,Intermediate,,1655.0,F,,
6514,Actinomyces naeslundii,,CHEMBL875275,Plaque bactericidal index against Actinomyces naeslundii N/3,,9560,,50296,,,BAO_0000218,,Intermediate,,1655.0,F,,
6515,Artemia salina,,CHEMBL624391,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,,114,,50056,,,BAO_0000218,,Intermediate,,85549.0,F,,
6516,Artemia salina,,CHEMBL623636,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",,114,,50056,,,BAO_0000218,,Intermediate,,85549.0,F,,
6517,Ascaris suum,,CHEMBL623637,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,,10841,,50532,,,BAO_0000218,,Intermediate,,6253.0,F,,
6518,Ascaris suum,,CHEMBL623638,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,,10841,,50532,,,BAO_0000218,,Intermediate,,6253.0,F,,
6519,Ascaris suum,,CHEMBL623639,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,,10841,,50532,,,BAO_0000218,,Intermediate,,6253.0,F,,
6520,Ascaris suum,,CHEMBL623640,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,,10841,,50532,,,BAO_0000218,,Intermediate,,6253.0,F,,
6521,Ascaris suum,,CHEMBL623641,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,,10841,,50532,,,BAO_0000218,,Intermediate,,6253.0,F,,
6522,Ascaris suum,,CHEMBL623642,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,,10841,,50532,,,BAO_0000218,,Intermediate,,6253.0,F,,
6523,Ascaris suum,,CHEMBL623643,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,,10841,,50532,,,BAO_0000218,,Intermediate,,6253.0,F,,
6524,Ascaris suum,,CHEMBL623644,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,,10841,,50532,,,BAO_0000218,,Intermediate,,6253.0,F,,
6525,Ascaris suum,,CHEMBL623645,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,,10841,,50532,,,BAO_0000218,,Intermediate,,6253.0,F,,
6526,Ascaris suum,,CHEMBL623646,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,,10841,,50532,,,BAO_0000218,,Intermediate,,6253.0,F,,
6527,Ascaris suum,,CHEMBL623647,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,,10841,,50532,,,BAO_0000218,,Intermediate,,6253.0,F,,
6528,Ascaris suum,,CHEMBL623648,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,,10841,,50532,,,BAO_0000218,,Intermediate,,6253.0,F,,
6529,Actinomyces viscosus,,CHEMBL623649,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,8117,,50366,,,BAO_0000218,,Intermediate,,1656.0,F,,
6530,Actinomyces viscosus,,CHEMBL623650,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,8117,,50366,,,BAO_0000218,,Intermediate,,1656.0,F,,
6531,Actinomyces viscosus,,CHEMBL623651,Chlorohexidine coefficient for Actinomyces viscosus 8A06,,9560,,50366,,,BAO_0000218,,Intermediate,,1656.0,F,,
6532,Actinomyces viscosus,,CHEMBL623652,Chlorohexidine coefficient for Actinomyces viscosus M-100,,9560,,50366,,,BAO_0000218,,Expert,,1656.0,F,,
6533,Actinomyces viscosus,,CHEMBL623653,Chlorohexidine coefficient for Actinomyces viscosus M-626,,9560,,50366,,,BAO_0000218,,Intermediate,,1656.0,F,,
6534,Actinomyces viscosus,,CHEMBL623654,Chlorohexidine coefficient for Actinomyces viscosus T14V,,9560,,50366,,,BAO_0000218,,Intermediate,,1656.0,F,,
6535,Actinomyces viscosus,,CHEMBL623655,Plaque bactericidal index against Actinomyces viscosus 8A06,,9560,,50366,,,BAO_0000218,,Intermediate,,1656.0,F,,
6536,Actinomyces viscosus,,CHEMBL623656,Plaque bactericidal index against Actinomyces viscosus M-100,,9560,,50366,,,BAO_0000218,,Intermediate,,1656.0,F,,
6537,Actinomyces viscosus,,CHEMBL623657,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,,9560,,50366,,,BAO_0000218,,Expert,,1656.0,F,,
6538,Actinomyces viscosus,,CHEMBL623658,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,9560,,50366,,,BAO_0000218,,Intermediate,,1656.0,F,,
6539,Actinomyces viscosus,,CHEMBL623659,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,9560,,50366,,,BAO_0000218,,Intermediate,,1656.0,F,,
6540,Actinomyces viscosus,,CHEMBL623660,Plaque bactericidal index against Actinomyces viscosus 626,,9560,,50366,,,BAO_0000218,,Intermediate,,1656.0,F,,
6541,Actinomyces viscosus,,CHEMBL623661,Plaque bactericidal index against Actinomyces viscosus T14V,,9560,,50366,,,BAO_0000218,,Intermediate,,1656.0,F,,
6542,Acanthocheilonema viteae,,CHEMBL875281,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,,10986,,50535,,,BAO_0000218,,Intermediate,,6277.0,F,,
6543,Acanthocheilonema viteae,,CHEMBL623662,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,,10986,,50535,,,BAO_0000218,,Intermediate,,6277.0,F,,
6544,Acanthocheilonema viteae,,CHEMBL623663,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,,10986,,50535,,,BAO_0000218,,Intermediate,,6277.0,F,,
6545,Acanthocheilonema viteae,,CHEMBL623664,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,,10986,,50535,,,BAO_0000218,,Intermediate,,6277.0,F,,
6546,Acanthocheilonema viteae,,CHEMBL623665,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,,10986,,50535,,,BAO_0000218,,Intermediate,,6277.0,F,,
6547,Homo sapiens,,CHEMBL621856,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,,10708,,80023,,,BAO_0000219,,Intermediate,,9606.0,F,,A673
6548,Homo sapiens,,CHEMBL620432,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,,10708,,80661,,,BAO_0000219,,Intermediate,,9606.0,F,,A704
6549,Rattus norvegicus,,CHEMBL620433,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,,416,,22226,,,BAO_0000219,,Autocuration,,10116.0,F,,
6550,Mus musculus,,CHEMBL620434,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,14354,,80024,,,BAO_0000219,,Intermediate,,10090.0,F,,A9
6551,Mus musculus,,CHEMBL620435,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,14354,,80024,,,BAO_0000219,,Intermediate,,10090.0,F,,A9
6552,Homo sapiens,,CHEMBL620436,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,,5116,,80024,,,BAO_0000219,,Intermediate,,9606.0,F,,A9
6553,Homo sapiens,,CHEMBL876597,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,,5116,,80024,,,BAO_0000219,,Intermediate,,9606.0,F,,A9
6554,Homo sapiens,,CHEMBL620437,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,,15694,,81037,,,BAO_0000219,,Expert,,9606.0,F,,Human ovarian carcinoma cell line
6555,Mus musculus,,CHEMBL620438,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",,13038,,80024,,,BAO_0000219,,Expert,,10090.0,F,,A9
6556,Mus musculus,,CHEMBL620439,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,,13038,,80024,,,BAO_0000219,,Expert,,10090.0,F,,A9
6557,Mus musculus,,CHEMBL619657,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,,10923,,80024,,,BAO_0000219,,Expert,,10090.0,F,,A9
6558,Mus musculus,,CHEMBL619658,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,,10923,,80024,,,BAO_0000219,,Intermediate,,10090.0,F,,A9
6559,Mus musculus,,CHEMBL619659,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,,10923,,80024,,,BAO_0000219,,Intermediate,,10090.0,F,,A9
6560,,,CHEMBL619660,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",,10923,,10649,,,BAO_0000019,,Expert,,,F,,
6561,Mus musculus,,CHEMBL619661,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,,10923,,80024,,,BAO_0000219,,Intermediate,,10090.0,F,,A9
6562,Mus musculus,,CHEMBL619662,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,,10923,,80024,,,BAO_0000219,,Intermediate,,10090.0,F,,A9
6563,Cricetulus griseus,,CHEMBL619663,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,,8158,,80663,,,BAO_0000219,,Intermediate,,10029.0,F,,AA6
6564,Homo sapiens,,CHEMBL619664,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,,15494,,22226,,,BAO_0000219,,Autocuration,,9606.0,F,,
6565,Homo sapiens,,CHEMBL619665,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",,15494,,22226,,,BAO_0000219,,Autocuration,,9606.0,F,,
6566,Homo sapiens,,CHEMBL883244,Anti -HIV activity was measured against AA5/HIV-1(IIIB),,12348,,80662,,,BAO_0000219,,Intermediate,,9606.0,F,,AA5
6567,Homo sapiens,,CHEMBL884011,Cytotoxicity was measured against AA5/HIV-1(IIIB),,12348,,80662,,,BAO_0000219,,Intermediate,,9606.0,F,,AA5
6568,Homo sapiens,,CHEMBL619666,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,,2726,,80662,,,BAO_0000219,,Intermediate,,9606.0,F,,AA5
6569,Homo sapiens,,CHEMBL619667,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,,2726,,80566,,,BAO_0000219,,Intermediate,,9606.0,F,,U-937
6570,Cricetulus griseus,,CHEMBL619668,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,,10747,,80578,,,BAO_0000219,,Intermediate,,10029.0,F,,UV4
6571,Cricetulus griseus,,CHEMBL619669,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,11005,,80089,,,BAO_0000219,,Expert,,10029.0,F,,CHO-AA8
6572,Cricetulus griseus,,CHEMBL876608,Average intracellular compound concentration when the hypoxic SER=1.6,,12687,,80089,,,BAO_0000219,,Intermediate,,10029.0,F,,CHO-AA8
6573,Cricetulus griseus,,CHEMBL619670,Average intracellular compound concentration when the hypoxic SER=1.6.,,12687,,80089,,,BAO_0000219,,Intermediate,,10029.0,F,,CHO-AA8
6574,Cricetulus griseus,,CHEMBL619671,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,,12687,,80089,,,BAO_0000219,,Intermediate,,10029.0,F,,CHO-AA8
6575,Cricetulus griseus,,CHEMBL619672,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,,12687,,80089,,,BAO_0000219,,Intermediate,,10029.0,F,,CHO-AA8
6576,Cricetulus griseus,,CHEMBL619673,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,,12687,,80089,,,BAO_0000219,,Intermediate,,10029.0,F,,CHO-AA8
6577,Cricetulus griseus,,CHEMBL619674,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",,13436,,80089,,,BAO_0000219,,Intermediate,,10029.0,F,,CHO-AA8
6578,Cricetulus griseus,,CHEMBL619675,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",,13435,,80089,,,BAO_0000219,,Intermediate,,10029.0,F,,CHO-AA8
6579,Cricetulus griseus,,CHEMBL619676,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,,13302,,80089,,,BAO_0000219,,Intermediate,,10029.0,F,,CHO-AA8
6580,Cricetulus griseus,,CHEMBL619677,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,12687,,80089,,,BAO_0000219,,Intermediate,,10029.0,F,,CHO-AA8
6581,Cricetulus griseus,,CHEMBL619678,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,12687,,80089,,,BAO_0000219,,Intermediate,,10029.0,A,,CHO-AA8
6582,Cricetulus griseus,,CHEMBL619679,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,,12687,,80089,,,BAO_0000219,,Intermediate,,10029.0,A,,CHO-AA8
6583,Cricetulus griseus,,CHEMBL619680,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,,12878,,80089,,,BAO_0000219,,Expert,,10029.0,A,,CHO-AA8
6584,Cricetulus griseus,,CHEMBL621457,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,,12878,,80089,,,BAO_0000219,,Intermediate,,10029.0,A,,CHO-AA8
6585,Cricetulus griseus,,CHEMBL876609,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,,14367,,80089,,,BAO_0000219,,Expert,,10029.0,F,,CHO-AA8
6586,Cricetulus griseus,,CHEMBL621458,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,,14367,,80089,,,BAO_0000219,,Intermediate,,10029.0,F,,CHO-AA8
6587,hampster,,CHEMBL621459,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,,12398,,80089,,,BAO_0000219,,Expert,,36483.0,F,,CHO-AA8
6588,Cricetulus griseus,,CHEMBL621460,Aerobic growth inhibition in Chinese hamster cell line AA8,,12878,,80089,,,BAO_0000219,,Expert,,10029.0,F,,CHO-AA8
6589,Cricetulus griseus,,CHEMBL621461,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,,13820,,80089,,,BAO_0000219,,Expert,,10029.0,F,,CHO-AA8
6590,Cricetulus griseus,,CHEMBL621462,Inhibition of growth under aerobic conditions in AA8 cells,,13436,,80089,,,BAO_0000219,,Expert,,10029.0,F,,CHO-AA8
6591,Canis lupus familiaris,,CHEMBL621463,Oral bioavailability in dog (dose 10 mg/kg),In vivo,6084,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6592,Canis lupus familiaris,,CHEMBL621464,Oral bioavailability in dog at 10 mg/kg of the compound,In vivo,5711,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6593,Canis lupus familiaris,,CHEMBL621465,Oral bioavailability in dog (dose 5 uM/kg),In vivo,4353,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6594,Canis lupus familiaris,,CHEMBL621466,Oral bioavailability in dog (dose 5 uM/kg),In vivo,4353,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6595,Canis lupus familiaris,,CHEMBL621467,Oral bioavailability in dog (mongrel),In vivo,17800,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6596,Canis lupus familiaris,,CHEMBL621468,Oral bioavailability in dog (dose 10 mg/kg),In vivo,3994,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6597,Canis lupus familiaris,,CHEMBL876734,Oral bioavailability in dog (dose 10 mg/kg),In vivo,3994,,50588,,,BAO_0000218,,Intermediate,,9615.0,F,,
6598,Canis lupus familiaris,,CHEMBL618476,Bioavailability in dog,In vivo,5145,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6599,Canis lupus familiaris,,CHEMBL618477,Bioavailability in dog (dose 1 mg/kg i.v.),In vivo,16452,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6600,Canis lupus familiaris,,CHEMBL618478,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),In vivo,16452,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6601,Canis lupus familiaris,,CHEMBL618479,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,In vivo,5983,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6602,Canis lupus familiaris,,CHEMBL618480,Bioavailability in dog,In vivo,4273,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6603,Canis lupus familiaris,,CHEMBL618481,Bioavailability in dog (dose 3-10 mg/kg),In vivo,12500,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6604,Canis lupus familiaris,1969.0,CHEMBL618482,The compound was tested for bioavailability of compound in plasma of dog; Complete,In vivo,12500,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6605,Canis lupus familiaris,,CHEMBL618483,Oral bioavailability in dog,In vivo,3639,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6606,Canis lupus familiaris,,CHEMBL618484,Oral bioavailability in dog,In vivo,3880,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6607,Canis lupus familiaris,,CHEMBL618485,Bioavailability in dog,In vivo,4838,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6608,Canis lupus familiaris,,CHEMBL618486,oral bioavailability was measured in dogs,In vivo,15600,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6609,Canis lupus familiaris,,CHEMBL618487,Compound was tested for plasma protein binding in dog; Not determined,,17248,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6610,Canis lupus familiaris,,CHEMBL618488,Compound was tested for plasma protein binding of dog,,17248,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6611,Canis lupus familiaris,,CHEMBL876735,Compound was tested for plasma protein binding of dog; Not determined,,17248,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6612,Canis lupus familiaris,,CHEMBL618489,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,,17443,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6613,Canis lupus familiaris,,CHEMBL618490,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,In vivo,4186,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6614,Canis lupus familiaris,,CHEMBL618491,Half life was determined,,3749,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6615,Canis lupus familiaris,,CHEMBL618492,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,In vivo,3249,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6616,Canis lupus familiaris,,CHEMBL873354,Half life was evaluated in dog,,3022,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6617,Canis lupus familiaris,,CHEMBL618493,Half life was determined,,3749,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6618,Canis lupus familiaris,,CHEMBL618494,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),In vivo,2517,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6619,Canis lupus familiaris,948.0,CHEMBL618495,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),In vivo,2517,Heart,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6620,Canis lupus familiaris,2113.0,CHEMBL618496,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),In vivo,2517,Kidney,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6621,Canis lupus familiaris,2107.0,CHEMBL618497,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),In vivo,2517,Liver,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6622,Canis lupus familiaris,2048.0,CHEMBL618498,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),In vivo,2517,Lung,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6623,Canis lupus familiaris,2106.0,CHEMBL618499,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),In vivo,2517,Spleen,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6624,Canis lupus familiaris,,CHEMBL876736,LogP in dog,,3639,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6625,Canis lupus familiaris,,CHEMBL618500,Partition coefficient (logP),,6227,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6626,Canis lupus familiaris,,CHEMBL857831,Partition coefficient in dog,,6227,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6627,Canis lupus familiaris,,CHEMBL618501,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,In vivo,17764,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6628,Canis lupus familiaris,,CHEMBL618502,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),In vivo,4809,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6629,Canis lupus familiaris,,CHEMBL618503,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,,5600,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6630,Canis lupus familiaris,,CHEMBL618504,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),,14294,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6631,Canis lupus familiaris,,CHEMBL618505,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),,14294,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6632,Canis lupus familiaris,,CHEMBL618506,Metabolism of compound in dog S9 microsomes; Trace,,14294,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6633,Canis lupus familiaris,2107.0,CHEMBL618507,In vitro metabolic potential in dog liver microsomes,,6251,Liver,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6634,Canis lupus familiaris,,CHEMBL876737,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,In vivo,3748,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6635,Canis lupus familiaris,,CHEMBL618508,Oral bioavailability in dog,In vivo,2713,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6636,Canis lupus familiaris,,CHEMBL618509,Oral bioavailability in dog,In vivo,6512,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6637,Canis lupus familiaris,,CHEMBL618510,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,In vivo,6679,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6638,Canis lupus familiaris,,CHEMBL618511,The compound was tested for bioavailability in dogs,In vivo,3749,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6639,Canis lupus familiaris,,CHEMBL618512,The compound was tested for oral bioavailability in dogs,In vivo,3749,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6640,Canis lupus familiaris,,CHEMBL618513,Oral bioavailability in dog,In vivo,6742,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6641,Canis lupus familiaris,,CHEMBL618514,Compound was tested for percent protein binding (PB) in dog,,6227,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6642,Canis lupus familiaris,,CHEMBL620052,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,,6874,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6643,Canis lupus familiaris,1969.0,CHEMBL620053,Compound was evaluated for plasma clearance.,In vivo,2877,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6644,Canis lupus familiaris,1969.0,CHEMBL620054,The compound was tested for plasma clearance in dog,In vivo,12500,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6645,Canis lupus familiaris,1969.0,CHEMBL620055,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,In vivo,12500,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6646,Canis lupus familiaris,,CHEMBL620056,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,,4709,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6647,Canis lupus familiaris,2107.0,CHEMBL620057,In vitro relative rate of metabolism was determined in dog liver microsomes,,5542,Liver,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6648,Canis lupus familiaris,,CHEMBL618939,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,In vivo,17594,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6649,Canis lupus familiaris,,CHEMBL618940,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,In vivo,2652,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6650,Canis lupus familiaris,,CHEMBL618941,Half life after intravenous administration in dogs at 1.2 uM/kg,In vivo,17764,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6651,Mus musculus,2048.0,CHEMBL624473,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,,6599,Lung,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6652,Mus musculus,2048.0,CHEMBL624474,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,,6599,Lung,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6653,Mus musculus,2048.0,CHEMBL624475,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,,6599,Lung,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6654,Mus musculus,,CHEMBL624476,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,,6599,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6655,Mus musculus,,CHEMBL623478,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,,6599,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6656,Mus musculus,,CHEMBL623479,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,,6599,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6657,Mus musculus,,CHEMBL623480,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,,6599,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6658,Mus musculus,,CHEMBL623481,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,,6599,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,CCRF S-180
6659,Mus musculus,955.0,CHEMBL623482,C2 in brain of mice at the oral dose of 50 mg/kg,,17641,Brain,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6660,Mus musculus,2113.0,CHEMBL623483,C2 in kidney of mice at the oral dose of 50 mg/kg,,17641,Kidney,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6661,Mus musculus,2107.0,CHEMBL623484,C2 in liver of mice at the oral dose of 50 mg/kg,,17641,Liver,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6662,Mus musculus,2048.0,CHEMBL623485,C2 in lungs of mice at the oral dose of 50 mg/kg,,17641,Lung,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6663,Mus musculus,2106.0,CHEMBL623486,C2 in spleen of mice at the oral dose of 50 mg/kg,,17641,Spleen,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6664,Mus musculus,,CHEMBL623487,Plasma clearance in mouse,In vivo,17852,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6665,Mus musculus,,CHEMBL623488,Clearance of compound after intravenous administration in mice at 24 uM/kg,In vivo,17764,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6666,Mus musculus,,CHEMBL623489,Clearance from mouse blood following i.v. administration of 10 mg/kg,In vivo,17837,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6667,Mus musculus,,CHEMBL875157,Clearance was evaluated in mice after intravenous administration,In vivo,2675,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6668,Mus musculus,,CHEMBL623490,Clearance was evaluated in mice after oral administration,In vivo,2675,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6669,Mus musculus,,CHEMBL623491,Pharmacokinetic property (Plasma clearance) was measured in mouse,In vivo,4239,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6670,Mus musculus,,CHEMBL623492,Plasma clearance of compound was determined at 40 mg/Kg,In vivo,17753,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6671,Mus musculus,,CHEMBL623493,Plasma clearance of at 24 mg/Kg,In vivo,17753,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6672,Mus musculus,,CHEMBL623494,Plasma clearance at 24 mg/Kg,In vivo,17753,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6673,Mus musculus,,CHEMBL623495,Plasma clearance at 5 mg/Kg,In vivo,17753,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6674,Mus musculus,,CHEMBL623496,Plasma clearance in mice,In vivo,5727,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6675,Mus musculus,,CHEMBL623497,Plasma clearance value upon iv administration in mouse,In vivo,2862,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6676,Mus musculus,1969.0,CHEMBL623498,Total plasma clearance in mice,In vivo,5980,Plasma,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6677,Mus musculus,,CHEMBL623499,Clearance in mouse,In vivo,17592,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6678,Mus musculus,,CHEMBL623500,Clearance value was determined,In vivo,17718,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6679,Mus musculus,,CHEMBL623501,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,In vivo,16597,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6680,,,CHEMBL875158,Calculated partition coefficient (clogP),,17384,,22229,,,BAO_0000100,,Intermediate,,,P,,
6681,Mus musculus,,CHEMBL623502,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,In vivo,6062,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6682,Mus musculus,,CHEMBL623503,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,In vivo,17734,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6683,Mus musculus,,CHEMBL623504,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,In vivo,6348,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6684,Mus musculus,,CHEMBL623505,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,In vivo,5969,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6685,Mus musculus,,CHEMBL623506,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,In vivo,5969,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6686,Mus musculus,,CHEMBL623507,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,In vivo,5969,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6687,Mus musculus,,CHEMBL623508,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,In vivo,16597,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6688,Mus musculus,,CHEMBL623509,Cmax after oral administration at 30 mg/kg in ICR mouse,In vivo,5781,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6689,Mus musculus,,CHEMBL875159,Cmax after peroral administration in mice at 2.4 uM/kg,In vivo,17764,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6690,Mus musculus,955.0,CHEMBL623510,Cmax in brain of mice at the oral dose of 50 mg/kg,In vivo,17641,Brain,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6691,Mus musculus,2113.0,CHEMBL623511,Cmax in kidney of mice at the oral dose of 50 mg/kg,In vivo,17641,Kidney,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6692,Mus musculus,2107.0,CHEMBL623512,Cmax in liver of mice at the oral dose of 50 mg/kg,In vivo,17641,Liver,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6693,Mus musculus,2048.0,CHEMBL623513,Cmax in lungs of mice at the oral dose of 50 mg/kg,In vivo,17641,Lung,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6694,Mus musculus,,CHEMBL623514,Cmax in mice at 18 uM/kg i.p. administration,In vivo,17764,,50594,,,BAO_0000218,,Intermediate,,10090.0,F,,
6695,Mus musculus,,CHEMBL622609,Cmax in mice at 23 uM/kg i.v. administration,In vivo,17764,,50594,,,BAO_0000218,,Intermediate,,10090.0,F,,
6696,Mus musculus,,CHEMBL622610,Cmax in mice at 24 uM/kg i.p. administration,In vivo,17764,,50594,,,BAO_0000218,,Intermediate,,10090.0,F,,
6697,Mus musculus,,CHEMBL621823,Cmax in mice at 25 uM/kg i.p. administration,In vivo,17764,,50594,,,BAO_0000218,,Intermediate,,10090.0,F,,
6698,Mus musculus,,CHEMBL621824,Cmax in mice at 26 uM/kg i.p. administration,In vivo,17764,,50594,,,BAO_0000218,,Intermediate,,10090.0,F,,
6699,Mus musculus,2106.0,CHEMBL621825,Cmax in spleen of mice at the oral dose of 50 mg/kg,In vivo,17641,Spleen,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6700,Mus musculus,,CHEMBL621826,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,In vivo,16597,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6701,Mus musculus,,CHEMBL621827,Cmax value at a dose of 10 mg/kg peroral administration in mice.,In vivo,16597,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6702,Mus musculus,,CHEMBL621828,Cmax value was determined,In vivo,5727,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6703,Mus musculus,,CHEMBL621829,Cmax value in IRC mice,In vivo,5951,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6704,Mus musculus,,CHEMBL621830,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,In vivo,5506,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6705,Mus musculus,,CHEMBL621831,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,In vivo,5506,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6706,Mus musculus,1969.0,CHEMBL621832,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,In vivo,14239,Plasma,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6707,Mus musculus,1969.0,CHEMBL624579,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",In vivo,4890,Plasma,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6708,Mus musculus,,CHEMBL624580,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,In vivo,429,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6709,Acanthocheilonema viteae,,CHEMBL624581,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,,10986,,50535,,,BAO_0000218,,Intermediate,,6277.0,F,,
6710,Acanthocheilonema viteae,,CHEMBL624582,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,,10986,,50535,,,BAO_0000218,,Intermediate,,6277.0,F,,
6711,Acanthocheilonema viteae,,CHEMBL624583,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,,10986,,50535,,,BAO_0000218,,Intermediate,,6277.0,F,,
6712,Homo sapiens,,CHEMBL624584,Inhibitory activity against human tumor cell line A0375 melanoma.,,13227,,80018,,,BAO_0000219,,Intermediate,,9606.0,F,,A-375
6713,Rattus norvegicus,,CHEMBL624585,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,,4481,,12512,,,BAO_0000249,,Expert,Brain membranes,10116.0,B,,
6714,Homo sapiens,,CHEMBL875165,Forskolin-induced cAMP production at human A1 adenosine receptor,,16931,,114,,,BAO_0000019,,Expert,,9606.0,F,,
6715,,,CHEMBL619490,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,,3850,,114,,,BAO_0000219,,Autocuration,,,F,,CHO
6716,,,CHEMBL619491,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,3850,,114,,,BAO_0000219,,Autocuration,,,F,,CHO
6717,,,CHEMBL619492,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,,3850,,114,,,BAO_0000219,,Expert,,,F,,CHO
6718,,,CHEMBL619493,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,,3850,,114,,,BAO_0000219,,Expert,,,F,,CHO
6719,,,CHEMBL619494,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,,3850,,114,,,BAO_0000219,,Autocuration,,,F,,CHO
6720,,,CHEMBL619495,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,,3850,,114,,,BAO_0000219,,Autocuration,,,F,,CHO
6721,,,CHEMBL619496,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,,3850,,114,,,BAO_0000219,,Autocuration,,,F,,CHO
6722,Homo sapiens,,CHEMBL619497,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,3850,,114,,,BAO_0000219,,Expert,,9606.0,F,,CHO
6723,,,CHEMBL619498,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,,3850,,114,,,BAO_0000219,,Autocuration,,,F,,CHO
6724,,,CHEMBL619499,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,,3850,,114,,,BAO_0000219,,Autocuration,,,F,,CHO
6725,,,CHEMBL619500,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,,3850,,114,,,BAO_0000219,,Expert,,,F,,CHO
6726,,,CHEMBL619501,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,,3850,,114,,,BAO_0000219,,Autocuration,,,F,,CHO
6727,,,CHEMBL619502,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,,3850,,114,,,BAO_0000219,,Expert,,,F,,CHO
6728,,,CHEMBL619503,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,,3850,,114,,,BAO_0000219,,Autocuration,,,F,,CHO
6729,,,CHEMBL619504,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,3850,,114,,,BAO_0000219,,Autocuration,,,F,,CHO
6730,,,CHEMBL621298,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,,3850,,114,,,BAO_0000219,,Autocuration,,,F,,CHO
6731,,,CHEMBL621299,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,,3850,,114,,,BAO_0000219,,Expert,,,F,,CHO
6732,,,CHEMBL621300,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,,3850,,114,,,BAO_0000219,,Autocuration,,,F,,CHO
6733,,,CHEMBL621301,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,,3850,,114,,,BAO_0000219,,Autocuration,,,F,,CHO
6734,,,CHEMBL621302,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,3850,,114,,,BAO_0000219,,Expert,,,F,,CHO
6735,Oryctolagus cuniculus,,CHEMBL621303,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,,12680,,80013,,,BAO_0000219,,Intermediate,,9986.0,F,,A10
6736,Rattus norvegicus,,CHEMBL621304,In vitro potassium channel opening activity in A10 (smooth muscle) cells,,1313,,22226,,,BAO_0000219,,Autocuration,,10116.0,F,,A10
6737,Rattus norvegicus,,CHEMBL621305,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,,1313,,22226,,,BAO_0000219,,Autocuration,,10116.0,F,,A10
6738,Rattus norvegicus,,CHEMBL621306,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,,17567,,80013,,,BAO_0000219,,Intermediate,,10116.0,F,,A10
6739,Rattus norvegicus,,CHEMBL618444,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,,17567,,80013,,,BAO_0000219,,Intermediate,,10116.0,F,,A10
6740,Rattus norvegicus,,CHEMBL618445,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,,11819,,80013,,,BAO_0000219,,Intermediate,,10116.0,F,,A10
6741,Cricetulus griseus,,CHEMBL618446,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,,13436,,80089,,,BAO_0000219,,Intermediate,,10029.0,F,,CHO-AA8
6742,Cricetulus griseus,,CHEMBL618447,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,,12687,,80089,,,BAO_0000219,,Intermediate,,10029.0,F,,CHO-AA8
6743,Cricetulus griseus,,CHEMBL618448,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,,12651,,80089,,,BAO_0000219,,Intermediate,,10029.0,F,,CHO-AA8
6744,Cricetulus griseus,,CHEMBL618449,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,,13300,,80089,,,BAO_0000219,,Intermediate,,10029.0,F,,CHO-AA8
6745,Cricetulus griseus,,CHEMBL618637,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,15296,,80089,,,BAO_0000219,,Intermediate,,10029.0,F,,CHO-AA8
6746,Cricetulus griseus,,CHEMBL618638,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",,15328,,80089,,,BAO_0000219,,Intermediate,,10029.0,F,,CHO-AA8
6747,Cricetulus griseus,,CHEMBL618639,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),,13302,,80089,,,BAO_0000219,,Intermediate,,10029.0,F,,CHO-AA8
6748,Cricetulus griseus,,CHEMBL618640,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",,14367,,80089,,,BAO_0000219,,Expert,,10029.0,F,,CHO-AA8
6749,Cricetulus griseus,,CHEMBL618641,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,,17002,,80089,,,BAO_0000219,,Expert,,10029.0,F,,CHO-AA8
6750,Cricetulus griseus,,CHEMBL618642,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,,13436,,80089,,,BAO_0000219,,Intermediate,,10029.0,F,,CHO-AA8
6751,Cricetulus griseus,,CHEMBL618643,Inhibitory activity against aerobic growth of AA8 cells.,,13435,,80089,,,BAO_0000219,,Intermediate,,10029.0,F,,CHO-AA8
6752,Cricetulus griseus,,CHEMBL884013,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,10503,,80089,,,BAO_0000219,,Intermediate,,10029.0,A,,CHO-AA8
6753,Cricetulus griseus,,CHEMBL622723,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,10503,,80089,,,BAO_0000219,,Expert,,10029.0,F,,CHO-AA8
6754,Cricetulus griseus,,CHEMBL622724,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,10503,,80089,,,BAO_0000219,,Intermediate,,10029.0,F,,CHO-AA8
6755,Cricetulus griseus,,CHEMBL622725,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,,15090,,80089,,,BAO_0000219,,Expert,,10029.0,F,,CHO-AA8
6756,Cricetulus griseus,,CHEMBL622726,Cytotoxicity against AA8 cell line,,10368,,80089,,,BAO_0000219,,Expert,,10029.0,F,,CHO-AA8
6757,Cricetulus griseus,,CHEMBL622727,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),,12651,,80089,,,BAO_0000219,,Intermediate,,10029.0,F,,CHO-AA8
6758,Cricetulus griseus,,CHEMBL622728,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,12687,,80089,,,BAO_0000219,,Intermediate,,10029.0,A,,CHO-AA8
6759,Cricetulus griseus,,CHEMBL622729,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,12687,,80089,,,BAO_0000219,,Intermediate,,10029.0,F,,CHO-AA8
6760,Cricetulus griseus,,CHEMBL622730,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,12687,,80089,,,BAO_0000219,,Intermediate,,10029.0,A,,CHO-AA8
6761,Cricetulus griseus,,CHEMBL622731,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,,1890,,80089,,,BAO_0000219,,Intermediate,,10029.0,F,,CHO-AA8
6762,Cricetulus griseus,,CHEMBL622732,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,10747,,80089,,,BAO_0000219,,Intermediate,,10029.0,F,,CHO-AA8
6763,Cricetulus griseus,,CHEMBL622733,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,10747,,80089,,,BAO_0000219,,Intermediate,,10029.0,F,,CHO-AA8
6764,Cricetulus griseus,,CHEMBL622734,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),,11616,,22224,,,BAO_0000218,,Autocuration,,10029.0,F,,
6765,Cricetulus griseus,,CHEMBL622735,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,,11616,,80089,,,BAO_0000219,,Expert,,10029.0,F,,CHO-AA8
6766,Cricetulus griseus,,CHEMBL618746,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,,3471,,22224,,,BAO_0000219,,Autocuration,,10029.0,F,,CHO-AA8
6767,Cricetulus griseus,,CHEMBL618747,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,,3471,,22224,,,BAO_0000219,,Autocuration,,10029.0,F,,CHO-AA8
6768,Cricetulus griseus,,CHEMBL620540,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,,3471,,22224,,,BAO_0000219,,Autocuration,,10029.0,F,,CHO-AA8
6769,Cricetulus griseus,,CHEMBL620541,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,,3471,,22224,,,BAO_0000219,,Autocuration,,10029.0,F,,CHO-AA8
6770,Cricetulus griseus,,CHEMBL620542,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,,3471,,22224,,,BAO_0000219,,Autocuration,,10029.0,F,,CHO-AA8
6771,Cricetulus griseus,,CHEMBL620543,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,,3471,,22224,,,BAO_0000219,,Autocuration,,10029.0,F,,CHO-AA8
6772,Cricetulus griseus,,CHEMBL618832,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,,3471,,22224,,,BAO_0000219,,Autocuration,,10029.0,F,,CHO-AA8
6773,Cricetulus griseus,,CHEMBL618833,Concentration required to reduce AA8 cell survival by 10%,,11616,,80089,,,BAO_0000219,,Expert,,10029.0,F,,CHO-AA8
6774,Cricetulus griseus,,CHEMBL618834,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",,2656,,22224,,,BAO_0000219,,Autocuration,,10029.0,F,,CHO-AA8
6775,Cricetulus griseus,,CHEMBL618835,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,10518,,22224,,,BAO_0000219,,Autocuration,,10029.0,F,,CHO-AA8
6776,Cricetulus griseus,,CHEMBL618836,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,10518,,22224,,,BAO_0000219,,Autocuration,,10029.0,F,,CHO-AA8
6777,Cricetulus griseus,,CHEMBL618837,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,,10518,,22224,,,BAO_0000219,,Autocuration,,10029.0,F,,CHO-AA8
6778,Cricetulus griseus,,CHEMBL618838,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,,10518,,22224,,,BAO_0000219,,Autocuration,,10029.0,F,,CHO-AA8
6779,Cricetulus griseus,,CHEMBL618839,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,,16156,,22224,,,BAO_0000219,,Autocuration,,10029.0,F,,CHO-AA8
6780,Cricetulus griseus,,CHEMBL618840,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,,2656,,22224,,,BAO_0000219,,Autocuration,,10029.0,F,,CHO-AA8
6781,Cricetulus griseus,,CHEMBL618841,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,11005,,22224,,,BAO_0000019,,Autocuration,,10029.0,F,,
6782,Cricetulus griseus,,CHEMBL618842,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,,11942,,22224,,,BAO_0000219,,Autocuration,,10029.0,F,,CHO-AA8
6783,Cricetulus griseus,,CHEMBL618843,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,,2128,,22224,,,BAO_0000219,,Autocuration,,10029.0,F,,CHO-AA8
6784,Canis lupus familiaris,,CHEMBL618844,Half life period after 15 mg/kg iv dose in Dogs,In vivo,16907,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6785,Canis lupus familiaris,,CHEMBL618845,Half life period after 30 mg/kg po dose in Dogs,In vivo,16907,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6786,Canis lupus familiaris,,CHEMBL618846,Half life was measured after oral 2b administration (tested in 6 dogs),In vivo,9579,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6787,Canis lupus familiaris,,CHEMBL618847,Half life was measured in dog after oral 17b administration,In vivo,9579,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6788,Canis lupus familiaris,,CHEMBL618848,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,In vivo,9579,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6789,Canis lupus familiaris,,CHEMBL618849,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,In vivo,9579,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6790,Canis lupus familiaris,,CHEMBL618850,Tmax value after 15 mg/kg iv dose in Dogs,In vivo,16907,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6791,Canis lupus familiaris,,CHEMBL618851,Tmax value after 30 mg/kg po dose in Dogs,In vivo,16907,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6792,Canis lupus familiaris,,CHEMBL873815,Compound was evaluated for its half life when administered intravenously in dog,In vivo,3184,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6793,Canis lupus familiaris,1969.0,CHEMBL618852,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),In vivo,5017,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6794,Canis lupus familiaris,,CHEMBL618853,Elimination Half-life of compound was determined in dog,,6821,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6795,Canis lupus familiaris,,CHEMBL618854,Half life of compound in dog following oral administration,In vivo,17839,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6796,Canis lupus familiaris,,CHEMBL618855,Half life of compound was determined in dog,,17267,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6797,Canis lupus familiaris,178.0,CHEMBL618856,Half life of compound was determined in dog blood,,4727,Blood,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6798,Canis lupus familiaris,,CHEMBL875827,Half life after oral and iv dosing in dogs,In vivo,5238,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6799,Canis lupus familiaris,,CHEMBL618857,Half life in dogs in hours,,4942,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6800,Canis lupus familiaris,,CHEMBL618858,Half life on i.v. administration of 2 mg/kg was measured in dog,In vivo,6505,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6801,Canis lupus familiaris,,CHEMBL618859,t1/2 in dog after oral dose (1 mg/kg),In vivo,5130,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6802,Canis lupus familiaris,,CHEMBL618860,Half life was evaluated in dog,,1475,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6803,Canis lupus familiaris,,CHEMBL618861,Half life period of compound was determined after intravenous administration at 2 mg/kg,In vivo,17804,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6804,Canis lupus familiaris,,CHEMBL622539,Half life period of compound was determined after peroral administration at 2 mg/kg,In vivo,17804,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6805,Canis lupus familiaris,,CHEMBL622540,Half life period (10 mg/kg) was determined in dog,In vivo,6084,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6806,Canis lupus familiaris,,CHEMBL873803,Half life period (10 mg/kg) was determined in dog,In vivo,6084,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6807,Canis lupus familiaris,,CHEMBL873804,Half life period by iv administration in dog at a dose of 0.3 mg/kg,In vivo,5542,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6808,Canis lupus familiaris,,CHEMBL624311,Half life period by po administration in dog at a dose of 0.3 mg/kg,In vivo,5542,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6809,Canis lupus familiaris,,CHEMBL624312,Half life period in dog,,6084,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6810,Canis lupus familiaris,,CHEMBL624313,Half life period in dogs after oral administration at 1 mg/kg,In vivo,6241,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6811,Canis lupus familiaris,,CHEMBL624314,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,In vivo,1916,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6812,Canis lupus familiaris,,CHEMBL624315,Half-life of compound was determined in dogs,,6621,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6813,Canis lupus familiaris,1969.0,CHEMBL624316,Half-life in dog plasma,,1696,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6814,Canis lupus familiaris,,CHEMBL624317,Half-life in mongrel dogs was determined,,17800,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6815,Canis lupus familiaris,,CHEMBL624318,Half-life in dog upon oral administration,In vivo,17657,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6816,Canis lupus familiaris,,CHEMBL624319,Half-life in dog upon oral administration; Unable to calculate,In vivo,17657,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6817,Canis lupus familiaris,,CHEMBL624496,Half-life was measured in dog,,4239,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6818,Canis lupus familiaris,,CHEMBL624497,Half-life was measured in dog,,5985,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6819,Canis lupus familiaris,,CHEMBL624498,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,,9932,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6820,Canis lupus familiaris,,CHEMBL624499,Oral half life was determined,In vivo,5199,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6821,Canis lupus familiaris,1969.0,CHEMBL624500,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,In vivo,5199,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6822,Canis lupus familiaris,1969.0,CHEMBL624501,Plasma half life was evaluated,,1475,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6823,Canis lupus familiaris,1969.0,CHEMBL623666,Plasma half life was evaluated in Dog,,1475,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6824,Canis lupus familiaris,1969.0,CHEMBL623667,Plasma half life was evaluated in dog,,1475,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6825,Canis lupus familiaris,,CHEMBL623668,T1/2 (Half-life) was after oral administration at 5 mg/kg,In vivo,6316,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6826,Canis lupus familiaris,,CHEMBL623669,Tested for the half life value in dog,,4883,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6827,Canis lupus familiaris,,CHEMBL623670,Maximum time at the dose of 2 mg/kg in dog,In vivo,4727,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6828,Canis lupus familiaris,,CHEMBL623671,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,In vivo,1916,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6829,Canis lupus familiaris,178.0,CHEMBL875945,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,In vivo,1337,Blood,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6830,Canis lupus familiaris,178.0,CHEMBL623672,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,In vivo,1337,Blood,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6831,Canis lupus familiaris,,CHEMBL623673,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,In vivo,6265,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6832,Canis lupus familiaris,,CHEMBL623674,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),In vivo,4809,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6833,Canis lupus familiaris,,CHEMBL623675,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,In vivo,5983,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6834,Canis lupus familiaris,,CHEMBL872526,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",,5313,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6835,Canis lupus familiaris,,CHEMBL623676,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",In vivo,5313,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6836,Canis lupus familiaris,1969.0,CHEMBL623677,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,In vivo,17650,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6837,Canis lupus familiaris,1969.0,CHEMBL623678,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,In vivo,5199,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6838,Canis lupus familiaris,1969.0,CHEMBL623679,Time taken for maximum plasma concentration in dog,,933,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6839,Canis lupus familiaris,,CHEMBL623680,Time to reach Cmax after oral administration to dogs,In vivo,16367,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6840,Canis lupus familiaris,1969.0,CHEMBL623681,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,In vivo,6348,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6841,Canis lupus familiaris,,CHEMBL623682,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,In vivo,6316,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6842,Canis lupus familiaris,,CHEMBL623683,Tmax after peroral administration (1 mg/kg) was determined in dog,In vivo,6215,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6843,Canis lupus familiaris,,CHEMBL623684,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,In vivo,3598,,50588,,,BAO_0000218,,Expert,,9615.0,A,,
6844,Canis lupus familiaris,,CHEMBL622745,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,In vivo,4527,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6845,Canis lupus familiaris,,CHEMBL622746,Tmax after peroral administration in dogs at 2.4 uM/kg,In vivo,17764,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6846,Mus musculus,,CHEMBL622747,In vivo Cmax in mice at dose of 100 mg/kg,In vivo,5969,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6847,Mus musculus,,CHEMBL622748,In vivo Cmax in mice at dose of 50 mg/kg,In vivo,5969,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6848,Mus musculus,,CHEMBL622749,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,In vivo,4573,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6849,Mus musculus,1969.0,CHEMBL622750,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),In vivo,3277,Plasma,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6850,Mus musculus,1969.0,CHEMBL623411,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,In vivo,17734,Plasma,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6851,Mus musculus,1969.0,CHEMBL875946,Maximum concentration obtained in mouse plasma was determined,In vivo,3132,Plasma,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6852,Mus musculus,1969.0,CHEMBL623412,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,In vivo,3132,Plasma,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6853,Mus musculus,1969.0,CHEMBL623413,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,In vivo,6348,Plasma,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6854,Mus musculus,1969.0,CHEMBL623414,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,In vivo,17729,Plasma,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6855,Mus musculus,1969.0,CHEMBL623415,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,In vivo,17729,Plasma,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6856,Mus musculus,1969.0,CHEMBL623416,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,In vivo,17729,Plasma,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6857,Mus musculus,1969.0,CHEMBL623417,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,In vivo,17728,Plasma,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6858,Mus musculus,1969.0,CHEMBL623418,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,In vivo,17728,Plasma,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6859,Mus musculus,1969.0,CHEMBL623419,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,In vivo,17728,Plasma,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6860,Mus musculus,,CHEMBL622816,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,In vivo,4066,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6861,Mus musculus,,CHEMBL623313,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,In vivo,6178,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6862,Mus musculus,,CHEMBL623314,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,In vivo,6178,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6863,Mus musculus,,CHEMBL876788,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,In vivo,3760,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6864,Mus musculus,,CHEMBL623315,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,In vivo,3760,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6865,Mus musculus,,CHEMBL623316,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,In vivo,3760,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6866,Mus musculus,,CHEMBL623317,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,In vivo,3760,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6868,Mus musculus,,CHEMBL623319,Cmax in male mice after 2 mg/kg oral dose,In vivo,5961,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6869,Mus musculus,,CHEMBL623320,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,In vivo,6137,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6870,Mus musculus,,CHEMBL623321,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,In vivo,3802,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6871,Mus musculus,,CHEMBL623322,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,,3535,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6872,Mus musculus,,CHEMBL623323,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,,3535,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6873,Mus musculus,,CHEMBL623324,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,,3535,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6874,Mus musculus,,CHEMBL623325,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,,3535,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6875,Mus musculus,,CHEMBL623326,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,,3535,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6876,Mus musculus,,CHEMBL623327,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,,3535,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6877,Mus musculus,1969.0,CHEMBL623328,Maximum concentration in plasma upon oral administration in mouse,,2862,Plasma,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6878,Mus musculus,1969.0,CHEMBL623329,Maximum plasma concentration was evaluated in mice after oral administration,,2675,Plasma,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6879,Mus musculus,1969.0,CHEMBL623330,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,In vivo,2675,Plasma,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6880,Mus musculus,,CHEMBL876789,Dose at which the compound induced fecal excretion in mice,,5399,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
6893,Rattus norvegicus,,CHEMBL623333,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,,11819,,80013,,,BAO_0000219,,Expert,,10116.0,F,,A10
6894,Rattus norvegicus,,CHEMBL623334,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,,11819,,80013,,,BAO_0000219,,Expert,,10116.0,F,,A10
6895,Rattus norvegicus,,CHEMBL627536,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,,11819,,80013,,,BAO_0000219,,Expert,,10116.0,F,,A10
6896,Rattus norvegicus,,CHEMBL627537,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,,11819,,80013,,,BAO_0000219,,Expert,,10116.0,F,,A10
6897,Rattus norvegicus,,CHEMBL627538,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),,16361,,80013,,,BAO_0000219,,Intermediate,,10116.0,F,,A10
6898,Homo sapiens,,CHEMBL884106,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,,2288,,80655,,,BAO_0000219,,Intermediate,,9606.0,F,,A121
6899,Homo sapiens,,CHEMBL625294,Anticancer activity against human ovarian carcinoma A121 cells,,10404,,80655,,,BAO_0000219,,Intermediate,,9606.0,F,,A121
6900,Homo sapiens,,CHEMBL625295,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,,14790,,80655,,,BAO_0000219,,Intermediate,,9606.0,F,,A121
6901,Homo sapiens,,CHEMBL625296,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,,14790,,80655,,,BAO_0000219,,Intermediate,,9606.0,F,,A121
6902,Homo sapiens,,CHEMBL625297,Growth inhibition of human ovarian carcinoma (A121) cell line,,14253,,80655,,,BAO_0000219,,Expert,,9606.0,F,,A121
6903,Homo sapiens,,CHEMBL625298,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,,13617,,80655,,,BAO_0000219,,Expert,,9606.0,F,,A121
6904,Homo sapiens,,CHEMBL625960,Cytotoxicity against human A121 ovarian cells,,1003,,80655,,,BAO_0000219,,Intermediate,,9606.0,F,,A121
6905,Homo sapiens,,CHEMBL625961,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,,830,,80655,,,BAO_0000219,,Intermediate,,9606.0,F,,A121
6906,Homo sapiens,,CHEMBL625962,In vitro cytotoxicity against human ovarian carcinoma A21,,12307,,80655,,,BAO_0000219,,Intermediate,,9606.0,F,,A121
6907,Homo sapiens,,CHEMBL624717,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,,14254,,80655,,,BAO_0000219,,Intermediate,,9606.0,F,,A121
6908,Homo sapiens,,CHEMBL624718,Inhibitory activity of compound against human A121 ovarian cell line.,,13370,,80655,,,BAO_0000219,,Intermediate,,9606.0,F,,A121
6909,Homo sapiens,,CHEMBL624719,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,,14790,,80655,,,BAO_0000219,,Intermediate,,9606.0,F,,A121
6910,Homo sapiens,,CHEMBL624720,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,,3614,,80655,,,BAO_0000219,,Intermediate,,9606.0,F,,A121
6911,Homo sapiens,,CHEMBL624721,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,,2664,,80012,,,BAO_0000219,,Intermediate,,9606.0,F,,A 172
6912,Homo sapiens,,CHEMBL624722,In vitro cytotoxicity against A172 human tumor cell lines.,,2037,,80012,,,BAO_0000219,,Expert,,9606.0,F,,A 172
6913,Homo sapiens,,CHEMBL877597,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,,14539,,80012,,,BAO_0000219,,Intermediate,,9606.0,F,,A 172
6914,Homo sapiens,,CHEMBL624723,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,,2836,,80012,,,BAO_0000219,,Intermediate,,9606.0,F,,A 172
6915,Homo sapiens,,CHEMBL624724,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,,10708,,80012,,,BAO_0000219,,Intermediate,,9606.0,F,,A 172
6916,Canis lupus familiaris,,CHEMBL624725,Association constant against A2 adenosine receptor,,8975,,104729,,,BAO_0000224,,Autocuration,,9615.0,B,,
6917,fish,,CHEMBL624726,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,,7645,,80656,,,BAO_0000219,,Intermediate,,,F,,A2
6918,Rattus norvegicus,,CHEMBL857535,Ratio of Ki for adenosine A2 and A1 receptor binding,,11377,,104713,,,BAO_0000224,,Autocuration,,10116.0,B,,
6919,Homo sapiens,,CHEMBL624727,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,,13528,,80014,,,BAO_0000219,,Expert,,9606.0,F,,A204
6920,Homo sapiens,,CHEMBL624728,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,,10160,,80014,,,BAO_0000219,,Expert,,9606.0,F,,A204
6921,Homo sapiens,,CHEMBL624729,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,,15144,,80015,,,BAO_0000219,,Intermediate,,9606.0,F,,A2058
6922,Homo sapiens,,CHEMBL624730,Growth inhibition against Human squamous cell line(A 253),,13160,,80657,,,BAO_0000219,,Intermediate,,9606.0,F,,A253 cell line
6923,Homo sapiens,,CHEMBL624731,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,,12898,,80657,,,BAO_0000219,,Intermediate,,9606.0,F,,A253 cell line
6924,Homo sapiens,,CHEMBL624732,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,,13069,,80657,,,BAO_0000219,,Intermediate,,9606.0,F,,A253 cell line
6925,Homo sapiens,,CHEMBL883245,Growth inhibition of A253 cell lines.,,15984,,80657,,,BAO_0000219,,Intermediate,,9606.0,F,,A253 cell line
6926,Homo sapiens,,CHEMBL624733,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),,15564,,80657,,,BAO_0000219,,Intermediate,,9606.0,F,,A253 cell line
6927,Homo sapiens,,CHEMBL624734,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,15564,,80657,,,BAO_0000219,,Intermediate,,9606.0,F,,A253 cell line
6928,Homo sapiens,,CHEMBL624735,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,15564,,80657,,,BAO_0000219,,Intermediate,,9606.0,F,,A253 cell line
6929,Homo sapiens,,CHEMBL621780,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,,4720,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
6930,Homo sapiens,,CHEMBL877598,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,,16112,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
6931,Homo sapiens,,CHEMBL621781,Cytotoxic activity against A2780 human ovarian carcinoma cell line,,16597,,81034,,,BAO_0000219,,Expert,,9606.0,F,,A2780
6932,Homo sapiens,,CHEMBL621782,Cytotoxicity against human cancer cell lines A2780 (ovarian),,16378,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
6933,Homo sapiens,,CHEMBL621783,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,,16085,,81034,,,BAO_0000219,,Expert,,9606.0,F,,A2780
6934,Homo sapiens,,CHEMBL621784,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,,16317,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
6935,Homo sapiens,,CHEMBL621785,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,15748,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
6936,Homo sapiens,,CHEMBL621968,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,,16597,,81034,,,BAO_0000219,,Expert,,9606.0,F,,A2780
6937,Homo sapiens,,CHEMBL621969,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,,16597,,81034,,,BAO_0000219,,Expert,,9606.0,F,,A2780
6938,Homo sapiens,,CHEMBL621970,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,,16597,,81034,,,BAO_0000219,,Expert,,9606.0,F,,A2780
6939,Homo sapiens,,CHEMBL621971,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,,15608,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
6940,Homo sapiens,,CHEMBL621972,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,,15608,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
6941,Homo sapiens,,CHEMBL884108,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,,15608,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
6942,Cricetulus griseus,,CHEMBL623826,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,15296,,22224,,,BAO_0000019,,Autocuration,,10029.0,F,,
6943,Cricetulus griseus,,CHEMBL623827,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,,10251,,22224,,,BAO_0000219,,Autocuration,,10029.0,A,,CHO-AA8
6944,Cricetulus griseus,,CHEMBL623828,Evaluated for growth inhibition of AA8 cells under aerobic conditions,,10251,,22224,,,BAO_0000219,,Autocuration,,10029.0,F,,CHO-AA8
6945,Cricetulus griseus,,CHEMBL623829,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,,10251,,22224,,,BAO_0000219,,Autocuration,,10029.0,F,,CHO-AA8
6946,Cricetulus griseus,,CHEMBL623830,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),,10251,,22224,,,BAO_0000219,,Autocuration,,10029.0,F,,CHO-AA8
6947,Cricetulus griseus,,CHEMBL623831,Growth inhibition against CHO-derived cell line AA8,,11858,,22224,,,BAO_0000019,,Autocuration,,10029.0,F,,
6948,Cricetulus griseus,,CHEMBL623832,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],,11858,,22224,,,BAO_0000219,,Autocuration,,10029.0,F,,CHO-AA8
6949,hampster,,CHEMBL623833,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,,11616,,80089,,,BAO_0000219,,Expert,,36483.0,F,,CHO-AA8
6950,Cricetulus griseus,,CHEMBL623834,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,,11616,,80089,,,BAO_0000219,,Expert,,10029.0,F,,CHO-AA8
6951,Cricetulus griseus,,CHEMBL623835,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,,10518,,22224,,,BAO_0000219,,Autocuration,,10029.0,F,,CHO-AA8
6952,Cricetulus griseus,,CHEMBL623836,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,,11396,,22224,,,BAO_0000219,,Autocuration,,10029.0,F,,CHO-AA8
6953,Cricetulus griseus,,CHEMBL623837,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,,10518,,22224,,,BAO_0000219,,Autocuration,,10029.0,F,,CHO-AA8
6954,Cricetulus griseus,,CHEMBL623838,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,,11616,,80089,,,BAO_0000219,,Expert,,10029.0,F,,CHO-AA8
6955,,,CHEMBL623839,compound was evaluated for association constant (Ka) of isolated serum protein AAG,,14837,,12675,,,BAO_0000019,,Autocuration,,,F,,
6956,,,CHEMBL623840,Number of binding sites (n) of isolated serum protein AAG,,14837,,12675,,,BAO_0000019,,Autocuration,,,F,,
6957,,,CHEMBL623841,Association constant for binding to AATT duplex,,16037,,22222,,,BAO_0000225,,Intermediate,,,B,,
6958,Homo sapiens,,CHEMBL623842,Inhibition of ABAE human fibroblast cell proliferation,,16597,,100090,,,BAO_0000219,,Expert,,9606.0,F,,ABAE
6959,Mus musculus,,CHEMBL623843,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",,8831,,80668,,,BAO_0000218,,Intermediate,,10090.0,F,,AC755
6960,Oryctolagus cuniculus,,CHEMBL618669,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,,13419,,102444,,,BAO_0000218,,Expert,,9986.0,F,,
6961,Oryctolagus cuniculus,,CHEMBL618670,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,In vivo,13419,,102444,,,BAO_0000218,,Expert,,9986.0,F,,
6962,,,CHEMBL618671,Inhibitory activity against angiotensin-converting enzyme (ACE).,,15778,,69,,,BAO_0000357,,Autocuration,,,B,,
6963,,,CHEMBL618672,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,,15778,,69,,,BAO_0000357,,Autocuration,,,B,,
6964,Homo sapiens,,CHEMBL618673,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,,12988,,80669,,,BAO_0000219,,Intermediate,,9606.0,F,,ACH-2 cell line
6965,Homo sapiens,,CHEMBL618674,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),,12988,,80669,,,BAO_0000219,,Intermediate,,9606.0,F,,ACH-2 cell line
6966,Human immunodeficiency virus 1,,CHEMBL618675,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,,12988,,22224,,,BAO_0000219,,Autocuration,,11676.0,F,,T cell line
6967,Human immunodeficiency virus 1,,CHEMBL618676,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),,12988,,22224,,,BAO_0000219,,Autocuration,,11676.0,F,,T cell line
6968,Human immunodeficiency virus 1,,CHEMBL618677,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),,12988,,22224,,,BAO_0000219,,Autocuration,,11676.0,F,,T cell line
6969,Homo sapiens,,CHEMBL618678,Inhibition of growth of renal cancer ACHN cell line,,11843,,80025,,,BAO_0000219,,Intermediate,,9606.0,F,,ACHN
6970,Homo sapiens,,CHEMBL618679,Inhibition of growth of ACHN renal cancer cell line,,16939,,80025,,,BAO_0000219,,Intermediate,,9606.0,F,,ACHN
6971,Homo sapiens,,CHEMBL618680,Inhibitory concentration required against ACHN renal cancer cell line,,4782,,80025,,,BAO_0000219,,Intermediate,,9606.0,F,,ACHN
6972,Homo sapiens,,CHEMBL618681,Concentration required to inhibit growth of human renal (ACHN) cell line,,6310,,80025,,,BAO_0000219,,Expert,,9606.0,F,,ACHN
6973,Homo sapiens,,CHEMBL618682,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,,6310,,80025,,,BAO_0000219,,Intermediate,,9606.0,F,,ACHN
6974,Homo sapiens,,CHEMBL618683,Cytotoxic activity against ACHN Renal cancer cell line,,12858,,80025,,,BAO_0000219,,Intermediate,,9606.0,F,,ACHN
6975,Homo sapiens,,CHEMBL618684,Cytotoxicity evaluation against ACHN renal cancer cells,,17380,,80025,,,BAO_0000219,,Intermediate,,9606.0,F,,ACHN
6976,Homo sapiens,,CHEMBL618685,In vitro antitumor activity against human renal ACHN cell line,,5858,,80025,,,BAO_0000219,,Intermediate,,9606.0,F,,ACHN
6977,Homo sapiens,,CHEMBL876499,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,3838,,80025,,,BAO_0000219,,Intermediate,,9606.0,F,,ACHN
6978,Homo sapiens,,CHEMBL618686,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,3838,,80025,,,BAO_0000219,,Intermediate,,9606.0,F,,ACHN
6979,Homo sapiens,,CHEMBL618687,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",,5406,,80025,,,BAO_0000219,,Intermediate,,9606.0,F,,ACHN
6980,Homo sapiens,,CHEMBL618688,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,4071,,80025,,,BAO_0000219,,Intermediate,,9606.0,F,,ACHN
6981,Homo sapiens,,CHEMBL618689,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,4071,,80025,,,BAO_0000219,,Expert,,9606.0,F,,ACHN
6982,Homo sapiens,,CHEMBL618690,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,,4071,,80025,,,BAO_0000219,,Intermediate,,9606.0,F,,ACHN
6983,Homo sapiens,,CHEMBL618691,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,,15002,,80025,,,BAO_0000219,,Intermediate,,9606.0,F,,ACHN
6984,Homo sapiens,,CHEMBL619373,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,14769,,80025,,,BAO_0000219,,Intermediate,,9606.0,F,,ACHN
6985,Homo sapiens,,CHEMBL884008,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",,13958,,80025,,,BAO_0000219,,Intermediate,,9606.0,F,,ACHN
6986,Homo sapiens,,CHEMBL619374,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,,1665,,80025,,,BAO_0000219,,Intermediate,,9606.0,F,,ACHN
6987,Homo sapiens,,CHEMBL619375,Compound was tested for the growth inhibition of ACHN renal tumor cell line,,15354,,80025,,,BAO_0000219,,Intermediate,,9606.0,F,,ACHN
6988,Homo sapiens,,CHEMBL619376,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,,15354,,80025,,,BAO_0000219,,Intermediate,,9606.0,F,,ACHN
6989,Homo sapiens,,CHEMBL619377,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,,13978,,80025,,,BAO_0000219,,Intermediate,,9606.0,F,,ACHN
6990,Homo sapiens,,CHEMBL619378,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,,6798,,80025,,,BAO_0000219,,Intermediate,,9606.0,F,,ACHN
6991,Canis lupus familiaris,,CHEMBL872527,Tmax value after administration of 4 mg/Kg oral dose in dog,In vivo,2959,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6992,Canis lupus familiaris,,CHEMBL876500,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",,9932,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6993,Canis lupus familiaris,,CHEMBL619379,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,5546,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6994,Canis lupus familiaris,,CHEMBL619538,Volume distribution after 15 mg/kg iv dose in Dogs,In vivo,16907,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6995,Canis lupus familiaris,,CHEMBL619539,Volume distribution after 30 mg/kg po dose in Dogs,In vivo,16907,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6996,Canis lupus familiaris,,CHEMBL619540,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,In vivo,4257,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6997,Canis lupus familiaris,,CHEMBL619541,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,In vivo,4305,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6998,Canis lupus familiaris,,CHEMBL619542,Volume of distribution was evaluated in dog,In vivo,5472,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
6999,Canis lupus familiaris,,CHEMBL619543,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,In vivo,6062,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7000,Canis lupus familiaris,,CHEMBL619544,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,,3598,,50588,,,BAO_0000218,,Expert,,9615.0,A,,
7001,Canis lupus familiaris,,CHEMBL619545,The compound was tested for volume of distribution in dog,In vivo,12500,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7002,Canis lupus familiaris,,CHEMBL619546,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,In vivo,12500,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7003,Canis lupus familiaris,,CHEMBL619547,Vd (1 mg/kg) was determined in dog (in vivo),In vivo,6227,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7004,Canis lupus familiaris,,CHEMBL619548,Vd in dog,In vivo,6227,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7005,Canis lupus familiaris,,CHEMBL619549,Volume distribution was determined,In vivo,4219,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7006,Canis lupus familiaris,,CHEMBL619550,Volume of distribution in dog,In vivo,1696,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7007,Canis lupus familiaris,,CHEMBL876501,Volume of distribution by as 4 fold increase by iv administration in dogs,In vivo,5542,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7008,Canis lupus familiaris,,CHEMBL619551,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,In vivo,5199,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7009,Canis lupus familiaris,,CHEMBL619552,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,In vivo,6348,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7010,Canis lupus familiaris,,CHEMBL619553,Volume distribution at the dose of 2 mg/kg in dog,In vivo,4727,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7011,Canis lupus familiaris,,CHEMBL618722,Steady state volume of distribution was determined,In vivo,16367,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7012,Canis lupus familiaris,,CHEMBL618723,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,In vivo,2652,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7013,Canis lupus familiaris,,CHEMBL618724,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,In vivo,16452,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7014,Canis lupus familiaris,,CHEMBL618725,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,In vivo,16452,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7015,Canis lupus familiaris,,CHEMBL618726,Bioavailability in dog (dose 1 mg/kg i.v.),In vivo,16452,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7016,Canis lupus familiaris,,CHEMBL618727,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),In vivo,5334,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7017,Canis lupus familiaris,,CHEMBL624233,Pharmacokinetic property (vdss) was measured in dog,In vivo,4239,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7018,Canis lupus familiaris,,CHEMBL624234,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,In vivo,4709,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7019,Canis lupus familiaris,,CHEMBL624235,Vdss was determined after iv 0.1 mg/kg administration in dog,In vivo,5600,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7020,Canis lupus familiaris,,CHEMBL624236,Volume displacement was calculated in dog,In vivo,6057,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7021,Canis lupus familiaris,,CHEMBL624237,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,In vivo,5654,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7022,Canis lupus familiaris,,CHEMBL624238,Volume distribution constant was determined,In vivo,5505,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7023,Canis lupus familiaris,,CHEMBL624239,Volume distribution at a dose of 1 uM/kg in dog was determined,In vivo,4527,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7024,Canis lupus familiaris,,CHEMBL875829,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,In vivo,4521,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7025,Canis lupus familiaris,,CHEMBL624240,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,In vivo,4521,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7026,Canis lupus familiaris,,CHEMBL624241,Volume distribution (Vdss) was measured in dog,In vivo,15660,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7027,Canis lupus familiaris,,CHEMBL624242,Volume distribution (Vdss) was measured in dog,In vivo,15660,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7028,Canis lupus familiaris,,CHEMBL624243,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,In vivo,6679,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7029,Canis lupus familiaris,,CHEMBL624244,Volume of distribution in steady state was determined in dog,In vivo,5145,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7030,Canis lupus familiaris,,CHEMBL624245,Volume of distribution of compound was determined in dog,In vivo,6821,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7031,Canis lupus familiaris,,CHEMBL624246,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,In vivo,4137,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7032,Canis lupus familiaris,,CHEMBL624247,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),In vivo,5334,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7033,Canis lupus familiaris,,CHEMBL624248,Volume of distribution (Vdss) was measured in dog,In vivo,15660,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7034,Canis lupus familiaris,,CHEMBL624249,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),In vivo,6642,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7035,Canis lupus familiaris,,CHEMBL624250,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,6641,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7036,Canis lupus familiaris,,CHEMBL624251,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,6642,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7037,Canis lupus familiaris,,CHEMBL624252,Maximum rate of depolarization of the upstroke of the action potential,,11659,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7038,Canis lupus familiaris,,CHEMBL624253,Steady state volume distribution in dog,In vivo,6448,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7039,Canis lupus familiaris,,CHEMBL624950,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,In vivo,5474,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7040,Canis lupus familiaris,,CHEMBL624951,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,In vivo,1466,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7041,Canis lupus familiaris,,CHEMBL875830,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,In vivo,6535,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7042,Canis lupus familiaris,,CHEMBL624952,Volume distribution in dog after administration of 1 mg/kg iv,In vivo,6535,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7043,Canis lupus familiaris,,CHEMBL624953,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,In vivo,17764,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7044,Canis lupus familiaris,,CHEMBL624954,Vss after intravenous administration (0.5 mg/kg) was determined in dog,In vivo,6215,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7045,Canis lupus familiaris,,CHEMBL624955,Vss on i.v. administration of 2 mg/kg was measured in dog,In vivo,6505,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7046,Canis lupus familiaris,,CHEMBL624956,Vss was determined,,3639,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7047,Canis lupus familiaris,,CHEMBL625129,Vss in dog,,3639,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7048,Canis lupus familiaris,,CHEMBL625130,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,In vivo,6062,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7049,Canis lupus familiaris,,CHEMBL625131,Volume distribution in dogs,In vivo,4942,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7050,Canis lupus familiaris,,CHEMBL625132,Volume of distribution in dog,In vivo,17796,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7051,Canis lupus familiaris,,CHEMBL872263,Tested for the oral bioavailability in dog,In vivo,4883,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7060,Mus musculus,,CHEMBL624336,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,In vivo,17837,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7061,Mus musculus,,CHEMBL624337,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,In vivo,17729,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7062,Mus musculus,,CHEMBL624338,Bioavailability after peroral administration of 50 mg/kg of dose in mice,In vivo,17729,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7063,Mus musculus,,CHEMBL624339,Bioavailability was measured in mouse,In vivo,4239,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7064,Mus musculus,,CHEMBL624340,Bioavailability in mouse,In vivo,17592,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7065,Mus musculus,,CHEMBL624341,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,In vivo,6348,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7066,Mus musculus,,CHEMBL624342,Bioavailability in mouse,In vivo,2801,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7067,Mus musculus,,CHEMBL624343,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,In vivo,2801,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7068,Mus musculus,,CHEMBL624344,Oral bioavailability in mouse,In vivo,17718,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7069,Mus musculus,,CHEMBL624345,Oral availability at 50 mg/kg po in male mice,In vivo,5727,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7070,Mus musculus,,CHEMBL624346,Oral bioavailability in mouse (dose 10 mg/kg),In vivo,5302,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7071,Mus musculus,,CHEMBL624347,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,In vivo,3598,,50594,,,BAO_0000218,,Expert,,10090.0,A,,
7072,Mus musculus,,CHEMBL624348,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",In vivo,5961,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7074,Mus musculus,,CHEMBL622754,Oral bioavailability in mouse,In vivo,6091,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7075,Mus musculus,,CHEMBL622755,Oral bioavailability in vivo in mice;ND=Not determined,In vivo,6091,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7076,Mus musculus,,CHEMBL622756,Oral bioavailability in mouse at 10 mg/kg of the compound,In vivo,5711,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7077,Mus musculus,,CHEMBL622757,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),In vivo,17728,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7078,Mus musculus,,CHEMBL622758,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),In vivo,17728,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7079,Mus musculus,,CHEMBL622759,Tested for bioavailability of the compound,In vivo,3802,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7080,Mus musculus,,CHEMBL622760,Tested for half life at the dose of 10 mg/kg when administered intravenously,In vivo,3802,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7081,Mus musculus,1969.0,CHEMBL622761,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,,14029,Plasma,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7082,Mus musculus,1969.0,CHEMBL622762,The plasma half life of compound was determined on heparin prepared by human plasma. ,,14029,Plasma,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7083,Mus musculus,1969.0,CHEMBL622763,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,,14029,Plasma,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7084,Mus musculus,1969.0,CHEMBL622764,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,,14029,Plasma,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7085,Mus musculus,1969.0,CHEMBL622765,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,,14029,Plasma,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7086,Mus musculus,,CHEMBL622766,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,,17753,,50594,,,BAO_0000218,,Intermediate,,10090.0,F,,
7087,Mus musculus,,CHEMBL622767,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,,17753,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7088,Mus musculus,,CHEMBL622768,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,,17753,,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7089,Mus musculus,178.0,CHEMBL875948,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,10107,Blood,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7090,Mus musculus,178.0,CHEMBL622769,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,10107,Blood,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7091,Mus musculus,178.0,CHEMBL622770,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,10107,Blood,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7092,Mus musculus,178.0,CHEMBL622771,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,10107,Blood,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7093,Mus musculus,178.0,CHEMBL622772,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,10107,Blood,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7094,Mus musculus,178.0,CHEMBL622773,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,10107,Blood,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7095,Mus musculus,178.0,CHEMBL622774,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,10107,Blood,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7096,Mus musculus,10000001.0,CHEMBL621725,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,10107,Bone,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7097,Mus musculus,10000001.0,CHEMBL621726,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,In vivo,10107,Bone,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7098,Homo sapiens,,CHEMBL621727,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,,15608,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7099,Homo sapiens,,CHEMBL622413,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,,3290,,81034,,,BAO_0000219,,Expert,,9606.0,F,,A2780
7100,Homo sapiens,,CHEMBL622414,Compound was evaluated for cytotoxicity against A2780 cell line,,2859,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7101,Homo sapiens,,CHEMBL622415,Inhibition of A2780 cell clonogenic assay,,15688,,81034,,,BAO_0000219,,Expert,,9606.0,F,,A2780
7102,Homo sapiens,,CHEMBL884001,Cytotoxic effect on ovarian cancer cell line (A2780),,5642,,81034,,,BAO_0000219,,Expert,,9606.0,F,,A2780
7103,Homo sapiens,,CHEMBL622416,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,,6633,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7104,Homo sapiens,,CHEMBL622417,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",,3906,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7105,Homo sapiens,,CHEMBL622590,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,,6788,,81034,,,BAO_0000219,,Expert,,9606.0,F,,A2780
7106,Homo sapiens,,CHEMBL622591,Antiproliferative activity against human A2780 cells,,17582,,81034,,,BAO_0000219,,Expert,,9606.0,F,,A2780
7107,Homo sapiens,,CHEMBL622592,Inhibition of human A2780 cell proliferation,,17764,,81034,,,BAO_0000219,,Expert,,9606.0,F,,A2780
7108,Homo sapiens,,CHEMBL622593,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,,17764,,81034,,,BAO_0000219,,Expert,,9606.0,F,,A2780
7109,Homo sapiens,,CHEMBL622594,Inhibition of human A2780 cell proliferation (No data),,17764,,81034,,,BAO_0000219,,Expert,,9606.0,F,,A2780
7110,Homo sapiens,,CHEMBL622595,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,,2815,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7111,Homo sapiens,,CHEMBL622596,Compound was evaluated against human Ovarian carcinoma cell line A2780,,16930,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7112,Homo sapiens,,CHEMBL622597,Growth inhibition against A2780 wild-type ovarian cell lines,,17777,,81034,,,BAO_0000219,,Expert,,9606.0,F,,A2780
7113,Homo sapiens,,CHEMBL622598,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,,17777,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7114,Homo sapiens,,CHEMBL622599,Inhibition of tubulin polymerization in human ovarian cancer cell lines,,16936,,104766,,,BAO_0000019,,Autocuration,,9606.0,F,,
7115,Homo sapiens,,CHEMBL622600,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,13759,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7116,Homo sapiens,,CHEMBL622601,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,13759,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7117,Homo sapiens,,CHEMBL622602,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,13759,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7118,Homo sapiens,,CHEMBL622603,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,13759,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7119,Homo sapiens,,CHEMBL622604,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,15292,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7120,Homo sapiens,,CHEMBL622605,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,15292,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7121,Homo sapiens,,CHEMBL622606,In vitro inhibition of human ovarian cell line A2780,,15069,,81034,,,BAO_0000219,,Expert,,9606.0,F,,A2780
7122,Homo sapiens,,CHEMBL619463,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",,15069,,81034,,,BAO_0000219,,Expert,,9606.0,F,,A2780
7123,Homo sapiens,,CHEMBL619464,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),,14073,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7124,Homo sapiens,,CHEMBL619465,Concentration required to inhibit A2780-cell growth by 50%,,14553,,81034,,,BAO_0000219,,Expert,,9606.0,F,,A2780
7125,Homo sapiens,,CHEMBL619466,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,,13040,,81034,,,BAO_0000219,,Expert,,9606.0,F,,A2780
7126,Homo sapiens,,CHEMBL619467,Cytotoxic effect on human ovarian (A2780) cancer cell line,,6891,,81034,,,BAO_0000219,,Expert,,9606.0,F,,A2780
7127,Homo sapiens,,CHEMBL619468,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,,15569,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7128,Homo sapiens,,CHEMBL619469,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,,14190,,81034,,,BAO_0000219,,Expert,,9606.0,F,,A2780
7129,Homo sapiens,,CHEMBL619470,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,15014,,81034,,,BAO_0000219,,Expert,,9606.0,F,,A2780
7130,Homo sapiens,,CHEMBL619471,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,15014,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7131,Homo sapiens,,CHEMBL619472,Cytotoxicity against human ovarian carcinoma A2780 cell line,,17496,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7132,Homo sapiens,,CHEMBL619473,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",,13617,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7133,Homo sapiens,,CHEMBL874368,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",,13617,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7134,Homo sapiens,,CHEMBL884003,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",,13617,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7135,Homo sapiens,,CHEMBL622690,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",,13617,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7136,Homo sapiens,,CHEMBL622691,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,,17672,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7137,Homo sapiens,,CHEMBL622692,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,4544,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7138,Homo sapiens,,CHEMBL623406,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,4544,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7139,Homo sapiens,,CHEMBL884004,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",,16317,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7140,Homo sapiens,,CHEMBL623407,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,,15099,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7141,Homo sapiens,,CHEMBL623408,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,,13978,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7142,Homo sapiens,,CHEMBL623409,In vitro antitumor activity against A2780 cell line.,,12989,,81034,,,BAO_0000219,,Expert,,9606.0,F,,A2780
7143,Homo sapiens,,CHEMBL623410,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,,5574,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7144,Homo sapiens,,CHEMBL623576,In vitro cytotoxicity against A2780 human ovarian cancer cell line,,13528,,81034,,,BAO_0000219,,Expert,,9606.0,F,,A2780
7145,Homo sapiens,,CHEMBL623577,Inhibitory activity against kidney A-CHN tumor cell growth in culture,,12782,,80025,,,BAO_0000219,,Intermediate,,9606.0,F,,ACHN
7146,Homo sapiens,,CHEMBL623578,The IC50 value was measured on ACHN cell line in renal tumor type.,,14255,,80025,,,BAO_0000219,,Intermediate,,9606.0,F,,ACHN
7147,Homo sapiens,,CHEMBL623579,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,,16364,,80025,,,BAO_0000219,,Intermediate,,9606.0,F,,ACHN
7148,Homo sapiens,,CHEMBL623580,In vitro lethal concentration against most sensitive ACHN cell line,,17376,,80025,,,BAO_0000219,,Expert,,9606.0,F,,ACHN
7149,Homo sapiens,,CHEMBL623581,Tested for cytotoxic activity against renal cancer ACHN cell line,,12016,,80025,,,BAO_0000219,,Intermediate,,9606.0,F,,ACHN
7150,Homo sapiens,,CHEMBL857456,Compound tested for growth inhibition of renal cancer cell line ACHN,,6058,,80025,,,BAO_0000219,,Intermediate,,9606.0,F,,ACHN
7151,Homo sapiens,,CHEMBL623582,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,,17708,,80025,,,BAO_0000219,,Intermediate,,9606.0,F,,ACHN
7152,Homo sapiens,,CHEMBL623583,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,,15176,,80025,,,BAO_0000219,,Intermediate,,9606.0,F,,ACHN
7153,Homo sapiens,,CHEMBL623584,In vitro anticancer activity against ACHN renal cancer cell line,,2806,,80025,,,BAO_0000219,,Intermediate,,9606.0,F,,ACHN
7154,Homo sapiens,,CHEMBL623585,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,,15300,,80025,,,BAO_0000219,,Intermediate,,9606.0,F,,ACHN
7155,Homo sapiens,,CHEMBL623586,Percent selectivity was evaluated in renal ACHN cell lines,,16364,,80025,,,BAO_0000219,,Intermediate,,9606.0,F,,ACHN
7156,Homo sapiens,,CHEMBL623587,In vitro inhibitory activity against renal ACHN cancer cell line,,13859,,80025,,,BAO_0000219,,Intermediate,,9606.0,F,,ACHN
7157,Homo sapiens,,CHEMBL875279,Tested for cytotoxicity against ACHN cell lines in renal cancer,,11970,,80025,,,BAO_0000219,,Intermediate,,9606.0,F,,ACHN
7158,Homo sapiens,,CHEMBL623588,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,,2450,,80025,,,BAO_0000219,,Intermediate,,9606.0,F,,ACHN
7159,Homo sapiens,,CHEMBL623589,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,12696,,80025,,,BAO_0000219,,Intermediate,,9606.0,F,,ACHN
7160,Homo sapiens,,CHEMBL623590,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,,12400,,80025,,,BAO_0000219,,Intermediate,,9606.0,F,,ACHN
7161,Homo sapiens,,CHEMBL623591,Cytotoxic effect on renal cancer line ACHN,,12888,,80025,,,BAO_0000219,,Expert,,9606.0,F,,ACHN
7162,Homo sapiens,,CHEMBL623592,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,,3156,,80025,,,BAO_0000219,,Intermediate,,9606.0,F,,ACHN
7163,Homo sapiens,,CHEMBL623593,In vitro inhibition of Renal Cancer ACHN cell lines,,3381,,80025,,,BAO_0000219,,Intermediate,,9606.0,F,,ACHN
7164,Homo sapiens,,CHEMBL623594,Antitumor activity against human renal adenocarcinoma ACHN cells,,16747,,80025,,,BAO_0000219,,Intermediate,,9606.0,F,,ACHN
7165,Homo sapiens,,CHEMBL621833,Antitumor activity against human renal adenocarcinoma ACHN cells.,,16748,,80025,,,BAO_0000219,,Expert,,9606.0,F,,ACHN
7166,Homo sapiens,,CHEMBL621834,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,,12062,,80025,,,BAO_0000219,,Intermediate,,9606.0,F,,ACHN
7167,Homo sapiens,,CHEMBL621835,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,14769,,80025,,,BAO_0000219,,Intermediate,,9606.0,F,,ACHN
7168,Homo sapiens,,CHEMBL621836,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",,15895,,80025,,,BAO_0000219,,Intermediate,,9606.0,F,,ACHN
7169,Homo sapiens,,CHEMBL621837,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,,17376,,80025,,,BAO_0000219,,Intermediate,,9606.0,F,,ACHN
7170,Homo sapiens,,CHEMBL875280,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,14882,,80025,,,BAO_0000219,,Intermediate,,9606.0,F,,ACHN
7171,Homo sapiens,,CHEMBL621838,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,,14882,,80025,,,BAO_0000219,,Intermediate,,9606.0,F,,ACHN
7172,Homo sapiens,,CHEMBL621839,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,,15661,,80025,,,BAO_0000219,,Intermediate,,9606.0,F,,ACHN
7173,,,CHEMBL621840,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,9680,,22224,,,BAO_0000019,,Autocuration,,,A,,
7174,,,CHEMBL621841,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,,14579,,10647,,,BAO_0000019,,Autocuration,,,F,,
7175,Cytomegalovirus,,CHEMBL622979,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,,17290,,50529,,,BAO_0000218,,Expert,,10358.0,F,,HEL
7176,Cytomegalovirus,,CHEMBL876595,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,,17290,,50529,,,BAO_0000218,,Intermediate,,10358.0,F,,
7177,,,CHEMBL620221,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),,15891,,12159,,,BAO_0000357,,Autocuration,,,B,,
7178,,,CHEMBL620222,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),,15890,,12159,,,BAO_0000357,,Autocuration,,,B,,
7179,Bos taurus,,CHEMBL620506,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,,3801,,80670,,,BAO_0000219,,Intermediate,,9913.0,F,,ADDP cell line
7180,Mus musculus,,CHEMBL620507,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,,9222,,80671,,,BAO_0000219,,Intermediate,,10090.0,F,,ADJ/PC6
7181,Mus musculus,,CHEMBL620508,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,,9222,,80671,,,BAO_0000219,,Intermediate,,10090.0,F,,ADJ/PC6
7182,Mus musculus,,CHEMBL620509,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",,7257,,80671,,,BAO_0000219,,Intermediate,,10090.0,F,,ADJ/PC6
7183,Mus musculus,,CHEMBL620510,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,,7257,,80671,,,BAO_0000219,,Intermediate,,10090.0,F,,ADJ/PC6
7184,Mus musculus,,CHEMBL620511,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,,7257,,80671,,,BAO_0000219,,Intermediate,,10090.0,A,,ADJ/PC6
7185,Mus musculus,,CHEMBL620512,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,,8084,,80671,,,BAO_0000219,,Intermediate,,10090.0,F,,ADJ/PC6
7186,Mus musculus,,CHEMBL620513,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,,14943,,22224,,,BAO_0000019,,Autocuration,,10090.0,F,,
7187,Mus musculus,,CHEMBL620514,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,,14943,,22224,,,BAO_0000019,,Autocuration,,10090.0,F,,
7188,Mus musculus,,CHEMBL620515,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,,14943,,22224,,,BAO_0000019,,Autocuration,,10090.0,F,,
7189,Bacillus subtilis,,CHEMBL620516,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),In vivo,10524,,22224,,,BAO_0000218,,Autocuration,,1423.0,A,,
7190,Canis lupus familiaris,1969.0,CHEMBL620517,AUC value in dog after IV administration at a dose of 5 mg/kg,,3546,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7191,Canis lupus familiaris,1969.0,CHEMBL620518,AUC value in dog after oral administration at a dose of 5 mg/kg,,3546,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7192,Canis lupus familiaris,,CHEMBL620519,Cmax value in dog after oral administration at a dose of 5 mg/kg,In vivo,3546,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7193,Canis lupus familiaris,,CHEMBL621386,Bioavailability in dog after oral administration at a dose of 5 mg/kg,In vivo,3546,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7194,Canis lupus familiaris,,CHEMBL621387,Tmax value in dog after oral administration at a dose of 5 mg/kg,In vivo,3546,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7195,Canis lupus familiaris,,CHEMBL621388,Compound was evaluated for its clearance when administered intravenously in dog,In vivo,3184,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7196,Canis lupus familiaris,,CHEMBL621389,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,In vivo,16456,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7197,Canis lupus familiaris,,CHEMBL621390,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),In vivo,4809,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7198,,,CHEMBL621391,Calculated partition coefficient (clogP),,4219,,22229,,,BAO_0000100,,Intermediate,,,P,,
7199,Canis lupus familiaris,,CHEMBL621392,Half life in dog,,3748,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7200,Canis lupus familiaris,,CHEMBL621393,Time taken for EC90 was determined when tested in dog,,3132,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7201,Canis lupus familiaris,,CHEMBL621394,Half life (iv) was determined,,4219,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7202,Canis lupus familiaris,2107.0,CHEMBL621395,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,,16907,Liver,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7203,Canis lupus familiaris,,CHEMBL621396,Area under the curve was calculated in dog after iv administration,,6057,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7204,Canis lupus familiaris,,CHEMBL621397,Area under the curve was calculated in dog after peroral administration,,6057,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7205,Canis lupus familiaris,,CHEMBL621398,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,,17853,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7206,Canis lupus familiaris,,CHEMBL618818,pKa was evaluated in dog,,3639,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7207,Canis lupus familiaris,,CHEMBL618819,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,,14541,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7208,Canis lupus familiaris,,CHEMBL618820,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,In vivo,16456,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7209,Canis lupus familiaris,,CHEMBL873810,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,In vivo,16456,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7210,Canis lupus familiaris,,CHEMBL876606,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,In vivo,2652,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7211,Canis lupus familiaris,,CHEMBL618821,Compound was evaluated for the half-life (t 1/2) in hours,,3624,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7212,Canis lupus familiaris,178.0,CHEMBL618822,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,In vivo,1337,Blood,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7213,Canis lupus familiaris,178.0,CHEMBL618823,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,In vivo,1337,Blood,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7214,Canis lupus familiaris,,CHEMBL618824,Half life after intravenous administration of 1 mg/kg in dog,In vivo,4709,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7215,Canis lupus familiaris,,CHEMBL618825,Half life was measured in dog,,15660,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7216,Canis lupus familiaris,,CHEMBL618826,Half life period in dog after 5 mg/kg dose,In vivo,5302,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7217,Canis lupus familiaris,,CHEMBL618827,Half life period was evaluated in dog; 4-4.8,,17791,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7218,Canis lupus familiaris,,CHEMBL618828,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,In vivo,6348,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7219,Canis lupus familiaris,,CHEMBL618829,Half-life was determined in dog after a3 mg/kg of iv dose,In vivo,4257,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7220,Canis lupus familiaris,,CHEMBL618830,Half-life was determined,,3771,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7221,Canis lupus familiaris,,CHEMBL618831,Half life in dogs,,6305,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7222,Canis lupus familiaris,1969.0,CHEMBL619489,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,In vivo,13501,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7223,Canis lupus familiaris,,CHEMBL619649,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,In vivo,17594,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7224,Canis lupus familiaris,,CHEMBL876607,Compound was evaluated for the half life period after iv administration in Beagle dog.,In vivo,3045,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7225,Canis lupus familiaris,,CHEMBL619650,Compound was evaluated for the half life period after oral administration in conscious dog.,In vivo,3043,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7226,Canis lupus familiaris,,CHEMBL619651,Compound was tested for half life in dog,,4839,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7227,Canis lupus familiaris,,CHEMBL619652,Compound was tested for its half life in dog,,4839,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7228,Canis lupus familiaris,,CHEMBL619653,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,In vivo,5802,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7229,Canis lupus familiaris,,CHEMBL619654,Half life of compound in dog was determined,,17839,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7230,Canis lupus familiaris,,CHEMBL619655,Half life (iv) was determined,In vivo,4219,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7231,Canis lupus familiaris,178.0,CHEMBL619656,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),,13966,Blood,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7232,Canis lupus familiaris,1969.0,CHEMBL873812,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,In vivo,3994,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7233,Canis lupus familiaris,1969.0,CHEMBL621365,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,In vivo,3994,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,F,,
7234,Canis lupus familiaris,,CHEMBL621366,Half life in dog,,4453,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7235,Canis lupus familiaris,1969.0,CHEMBL621367,Half life in dog plasma,,6535,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7236,Canis lupus familiaris,1969.0,CHEMBL621368,Half life in dog plasma after administration of 0.25 mg/kg iv,In vivo,6535,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7237,Canis lupus familiaris,1969.0,CHEMBL621369,Half life in dog plasma after administration of 1 mg/kg iv,In vivo,6535,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7238,Canis lupus familiaris,1969.0,CHEMBL621370,Half life in dog plasma was determined at dose 10 mg/kg,In vivo,3132,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7239,Canis lupus familiaris,,CHEMBL621371,Half life in dog was determined,,5374,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7240,Canis lupus familiaris,,CHEMBL621372,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),In vivo,5007,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7241,Canis lupus familiaris,1969.0,CHEMBL621373,Half life upon exposure to human plasma,,16907,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7242,Canis lupus familiaris,,CHEMBL621374,Half life was calculated in dog,,6057,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7243,Canis lupus familiaris,,CHEMBL621375,Half life was determined,,5006,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7244,Canis lupus familiaris,,CHEMBL621376,Half life was determined,,5473,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7245,Canis lupus familiaris,,CHEMBL619624,Half life by intravenous administration of 1.2 mg/kg in dog,In vivo,4368,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7246,Canis lupus familiaris,,CHEMBL875840,Half life in dog,,6448,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7247,Canis lupus familiaris,,CHEMBL619625,Half life in dog after intra venous administration of the compound,,4353,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7248,Canis lupus familiaris,,CHEMBL619626,Half life in dog after intra venous administration of the compound; ND means Not determined,,4353,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7249,Canis lupus familiaris,,CHEMBL619627,Half life in dog after po administration of the compound,In vivo,4353,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7250,Canis lupus familiaris,,CHEMBL873817,Half life in dog after po administration of the compound; ND means Not determined,In vivo,4353,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7251,Canis lupus familiaris,,CHEMBL619628,Half life in dog at the single oral dose of 1 mg/kg,In vivo,6265,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7252,Canis lupus familiaris,,CHEMBL619629,Half life in dogs,,5006,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7253,Canis lupus familiaris,,CHEMBL619630,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,In vivo,5356,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7254,Canis lupus familiaris,,CHEMBL619631,Half life in rat,,405,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7255,Canis lupus familiaris,,CHEMBL619632,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),In vivo,6642,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7256,Mus musculus,10000001.0,CHEMBL619633,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,10107,Bone,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7257,Mus musculus,10000001.0,CHEMBL875841,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,10107,Bone,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7258,Mus musculus,10000001.0,CHEMBL619634,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,10107,Bone,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7259,Mus musculus,10000001.0,CHEMBL619635,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,10107,Bone,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7260,Mus musculus,10000001.0,CHEMBL619636,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,10107,Bone,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7261,Mus musculus,10000004.0,CHEMBL619637,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,10107,Gut,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7262,Mus musculus,10000004.0,CHEMBL619638,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,10107,Gut,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7263,Mus musculus,10000004.0,CHEMBL619639,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,10107,Gut,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7264,Mus musculus,10000004.0,CHEMBL619640,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,10107,Gut,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7265,Mus musculus,10000004.0,CHEMBL619641,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,10107,Gut,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7266,Mus musculus,10000004.0,CHEMBL619642,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,10107,Gut,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7267,Mus musculus,10000004.0,CHEMBL619643,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,10107,Gut,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7268,Mus musculus,948.0,CHEMBL619644,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,10107,Heart,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7269,Mus musculus,948.0,CHEMBL621112,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,10107,Heart,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7270,Mus musculus,948.0,CHEMBL621113,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,10107,Heart,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7271,Mus musculus,948.0,CHEMBL621114,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,10107,Heart,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7272,Mus musculus,948.0,CHEMBL621115,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,10107,Heart,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7273,Mus musculus,948.0,CHEMBL621116,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,10107,Heart,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7274,Mus musculus,948.0,CHEMBL621117,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,10107,Heart,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7275,Mus musculus,2113.0,CHEMBL621118,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,10107,Kidney,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7276,Mus musculus,2113.0,CHEMBL621119,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,In vivo,10107,Kidney,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7277,Mus musculus,2113.0,CHEMBL621120,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,10107,Kidney,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7278,Mus musculus,2113.0,CHEMBL621757,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,10107,Kidney,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7279,Mus musculus,2113.0,CHEMBL621758,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,10107,Kidney,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7280,Mus musculus,2113.0,CHEMBL621759,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,10107,Kidney,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7281,Mus musculus,2113.0,CHEMBL621760,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,10107,Kidney,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7282,Mus musculus,2107.0,CHEMBL621761,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,10107,Liver,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7283,Mus musculus,2107.0,CHEMBL621762,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,10107,Liver,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7284,Mus musculus,2107.0,CHEMBL621763,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,10107,Liver,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7285,Mus musculus,2107.0,CHEMBL624502,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,10107,Liver,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7286,Mus musculus,2107.0,CHEMBL624503,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,10107,Liver,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7287,Mus musculus,2107.0,CHEMBL624504,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,10107,Liver,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7288,Mus musculus,2107.0,CHEMBL624505,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,10107,Liver,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7289,Mus musculus,2048.0,CHEMBL624506,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,10107,Lung,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7290,Homo sapiens,,CHEMBL624507,In vitro cytotoxicity against A2780 (human ovarian cancer),,5895,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7291,Homo sapiens,,CHEMBL624508,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,,6338,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7292,Homo sapiens,,CHEMBL624509,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,,15163,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7293,Homo sapiens,,CHEMBL624510,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,,15163,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7294,Homo sapiens,,CHEMBL875956,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,,15000,,81034,,,BAO_0000219,,Expert,,9606.0,F,,A2780
7295,Homo sapiens,,CHEMBL839885,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,,15000,,81034,,,BAO_0000219,,Expert,,9606.0,F,,A2780
7296,Homo sapiens,,CHEMBL624511,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,,14729,,81034,,,BAO_0000219,,Expert,,9606.0,F,,A2780
7297,Homo sapiens,,CHEMBL624512,In vitro cytotoxicity against A2780 cell line,,17270,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7298,Homo sapiens,,CHEMBL624513,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,,5685,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7299,Homo sapiens,,CHEMBL624514,In vitro inhibitory activity against human ovarian cancer A2780 cell line,,3563,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7300,Homo sapiens,,CHEMBL618547,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,,17753,,81034,,,BAO_0000218,,Intermediate,,9606.0,F,,A2780
7301,Homo sapiens,,CHEMBL618548,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",,16317,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7302,Homo sapiens,,CHEMBL618549,Inhibition of tubulin polymerization in analogy of ca.,,16936,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7303,Homo sapiens,,CHEMBL618550,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,,3801,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7304,Homo sapiens,,CHEMBL618551,Cytotoxic effect in ovarian cancer cell line (A2780),,6181,,81034,,,BAO_0000219,,Expert,,9606.0,F,,A2780
7305,Homo sapiens,,CHEMBL618552,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,,5318,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7306,Homo sapiens,,CHEMBL618553,Tested for the cytotoxicity in A2780 ovarian cell line,,4840,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7307,Homo sapiens,,CHEMBL618554,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,15748,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7308,Homo sapiens,,CHEMBL618555,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,,15748,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7309,,,CHEMBL618556,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,,15748,,80017,,,BAO_0000219,,Intermediate,,,F,,A2780cisR
7310,,,CHEMBL618557,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,15748,,80017,,,BAO_0000219,,Intermediate,,,F,,A2780cisR
7311,,,CHEMBL618558,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,,15748,,80017,,,BAO_0000219,,Intermediate,,,F,,A2780cisR
7312,,,CHEMBL618559,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),,15748,,80017,,,BAO_0000219,,Intermediate,,,F,,A2780cisR
7313,Homo sapiens,,CHEMBL618560,In vivo log of cells killed after administration of compound in A2780 cell line,,17753,,81034,,,BAO_0000218,,Intermediate,,9606.0,F,,A2780
7314,Homo sapiens,,CHEMBL618561,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,In vivo,17753,,81034,,,BAO_0000218,,Intermediate,,9606.0,F,,A2780
7315,Homo sapiens,,CHEMBL618562,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,,16936,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7316,Homo sapiens,,CHEMBL618563,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,,16936,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7317,Homo sapiens,,CHEMBL618564,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,,16936,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7318,Homo sapiens,,CHEMBL618565,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,,16936,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7319,Homo sapiens,,CHEMBL618566,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),,17528,,81034,,,BAO_0000218,,Intermediate,,9606.0,F,,A2780
7320,Homo sapiens,,CHEMBL618567,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,,6633,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7321,Homo sapiens,,CHEMBL618568,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,,15000,,81034,,,BAO_0000219,,Expert,,9606.0,F,,A2780
7322,Homo sapiens,,CHEMBL618569,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,17528,,81034,,,BAO_0000219,,Expert,,9606.0,F,,A2780
7323,Homo sapiens,,CHEMBL621857,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,,16936,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7324,Homo sapiens,,CHEMBL621858,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,,16936,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7325,Homo sapiens,,CHEMBL621859,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,,16936,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7326,Homo sapiens,,CHEMBL621860,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",,16936,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7327,Homo sapiens,,CHEMBL621861,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),,16936,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7328,Homo sapiens,,CHEMBL621862,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",,16936,,81034,,,BAO_0000219,,Expert,,9606.0,F,,A2780
7329,Homo sapiens,,CHEMBL621863,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,16936,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7330,Homo sapiens,,CHEMBL621864,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,16936,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7331,Homo sapiens,,CHEMBL621865,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),,16936,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7332,Mus musculus,,CHEMBL621866,In vitro antiproliferative activity against A2780 cell line,,17737,,81034,,,BAO_0000219,,Intermediate,,10090.0,F,,A2780
7333,Mus musculus,,CHEMBL621867,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,,17764,,81034,,,BAO_0000219,,Expert,,10090.0,F,,A2780
7334,Homo sapiens,,CHEMBL621868,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,,3830,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7335,Homo sapiens,,CHEMBL875282,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,,3829,,81034,,,BAO_0000219,,Intermediate,,9606.0,F,,A2780
7336,Canis lupus familiaris,,CHEMBL621869,Vc value in dog after IV administration at a dose of 5 mg/kg,,3546,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7337,Canis lupus familiaris,,CHEMBL621870,Half life period in dog after IV administration at a dose of 5 mg/kg,In vivo,3546,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7338,Cercopithecidae,,CHEMBL621871,Area under curve was determine after peroral administration at 10 mpk in Rhesus,,5668,,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
7339,Cercopithecidae,1969.0,CHEMBL621243,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,3443,Plasma,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
7340,Cercopithecidae,1969.0,CHEMBL621244,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,3443,Plasma,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
7341,Macaca fascicularis,,CHEMBL621245,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,In vivo,4256,,22224,,,BAO_0000218,,Autocuration,,9541.0,A,,
7342,Macaca fascicularis,,CHEMBL621246,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,In vivo,4256,,22224,,,BAO_0000218,,Autocuration,,9541.0,A,,
7343,Macaca fascicularis,,CHEMBL621247,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,In vivo,4256,,22224,,,BAO_0000218,,Autocuration,,9541.0,A,,
7344,Rattus norvegicus,,CHEMBL618386,Oral Bioavailability in rat,In vivo,4256,,22224,,,BAO_0000218,,Autocuration,,10116.0,A,,
7345,Cercopithecidae,,CHEMBL618387,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,1916,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
7346,Cercopithecidae,,CHEMBL618388,Area under curve value in monkey at a dose of 5 mg/kg,,5302,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
7347,Cercopithecidae,,CHEMBL618389,Area under curve was determined in monkey after a 3 mg/kg of oral dose,,4257,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
7348,Cercopithecidae,,CHEMBL618574,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,,5355,,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
7349,Cercopithecidae,,CHEMBL618575,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,,5355,,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
7350,Cercopithecidae,,CHEMBL618576,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,,5355,,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
7351,Cercopithecidae,,CHEMBL618577,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,,6078,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
7352,Cercopithecidae,,CHEMBL876487,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,,6078,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
7353,Cercopithecidae,,CHEMBL618578,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,,6062,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
7354,Cercopithecidae,,CHEMBL618579,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,2661,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
7355,Cercopithecidae,,CHEMBL618580,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,2661,,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
7356,Cercopithecidae,,CHEMBL618581,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,,5394,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
7357,Cercopithecidae,,CHEMBL618582,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,,4397,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
7358,Cercopithecidae,,CHEMBL618583,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,,17509,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
7359,Cercopithecidae,,CHEMBL618584,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,,17509,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
7360,Cercopithecidae,,CHEMBL618585,Oral AUCN in monkey (dosed at 0.5 mpk iv ),In vivo,6641,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
7361,Cercopithecidae,,CHEMBL618586,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),,5355,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
7362,Cercopithecidae,,CHEMBL618587,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,In vivo,3443,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
7363,Cercopithecidae,,CHEMBL618588,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,In vivo,3443,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
7364,Cercopithecidae,,CHEMBL618589,Binding towards monkey plasma protein at 10 uM,,17409,,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
7365,Cercopithecidae,,CHEMBL618590,Binding towards monkey plasma protein at 100 uM,,17409,,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
7366,Cercopithecidae,,CHEMBL872262,Apparent bioavailability in squirrel monkey was determined,In vivo,1052,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
7367,Cercopithecidae,,CHEMBL618591,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,In vivo,13501,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
7368,monkey,,CHEMBL618592,Bioavailability in monkey (dose 2 mg/kg),In vivo,17509,,22224,,,BAO_0000218,,Autocuration,,9443.0,A,,
7369,Cercopithecidae,,CHEMBL876488,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,In vivo,5394,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
7370,Cercopithecidae,,CHEMBL618593,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,In vivo,2661,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
7371,monkey,,CHEMBL618594,Bioavailability in monkey (i.d. dosing),In vivo,11219,,22224,,,BAO_0000218,,Autocuration,,9443.0,A,,
7372,Cercopithecidae,,CHEMBL618595,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,In vivo,3045,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
7373,Cercopithecidae,,CHEMBL621469,Clearance of the drug was measured in cynomolgus,,17796,,22224,,,BAO_0000019,,Autocuration,,9527.0,A,,
7374,Cercopithecidae,,CHEMBL621470,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,In vivo,1399,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
7375,Cercopithecidae,,CHEMBL621471,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,In vivo,2661,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
7376,Macaca mulatta,1969.0,CHEMBL621472,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,In vivo,5005,Plasma,22224,,,BAO_0000218,,Autocuration,,9544.0,A,,
7377,Cercopithecidae,,CHEMBL621473,Plasma clearance in rhesus monkey was determined,In vivo,17267,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
7378,Cercopithecidae,,CHEMBL621474,Plasma clearance in monkey after administration of 1 mg/kg iv,In vivo,6535,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
7379,Cercopithecidae,,CHEMBL621475,Plasma clearance in cynomolgus monkey,In vivo,5922,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
7380,Cercopithecidae,,CHEMBL621476,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,In vivo,6221,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
7381,Cercopithecidae,,CHEMBL624290,Plasma clearance after peroral administration at 10 mpk in Rhesus,In vivo,5668,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
7382,Cercopithecidae,,CHEMBL624291,The total clearance was determined after intravenous administration in cynomolgus monkeys,In vivo,5355,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
7383,Cercopithecidae,,CHEMBL624292,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,In vivo,5355,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
7384,Cercopithecidae,,CHEMBL624293,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,In vivo,5355,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
7385,Cercopithecidae,,CHEMBL624294,Tested for Clearance upon iv administration to african green monkey,In vivo,4578,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
7386,Cercopithecidae,,CHEMBL624295,Clearance in monkey,In vivo,17592,,22224,,,BAO_0000218,,Autocuration,,9527.0,A,,
7387,Canis lupus familiaris,,CHEMBL624296,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,6641,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7388,Canis lupus familiaris,,CHEMBL624297,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,6642,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7389,Canis lupus familiaris,,CHEMBL624298,Half life was evaluated after intravenous administration to dogs,In vivo,16367,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7390,Canis lupus familiaris,,CHEMBL624299,Half life was evaluated in dog,,5472,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7391,Canis lupus familiaris,,CHEMBL624300,Half life was evaluated in dog,,5474,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7392,Canis lupus familiaris,,CHEMBL624301,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,In vivo,5654,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7393,Canis lupus familiaris,,CHEMBL624302,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),In vivo,6227,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7394,Canis lupus familiaris,,CHEMBL876026,Half life period after intravenous administration in dog,In vivo,6227,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7395,Canis lupus familiaris,,CHEMBL624303,Half life period after oral administration (2.5 mg/kg) in dog was determined,In vivo,6221,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7396,Canis lupus familiaris,,CHEMBL624304,Half life period at a dose of 1 uM/kg in dog was determined,,4527,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7397,Canis lupus familiaris,,CHEMBL624305,Half life period was determine after peroral administration at 10 mpk in dog,In vivo,5668,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7398,Canis lupus familiaris,,CHEMBL624306,Half life period was determine after peroral administration at 5 mpk in dog,In vivo,5668,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7399,Canis lupus familiaris,,CHEMBL624307,Half life period was determined,,3854,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7400,Canis lupus familiaris,,CHEMBL624308,Half life period was determined,,5505,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7401,Canis lupus familiaris,,CHEMBL624309,Half life period by iv administration in dog at a dose of 6 mg/kg,In vivo,6251,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7402,Canis lupus familiaris,,CHEMBL624310,Half life period was evaluated in dog,,1918,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7403,Canis lupus familiaris,,CHEMBL625003,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,In vivo,5546,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7404,Canis lupus familiaris,,CHEMBL625004,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),In vivo,4809,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7405,Canis lupus familiaris,,CHEMBL625005,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,In vivo,6215,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7406,Canis lupus familiaris,,CHEMBL873813,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,In vivo,4527,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7407,Canis lupus familiaris,,CHEMBL625006,Half-life after oral dose of compound at 3 mg/kg in dogs,In vivo,17594,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7408,Canis lupus familiaris,,CHEMBL625007,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,In vivo,17839,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7409,Canis lupus familiaris,,CHEMBL876027,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,In vivo,17839,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7410,Canis lupus familiaris,,CHEMBL625008,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,In vivo,17839,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7411,Canis lupus familiaris,,CHEMBL625009,Half-life of compound in dog following p.o. administration of 1 mg/kg,In vivo,17839,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7412,Canis lupus familiaris,1969.0,CHEMBL625010,Half-life of compound in plasma of dog was determined,,5210,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7413,Canis lupus familiaris,,CHEMBL625011,Half-life of compound was determined in dogs,,5210,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7414,Canis lupus familiaris,,CHEMBL621553,Half-life after administration of 4 mg/Kg oral dose in dog,In vivo,2959,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7415,Canis lupus familiaris,,CHEMBL621554,Half-life after intravenous administration of 1 mg/kg/h in dog,In vivo,4137,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7416,Canis lupus familiaris,,CHEMBL621555,Half-life in Dog,,5064,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7417,Canis lupus familiaris,,CHEMBL621556,Half-life in Dog,,5147,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7418,Canis lupus familiaris,,CHEMBL621557,Half-life in dog,,5145,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7419,Canis lupus familiaris,,CHEMBL621558,Half-life in dog after oral administration at 1 mg/kg,In vivo,6123,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7420,Canis lupus familiaris,,CHEMBL621559,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,In vivo,6123,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7421,Canis lupus familiaris,,CHEMBL621560,Half-life in dogs,,4333,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7422,Canis lupus familiaris,,CHEMBL876028,Half-life in dogs; ND indicates not determined,,4333,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7423,Canis lupus familiaris,1969.0,CHEMBL621561,Half-life in plasma of dog,,12500,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7424,Canis lupus familiaris,1969.0,CHEMBL621562,Half-life in plasma of dog at dose of 3-10 mgkg,,12500,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7425,Canis lupus familiaris,,CHEMBL621563,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,In vivo,6005,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7426,Canis lupus familiaris,,CHEMBL621564,Half-life was measured in dog after an iv dose of 1 mg/kg,In vivo,6062,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7427,Canis lupus familiaris,,CHEMBL621565,Half-life was measured in dogs after an oral dose of 10 uM/kg,In vivo,17650,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7428,Canis lupus familiaris,,CHEMBL621566,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,In vivo,5530,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7429,Canis lupus familiaris,,CHEMBL621567,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,In vivo,5530,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7430,Canis lupus familiaris,,CHEMBL622978,Half-life of the compound after 0.3 mg/kg po administration in dog,In vivo,5600,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7431,Canis lupus familiaris,,CHEMBL873814,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,In vivo,6039,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7432,Canis lupus familiaris,,CHEMBL623219,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,In vivo,6039,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7433,Canis lupus familiaris,,CHEMBL624477,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,In vivo,6039,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7434,Canis lupus familiaris,,CHEMBL624478,t1/2 in dog,,6227,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7435,Canis lupus familiaris,,CHEMBL624479,Half-life period measured in dogs,,14541,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7436,Canis lupus familiaris,,CHEMBL624480,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,In vivo,4521,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7437,Canis lupus familiaris,,CHEMBL623595,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,In vivo,4521,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7438,Canis lupus familiaris,,CHEMBL623596,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,In vivo,6679,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7439,Canis lupus familiaris,1969.0,CHEMBL623597,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",In vitro,1116,Plasma,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7440,Canis lupus familiaris,,CHEMBL623598,In vivo half life period was calculated at 1 mg/kg in dog,In vivo,5444,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7441,Canis lupus familiaris,,CHEMBL623599,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,In vivo,5444,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7442,Canis lupus familiaris,,CHEMBL623600,Longer half-life in dog (i.v.) at 0.5 mpk,In vivo,17853,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7443,Canis lupus familiaris,,CHEMBL623601,Oral bioavailability in dog (dose 5 uM/kg),In vivo,4353,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7444,Canis lupus familiaris,,CHEMBL623602,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,In vivo,16452,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7445,Canis lupus familiaris,,CHEMBL623603,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,In vivo,16452,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7446,Canis lupus familiaris,,CHEMBL623604,Bioavailability in dog (dose 1 mg/kg i.v.),In vivo,16452,,50588,,,BAO_0000218,,Intermediate,,9615.0,A,,
7447,Mus musculus,2048.0,CHEMBL623605,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,In vivo,10107,Lung,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7448,Mus musculus,2048.0,CHEMBL623606,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,10107,Lung,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7449,Mus musculus,2048.0,CHEMBL623607,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,10107,Lung,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7450,Mus musculus,2048.0,CHEMBL623608,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,10107,Lung,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7451,Mus musculus,2048.0,CHEMBL623609,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,10107,Lung,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7452,Mus musculus,2048.0,CHEMBL623610,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,10107,Lung,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7453,Mus musculus,2385.0,CHEMBL623611,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,10107,Muscle tissue,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7454,Mus musculus,2385.0,CHEMBL623612,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,In vivo,10107,Muscle tissue,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7455,Mus musculus,2385.0,CHEMBL623613,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,10107,Muscle tissue,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7456,Mus musculus,2385.0,CHEMBL623614,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,10107,Muscle tissue,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7457,Mus musculus,2385.0,CHEMBL623615,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,10107,Muscle tissue,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7458,Mus musculus,2385.0,CHEMBL623616,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,10107,Muscle tissue,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7459,Mus musculus,2385.0,CHEMBL623617,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,10107,Muscle tissue,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7460,Mus musculus,14.0,CHEMBL875944,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,10107,Zone of skin,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7461,Mus musculus,14.0,CHEMBL623618,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,10107,Zone of skin,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7462,Mus musculus,14.0,CHEMBL623619,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,10107,Zone of skin,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7463,Mus musculus,14.0,CHEMBL623620,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,10107,Zone of skin,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7464,Mus musculus,14.0,CHEMBL623621,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,10107,Zone of skin,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7465,Mus musculus,14.0,CHEMBL623622,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,10107,Zone of skin,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7466,Mus musculus,14.0,CHEMBL623623,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,10107,Zone of skin,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7467,Mus musculus,2106.0,CHEMBL623624,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,10107,Spleen,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7468,Mus musculus,2106.0,CHEMBL618521,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,10107,Spleen,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7469,Mus musculus,2106.0,CHEMBL618522,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,10107,Spleen,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7470,Mus musculus,2106.0,CHEMBL618523,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,10107,Spleen,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7471,Mus musculus,2106.0,CHEMBL618524,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,10107,Spleen,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7472,Mus musculus,2106.0,CHEMBL618525,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,10107,Spleen,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7473,Mus musculus,2106.0,CHEMBL624586,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,10107,Spleen,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7474,Mus musculus,945.0,CHEMBL624587,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,10107,Stomach,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7475,Mus musculus,945.0,CHEMBL624588,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,10107,Stomach,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7476,Mus musculus,945.0,CHEMBL624589,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,10107,Stomach,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7477,Mus musculus,945.0,CHEMBL624590,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,10107,Stomach,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7478,Mus musculus,945.0,CHEMBL624591,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,10107,Stomach,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7479,Mus musculus,945.0,CHEMBL624592,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,10107,Stomach,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7480,Mus musculus,945.0,CHEMBL624593,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,10107,Stomach,50594,,,BAO_0000218,,Intermediate,,10090.0,A,,
7481,Rattus norvegicus,,CHEMBL624594,Oral bioavailability in rat,In vivo,4689,,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
7482,Rattus norvegicus,,CHEMBL624595,Tested for the bioavailability in rat,In vivo,4950,,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
7483,Rattus norvegicus,,CHEMBL624596,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),In vivo,5328,,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
7484,Rattus norvegicus,,CHEMBL624597,Bioavailability in rat,In vivo,406,,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
7485,Rattus norvegicus,,CHEMBL624598,Bioavailability in rat,In vivo,12500,,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
7486,Rattus norvegicus,,CHEMBL624599,Bioavailability in rat (dose 3-10 mg/kg),In vivo,12500,,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
7487,Rattus norvegicus,,CHEMBL875166,Bioavailability in rat,In vivo,5247,,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
7488,Rattus norvegicus,1969.0,CHEMBL624600,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,In vivo,4186,Plasma,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
7489,Rattus norvegicus,1969.0,CHEMBL624601,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,In vivo,4186,Plasma,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
7490,Rattus norvegicus,,CHEMBL624602,Half life after oral administration was determined in rats at 6 mg/kg,In vivo,6647,,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
7491,Rattus norvegicus,,CHEMBL624603,Half life was determined,,6484,,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
7492,Rattus norvegicus,,CHEMBL624604,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,In vivo,3249,,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
7493,Rattus norvegicus,1969.0,CHEMBL624605,Plasma half life in rat at oral dose 2.8 mg/mk body weight,In vivo,6281,Plasma,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
7494,Rattus norvegicus,,CHEMBL624606,Half life in rats,,3307,,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
7495,Rattus norvegicus,178.0,CHEMBL624607,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,In vivo,12058,Blood,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
7496,Rattus norvegicus,,CHEMBL624608,Hill coefficient of the compound,,8833,,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
7497,Rattus norvegicus,178.0,CHEMBL624609,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,,3193,Blood,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
7498,Rattus norvegicus,178.0,CHEMBL624610,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,,3193,Blood,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
7499,Rattus norvegicus,178.0,CHEMBL624611,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,,3193,Blood,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
7500,Rattus norvegicus,178.0,CHEMBL624612,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,,3193,Blood,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
7501,Rattus norvegicus,178.0,CHEMBL875167,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,,3193,Blood,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
7502,Rattus norvegicus,178.0,CHEMBL624613,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,,3193,Blood,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
7503,Rattus norvegicus,178.0,CHEMBL624614,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",,3193,Blood,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
7504,Rattus norvegicus,,CHEMBL624392,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,,5960,,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
7505,Rattus norvegicus,955.0,CHEMBL624393,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,In vivo,13950,Brain,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
7506,Rattus norvegicus,955.0,CHEMBL624394,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,In vivo,13950,Brain,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
7507,Rattus norvegicus,955.0,CHEMBL624395,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,In vivo,13950,Brain,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
7508,Rattus norvegicus,955.0,CHEMBL624396,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,In vivo,13950,Brain,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
7509,Rattus norvegicus,955.0,CHEMBL624397,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,In vivo,13950,Brain,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
7510,Rattus norvegicus,2046.0,CHEMBL624398,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,In vivo,13950,Thyroid gland,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
7511,Rattus norvegicus,2046.0,CHEMBL624399,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,In vivo,13950,Thyroid gland,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
7512,Rattus norvegicus,2046.0,CHEMBL624400,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,In vivo,13950,Thyroid gland,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
7513,Rattus norvegicus,2046.0,CHEMBL624401,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,In vivo,13950,Thyroid gland,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
7514,Rattus norvegicus,2046.0,CHEMBL624402,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,In vivo,13950,Thyroid gland,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
7515,Rattus norvegicus,178.0,CHEMBL624403,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,In vivo,9866,Blood,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
7516,Rattus norvegicus,178.0,CHEMBL624404,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,In vivo,9866,Blood,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
7517,Rattus norvegicus,178.0,CHEMBL624405,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,In vivo,9866,Blood,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
7518,Rattus norvegicus,10000001.0,CHEMBL624406,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,In vivo,9866,Bone,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
7519,Rattus norvegicus,10000001.0,CHEMBL624407,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,In vivo,9866,Bone,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
7520,Rattus norvegicus,10000001.0,CHEMBL624408,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,In vivo,9866,Bone,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
7521,Rattus norvegicus,948.0,CHEMBL618644,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,In vivo,9866,Heart,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
7522,Rattus norvegicus,948.0,CHEMBL618645,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,In vivo,9866,Heart,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
7523,Rattus norvegicus,948.0,CHEMBL618646,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,In vivo,9866,Heart,50597,,,BAO_0000218,,Intermediate,,10116.0,A,,
